EP1383894A2 - Molecules for disease detection and treatment - Google Patents

Molecules for disease detection and treatment

Info

Publication number
EP1383894A2
EP1383894A2 EP02744104A EP02744104A EP1383894A2 EP 1383894 A2 EP1383894 A2 EP 1383894A2 EP 02744104 A EP02744104 A EP 02744104A EP 02744104 A EP02744104 A EP 02744104A EP 1383894 A2 EP1383894 A2 EP 1383894A2
Authority
EP
European Patent Office
Prior art keywords
polynucleotide
mar30
may17
protein
homo sapiens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP02744104A
Other languages
German (de)
French (fr)
Inventor
Abel Daffo
Anissa L. Jones
Alanna-Phung B. Tran
Christopher R. Dahl
Darryl Gietzen
Joyce Chinn
Gerard E. Dufour
Jennifer L. Hillman
Jimmy Y. Yu
Olivia Tuason
Pierre E. Yap
Stefan R. Amshey
Sean C. Daugherty
Tam C. Dam
Tommy F. Liu
Duy-Viet An Nguyen
Yael Kleefeld
Edward H. Gerstin, Jr.
Careyna H. Peralta
Marie H. David
Samantha A. Lewis
Alice J. Chen
Scott R. Panzer
Bernard Harris
Vincent Mullahy-Flores
Rakesh Marwaha
Audrey Lo
Ruth Y. Lan
Michael E. Urashka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc filed Critical Incyte Genomics Inc
Publication of EP1383894A2 publication Critical patent/EP1383894A2/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Definitions

  • the present invention relates to molecules for disease detection and treatment and to the use of these sequences in the diagnosis, study, prevention, and treatment of diseases associated with, as well as effects of exogenous compounds on, the expression of molecules for disease detection and treatment.
  • the human genome is comprised of thousands of genes, many encoding gene products that function in the maintenance and growth of the various cells and tissues in the body. Aberrant expression or mutations in these genes and their products is the cause of, or is associated with, a variety of human diseases such as cancer and other cell proliferative disorders.
  • the identification of these genes and their products is the basis of an ever-expanding effort to find markers for early detection of diseases, and targets for their prevention and treatment.
  • cancer represents a type of cell proliferative disorder that affects nearly every tissue in the body.
  • Cell proliferation must be regulated to maintain both the number of cells and their spatial organization. This regulation depends upon the appropriate expression of proteins which control cell cycle progression in response to extracellular signals such as growth factors and other mitogens, and intracellular cues such as DNA damage or nutrient starvation.
  • Molecules which directly or indirectly modulate cell cycle progression fall into several categories, including growth factors and their receptors, second messenger and signal transduction proteins, oncogene products, tumor-suppressor proteins, and mitosis-promoting factors.
  • Oncogenes are genes generally derived from normal genes that, through abnormal expression or mutation, can effect the transformation of a normal cell to a malignant one (oncogenesis).
  • Oncoproteins, encoded by oncogenes can affect cell proliferation in a variety of ways and include growth factors, growth factor receptors, intracellular signal transducers, nuclear transcription factors, and cell-cycle control proteins.
  • tumor-suppressor genes are involved in inhibiting cell proliferation. Mutations which cause reduced or loss of function in tumor-suppressor genes result in aberrant cell proliferation and cancer.
  • DNA-based arrays can provide a simple way to explore the expression of a single polymo ⁇ hic gene or a large number of genes. When the expression of a single gene is explored,
  • DNA-based arrays are employed to detect the expression of specific gene variants.
  • a p53 tumor suppressor gene array is used to determine whether individuals are carrying mutations that predispose them to cancer.
  • a cytochrome p450 gene array is useful to determine whether individuals have one of a number of specific mutations that could result in increased drug metabolism, drug resistance or drug toxicity.
  • DNA-based array technology is especially relevant for the rapid screening of expression of a large number of genes.
  • a genetic predisposition, disease or therapeutic treatment may affect, directly or indirectly, the expression of a large number of genes.
  • the interactions may be expected, such as when the genes are part of the same signaling pathway.
  • the interactions may be totally unexpected. Therefore, DNA-based arrays can be used to investigate how genetic predisposition, disease, or therapeutic treatment affects the expression of a large number of genes.
  • the present invention relates to human disease detection and treatment molecule polynucleotides (mddt) as presented in the Sequence Listing.
  • mddt human disease detection and treatment molecule polynucleotides
  • the invention provides an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d).
  • the polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396. In another alternative, the polynucleotide comprises at least 30 contiguous nucleotides of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; b) a polynucleotide comprising a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d
  • the polynucleotide comprises at least 60 contiguous nucleotides of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; b) a polynucleotide comprising a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d).
  • the invention further provides a composition for the detection of expression of disease detection and treatment molecule polynucleotides comprising at least one isolated polynucleotide comprising a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d); and a detectable label.
  • the invention also provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a polynucleotide sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence of a polynucleotide selected from the group consisting of SEQ ID NO: 1-396; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d).
  • the method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.
  • the invention also provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d).
  • a target polynucleotide having a polynucleotide selected from the group consisting of a) a polynucle
  • the method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleot e, un er conditions whereby a hybridization complex is formed between said probe and said target polynucleotide, and b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.
  • the invention provides a composition comprising a target polynucleotide of the method, wherein said probe comprises at least 30 contiguous nucleotides.
  • the invention provides a composition comprising a target polynucleotide of the method, wherein said probe comprises at least 60 contiguous nucleotides.
  • the invention further provides a recombinant polynucleotide comprising a promoter sequence operably linked to an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d).
  • the invention provides a cell transformed with the recombinant polynucleotide.
  • the invention provides a transgenic organism comprising the recombin
  • the invention also provides a method for producing a disease detection and treatment molecule polypeptide, the method comprising a) culturing a cell under conditions suitable for expression of the disease detection and treatment molecule polypeptide, wherein said cell is transformed with a recombinant polynucleotide, said recombinant polynucleotide comprising an isolated polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; iii) a polynucleotide complementary to the polynucleotide of i); iv) a polynucleotide complementary to the polynucleotide
  • the invention also provides an isolated disease detection and treatment molecule polypeptide (MDDT) encoded by at least one polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396.
  • MDDT disease detection and treatment molecule polypeptide
  • the invention further provides a method of screening for a test compound that specifically binds to the polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:397-792.
  • the method comprises a) combining the polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:397-792 with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide having an amino aci sequence selected from the group consisting of SEQ ID NO:397-7 to the test compound, thereby identifying a compound that specifically binds to the polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:397-792.
  • the invention further provides a microarray wherein at least one element of the microarray is
  • an isolated polynucleotide comprising at least 30 contiguous nucleotides of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; c) a polynucleotide complementary to the polynucleotide of a); d) a o polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d).
  • the invention also provides a method for generating a transcript image of a sample which contains polynucleotides.
  • the method comprises a) labeling the polynucleotides of the sample, b) contacting the elements of the microarray with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and c) quantifying the expression of the polynucleotides 5 in the sample.
  • the invention provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; b) a polynucleotide comprising a 0 naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d).
  • a target polynucleotide comprises a polynucleotide selected from the group consisting of
  • the method comprises a) exposing a sample comprising the target polynucleotide to a compound, b) detecting altered expression of the target polynucleotide, and c) 5 comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.
  • the invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 o contiguous nucleotides of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; iii) a polynucleotide complementary to the polynucleotide of i); iv) a polynucleotide complementary to the polynucleotide specific hybridization complex is formed between said probe and a target
  • the invention further provides an isolated polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:397-792, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ED NO:397-792, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:397-792, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:397-792.
  • the invention provides an isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:397-792.
  • the invention further provides an isolated polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 397-792, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:397-792, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:397-792, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:397- 792.
  • the polynucleotide encodes a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:397-792. In another alternative, the polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396.
  • the invention provides an isolated antibody which specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:397-792, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ED NO:397-792, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:397-792, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ED NO:397-792.
  • the invention further provides a composition comprising a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ED NO:397-792, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ED NO:397- 792, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ED NO:397-792, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ED NO:397-792, and a pharmaceutically acceptable excipient.
  • the composition comprises a polypeptide having an amino acid sequence selected from the group consisting of SEQ ED NO:397-792.
  • the invention additionally provides a method of treating a disease or condition associated with decreased expression of functional MDDT, comprising administering to a patient in need of such treatment the composition.
  • the invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ED NO:397-792, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ED NO: 397-792, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ED NO:397-792, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ED NO:397-792.
  • the method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample.
  • the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient.
  • the invention provides a method of treating a disease or condition associated with decreased expression of functional MDDT, comprising administering to a patient in need of such treatment the composition.
  • the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ED NO:397-792, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:397-792, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID
  • the method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample.
  • the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient.
  • the invention provides a method of treating a disease or condition associated with overexpression of functional
  • MDDT comprising administering to a patient in need of such treatment the composition.
  • the invention further provides a method of screening for a compound that modulates the activity of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ED NO:397-792, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ED NO:397-792, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ED NO:397-792, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ED NO: 397-792.
  • the method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.
  • Table 1 shows the sequence identification numbers (SEQ ED NO:s) and template identification numbers (template EDs) corresponding to the polynucleotides of the present invention, along with the sequence identification numbers (SEQ ED NO:s) and open reading frame identification numbers (ORF EDs) corresponding to polypeptides encoded by the template ED.
  • Table 2 shows the sequence identification numbers (SEQ ED NO:s) and template identification numbers (template EDs) corresponding to the polynucleotides of the present invention, along with their GenBank hits (GI Numbers), probability scores, and functional annotations corresponding to the GenBank hits.
  • Table 3 shows the sequence identification numbers (SEQ ED NO:s) and template identification numbers (template EDs) corresponding to the polynucleotides of the present invention, along with polynucleotide segments of each template sequence as defined by the indicated “start” and “stop” nucleotide positions.
  • SEQ ED NO:s sequence identification numbers
  • template EDs template identification numbers
  • Table 4 shows the sequence identification numbers (SEQ ED NO:s) and template identification numbers (template EDs) corresponding to the polynucleotides of the present invention, along with 5 polynucleotide segments of each template sequence as defined by the indicated “start” and “stop” nucleotide positions.
  • the reading frames of the polynucleotide segments are shown, and the polypeptides encoded by the polynucleotide segments constitute either signal peptide (SP) or transmembrane (TM) domains, as indicated.
  • SP signal peptide
  • TM transmembrane
  • the membrane topology of the encoded polypeptide sequence is indicated as being transmembrane or on the cytosolic or non-cytosolic side of o the cell membrane or organelle.
  • Table 5 shows the sequence identification numbers and template identification numbers (/template EDs) corresponding to the polynucleotides of the present invention, along with component sequence identification spans corresponding to each template.
  • the component sequences, which were used to assemble the template sequences, are defined by the spans indicating the nucleotide 5 positions along each template.
  • Table 6 shows the tissue distribution profiles for the templates of the invention.
  • Table 7 shows the sequence identification numbers (SEQ ED NO:s) corresponding to the polypeptides of the present invention, along with the reading frames used to obtain the polypeptide segments, the lengths of the polypeptide segments, the "start” and “stop” nucleotide positions of the 0 polynucleotide sequences used to define the encoded polypeptide segments, the GenBank hits (GI Numbers), probability scores, and functional annotations corresponding to the GenBank hits.
  • SEQ ED NO:s sequence identification numbers
  • Table 8 summarizes the bioinformatics tools which are useful for analysis of the polynucleotides of the present invention.
  • the first column of Table 8 lists analytical tools, programs, and algorithms, the second column provides brief descriptions thereof, the third column presents 5 appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score, the greater the homology between two sequences).
  • mddt refers to a nucleic acid sequence
  • MDDT refers to an amino acid sequence encoded by mddt
  • a “full-length” mddt refers to a nucleic acid sequence containing the entire coding region of a gene endogenously expressed in human tissue.
  • adjuvants are materials such as Freund's adjuvant, mineral gels (aluminum hydroxide), and surface active substances (lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol) which may be administered to increase a host's immunological response.
  • Alleles refers to an alternative form of a nucleic acid sequence. Alleles result from a “mutation,” a change or an alternative reading of the genetic code. Any given gene may have none, one, or many allelic forms. Mutations which give rise to alleles include deletions, additions, or substitutions of nucleotides. Each of these changes may occur alone, or in combination with the others, one or more times in a given nucleic acid sequence.
  • the present invention encompasses allelic mddt.
  • allelic variant is an alternative form of the gene encoding MDDT. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.
  • altered nucleic acid sequences encoding MDDT include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as MDDT or a polypeptide with at least one functional characteristic of MDDT. Included within this definition are polymo ⁇ hisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding MDDT, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding MDDT.
  • the encoded protein may also be "altered,” and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent MDDT.
  • Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of MDDT is retained.
  • negatively charged amino acids may include aspartic acid and glutamic acid
  • positively charged amino acids may include lysine and arginine.
  • Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine.
  • Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.
  • amino acid sequence refers to a peptide, a polypeptide, or a protein of either natural or synthetic origin.
  • the amino acid sequence is not limited to the complete, endogenous amino acid sequence and may be a fragment, epitope, variant, or derivative of a protein expressed by a nucleic acid sequence.
  • Amplification refers to the production of additional copies of a sequence and is carried out using polymerase chain reaction (PCR) technologies well known in the art.
  • PCR polymerase chain reaction
  • Antibody refers to intact molecules as well as to fragments thereof, such as Fab, F(ab') 2 , and Fv fragments, which are capable of binding the epitopic determinant.
  • Antibodies that bind MDDT polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen.
  • the polypeptide or peptide used to immunize an animal e.g., a mouse, a rat, or a rabbit
  • an animal e.g., a mouse, a rat, or a rabbit
  • RNA e.g., a mouse, a rat, or a rabbit
  • Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.
  • aptamer refers to a nucleic acid or oligonucleotide molecule that binds to a specific molecular target.
  • Aptamers are derived from an in vitro evolutionary process (e.g., SELEX (Systematic Evolution of Ligands by Exponential Enrichment), described in U.S. Patent No. 5,270,163), which selects for target-specific aptamer sequences from large combinatorial libraries.
  • Aptamer compositions may be double-stranded or single-stranded, and may include deoxyribonucleotides, ribonucleotides, nucleotide derivatives, or other nucleotide-like molecules.
  • the nucleotide components of an aptamer may have modified sugar groups (e.g., the 2'-OH group of a ribonucleotide may be replaced by 2'-F or 2'-NH 2 ), which may improve a desired property, e.g., resistance to nucleases or longer lifetime in blood.
  • Aptamers may be conjugated to other molecules, e.g., a high molecular weight carrier to slow clearance of the aptamer from the circulatory system.
  • Aptamers may be specifically cross-linked to their cognate ligands, e.g., by photo-activation of a cross-linker. (See, e.g., Brody, E.N. and L. Gold (2000) J. Biotechnol. 74:5-13.)
  • RNA aptamer refers to an aptamer which is expressed in vivo.
  • a vaccinia virus-based RNA expression system has been used to express specific RNA aptamers at high levels in the cytoplasm of leukocytes (Blind, M. et al. (1999) Proc. Natl Acad. Sci. USA 96:3606-3610).
  • spiegelmer refers to an aptamer which includes L-DNA, L-RNA, or other left- handed nucleotide derivatives or nucleotide-like molecules. Aptamers containing left-handed nucleotides are resistant to degradation by naturally occurring enzymes, which normally act on substrates containing right-handed nucleotides.
  • Antisense sequence refers to a sequence capable of specifically hybridizing to a target sequence.
  • the antisense sequence may include DNA, RNA, or any nucleic acid mimic or analog such as peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine.
  • PNA peptide nucleic acid
  • Antisense technology refers to any technology which relies on the specific hybridization of an antisense sequence to a target sequence.
  • a “bin” is a portion of computer memory space used by a computer program for storage of data, and bounded in such a manner that data stored in a bin may be retrieved by the program.
  • “Biologically active” refers to an amino acid sequence having a structural, regulatory, or biochemical function of a naturally occurring amino acid sequence.
  • “Clone joining” is a process for combining gene bins based upon the bins' containing sequence information from the same clone.
  • the sequences may assemble into a primary gene transcript as well as one or more splice variants.
  • “Complementary” describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing (5'-A-G-T-3' pairs with its complement 3'-T-C-A-5').
  • a “component sequence” is a nucleic acid sequence selected by a computer program such as PHRED and used to assemble a consensus or template sequence from one or more component sequences.
  • a “consensus sequence” or “template sequence” is a nucleic acid sequence which has been assembled from overlapping sequences, using a computer program for fragment assembly such as the GELVEEW fragment assembly system (Genetics Computer Group (GCG), Madison WI) or using a relational database management system (RDMS).
  • GCG Genetics Computer Group
  • RDMS relational database management system
  • Constant amino acid substitutions are those substitutions that, when made, least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions.
  • the table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative substitutions.
  • Conservative substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.
  • “Deletion” refers to a change in either a nucleic or amino acid sequence in which at least one nucleotide or amino acid residue, respectively, is absent.
  • Derivative refers to the chemical modification of a nucleic acid sequence, such as by replacement of hydrogen by an alkyl, acyl, amino, hydroxyl, or other group.
  • “Differential expression” refers to increased or upregulated; or decreased, downregulated, or absent gene or protein expression, determined by comparing at least two different samples. Such comparisons may be carried out between, for example, a treated and an untreated sample, or a diseased and a normal sample.
  • element and “array element” refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.
  • modulate refers to a change in the activity o MDDT. For examp e, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of MDDT.
  • E-value refers to the statistical probability that a match between two sequences occurred by chance.
  • Exon shuffling refers to the recombination of different coding regions (exons). Since an exon may represent a structural or functional domain of the encoded protein, new proteins may be assembled through the novel reassortment of stable substructures, thus allowing acceleration of the evolution of new protein functions.
  • a "fragment” is a unique portion of mddt or MDDT which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 10 to 1000 contiguous amino acid residues or nucleotides.
  • a fragment used as a probe, primer, antigen, therapeutic molecule, or for other pu ⁇ oses may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous amino acid residues or nucleotides in length. Fragments may be preferentially selected from certain regions of a molecule.
  • a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence.
  • these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing and the figures, may be encompassed by the present embodiments.
  • a fragment of mddt comprises a region of unique polynucleotide sequence that specifically identifies mddt, for example, as distinct from any other sequence in the same genome.
  • a fragment of mddt is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish mddt from related polynucleotide sequences.
  • the precise length of a fragment of mddt and the region of mddt to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended pu ⁇ ose for the fragment.
  • a fragment of MDDT is encoded by a fragment of mddt.
  • a fragment of MDDT comprises a region of unique amino acid sequence that specifically identifies MDDT.
  • a fragment of MDDT is useful as an immunogenic peptide for the development of antibodies that specifically recognize MDDT.
  • the precise length of a fragment of MDDT and the region of MDDT to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended pu ⁇ ose for the fragment.
  • a “full length” nucleotide sequence is one containing at least a start site for translation to a protein sequence, followed by an open reading frame and a stop site, and encoding a "full length” polypeptide. "Hit” refers to a sequence whose annotation will be used to describe a given template.
  • Criteria for selecting the top hit are as follows: if the template has one or more exact nucleic acid matches, the top hit is the exact match with highest percent identity. If the template has no exact matches but has significant protein hits, the top hit is the protein hit with the lowest E-value. If the template has no significant protein hits, but does have significant non-exact nucleotide hits, the top hit is the nucleotide hit with the lowest E-value.
  • Homology refers to sequence similarity either between a reference nucleic acid sequence and at least a fragment of an mddt or between a reference amino acid sequence and a fragment of an
  • Hybridization refers to the process by which a strand of nucleotides anneals with a complementary strand through base pairing. Specific hybridization is an indication that two nucleic acid sequences share a high degree of identity. Specific hybridization complexes form under defined annealing conditions, and remain hybridized after the "washing" step.
  • the defined hybridization conditions include the annealing conditions and the washing step(s), the latter of which is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid probes that are not perfectly matched.
  • Permissive conditions for annealing of nucleic acid sequences are routinely determinable and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency.
  • stringency of hybridization is expressed with reference to the temperature under which the wash step is carried out.
  • wash temperatures are selected to be about 5°C to 20°C lower than the thermal melting point (T m ) for the specific sequence at a defined ionic strength and pH.
  • T m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe.
  • High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, or 55°C may be used. SSC concentration may be varied from about 0.2 to 2 x SSC, with SDS being present at about 0.1%.
  • blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, denatured salmon sperm DNA at about 100-200 ⁇ g/ml. Useful variations on these conditions will be readily apparent to those skilled in the art.
  • Hybridization, particularly under high stringency conditions may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their resultant proteins.
  • RNA:DNA hybridizations may also be used under particular circumstances, such as RNA:DNA hybridizations. Appropriate hybridization conditions are routinely determinable by one of ordinary skill in the art.
  • Immunologically active or “immunogenic” describes the potential for a natural, recombinant, or synthetic peptide, epitope, polypeptide, or protein to induce antibody production in appropriate animals, cells, or cell lines.
  • Immunune response can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.
  • an “immunogenic fragment” is a polypeptide or oligopeptide fragment of ABBR which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal.
  • the term “immunogenic fragment” also includes any polypeptide or oligopeptide fragment of ABBR which is useful in any of the antibody production methods disclosed herein or known in the art.
  • “Insertion” or “addition” refers to a change in either a nucleic or amino acid sequence in which at least one nucleotide or residue, respectively, is added to the sequence.
  • Labeling refers to the covalent or noncovalent joining of a polynucleotide, polypeptide, or antibody with a reporter molecule capable of producing a detectable or measurable signal.
  • “Microarray” is any arrangement of nucleic acids, amino acids, antibodies, etc., on a substrate.
  • the substrate may be a solid support such as beads, glass, paper, nitrocellulose, nylon, or an appropriate membrane.
  • Linkers are short stretches of nucleotide sequence which may be added to a vector or an mddt to create restriction endonuclease sites to facilitate cloning.
  • Polylinkers are engineered to inco ⁇ orate multiple restriction enzyme sites and to provide for the use of enzymes which leave 5 ' or 3' overhangs (e.g., BamHI, EcoRI, and Hindlll) and those which provide blunt ends (e.g., EcoRV, SnaBI, and Stul).
  • Naturally occurring refers to an endogenous polynucleotide or polypeptide that may be isolated from viruses or prokaryotic or eukaryotic cells.
  • Nucleic acid sequence refers to the specific order of nucleotides joined by phosphodiester bonds in a linear, polymeric arrangement. Depending on the number of nucleotides, the nucleic acid sequence can be considered an oligomer, oligonucleotide, or polynucleotide.
  • the nucleic acid can be DNA, RNA, or any nucleic acid analog, such as PNA, may be of genomic or synthetic origin, may be either double-stranded or single-stranded, and can represent either the sense or antisense
  • Oligomer refers to a nucleic acid sequence of at least about 6 nucleotides and as many as about 60 nucleotides, preferably about 15 to 40 nucleotides, and most preferably between about 20 and
  • Oligomers may be used as, e.g., primers for PCR, and are usually chemically synthesized.
  • operably linked refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence.
  • a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence.
  • operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.
  • PNA protein nucleic acid
  • PNAs refers to a DNA mimic in which nucleotide bases are attached to a pseudopeptide backbone to increase stability. PNAs, also designated antigene agents, can prevent gene expression by targeting complementary messenger RNA.
  • percent identity and % identity refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.
  • the "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequence pairs.
  • NCBI National Center for Biotechnology Information
  • BLAST Basic Local Alignment Search Tool
  • the BLAST software suite includes various sequence analysis programs including "BLASTN,” that is used to determine alignment between a known polynucleotide sequence and other sequences on a variety of databases. Also available is a tool called "BLAST 2
  • BLAST 2 Sequences that is used for direct pairwise comparison of two nucleotide sequences.
  • BLAST 2 Sequences can be accessed and used interactively at http://www.ncbi.nlm.nih.gov/gorf/bl2/.
  • the "BLAST 2 Sequences” tool can be used for both BLASTN and BLASTP (discussed below).
  • BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use BLASTN with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such default parameters may be, for example:
  • Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ED number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides.
  • Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in figures or Sequence Listings, may be used to describe a length over which percentage identity may be measured.
  • nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.
  • percent identity and % identity refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm.
  • Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the hydrophobicity and acidity of the substituted residue, thus preserving the structure (and therefore function) of the folded polypeptide.
  • NCBI BLAST software suite may be used.
  • BLAST 2 Sequences Version 2.0.9 (May-07-1999) with BLASTP set at default parameters.
  • BLASTP set at default parameters.
  • Such default parameters may be, for example: Matrix: BLOSUM62
  • Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ED number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues.
  • Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in figures or Sequence Listings, may be used to describe a length over which percentage identity may be measured.
  • Post-translational modification of an MDDT may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu and the MDDT.
  • Probe refers to mddt or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences.
  • Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes.
  • Primmers are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme.
  • Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a nown sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the figures and Sequence Listing, may be used.
  • PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that pu ⁇ ose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).
  • Oligonucleotides for use as primers are selected using software known in the art for such pu ⁇ ose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have inco ⁇ orated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome- wide scope.
  • the Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.)
  • the PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences.
  • this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments.
  • the oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.
  • “Purified” refers to molecules, either polynucleotides or polypeptides that are isolated or separated from their natural environment and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other compounds with which they are naturally associated.
  • a "recombinant nucleic acid” is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra.
  • the term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid.
  • a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.
  • such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be use to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.
  • regulatory element refers to a nucleic acid sequence from nontranslated regions of a gene, and includes enhancers, promoters, introns, and 3' untranslated regions, which interact with host proteins to carry out or regulate transcription or translation.
  • Reporter molecules are chemical or biochemical moieties used for labeling a nucleic acid, an amino acid, or an antibody. They include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.
  • RNA equivalent in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose. "Sample” is used in its broadest sense.
  • Samples may contain nucleic or amino acids, antibodies, or other materials, and may be derived from any source (e.g., bodily fluids including, but not limited to, saliva, blood, and urine; chromosome(s), organelles, or membranes isolated from a cell; genomic DNA, RNA, or cDNA in solution or bound to a substrate; and cleared cells or tissues or blots or imprints from such cells or tissues).
  • source e.g., bodily fluids including, but not limited to, saliva, blood, and urine; chromosome(s), organelles, or membranes isolated from a cell; genomic DNA, RNA, or cDNA in solution or bound to a substrate; and cleared cells or tissues or blots or imprints from such cells or tissues.
  • Specific binding or “specifically binding” refers to the interaction between a protein or peptide and its agonist, antibody, antagonist, or other binding partner. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic
  • an antibody is specific for epitope "A”
  • the presence of a polypeptide containing epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.
  • Substitution refers to the replacement of at least one nucleotide or amino acid by a different nucleotide or amino acid.
  • Substrate refers to any suitable rigid or semi-rigid support including, e.g., membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles or capillaries.
  • the substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.
  • a “transcript image” refers to the collective pattern of gene expression by a particular tissue or cell type under given conditions at a given time.
  • Transformation refers to a process by which exogenous DNA enters a recipient cell.
  • Transformation may occur under natural or artificial conditions using various methods well known in the art. Transformation may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method is selected based on the host cell being transformed.
  • Transformants include stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as cells which transiently express inserted DNA or RNA.
  • a "transgenic organism,” as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art.
  • the nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus.
  • the term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule.
  • the transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, and plants and animals.
  • the isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.
  • a "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 25% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using BLASTN with the "BLAST 2 Sequences” tool Version 2.0.9 ( May-
  • Such a pair of nucleic acids may show, for example, at least 30%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length.
  • the variant may result in "conservative" amino acid changes which do not affect structural and/or chemical properties.
  • a variant may be described as, for example, an "allelic” (as defined above), “splice,” “species,” or “polymo ⁇ hic” variant.
  • a splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing.
  • the corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule.
  • Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other.
  • a polymo ⁇ hic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species.
  • Polymo ⁇ hic variants also may encompass "single nucleotide polymo ⁇ hisms" (SNPs) in which the polynucleotide sequence varies by one base.
  • SNPs single nucleotide polymo ⁇ hisms
  • the presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.
  • variants of the polynucleotides of the present invention may be generated through recombinant methods.
  • One possible method is a DNA shuffling technique such as MOLECULARBREEDENG (Maxygen Inc., Santa Clara CA; described in U.S. Patent Number 5,837,458; Chang, C-C. et al. (1999) Nat. Biotechnol.
  • DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening.
  • fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized.
  • fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.
  • a "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using BLASTP with the "BLAST 2 Sequences" tool Version 2.0.9 (May- 07-1999) set at default parameters.
  • Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length of one of the polypeptides.
  • cDNA sequences derived from human tissues and cell lines were aligned based on nucleotide sequence identity and assembled into "consensus" or "template” sequences which are designated by the template identification numbers (template EDs) in column 2 of Table 2.
  • template identification numbers SEQ ED NO:s
  • SEQ ED NO:s sequence identification numbers corresponding to the template EDs are shown in column 1.
  • the template sequences have similarity to GenBank sequences, or "hits,” as designated by the GI Numbers in column 3.
  • the statistical probability of each GenBank hit is indicated by a probability score in column 4, and the functional annotation corresponding to each GenBank hit is listed in column 5.
  • the invention inco ⁇ orates the nucleic acid sequences of these templates as disclosed in the Sequence Listing and the use of these sequences in the diagnosis and treatment of disease states characterized by defects in disease detection and treatment molecules.
  • the invention further utilizes these sequences in hybridization and amplification technologies, and in particular, in technologies which assess gene expression patterns correlated with specific cells or tissues and their responses in vivo or in vitro to pharmaceutical agents, toxins, and other treatments. In this manner, the sequences of the present invention are used to develop a transcript image for a particular cell or tissue.
  • cDNA was isolated from libraries constructed using RNA derived from normal and diseased human tissues and cell lines.
  • the human tissues and cell lines used for cDNA library construction were selected from a broad range of sources to provide a diverse population of cDNAs representative of gene transcription throughout the human body. Descriptions of the human tissues and cell lines used for cDNA library construction are provided in the LIFESEQ database (Incyte Genomics, Inc. (Incyte), Palo Alto CA).
  • Human tissues were broadly selected from, for example, cardiovascular, dermatologic, endocrine, gastrointestinal, hematopoietic/immune system, musculoskeletal, neural, reproductive, and urologic sources.
  • Cell lines used for cDNA library construction were derived from, for example, leukemic cells, teratocarcinomas, neuroepitheliomas, cervical carcinoma, lung fibroblasts, and endothelial cells. Such cell lines include, for example, THP-1, Jurkat, HUVEC, hNT2, WI38, HeLa, and other cell lines commonly used and available from public depositories (American Type Culture Collection, Manassas VA).
  • cell lines Prior to mRNA isolation, cell lines were untreated, treated with a pharmaceutical agent such as 5'-aza-2'-deoxycytidine, treated with an activating agent such as lipopolysaccharide in the case of leukocytic cell lines, or, in the case of endothelial cell lines, subjected to shear stress.
  • a pharmaceutical agent such as 5'-aza-2'-deoxycytidine
  • an activating agent such as lipopolysaccharide in the case of leukocytic cell lines, or, in the case of endothelial cell lines, subjected to shear stress.
  • Chain termination reaction products may be electrophoresed on urea- polyacrylamide gels and detected either by autoradiography (for radioisotope-labeled nucleotides) or by fluorescence (for fluorophore-labeled nucleotides).
  • Automated methods for mechanized reaction preparation, sequencing, and analysis using fluorescence detection methods have been developed.
  • Machines used to prepare cDNAs for sequencing can include the MICROLAB 2200 liquid transfer system (Hamilton Company (Hamilton), Reno NV), Peltier thermal cycler (PTC200; MJ Research, Inc.
  • Sequencing can be carried out using, for example, the ABI 373 or 377 (Applied Biosystems) or MEGABACE 1000 (Molecular Dynamics, Inc. (Molecular Dynamics), Sunnyvale CA) DNA sequencing systems, or other automated and manual sequencing systems well known in the art.
  • nucleotide sequences of the Sequence Listing have been prepared by current, state-of- the-art, automated methods and, as such, may contain occasional sequencing errors or unidentified nucleotides. Such unidentified nucleotides are designated by an N. These infrequent unidentified bases do not represent a hindrance to practicing the invention for those skilled in the art.
  • Several methods employing standard recombinant techniques may be used to correct errors and complete the missing sequence information. (See, e.g., those described in Ausubel, F.M. et al. (1997) Short Protocols in Molecular Biologv. John Wiley & Sons, New York NY; and Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY.)
  • Human polynucleotide sequences may be assembled using programs or algorithms well known in the art. Sequences to be assembled are related, wholly or in part, and may be derived from a single or many different transcripts. Assembly of the sequences can be performed using such programs as
  • cDNA sequences are used as "component” sequences that are assembled into “template” or “consensus” sequences as follows. Sequence chromatograms are processed, verified, and quality scores are obtained using PHRED. Raw sequences are edited using an editing pathway known as Block 1 (See, e.g., the LEFESEQ Assembled User Guide, Incyte Genomics, Palo Alto, CA).
  • RNA sequences are then loaded into a relational database management system (RDMS) which assigns edited sequences to existing templates, if available.
  • RDMS relational database management system
  • a process is initiated which modifies existing templates or creates new templates from works in progress (i.e., nonfinal assembled sequences) containing queued sequences or the sequences themselves.
  • the templates can be merged into bins. If multiple templates exist in one bin, the bin can be split and the templates reannotated.
  • bins are "clone joined" based upon clone information. Clone joining occurs when the 5' sequence of one clone is present in one bin and the 3' sequence from the same clone is present in a different bin, indicating that the two bins should be merged into a single bin. Only bins which share at least two different clones are merged.
  • a resultant template sequence may contain either a partial or a full length open reading frame, or all or part of a genetic regulatory element. This variation is due in part to the fact that the full length cDNAs of many genes are several hundred, and sometimes several thousand, bases in length. With current technology, cDNAs comprising the coding regions of large genes cannot be cloned because of vector limitations, incomplete reverse transcription of the mRNA, or incomplete "second strand" synthesis. Template sequences may be extended to include additional contiguous sequences derived from the parent RNA transcript using a variety of methods known to those of skill in the art. Extension may thus be used to achieve the full length coding sequence of a gene.
  • the cDNA sequences are analyzed using a variety of programs and algorithms which are well known in the art. (See, e.g., Ausubel, 1997, supra. Chapter 7.7; Meyers, R.A. (Ed.) (1995) Molecular Biology and Biotechnology. Wiley VCH, New York NY, pp. 856-853; and Table 8.) These analyses comprise both reading frame determinations, e.g., based on triplet codon periodicity for particular organisms (Fickett, J.W. (1982) Nucleic Acids Res. 10:5303-5318); analyses of potential start and stop codons; and homology searches.
  • Computer programs known to those of skill in the art for performing computer-assisted searches for amino acid and nucleic acid sequence similarity include, for example, Basic Local Alignment Search Tool (BLAST; Altschul, S.F. (1993) J. Mol. Evol. 36:290-300; Altschul, S.F. et al.
  • BLAST Basic Local Alignment Search Tool
  • BLAST is especially useful in determining exact matches and comparing two sequence fragments of arbitrary but equal lengths, whose alignment is locally maximal and for which the alignment score meets or exceeds a threshold or cutoff score set by the user
  • Protein hierarchies can be assigned to the putative encoded polypeptide based on, e.g., motif, BLAST, or biological analysis. Methods for assigning these hierarchies are described, for example, in
  • the mddt of the present invention may be used for a variety of diagnostic and therapeutic pu ⁇ oses.
  • an mddt may be used to diagnose a particular condition, disease, or disorder associated with disease detection and treatment molecules.
  • Such conditions, diseases, and disorders include, but are not limited to, a cell proliferative disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, a cancer of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis
  • the mddt can be used to detect the presence of, or to quantify the amount of, an mddt- related polynucleotide in a sample. This information is then compared to information obtained from appropriate reference samples, and a diagnosis is established.
  • a polynucleotide complementary to a given mddt can inhibit or inactivate a therapeutically relevant gene related to the mddt.
  • the expression of mddt may be routinely assessed by hybridization-based methods to determine, for example, the tissue-specificity, disease-specificity, or developmental stage-specificity of mddt expression.
  • the level of expression of mddt may be compared among different cell types or tissues, among diseased and normal cell types or tissues, among cell types or tissues at different developmental stages, or among cell types or tissues undergoing various treatments.
  • This type of analysis is useful, for example, to assess the relative levels of mddt expression in fully or partially differentiated cells or tissues, to determine if changes in mddt expression levels are correlated with the development or progression of specific disease states, and to assess the response of a cell or tissue to a specific therapy, for example, in pharmacological or toxicological studies.
  • Methods for the analysis of mddt expression are based on hybridization and amplification technologies and include membrane-based procedures such as northern blot analysis, high-throughput procedures that utilize, for example, microarrays, and PCR-based procedures.
  • the mddt, their fragments, or complementary sequences may be used to identify the presence of and/or to determine the degree of similarity between two (or more) nucleic acid sequences.
  • the mddt may be hybridized to naturally occurring or recombinant nucleic acid sequences under appropriately selected temperatures and salt concentrations.
  • Hybridization with a probe based on the nucleic acid sequence of at least one of the mddt allows for the detection of nucleic acid sequences, including genomic sequences, which are identical or related to the mddt of the Sequence Listing.
  • Probes may be selected from non-conserved or unique regions of at least one of the polynucleotides of SEQ ED NO: 1-396 and tested for their ability to identify or amplify the target nucleic acid sequence using standard protocols.
  • Polynucleotide sequences that are capable of hybridizing, in particular, to those shown in SEQ ED NO: 1-396 and fragments thereof, can be identified using various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) Methods Enzymol. 152:399-407; Kimmel, A.R. (1987) Methods Enzymol. 152:507-511.) Hybridization conditions are discussed in "Definitions.”
  • a probe for use in Southern or northern hybridization may be derived from a fragment of an mddt sequence, or its complement, that is up to several hundred nucleotides in length and is either single-stranded or double-stranded. Such probes may be hybridized in solution to biological materials such as plasmids, bacterial, yeast, or human artificial chromosomes, cleared or sectioned tissues, or to artificial substrates containing mddt. Microarrays are particularly suitable for identifying the presence of and detecting the level of expression for multiple genes of interest by examining gene expression correlated with, e.g., various stages of development, treatment with a drug or compound, or disease progression.
  • An array analogous to a dot or slot blot may be used to arrange and link polynucleotides to the surface of a substrate using one or more of the following: mechanical (vacuum), chemical, thermal, or UV bonding procedures.
  • Such an array may contain any number of mddt and may be produced by hand or by using available devices, materials, and machines.
  • Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad.
  • Probes may be labeled by either PCR or enzymatic techniques using a variety of commercially available reporter molecules.
  • commercial kits are available for radioactive and chemiluminescent labeling (Amersham Pharmacia Biotech) and for alkaline phosphatase labeling (Life Technologies).
  • mddt may be cloned into commercially available vectors for the production of RNA probes.
  • Such probes may be transcribed in the presence of at least one labeled nucleotide (e.g., 32 P-ATP, Amersham Pharmacia Biotech).
  • polynucleotides of SEQ ED NO: 1-396 or suitable fragments thereof can be used to isolate full length cDNA sequences utilizing hybridization and/or amplification procedures well known in the art, e.g., cDNA library screening, PCR amplification, etc.
  • the molecular cloning of such full length cDNA sequences may employ the method of cDNA library screening with probes using the hybridization, stringency, washing, and probing strategies described above and in Ausubel, supra. Chapters 3, 5, and 6.
  • These procedures may also be employed with genomic libraries to isolate genomic sequences of mddt in order to analyze, e.g., regulatory elements.
  • Gene identification and mapping are important in the investigation and treatment of almost all conditions, diseases, and disorders. Cancer, cardiovascular disease, Alzheimer's disease, arthritis, diabetes, and mental illnesses are of particular interest. Each of these conditions is more complex than the single gene defects of sickle cell anemia or cystic fibrosis, with select groups of genes being predictive of predisposition for a particular condition, disease, or disorder.
  • cardiovascular disease may result from malfunctioning receptor molecules that fail to clear cholesterol from the bloodstream, and diabetes may result when a particular individual's immune system is activated by an infection and attacks the insulin-producing cells of the pancreas.
  • Alzheimer's disease has been linked to a gene on chromosome 21; other studies predict a different gene and location.
  • Mapping of disease genes is a complex and reiterative process and generally proceeds from genetic linkage analysis to physical mapping.
  • a genetic linkage map traces parts of chromosomes that are inherited in the same pattern as the condition.
  • Statistics link the inheritance of particular conditions to particular regions of chromosomes, as defined by RFLP or other markers.
  • RFLP Radio Resource Linearity
  • markers and their locations are known from previous studies. More often, however, the markers are simply stretches of DNA that differ among individuals. Examples of genetic linkage maps can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMEM) World Wide Web site.
  • mddt sequences may be used to generate hybridization probes useful in chromosomal mapping of naturally occurring genomic sequences. Either coding or noncoding sequences of mddt may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of an mddt coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping.
  • sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial PI constructions, or single chromosome cDNA libraries.
  • HACs human artificial chromosomes
  • YACs yeast artificial chromosomes
  • BACs bacterial artificial chromosomes
  • PI constructions e.g., single chromosome cDNA libraries.
  • Fluorescent in situ hybridization may be correlated with other physical chromosome mapping techniques and genetic map data. (See, e.g., Meyers, supra, pp. 965-968.) Correlation between the location of mddt on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder.
  • the mddt sequences may also be used to detect polymo ⁇ hisms that are genetically linked to the inheritance of a particular condition, disease, or disorder.
  • In situ hybridization of chromosomal preparations and genetic mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending existing genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of the corresponding human chromosome is not known.
  • These new marker sequences can be mapped to human chromosomes and may provide valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques.
  • any sequences mapping to that area may represent associated or regulatory genes for further investigation.
  • the nucleotide sequences of the subject invention may also be used to detect differences in chromosomal architecture due to translocation, inversion, etc., among normal, carrier, or affected individuals.
  • a disease-associated gene is mapped to a chromosomal region, the gene must be cloned in order to identify mutations or other alterations (e.g., translocations or inversions) that may be correlated with disease.
  • This process requires a physical map of the chromosomal region containing the disease-gene of interest along with associated markers. A physical map is necessary for determining the nucleotide sequence of and order of marker genes on a particular chromosomal region. Physical mapping techniques are well known in the art and require the generation of overlapping sets of cloned DNA fragments from a particular organelle, chromosome, or genome. These clones are analyzed to reconstruct and catalog their order. Once the position of a marker is determined, the DNA from that region is obtained by consulting the catalog and selecting clones from that region. The gene of interest is located through positional cloning techniques using hybridization or similar methods.
  • the mddt of the present invention may be used to design probes useful in diagnostic assays. Such assays, well known to those skilled in the art, may be used to detect or confirm conditions, disorders, or diseases associated with abnormal levels of mddt expression. Labeled probes developed from mddt sequences are added to a sample under hybridizing conditions of desired stringency. In some instances, mddt, or fragments or oligonucleotides derived from mddt, may be used as primers in amplification steps prior to hybridization. The amount of hybridization complex formed is quantified and compared with standards for that cell or tissue. If mddt expression varies significantly from the standard, the assay indicates the presence of the condition, disorder, or disease.
  • Qualitative or quantitative diagnostic methods may include northern, dot blot, or other membrane or dip-stick based technologies or multiple-sample format technologies such as PCR, enzyme-linked immunosorbent assay (ELISA)-like, pin, or chip-based assays.
  • PCR enzyme-linked immunosorbent assay
  • the probes described above may also be used to monitor the progress of conditions, disorders, or diseases associated with abnormal levels of mddt expression, or to evaluate the efficacy of a particular therapeutic treatment.
  • the candidate probe may be identified from the mddt that are specific to a given human tissue and have not been observed in GenBank or other genome databases. Such a probe may be used in animal studies, preclinical tests, clinical trials, or in monitoring the treatment of an individual patient.
  • standard expression is established by methods well known in the art for use as a basis of comparison, samples from patients affected by the disorder or disease are combined with the probe to evaluate any deviation from the standard profile, and a therapeutic agent is administered and effects are monitored to generate a treatment profile. Efficacy is evaluated by determining whether the expression progresses toward or returns to the standard normal pattern. Treatment profiles may be generated over a period of several days or several months. Statistical methods well known to those skilled in the art may be use to determine the significance of such therapeutic agents.
  • the polynucleotides are also useful for identifying individuals from minute biological samples, for example, by matching the RFLP pattern of a sample's DNA to that of an individual's DNA.
  • the polynucleotides of the present invention can also be used to determine the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, an individual can be identified through a unique set of DNA sequences. Once a unique ID database is established for an individual, positive identification of that individual can be made from extremely small tissue samples.
  • oligonucleotide primers derived from the mddt of the invention may be used to detect single nucleotide polymo ⁇ hisms (SNPs).
  • SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans.
  • Methods of SNP detection include, but are not limited to, single-stranded conformation polymo ⁇ hism (SSCP) and fluorescent SSCP (fSSCP) methods.
  • SSCP single-stranded conformation polymo ⁇ hism
  • fSSCP fluorescent SSCP
  • oligonucleotide primers derived from mddt are used to amplify DNA using the polymerase chain reaction (PCR).
  • the DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like.
  • SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels.
  • the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high- throughput equipment such as DNA sequencing machines.
  • sequence database analysis methods termed in silico SNP (isSNP) are capable of identifying polymo ⁇ hisms by comparing the sequences of individual overlapping DNA fragments which assemble into a common consensus sequence.
  • DNA-based identification techniques are critical in forensic technology. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, etc., can be amplified using, e.g., PCR, to identify individuals. (See, e.g., Erlich, H. (1992) PCR Technology, Freeman and Co., New York, NY). Similarly, polynucleotides of the present invention can be used as polymo ⁇ hic markers.
  • reagents capable of identifying the source of a particular tissue.
  • Appropriate reagents can comprise, for example, DNA probes or primers prepared from the sequences of the present invention that are specific for particular tissues. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.
  • the polynucleotides of the present invention can also be used as molecular weight markers on nucleic acid gels or Southern blots, as diagnostic probes for the presence of a specific mRNA in a particular cell type, in the creation of subtracted cDNA libraries which aid in the discovery of novel polynucleotides, in selection and synthesis of oligomers for attachment to an array or other support, and as an antigen to elicit an immune response.
  • Disease Model Systems Using mddt The mddt of the invention or their mammalian homologs may be "knocked out" in an animal model system using homologous recombination in embryonic stem (ES) cells.
  • mouse ES cells such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture.
  • the ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M.R. (1989) Science 244:1288-1292).
  • a marker gene e.g., the neomycin phosphotransferase gene (neo; Capecchi, M.R. (1989) Science 244:1288-1292).
  • the vector integrates into the corresponding region of the host genome by homologous recombination.
  • homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999- 2002; Wagner, K.U. et al. (1997) Nucleic Acids Res. 25:4323-4330).
  • Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain.
  • the blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.
  • the mddt of the invention may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al. (1998)
  • the mddt of the invention can also be used to create "knockin" humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of mddt is injected into animal ES cells, and the injected sequence integrates into the animal cell genome.
  • Transformed cells are injected into blastulae, and the blastulae are implanted as described above.
  • Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease.
  • a mammal inbred to overexpress mddt resulting, e.g., in the secretion of MDDT in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).
  • Screening Assays MDDT encoded by polynucleotides of the present invention may be used to screen for molecules that bind to or are bound by the encoded polypeptides.
  • the binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the bound molecule.
  • Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.
  • the molecule is closely related to the natural ligand of the polypeptide, e.g., a ligand or fragment thereof, a natural substrate, or a structural or functional mimetic.
  • the molecule can be closely related to the natural receptor to which the polypeptide binds, or to at least a fragment of the receptor, e.g., the active site. In either case, the molecule can be rationally designed using known techniques.
  • the screening for these molecules involves producing appropriate cells which express the polypepti e, e t er as a secreted protein or on the cell membrane.
  • Preferred cells include cells from mammals, yeast, Drosophila. or E. coli.
  • Cells expressing the polypeptide or cell membrane fractions which contain the expressed polypeptide are then contacted with a test compound and binding, stimulation, or inhibition of activity of either the polypeptide or the molecule is analyzed.
  • An assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. Alternatively, the assay may assess binding in the presence of a labeled competitor.
  • the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures.
  • the assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.
  • an ELISA assay using, e.g., a monoclonal or polyclonal antibody can measure polypeptide level in a sample.
  • the antibody can measure polypeptide level by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.
  • All of the above assays can be used in a diagnostic or prognostic context.
  • the molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule.
  • the assays can discover agents which may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues.
  • a transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent Number 5,840,484, expressly inco ⁇ orated by reference herein.)
  • a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type.
  • the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray.
  • the resultant transcript image would provide a profile of gene activity pertaining to disease detection and treatment molecules.
  • Transcript images which profile mddt expression may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples.
  • the transcript image may thus reflect mddt expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.
  • Transcript images which profile mddt expression may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular finge ⁇ rints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E. F. et al. (1999) Mol. Carcinog. 24:153- 159; Steiner, S. and Anderson, N. L. (2000) Toxicol. Lett. 112-113:467-71, expressly inco ⁇ orated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties.
  • finge ⁇ rints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome- wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in inte ⁇ retation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity.
  • the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound.
  • Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified.
  • the transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.
  • proteome refers to the global pattern of protein expression in a particular tissue or cell type.
  • proteome expression patterns, or profiles are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time.
  • a profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type.
  • the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, supra).
  • the proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains.
  • the optical density of each protein spot is generally proportional to the level of the protein in the sample.
  • the optical densities of equivalently positioned protein spots from different samples for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment.
  • the proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry.
  • the identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.
  • a proteomic profile may also be generated using antibodies specific for MDDT to quantify the levels of MDDT expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) Anal. Biochem.
  • Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.
  • Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level.
  • There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N. L. and Seilhamer, J. (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile.
  • the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.
  • the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound.
  • Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified.
  • the amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.
  • Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the MDDT encoded by polynucleotides of the present invention.
  • the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the MDDT encoded by polynucleotides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Transcript images may be used to profile mddt expression in distinct tissue types. This process can be used to determine disease detection and treatment molecule activity in a particular tissue type relative to this activity in a different tissue type.
  • Transcript images may be used to generate a profile of mddt expression characteristic of diseased tissue.
  • Transcript images of tissues before and after treatment may be used for diagnostic pu ⁇ oses, to monitor the progression of disease, and to monitor the efficacy of drug treatments for diseases which affect the activity of disease detection and treatment molecules.
  • Transcript images of cell lines can be used to assess disease detection and treatment molecule activity and/or to identify cell lines that lack or misregulate this activity. Such cell lines may then be treated with pharmaceutical agents, and a transcript image following treatment may indicate the efficacy of these agents in restoring desired levels of this activity. A similar approach may be used to assess the toxicity of pharmaceutical agents as reflected by undesirable changes in disease detection and treatment molecule activity. Candidate pharmaceutical agents may be evaluated by comparing their associated transcript images with those of pharmaceutical agents of known effectiveness.
  • the polynucleotides of the present invention are useful in antisense technology.
  • Antisense technology or therapy relies on the modulation of expression of a target protein through the specific binding of an antisense sequence to a target sequence encoding the target protein or directing its expression.
  • Agrawal, S., ed. 1996 Antisense Therapeutics, Humana Press Inc., Totawa NJ; Alama, A. et al. (1997) Pharmacol. Res. 36(3):171-178; Crooke, S.T. (1997) Adv. Pharmacol. 40:1-49; Sharma, H.W. and R. Narayanan (1995) Bioessays 17(12):1055-1063; and Lavrosky, Y.
  • An antisense sequence is a polynucleotide sequence capable of specifically hybridizing to at least a portion of the target sequence. Antisense sequences bind to cellular mRNA and/or genomic DNA, affecting translation and/or transcription. Antisense sequences can be DNA, RNA, or nucleic acid mimics and analogs. (See, e.g., Rossi, J.J. et al. (1991) Antisense Res. Dev. l(3):285-288; Lee, R. et al. (1998) Biochemistry 37(3):900-1010; Pardridge,
  • the binding which results in modulation of expression occurs through hybridization or binding of complementary base pairs.
  • Antisense sequences can also bind to DNA duplexes through specific interactions in the major groove of the double helix.
  • polynucleotides of the present invention and fragments thereof can be used as antisense sequences to modify the expression of the polypeptide encoded by mddt.
  • the antisense sequences can be produced ex vivo, such as by using any of the ABI nucleic acid synthesizer series (Applied
  • Antisense sequences can also be produced biologically, such as by transforming an appropriate host cell with an expression vector containing the sequence of interest. (See, e.g., Agrawal, supra.)
  • Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein.
  • Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors.
  • the nucleotide sequences encoding MDDT or fragments thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host.
  • an appropriate expression vector i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host.
  • Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding MDDT and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, supra. Chapters 4, 8, 16, and 17; and Ausubel, supra. Chapters 9, 10, 13, and 16.)
  • a variety of expression vector/host systems may be utilized to contain and express sequences encoding MDDT. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal (mammalian) cell systems.
  • microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors
  • yeast transformed with yeast expression vectors insect cell systems infected with viral expression vectors (e.g., baculovirus)
  • plant cell systems transformed with viral expression vectors e.g., cauliflower mosaic virus
  • Expression vectors derived from retroviruses, adenoviruses, or he ⁇ es or vaccinia viruses, or from various bacterial plasmids may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population.
  • sequences encoding MDDT can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Any number of selection systems may be used to recover transformed cell lines.
  • the mddt of the invention may be used for somatic or germline gene therapy.
  • Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCED)-Xl disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) Science 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R.M. et al. (1995) Science 270:475-480; Bordignon, C et al. (1995) Science 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) Cell 75:207-
  • a genetic deficiency e.g., in the cases of severe combined immunodeficiency (SCED)-Xl disease characterized by X-linked inheritance (Cavazza
  • HBV hepatitis B or C virus
  • fungal parasites such as Candida albicans and Paracoccidioides brasiliensis
  • protozoan parasites such as
  • mddt Plasmodium falciparum and Trvpanosoma cruzi.
  • the expression of mddt from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.
  • diseases or disorders caused by deficiencies in mddt are treated by constructing mammalian expression vectors comprising mddt and introducing these vectors by mechanical means into mddt-deficient cells.
  • Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and Anderson, W.F. (1993) Annu. Rev. Biochem. 62:191- 217; Ivies, Z. (1997) Cell 91:501-510; Boulay, J-L. and Recipon, H. (1998) Curr. Opin. Biotechnol. 9:445-450).
  • Expression vectors that may be effective for the expression of mddt include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA).
  • the mddt of the invention may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or ⁇ -actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and Bujard, H. (1992) Proc. Natl. Acad. Sci. U.S.A. 89:5547-5551; Gossen, M. et al., (1995) Science 268:1766-1769; Rossi, F.M.V. and Blau, H.M.
  • a constitutively active promoter e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or ⁇ -actin genes
  • TRANSFECTION KIT available from Invitrogen
  • transformation is performed using the calcium phosphate method (Graham, F.L. and Eb, A.J. (1973) Virology 52:456-467), or by electroporation (Neumann, E. et al.
  • diseases or disorders caused by genetic defects with respect to mddt expression are treated by constructing a retrovirus vector consisting of (i) mddt under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus s-acting RNA sequences and coding sequences required for efficient vector propagation.
  • Retrovirus vectors e.g., PFB and PFBNEO
  • Retrovirus vectors are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc. Natl. Acad. Sci. U.S.A.
  • the vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) J. Virol. 61:1647-1650; Bender, M.A. et al. (1987) J. Virol. 61:1639-1646; Adam, M.A. and Miller, A.D. (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol. 72:8463-8471; Zufferey, R. et al.
  • VSVg vector producing cell line
  • U.S. Patent Number 5,910,434 to Rigg discloses a method for obtaining retrovirus packaging cell lines and is hereby inco ⁇ orated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4 + T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al.
  • an adenovirus-based gene therapy delivery system is used to deliver mddt to cells which have one or more genetic abnormalities with respect to the expression of mddt.
  • the construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M.E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent Number 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby inco ⁇ orated by reference.
  • a he ⁇ es-based, gene therapy delivery system is used to deliver mddt to target cells which have one or more genetic abnormalities with respect to the expression of mddt.
  • HSV he ⁇ es simplex virus
  • the use of he ⁇ es simplex virus (HSV)-based vectors may be especially valuable for introducing mddt to cells of the central nervous system, for which HSV has a tropism.
  • the construction and packaging of he ⁇ es-based vectors are well known to those with ordinary skill in the art.
  • a replication-competent he ⁇ es simplex virus (HSV) type 1 -based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) Exp.
  • HSV-1 virus vector has also been disclosed in detail in U.S. Patent Number 5,804,413 to DeLuca ("He ⁇ es simplex virus strains for gene transfer"), which is hereby inco ⁇ orated by reference.
  • U.S. Patent Number 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for pu ⁇ oses including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22.
  • HSV vectors see also Goins, W. F. et al.
  • an alphavirus (positive, single-stranded RNA virus) vector is used to deliver mddt to target cells.
  • SFV Semliki Forest Virus
  • RNA replicates to higher levels than the full-length genomic RNA, resulting in the ove ⁇ roduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase).
  • enzymatic activity e.g., protease and polymerase.
  • inserting mddt into the alphavirus genome in place of the capsid-coding region results in the production of a large number of mddt RNAs and the synthesis of high levels of MDDT in vector transduced cells.
  • alphavirus infection is typically associated with cell lysis within a few days
  • the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SEN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) Virology 228:74-83).
  • the wide host range of alphaviruses will allow the introduction of mddt into a variety of cell types.
  • the specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction.
  • the methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.
  • Anti-MDDT antibodies may be used to analyze protein expression levels. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, and Fab fragments. For descriptions of and protocols of antibody technologies, see, e.g., Pound J.D. (1998) Immunochemical Protocols, Humana Press, Totowa, NJ. The amino acid sequence encoded by the mddt of the Sequence Listing may be analyzed by appropriate software (e.g., LASERGENE NAVIGATOR software, DNASTAR) to determine regions of high immunogenicity.
  • appropriate software e.g., LASERGENE NAVIGATOR software, DNASTAR
  • the optimal sequences for immunization are selected from the C- terminus, the N-terminus, and those intervening, hydrophilic regions of the polypeptide which are likely to be exposed to the external environment when the polypeptide is in its natural conformation. Analysis used to select appropriate epitopes is also described by Ausubel (1997, supra. Chapter 11.7). Peptides used for antibody induction do not need to have biological activity; however, they must be antigenic. Peptides used to induce specific antibodies may have an amino acid sequence consisting of at least five amino acids, preferably at least 10 amino acids, and most preferably at least 15 amino acids.
  • a peptide which mimics an antigenic fragment of the natural polypeptide may be fused with another protein such as keyhole hemolimpet cyanin (KLH; Sigma, St. Louis MO) for antibody production.
  • KLH keyhole hemolimpet cyanin
  • a peptide encompassing an antigenic region may be expressed from an mddt, synthesized as described above, or purified from human cells.
  • mice, goats, and rabbits may be immunized by injection with a peptide.
  • various adjuvants may be used to increase immunological response.
  • peptides about 15 residues in length may be synthesized using an ABI 431 A peptide synthesizer (Applied Biosystems) using fmoc -chemistry and coupled to KLH (Sigma) by reaction with M-maleimidobenzoyl-N-hydroxysuccinimide ester (Ausubel, 1995, supra).
  • Rabbits are immunized with the peptide-KLH complex in complete Freund's adjuvant.
  • the resulting antisera are tested for antipeptide activity by binding the peptide to plastic, blocking with 1% bovine serum albumin (BSA), reacting with rabbit antisera, washing, and reacting with radioiodinated goat anti-rabbit IgG.
  • Antisera with antipeptide activity are tested for anti-MDDT activity using protocols well known in the art, including ELISA, radioimmunoassay (RIA), and immunoblotting.
  • isolated and purified peptide may be used to immunize mice (about 100 ⁇ g of peptide) or rabbits (about 1 mg of peptide). Subsequently, the peptide is radioiodinated and used to screen the immunized animals' B-lymphocytes for production of antipeptide antibodies. Positive cells are then used to produce hybridomas using standard techniques. About 20 mg of peptide is sufficient for labeling and screening several thousand clones. Hybridomas of interest are detected by screening with radioiodinated peptide to identify those fusions producing peptide-specific monoclonal antibody.
  • wells of a multi-well plate (FAST, Becton-Dickinson, Palo Alto, CA) are coated with affinity-purified, specific rabbit-anti-mouse (or suitable anti-species IgG) antibodies at
  • the coated wells are blocked with 1% BSA and washed and exposed to supernatants from hybridomas. After incubation, the wells are exposed to radiolabeled peptide at 1 mg/ml.
  • Clones producing antibodies bind a quantity of labeled peptide that is detectable above background. Such clones are expanded and subjected to 2 cycles of cloning. Cloned hybridomas are injected into pristane-treated mice to produce ascites, and monoclonal antibody is purified from the ascitic fluid by affinity chromatography on protein A (Amersham Pharmacia Biotech). Several procedures for the production of monoclonal antibodies, including in vitro production, are described in Pound (supra). Monoclonal antibodies with antipeptide activity are tested for anti-MDDT activity using protocols well known in the art, including ELISA, RIA, and immunoblotting.
  • Antibody fragments containing specific binding sites for an epitope may also be generated.
  • such fragments include, but are not limited to, the F(ab')2 fragments produced by pepsin digestion of the antibody molecule, and the Fab fragments generated by reducing the disulfide bridges of the F(ab')2 fragments.
  • construction of Fab expression libraries in filamentous bacteriophage allows rapid and easy identification of monoclonal fragments with desired specificity (Pound, supra. Chaps. 45-47).
  • Antibodies generated against polypeptide encoded by mddt can be used to purify and characterize full-length MDDT protein and its activity, binding partners, etc.
  • Anti-MDDT antibodies may be used in assays to quantify the amount of MDDT found in a particular human cell. Such assays include methods utilizing the antibody and a label to detect expression level under normal or disease conditions.
  • the peptides and antibodies of the invention may be used with or without modification or labeled by joining them, either covalently or noncovalently, with a reporter molecule. Protocols for detecting and measuring protein expression using either polyclonal or monoclonal antibodies are well known in the art. Examples include ELISA, RIA, and fluorescent activated cell sorting (FACS).
  • Such immunoassays typically involve the formation of complexes between the MDDT and its specific antibody and the measurement of such complexes.
  • RNA was purchased from CLONTECH Laboratories, Inc. (Palo Alto CA) or isolated from various tissues. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated with either isopropanol or sodium acetate and ethanol, or by other routine methods.
  • RNA was provided with RNA and constructed the corresponding cDNA libraries.
  • cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene Cloning Systems, Inc. (Stratagene), La Jolla CA) or SUPERSCRIPT plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra. Chapters 5.1 through 6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes.
  • the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis.
  • cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad CA), PBK-CMV plasmid (Stratagene), PCR2-TOPOTA plasmid (Invitrogen), PCMV-ICIS plasmid (Stratagene), pIGEN (Incyte Genomics, Palo Alto CA), pRARE (Incyte Genomics), or pENCY (Incyte Genomics), or derivatives thereof.
  • Recombinant plasmids were transformed into competent E. coli cells including XLl-Blue, XLl-BlueMRF, or SOLR from Stratagene or DH5 ⁇ , DH10B, or ElectroMAX DH10B from Life Technologies.
  • Plasmids were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: the Magic or WIZARD Minipreps DNA purification system (Promega); the AGTC Miniprep purification kit (Edge BioSystems, Gaithersburg MD); and the QIAWELL 8, QIAWELL 8 Plus, and QIAWELL 8 Ultra plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit (QIAGEN).
  • plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format.
  • Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Inc. (Molecular Probes), Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).
  • cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGAB ACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra. Chapter 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.
  • Component sequences from chromatograms were subject to PHRED analysis and assigned a quality score.
  • the sequences having at least a required quality score were subject to various preprocessing editing pathways to eliminate, e.g., low quality 3' ends, vector and linker sequences, polyA tails, Alu repeats, mitochondrial and ribosomal sequences, bacterial contamination sequences, and sequences smaller than 50 base pairs.
  • low-information sequences and repetitive elements e.g., dinucleotide repeats, Alu repeats, etc.
  • sequences were then subject to assembly procedures in which the sequences were assigned to gene bins (bins). Each sequence could only belong to one bin. Sequences in each gene bin were assembled to produce consensus sequences (templates). Subsequent new sequences were added to existing bins using BLASTN (v.1.4 WashU) and CROSSMATCH. Candidate pairs were identified as all BLAST hits having a quality score greater than or equal to 150. Alignments of at least 82% local identity were accepted into the bin. The component sequences from each bin were assembled using a version of PHRAP. Bins with several overlapping component sequences were assembled using DEEP PHRAP. The orientation (sense or antisense) of each assembled template was determined based on the number and orientation of its component sequences.
  • Template sequences as disclosed in the sequence listing correspond to sense strand sequences (the "forward" reading frames), to the best determination.
  • the complementary (antisense) strands are inherently disclosed herein.
  • the component sequences which were used to assemble each template consensus sequence are listed in Table 5, along with their positions along the template nucleotide sequences.
  • Bins were compared against each other and those having local similarity of at least 82% were combined and reassembled. Reassembled bins having templates of insufficient overlap (less than 95% local identity) were re-split. Assembled templates were also subject to analysis by STITCHER/EXON MAPPER algorithms which analyze the probabilities of the presence of splice variants, alternatively spliced exons, splice junctions, differential expression of alternative spliced genes across tissue types or disease states, etc. These resulting bins were subject to several rounds of the above assembly procedures.
  • bins were clone joined based upon clone information. If the 5' sequence of one clone was present in one bin and the 3' sequence from the same clone was present in a different bin, it was likely that the two bins actually belonged together in a single bin.
  • the resulting combined bins underwent assembly procedures to regenerate the consensus sequences.
  • the final assembled templates were subsequently annotated using the following procedure.
  • Patent Number 6,023,659 "Relational Database for Storing Biomolecule Information," U.S.S.N. 08/947,845, filed October 9, 1997; "Project-Based Full-Length Biomolecular Sequence Database,” U.S. Patent Number 5,953,727, filed March 6, 1997; and "Relational Database and System for Storing Information Relating to Biomolecular Sequences," U.S.S.N. 09/034,807, filed March 4, 1998, all of which are inco ⁇ orated by reference herein.
  • the template sequences were further analyzed by translating each template in all three forward reading frames and searching each translation against the Pfam database of hidden Markov model-based protein families and domains using the HMMER software package (available to the public from Washington University School of Medicine, St. Louis MO). Regions of templates which, when translated, contain similarity to Pfam consensus sequences are reported in Table 3, along with descriptions of Pfam protein domains and families. Only those Pfam hits with an E-value of ⁇ 1 x 10 '3 are reported. (See also World Wide Web site http://pfam.wustl.edu/ for detailed descriptions of Pfam protein domains and families.)
  • the template sequences were translated in all three forward reading frames, and each translation was searched against hidden Markov models for signal peptides using the HMMER software package. Construction of hidden Markov models and their usage in sequence analysis has been described. (See, for example, Eddy, S.R. (1996) Curr. Opin. Str. Biol. 6:361-365.) Only those signal peptide hits with a cutoff score of 11 bits or greater are reported. A cutoff score of 11 bits or greater corresponds to at least about 91-94% true-positives in signal peptide prediction.
  • Template sequences were also translated in all three forward reading frames, and each translation was searched against TMHMMER, a program that uses a hidden Markov model (HMM) to delineate transmembrane segments on protein sequences and determine orientation (Sonnhammer, E.L. et al. (1 Proc. xt nt . Con . n ntelligent Systems for Mol. Biol., Glasgow et al., eds., The Am.
  • HMM hidden Markov model
  • BLAST analysis as reported in Table 2 or may suggest alternative or additional properties of template- encoded polypeptides not previously uncovered by BLAST or other analyses.
  • Template sequences are further analyzed using the bioinformatics tools listed in Table 8, or using sequence analysis software known in the art such as MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR).
  • sequence analysis software known in the art such as MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR).
  • Template sequences may be further queried against public databases such as the GenBank rodent, mammalian, vertebrate, prokaryote, and eukaryote databases.
  • polypeptide sequences were translated to derive the corresponding longest open reading frame as presented by the polypeptide sequences as reported in Table 7.
  • a polypeptide of the invention may begin at any of the methionine residues within the full length translated polypeptide.
  • Polypeptide sequences were subsequently analyzed by querying against the GenBank protein database (GENPEPT, (GenBank version 128)).
  • Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR).
  • Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as inco ⁇ orated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.
  • Table 7 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (GENPEPT) database.
  • Column 1 shows the polypeptide sequence identification number (SEQ TD NO:) for the polypeptide segments of the invention.
  • Column 2 shows the reading frame used in the translation of the polynucleotide sequences encoding the polypeptide segments.
  • Column 3 shows the length of the translated polypeptide segments.
  • Columns 4 and 5 show the start and stop nucleotide positions of the polynucleotide sequences encoding the polypeptide segments.
  • Column 6 shows the GenBank identification number (GI Number) of the nearest GenBank homolog.
  • Column 7 shows the probability score for the match between each polypeptide and its GenBank homolog.
  • the product score takes into account both the degree of similarity between two sequences and the length of the sequence match.
  • the product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences).
  • the BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score.
  • the product score represents a balance between fractional overlap and quality in a BLAST alignment.
  • a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared.
  • a product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other.
  • a product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.
  • a tissue distribution profile is determined for each template by compiling the cDNA library tissue classifications of its component cDNA sequences.
  • Each component sequence is derived from a cDNA library constructed from a human tissue.
  • Each human tissue is classified into one of the following categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract.
  • Template sequences, component sequences, and cDNA library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA).
  • Table 6 shows the tissue distribution profile for the templates of the invention. For each template, the three most frequently observed tissue categories are shown in column 3, along with the percentage of component sequences belonging to each category. Only tissue categories with percentage values of ⁇ 10% are shown. A tissue distribution of "widely distributed" in column 3 indicates percentage values of ⁇ 10% in all tissue categories.
  • Transcript images are generated as described in Seilhamer et al., "Comparative Gene
  • Oligonucleotide primers designed using an mddt of the Sequence Listing are used to extend the nucleic acid sequence.
  • One primer is synthesized to initiate 5' extension of the template, and the other primer, to initiate 3' extension of the template.
  • the initial primers may be designed using OLIGO 4.06 software (National Biosciences, Inc. (National Biosciences), Plymouth MN), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68 °C to about 72 °C Any stretch of nucleotides which would result in hahpin structures and primer-primer dimerizations are avoided.
  • Selected human cDNA libraries are used to extend the sequence. If more than one extension is necessary or desired, additional or nested sets of primers are designed.
  • PCR is performed in 96-well plates using the PTC-200 thermal cycler (MJ Research).
  • the reaction mix contains DNA template, 200 nmol of each primer, reaction buffer containing Mg 2+ , (NH 4 ) 2 S0 4 , and ⁇ - mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68 °C, 5 min; Step 7: storage at 4°C
  • the parameters for primer pair T7 and SK+ are as follows: Step 1: 94°C, 3 min; Step 2: 94°C,
  • the concentration of DNA in each well is determined by dispensing 100 ⁇ l PICOGREEN quantitation reagent (0.25% (v/v); Molecular Probes) dissolved in IX Tris-EDTA (TE) and 0.5 ⁇ l of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Inco ⁇ orated (Corning), Corning NY), allowing the DNA to bind to the reagent.
  • the plate is scanned in a FLUOROSKAN II
  • a 5 ⁇ l to 10 ⁇ l aliquot of the reaction mixture is analyzed by electrophoresis on a 1 % agarose mini-gel to determine which reactions are successful in extending the sequence.
  • the extended nucleotides are desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech).
  • the digested nucleotides are separated on low concentration (0.6 to 0.8%) agarose gels, fragments are excised, and agar digested with AGAR ACE (Promega).
  • Extended clones are religated using T4 ligase (New England Biolabs, Inc., Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent E. coli cells. Transformed cells are selected on antibiotic -containing media, individual colonies are picked and cultured overnight at 37 °C in 384-well plates in LB/2x carbenicillin liquid media. The cells are lysed, and DNA is amplified by PCR using Taq DNA polymerase (Amersham
  • Step 1 94°C, 3 min
  • Step 2 94°C, 15 sec
  • Step 3 60°C, 1 min
  • Step 4 72°C, 2 min
  • Step 5 steps 2, 3, and 4 repeated 29 times
  • Step 6 72°C, 5 min
  • Step 7 storage at 4°C DNA is quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries are reamplified using the same conditions as described above.
  • Samples are diluted with 20% dimethysulf oxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).
  • the mddt is used to obtain regulatory sequences (promoters, introns, and enhancers) using the procedure above, oligonucleotides designed for such extension, and an appropriate genomic library.
  • Hybridization probes derived from the mddt of the Sequence Listing are employed for screening cDNAs, mRNAs, or genomic DNA.
  • the labeling of probe nucleotides between 100 and 1000 nucleotides in length is specifically described, but essentially the same procedure may be used with larger cDNA fragments.
  • Probe sequences are labeled at room temperature for 30 minutes using a T4 polynucleotide kinase, ⁇ 32 P-ATP, and 0.5X One-Phor-All Plus (Amersham Pharmacia Biotech) buffer and purified using a ProbeQuant G-50 Microcolumn (Amersham Pharmacia Biotech).
  • the probe mixture s i uted to IO dpm/ ⁇ g/ml hybridization buffer and used in a typical membrane-based hybridization analysis.
  • the DNA is digested with a restriction endonuclease such as Eco RV and is electrophoresed through a 0.7% agarose gel.
  • the DNA fragments are transferred from the agarose to nylon membrane (NYTRAN Plus, Schleicher & Schuell, Inc., Keene NH) using procedures specified by the manufacturer of the membrane. Prehybridization is carried out for three or more hours at 68 °C, and hybridization is carried out overnight at 68 °C. To remove non-specific signals, blots are sequentially washed at room temperature under increasingly stringent conditions, up to 0.1 x saline sodium citrate
  • RNA samples are placed in a PHOSPHOREMAGER cassette (Molecular Dynamics) or are exposed to autoradiography film, hybridization patterns of standard and experimental lanes are compared. Essentially the same procedure is employed when screening RNA.
  • SEQ ED NO: 1-396 are described as ranges, or intervals, of human chromosomes.
  • the map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm.
  • centiMorgan is a unit of measurement based on recombination frequencies between chromosomal markers.
  • cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.
  • Mb megabase
  • the cM distances are based on genetic markers mapped by Genethon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters.
  • Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and polyA + RNA is purified using the oligo (dT) cellulose method.
  • Each polyA + RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/ ⁇ l oligo-dT primer (21mer), IX first strand buffer, 0.03 units/ ⁇ l RNase inhibitor, 500 ⁇ M dATP, 500 ⁇ M dGTP, 500 ⁇ M dTTP, 40 ⁇ M dCTP, 40 ⁇ M dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech).
  • the reverse transcription reaction is performed in a 25 ml volume containing 200 ng polyA + RNA with GEMBRIGHT kits (Incyte).
  • Specific control polyA + RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA (W. Lei, unpublished). As quantitative controls, the control mRNAs at 0.002 ng,
  • 0.02 ng, 0.2 ng, and 2 ng are diluted into reverse transcription reaction at ratios of 1:100,000, 1:10,000,
  • each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85° C to the stop the reaction and degrade the RNA.
  • Probes are purified using two successive CHROMA SPEN 30 gel filtration spin columns (CLONTECH Laboratories, Inc.
  • reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol.
  • the probe is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and resuspended in 14 ⁇ l 5X SSC/0.2% SDS.
  • Microarray Preparation Sequences of the present invention are used to generate array elements.
  • Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts.
  • PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert.
  • Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 ⁇ g.
  • Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech). Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments.
  • Array elements are applied to the coated glass substrate using a procedure described in US Patent No. 5,807,522, inco ⁇ orated herein by reference.
  • 1 ⁇ l of the array element DNA is loaded into the open capillary printing element by a high-speed robotic apparatus.
  • the apparatus then deposits about 5 nl of array element sample per slide.
  • Microarrays are UV-crosslinked using a STRATALENKER UV-crosslinker (Stratagene).
  • Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford, MA) for 30 minutes at 60° C followed by washes in 0.2% SDS and distilled water as before.
  • PBS phosphate buffered saline
  • Hybridization reactions contain 9 ⁇ l of probe mixture consisting of 0.2 ⁇ g each of Cy3 and Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer.
  • the probe mixture is heated to 65° C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm 2 coverslip.
  • the arrays are transferred to a wate ⁇ roof chamber having a cavity just slightly larger than a microscope slide.
  • the chamber is kept at 100% humidity internally by the addition of 140 ⁇ l of 5x SSC in a corner of the chamber.
  • the chamber containing the arrays is incubated for about 6.5 hours at 60° C.
  • the arrays are washed for 10 min at 45° C in a first wash buffer (IX SSC, 0.1% SDS), three times for 10 minutes each at 45°C in a second wash buffer (0.1X SSC), and dried.
  • Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5.
  • the excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY).
  • the slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster- scanned past the objective.
  • the 1.8 cm x 1.8 cm array used in the present example is scanned with a resolution of 20 micrometers. In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially.
  • Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores.
  • Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals.
  • the emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5.
  • Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.
  • the sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the probe mix at a known concentration.
  • a specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000.
  • the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.
  • the output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital
  • A/D conversion board Analog Devices, Inc., Norwood, MA
  • the digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal).
  • the data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore 's emission spectrum.
  • a grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid.
  • the fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal.
  • the software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).
  • Sequences complementary to the mddt are used to detect, decrease, or inhibit expression of the naturally occurring nucleotide.
  • the use of oligonucleotides comprising from about 15 to 30 base pairs is typical in the art. However, smaller or larger sequence fragments can also be used.
  • Appropriate oligonucleotides are designed from the mddt using OLIGO 4.06 software (National Biosciences) or other appropriate programs and are synthesized using methods standard in the art or ordered from a commercial supplier.
  • OLIGO 4.06 software National Biosciences
  • a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent transcription factor binding to the promoter sequence.
  • To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding and processing of the transcript.
  • MDDT expression and purification of MDDT is accomplished using bacterial or virus-based expression systems.
  • cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription.
  • promoters include, but are not limited to, the trp-lac (tac) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the lac operator regulatory element.
  • Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3).
  • Antibiotic resistant bacteria express MDDT upon induction with isopropyl beta-D- thiogalactopyranoside (IPTG).
  • IPTG isopropyl beta-D- thiogalactopyranoside
  • AcMNPV baculovirus
  • the nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding MDDT by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription.
  • Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases.
  • MDDT is synthesized as a fusion protein with, e.g., glutathione S- transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates.
  • GST glutathione S- transferase
  • a peptide epitope tag such as FLAG or 6-His
  • FLAG an 8-amino acid peptide
  • 6-His a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra. Chapters 10 and 16). Purified MDDT obtained by these methods can be used directly in the following activity assay. XIV. Demonstration of MDDT Activity
  • MDDT or biologically active fragments thereof, are labeled with 125 I Bolton-Hunter reagent.
  • Bolton-Hunter reagent See, e.g., Bolton, A.E. and W.M. Hunter (1973) Biochem. J. 133:529-539.
  • Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled MDDT, washed, and any wells with labeled MDDT complex are assayed. Data obtained using different concentrations of MDDT are used to calculate values for the number, affinity, and association of MDDT with the candidate molecules.
  • molecules interacting with MDDT are analyzed using the yeast two-hybrid system as described in Fields, S. and O.
  • MDDT may also be used in the PATHCALLENG process (CuraGen Co ⁇ ., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S.
  • MDDT function is assessed by expressing mddt at physiologically elevated levels in mammalian cell culture systems.
  • cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression.
  • Vectors of choice include pCMV SPORT (Life Technologies) and pCR3.1 (Invitrogen Co ⁇ oration, Carlsbad CA), both of which contain the cytomegalovirus promoter.
  • 5-10 ⁇ g of recombinant vector are transiently transfected into a human cell line, preferably of endothelial or hematopoietic origin, using either liposome formulations or electroporation.
  • 1-2 ⁇ g of an additional plasmid containing sequences encoding a marker protein are co-transfected.
  • marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector.
  • Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; CLONTECH), CD64, or a CD64-GFP fusion protein.
  • FCM Flow cytometry
  • FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M. G. (1994) Flow Cytometry, Oxford, New York NY.
  • CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG).
  • Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Inc., Lake Success NY).
  • mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding MDDT and other genes of interest can be analyzed by northern analysis or microarray techniques.
  • the MDDT amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding peptide is synthesized and used to raise antibodies by means known to those of skill in the art.
  • LASERGENE software DNASTAR
  • Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra. Chapter 11.)
  • peptides 15 residues in length are synthesized using an ABI 431 A peptide synthesizer (Applied Biosystems) using fmoc-chemistry and coupled to KLH (Sigma) by reaction with
  • N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity.
  • MBS N-maleimidobenzoyl-N-hydroxysuccinimide ester
  • Naturally occurring or recombinant MDDT is substantially purified by immunoaffinity chromatography using antibodies specific for MDDT.
  • An immunoaffinity column is constructed by covalently coupling anti-MDDT antibody to an activated chromatographic resin, such as
  • Media containing MDDT are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of MDDT (e.g., high ionic strength buffers in the presence of detergent).
  • the column is eluted under conditions that disrupt antibody MDDT binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and MDDT is collected.
  • RCK2 protein (AA 1-530) (Rattus rattus)

Abstract

The present invention provides purified disease detection and treatment molecule polynucleotides (mddt). Also encompassed are the polypeptides (MDDT) encoded by mddt. The invention also provides for the use of mddt, or complements, oligonucleotides, or fragments thereof in diagnostic assays. The invention further provides for vectors and host cells containing mddt for the expression of MDDT. The invention additionally provides for the use of isolated and purified MDDT to induce antibodies and to screen libraries of compounds and the use of anti-MDDT antibodies in diagnostic assays. Also provided are microarrays containing mddt and methods of use.

Description

MOLECULES FOR DISEASE DETECTION AND TREATMENT
TECHNICAL FIELD
The present invention relates to molecules for disease detection and treatment and to the use of these sequences in the diagnosis, study, prevention, and treatment of diseases associated with, as well as effects of exogenous compounds on, the expression of molecules for disease detection and treatment.
BACKGROUND OF THE INVENTION The human genome is comprised of thousands of genes, many encoding gene products that function in the maintenance and growth of the various cells and tissues in the body. Aberrant expression or mutations in these genes and their products is the cause of, or is associated with, a variety of human diseases such as cancer and other cell proliferative disorders. The identification of these genes and their products is the basis of an ever-expanding effort to find markers for early detection of diseases, and targets for their prevention and treatment. For example, cancer represents a type of cell proliferative disorder that affects nearly every tissue in the body. A wide variety of molecules, either aberrantly expressed or mutated, can be the cause of, or involved with, various cancers because tissue growth involves complex and ordered patterns of cell proliferation, cell differentiation, and apoptosis. Cell proliferation must be regulated to maintain both the number of cells and their spatial organization. This regulation depends upon the appropriate expression of proteins which control cell cycle progression in response to extracellular signals such as growth factors and other mitogens, and intracellular cues such as DNA damage or nutrient starvation. Molecules which directly or indirectly modulate cell cycle progression fall into several categories, including growth factors and their receptors, second messenger and signal transduction proteins, oncogene products, tumor-suppressor proteins, and mitosis-promoting factors. Aberrant expression or mutations in any of these gene products can result in cell proliferative disorders such as cancer. Oncogenes are genes generally derived from normal genes that, through abnormal expression or mutation, can effect the transformation of a normal cell to a malignant one (oncogenesis). Oncoproteins, encoded by oncogenes, can affect cell proliferation in a variety of ways and include growth factors, growth factor receptors, intracellular signal transducers, nuclear transcription factors, and cell-cycle control proteins. In contrast, tumor-suppressor genes are involved in inhibiting cell proliferation. Mutations which cause reduced or loss of function in tumor-suppressor genes result in aberrant cell proliferation and cancer. Thus a wide variety of genes and their products have been found that are associated with cell proliferative disorders such as cancer, but many more may exist that are yet to be discovered. DNA-based arrays can provide a simple way to explore the expression of a single polymoφhic gene or a large number of genes. When the expression of a single gene is explored,
DNA-based arrays are employed to detect the expression of specific gene variants. For example, a p53 tumor suppressor gene array is used to determine whether individuals are carrying mutations that predispose them to cancer. A cytochrome p450 gene array is useful to determine whether individuals have one of a number of specific mutations that could result in increased drug metabolism, drug resistance or drug toxicity.
DNA-based array technology is especially relevant for the rapid screening of expression of a large number of genes. There is a growing awareness that gene expression is affected in a global fashion. A genetic predisposition, disease or therapeutic treatment may affect, directly or indirectly, the expression of a large number of genes. In some cases the interactions may be expected, such as when the genes are part of the same signaling pathway. In other cases, such as when the genes participate in separate signaling pathways, the interactions may be totally unexpected. Therefore, DNA-based arrays can be used to investigate how genetic predisposition, disease, or therapeutic treatment affects the expression of a large number of genes. The discovery of new molecules for disease detection and treatment satisfies a need in the art by providing new compositions which are useful in the diagnosis, study, prevention, and treatment of diseases associated with, as well as effects of exogenous compounds on, the expression of molecules for disease detection and treatment.
SUMMARY OF THE INVENTION
The present invention relates to human disease detection and treatment molecule polynucleotides (mddt) as presented in the Sequence Listing. The mddt uniquely identify genes encoding structural, functional, and regulatory disease detection and treatment molecules.
The invention provides an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). In one alternative, the polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396. In another alternative, the polynucleotide comprises at least 30 contiguous nucleotides of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; b) a polynucleotide comprising a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). In another alternative, the polynucleotide comprises at least 60 contiguous nucleotides of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; b) a polynucleotide comprising a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d).
The invention further provides a composition for the detection of expression of disease detection and treatment molecule polynucleotides comprising at least one isolated polynucleotide comprising a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d); and a detectable label.
The invention also provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a polynucleotide sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence of a polynucleotide selected from the group consisting of SEQ ID NO: 1-396; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.
The invention also provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleot e, un er conditions whereby a hybridization complex is formed between said probe and said target polynucleotide, and b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof. In one alternative, the invention provides a composition comprising a target polynucleotide of the method, wherein said probe comprises at least 30 contiguous nucleotides. In one alternative, the invention provides a composition comprising a target polynucleotide of the method, wherein said probe comprises at least 60 contiguous nucleotides.
The invention further provides a recombinant polynucleotide comprising a promoter sequence operably linked to an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.
The invention also provides a method for producing a disease detection and treatment molecule polypeptide, the method comprising a) culturing a cell under conditions suitable for expression of the disease detection and treatment molecule polypeptide, wherein said cell is transformed with a recombinant polynucleotide, said recombinant polynucleotide comprising an isolated polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; iii) a polynucleotide complementary to the polynucleotide of i); iv) a polynucleotide complementary to the polynucleotide of ii); and v) an RNA equivalent of i) through iv), and b) recovering the disease detection and treatment molecule polypeptide so expressed. The invention additionally provides a method wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO:397-792pp range - upper pp range].
The invention also provides an isolated disease detection and treatment molecule polypeptide (MDDT) encoded by at least one polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396. The invention further provides a method of screening for a test compound that specifically binds to the polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:397-792. The method comprises a) combining the polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:397-792 with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide having an amino aci sequence selected from the group consisting of SEQ ID NO:397-7 to the test compound, thereby identifying a compound that specifically binds to the polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:397-792.
The invention further provides a microarray wherein at least one element of the microarray is
5 an isolated polynucleotide comprising at least 30 contiguous nucleotides of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; c) a polynucleotide complementary to the polynucleotide of a); d) a o polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). The invention also provides a method for generating a transcript image of a sample which contains polynucleotides. The method comprises a) labeling the polynucleotides of the sample, b) contacting the elements of the microarray with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and c) quantifying the expression of the polynucleotides 5 in the sample.
Additionally, the invention provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; b) a polynucleotide comprising a 0 naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). The method comprises a) exposing a sample comprising the target polynucleotide to a compound, b) detecting altered expression of the target polynucleotide, and c) 5 comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.
The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 o contiguous nucleotides of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; iii) a polynucleotide complementary to the polynucleotide of i); iv) a polynucleotide complementary to the polynucleotide specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ED NO: 1-396; ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396; iii) a polynucleotide complementary to the polynucleotide of i); iv) a polynucleotide complementary to the polynucleotide of ii); and v) an RNA equivalent of i) through iv), and alternatively, the target polynucleotide comprises a polynucleotide sequence of a fragment of a polynucleotide selected from the group consisting of i-v above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.
The invention further provides an isolated polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:397-792, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ED NO:397-792, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:397-792, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:397-792. In one alternative, the invention provides an isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:397-792.
The invention further provides an isolated polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 397-792, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:397-792, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:397-792, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:397- 792. In one alternative, the polynucleotide encodes a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:397-792. In another alternative, the polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396. Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:397-792, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ED NO:397-792, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:397-792, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ED NO:397-792.
The invention further provides a composition comprising a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ED NO:397-792, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ED NO:397- 792, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ED NO:397-792, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ED NO:397-792, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises a polypeptide having an amino acid sequence selected from the group consisting of SEQ ED NO:397-792. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional MDDT, comprising administering to a patient in need of such treatment the composition.
The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ED NO:397-792, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ED NO: 397-792, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ED NO:397-792, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ED NO:397-792. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional MDDT, comprising administering to a patient in need of such treatment the composition.
Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ED NO:397-792, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:397-792, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID
NO:397-792, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ED NO:397-792. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional
MDDT, comprising administering to a patient in need of such treatment the composition.
The invention further provides a method of screening for a compound that modulates the activity of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ED NO:397-792, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ED NO:397-792, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ED NO:397-792, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ED NO: 397-792. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.
DESCRIPTION OF THE TABLES
Table 1 shows the sequence identification numbers (SEQ ED NO:s) and template identification numbers (template EDs) corresponding to the polynucleotides of the present invention, along with the sequence identification numbers (SEQ ED NO:s) and open reading frame identification numbers (ORF EDs) corresponding to polypeptides encoded by the template ED.
Table 2 shows the sequence identification numbers (SEQ ED NO:s) and template identification numbers (template EDs) corresponding to the polynucleotides of the present invention, along with their GenBank hits (GI Numbers), probability scores, and functional annotations corresponding to the GenBank hits.
Table 3 shows the sequence identification numbers (SEQ ED NO:s) and template identification numbers (template EDs) corresponding to the polynucleotides of the present invention, along with polynucleotide segments of each template sequence as defined by the indicated "start" and "stop" nucleotide positions. The reading frames of the polynucleotide segments and the Pfam hits, Pfam descriptions, and E-values corresponding to the polypeptide domains encoded by the polynucleotide segments are indicated.
Table 4 shows the sequence identification numbers (SEQ ED NO:s) and template identification numbers (template EDs) corresponding to the polynucleotides of the present invention, along with 5 polynucleotide segments of each template sequence as defined by the indicated "start" and "stop" nucleotide positions. The reading frames of the polynucleotide segments are shown, and the polypeptides encoded by the polynucleotide segments constitute either signal peptide (SP) or transmembrane (TM) domains, as indicated. For TM domains, the membrane topology of the encoded polypeptide sequence is indicated as being transmembrane or on the cytosolic or non-cytosolic side of o the cell membrane or organelle.
Table 5 shows the sequence identification numbers and template identification numbers (/template EDs) corresponding to the polynucleotides of the present invention, along with component sequence identification spans corresponding to each template. The component sequences, which were used to assemble the template sequences, are defined by the spans indicating the nucleotide 5 positions along each template.
Table 6 shows the tissue distribution profiles for the templates of the invention.
Table 7 shows the sequence identification numbers (SEQ ED NO:s) corresponding to the polypeptides of the present invention, along with the reading frames used to obtain the polypeptide segments, the lengths of the polypeptide segments, the "start" and "stop" nucleotide positions of the 0 polynucleotide sequences used to define the encoded polypeptide segments, the GenBank hits (GI Numbers), probability scores, and functional annotations corresponding to the GenBank hits.
Table 8 summarizes the bioinformatics tools which are useful for analysis of the polynucleotides of the present invention. The first column of Table 8 lists analytical tools, programs, and algorithms, the second column provides brief descriptions thereof, the third column presents 5 appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score, the greater the homology between two sequences).
o DETAILED DESCRIPTION OF THE INVENTION
Before the nucleic acid sequences and methods are presented, it is to be understood that this invention is not limited to the particular machines, methods, and materials described. Although particular embodiments are described, machines, methods, and materials similar or equivalent to these embodiments may be used to practice the invention. The preferred machines, methods, and materials set forth are not intended to limit the scope of the invention which is limited only by the appended claims.
The singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. All technical and scientific terms have the meanings commonly understood by one of ordinary skill in the art. All publications are incoφorated by reference for the puφose of describing and disclosing the cell lines, vectors, and methodologies which are presented and which might be used in connection with the invention. Nothing in the specification is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.
Definitions
As used herein, the lower case "mddt" refers to a nucleic acid sequence, while the upper case "MDDT" refers to an amino acid sequence encoded by mddt. A "full-length" mddt refers to a nucleic acid sequence containing the entire coding region of a gene endogenously expressed in human tissue. "Adjuvants" are materials such as Freund's adjuvant, mineral gels (aluminum hydroxide), and surface active substances (lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol) which may be administered to increase a host's immunological response.
"Allele" refers to an alternative form of a nucleic acid sequence. Alleles result from a "mutation," a change or an alternative reading of the genetic code. Any given gene may have none, one, or many allelic forms. Mutations which give rise to alleles include deletions, additions, or substitutions of nucleotides. Each of these changes may occur alone, or in combination with the others, one or more times in a given nucleic acid sequence. The present invention encompasses allelic mddt.
An "allelic variant" is an alternative form of the gene encoding MDDT. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.
"Altered" nucleic acid sequences encoding MDDT include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as MDDT or a polypeptide with at least one functional characteristic of MDDT. Included within this definition are polymoφhisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding MDDT, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding MDDT.
The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent MDDT.
Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of MDDT is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.
"Amino acid sequence" refers to a peptide, a polypeptide, or a protein of either natural or synthetic origin. The amino acid sequence is not limited to the complete, endogenous amino acid sequence and may be a fragment, epitope, variant, or derivative of a protein expressed by a nucleic acid sequence.
"Amplification" refers to the production of additional copies of a sequence and is carried out using polymerase chain reaction (PCR) technologies well known in the art.
"Antibody" refers to intact molecules as well as to fragments thereof, such as Fab, F(ab')2, and Fv fragments, which are capable of binding the epitopic determinant. Antibodies that bind MDDT polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or peptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.
The term "aptamer" refers to a nucleic acid or oligonucleotide molecule that binds to a specific molecular target. Aptamers are derived from an in vitro evolutionary process (e.g., SELEX (Systematic Evolution of Ligands by Exponential Enrichment), described in U.S. Patent No. 5,270,163), which selects for target-specific aptamer sequences from large combinatorial libraries. Aptamer compositions may be double-stranded or single-stranded, and may include deoxyribonucleotides, ribonucleotides, nucleotide derivatives, or other nucleotide-like molecules. The nucleotide components of an aptamer may have modified sugar groups (e.g., the 2'-OH group of a ribonucleotide may be replaced by 2'-F or 2'-NH2), which may improve a desired property, e.g., resistance to nucleases or longer lifetime in blood. Aptamers may be conjugated to other molecules, e.g., a high molecular weight carrier to slow clearance of the aptamer from the circulatory system. Aptamers may be specifically cross-linked to their cognate ligands, e.g., by photo-activation of a cross-linker. (See, e.g., Brody, E.N. and L. Gold (2000) J. Biotechnol. 74:5-13.)
The term "intramer" refers to an aptamer which is expressed in vivo. For example, a vaccinia virus-based RNA expression system has been used to express specific RNA aptamers at high levels in the cytoplasm of leukocytes (Blind, M. et al. (1999) Proc. Natl Acad. Sci. USA 96:3606-3610). The term "spiegelmer" refers to an aptamer which includes L-DNA, L-RNA, or other left- handed nucleotide derivatives or nucleotide-like molecules. Aptamers containing left-handed nucleotides are resistant to degradation by naturally occurring enzymes, which normally act on substrates containing right-handed nucleotides. "Antisense sequence" refers to a sequence capable of specifically hybridizing to a target sequence. The antisense sequence may include DNA, RNA, or any nucleic acid mimic or analog such as peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine.
"Antisense technology" refers to any technology which relies on the specific hybridization of an antisense sequence to a target sequence.
A "bin" is a portion of computer memory space used by a computer program for storage of data, and bounded in such a manner that data stored in a bin may be retrieved by the program. "Biologically active" refers to an amino acid sequence having a structural, regulatory, or biochemical function of a naturally occurring amino acid sequence.
"Clone joining" is a process for combining gene bins based upon the bins' containing sequence information from the same clone. The sequences may assemble into a primary gene transcript as well as one or more splice variants. "Complementary" describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing (5'-A-G-T-3' pairs with its complement 3'-T-C-A-5').
A "component sequence" is a nucleic acid sequence selected by a computer program such as PHRED and used to assemble a consensus or template sequence from one or more component sequences. A "consensus sequence" or "template sequence" is a nucleic acid sequence which has been assembled from overlapping sequences, using a computer program for fragment assembly such as the GELVEEW fragment assembly system (Genetics Computer Group (GCG), Madison WI) or using a relational database management system (RDMS).
"Conservative amino acid substitutions" are those substitutions that, when made, least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative substitutions.
Original Residue Conservative Substitution
Ala Gly, Ser
Arg His, Lys
Asn Asp, Gin, His
Asp Asn, Glu Cys Ala, Ser
Gin Asn, Glu, His
Glu Asp, Gin, His
Gly Ala
His Asn, Arg, Gin, Glu He Leu, Val
Leu He, Val
Lys Arg, Gin, Glu
Met Leu, He
Phe His, Met, E^u, Tφ, Tyr Ser Cys, Thr Thr Ser, Val Tφ Phe, Tyr Tyr His, Phe, Tφ Val He, I^eu, Thr
Conservative substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. "Deletion" refers to a change in either a nucleic or amino acid sequence in which at least one nucleotide or amino acid residue, respectively, is absent.
"Derivative" refers to the chemical modification of a nucleic acid sequence, such as by replacement of hydrogen by an alkyl, acyl, amino, hydroxyl, or other group.
"Differential expression" refers to increased or upregulated; or decreased, downregulated, or absent gene or protein expression, determined by comparing at least two different samples. Such comparisons may be carried out between, for example, a treated and an untreated sample, or a diseased and a normal sample.
The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray. The term "modulate" refers to a change in the activity o MDDT. For examp e, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of MDDT.
"E-value" refers to the statistical probability that a match between two sequences occurred by chance.
"Exon shuffling" refers to the recombination of different coding regions (exons). Since an exon may represent a structural or functional domain of the encoded protein, new proteins may be assembled through the novel reassortment of stable substructures, thus allowing acceleration of the evolution of new protein functions. A "fragment" is a unique portion of mddt or MDDT which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 10 to 1000 contiguous amino acid residues or nucleotides. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other puφoses, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous amino acid residues or nucleotides in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing and the figures, may be encompassed by the present embodiments.
A fragment of mddt comprises a region of unique polynucleotide sequence that specifically identifies mddt, for example, as distinct from any other sequence in the same genome. A fragment of mddt is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish mddt from related polynucleotide sequences. The precise length of a fragment of mddt and the region of mddt to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended puφose for the fragment.
A fragment of MDDT is encoded by a fragment of mddt. A fragment of MDDT comprises a region of unique amino acid sequence that specifically identifies MDDT. For example, a fragment of MDDT is useful as an immunogenic peptide for the development of antibodies that specifically recognize MDDT. The precise length of a fragment of MDDT and the region of MDDT to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended puφose for the fragment.
A "full length" nucleotide sequence is one containing at least a start site for translation to a protein sequence, followed by an open reading frame and a stop site, and encoding a "full length" polypeptide. "Hit" refers to a sequence whose annotation will be used to describe a given template.
Criteria for selecting the top hit are as follows: if the template has one or more exact nucleic acid matches, the top hit is the exact match with highest percent identity. If the template has no exact matches but has significant protein hits, the top hit is the protein hit with the lowest E-value. If the template has no significant protein hits, but does have significant non-exact nucleotide hits, the top hit is the nucleotide hit with the lowest E-value.
"Homology" refers to sequence similarity either between a reference nucleic acid sequence and at least a fragment of an mddt or between a reference amino acid sequence and a fragment of an
MDDT. "Hybridization" refers to the process by which a strand of nucleotides anneals with a complementary strand through base pairing. Specific hybridization is an indication that two nucleic acid sequences share a high degree of identity. Specific hybridization complexes form under defined annealing conditions, and remain hybridized after the "washing" step. The defined hybridization conditions include the annealing conditions and the washing step(s), the latter of which is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid probes that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency. Generally, stringency of hybridization is expressed with reference to the temperature under which the wash step is carried out. Generally, such wash temperatures are selected to be about 5°C to 20°C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating Tm and conditions for nucleic acid hybridization is well known and can be found in Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.
High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, or 55°C may be used. SSC concentration may be varied from about 0.2 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, denatured salmon sperm DNA at about 100-200 μg/ml. Useful variations on these conditions will be readily apparent to those skilled in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their resultant proteins.
Other parameters, such as temperature, salt concentration, and detergent concentration may be varied to achieve the desired stringency. Denaturants, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as RNA:DNA hybridizations. Appropriate hybridization conditions are routinely determinable by one of ordinary skill in the art.
"Immunologically active" or "immunogenic" describes the potential for a natural, recombinant, or synthetic peptide, epitope, polypeptide, or protein to induce antibody production in appropriate animals, cells, or cell lines. "Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.
An "immunogenic fragment" is a polypeptide or oligopeptide fragment of ABBR which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of ABBR which is useful in any of the antibody production methods disclosed herein or known in the art.
"Insertion" or "addition" refers to a change in either a nucleic or amino acid sequence in which at least one nucleotide or residue, respectively, is added to the sequence.
"Labeling" refers to the covalent or noncovalent joining of a polynucleotide, polypeptide, or antibody with a reporter molecule capable of producing a detectable or measurable signal.
"Microarray" is any arrangement of nucleic acids, amino acids, antibodies, etc., on a substrate. The substrate may be a solid support such as beads, glass, paper, nitrocellulose, nylon, or an appropriate membrane.
"Linkers" are short stretches of nucleotide sequence which may be added to a vector or an mddt to create restriction endonuclease sites to facilitate cloning. "Polylinkers" are engineered to incoφorate multiple restriction enzyme sites and to provide for the use of enzymes which leave 5 ' or 3' overhangs (e.g., BamHI, EcoRI, and Hindlll) and those which provide blunt ends (e.g., EcoRV, SnaBI, and Stul).
"Naturally occurring" refers to an endogenous polynucleotide or polypeptide that may be isolated from viruses or prokaryotic or eukaryotic cells.
"Nucleic acid sequence" refers to the specific order of nucleotides joined by phosphodiester bonds in a linear, polymeric arrangement. Depending on the number of nucleotides, the nucleic acid sequence can be considered an oligomer, oligonucleotide, or polynucleotide. The nucleic acid can be DNA, RNA, or any nucleic acid analog, such as PNA, may be of genomic or synthetic origin, may be either double-stranded or single-stranded, and can represent either the sense or antisense
(complementary) strand.
"Oligomer" refers to a nucleic acid sequence of at least about 6 nucleotides and as many as about 60 nucleotides, preferably about 15 to 40 nucleotides, and most preferably between about 20 and
30 nucleotides, that may be used in hybridization or amplification technologies. Oligomers may be used as, e.g., primers for PCR, and are usually chemically synthesized.
"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.
"Peptide nucleic acid" (PNA) refers to a DNA mimic in which nucleotide bases are attached to a pseudopeptide backbone to increase stability. PNAs, also designated antigene agents, can prevent gene expression by targeting complementary messenger RNA.
The phrases "percent identity" and "% identity", as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.
Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incoφorated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and Shaφ, P.M. (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequence pairs. Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at http://www.ncbi.nlm.nih.gov/BLAST/. The BLAST software suite includes various sequence analysis programs including "BLASTN," that is used to determine alignment between a known polynucleotide sequence and other sequences on a variety of databases. Also available is a tool called "BLAST 2
Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at http://www.ncbi.nlm.nih.gov/gorf/bl2/. The "BLAST 2 Sequences" tool can be used for both BLASTN and BLASTP (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use BLASTN with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such default parameters may be, for example:
Matrix: BLOSUM62 Reward for match: 1
Penalty for mismatch: -2 Open Gap: 5 and Extension Gap: 2 penalties Gap x drop-off: 50 Expect: 10 Word Size: 11
Filter: on
Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ED number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in figures or Sequence Listings, may be used to describe a length over which percentage identity may be measured.
Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.
The phrases "percent identity" and "% identity", as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the hydrophobicity and acidity of the substituted residue, thus preserving the structure (and therefore function) of the folded polypeptide.
Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incoφorated into the MEGALIGN version 3.12e sequence a gnment program ( escribed and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=l, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.
Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) with BLASTP set at default parameters. Such default parameters may be, for example: Matrix: BLOSUM62
Open Gap: 11 and Extension Gap: 1 penalty Gap x drop-off: 50 Expect: 10 Word Size: 3 Filter: on
Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ED number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in figures or Sequence Listings, may be used to describe a length over which percentage identity may be measured.
"Post-translational modification" of an MDDT may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu and the MDDT.
"Probe" refers to mddt or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. "Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR). Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a nown sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the figures and Sequence Listing, may be used.
Methods for preparing and using probes and primers are described in the references, for example Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual. 2nd ed., vol. 1-3, Cold
Spring Harbor Press, Plainview NY; Ausubel et al.,1987, Current Protocols in Molecular Biologv,
Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis et al., 1990, PCR Protocols, A Guide to Methods and Applications. Academic Press, San Diego CA. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that puφose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).
Oligonucleotides for use as primers are selected using software known in the art for such puφose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incoφorated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome- wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above. "Purified" refers to molecules, either polynucleotides or polypeptides that are isolated or separated from their natural environment and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other compounds with which they are naturally associated.
A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell. Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be use to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.
"Regulatory element" refers to a nucleic acid sequence from nontranslated regions of a gene, and includes enhancers, promoters, introns, and 3' untranslated regions, which interact with host proteins to carry out or regulate transcription or translation.
"Reporter" molecules are chemical or biochemical moieties used for labeling a nucleic acid, an amino acid, or an antibody. They include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.
An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose. "Sample" is used in its broadest sense. Samples may contain nucleic or amino acids, antibodies, or other materials, and may be derived from any source (e.g., bodily fluids including, but not limited to, saliva, blood, and urine; chromosome(s), organelles, or membranes isolated from a cell; genomic DNA, RNA, or cDNA in solution or bound to a substrate; and cleared cells or tissues or blots or imprints from such cells or tissues). "Specific binding" or "specifically binding" refers to the interaction between a protein or peptide and its agonist, antibody, antagonist, or other binding partner. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide containing epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.
"Substitution" refers to the replacement of at least one nucleotide or amino acid by a different nucleotide or amino acid. "Substrate" refers to any suitable rigid or semi-rigid support including, e.g., membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles or capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.
A "transcript image" refers to the collective pattern of gene expression by a particular tissue or cell type under given conditions at a given time.
"Transformation" refers to a process by which exogenous DNA enters a recipient cell.
Transformation may occur under natural or artificial conditions using various methods well known in the art. Transformation may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method is selected based on the host cell being transformed.
"Transformants" include stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as cells which transiently express inserted DNA or RNA.
A "transgenic organism," as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, and plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.
A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 25% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using BLASTN with the "BLAST 2 Sequences" tool Version 2.0.9 (May-
07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 30%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length. The variant may result in "conservative" amino acid changes which do not affect structural and/or chemical properties. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymoφhic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymoφhic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymoφhic variants also may encompass "single nucleotide polymoφhisms" (SNPs) in which the polynucleotide sequence varies by one base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state. In an alternative, variants of the polynucleotides of the present invention may be generated through recombinant methods. One possible method is a DNA shuffling technique such as MOLECULARBREEDENG (Maxygen Inc., Santa Clara CA; described in U.S. Patent Number 5,837,458; Chang, C-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat. Biotechnol. 17:259-264; and Crameri, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of MDDT, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Altematively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.
A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using BLASTP with the "BLAST 2 Sequences" tool Version 2.0.9 (May- 07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length of one of the polypeptides.
THE INVENTION In a particular embodiment, cDNA sequences derived from human tissues and cell lines were aligned based on nucleotide sequence identity and assembled into "consensus" or "template" sequences which are designated by the template identification numbers (template EDs) in column 2 of Table 2. The sequence identification numbers (SEQ ED NO:s) corresponding to the template EDs are shown in column 1. The template sequences have similarity to GenBank sequences, or "hits," as designated by the GI Numbers in column 3. The statistical probability of each GenBank hit is indicated by a probability score in column 4, and the functional annotation corresponding to each GenBank hit is listed in column 5.
The invention incoφorates the nucleic acid sequences of these templates as disclosed in the Sequence Listing and the use of these sequences in the diagnosis and treatment of disease states characterized by defects in disease detection and treatment molecules. The invention further utilizes these sequences in hybridization and amplification technologies, and in particular, in technologies which assess gene expression patterns correlated with specific cells or tissues and their responses in vivo or in vitro to pharmaceutical agents, toxins, and other treatments. In this manner, the sequences of the present invention are used to develop a transcript image for a particular cell or tissue.
Derivation of Nucleic Acid Sequences cDNA was isolated from libraries constructed using RNA derived from normal and diseased human tissues and cell lines. The human tissues and cell lines used for cDNA library construction were selected from a broad range of sources to provide a diverse population of cDNAs representative of gene transcription throughout the human body. Descriptions of the human tissues and cell lines used for cDNA library construction are provided in the LIFESEQ database (Incyte Genomics, Inc. (Incyte), Palo Alto CA). Human tissues were broadly selected from, for example, cardiovascular, dermatologic, endocrine, gastrointestinal, hematopoietic/immune system, musculoskeletal, neural, reproductive, and urologic sources. Cell lines used for cDNA library construction were derived from, for example, leukemic cells, teratocarcinomas, neuroepitheliomas, cervical carcinoma, lung fibroblasts, and endothelial cells. Such cell lines include, for example, THP-1, Jurkat, HUVEC, hNT2, WI38, HeLa, and other cell lines commonly used and available from public depositories (American Type Culture Collection, Manassas VA). Prior to mRNA isolation, cell lines were untreated, treated with a pharmaceutical agent such as 5'-aza-2'-deoxycytidine, treated with an activating agent such as lipopolysaccharide in the case of leukocytic cell lines, or, in the case of endothelial cell lines, subjected to shear stress.
Sequencing of the cDNAs Methods for DNA sequencing are well known in the art. Conventional enzymatic methods employ the Klenow fragment of DNA polymerase I, SEQUENASE DNA polymerase (U.S. Biochemical Coφoration, Cleveland OH), Taq polymerase (Applied Biosystems, Foster City CA), thermostable T7 polymerase (Amersham Pharmacia Biotech, Inc. (Amersham Pharmacia Biotech), Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies Inc. (Life Technologies), Gaithersburg MD), to extend the nucleic acid sequence from an oligonucleotide primer annealed to the DNA template of interest. Methods have been developed for the use of both single-stranded and double- stranded templates. Chain termination reaction products may be electrophoresed on urea- polyacrylamide gels and detected either by autoradiography (for radioisotope-labeled nucleotides) or by fluorescence (for fluorophore-labeled nucleotides). Automated methods for mechanized reaction preparation, sequencing, and analysis using fluorescence detection methods have been developed. Machines used to prepare cDNAs for sequencing can include the MICROLAB 2200 liquid transfer system (Hamilton Company (Hamilton), Reno NV), Peltier thermal cycler (PTC200; MJ Research, Inc. (MJ Research), Watertown MA), and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing can be carried out using, for example, the ABI 373 or 377 (Applied Biosystems) or MEGABACE 1000 (Molecular Dynamics, Inc. (Molecular Dynamics), Sunnyvale CA) DNA sequencing systems, or other automated and manual sequencing systems well known in the art.
The nucleotide sequences of the Sequence Listing have been prepared by current, state-of- the-art, automated methods and, as such, may contain occasional sequencing errors or unidentified nucleotides. Such unidentified nucleotides are designated by an N. These infrequent unidentified bases do not represent a hindrance to practicing the invention for those skilled in the art. Several methods employing standard recombinant techniques may be used to correct errors and complete the missing sequence information. (See, e.g., those described in Ausubel, F.M. et al. (1997) Short Protocols in Molecular Biologv. John Wiley & Sons, New York NY; and Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY.)
Assembly of cDNA Sequences
Human polynucleotide sequences may be assembled using programs or algorithms well known in the art. Sequences to be assembled are related, wholly or in part, and may be derived from a single or many different transcripts. Assembly of the sequences can be performed using such programs as
PHRAP (Phils Revised Assembly Program) and the GELVEEW fragment assembly system (GCG), or other methods known in the art.
Alternatively, cDNA sequences are used as "component" sequences that are assembled into "template" or "consensus" sequences as follows. Sequence chromatograms are processed, verified, and quality scores are obtained using PHRED. Raw sequences are edited using an editing pathway known as Block 1 (See, e.g., the LEFESEQ Assembled User Guide, Incyte Genomics, Palo Alto, CA).
A series of BLAST comparisons is performed and low-information segments and repetitive elements
(e.g., dinucleotide repeats, Alu repeats, etc.) are replaced by "n's", or masked, to prevent spurious matches. Mitochondrial and ribosomal RNA sequences are also removed. The processed sequences are then loaded into a relational database management system (RDMS) which assigns edited sequences to existing templates, if available. When additional sequences are added into the RDMS, a process is initiated which modifies existing templates or creates new templates from works in progress (i.e., nonfinal assembled sequences) containing queued sequences or the sequences themselves. After the new sequences have been assigned to templates, the templates can be merged into bins. If multiple templates exist in one bin, the bin can be split and the templates reannotated.
Once gene bins have been generated based upon sequence alignments, bins are "clone joined" based upon clone information. Clone joining occurs when the 5' sequence of one clone is present in one bin and the 3' sequence from the same clone is present in a different bin, indicating that the two bins should be merged into a single bin. Only bins which share at least two different clones are merged.
A resultant template sequence may contain either a partial or a full length open reading frame, or all or part of a genetic regulatory element. This variation is due in part to the fact that the full length cDNAs of many genes are several hundred, and sometimes several thousand, bases in length. With current technology, cDNAs comprising the coding regions of large genes cannot be cloned because of vector limitations, incomplete reverse transcription of the mRNA, or incomplete "second strand" synthesis. Template sequences may be extended to include additional contiguous sequences derived from the parent RNA transcript using a variety of methods known to those of skill in the art. Extension may thus be used to achieve the full length coding sequence of a gene.
Analysis of the cDNA Sequences
The cDNA sequences are analyzed using a variety of programs and algorithms which are well known in the art. (See, e.g., Ausubel, 1997, supra. Chapter 7.7; Meyers, R.A. (Ed.) (1995) Molecular Biology and Biotechnology. Wiley VCH, New York NY, pp. 856-853; and Table 8.) These analyses comprise both reading frame determinations, e.g., based on triplet codon periodicity for particular organisms (Fickett, J.W. (1982) Nucleic Acids Res. 10:5303-5318); analyses of potential start and stop codons; and homology searches.
Computer programs known to those of skill in the art for performing computer-assisted searches for amino acid and nucleic acid sequence similarity, include, for example, Basic Local Alignment Search Tool (BLAST; Altschul, S.F. (1993) J. Mol. Evol. 36:290-300; Altschul, S.F. et al.
(1990) J. Mol. Biol. 215:403-410). BLAST is especially useful in determining exact matches and comparing two sequence fragments of arbitrary but equal lengths, whose alignment is locally maximal and for which the alignment score meets or exceeds a threshold or cutoff score set by the user
(Karlin, S. et al. (1988) Proc. Natl. Acad. Sci. USA 85:841-845). Using an appropriate search tool (e.g., BLAST or HMM), GenBank, SwissProt, BLOCKS, PFAM and other databases may be searched for sequences containing regions of homology to a query mddt or MDDT of the present invention.
Other approaches to the identification, assembly, storage, and display of nucleotide and polypeptide sequences are provided in "Relational Database for Storing Biomolecule Information," U.S.S.N. 08/947,845, filed October 9, 1997; "Project-Based Full-Length Biomolecular Sequence
Database," U.S. Patent Number 5,953,727; and "Relational Database and System for Storing
Information Relating to Biomolecular Sequences," U.S.S.N. 09/034,807, filed March 4, 1998, all of which are incoφorated by reference herein in their entirety.
Protein hierarchies can be assigned to the putative encoded polypeptide based on, e.g., motif, BLAST, or biological analysis. Methods for assigning these hierarchies are described, for example, in
"Database System Employing Protein Function Hierarchies for Viewing Biomolecular Sequence
Data," U.S. Patent Number 6,023,659, incoφorated herein by reference.
Human Disease Detection and Treatment Molecule Sequences The mddt of the present invention may be used for a variety of diagnostic and therapeutic puφoses. For example, an mddt may be used to diagnose a particular condition, disease, or disorder associated with disease detection and treatment molecules. Such conditions, diseases, and disorders include, but are not limited to, a cell proliferative disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, a cancer of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; and an autoimmune/inflammatory disorder, such as actinic keratosis, acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, arteriosclerosis, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, bronchitis, bursitis, cholecystitis, cirrhosis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, paroxysmal nocturnal hemoglobinuria, hepatitis, hypereosinophilia, irritable bowel syndrome, episodic lymphopenia with lymphocytotoxins, mixed connective tissue disease (MCTD), multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, myelofibrosis, osteoarthritis, osteoporosis, pancreatitis, polycythemia vera, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjogren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, primary thrombocythemia, thrombocytopenic puφura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracoφoreal circulation, trauma, and hematopoietic cancer including lymphoma, leukemia, and myeloma. The mddt can be used to detect the presence of, or to quantify the amount of, an mddt- related polynucleotide in a sample. This information is then compared to information obtained from appropriate reference samples, and a diagnosis is established. Alternatively, a polynucleotide complementary to a given mddt can inhibit or inactivate a therapeutically relevant gene related to the mddt.
Analysis of mddt Expression Patterns
The expression of mddt may be routinely assessed by hybridization-based methods to determine, for example, the tissue-specificity, disease-specificity, or developmental stage-specificity of mddt expression. For example, the level of expression of mddt may be compared among different cell types or tissues, among diseased and normal cell types or tissues, among cell types or tissues at different developmental stages, or among cell types or tissues undergoing various treatments. This type of analysis is useful, for example, to assess the relative levels of mddt expression in fully or partially differentiated cells or tissues, to determine if changes in mddt expression levels are correlated with the development or progression of specific disease states, and to assess the response of a cell or tissue to a specific therapy, for example, in pharmacological or toxicological studies. Methods for the analysis of mddt expression are based on hybridization and amplification technologies and include membrane-based procedures such as northern blot analysis, high-throughput procedures that utilize, for example, microarrays, and PCR-based procedures.
Hybridization and Genetic Analysis The mddt, their fragments, or complementary sequences, may be used to identify the presence of and/or to determine the degree of similarity between two (or more) nucleic acid sequences. The mddt may be hybridized to naturally occurring or recombinant nucleic acid sequences under appropriately selected temperatures and salt concentrations. Hybridization with a probe based on the nucleic acid sequence of at least one of the mddt allows for the detection of nucleic acid sequences, including genomic sequences, which are identical or related to the mddt of the Sequence Listing.
Probes may be selected from non-conserved or unique regions of at least one of the polynucleotides of SEQ ED NO: 1-396 and tested for their ability to identify or amplify the target nucleic acid sequence using standard protocols.
Polynucleotide sequences that are capable of hybridizing, in particular, to those shown in SEQ ED NO: 1-396 and fragments thereof, can be identified using various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) Methods Enzymol. 152:399-407; Kimmel, A.R. (1987) Methods Enzymol. 152:507-511.) Hybridization conditions are discussed in "Definitions."
A probe for use in Southern or northern hybridization may be derived from a fragment of an mddt sequence, or its complement, that is up to several hundred nucleotides in length and is either single-stranded or double-stranded. Such probes may be hybridized in solution to biological materials such as plasmids, bacterial, yeast, or human artificial chromosomes, cleared or sectioned tissues, or to artificial substrates containing mddt. Microarrays are particularly suitable for identifying the presence of and detecting the level of expression for multiple genes of interest by examining gene expression correlated with, e.g., various stages of development, treatment with a drug or compound, or disease progression. An array analogous to a dot or slot blot may be used to arrange and link polynucleotides to the surface of a substrate using one or more of the following: mechanical (vacuum), chemical, thermal, or UV bonding procedures. Such an array may contain any number of mddt and may be produced by hand or by using available devices, materials, and machines.
Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad.
Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application W095/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.)
Probes may be labeled by either PCR or enzymatic techniques using a variety of commercially available reporter molecules. For example, commercial kits are available for radioactive and chemiluminescent labeling (Amersham Pharmacia Biotech) and for alkaline phosphatase labeling (Life Technologies). Alternatively, mddt may be cloned into commercially available vectors for the production of RNA probes. Such probes may be transcribed in the presence of at least one labeled nucleotide (e.g., 32P-ATP, Amersham Pharmacia Biotech). Additionally the polynucleotides of SEQ ED NO: 1-396 or suitable fragments thereof can be used to isolate full length cDNA sequences utilizing hybridization and/or amplification procedures well known in the art, e.g., cDNA library screening, PCR amplification, etc. The molecular cloning of such full length cDNA sequences may employ the method of cDNA library screening with probes using the hybridization, stringency, washing, and probing strategies described above and in Ausubel, supra. Chapters 3, 5, and 6. These procedures may also be employed with genomic libraries to isolate genomic sequences of mddt in order to analyze, e.g., regulatory elements.
Genetic Mapping
Gene identification and mapping are important in the investigation and treatment of almost all conditions, diseases, and disorders. Cancer, cardiovascular disease, Alzheimer's disease, arthritis, diabetes, and mental illnesses are of particular interest. Each of these conditions is more complex than the single gene defects of sickle cell anemia or cystic fibrosis, with select groups of genes being predictive of predisposition for a particular condition, disease, or disorder. For example, cardiovascular disease may result from malfunctioning receptor molecules that fail to clear cholesterol from the bloodstream, and diabetes may result when a particular individual's immune system is activated by an infection and attacks the insulin-producing cells of the pancreas. In some studies, Alzheimer's disease has been linked to a gene on chromosome 21; other studies predict a different gene and location. Mapping of disease genes is a complex and reiterative process and generally proceeds from genetic linkage analysis to physical mapping. As a condition is noted among members of a family, a genetic linkage map traces parts of chromosomes that are inherited in the same pattern as the condition. Statistics link the inheritance of particular conditions to particular regions of chromosomes, as defined by RFLP or other markers. (See, for example, Lander, E. S. and Botstein, D. (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.) Occasionally, genetic markers and their locations are known from previous studies. More often, however, the markers are simply stretches of DNA that differ among individuals. Examples of genetic linkage maps can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMEM) World Wide Web site.
In another embodiment of the invention, mddt sequences may be used to generate hybridization probes useful in chromosomal mapping of naturally occurring genomic sequences. Either coding or noncoding sequences of mddt may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of an mddt coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial PI constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat.
Genet. 15:345-355; Price, CM. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet.
7:149-154.)
Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data. (See, e.g., Meyers, supra, pp. 965-968.) Correlation between the location of mddt on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder.
The mddt sequences may also be used to detect polymoφhisms that are genetically linked to the inheritance of a particular condition, disease, or disorder. In situ hybridization of chromosomal preparations and genetic mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending existing genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of the corresponding human chromosome is not known. These new marker sequences can be mapped to human chromosomes and may provide valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once a disease or syndrome has been crudely correlated by genetic linkage with a particular genomic region, e.g., ataxia-telangiectasia to llq22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequences of the subject invention may also be used to detect differences in chromosomal architecture due to translocation, inversion, etc., among normal, carrier, or affected individuals.
Once a disease-associated gene is mapped to a chromosomal region, the gene must be cloned in order to identify mutations or other alterations (e.g., translocations or inversions) that may be correlated with disease. This process requires a physical map of the chromosomal region containing the disease-gene of interest along with associated markers. A physical map is necessary for determining the nucleotide sequence of and order of marker genes on a particular chromosomal region. Physical mapping techniques are well known in the art and require the generation of overlapping sets of cloned DNA fragments from a particular organelle, chromosome, or genome. These clones are analyzed to reconstruct and catalog their order. Once the position of a marker is determined, the DNA from that region is obtained by consulting the catalog and selecting clones from that region. The gene of interest is located through positional cloning techniques using hybridization or similar methods.
Diagnostic Uses The mddt of the present invention may be used to design probes useful in diagnostic assays. Such assays, well known to those skilled in the art, may be used to detect or confirm conditions, disorders, or diseases associated with abnormal levels of mddt expression. Labeled probes developed from mddt sequences are added to a sample under hybridizing conditions of desired stringency. In some instances, mddt, or fragments or oligonucleotides derived from mddt, may be used as primers in amplification steps prior to hybridization. The amount of hybridization complex formed is quantified and compared with standards for that cell or tissue. If mddt expression varies significantly from the standard, the assay indicates the presence of the condition, disorder, or disease. Qualitative or quantitative diagnostic methods may include northern, dot blot, or other membrane or dip-stick based technologies or multiple-sample format technologies such as PCR, enzyme-linked immunosorbent assay (ELISA)-like, pin, or chip-based assays.
The probes described above may also be used to monitor the progress of conditions, disorders, or diseases associated with abnormal levels of mddt expression, or to evaluate the efficacy of a particular therapeutic treatment. The candidate probe may be identified from the mddt that are specific to a given human tissue and have not been observed in GenBank or other genome databases. Such a probe may be used in animal studies, preclinical tests, clinical trials, or in monitoring the treatment of an individual patient. In a typical process, standard expression is established by methods well known in the art for use as a basis of comparison, samples from patients affected by the disorder or disease are combined with the probe to evaluate any deviation from the standard profile, and a therapeutic agent is administered and effects are monitored to generate a treatment profile. Efficacy is evaluated by determining whether the expression progresses toward or returns to the standard normal pattern. Treatment profiles may be generated over a period of several days or several months. Statistical methods well known to those skilled in the art may be use to determine the significance of such therapeutic agents.
The polynucleotides are also useful for identifying individuals from minute biological samples, for example, by matching the RFLP pattern of a sample's DNA to that of an individual's DNA. The polynucleotides of the present invention can also be used to determine the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, an individual can be identified through a unique set of DNA sequences. Once a unique ID database is established for an individual, positive identification of that individual can be made from extremely small tissue samples.
In a particular aspect, oligonucleotide primers derived from the mddt of the invention may be used to detect single nucleotide polymoφhisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymoφhism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from mddt are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSCCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high- throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed in silico SNP (isSNP), are capable of identifying polymoφhisms by comparing the sequences of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego CA). DNA-based identification techniques are critical in forensic technology. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, etc., can be amplified using, e.g., PCR, to identify individuals. (See, e.g., Erlich, H. (1992) PCR Technology, Freeman and Co., New York, NY). Similarly, polynucleotides of the present invention can be used as polymoφhic markers.
There is also a need for reagents capable of identifying the source of a particular tissue. Appropriate reagents can comprise, for example, DNA probes or primers prepared from the sequences of the present invention that are specific for particular tissues. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.
The polynucleotides of the present invention can also be used as molecular weight markers on nucleic acid gels or Southern blots, as diagnostic probes for the presence of a specific mRNA in a particular cell type, in the creation of subtracted cDNA libraries which aid in the discovery of novel polynucleotides, in selection and synthesis of oligomers for attachment to an array or other support, and as an antigen to elicit an immune response. Disease Model Systems Using mddt The mddt of the invention or their mammalian homologs may be "knocked out" in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Patent Number 5,175,383 and U.S. Patent Number 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M.R. (1989) Science 244:1288-1292).
The vector integrates into the corresponding region of the host genome by homologous recombination.
Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999- 2002; Wagner, K.U. et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain.
The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents. The mddt of the invention may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al. (1998)
Science 282:1145-1147). The mddt of the invention can also be used to create "knockin" humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of mddt is injected into animal ES cells, and the injected sequence integrates into the animal cell genome.
Transformed cells are injected into blastulae, and the blastulae are implanted as described above.
Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress mddt, resulting, e.g., in the secretion of MDDT in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).
Screening Assays MDDT encoded by polynucleotides of the present invention may be used to screen for molecules that bind to or are bound by the encoded polypeptides. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the bound molecule. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules. Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a ligand or fragment thereof, a natural substrate, or a structural or functional mimetic. (See, Coligan et al., (1991) Current Protocols in Immunology 1(2): Chapter 5.) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or to at least a fragment of the receptor, e.g., the active site. In either case, the molecule can be rationally designed using known techniques. Preferably, the screening for these molecules involves producing appropriate cells which express the polypepti e, e t er as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila. or E. coli. Cells expressing the polypeptide or cell membrane fractions which contain the expressed polypeptide are then contacted with a test compound and binding, stimulation, or inhibition of activity of either the polypeptide or the molecule is analyzed. An assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. Alternatively, the assay may assess binding in the presence of a labeled competitor.
Additionally, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.
Preferably, an ELISA assay using, e.g., a monoclonal or polyclonal antibody, can measure polypeptide level in a sample. The antibody can measure polypeptide level by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.
All of the above assays can be used in a diagnostic or prognostic context. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues.
Transcript Imaging and Toxicological Testing
Another embodiment relates to the use of mddt to develop a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent Number 5,840,484, expressly incoφorated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity pertaining to disease detection and treatment molecules.
Transcript images which profile mddt expression may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect mddt expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.
Transcript images which profile mddt expression may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingeφrints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E. F. et al. (1999) Mol. Carcinog. 24:153- 159; Steiner, S. and Anderson, N. L. (2000) Toxicol. Lett. 112-113:467-71, expressly incoφorated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingeφrints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome- wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in inteφretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29, 2000, available at http://www.niehs.nih.gov/oc/news/toxchip.htm.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.
In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.
Another particular embodiment relates to the use of MDDT encoded by polynucleotides of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, supra). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification. A proteomic profile may also be generated using antibodies specific for MDDT to quantify the levels of MDDT expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) Anal. Biochem. 270:103-11; Mendoze, L. G. et al. (1999) Biotechniques 27:778-88). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.
Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N. L. and Seilhamer, J. (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases. In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the MDDT encoded by polynucleotides of the present invention.
In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the MDDT encoded by polynucleotides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Transcript images may be used to profile mddt expression in distinct tissue types. This process can be used to determine disease detection and treatment molecule activity in a particular tissue type relative to this activity in a different tissue type. Transcript images may be used to generate a profile of mddt expression characteristic of diseased tissue. Transcript images of tissues before and after treatment may be used for diagnostic puφoses, to monitor the progression of disease, and to monitor the efficacy of drug treatments for diseases which affect the activity of disease detection and treatment molecules.
Transcript images of cell lines can be used to assess disease detection and treatment molecule activity and/or to identify cell lines that lack or misregulate this activity. Such cell lines may then be treated with pharmaceutical agents, and a transcript image following treatment may indicate the efficacy of these agents in restoring desired levels of this activity. A similar approach may be used to assess the toxicity of pharmaceutical agents as reflected by undesirable changes in disease detection and treatment molecule activity. Candidate pharmaceutical agents may be evaluated by comparing their associated transcript images with those of pharmaceutical agents of known effectiveness.
Antisense Molecules
The polynucleotides of the present invention are useful in antisense technology. Antisense technology or therapy relies on the modulation of expression of a target protein through the specific binding of an antisense sequence to a target sequence encoding the target protein or directing its expression. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa NJ; Alama, A. et al. (1997) Pharmacol. Res. 36(3):171-178; Crooke, S.T. (1997) Adv. Pharmacol. 40:1-49; Sharma, H.W. and R. Narayanan (1995) Bioessays 17(12):1055-1063; and Lavrosky, Y. et al. (1997) Biochem. Mol. Med. 62(1): 11-22.) An antisense sequence is a polynucleotide sequence capable of specifically hybridizing to at least a portion of the target sequence. Antisense sequences bind to cellular mRNA and/or genomic DNA, affecting translation and/or transcription. Antisense sequences can be DNA, RNA, or nucleic acid mimics and analogs. (See, e.g., Rossi, J.J. et al. (1991) Antisense Res. Dev. l(3):285-288; Lee, R. et al. (1998) Biochemistry 37(3):900-1010; Pardridge,
W.M. et al. (1995) Proc. Natl. Acad. Sci. USA 92(12):5592-5596; and Nielsen, P. E. and Haaima, G.
(1997) Chem. Soc. Rev. 96:73-78.) Typically, the binding which results in modulation of expression occurs through hybridization or binding of complementary base pairs. Antisense sequences can also bind to DNA duplexes through specific interactions in the major groove of the double helix.
The polynucleotides of the present invention and fragments thereof can be used as antisense sequences to modify the expression of the polypeptide encoded by mddt. The antisense sequences can be produced ex vivo, such as by using any of the ABI nucleic acid synthesizer series (Applied
Biosystems) or other automated systems known in the art. Antisense sequences can also be produced biologically, such as by transforming an appropriate host cell with an expression vector containing the sequence of interest. (See, e.g., Agrawal, supra.)
In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J.E., et al. (1998) J. Allergy Clin. Immunol. 102(3):469-475; and Scanlon, K.J., et al. (1995) 9(13): 1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) Blood 76:271; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY; Uckert, W. and W. Walther (1994) Pharmacol. Ther. 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J.J. (1995) Br. Med. Bull. 51(l):217-225; Boado, RJ. et al. (1998) J. Pharm. Sci. 87(11): 1308-1315; and Morris, M.C et al. (1997) Nucleic Acids Res. 25(14):2730-2736.)
Expression
In order to express a biologically active MDDT, the nucleotide sequences encoding MDDT or fragments thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding MDDT and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, supra. Chapters 4, 8, 16, and 17; and Ausubel, supra. Chapters 9, 10, 13, and 16.)
A variety of expression vector/host systems may be utilized to contain and express sequences encoding MDDT. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal (mammalian) cell systems. (See, e.g., Sambrook, supra; Ausubel, 1995, supra. Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Bitter, G.A. et al. (1987) Methods Enzymol.
153:516-544; Scorer, CA. et al. (1994) Bio/Technology 12:181-184; Engelhard, E.K. et al. (1994)
Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945;
Takamatsu, N. (1987) EMBO J. 6:307-311; Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196; Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659; and Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or heφes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M. et al., (1993) Proc. Natl. Acad. Sci. USA 90(13):6340-6344; Buller, R.M. et al. (1985) Nature 317(6040):813-815; McGregor, D.P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, I.M. and N. Somia (1997) Nature 389:239-242.) The invention is not limited by the host cell employed. For long term production of recombinant proteins in mammalian systems, stable expression of
MDDT in cell lines is preferred. For example, sequences encoding MDDT can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Any number of selection systems may be used to recover transformed cell lines. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.; Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14; Hartman, S.C. and R.CMulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051; Rhodes, CA. (1995) Methods Mol. Biol. 55:121-131.)
Therapeutic Uses of mddt
The mddt of the invention may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCED)-Xl disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) Science 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R.M. et al. (1995) Science 270:475-480; Bordignon, C et al. (1995) Science 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) Cell 75:207-
216; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:643-666; Crystal, R.G. et al. (1995) Hum. Gene
Therapy 6:667-703), thalassemias, familial hypercholesterolemia, and hemophilia resulting from Factor
VIII or Factor IX deficiencies (Crystal, R.G. (1995) Science 270:404-410; Verma, I.M. and Somia, N. (1997) Nature 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) Nature 335:395-396; Poeschla, E. et al. (1996)
Proc. Natl. Acad. Sci. USA. 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as
Plasmodium falciparum and Trvpanosoma cruzi). In the case where a genetic deficiency in mddt expression or regulation causes disease, the expression of mddt from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.
In a further embodiment of the invention, diseases or disorders caused by deficiencies in mddt are treated by constructing mammalian expression vectors comprising mddt and introducing these vectors by mechanical means into mddt-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and Anderson, W.F. (1993) Annu. Rev. Biochem. 62:191- 217; Ivies, Z. (1997) Cell 91:501-510; Boulay, J-L. and Recipon, H. (1998) Curr. Opin. Biotechnol. 9:445-450).
Expression vectors that may be effective for the expression of mddt include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). The mddt of the invention may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β-actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and Bujard, H. (1992) Proc. Natl. Acad. Sci. U.S.A. 89:5547-5551; Gossen, M. et al., (1995) Science 268:1766-1769; Rossi, F.M.V. and Blau, H.M. (1998) Curr. Opin. Biotechnol. 9:451-456), commercially available in the T-REX plasmid (Invitrogen); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V. and Blau, H.M. supra), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding MDDT from a normal individual. Commercially available liposome transformation kits (e.g., the PERFECT LIPED
TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and Eb, A.J. (1973) Virology 52:456-467), or by electroporation (Neumann, E. et al.
(1982) EMBO J. 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.
In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to mddt expression are treated by constructing a retrovirus vector consisting of (i) mddt under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus s-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc. Natl. Acad. Sci. U.S.A. 92:6733-6737), incoφorated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) J. Virol. 61:1647-1650; Bender, M.A. et al. (1987) J. Virol. 61:1639-1646; Adam, M.A. and Miller, A.D. (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol. 72:8463-8471; Zufferey, R. et al. (1998) J. Virol. 72:9873-9880). U.S. Patent Number 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incoφorated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4+ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M.L. (1997) J. Virol. 71:4707-4716; Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. U.S.A. 95:1201- 1206; Su, L. (1997) Blood 89:2283-2290).
In the alternative, an adenovirus-based gene therapy delivery system is used to deliver mddt to cells which have one or more genetic abnormalities with respect to the expression of mddt. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M.E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent Number 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incoφorated by reference. For adenoviral vectors, see also Antinozzi, PA. et al. (1999) Annu. Rev. Nutr. 19:511-544 and Verma, I.M. and Somia, N. (1997) Nature 18:389:239-242, both incoφorated by reference herein.
In another alternative, a heφes-based, gene therapy delivery system is used to deliver mddt to target cells which have one or more genetic abnormalities with respect to the expression of mddt. The use of heφes simplex virus (HSV)-based vectors may be especially valuable for introducing mddt to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of heφes-based vectors are well known to those with ordinary skill in the art. A replication-competent heφes simplex virus (HSV) type 1 -based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) Exp. Eye Res.169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Patent Number 5,804,413 to DeLuca ("Heφes simplex virus strains for gene transfer"), which is hereby incoφorated by reference. U.S. Patent Number 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for puφoses including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W. F. et al. 1999 J. Virol. 73:519-532 and Xu, H. et al., (1994) Dev. Biol. 163:152-161, hereby incoφorated by reference. The manipulation of cloned heφesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large heφesvirus genomes, the growth and propagation of heφesvirus, and the infection of cells with heφesvirus are techniques well known to those of ordinary skill in the art.
In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver mddt to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and Li, K-J. (1998) Curr. Opin. Biotech. 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full-length genomic RNA, resulting in the oveφroduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting mddt into the alphavirus genome in place of the capsid-coding region results in the production of a large number of mddt RNAs and the synthesis of high levels of MDDT in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SEN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) Virology 228:74-83). The wide host range of alphaviruses will allow the introduction of mddt into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.
Antibodies
Anti-MDDT antibodies may be used to analyze protein expression levels. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, and Fab fragments. For descriptions of and protocols of antibody technologies, see, e.g., Pound J.D. (1998) Immunochemical Protocols, Humana Press, Totowa, NJ. The amino acid sequence encoded by the mddt of the Sequence Listing may be analyzed by appropriate software (e.g., LASERGENE NAVIGATOR software, DNASTAR) to determine regions of high immunogenicity. The optimal sequences for immunization are selected from the C- terminus, the N-terminus, and those intervening, hydrophilic regions of the polypeptide which are likely to be exposed to the external environment when the polypeptide is in its natural conformation. Analysis used to select appropriate epitopes is also described by Ausubel (1997, supra. Chapter 11.7). Peptides used for antibody induction do not need to have biological activity; however, they must be antigenic. Peptides used to induce specific antibodies may have an amino acid sequence consisting of at least five amino acids, preferably at least 10 amino acids, and most preferably at least 15 amino acids. A peptide which mimics an antigenic fragment of the natural polypeptide may be fused with another protein such as keyhole hemolimpet cyanin (KLH; Sigma, St. Louis MO) for antibody production. A peptide encompassing an antigenic region may be expressed from an mddt, synthesized as described above, or purified from human cells.
Procedures well known in the art may be used for the production of antibodies. Various hosts including mice, goats, and rabbits, may be immunized by injection with a peptide. Depending on the host species, various adjuvants may be used to increase immunological response.
In one procedure, peptides about 15 residues in length may be synthesized using an ABI 431 A peptide synthesizer (Applied Biosystems) using fmoc -chemistry and coupled to KLH (Sigma) by reaction with M-maleimidobenzoyl-N-hydroxysuccinimide ester (Ausubel, 1995, supra). Rabbits are immunized with the peptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity by binding the peptide to plastic, blocking with 1% bovine serum albumin (BSA), reacting with rabbit antisera, washing, and reacting with radioiodinated goat anti-rabbit IgG. Antisera with antipeptide activity are tested for anti-MDDT activity using protocols well known in the art, including ELISA, radioimmunoassay (RIA), and immunoblotting.
In another procedure, isolated and purified peptide may be used to immunize mice (about 100 μg of peptide) or rabbits (about 1 mg of peptide). Subsequently, the peptide is radioiodinated and used to screen the immunized animals' B-lymphocytes for production of antipeptide antibodies. Positive cells are then used to produce hybridomas using standard techniques. About 20 mg of peptide is sufficient for labeling and screening several thousand clones. Hybridomas of interest are detected by screening with radioiodinated peptide to identify those fusions producing peptide-specific monoclonal antibody. In a typical protocol, wells of a multi-well plate (FAST, Becton-Dickinson, Palo Alto, CA) are coated with affinity-purified, specific rabbit-anti-mouse (or suitable anti-species IgG) antibodies at
10 mg/ml. The coated wells are blocked with 1% BSA and washed and exposed to supernatants from hybridomas. After incubation, the wells are exposed to radiolabeled peptide at 1 mg/ml.
Clones producing antibodies bind a quantity of labeled peptide that is detectable above background. Such clones are expanded and subjected to 2 cycles of cloning. Cloned hybridomas are injected into pristane-treated mice to produce ascites, and monoclonal antibody is purified from the ascitic fluid by affinity chromatography on protein A (Amersham Pharmacia Biotech). Several procedures for the production of monoclonal antibodies, including in vitro production, are described in Pound (supra). Monoclonal antibodies with antipeptide activity are tested for anti-MDDT activity using protocols well known in the art, including ELISA, RIA, and immunoblotting.
Antibody fragments containing specific binding sites for an epitope may also be generated. For example, such fragments include, but are not limited to, the F(ab')2 fragments produced by pepsin digestion of the antibody molecule, and the Fab fragments generated by reducing the disulfide bridges of the F(ab')2 fragments. Alternatively, construction of Fab expression libraries in filamentous bacteriophage allows rapid and easy identification of monoclonal fragments with desired specificity (Pound, supra. Chaps. 45-47). Antibodies generated against polypeptide encoded by mddt can be used to purify and characterize full-length MDDT protein and its activity, binding partners, etc.
Assays Using Antibodies Anti-MDDT antibodies may be used in assays to quantify the amount of MDDT found in a particular human cell. Such assays include methods utilizing the antibody and a label to detect expression level under normal or disease conditions. The peptides and antibodies of the invention may be used with or without modification or labeled by joining them, either covalently or noncovalently, with a reporter molecule. Protocols for detecting and measuring protein expression using either polyclonal or monoclonal antibodies are well known in the art. Examples include ELISA, RIA, and fluorescent activated cell sorting (FACS). Such immunoassays typically involve the formation of complexes between the MDDT and its specific antibody and the measurement of such complexes. These and other assays are described in Pound (supra). Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. The disclosures of all patents, applications, and publications mentioned above and below, including U.S. Ser. No. 60/280,067, U.S. Ser. No. 60/279,619, U.S. Ser. No. 60/280,068, U.S. Ser.
No.60/291,280, U.S. Ser. No. 60/291,849, U.S. Ser. No. 60/291,829, U.S. Ser. No. 60/299,428, U.S.
Ser. No. 60/300,001, and U.S. Ser. No. 60/299J76, are hereby expressly incoφorated by reference.
EXAMPLES
I. Construction of cDNA Libraries
RNA was purchased from CLONTECH Laboratories, Inc. (Palo Alto CA) or isolated from various tissues. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated with either isopropanol or sodium acetate and ethanol, or by other routine methods.
Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In most cases, RNA was treated with DNase. For most libraries, poly(A+) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega Coφoration (Promega), Madison WI), OLIGOTEX latex particles (QIAGEN, Inc. (QIAGEN), Valencia CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Inc., Austin TX).
In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene Cloning Systems, Inc. (Stratagene), La Jolla CA) or SUPERSCRIPT plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra. Chapters 5.1 through 6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad CA), PBK-CMV plasmid (Stratagene), PCR2-TOPOTA plasmid (Invitrogen), PCMV-ICIS plasmid (Stratagene), pIGEN (Incyte Genomics, Palo Alto CA), pRARE (Incyte Genomics), or pENCY (Incyte Genomics), or derivatives thereof. Recombinant plasmids were transformed into competent E. coli cells including XLl-Blue, XLl-BlueMRF, or SOLR from Stratagene or DH5α, DH10B, or ElectroMAX DH10B from Life Technologies.
II. Isolation of cDNA Clones
Plasmids were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: the Magic or WIZARD Minipreps DNA purification system (Promega); the AGTC Miniprep purification kit (Edge BioSystems, Gaithersburg MD); and the QIAWELL 8, QIAWELL 8 Plus, and QIAWELL 8 Ultra plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit (QIAGEN). Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format. (Rao, V.B. (1994) Anal. Biochem. 216:1-14.) Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Inc. (Molecular Probes), Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).
III. Sequencing and Analysis cDNA sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 thermal cycler (Applied Biosystems) or the PTC- 200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins
Scientific Coφ., Sunnyvale CA) or the MICROLAB 2200 liquid transfer system (Hamilton). cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGAB ACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra. Chapter 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.
IV. Assembly and Analysis of Sequences
Component sequences from chromatograms were subject to PHRED analysis and assigned a quality score. The sequences having at least a required quality score were subject to various preprocessing editing pathways to eliminate, e.g., low quality 3' ends, vector and linker sequences, polyA tails, Alu repeats, mitochondrial and ribosomal sequences, bacterial contamination sequences, and sequences smaller than 50 base pairs. In particular, low-information sequences and repetitive elements (e.g., dinucleotide repeats, Alu repeats, etc.) were replaced by "n's", or masked, to prevent spurious matches.
Processed sequences were then subject to assembly procedures in which the sequences were assigned to gene bins (bins). Each sequence could only belong to one bin. Sequences in each gene bin were assembled to produce consensus sequences (templates). Subsequent new sequences were added to existing bins using BLASTN (v.1.4 WashU) and CROSSMATCH. Candidate pairs were identified as all BLAST hits having a quality score greater than or equal to 150. Alignments of at least 82% local identity were accepted into the bin. The component sequences from each bin were assembled using a version of PHRAP. Bins with several overlapping component sequences were assembled using DEEP PHRAP. The orientation (sense or antisense) of each assembled template was determined based on the number and orientation of its component sequences. Template sequences as disclosed in the sequence listing correspond to sense strand sequences (the "forward" reading frames), to the best determination. The complementary (antisense) strands are inherently disclosed herein. The component sequences which were used to assemble each template consensus sequence are listed in Table 5, along with their positions along the template nucleotide sequences.
Bins were compared against each other and those having local similarity of at least 82% were combined and reassembled. Reassembled bins having templates of insufficient overlap (less than 95% local identity) were re-split. Assembled templates were also subject to analysis by STITCHER/EXON MAPPER algorithms which analyze the probabilities of the presence of splice variants, alternatively spliced exons, splice junctions, differential expression of alternative spliced genes across tissue types or disease states, etc. These resulting bins were subject to several rounds of the above assembly procedures.
Once gene bins were generated based upon sequence alignments, bins were clone joined based upon clone information. If the 5' sequence of one clone was present in one bin and the 3' sequence from the same clone was present in a different bin, it was likely that the two bins actually belonged together in a single bin. The resulting combined bins underwent assembly procedures to regenerate the consensus sequences. The final assembled templates were subsequently annotated using the following procedure.
Template sequences were analyzed using BLASTN (v2.0, NCBI) versus gbpri (GenBank version 128). "Hits" were defined as an exact match having from 95% local identity over 200 base pairs through 100% local identity over 100 base pairs, or a homolog match having an E-value, i.e. a probability score, of < 1 x 10'8. The hits were subject to frameshift FASTx versus GENPEPT
(GenBank version 128). (See Table 8). In this analysis, a homolog match was defined as having an E-value of < 1 x IO"8. The assembly method used above was described in "System and Methods for Analyzing Biomolecular Sequences," U.S.S.N. 09/276,534, filed March 25, 1999, and the LEFESEQ Gold user manual (Incyte) both incoφorated by reference herein. Following assembly, template sequences were subjected to motif, BLAST, and functional analyses, and categorized in protein hierarchies using methods described in, e.g., "Database System Employing Protein Function Hierarchies for Viewing Biomolecular Sequence Data," U.S. Patent Number 6,023,659; "Relational Database for Storing Biomolecule Information," U.S.S.N. 08/947,845, filed October 9, 1997; "Project-Based Full-Length Biomolecular Sequence Database," U.S. Patent Number 5,953,727, filed March 6, 1997; and "Relational Database and System for Storing Information Relating to Biomolecular Sequences," U.S.S.N. 09/034,807, filed March 4, 1998, all of which are incoφorated by reference herein.
The template sequences were further analyzed by translating each template in all three forward reading frames and searching each translation against the Pfam database of hidden Markov model-based protein families and domains using the HMMER software package (available to the public from Washington University School of Medicine, St. Louis MO). Regions of templates which, when translated, contain similarity to Pfam consensus sequences are reported in Table 3, along with descriptions of Pfam protein domains and families. Only those Pfam hits with an E-value of < 1 x 10'3 are reported. (See also World Wide Web site http://pfam.wustl.edu/ for detailed descriptions of Pfam protein domains and families.)
Additionally, the template sequences were translated in all three forward reading frames, and each translation was searched against hidden Markov models for signal peptides using the HMMER software package. Construction of hidden Markov models and their usage in sequence analysis has been described. (See, for example, Eddy, S.R. (1996) Curr. Opin. Str. Biol. 6:361-365.) Only those signal peptide hits with a cutoff score of 11 bits or greater are reported. A cutoff score of 11 bits or greater corresponds to at least about 91-94% true-positives in signal peptide prediction. Template sequences were also translated in all three forward reading frames, and each translation was searched against TMHMMER, a program that uses a hidden Markov model (HMM) to delineate transmembrane segments on protein sequences and determine orientation (Sonnhammer, E.L. et al. (1 Proc. xt nt . Con . n ntelligent Systems for Mol. Biol., Glasgow et al., eds., The Am.
Assoc. for Artificial Intelligence (AAAI) Press, Menlo Park, CA, and MIT Press, Cambridge, MA, pp. 175-182.) Regions of templates which, when translated, contain similarity to signal peptide or transmembrane consensus sequences are reported in Table 4. The results of HMMER analysis as reported in Tables 3 and 4 may support the results of
BLAST analysis as reported in Table 2 or may suggest alternative or additional properties of template- encoded polypeptides not previously uncovered by BLAST or other analyses.
Template sequences are further analyzed using the bioinformatics tools listed in Table 8, or using sequence analysis software known in the art such as MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR).
Template sequences may be further queried against public databases such as the GenBank rodent, mammalian, vertebrate, prokaryote, and eukaryote databases.
The template sequences were translated to derive the corresponding longest open reading frame as presented by the polypeptide sequences as reported in Table 7. Alternatively, a polypeptide of the invention may begin at any of the methionine residues within the full length translated polypeptide. Polypeptide sequences were subsequently analyzed by querying against the GenBank protein database (GENPEPT, (GenBank version 128)). Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as incoφorated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.
Table 7 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (GENPEPT) database. Column 1 shows the polypeptide sequence identification number (SEQ TD NO:) for the polypeptide segments of the invention. Column 2 shows the reading frame used in the translation of the polynucleotide sequences encoding the polypeptide segments. Column 3 shows the length of the translated polypeptide segments. Columns 4 and 5 show the start and stop nucleotide positions of the polynucleotide sequences encoding the polypeptide segments. Column 6 shows the GenBank identification number (GI Number) of the nearest GenBank homolog. Column 7 shows the probability score for the match between each polypeptide and its GenBank homolog. Column 8 shows the annotation of the GenBank homolog. V. Analysis of Polynucleotide Expression Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel, 1995, supra, ch. 4 and 16.)
Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:
BLAST Score x Percent Identity
5 x minimum {length(Seq. 1), length(Seq. 2)}
The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.
VI. Tissue Distribution Profiling
A tissue distribution profile is determined for each template by compiling the cDNA library tissue classifications of its component cDNA sequences. Each component sequence, is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract. Template sequences, component sequences, and cDNA library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA).
Table 6 shows the tissue distribution profile for the templates of the invention. For each template, the three most frequently observed tissue categories are shown in column 3, along with the percentage of component sequences belonging to each category. Only tissue categories with percentage values of ≥ 10% are shown. A tissue distribution of "widely distributed" in column 3 indicates percentage values of <10% in all tissue categories.
VII. Transcript Image Analysis Transcript images are generated as described in Seilhamer et al., "Comparative Gene
Transcript Analysis," U.S. Patent Number 5,840,484, incoφorated herein by reference.
VIII. Extension of Polynucleotide Sequences and Isolation of a Full-length cDNA
Oligonucleotide primers designed using an mddt of the Sequence Listing are used to extend the nucleic acid sequence. One primer is synthesized to initiate 5' extension of the template, and the other primer, to initiate 3' extension of the template. The initial primers may be designed using OLIGO 4.06 software (National Biosciences, Inc. (National Biosciences), Plymouth MN), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68 °C to about 72 °C Any stretch of nucleotides which would result in hahpin structures and primer-primer dimerizations are avoided. Selected human cDNA libraries are used to extend the sequence. If more than one extension is necessary or desired, additional or nested sets of primers are designed.
High fidelity amplification is obtained by PCR using methods well known in the art. PCR is performed in 96-well plates using the PTC-200 thermal cycler (MJ Research). The reaction mix contains DNA template, 200 nmol of each primer, reaction buffer containing Mg2+, (NH4)2S04, and β- mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68 °C, 5 min; Step 7: storage at 4°C In the alternative, the parameters for primer pair T7 and SK+ are as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C
The concentration of DNA in each well is determined by dispensing 100 μl PICOGREEN quantitation reagent (0.25% (v/v); Molecular Probes) dissolved in IX Tris-EDTA (TE) and 0.5 μl of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Incoφorated (Corning), Corning NY), allowing the DNA to bind to the reagent. The plate is scanned in a FLUOROSKAN II
(Labsystems Oy) to measure the fluorescence of the sample and to quantify the concentration of
DNA. A 5 μl to 10 μl aliquot of the reaction mixture is analyzed by electrophoresis on a 1 % agarose mini-gel to determine which reactions are successful in extending the sequence. The extended nucleotides are desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides are separated on low concentration (0.6 to 0.8%) agarose gels, fragments are excised, and agar digested with AGAR ACE (Promega). Extended clones are religated using T4 ligase (New England Biolabs, Inc., Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent E. coli cells. Transformed cells are selected on antibiotic -containing media, individual colonies are picked and cultured overnight at 37 °C in 384-well plates in LB/2x carbenicillin liquid media. The cells are lysed, and DNA is amplified by PCR using Taq DNA polymerase (Amersham
Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C DNA is quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries are reamplified using the same conditions as described above. Samples are diluted with 20% dimethysulf oxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).
In like manner, the mddt is used to obtain regulatory sequences (promoters, introns, and enhancers) using the procedure above, oligonucleotides designed for such extension, and an appropriate genomic library.
IX. Labeling of Probes and Southern Hybridization Analyses
Hybridization probes derived from the mddt of the Sequence Listing are employed for screening cDNAs, mRNAs, or genomic DNA. The labeling of probe nucleotides between 100 and 1000 nucleotides in length is specifically described, but essentially the same procedure may be used with larger cDNA fragments. Probe sequences are labeled at room temperature for 30 minutes using a T4 polynucleotide kinase, γ32P-ATP, and 0.5X One-Phor-All Plus (Amersham Pharmacia Biotech) buffer and purified using a ProbeQuant G-50 Microcolumn (Amersham Pharmacia Biotech). The probe mixture s i uted to IO dpm/μg/ml hybridization buffer and used in a typical membrane-based hybridization analysis.
The DNA is digested with a restriction endonuclease such as Eco RV and is electrophoresed through a 0.7% agarose gel. The DNA fragments are transferred from the agarose to nylon membrane (NYTRAN Plus, Schleicher & Schuell, Inc., Keene NH) using procedures specified by the manufacturer of the membrane. Prehybridization is carried out for three or more hours at 68 °C, and hybridization is carried out overnight at 68 °C. To remove non-specific signals, blots are sequentially washed at room temperature under increasingly stringent conditions, up to 0.1 x saline sodium citrate
(SSC) and 0.5% sodium dodecyl sulfate. After the blots are placed in a PHOSPHOREMAGER cassette (Molecular Dynamics) or are exposed to autoradiography film, hybridization patterns of standard and experimental lanes are compared. Essentially the same procedure is employed when screening RNA.
X. Chromosome Mapping of mddt The cDNA sequences which were used to assemble SEQ ED NO: 1-396 are compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that match SEQ TD NO: 1-396 are assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as PHRAP (Table 8). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Genethon are used to determine if any of the clustered sequences have been previously mapped. Inclusion of a mapped sequence in a cluster will result in the assignment of all sequences of that cluster, including its particular SEQ TD NO:, to that map location. The genetic map locations of SEQ ED NO: 1-396 are described as ranges, or intervals, of human chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Genethon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters.
XI. Microarray Analysis
Probe Preparation from Tissue or Cell Samples
Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and polyA+ RNA is purified using the oligo (dT) cellulose method. Each polyA+ RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/μl oligo-dT primer (21mer), IX first strand buffer, 0.03 units/μl RNase inhibitor, 500 μM dATP, 500 μM dGTP, 500 μM dTTP, 40 μM dCTP, 40 μM dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng polyA+ RNA with GEMBRIGHT kits (Incyte). Specific control polyA+ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA (W. Lei, unpublished). As quantitative controls, the control mRNAs at 0.002 ng,
0.02 ng, 0.2 ng, and 2 ng are diluted into reverse transcription reaction at ratios of 1:100,000, 1:10,000,
1:1000, 1:100 (w/w) to sample mRNA respectively. The control mRNAs are diluted into reverse transcription reaction at ratios of 1:3, 3:1, 1:10, 10:1, 1:25, 25:1 (w/w) to sample mRNA differential expression patterns. After incubation at 37° C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85° C to the stop the reaction and degrade the RNA. Probes are purified using two successive CHROMA SPEN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The probe is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and resuspended in 14 μl 5X SSC/0.2% SDS.
Microarray Preparation Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 μg. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech). Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Coφoration (VWR), West Chester, PA), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C oven.
Array elements are applied to the coated glass substrate using a procedure described in US Patent No. 5,807,522, incoφorated herein by reference. 1 μl of the array element DNA, at an average concentration of 100 ng/μl, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide. Microarrays are UV-crosslinked using a STRATALENKER UV-crosslinker (Stratagene).
Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford, MA) for 30 minutes at 60° C followed by washes in 0.2% SDS and distilled water as before.
Hybridization
Hybridization reactions contain 9 μl of probe mixture consisting of 0.2 μg each of Cy3 and Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer. The probe mixture is heated to 65° C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm2 coverslip. The arrays are transferred to a wateφroof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 μl of 5x SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60° C. The arrays are washed for 10 min at 45° C in a first wash buffer (IX SSC, 0.1% SDS), three times for 10 minutes each at 45°C in a second wash buffer (0.1X SSC), and dried.
Detection
Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster- scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a resolution of 20 micrometers. In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially.
Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously. The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the probe mix at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two probes from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the puφose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.
The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital
(A/D) conversion board (Analog Devices, Inc., Norwood, MA) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore 's emission spectrum.
A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).
XII. Complementary Nucleic Acids
Sequences complementary to the mddt are used to detect, decrease, or inhibit expression of the naturally occurring nucleotide. The use of oligonucleotides comprising from about 15 to 30 base pairs is typical in the art. However, smaller or larger sequence fragments can also be used. Appropriate oligonucleotides are designed from the mddt using OLIGO 4.06 software (National Biosciences) or other appropriate programs and are synthesized using methods standard in the art or ordered from a commercial supplier. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent transcription factor binding to the promoter sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding and processing of the transcript.
XIII. Expression of MDDT
Expression and purification of MDDT is accomplished using bacterial or virus-based expression systems. For expression of MDDT in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the trp-lac (tac) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the lac operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express MDDT upon induction with isopropyl beta-D- thiogalactopyranoside (IPTG). Expression of MDDT in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus
(AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding MDDT by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases.
Infection of the latter requires additional genetic modifications to baculovirus. (See e.g., Engelhard, supra; and Sandig, supra.)
In most expression systems, MDDT is synthesized as a fusion protein with, e.g., glutathione S- transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma iaponicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from MDDT at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak Company, Rochester NY). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra. Chapters 10 and 16). Purified MDDT obtained by these methods can be used directly in the following activity assay. XIV. Demonstration of MDDT Activity
MDDT, or biologically active fragments thereof, are labeled with 125I Bolton-Hunter reagent. (See, e.g., Bolton, A.E. and W.M. Hunter (1973) Biochem. J. 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled MDDT, washed, and any wells with labeled MDDT complex are assayed. Data obtained using different concentrations of MDDT are used to calculate values for the number, affinity, and association of MDDT with the candidate molecules. Alternatively, molecules interacting with MDDT are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989) Nature 340:245-246, or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (CLONTECH). MDDT may also be used in the PATHCALLENG process (CuraGen Coφ., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S.
Patent No. 6,057,101). XV. Functional Assays
MDDT function is assessed by expressing mddt at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT (Life Technologies) and pCR3.1 (Invitrogen Coφoration, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 μg of recombinant vector are transiently transfected into a human cell line, preferably of endothelial or hematopoietic origin, using either liposome formulations or electroporation. 1-2 μg of an additional plasmid containing sequences encoding a marker protein are co-transfected.
Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; CLONTECH), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties.
FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M. G. (1994) Flow Cytometry, Oxford, New York NY.
The influence of MDDT on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding MDDT and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Inc., Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding MDDT and other genes of interest can be analyzed by northern analysis or microarray techniques. XVI. Production of Antibodies MDDT substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g.,
Harrington, M.G. (1990) Methods Enzymol. 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.
Alternatively, the MDDT amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding peptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra. Chapter 11.)
Typically, peptides 15 residues in length are synthesized using an ABI 431 A peptide synthesizer (Applied Biosystems) using fmoc-chemistry and coupled to KLH (Sigma) by reaction with
N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g.,
Ausubel, supra.) Rabbits are immunized with the peptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide activity by, for example, binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio- iodinated goat anti-rabbit IgG. Antisera with antipeptide activity are tested for anti-MDDT activity using protocols well known in the art, including ELISA, RIA, and immunoblotting.
XVII. Purification of Naturally Occurring MDDT Using Specific Antibodies
Naturally occurring or recombinant MDDT is substantially purified by immunoaffinity chromatography using antibodies specific for MDDT. An immunoaffinity column is constructed by covalently coupling anti-MDDT antibody to an activated chromatographic resin, such as
CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.
Media containing MDDT are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of MDDT (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody MDDT binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and MDDT is collected.
All publications and patents mentioned in the above specification are herein incoφorated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention.
Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.
o
/-. rv oo o θ '— co '^r i o r oo o O '— CM co ^- i o rv C0 O O -— CN cO ^ lO O rv oO O O '— CM cO ' LO -O rv oO O O '— CM CO ^ LO -O
U tl 'ϊ ^ LO UJ L LO LO i L L tO tO .O O -O 'O -O O -O O <) <3 rv. rv rv rv. rv rv rv rv iv, rv co co co co co co oo oo oo oo c> c> c> c> c c> c
- σ co <
Λ '- CM c l iO O S CO O '- CN O CM CO 'ϊ lO O rv cO O O -— N cO '^- LO O rv cO O O i— CM CO ^J- LO -O (v. 00 o o
— LO IO LO LO LO LO IO IO LO O -O -O -O o o o -o o rv rv rv rv r rv r rv rv rv CO CO OO CO CO CO OO OO CO CO O O o o c o o o o o o o 3 LO -O rv CO O O '—
G o LU OO O
O
00 o o o> O ■— CM CO 't LO -O 00 O CD ■— ( CTHO O CO O O '- CN cO '^ LO O rv cO O O '— CM O ^ LO O rv oO O O ■— CM CO 3 LO O Q O O CD O O O O O CM CM CM CM CM CM CM CM CN CM CO CO CO CO CO CO CO CO CO CO ^- "=ϊ -^ <g- <g-
^ ^ l Lθ L0 LO tO LO lO L0 L0 lO L0 L0 L0 Lθ L0 Lθ l0 Lθ L0 LO L0 L0 L0 L0 L0 L0 t0 L0 L0 L0 l0 L0 L0 L0 L0 LO LO L^ s ^
LO LO LO
CO
CO
<
o
^ •— CN CO ^j LO O rv OO O O •— C O <J lO O N CO C> O - CN CO -vT LO O Iv. cO O O '— CN CO 'vT lO O rv cO O O '— CN CO 'q- LO O rv oO O O O CO CO C C CO C C CO O ^ '^ '^ ^ '^ '^ 'vl- ^ ^ ^I LO r- o o o o o o o o o — — — — — r— — r— r- r- CM CM CN CM C CN CN CN CN CN c o a - - - - - - - - - - U o CO O
TABLE 1
SEQ ID NO: Template ID SEQ ID NO: ORF ID
151 LG:006242J:2001MAR30 547 LG:006242J.orf3:2001 MAR30
152 LG:027320J:2001MAR30 548 LG:027320J.orf2:2001 MAR30
153 LG: 147541.44:2001 MAR30 549 LG:147541.44.orf2:2001MAR30
154 LG:228319.2:2001MAR30 550 LG:228319.2.orfl:2001MAR30
155 LG:238754.19:2001 MAR30 551 LG:238754.19.orf 1 :2001 MAR30
156 LG:405751.12:2001 MAR30 552 LG:405751.12.orf2:2001 MAR30
157 U:011822.6:2001 MAY17 553 U:011822.6.orf3:2001MAY17
158 LI: 1012467.2:2001 MAY17 554 LI: 1012467.2.orf3:2001 MAY17
159 LI: 1169981.13:2001 MAY17 555 U:l 169981.13.orf2:2001 MAY 17
160 U:1171553.1:2001MAY17 556 U:1171553.1.orf3:2001MAY17
161 LI: 1183156.3:2001 MAY17 557 LI: 1183156.3.orf2:2001 MAY17
162 LI: 1188500.6:2001 MAY17 558 Ll:l 188500.6.orf3:2001MAY17
163 LI: 147333.12:2001 MAY17 559 LI: 147333.12.orf2:2001 MAY17
164 LI: 147523.7:2001 MAY17 560 LI: 147523J.orf3:2001 MAY17
165 LI: 197388.10:2001 MAY17 561 LI: 197388.10.orf2:2001 MAY17
166 LI:2049216.1:2001MAY17 562 U:2049216.1.orf2:2001MAY17
167 Ll:2051624.2:2001 MAY17 563 Ll:2051624.2.orf3:2001 MAY17
168 U:2121838.1:2001MAY17 564 LI:2121838.1.orf3:2001MAY17
169 U:2122954.8:2001 MAY17 565 U:2122954.8.orfl:2001MAY17
170 LI:2198064.2:2001MAY17 566 U:2198064.2.orf3:2001MAY17
171 U:2206583.1:2001MAY17 567 Ll:2206583.1.orf3:2001 MAY17
172 LI:235663.6:2001MAY17 568 U:235663.6.orf3:2001 MAY17
173 LI:236386J:2001MAY17 569 LI:236386J.orf2:2001 MAY17
174 U:236654.3:2001MAY17 570 Ll:236654.3.orf3:2001 MAY17
175 U:256059.46:2001MAY17 571 U:256059.46.orf 1 :2001 MAY17
176 U:279978.22:2001MAY17 572 Ll:279978.22.orf2:2001 MAY! 7
177 U:311541.6:2001 MAY17 573 LI:311541.6.orf3:2001MAY17
178 U:346123.1:2001MAY17 574 U:346123.1.orf2:2001MAY17
179 Ll:381211.5:2001 MAY17 575 U:381211.5.orf3:2001MAY17
180 U:412197.82:2001MAY17 576 U:412197.82.orf2:2001 MAY17
181 Ll:412936.49:2001 MAY17 577 Ll:412936.49.orf 1 :2001 MAY17
182 LI:427792.139:2001MAY17 578 LL427792.139.orf3:2001 MAY17
183 Ll:450229.1:2001 MAY 17 579 Ll:450229.1.orf 1 :2001 MAY17
184 Ll:475565.243:2001 MAY17 580 Ll:475565.243.orf3:2001 MAY17
185 LIJ64701.8:2001 MAY17 581 LIJ64701 ,8.orf2:2001 MAY17
186 Ll:024124.2:2001 MAY17 582 Ll:024124.2.orf3:2001 MAY17
187 U:038252.3:2001MAY17 583 Ll:038252.3.orf 1 :2001 MAY17
188 Ll:056882.1:2001 MAY 17 584 Ll:056882.1.orf 1 :2001 MAY17
189 U:059530.1:2001MAY17 585 U:059530.1.orf2:2001MAY17
190 LI:089950.30:2001MAY17 586 U:089950.30.orf3:2001 MAY17
191 LI: 1072906.38:2001 MAY17 587 LI: 1072906.38.orf2:2001 MAY17
192 LI: 1158936.4:2001 MAY17 588 LI: 1158936.4.orf 1 :2001 MAY17
1 3 LI: 1173412.15:2001 MAY17 589 U:1173412.15.orf2:2001MAY17
194 U:1174279.14:2001MAY17 590 LI: 1174279.14,orf3:2001 MAY17
195 LI:1174809.1:2001MAY17 591 LI: 1174809.1.orf2:2001 MAY17
196 LI:1175131.1:2001MAY17 592 LI:1175131.1.orf2:2001MAY17
197 LI: 1188801.10:2001 MAY17 593 LI: 1188801.10.orf 1 :2001 MAY17
198 LI: 1189176.27:2001 MAY17 594 LI: 1189176.27.orf2:2001 MAY17
199 LI: 197739.4:2001 MAY17 595 LI: 197739.4.orf3:2001 MAY17
200 LI:2049016.1:2001MAY17 596 Ll:2049016.1.orf2:2001 MAY17 TABLE 1
SEQ ID NO Template ID SEQ ID NO: ORF ID
201 U:2049137.1:2001MAY17 597 Ll:2049137.1 ,orf2:2001 MAY17
202 LI:2051907.1:2001MAY17 598 Ll:2051907.1.orf3:2001 MAY17
203 U:2117996.13:2001 MAY17 599 Ll:2117996.13.orf3:2001MAYl 7
204 Ll:2118683.15:2001 MAY17 600 U:2118683.15.orfl:2001MAY17
205 11:2120312.1:2001MAY17 601 LI:2120312.1.orf2:2001MAY17
206 Ll:2121328.17:2001 MAY17 602 U:2121328.17.orf3:2001MAY17
207 Ll:2121802.5:2001 MAY17 603 Ll:2121802.5.orf2:2001 MAY17
208 Ll:2123406.9:2001 MAY17 604 Ll:2123406.9.orf 1 :2001 MAY17
209 Ll:216129.45:2001 MAY17 605 Ll:216129.45.orf3:2001 MAY17
210 U:2186630.1:2001MAY17 606 Ll:2186630.1.orf3:2001 MAY17
211 11:2188206.2:2001 MAY17 607 Ll:2188206.2.orf3:2001 MAY17
212 U:2199710.9:2001MAY17 608 LI:2199710.9.orf3:2001MAY17
213 11:2209335.2:2001 MAY17 609 Ll:2209335.2.orf3:2001 MAY17
214 Ll:230980.13:2001 MAY17 610 Ll:230980.13.orf 1 :2001 MAY17
215 Ll:244421.37:2001 MAY17 611 LI:244421.37.orf2:2001MAY17
216 U:341998.1:2001MAY17 612 Ll:341998.1.orf2:2001 MAY17
217 Ll:347931.10:2001 MAY17 613 LL347931.10.orf2:2001 MAY! 7
218 Ll:350771.42:2001 MAY17 614 LI:350771.42.orf3:2001MAY17
219 LI:354423.6:2001MAY17 615 U:354423.6.orf3:2001 MAY17
220 U:399333.8:2001MAY17 616 U:399333.8.orf2:2001 MAY17
221 U:445084.36:2001MAY17 617 Ll:445084.36.orf3:2001 MAY17
222 LI:454087.3:2001MAY17 618 U:454087.3.orf 1 :2001 MAY17
223 U:474887.1:2001MAY17 619 Ll:474887.1 ,orf2:2001 MAY17
224 LI:745251.1:2001MAY17 620 U:745251.1.orfl:2001MAY17
225 LIJ47717.9:2001 MAY17 621 LIJ47717.9.orf 1 :2001 MAY17
226 Ll:806211.3:2001 MAY17 622 Ll:806211.3.orf3:2001MAY17
227 U:815072.1:2001MAY17 623 U:815072.1. orf 1:2001 MAY17
228 Ll:817052.8:2001 MAY17 624 U:817052.8.orfl:2001MAY17
229 U:903392.45:2001MAY17 625 Ll:903392.45.orf3:2001 MAY17
230 U:013724.1:2001MAY17 626 U:013724.1.orf2:2001MAY17
231 U:191726.16:2001MAY17 627 U:191726.16.orf2:2001MAY17
232 U:202270.2:2001MAY17 628 U:202270.2.orf3:2001 MAY17
233 Ll:2119352.6:2001 MAY17 629 U:2119352.6.orfl:2001MAY17
234 U:2207776.11:2001MAY17 630 U:2207776.11.orf3:2001 MAY17
235 Ll:256442.1:2001 MAY! 7 631 LL256442.1 ,orf3:2001 MAY17
236 LI:330497J:2001MAY17 632 LI:330497J.orf 1 :2001 MAY17
237 U:018494.1:2001MAY17 633 U:018494.1.orf 1 :2001 MAY17
238 Ll:023518.2:2001 MAY17 634 U:023518.2.orf3:2001 MAY17
239 U:053488.46:2001MAY17 635 U:053488.46.orf 1 :2001 MAY17
240 LI:058298.27:2001MAY17 636 U:058298.27.orf2:2001 MAY17
241 LI: 1110046.1 :2001MAY17 637 LI: 1110046.1. orf3:2001MAYl 7
242 U:1166752.11:2001MAY17 638 LI: 1166752.11.orf3:2001 MAY17
243 U:1173766.1:2001MAY17 639 LI: 1173766.1. orf 1:2001 MAY17
244 LI: 1177952.4:2001 MAY17 640 LI: 1177952.4.orf3:2001 MAY17
245 LI: 1178064.3:2001 MAY17 641 LI: 1178064.3.orf 1 :2001 MAY17
246 U:1183121.1:2001MAY17 642 LI:1183121.1.orf3:2001MAY17
247 LI: 1190431.13:2001 MAY17 643 Ll:l 190431.13.orfl:2001MAY17
248 U:199121.14:2001MAY17 644 U:199121.14.orf3:2001MAY17
249 U:202630.5:2001MAY17 645 U:202630.5.orf2:2001 MAY17
250 LI:2034488.1:2001MAY17 646 Ll:2034488.1.orf2:2001 MAY17 r rv r r v rv rv rv, v r rv r-. ρ» r r r rv
© r- . ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ r- r- ^ -- ^ -. ^ -. o
CΛ <<<<<^<^<^< < < < < >; <<<<<<>;<
∑s : 22 < 2 < <2 < : :≥ :∑
H o ooδδr- — o — o — o -— δ ■— δ — δ — — — δ δδδδδ — δ U O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O α. C CM CM CM CM O CM O CM O CM O CM O C O CN O CM O O O CN CM CN CM CN CM O CM
- - < ^ - - ^ - ^ c cd ^ c" ^ " ^ ^ ^ t t t t t - t CM t CM t cM t CM t co t N t CM CN CN t t t t t t CM t o o o o o o t o t o t o o t o o t o o o o o o o 0d > ^ td M" 9 ^ 9 cd 9 cM" 9 cM" 9 cd 9 Ld 9 Ld 9 9 O
O N fr (N 0 U0 0- O C0 3 ^ ^ <3 C> ^ Λ N N U5 C ^ C i 0 ) C0 ifi c <3 f> ι- ^ ^ ^ O ^ ^ CO l & N CO i- O N ^ N O n tO tO -O O- CO CO 'a-
Q ■- ω ω c^ O N ^ c ) ω ύ ^ c^ o ) ) ^ o ^ <) O N '- oo c^ ^ ^ι c o '0
— LO ■— CO O cO O O lO lO O O O 'vT CN i— O <J rv CM CN <— OO O O O CN CO CM CO O
LvL.. <OJ >— <ς—M C '-N CON CCON OCNO 'c^ LcO cLO O'^ r^- —^ L^O 0^0 OCO —∞ ■— O CM O O r- r— CN CM CM CO CO ^
0 -J -J -J -J -J -- -- -- -- -- -J -J -. -J -J -- -- J -- -- -- --
o CN CO N
CO O •— o o T lO o
-o o o o c -o> o o o o o o
V_
CN CN c
cO O '— CM CN CM CM
ON CO
LC3 LC3 lO 3 LO o rv 00 - ,— CN CO sT LO o rv oo o o — CN o ^ io rv oo o O '— CM co ^r to o rv oo o o CM CO ' T tO O Iv. cO O to LO LO lO LfJ <3 O •O O O 3 O -O -O i r N r N i s N co co co co co co co co co co o o o o o o o o o o o
— CM C CN CN C CM C C C C C C C C oCN C CN CN CM CM CM C C CM CM CN CM CN CN CN CM CM C C C C^ o o Q o LU co O
TABLE 1
SEQ ID NO: Template ID SEQ ID NO: ORF ID
301 Ll:243871.4:2001 MAY17 697 LI:243871.4.orf2:2001 AY17
302 U:245597J:2001 MAY17 698 Ll:245597.7.orf2:2001 MAY17
303 U:256009.31 :2001 MAY17 699 Ll:256009.31.orfl :2001 MAY17
304 U:262221.1 :2001 MAY17 700 LL262221.1.orf3:2001 MAY17
305 U:332957.8:2001 MAY17 701 Ll:332957.8.orf3:2001 MAY17
306 U:335352.13:2001 MAY17 702 Ll:335352.13.orf2:2001 MAY17
307 LI:343844J:2001 MAY17 703 Ll:343844.7.orf3:2001 MAY17
308 U:344528.1 :2001 MAY17 704 LL344528.1.orfl :2001 MAY17
309 LI:374578.27:2001 MAY17 705 U:374578.27.orf 1 :2001 MAY17
310 U:381993.13:2001 MAY17 706 U:381993.13.orf3:2001 MAY17
31 1 LI:400373.2:2001 MAY17 707 Ll:400373.2.orf 1 :2001 MAY17
312 LI:400963.ό:2001 MAY17 708 U:400963.6.orf3:2001 MAY17
313 LI:404874.8:2001 MAY17 709 Ll:404874.8.orf2:2001 MAY17
314 U:405158.18:2001 MAY17 710 LL405158.18.orf2:2001 MAY17
315 U:405889.22:2001 MAY17 71 1 Ll:405889.22.orf2:2001 MAY17
316 Ll:41 1 151.31 :2001 MAY17 712 U:41 1 151.31.orfl :2001 MAY17
317 LI:41 1313.51 :2001 MAY17 713 LI:41 1313.51.orf2:2001 MAY17
318 Ll:417127.1 :2001 MAY17 714 LI:417127.1.orfl :2001 MAY17
319 Ll:429817.44:2001 MAY17 715 Ll:429817.44.orf3:2001 MAY17
320 U:474134.23:2001 MAY17 716 U:474134.23.orf3:2001 MAY17
321 U:475378.3:2001 MAY17 717 Ll:475378.3.orf2:2001 MAY17
322 UJ49588.15:2001 MAY17 718 LIJ49588.15.orf3:2001 MAY17
323 UJ57736.17:2001 MAY17 719 LIJ57736.17.orf 1 :2001 MAY17
324 Ll:817278.4:2001 MAY 17 720 U:817278.4.orf2:2001 MAY17
325 U:027320.5:2001 MAY17 721 Ll:027320.5.orf2:2001 MAY17
326 U:204635.5:2001 MAY17 722 Ll:204635.5.orf2:2001 MAY17
327 U:215532.38:2001 MAY17 723 U:215532.38.orf2:2001 MAY17
328 U:228319.6:2001 MAY17 724 U:228319.6.orf2:2001 MAY17
329 U:236589.24:2001 MAY17 725 Ll:236589.24.orf2:2001 MAY17
330 LI:247444.3:2001 MAY17 726 Ll:247444.3.orf2:2001 MAY17
331 LI:332404.20:2001 MAY17 727 Ll:332404.20.orf3:2001 MAY17
332 LG: 1088459.4:2001 JUN22 728 LG: 1088459.4.orf2:200UUN22
333 LG: 1501495.1 :2001JUN22 729 LG: 1501495.1.orfl :200UUN22
334 LG:334284.10:2001 JUN22 730 LG:334284.10.orf 1 :2001 JUN22
335 LG:345279.19:2001 JUN22 731 LG:345279.19.orf 1 :2001JUN22
336 LG:7689681.1 :2001JUN22 732 LGJ689681.1.orfl :2001 JUN22
337 LG:7690093.1 :2001JUN22 733 LGJ690093.1.orf3:2001 JUN22
338 LGJ690175.3:2001 JUN22 734 LGJ690175.3.orf2:2001JUN22
339 LG:7697128.1 :2001JUN22 735 LGJ697128.1.orf2:200UUN22
340 LG:006394.20:2001JUN22 736 LG:006394.20.orfl :2001 JUN22
341 LG:1012069.1 :2001JUN22 737 LG: 1012069.1.orfl :2001JUN22
342 LG: 104533.1 1 :2001 JUN22 738 LG: 104533.1 1.orf2:2001 JUN22
343 LG:1045853.23:2001JUN22 739 LG: 1045853.23.orfl :2001JUN22
344 LG:1081017.8:2001JUN22 740 LG: 1081017.8.orf3:2001 JUN22
345 LG:1090358.6:2001JUN22 741 LG: 1090358.6.orf3:2001JUN22
346 LG:1 135312.7:2001JUN22 742 LG: 1 135312J.orf2:2001JUN22
347 LG: 1328501.2:2001 JUN22 743 LG: 1328501.2.orfl :200UUN22
348 LG:133095.1 :2001 JUN22 744 LG: 133095.1 ,orf3:200UUN22
349 LG:135379.5:2001 JUN22 745 LG:135379.5.orfl :2001JUN22
350 LG:1365581.3:2001JUN22 746 LG:1365581.3.orf 1 :200UUN22
Table 2
SEQ ID NO: Template ID Gl Number Probability Score Annotation
1 LG:036272.1 :2001 MAR30 g 12846107 1.00E-1 12 putative (Mus musculus]
2 LG:093337.3:2001 MAR30 g 12652727 2.00E-31 Unknown (protein for IMAGE:3352566) (Homo sapiens)
3 LG: 1049927.6:2001 MAR30 g 16551755 6.00E-49 unnamed protein product (Homo sapiens)
4 LG: 1051891.34:2001 MAR30 g38032 0 ZNF43 (Homo sapiens)
5 LG: 1089626.1 :2001 MAR30 g 16549180 0 unnamed protein product (Homo sapiens)
6 LG: 1 101416.6:2001 MAR30 g872315 4.00E-47 40S ribosomal protein SI 2 (Sus scrofa)
7 LG: 1295974.1 :2001 MAR30 g485373 1.00E-104 ferritin heavy chain (Mus musculus)
8 LG: 1400572.2:2001 MAR30 g 12052983 2.00E-62 hypothetical protein (Homo sapiens)
9 LG: 1446621.1 :2001 MAR30 g7959207 2.00E-38 KIAA1473 protein (Homo sapiens)
10 LG:1499752.1 :2001 MAR30 g339697 2.00E-18 thymosin beta- 10 (Homo sapiens)
1 1 LG: 1503044.7:2001 MAR30 g 15929821 l .OOE-1 17 putative Rab5 GDP/GTP exchange factor homologue (Homo sapiens)
12 LG: 1503588.1 :2001 MAR30 g7959207 1.00E-38 KIAA1473 protein (Homo sapiens)
13 LG: 1503589.2:2001 MAR30 g 16552245 l .OOE-162 unnamed protein product (Homo sapiens)
14 LG: 1506339.4:2001 MAR30 g 17512041 l .OOE-124 Unknown (protein for MGC:20302) (Homo sapiens)
15 LG:220648.6:2001 MAR30 gl 2310941 2.00E-60 unnamed protein product (Homo sapiens)
16 LG:236654.1 :2001 MAR30 g 12843135 l .OOE-l 35 putative (Mus musculus)
17 LG:237699.26:2001 MAR30 g388168 l .OOE-127 Bax beta (Homo sapiens)
18 LG:31 1541.16:2001 MAR30 g 15209690 0 unnamed protein product (Homo sapiens)
19 LG:335923J:2001 MAR30 gl 5717944 4.00E-76 bA14C22.1 (novel protein similar to lysozyme) (Homo sapiens)
20 LG:350342.14:2001 MAR30 g 15079361 3.00E-94 Similar to PCTAIRE-motif protein kinase 3 (Homo sapiens)
21 LG:369301.32:2001 MAR30 g 14149068 0 hypothetical protein (Homo sapiens)
22 LG:452089.1 :2001 MAR30 g7340874 5.00E-88 ESTs DI 5590(00900), D48950(S15542), D22684(C0900) correspond to a regi of the predicted gene. -Similar to Arabidopsis thaliana 60S ribosomal protein LI 1 A (L16A). (P42795) (Oryza sativa)
23 LG:454087.3:2001 MAR30 g2689446 0 R27945J (Homo sapiens)
24 LG:466302.1 :2001 MAR30 g 12847061 5.00E-97 putative (Mus musculus)
25 LG:474267.1 :2001 MAR30 g 15487218 6.00E-17 MORN-domain protein (Leishmania major)
26 LG:995613.10:2001 MAR30 g6807718 l .OOE-128 hypothetical protein (Homo sapiens)
27 LG:01 1843.5:2001 MAR30 g 10998440 0 EGF-related protein SCUBE1 (Mus musculus)
28 LG:075904.32:2001 MAR30 g 12005908 l .OOE-146 AD037 (Homo sapiens)
29 LG: 1004781.3:2001 MAR30 g 14794726 0 CUB and sushi multiple domains 1 protein (Homo sapiens)
Table 2
SEQ ID NO: Template ID Gl Number Probability Score Annotation
30 LG: 1041807.8:2001 MAR30 g2477513 0 F25965_3 (Homo sapiens)
31 LG: 1044448.2:2001 MAR30 g 14307916 0 myosin phosphatase targeting subunit 3 MYPT3 (Mus musculus)
32 LG: 1080598.9:2001 MAR30 g7019945 l .OOE-179 unnamed protein product (Homo sapiens)
33 LG:1081017.1 :2001 MAR30 g340080 7.00E-34 UDP-glucuronosyltransferase (EC 2.4.1.17) (Homo sapiens)
34 LG: 1083120.2:2001 MAR30 g 14348588 5.00E-69 KRAB zinc finger protein (Homo sapiens)
35 LG: 1097492.12:2001 MAR30 g2224529 0 KIAA0294 (Homo sapiens)
36 LG: 1 18834.9:2001 MAR30 g7301264 1.00E-89 CG9996 gene product (Drosophila melanogaster)
37 LG: 1227408.25:2001 MAR30 gl3121981 3.00E-90 unnamed protein product (Homo sapiens)
38 LG: 1326953.1 :2001 MAR30 g 190814 3.00E-40 Wilm's tumor-related protein (Homo sapiens)
39 LG: 1397821.17:2001 MAR30 g 12847582 0 putative (Mus musculus)
40 LG: 1512507.1 :2001 MAR30 g 12832255 3.00E-79 putative (Mus musculus)
41 LG: 196583.5:2001 MAR30 g 17483854 0 a disintegrin-like and metalloprotease with thrombospondin type 1 motif precursor (Homo sapiens)
~4
© 42 LG: 198669.1 :2001 MAR30 g4160198 1.00E-120 dJ327J16.3 (supported by GENSCAN, FGENES and GENEWISE) (Homo sapiens)
43 LG:202943.1 :2001 MAR30 gl l l 77164 0 polydom protein (Mus musculus)
44 LG:204724.3:2001 MAR30 g58491 0 El b 55k protein (transformation) (Human adenovirus type 5)
45 LG:206425.10:2001 MAR30 gl 174187 0 purine nucleotide binding protein (Mus musculus)
46 LG:208190.2:2001 MAR30 g 15559603 0 Unknown (protein for MGC20847) (Homo sapiens)
47 LG:222927.2:2001 MAR30 g 12836052 0 putative (Mus musculus)
48 LG:228046.5:2001 MAR30 g3413918 0 KIAA0478 protein (Homo sapiens)
49 LG:230980.1 :2001 MAR30 g 12842288 0 putative (Mus musculus)
50 LG:236976.2:2001 MAR30 g3900848 3.00E-81 match to EST AA361 1 17 (NID:g2013436) (Homo sapiens)
51 LG:238322.6:2001 MAR30 g 12081909 0 semaphorin Y (Homo sapiens)
52 LG:341461.1 :2001 MAR30 g 14334177 1.00E-1 19 beta cysteine string protein (Homo sapiens)
53 LG:354088.1 :2001 MAR30 g7959193 2.00E-70 KIAA1466 protein (Homo sapiens)
54 LG:376275.1 :2001 MAR30 g6249687 6.00E-59 R31 155_l (Homo sapiens)
55 LG:399281.3:2001 MAR30 g6634025 l .OOE-151 KIAA0379 protein (Homo sapiens)
56 LG:404921.10:2001 MAR30 g 16741323 0 Similar to hypothetical protein DKFZp434L0718 (Mus musculus)
57 LG:444677.34:2001 MAR30 g 14424793 2.00E-59 Unknown (protein for MGC.15165) (Homo sapiens)
58 LG:968691.1 :2001 MAR30 g! 7105197 l .OOE-108 kelch-like protein KLHL6 (Homo sapiens)
Table 2
SEQ ID NO: Template ID Gl Number Probability Score Annotation
59 LG:983862.1 :2001 MAR30 g 14274810 0 unnamed protein product (Homo sapiens)
60 LG:984130.1 :2001 MAR30 g 10434090 0 unnamed protein product (Homo sapiens)
61 LG:986291.1 :2001 MAR30 g206734 l .OOE-165 ribosomal protein L5 (Rattus norvegicus)
62 LG:045210.8:2001 MAR30 g2827474 5.00E-87 predicted protein dJ257A7.2 (Homo sapiens)
63 LG:229284.39:2001 MAR30 g5419859 0 hypothetical protein (Homo sapiens)
64 LG:337810.20:2001 MAR30 g4106984 l .OOE-120 R30923J (Homo sapiens)
65 LG:463420.1 :2001 MAR30 g7959265 0 KIAA1502 protein (Homo sapiens)
66 LG: 1080918.1 :2001 MAR30 g 16549907 0 unnamed protein product (Homo sapiens)
67 LG: 1093747.15:2001 MAR30 g 13436440 0 Unknown (protein for MGC:4400) (Homo sapiens)
68 LG: 1096896.47:2001 MAR30 g 12655061 1.00E-89 succinate dehydrogenase complex, subunit A, flavoprotein (Fp) (Homo
69 LG: 1098931.39:2001 MAR30 g452316 0 acetyl-CoA carboxylase (Homo sapiens)
70 LG: 1 100823.1 :2001 MAR30 g5410605 5.00E-57 tetraspanin membrane protein CD63 (Mus musculus)
71 LG: 1 166387.1 :2001 MAR30 g7159799 0 dJ351 K20.1.1 (novel C3HC4 type Zinc finger (RING finger) protein (isoform 1)) (Homo sapiens)
72 LG: 1383036.49:2001 MAR30 g296650 l .OOE-157 hnrnp al protein (Homo sapiens)
73 LG: 1452353.14:2001 M AR30 g309453 0 neurofibromin (Mus musculus)
74 LG: 1452435.15:2001 MAR30 g 178646 0 ankyrin (Homo sapiens)
75 LG: 1498774.1 :2001 MAR30 g2668738 3.00E-89 translation initiation factor 5A (Zea mays)
76 LG: 197180.1 :2001 MAR30 g556301 0 elongation factor Tu (Mus musculus)
77 LG:199489.1 :2001 MAR30 g476725 0 T-cell early activation protein (Mus musculus)
78 LG:201908.3:2001 MAR30 g 17391340 0 Unknown (protein for MGC:20009) (Homo sapiens)
79 LG:247245.26:2001 MAR30 g 16551429 l .OOE-161 unnamed protein product (Homo sapiens)
80 LG:256365.2:2001 MAR30 g 15929959 l .OOE-105 Similar to tropomyosin 4 (Homo sapiens)
81 LG:332923.4:2001 MAR30 g 13874450 0 hypothetical protein (Macaca fascicularis)
82 LG:335276.1 :2001 MAR30 g 1477588 l .OOE-140 DLX-1 (Mus musculus)
83 LG:350272.2:2001 MAR30 g 12845866 1.00E-72 putative (Mus musculus)
84 LG:350921.2:2001 MAR30 g 16508652 0 unnamed protein product (Homo sapiens)
85 LG:406568.1 :2001 MAR30 g 12656196 l .OOE-122 cardiac leiomodin (Mus musculus)
86 LG:41 1043.3:2001 MAR30 g 12861800 0 putative (Mus musculus)
87 LG:414376.20:2001 MAR30 g57667 0 put. RCK2 protein (AA 1-530) (Rattus rattus)
88 LG:457695.1 :2001 MAR30 g 15810196 l .OOE-1 1 1 AT3gl 3580/K20M4_2 (Arabidopsis thaliana)
Table 2
SEQ ID NO: Template ID Gl Number Probability Score Annotation
89 LG:902390.2:2001 MAR30 g 12860912 4.00E-36 putative (Mus musculus)
90 LG:903565.20:2001 MAR30 g769701 0 PACE4A (Mus musculus)
91 LG:978182.4:2001 MAR30 g9651646 0 MRE1 1 (Rattus norvegicus)
92 LG:986827.1 :2001 MAR30 g 12855841 1.00E-75 putative (Mus musculus)
93 LG:013792.1 :2001 MAR30 gl5021881 5.00E-09 hypothetical protein (Macaca fascicularis)
94 LG:018258.1 :2001 MAR30 g 12832288 l .OOE-1 1 1 putative (Mus musculus)
95 LG:023126.3:2001 MAR30 g2276313 2.00E-19 match: multiple proteins; match: Q08151 P28185 Q01 1 1 1 Q43554; match: Q08150 Q40195 P20340 Q39222; match: Q40368 P36412 P40393 Q40723; match: CE01798 Q38923 Q40191 Q41022; match: Q39433 Q40177 Q4021 Q08146; match: P10949 PI 1023 Q16948 Q20337; match: Q25389 P25228 P20336 P05713; match: P35276 Q08147 P17609 P22128; match: Q15771 P36410 P35291 ; GTP-binding (Homo sapiens)
96 LG:023618.1 :2001 MAR30 g854065 2.00E-25 U88 (Human herpesvirus 6)
97 LG:030999.1 :2001 MAR30 g7271471 l .OOE-158 Rab-related GTP-binding protein RabJ (Homo sapiens)
98 LG: 103508.1 :2001 MAR30 g 14597533 l .OOE-171 unnamed protein product (Homo sapiens)
99 LG: 107976.15:2001 MAR30 gl 7128217 0 unnamed protein product (Homo sapiens)
100 LG: 1080096.1 :2001 MAR30 g5080758 0 BC331 191J (Homo sapiens)
101 LG:1080275.1 :2001 MAR30 g5262557 1.00E-88 hypothetical protein (Homo sapiens)
102 LG: 1090358.10:2001 MAR30 g3540177 l .OOE-108 F23269_2 (Homo sapiens)
103 LG: 1095833.9:2001 MAR30 g4240143 0 KIAA0827 protein (Homo sapiens)
104 LG: 1383121.25:2001 MAR30 g7582292 3.00E-60 BM-010 (Homo sapiens)
105 LG:1386609.2:2001 MAR30 g6330433 0 KIAA1203 protein (Homo sapiens)
106 LG:1398465.1 :2001 MAR30 g5410334 1.00E-128 WSB-1 isoform (Homo sapiens)
107 LG:1453417.10:2001 MAR30 g9828190 0 FLAMINGO 1 (Homo sapiens)
108 LG: 147869.3:2001 MAR30 g 16549477 0 unnamed protein product (Homo sapiens)
109 LG: 148485.5:2001 MAR30 g 16768654 5.00E-45 HL01494p (Drosophila melanogaster)
1 10 LG: 1501818.12:2001 MAR30 gl 3182779 0 HCOBP (Homo sapiens)
1 1 1 LG:1508275.1 :2001 MAR30 g57175 6.00E-48 S-100 protein (Rattus norvegicus)
1 12 LG: 1509771.1 :2001 MAR30 g 12804565 4.00E-41 Unknown (protein for IMAGE:2989556) (Homo sapiens)
1 13 LG: 1512998.13:2001 MAR30 g 15625568 l .OOE-166 Run- and FYVE-domain containing protein Rabip4R (Homo sapiens)
1 14 LG: 198251.7:2001 MAR30 gl 1493516 6.00E-34 PRO! 107 (Homo sapiens)
Table 2
SEQ ID NO: Template ID Gl Number Probability Score Annotation
1 15 LG: 198296.1 :2001 MAR30 g701991 1 0 unnamed protein product (Homo sapiens)
1 16 LG: 198876.13:2001 MAR30 g 13359199 0 KIAA1663 protein (Homo sapiens)
1 17 LG:2∞7(M.1 :2001 MA 30 g9651089 l .OOE-166 hypothetical protein (Macaca fascicularis)
1 18 LG:206593.3:2001 MAR30 g 12052983 l .OOE-1 10 hypothetical protein (Homo sapiens)
1 19 LG-.223970.1 1 :2001 MAR30 g4514554 0 Rodl (Homo sapiens)
120 LG:227500.5:2001 MAR30 g 16356673 0 LIM protein prickle b (Xenopus laevis)
121 LG:227722.7:2001 MAR30 g3128218 1.00E-52 putative katanin (Arabidopsis thaliana)
122 LG:229105.1 :2001 MAR30 g 16554016 0 unnamed protein product (Homo sapiens)
123 LG:233761.4:2001 MAR30 g 12407377 0 tripartite motif protein TRIM4 isoform alpha (Homo sapiens)
124 LG:234326.67:2001 MAR30 gl 1610575 0 RTN-xL (Homo sapiens)
125 LG:236056.27:2001 MAR30 gl 35431 10 0 Similar to SWI/SNF related, matrix associated, actin dependent regulator chromatin, subfamily d, member 2 (Mus musculus)
126 LG .253889.31 :2001 MAR30 gl89310 l .OOE-163 nucleolysin TIAR (Homo sapiens)
-4 127 LG:270833.135:2001 MAR30 g 12844788 4.00E-67 putative (Mus musculus) J
128 LG:292613.7:2001 MAR30 gl0241461 l .OOE-107 dJl 121 Gl 2.1.2 (A novel protein containing a putative PHD finger domai isoform 2) (Homo sapiens)
129 LG:331546.2:2001 MAR30 gl401 126 0 TAK1 binding protein (Homo sapiens)
130 LG:332027.6:2001 MAR30 g 12832845 l .OOE-162 putative (Mus musculus)
131 LG:336998.1 :2001 MAR30 g347377 0 MLL-AF4 der(l 1) fusion protein (Homo sapiens)
132 LG:338010.8:2001 MAR30 g 12860837 l .OOE-163 putative (Mus musculus)
133 LG:344597.1 :2001 MAR30 g 13603398 0 SEZ6L (Homo sapiens)
134 LG:347361.2:2001 MAR30 g2914017 0 Ankhzn (Mus musculus)
135 LG:349293.17:2001 MAR30 g7239366 0 groucho-related protein 4 (Mus musculus)
136 LG:410595.19:2001 MAR30 g 13960126 l .OOE-124 Similar to leucine-rich neuronal protein (Homo sapiens)
137 LG:41 1 151.35:2001 MAR30 g6969629 0 oracle 1 protein (Mus musculus)
138 LG:41 1334.8:2001 MAR30 g 1537017 0 LIM protein (Homo sapiens)
139 LG:458583.1 :2001 MAR30 g7020724 6.00E-76 unnamed protein product (Homo sapiens)
140 LG:475378.1 :2001 MAR30 g7243105 l .OOE-1 18 KIAA1362 protein (Homo sapiens)
141 LG:481572.1 :2001 MAR30 g6331213 0 KIAA1268 protein (Homo sapiens)
142 LG:481704.1 :2001 MAR30 g7959193 2.00E-81 KIAA1466 protein (Homo sapiens)
143 LG:898195.4:2001 MAR30 g7243777 0 Diablo (Drosophila melanogaster)
Table 2
SEQ ID NO: Template ID Gl Number Probability Score Annotation
144 LG:903785.1 :2001 MAR30 g7242951 0 KIAA1298 protein (Homo sapiens)
145 LG:977454.3:2001 MAR30 g12844142 2.00E-68 putative (Mus musculus)
146 LG:977724.12:2001 MAR30 g10432612 0 unnamed protein product (Homo sapiens)
147 LG:978215.19:2001 MAR30 g9309467 l.OOE-136 leucine-rich glioma-inactivated 1 protein precursor (Mus musculus)
148 LG:981795.1 :2001 MAR30 g5410527 l.OOE-150 paracellin-1 (Homo sapiens)
149 LG:982784.1 :2001 MAR30 g16553391 l.OOE-136 unnamed protein product (Homo sapiens)
150 LG:987322.4:2001 MAR30 gl!596121 0 SIR2alpha protein (Homo sapiens)
151 LG:006242J:2001 MAR30 g9997097 0 unnamed protein product (Homo sapiens)
152 LG:027320J:2001 MAR30 g16553765 0 unnamed protein product (Homo sapiens)
153 LG: 147541.44:2001 MAR30 g14318590 l.OOE-103 Unknown (protein for MGCJ100) (Mus musculus)
154 LG:228319.2:2001 MAR30 g16041142 l.OOE-133 hypothetical protein (Macaca fascicularis)
155 LG:238754.19:2001 MAR30 g13477109 1.00E-67 RIKEN cDNA 0610043B10 gene (Homo sapiens)
156 LG:405751.12:2001 MAR30 gl711238 0 TIS (Mus musculus)
157 Ll:01 1822.6:2001 MAY17 g16359265 6.00E-87 Similar to hypothetical protein DKFZp434G2226 (Mus musculus)
158 LI: 1012467.2:2001 MAY17 g16550592 l.OOE-169 unnamed protein product (Homo sapiens)
159 LI: 1 169981.13:2001 MAY17 g4235144 l.OOE-158 BC39498J (Homo sapiens)
160 LI: 1 171553.1 :2001 AY17 gl6549180 0 unnamed protein product (Homo sapiens)
161 LI:1 183156.3:2001 MAY17 g4164083 0 zinc finger protein EZNF (Homo sapiens)
162 LI: 1 188500.6:2001 MAY17 g16508614 0 unnamed protein product (Homo sapiens)
163 LI: 147333.12:2001 MAY17 g12654987 1.00E-60 Unknown (protein for MGC:5621) (Homo sapiens)
164 U:l 47523.7:2001 MAY17 g6018682 2.00E-85 superoxide dismutase-4AP (Zea mays)
165 LI: 197388.10:2001 MAY17 g13279311 l.OOE-165 Similar to RIKEN cDNA 1500017E 18 gene (Homo sapiens)
166 U:2049216.1 :2001 MAY17 g15866260 l.OOE-148 MRIP2 (Homo sapiens)
167 U:2051624.2:2001 MAY17 g14602654 0 Unknown (protein for MGC: 15400) (Homo sapiens)
168 LI:2121838.1 :2001 MAY17 gl6552172 1.00E-114 unnamed protein product (Homo sapiens)
169 Ll:2122954.8:2001 MAY17 g10435738 l.OOE-124 unnamed protein product (Homo sapiens)
170 U:2198064.2:2001 MAY17 g12652727 3.00E-29 Unknown (protein for IMAGE:3352566) (Homo sapiens)
171 U:2206583.1 :2001 MAY17 g16553223 l.OOE-l 06 unnamed protein product (Homo sapiens)
172 U:235663.6:2001 MAY17 g16973457 6.00E-56 beta-3-galactosyltransferase (Danio rerio)
173 U:236386J:2001 MAY17 g17511850 0 Unknown (protein for MGC:32065) (Homo sapiens)
174 U:236654.3:2001 MAY17 gl 1602755 l.OOE-l 33 zinc finger protein (Mus musculus)
Table 2
SEQ ID NO Template ID Gl Number Probability Sc Annotation
175 LI:256059.46:2001 MAY17 g9971 1 14 l .OOE-1 15 MHC class I antigen (Homo sapiens)
176 LI:279978.22:2001 MAY17 g 13517077 0 lipoate-activating enzyme (Bos taurus)
177 LI :31 1541.6:2001 MAY 17 g 15209690 0 unnamed protein product (Homo sapiens)
178 U:346123.1 :2001 MAY17 g 168647 l .OOE-143 triosephosphate isomerase 1 (Zea mays)
179 Ll:38121 1.5:2001 MAY17 g 13160045 0 dJ734P14.5 (novel C2H2 type zinc finger protein) (Homo sapiens)
180 LI:412197.82:2001 MAY17 gl 7512041 3.00EJ1 Unknown (protein for MGC20302) (Homo sapiens)
181 Ll:412936.49:2001 MAY17 g 10801585 l .OOE-109 PQBP-l b/c (Homo sapiens)
182 Ll:427792.139:2001 MAY17 gl81 178 2.00E-61 lysosomal proteinase cathepsin B (Homo sapiens)
183 U:450229.1 :2001 MAY17 g4588906 1.00E-96 ribosomal protein S7 (Secale cereale)
184 LI:475565.243:2001 MAY17 g 16553223 4.00E-99 unnamed protein product (Homo sapiens)
185 UJ64701.8:2001 MAY17 gl284131 1 8.00E-90 putative (Mus musculus)
186 Ll:024124.2:2001 MAY17 gl 1094295 0 brain link protein-1 (Mus musculus)
187 U:038252.3:2001 MAY17 g4186185 0 unknown (Homo sapiens)
-4 Ul 188 LI:056882.1 :2001 MAY17 g6249687 3.00E-59 R31 155 (Homo sapiens)
189 U:059530.1 :2001 MAY17 g232783 7.00E-33 Purkinje cell protein 2; Pcp-2 (Mus sp.)
190 U:089950.30:2001 MAY17 g 14042915 0 unnamed protein product (Homo sapiens)
191 LI: 1072906.38:2001 MAY17 g 13279044 0 hypothetical protein PR01741 (Homo sapiens)
192 U:1 158936.4:2001 MAY17 g 1327461 1 l .OOE-169 glutamate rich WD repeat protein (Homo sapiens)
193 U: 1 173412.15:2001 MAY17 g 14602971 0 Unknown (protein for MGC: 14981) (Homo sapiens)
194 LI:1 174279.14:2001 MAY17 g3540177 0 F23269_2 (Homo sapiens)
195 U: 1 174809.1 :2001 MAY17 g7959207 l .OOE-126 KIAA1473 protein (Homo sapiens)
196 U: 1 175131.1 :2001 MAY17 g6467202 0 gonadotropin inducible transcription repressor-2 (Homo sapiens)
197 LI: 1 188801.10:2001 MAY17 g5231271 0 autoimmune enteropathy-related antigen AIE-75 (Homo sapiens)
198 LI: 1 189176.27:2001 MAY17 g 15823640 4.00E-79 Als2 (Mus musculus)
199 U:197739.4:2001 MAY17 g3417297 0 Unknown gene product (Homo sapiens)
200 LI:2049016.1 :2001 MAY17 g 16550359 3.00E-39 unnamed protein product (Homo sapiens)
201 LI:2049137.1 :2001 MAY17 g 13937909 l .OOE-108 Similar to KIAA0961 protein (Homo sapiens)
202 U:2051907.1 :2001 MAY17 g 16549529 0 unnamed protein product (Homo sapiens)
203 U:21 17996.13:2001 MAY17 g3256185 l .OOE-121 dJ510H16.1 (target of mybl (chicken) homolog) (Homo sapiens)
204 U:21 18683.15:2001 MAY17 g 13676443 l .OOE-1 16 hypothetical protein (Macaca fascicularis)
205 LI:2120312.1 :2001 MAY17 gl5213812 2.00E-38 ribosomal protein SI 2 (Spodoptera frugiperda)
Table 2
SEQ ID NO: Template ID Gl Number Probability Score Annotation
206 LI:2121328.17:2001 MAY17 gl2314195 8.00E-74 bA255Al 1.3 (novel protein similar to KIAA1074) (Homo sapiens)
207 LI:2121802.5:2001 MAY17 g 16550359 0 unnamed protein product (Homo sapiens)
208 U:2123406.9:2001 MAY17 g 15620839 9.00E-95 KIAA1890 protein (Homo sapiens)
209 U:216129.45:2001 MAY17 g 13160494 0 UBX domain-containing protein 1 (Homo sapiens)
210 LI:2186630.1 :2001 MAY17 g 16549907 4.00E-41 unnamed protein product (Homo sapiens)
21 1 Ll:2188206.2:2001 MAY17 g4185943 1.00E-73 pol protein (Human endogenous retrovirus K)
212 U:2199710.9:2001 MAY17 g499204 1.00E-84 D-E-A-D box protein (Drosophila melanogaster)
213 LI:2209335.2:2001 MAY17 gl2314164 l .OOE-150 bA526D8.2 (novel protein similar to KIAA1074) (Homo sapiens)
214 Ll:230980.13:2001 MAY17 g 12842288 l .OOE-166 putative (Mus musculus)
215 Ll:244421.37:2001 MAY17 g7188556 l .OOE-104 CpG binding protein (Homo sapiens)
216 U:341998.1 :2001 MAY17 g 17016967 3.00E-67 NUANCE (Homo sapiens)
217 Ll:347931.10:2001 MAY17 g6634023 0 KIAA0356 protein (Homo sapiens)
218 Ll:350771.42:2001 MAY17 g 15963476 l .OOE-103 alpha-adaptin A related protein (Homo sapiens)
219 LI:354423.6:2001 MAY17 g 14042035 0 unnamed protein product (Homo sapiens)
220 U:399333.8:2001 MAY17 g 15559519 0 Unknown (protein for IMAGE:4561365) (Homo sapiens)
221 U:445084.36:2001 MAY17 g 12840887 3.00E-55 putative (Mus musculus)
222 U:454087.3:2001 MAY17 g2689446 0 R27945J (Homo sapiens)
223 U:474887.1 :2001 MAY17 g2597931 1.00E-42 ubiquitin-conjugating enzyme, UBC9 (Homo sapiens)
224 LI:745251.1 :2001 MAY17 gl 7105197 l .OOE-174 keich-like protein KLHL6 (Homo sapiens)
225 LIJ47717.9:2001 MAY17 gl 1544425 0 bG15303.1 (similar to C. elegans hemicentin precursor) (Homo sapiens)
226 Ll:80621 1.3:2001 MAY17 g7019945 l .OOE-1 19 unnamed protein product (Homo sapiens)
227 U:815072.1 :2001 MAY17 g402827 3.00E-40 QM (Homo sapiens)
228 Ll:817052.8:2001 MAY17 g6331377 0 KIAA1285 protein (Homo sapiens)
229 U:903392.45:2001 MAY17 g 15072406 l .OOE-147 TNFAIPl-like protein (Homo sapiens)
230 LI:013724.1 :2001 MAY17 g 13277864 l .OOE-161 Similar to ATPase, H+ transporting, lysosomal (vacuolar proton pump) 42k (Mus musculus)
231 LI: 191726.16:2001 MAY17 g 1208742 0 protein B (Homo sapiens)
232 LI:202270.2:2001 MAY17 g 16549383 4.00E-74 unnamed protein product (Homo sapiens)
233 U:21 19352.6:2001 MAY17 g 14043223 2.00E-95 Unknown (protein for MGC: 15677) (Homo sapiens)
234 U:2207776.1 1 :2001 MAY17 g7294748 9.00E-99 CG7616 gene product (Drosophila melanogaster)
235 LI:256442.1 :2001 MAY17 g 16265875 4.00E-51 proline-rich acidic protein (Homo sapiens)
Table 2
SEQ ID NO Template ID Gl Number Probability Score Annotation
236 LI:330497J:2001 MAY17 gl 7064172 1.00E-80 NALP4 (Homo sapiens)
237 LI:018494.1 :2001 MAY17 g 17389275 0 Unknown (protein for MGC: 19357) (Mus musculus)
238 Ll:023518.2:2001 MAY17 g3955100 4.00E-75 vacuolar adenosine triphosphatase subunit D (Mus musculus)
239 U:053488.46:2001 MAY17 g3712671 l .OOE-136 vascular endothelial growth factor (Homo sapiens)
240 LI:058298.27:2001 MAY17 g 17045994 l .OOE-100 unnamed protein product (Homo sapiens)
241 LI: 1 1 10046.1.2001 MAY17 g 1854374 l .OOE-172 aquaporin 3 (Homo sapiens)
242 U:1 166752.1 1 :2001 MAY17 g 15929737 l .OOE-131 Similar to zinc finger protein 347 (Mus musculus)
243 U:1 173766.1 :2001 MAY17 g7239109 0 HSPC059 (Homo sapiens)
244 LI: 1 177952.4:2001 MAY17 g 14042590 l .OOE-1 16 unnamed protein product (Homo sapiens)
245 LI: 1 178064.3:2001 MAY17 g5262591 0 hypothetical protein (Homo sapiens)
246 LI: 1 83121.1 :2001 MAY17 g 15489325 l .OOE-163 Similar to hypothetical protein MGC 10520 (Homo sapiens)
247 LI: 1 190431.13:2001 MAY17 g451303 0 complement receptor 1 (Homo sapiens)
248 LI: 199121.14:2001 MAY17 g 15593660 0 unnamed protein product (synthetic construct)
-4 249 U:202630.5:2001 MAY17 0
~-4 g 14134965 unnamed protein product (Homo sapiens)
250 U:2034488.1 :2001 MAY17 g 15277259 l .OOE-156 zinc finger protein homologous to mouse Zfp91 (Homo sapiens)
251 U:2051434.8:2001 MAY17 g 13436164 l .OOE-151 carbonic anhydrase III, muscle specific (Homo sapiens)
252 U:21 18475.9:2001 MAY17 g37605 0 urokinase plasminogen activator receptor (Homo sapiens)
253 Ll:218849.24:2001 MAY17 g4240249 0 KIAA0880 protein (Homo sapiens)
254 LI:2199824.5:2001 MAY17 g 15929959 l .OOE-l 05 Similar to tropomyosin 4 (Homo sapiens)
255 U:233018.32:2001 MAY17 g 15928921 0 hypothetical protein FU 14393 (Homo sapiens)
256 LI:236295.8:2001 MAY17 g33967 l .OOE-124 interferon regulatory factor-2 (AA 1-349) (Homo sapiens)
257 LI:286989.14:2001 MAY17 g2967646 0 Smad2 (Homo sapiens)
258 LI:345320.4:2001 MAY17 g2330595 0 Ikaros transcription factor (Gallus gallus)
259 Ll:355693.18:2001 MAY17 g961515 0 plexin (Xenopus laevis)
260 LI:359876.1 :2001 MAY17 g 15293713 l .OOE-123 olfactory receptor (Homo sapiens)
261 LI:406664.32:2001 MAY17 g432656 0 serum response factor-related protein (Homo sapiens)
262 LI:410324.1 :2001 MAY17 g 14009459 0 protocadherin-betal 1 (Homo sapiens)
263 LI:414376.12:2001 MAY17 g 199893 0 murine potassium channel protein (Mus musculus)
264 U:452089.1 :2001 MAY17 g7340874 4.00E-96 ESTs D15590(C0900),D48950(S15542),D22684(C0900) correspond to a regi of the predicted gene. -Similar to Arabidopsis thaliana 60S ribosomal protein LI 1 A (L16A). (P42795) (Oryza sativa)
Table :
SEQ ID NO: Template ID Gl Number Probability Score Annotation
265 U:481614.43:2001 MAY17 g14522878 0 calcium/calmodulin-dependent protein kinase kinase b2 (Homo sapiens
266 LI:809605.2:2001 MAY17 g4096339 0 zinc finger protein (Homo sapiens)
267 U:816437.25:2001 MAY17 g475560 0 N-methyl-D-aspartate receptor NMDARl-2b subunit (Rattus norvegicus)
268 Ll:817827.5:2001 MAY17 g2668738 3.00E-89 translation initiation factor 5A (Zea mays)
269 Ll:002345.15:2001 MAY17 g12405805 0 unnamed protein product (Homo sapiens)
270 U:022629.5:2001 MAY17 g13879442 l.OOE-119 Similar to RIKEN cDNA 2310035M22 gene (Mus musculus)
271 Ll:061031.4:2001 MAY17 g1763638 l.OOE-110 alpha 1 A-voltage-dependent calcium channel (Homo sapiens)
272 LI:108232.2:2001 MAY17 g12837586 4.00E-64 putative (Mus musculus)
273 LI: 1085493.16:2001 MAY17 g14042544 l.OOE-158 unnamed protein product (Homo sapiens)
274 LI: 1085513.2:2001 MAY17 g16307285 0 Unknown (protein for IMAGE:3877337) (Homo sapiens)
275 LI: 1086797.9:2001 MAY17 gl4133251 0 KIAA1479 protein (Homo sapiens)
276 LI:1088446.1 :2001 MAY17 g13676461 0 hypothetical protein (Macaca fascicularis)
277 LI: 1 133764.3:2001 MAY17 g5262574 0 hypothetical protein (Homo sapiens)
-4 278 LI: 1 147614.5:2001 MAY17 g17049366 0 unnamed protein product (Homo sapiens)
90
279 U:1 181710.1 :2001 MAY17 g7959207 2.00E-60 KIAA1473 protein (Homo sapiens)
280 LI: 1 183192.1 :2001 AY17 g13938261 7.00E-91 Unknown (protein for MGC: 15514) (Homo sapiens)
281 LI: 1 188786.15:2001 MAY17 g7020611 0 unnamed protein product (Homo sapiens)
282 U: 145626.1 :2001 MAY17 g14787176 0 CSMD1 (Mus musculus)
283 LI: 147869.3:2001 MAY17 g16549477 0 unnamed protein product (Homo sapiens)
284 LI: 151747.4:2001 MAY17 g3643115 0 protein inhibitor of activated STAT protein PIASx-beta (Homo sapiens)
285 U: 198296.1 :2001 MAY17 g12853497 0 putative (Mus musculus)
286 Ll:200n 7.4:2001 MAY17 g13358646 2.00E-96 hypothetical protein (Macaca fascicularis)
287 LI:200704.1 :2001 MAY17 g16551759 0 unnamed protein product (Homo sapiens)
288 LI:2049995.3:2001 MAY17 g6063017 0 tousled-like kinase 1 (Homo sapiens)
289 U:2052097.2:2001 MAY17 gl3195460 0 putative acetyltransferase (Homo sapiens)
290 Ll:209351.22:2001 MAY17 g12856025 0 putative (Mus musculus)
291 LI:2120481.1 :2001 MAY17 g10800564 0 bA338Ll 1.1 (novel CUB domain protein similar to attractin) (Homo sapie
292 LI:2121610.13:2001 MAY17 g8919698 l.OOE-113 olfactory receptor (Mus musculus)
293 LI:2191585.1 :2001 MAY17 g12846015 l.OOE-169 putative (Mus musculus)
294 LI:2198562.3:2001 MAY17 g3513571 l.OOE-164 C-terminal binding protein 2 CtBP2 (Mus musculus)
295 LI:2209684.5:2001 MAY17 g15020827 0 dJ29Kl .2 (KIAA0426 (C2H2 type zinc finger protein)) (Homo sapiens)
Table 2
SEQ ID NO: Template ID Gl Number Probability Score Annotation
296 LI:222795.28:2001 MAY17 g 14602998 0 Unknown (protein for IMAGE:4121355) (Homo sapiens)
297 U:228273.25:2001 MAY17 g 1 1323324 0 dJ138B7.3.2 (lethal (3) malignant brain tumor (l(3)mbt) protein (Drosophil homolog (isoform 2) (KIAA0681)) (Homo sapiens)
298 U:232386.31 :2001 MAY17 g3142288 0 protein kinase C-binding protein RACK7 (Homo sapiens)
299 U:233089.2:2001 MAY17 g7242977 0 KIAA131 1 protein (Homo sapiens)
300 U:240641.10:2001 MAY17 g7019901 0 unnamed protein product (Homo sapiens)
301 U:243871.4:2001 MAY17 g6729590 l .OOE-1 10 Fas-associated factor, FAF1 (Homo sapiens)
302 U:245597J:2001 MAY17 g63180 7.00E-57 p54 (c-ets) protein (AA 1-441) (Gallus gallus)
303 LI:256009.31 :2001 MAY17 g 10445221 1.00E-74 GTP-binding protein SARI (Homo sapiens)
304 LI:262221.1 :2001MAY17 g7959343 l .OOE-161 KIAA1538 protein (Homo sapiens)
305 LI:332957.8:2001 MAY17 g 10434090 l .OOE-141 unnamed protein product (Homo sapiens)
306 Ll:335352.13:2001 MAY17 g306487 l .OOE-129 cap-binding protein (Homo sapiens)
307 LI:343844J:2001 MAY17 g5102580 9.00E-98 hypothetical protein, similar to (AF134804) putative zinc finger transcriptio factor OVOl (Mus musculus) (Homo sapiens)
308 LI:344528.1 :2001 MAY17 g3256266 0 MTG8-related protein MTGlόb (Homo sapiens)
309 LI:374578.27:2001 MAY17 g2664429 0 hypothetical protein (Homo sapiens)
310 Ll:381993.13:2001 MAY17 g 17223624 0 ATP-binding cassette A9 (Homo sapiens)
31 1 U:400373.2:2001 MAY17 g 17386053 0 Jedi protein (Mus musculus)
312 U:400963.6:2001 MAY17 gό634025 0 KIAA0379 protein (Homo sapiens)
313 U:404874.8:2001 MAY17 g3253159 0 translation initiation factor elF2C (Oryctolagus cuniculus)
314 Ll:405158.18:2001 MAY17 g6807862 0 hypothetical protein (Homo sapiens)
315 LI:405889.22:2001 MAY17 g8885518 0 hypothetical protein (Mus musculus)
316 Ll:41 1 151.31 :2001 MAY! 7 g6969631 0 oracle 2 protein (Mus musculus)
317 U:41 1313.51 :2001 MAY17 g4239984 0 insulin receptor substrate protein of 53 kDa (a shorter form) (Homo sapien
318 LI:417127.1 :2001 MAY17 g 12652727 3.00E-43 Unknown (protein for IMAGE:3352566) (Homo sapiens)
319 Ll:429817.44:2001 MAY17 g 10443902 l .OOE-1 16 TESTIN 2 (Homo sapiens)
320 Ll:474134.23:2001 MAY17 g 13516831 0 MAIL (Homo sapiens)
321 U:475378.3:2001 MAY17 g7243105 l .OOE-1 18 KIAA1362 protein (Homo sapiens)
322 LIJ49588.15:2001 MAY! 7 g4185940 0 env protein (Human endogenous retrovirus K)
323 UJ57736.17:2001 MAY17 g 16550160 0 unnamed protein product (Homo sapiens)
324 Ll:817278.4:2001 MAY! 7 g 13477159 2.00E-63 TLS-associated serine-arginine protein 2 (Homo sapiens)
Table 2
SEQ ID NO: Template ID Gl Number Probability Score Annotation
325 LI:027320.5:2001 MAY17 g 12839186 0 putative (Mus musculus)
326 U:204635.5:2001 MAY17 gl331 1008 2.00E-1 1 Homo sapiens NYD-SP16 mRN complete eds.
327 Ll:215532.38:2001 MAY17 g 12803351 0 Unknown (protein for IMAGE:3050476) (Homo sapiens)
328 LI.228319.6:2001 MAY17 g 16041 142 l .OOE-133 hypothetical protein (Macaca fascicularis)
329 U:236589.24:2001 MAY17 gl 7064170 0 HSV-I stimulating-related protein (Homo sapiens)
330 LI:247444.3:2001 MAY17 g 13435476 l .OOE-133 Unknown (protein for MGC6708) (Mus musculus)
331 U:332404.20:2001 MAY17 g 14388334 0 hypothetical protein (Macaca fascicularis)
332 LG:1088459.4:2001JUN22 g2306773 2.00E-21 zinc finger protein (Homo sapiens)
333 LG:1501495.1 :2001JUN22 g38032 0 ZNF43 (Homo sapiens)
334 LG:334284.10:2001JUN22 g 12855389 2.00E-41 putative (Mus musculus)
335 LG:345279.19:2001JUN22 gl 199602 l .OOE-1 15 cyclophilin-like protein (Homo sapiens)
336 LG:7689681.1 :2001JUN22 gl 751 1871 9.00E-96 Unknown (protein for MGC:32104) (Homo sapiens)
337 LG:7690093.1 :2001 JUN22 g38032 0 ZNF43 (Homo sapiens)
338 LGJ690175.3:2001 JUN22 g 12052983 l .OOE-l 15 hypothetical protein (Homo sapiens)
339 LG:7697128.1 :2001JUN22 g 1751 1825 1.OOE-70 Similar to immunoglobulin kappa constant (Homo sapiens)
340 LG:006394.20:2001JUN22 g6808105 3.00E-79 hypothetical protein (Homo sapiens)
341 LG: 1012069.1 :2001 JUN22 g 15451412 l .OOE-105 hypothetical protein (Macaca fascicularis)
342 LG: 104533.1 1 :2001 JUN22 g5050962 2.00E-29 dJ34B21.5 (PUTATIVE novel protein with ZU5 domain similar to part of Tigh Junction Protein ZOl (TJP1) and UNC5 Homologs) (Homo sapiens)
343 LG:1045853.23:2001JUN22 g7297900 l .OOE-l 32 CG6734 gene product (Drosophila melanogaster)
344 LG: 1081017.8:2001JUN22 g7768736 l .OOE-13 putative gene, ankirin like, possible dual specifity Ser/Thr/Tyr kinase dom (Homo sapiens)
345 LG: 1090358.6:2001JUN22 g5080758 3.00E-16 BC331 191J (Homo sapiens)
346 LG: 1 135312.7:2001JUN22 g 14279194 0 aldo-keto reductase loopADR (Homo sapiens)
347 LG:1328501.2:2001 JUN22 g 16551783 1.00E-1 15 unnamed protein product (Homo sapiens)
348 LG: 133095.1 :2001JUN22 g 16877077 0 Unknown (protein for MGC24494) (Homo sapiens)
349 LG: 135379.5:2001 JUN22 g 16552010 0 unnamed protein product (Homo sapiens)
350 LG:1365581.3:2001JUN22 g347906 8.00E-17 zinc finger protein (Homo sapiens)
351 LG: 1383156.20:2001 JUN22 g387030 l .OOE-104 pulmonary surfactant protein SP-C1 (Homo sapiens)
352 LG: 1501767.18:2001JUN22 gl lόl l571 l .OOE-1 15 hypothetical protein (Macaca fascicularis)
353 LG:1501890.8:2001JUN22 g7021971 0 unnamed protein product (Homo sapiens)
Table 2
SEQ ID NO Template ID Gl Number Probability Score Annotation
354 LG:203434.23:2001JUN22 g4902831 1.00E-65 put. keratin K7 (Homo sapiens)
355 LG:204724.5:2001JUN22 g209820 0 transformation-associated protein (Human adenovirus type 2)
356 LG:257107.16:2001 JUN22 g9992893 0 phosphoinositol 3-phosphate binding protein-1 (Homo sapiens)
357 LG:353530.4:2001JUN22 g6329945 0 KIAA1 140 protein (Homo sapiens)
358 LG:7683573.3:2001JUN22 g 16550444 1.00E-27 unnamed protein product (Homo sapiens)
359 LG:7684224.1 :2001JUN22 g487284 l .OOE-l 30 CRP2 (cysteine-rich protein 2) (Rattus norvegicus)
360 LG:7690365.2:2001JUN22 g 12052983 l .OOE-176 hypothetical protein (Homo sapiens)
361 LG:968691.1 :2001JUN22 gl 7105197 l .OOE-120 kelch-like protein KLHL6 (Homo sapiens)
362 LG:983076.7:2001JUN22 g 15559519 0 Unknown (protein for IMAGE:4561365) (Homo sapiens)
363 LG:986291.1 :2001JUN22 g206734 l .OOE-173 ribosomal protein L5 (Rattus norvegicus)
364 LG:990347.41 :2001JUN22 g3327090 l .OOE-1 18 KIAA0638 protein (Homo sapiens)
365 LG:998305.4:2001JUN22 g 12314195 l .OOE-120 bA255Al 1.3 (novel protein similar to KIAA1074) (Homo sapiens)
366 LG:463420.16:2001JUN22 g7959265 0 KIAA1502 protein (Homo sapiens)
367 LG:979059.3:2001JUN22 g 15862442 0 unnamed protein product (Homo sapiens)
368 LG: 1045509.22:2001JUN22 g 12653241 1.00E-41 transmembrane 4 superfamily member 7 (Homo sapiens)
369 LG:246935.4:2001JUN22 g 12232324 l .OOE-162 hUPF3B (Homo sapiens)
370 LG:321069.2:2001JUN22 g 12856090 1.00E-60 putative (Mus musculus)
371 LG:346724.14:2001 JUN22 g508729 0 thymopoietin gamma (Homo sapiens)
372 LG:41 1043.3:2001JUN22 g 12861800 0 putative (Mus musculus)
373 LG:978620.7:2001JUN22 g438007 2.00E-22 alpha-2-macroglobulin receptor (Gallus gallus)
374 LG:982784.1 :2001JUN22 g 16553391 l .OOE-136 unnamed protein product (Homo sapiens)
375 LG:007574.21 :2001JUN22 g4589670 0 KIAA1010 protein (Homo sapiens)
376 LG:013856.18:2001 JUN22 g7307264 0 formin binding protein 30 (Mus musculus)
377 LG:027320.7:2001JUN22 g 16553765 0 unnamed protein product (Homo sapiens)
378 LG:077967.9:2001JUN22 g 12804209 0 Similar to spleen tyrosine kinase (Homo sapiens)
379 LG: 128475.9:2001JUN22 g 13516831 3.00E-26 MAIL (Homo sapiens)
380 LG: 1398104.15:2001JUN22 g 15072406 l .OOE-102 TNFAIPl-like protein (Homo sapiens)
381 LG:1454018.10:2001JUN22 g 1504261 1 0 Ser/Thr protein kinase PAR-l Balpha (Homo sapiens)
382 LG:221548.14:2001JUN22 g 10437204 0 unnamed protein product (Homo sapiens)
383 LG:227500.5:2001JUN22 g 16551917 0 unnamed protein product (Homo sapiens)
384 LG:228273.22:2001JUN22 g38U 1 1 1 0 l(3)mbt protein homolog (Homo sapiens)
Table 2
SEQ ID NO: Template ID Gl Number Probability Score Annotation
385 LG:235432.1 :2001JUN22 g12655229 0 glucocorticoid modulatory element binding protein 1 (Homo sapiens)
386 LG:236904.20:2001JUN22 g6691099 0 SWAP-70 (Homo sapiens)
387 LG:253193.21 :2001JUN22 g7578783 4.00E-44 HT015 protein (Homo sapiens)
388 LG:332161.3:2001 JUN22 g16555334 l.OOE-l09 Rig protein (Homo sapiens)
389 LG:332923.5:2001JUN22 g14388339 0 hypothetical protein (Macaca fascicularis)
390 LG:343500.27:2001JUN22 g12854500 3.00E-88 putative (Mus musculus)
391 LG:369703.9:2001JUN22 g16741627 0 Similar to RIKEN cDNA 3830421 M04 gene (Homo sapiens)
392 LG:415378.3:2001JUN22 gl 1320820 0 VSGP/F-spondin (Homo sapiens)
393 LG:458583.1 :2001JUN22 g7020724 9.00E-76 unnamed protein product (Homo sapiens)
394 LG:7690373.1 :2001JUN22 g7959207 2.00E-60 KIAA1473 protein (Homo sapiens)
395 LG:898324.13:2001JUN22 g16551459 l.OOE-l00 unnamed protein product (Homo sapiens)
396 LG:979167.5:2001 JUN22 g15788437 l.OOE-l 31 cyclin-box carrying protein (Homo sapiens)
90
TABLE 3
SEQ ID NO: Template ID Start Stop Frame Pfam Hit Pfam Description E-value
1 LG:036272.1 :2001 MAR30 1664 21 19 forward 2 Acyl-CoA_dh Acyl-CoA dehydrogenase, C-terminal domain 4.90E-51
2 LG:093337.3:2001 MAR30 245 367 forward 2 KRAB KRAB box 2.10E-2
3 LG: 1049927.6:2001 MAR30 297 584 forward 3 SCAN SCAN domain 7.50E-61
4 LG: 1051891.34:2001 MAR30 916 984 forward 1 zf-C2H2 Zinc finger, C2H2 type 4.10E-0
5 LG:1089626.1 :2001 MAR30 861 929 forward 3 zf-C2H2 Zinc finger, C2H2 type 3.80E-0
6 LG: 1 101416.6:2001 MAR30 283 531 forward 1 Ribosomal_L7Ae Ribosomal protein L7Ae/L30e/S12e/Gadd45 1.20E-21 family
7 LG:1295974.1 :2001 MAR30 185 655 forward 2 ferritin Ferritin 9.00E-1 1
8 LG: 1400572.2:2001 MAR30 147 215 forward 3 zf-C2H2 Zinc finger, C2H2 type 2.30E-0
9 LG:1446621.1 :2001 MAR30 405 527 forward 3 KRAB KRAB box 4.00E-2
10 LG: 1499752.1 :2001 MAR30 67 189 forward 1 Thymosin Thymosin beta-4 family 1.80E-2
1 1 LG: 1503044.7:2001 MAR30 367 441 forward 1 zf-A20 A20-like zinc finger 7.20E-1 1
12 LG:1503588.1 :2001 MAR30 130 252 forward 1 KRAB KRAB box 4.00E-2
13 LG: 1503589.2:2001 MAR30 861 929 forward 3 zf-C2H2 Zinc finger, C2H2 type 2.00E-0
13 LG: 1503589.2:2001 MAR30 64 132 forward 1 zf-C2H2 Zinc finger, C2H2 type 4.90E-0
14 LG: 1506339.4:2001 MAR30 101 514 forward 2 Ribosomal_S5 Ribosomal protein S5 2.10E-8
15 LG:220648.6:2001 MAR30 285 503 forward 3 UPAR_LY6 u-PAR/Ly-6 domain 3.20E-1
16 LG:236654.1 :2001 MAR30 820 888 forward 1 zf-C2H2 Zinc finger, C2H2 type 1.20E-0
17 LG:237699.26:2001 MAR30 228 515 forward 3 Bcl-2 Apoptosis regulator proteins, Bcl-2 family 1.90E-4
18 LG:31 1541.16:2001 MAR30 866 1222 forward 2 lectin_c Lectin C-type domain 9.40E-1
18 LG:31 1541.16:2001 MAR30 8 493 forward 2 SCP SCP-like extracellular protein 7.20E-0
19 LG:335923J:2001 MAR30 53 400 forward 2 lys C-type lysozyme/alpha-lactalbumin family 2.30E-4
20 LG:350342.14:2001 MAR30 150 860 forward 3 pkinase Protein kinase domain 1.30E-1
21 LG:369301.32:2001 MAR30 454 789 forward 1 PX PX domain 3.50E-1
22 LG:452089.1 :2001 MAR30 107 268 forward 2 Ribosomal_L5 Ribosomal protein L5 6.10E-2
22 LG:452089.1 :2001 MAR30 278 577 forward 2 Ribosomal_L5_C ribosomal L5P family C-terminus 2.60E-5
23 LG:454087.3:2001 MAR30 181 303 forward 1 KRAB KRAB box 3.30E-2
23 LG:454087.3:2001 MAR30 754 822 forward 1 zf-C2H2 Zinc finger, C2H2 type 1.80E-0
24 LG:466302.1 :2001 MAR30 79 486 forward 1 Ribosomal_L22 Ribosomal protein L22p/Ll 7e 4.10E-6
25 LG:474267.1 :2001 MAR30 513 581 forward 3 MORN MORN repeat 2.10E-0
26 LG:995613.10:2001 MAR30 1342 1470 forward 1 ldl_recept_b Low-density lipoprotein receptor repeat class B 1.10E-0
27 LG:01 1843.5:2001 MAR30 1599 1928 forward 3 CUB CUB domain 3.90E-1
TABLE 3
SEQ ID NO: Template ID Start Stop Frame Pfam Hit Pfam Description E-value
27 LG:01 1843.5:2001 MAR30 303 410 forward 3 EGF EGF-like domain 2.30E-05
28 LG:075904.32:2001 MAR30 1263 1601 forward 3 RA Ras association (RalGDS/AF-6) domain 4.60E-09
29 LG: 1004781.3:2001 MAR30 637 804 forward 1 sushi Sushi domain (SCR repeat) 5.20E-14
30 LG: 1041807.8:2001 MAR30 3 335 forward 3 RhoGAP RhoGAP domain 2.60E-0
31 LG: 1044448.2:2001 MAR30 1821 1919 forward 3 ank Ankyrin repeat 3.50E-08
32 LG: 1080598.9:2001 MAR30 315 437 forward 3 KRAB KRAB box 1.80E-22
32 LG: 1080598.9:2001 MAR30 1 1 19 1 187 forward 3 zf-C2H2 Zinc finger, C2H2 type 2.30E-06
33 LG:1081017.1 :2001 MAR30 386 484 forward 2 ank Ankyrin repeat 6.20E-08
34 LG: 1083120.2:2001 MAR30 77 199 forward 2 KRAB KRAB box 1.20E-24
34 LG: 1083120.2:2001 MAR30 707 775 forward 2 zf-C2H2 Zinc finger, C2H2 type 2.50E-06
35 LG: 1097492.12:2001MAR30 707 1255 forward 2 RhoGEF RhoGEF domain 2J0E-33
36 LG: 1 18834.9:2001 MAR30 139 957 forward 1 Glyco_transf_8 Glycosyl transferase family 8 2.30E-04
37 LG: 1227408.25:2001 MAR30 986 1096 forward 2 WD40 WD domain, G-beta repeat 2.90E-07
38 LG: 1326953.1 :2001 MAR30 1 360 forward 1 RibosomaLLl 0e Ribosomal L10 1.10E-07
39 LG: 1397821.17:2001 MAR30 210 989 forward 3 pkinase Protein kinase domain 5.00E-14
40 LG: 1512507.1 :2001 MAR30 305 469 forward 2 HTH_3 Helix-turn-helix 1.20E-10
41 LG:196583.5:2001 MAR30 602 757 forward 2 tsp_l Thrombospondin type 1 domain 3.80E-08
42 LG: 198669.1 :2001 MAR30 65 187 forward 2 chromo 'chromo' (CHRromatin Organization Modifier) 1.40E-16 domain
43 LG:202943.1 :2001 MAR30 235 339 forward 1 EGF EGF-like domain 1.60E-05
43 LG:202943.1 :2001 MAR30 1426 1587 forward 1 sushi Sushi domain (SCR repeat) 3.80E-18
44 LG:204724.3:2001 MAR30 3 482 forward 3 Adeno_El B_19K Adenovirus E1 B 19K protein / small t-antigen 2.80E-9
44 LG:204724.3:2001 MAR30 61 1 1762 forward 2 Adeno_El B_55K Adenovirus EB1 55K protein / large t-antigen 4.80E-26
45 LG:206425.10:2001 MAR30 472 1299 forward 1 GBP Guanylate-binding protein, N-terminal domain 5.40E-18
45 LG:206425.10:2001 MAR30 1303 2178 forward 1 GBP_C Guanylate-binding protein, C-terminai domain 2.30E-1 1
46 LG:208190.2:2001 MAR30 181 303 forward 1 KRAB KRAB box 4.50E-24
46 LG:208190.2:2001 MAR30 1042 1 1 10 forward 1 zf-C2H2 Zinc finger, C2H2 type 4.80E-07
47 LG:222927.2:2001 MAR30 418 702 forward 1 Fork_head Fork head domain 9J0E-27
48 LG:228046.5:2001 MAR30 846 914 forward 3 zf-C2H2 Zinc finger, C2H2 type 9.10E-0
49 LG:230980.1 :2001 MAR30 21 1 309 forward 1 ank Ankyrin repeat 4.50E-1
50 LG:236976.2:2001 MAR30 336 506 forward 3 homeobox Homeobox domain 5.50E-23
51 LG:238322.6:2001 MAR30 536 1519 forward 2 Semσ Sema domain 1.20E-21
TABLE 3
SEQ ID NO. Template ID Start Stop Frame Pfam Hit Pfam Description E-value
51 LG:238322.6:2001 MAR30 706 1668 forward 1 Sema Sema domain 1.20E-05
52 LG:341461.1 :2001 MAR30 288 485 forward 3 DnaJ DnaJ domain 3.90E-35
53 LG:354088.1 :2001 MAR30 135 587 forward 3 rve ■ Integrase core domain 2.80E-21
54 LG:376275.1 :2001 MAR30 709 831 forward 1 KRAB KRAB box 1.80E-24
55 LG:399281.3:2001 MAR30 654 752 forward 3 ank Ankyrin repeat 3.20E-09
55 LG:399281.3:2001 MAR30 1618 1716 forward 1 ank Ankyrin repeat 6.80E-06
56 LG:404921.10:2001 MAR30 2555 2653 forward 2 ank Ankyrin repeat 1.20E-10
56 LG:404921.10:2001 MAR30 917 1231 forward 2 VPS9 Vacuolar sorting protein 9 (VPS9) domain 2.50E-12
57 LG:444677.34:2001 MAR30 395 817 forward 2 FAA_hydrolase Fumarylacetoacetate (FAA) hydrolase family 2.00E-26
58 LG:968691.1 :2001 MAR30 208 531 forward 1 BTB BTB/POZ domain 2.40E-30
59 LG:983862.1 :2001 MAR30 226 399 forward 1 PBD P21-Rho-binding domain 1.00E-08
59 LG:983862.1 :2001 MAR30 141 1 2166 forward 1 pkinase Protein kinase domain 1.40E-80
60 LG:984130.1 :2001 MAR30 302 625 forward 2 BTB BTB/POZ domain 6.90E-33
60 LG:984130.1 :2001 MAR30 1 196 1348 forward 2 Kelch Kelch motif 3.10E-08
61 LG:986291.1 :2001 MAR30 127 570 forward 1 RibosomalJ δp Ribosomal L18p/L5e family 4.10E-74
62 LG:045210.8:2001 MAR30 1 15 192 forward 1 RPEL RPEL repeat 1.10E-06
63 LG:229284.39:2001 MAR30 1914 2792 forward 3 TTL Tubulin-tyrosine ligase family 1.90E-12
64 LG:337810.20:2001 MAR30 227 355 forward 2 Armadillo_seg Armadillo/beta-catenin-like repeat 1.50E-04
65 LG:463420.1 :2001 MAR30 2441 2995 forward 2 Glyco_transf_25 Glycosyltransferase family 25 (LPS biosynthesis 2.00E-72 protein)
66 LG: 1080918.1 :2001 MAR30 1003 1071 forward 1 zf-C2H2 Zinc finger, C2H2 type 2.90E-07
67 LG: 1093747.15:2001 MAR30 540 662 forward 3 KRAB KRAB box 4.00E-22
67 LG: 1093747.15:2001 MAR30 1 1 13 1 181 forward 3 zf-C2H2 Zinc finger, C2H2 type 2.30E-07
68 LG: 1096896.47:2001 MAR30 185 601 forward 2 succ_DH_flav_C Fumarate reductase/succinate 8.30E-60 dehydrogenase flavoprotein C-terminal
69 LG: 1098931.39:2001 MAR30 1615 1902 forward 1 Biotin_carb_C Biotin carboxylase C-terminal domain l .OOE-l 0
69 LG: 1098931.39:2001 MAR30 1694 1864 forward 2 Biotin_carb_C Biotin carboxylase C-terminal domain 7.70E-04
69 LG: 1098931.39:2001 MAR30 2314 2514 forward 1 biotinjipoyl Biotin-requiring enzyme 2.30E-22
69 LG: 1098931.39:2001 MAR30 5012 6721 forward 2 Carboxyljrans Carboxyl transferase domain 9.30E-30
69 LG: 1098931.39:2001 M AR30 524 895 forward 2 CPSase_L_chain Carbamoyl-phosphate synthase L chain, N- 1.00E-57 terminal domain
TABLE 3
SEQ ID NO: Template ID Start Stop Frame Pfam Hit Pfam Description E-value
69 LG: 1098931.39:2001 MAR30 899 1675 forward 2 CPSase_L_D2 Carbamoyl-phosphate synthase L chain, ATP 5.00E-14 binding domain
70 LG: 1 100823.1 :2001 MAR30 88 792 forward 1 tτansmembrane4 Tetraspanin family 7.00E-07
70 LG: 1 100823.1 :2001 MAR30 197 733 forward 2 transmembrane4 Tetraspanin family 1.80E-0
71 LG: 1 166387.1 :2001 MAR30 731 958 forward 2 WWE WWE domain 6.40E-20
71 LG: 1 166387.1 :2001 MAR30 563 676 forward 2 zf-C3HC4 Zinc finger, C3HC4 type (RING finger) 4.70E-04
72 LG: 1383036.49:2001 MAR30 333 545 forward 3 rrm RNA recognition motif, (a.k.a. RRM, RBD, or RNP 1.30E-23 domain)
73 LG: 1452353.14:2001 MAR30 3974 4501 forward 2 RasGAP GTPase-activator protein for Ras-like GTPase 2.90E-10
74 LG: 1452435.15:2001 MAR30 2148 2246 forward 3 ank Ankyrin repeat 2.90E-1 1
74 LG: 1452435.15:2001 MAR30 310 408 forward 1 ank Ankyrin repeat 3.80E-10
74 LG: 1452435.15:2001 MAR30 869 967 forward 2 ank Ankyrin repeat 9.10E-07
74 LG: 1452435.15:2001 MAR30 4260 451 1 forward 3 death Death domain 4.80E-25
74 LG: 1452435.15:2001 MAR30 2781 3095 forward 3 ZU5 ZU5 domain 5J0E-62
75 LG: 1498774.1 :2001 MAR30 329 538 forward 2 elF-5a Eukaryotic initiation factor 5A hypusine, DNA- 3.40E-36 binding OB fold
75 LG:1498774.1 :2001 MAR30 101 325 forward 2 elF-5a_N Eukaryotic initiation factor 5A hypusine, SH3-like 2.30E-50 barrel domain
76 LG: 197180.1 :2001 MAR30 66 554 forward 3 GTP_EFTU Elongation factor Tu GTP binding domain 5.40E-08
76 LG:197180.1 :2001 MAR30 40 504 forward 1 GTP_EFU Elongation factor Tu GTP binding domain 7.60E-0
76 LG:197180.1 :2001 MAR30 864 1 154 forward 3 GTP_EFTU_D3 Elongation factor Tu C-terminal domain 1.30E-40
77 LG: 199489.1 :2001 MAR30 257 1810 forward 2 aa_permeases Amino acid permease 1.20E-07
78 LG:201908.3:2001 MAR30 274 396 forward 1 KRAB KRAB box 3.80E-10
78 LG:201908.3:2001 MAR30 2194 2262 forward 1 zf-C2H2 Zinc finger, C2H2 type 2.20E-06
79 LG:247245.26:2001 MAR30 434 556 forward 2 KRAB KRAB box 8.00E-21
79 LG:247245.26:2001 MAR30 1364 1432 forward 2 zf-C2H2 Zinc finger, C2H2 type 1.60E-06
80 LG:256365.2:2001 MAR30 480 1 151 forward 3 Tropomyosin Tropomyosin 1.50E-58
80 LG:256365.2:2001 MAR30 458 1 189 forward 2 Tropomyosin Tropomyosin 6.20E-0
81 LG:332923.4:2001 MAR30 1845 21 14 forward 3 cadherin Cadherin domain 1.00E-23
82 LG:33527ό.1 :2001 MAR30 726 896 forward 3 homeobox Homeobox domain 1.30E-27
83 LG:350272.2:2001 MAR30 562 930 forward 1 SPRY SPRY domain l . lOE-10
84 LG:350921.2:2001 MAR30 1388 1648 forward 2 UCH-2 Ubiquitin carboxyl-terminal hydrolase family 2 7.50E-16
TABLE 3
SEQ ID NO Template ID Start Stop Frame Pfam Hit Pfam Description E-value
85 LG:406568.1 :2001 MAR30 21 1 1 197 forward 1 Tropomodulin Tropomodulin 9.30E-91
86 LG:41 1043.3:2001 MAR30 213 1 199 forward 3 adh_zinc Zinc-binding dehydrogenase l .OOE-19
87 LG:414376.20:2001 MAR30 1637 2224 forward 2 ionjrans Ion transport protein 6.60E-44
87 LG:414376.20:2001 MAR30 976 1272 forward 1 KJetra K+ channel tetramerisation domain 2.40E-4
88 LG:457695.1 :2001 MAR30 278 436 forward 2 Ribosomal_L30 Ribosomal protein L30p/L7e 3.80E-23
89 LG:902390.2:2001 MAR30 44 298 forward 2 ACBP Acyl CoA binding protein 1.70E-46
90 LG:903565.20:2001 MAR30 1288 1704 forward 1 P Proprotein convertase P-domain 2.60E-77
90 LG:903565.20:2001 MAR30 306 1529 forward 3 Peptidase_S8 Subtilase family 3.70E-63
90 LG:903565.20:2001 MAR30 538 1254 forward 1 Peptidase_S8 Subtilase family 1.40E-05
91 LG:978182.4:2001 MAR30 215 925 forward 2 Metallophos Calcineurin-like phosphoesterase 4.30E-22
92 LG:986827.1 :2001 MAR30 104 673 forward 2 arf ADP-ribosylation factor family 2.60E-1 1
93 LG:013792.1 :2001 MAR30 620 742 forward 2 KRAB KRAB box 3.00E-21
94 LG:018258.1 :2001 MAR30 299 730 forward 2 Nitroreductase Nitroreductase family 9.00E-05
95 LG:023126.3:2001 MAR30 469 852 forward 1 ras Ras family 1.50E-07
90 -4 96 LG:023618.1 :2001 MAR30 237 479 forward 3 Acetyltransf Acetyltransferase (GNAT) family 1.90E-17
97 LG:030999.1 :2001 MAR30 16 576 forward 1 arf ADP-ribosylation factor family 5.60E-0
97 LG:030999.1 :2001 MAR30 670 867 forward 1 DnaJ DnaJ domain 2.90E-0
97 LG:030999.1 ;2001 MAR30 73 627 forward 1 ras Ras family 6.70E-2
98 LG: 103508.1 :2001 MAR30 771 1346 forward 3 GalactosyLT Galactosyltransferase 1.30E-40
99 LG: 107976.15:2001 MAR30 3214 3438 forward 1 PDZ PDZ domain (Also known as DHR or GLGF). 5.90E-0
99 LG: 107976.15:2001 MAR30 2441 3007 forward 2 Rap_GAP Rap/ran-GAP 2.30E-13
100 LG: 1080096.1 :2001 MAR30 1708 1776 forward 1 zf-C2H2 Zinc finger, C2H2 type 1.70E-07
101 LG: 1080275.1 :2001 MAR30 550 618 forward 1 zf-C2H2 Zinc finger, C2H2 type 2.20E-06
102 LG: 1090358.10:2001 MAR30 781 903 forward 1 KRAB KRAB box 3.90E-27
102 LG: 1090358.10:2001 MAR30 1425 1493 forward 3 zf-C2H2 Zinc finger, C2H2 type 2.70E-07
102 LG: 1090358.10:2001 MAR30 1258 1326 forward 1 zf-C2H2 Zinc finger, C2H2 type 7.70E-07
103 LG: 1095833.9:2001 MAR30 1655 1948 forward 2 TIG IPT/TIG domain 1.30E-1
104 LG:1383121 .25:2001 MAR30 106 807 forward 1 DEAD DEAD/DEAH box helicase 2.60E-0
104 LG: 1383121.25:2001 MAR30 1587 1805 forward 3 helicase_C Helicase conserved C-terminal domain 2.80E-2
105 LG: 1386609.2:2001 MAR30 638 823 forward 2 UCH-2 Ubiquitin carboxyl-terminal hydrolase family 2 9.50E-27
106 LG: 1398465.1 :2001 MAR30 2392 2502 forward 1 WD40 WD domain, G-beta repeat 6.80E-10
106 LG: 1398465.1 :2001 MAR30 83 196 forward 2 WD40 WD domain, G-beta repeat 5.10E-08
TABLE 3
SEQ ID NO: Template ID Start Stop Frame Pfam Hit Pfam Description E-value
107 LG: 1453417.10:2001 MAR30 7031 7762 forward 2 7tm_2 7 transmembrane receptor (Secretin family) 4.10E-5
107 LG:1453417.10:2001 MAR30 1 124 1402 forward 2 cadherin Cadherin domain 3.30E-2
107 LG: 1453417.10:2001 MAR30 4646 4741 forward 2 EGF EGF-like domain 7.40E-0
107 LG:1453417.10:2001 MAR30 6857 7018 forward 2 GPS Latrophilin/CL- 1 -like GPS domain 1.50E-2
107 LG: 1453417.10:2001 MAR30 5831 6004 forward 2 HRM Hormone receptor domain 1.60E-1
107 LG: 1453417.10:2001 MAR30 5684 5821 forward 2 laminin_EGF Laminin EGF-like (Domains III and V) 5.20E-1 1
107 LG: 1453417.10:2001 MAR30 4097 4585 forward 2 laminin_G Laminin G domain l .OOE-l
108 LG:147869.3:2001 MAR30 1 2034 forward 1 Patched Patched family 3.60E-1
109 LG:148485.5:2001 MAR30 54 857 forward 3 FGGY FGGY family of carbohydrate kinases, N- 4.10E-3 terminal domain
1 10 LG: 1501818.12:2001 MAR30 306 1 172 forward 3 cobW Cobalamin synthesis protein/P47K 3J0E-5
1 1 1 LG:1508275.1 :2001 MAR30 194 280 forward 2 efhand EF hand 5.40E-0
1 1 1 LG: 1508275.1 :2001 MAR30 47 178 forward 2 S_100 S-100/ICaBP type calcium binding domain 3.60E-2
1 12 LG: 1509771.1 :2001 MAR30 67 384 forward 1 Rhodanese Rhodanese-like domain 1.10E-1
1 13 LG: 1512998.13:2001 MAR30 859 1053 forward 1 FYVE FYVE zinc finger 2.50E-2
1 14 LG: 198251.7:2001 MAR30 293 397 forward 2 G-gamma GGL domain 2.80E-0
1 15 LG: 198296.1 :2001 MAR30 646 783 forward 1 Kelch Kelch motif 5.50E-1
1 16 LG: 198876.13:2001 MAR30 343 813 forward 1 Ant oroliferat BTG1 family 2.20E-10
1 17 LG:200704.1 :2001 MAR30 862 1044 forward 1 ig Immunoglobulin domain 3.00E-0
1 18 LG:206593.3:2001 MAR30 704 772 forward 2 zf-C2H2 Zinc finger, C2H2 type 1.30E-0
1 18 LG:206593.3:2001 MAR30 295 363 forward 1 zf-C2H2 Zinc finger, C2H2 type 7.00E-0
1 18 LG:206593.3:2001 MAR30 222 290 forward 3 zf-C2H2 Zinc finger, C2H2 type 1.10E-0
1 19 LG:223970.1 1 :2001 MAR30 492 695 forward 3 rrm RNA recognition motif, (a.k.a. RRM, RBD, or RNP 3J0E-0 domain)
120 LG:227500.5:2001 MAR30 869 1042 forward 2 LIM LIM domain 5.80E-1 1
121 LG:227722J:2001 MAR30 2 472 forward 2 AAA ATPase family associated with various cellular 3.10E-21 activities (AAA)
122 LG:229105.1 :2001 MAR30 84 323 forward 3 heme_l Heme/Steroid binding domain 4.60E-1
123 LG:233761.4:2001 MAR30 1200 1562 forward 3 SPRY SPRY domain 2.90E-1
123 LG:2337όl .4:2001 MAR30 315 440 forward 3 zf-B_box B-box zinc finger. 4J0E-1
123 LG:233761.4:2001 MAR30 107 229 forward 2 zf-C3HC4 Zinc finger, C3HC4 type (RING finger) 8.20E-1
124 LG:234326.67:2001 MAR30 3134 3709 forward 2 Reticulon Reticulon 4.00E-10
TABLE 3
SEQ ID NO: Template ID Start Stop Frame Pfam Hit Pfam Description E-value
125 LG:236056.27:2001 MAR30 1003 1242 forward 1 SWIB BAFόOb domain of the SWIB complex 1.20E-23
126 LG:253889.31 :2001 MAR30 404 619 forward 2 rrm RNA recognition motif, (a.k.a. RRM, RBD, or RNP 6.40E-2 domain)
127 LG:270833.135:2001 MAR30 78 290 forward 3 RNA_pol_L RNA polymerases L / 13 to 16 kDa subunit 2.90E-21
128 LG-.292613.7:2001 MAR30 1206 1346 forward 3 PHD PHD-finger 3.60E-0
129 LG:331546.2:2001 MAR30 241 1038 forward 1 PP2C Protein phosphatase 2C 4.40E-57
130 LG:332027.6:2001 MAR30 660 1643 forward 3 Methyltransf_5 MraW methylase family 1.00E-90
131 LG:336998.1 :2001 MAR30 4500 4679 forward 3 PHD PHD-finger 5.20E-1 1
131 LG:336998.1 :2001 MAR30 1 1241 1 1627 forward 3 SET SET domain 1.30E-61
131 LG:336998.1 :2001 MAR30 3237 3380 forward 3 zf-CXXC CXXC zinc finger 9J0E-2
132 LG:338010.8:2001 MAR30 524 718 forward 2 zf-DHHC DHHC zinc finger domain 6J0E-27
133 LG:344597.1 :2001 MAR30 1 174 1500 forward 1 CUB CUB domain 3.00E-15
133 LG:344597.1 :2001 MAR30 1525 1692 forward 1 sushi Sushi domain (SCR repeat) 1.30E-14
134 LG:347361.2:2001 MAR30 2254 2352 forward 1 ank Ankyrin repeat 1.20E-1 1
134 LG:347361.2:2001 MAR30 1497 1595 forward 3 ank Ankyrin repeat 1.50E-07
134 LG:347361.2:2001 MAR30 201 515 forward 3 BTB BTB/POZ domain 9.00E-13
134 LG:347361.2:2001 MAR30 3253 3444 forward 1 FYVE FYVE zinc finger 7.00E-21
135 LG:349293.17:2001 MAR30 1908 2018 forward 3 WD40 WD domain, G-beta repeat 2.90E-0
136 LG:410595.19:2001 MAR30 727 1029 forward 1 CH Calponin homology (CH) domain 8J0E-0
137 LG:41 1 151.35:2001 MAR30 1548 1718 forward 3 LIM LIM domain 3.90E-1
137 LG:41 1 151.35:2001 MAR30 60 299 forward 3 PDZ PDZ domain (Also known as DHR or GLGF). 1.50E-1
138 LG:41 1334.8:2001 MAR30 1680 1856 forward 3 LIM LIM domain 2J0E-1 1
139 LG:458583.1 :2001 MAR30 31 141 forward 1 WD40 WD domain, G-beta repeat 4.60E-08
140 LG:475378.1 :2001 MAR30 1936 2133 forward 1 FYVE FYVE zinc finger 1.50E-1
140 LG:475378.1 :2001 MAR30 1567 1848 forward 1 PH PH domain 4.40E-13
140 LG:475378.1 :2001 MAR30 913 1476 forward 1 RhoGEF RhoGEF domain 2.40E-07
141 LG:481572.1 :2001 MAR30 502 858 forward 1 Al pp Appr-l"-p processing enzyme family 1.10E-31
141 LG:481572.1 :2001 MAR30 2492 2728 forward 2 WWE WWE domain 3.20E-2
142 LG:481704.1 :2001 MAR30 1 14 575 forward 3 rve Integrase core domain 3.40E-3
143 LG:898195.4:2001 MAR30 365 688 forward 2 BTB BTB/POZ domain 4.00E-4
143 LG:898195.4:2001 MAR30 1397 1534 forward 2 Kelch Kelch motif 7.50E-1
144 LG:903785.1 :2001 MAR30 210 629 forward 3 DSPc Dual specificity phosphatase, catalytic 6.60E-3
TABLE 3
SEQ ID NO' Template ID Start Stop Frame Pfam Hit Pfam Description E-value
145 LG:977454.3:2001 MAR30 10 327 forward 1 GSHPx Glutathione peroxidase •1 JOE- 19
146 LG:977724.12:2001 MAR30 1606 1776 forward 1 SH3 SH3 domain 1 J0E-16
146 LG:977724.12:2001 MAR30 298 420 forward 1 zf-C3HC4 Zinc finger, C3HC4 type (RING finger) 5.20E-07
147 LG:978215.19:2001 MAR30 1050 1 199 forward 3 LRRCT Leucine rich repeat C-terminal domain 4.80E-10
148 LG.981795.1 :2001 MAR30 265 807 forward 1 PMP22_Claudin PMP-22/EMP/MP20/Claudin family 3.10E-05
149 LG:982784.1 :2001 MAR30 582 650 forward 3 zf-C2H2 Zinc finger, C2H2 type 2.90E-05
150 LG:987322.4:2001 MAR30 863 1423 forward 2 SIR2 Sir2 family 4.10E-10
151 LG:006242J:2001 MAR30 87 443 forward 3 DUF232 Putative transcriptional regulator 2.00E-27
152 LG:027320J:2001 MAR30 158 358 forward 2 SAM SAM domain (Sterile alpha motif) 6.30E-06
153 LG: 147541.44:2001 MAR30 106 849 forward 1 DUF259 Protein of unknown function, DUF259 2.90E-04
154 LG:228319.2:2001 MAR30 81 1 1032 forward 1 mbt mbt repeat 6.30E-39
155 LG:238754.19:2001 MAR30 205 534 forward 1 Yippee Yippee putative zinc-binding protein 8J0E-69
156 LG:405751.12:2001 MAR30 1241 1582 forward 2 MA3 MA3 domain 4.30E-46
157 Ll:01 1822.6:2001 MAY17 306 1 199 forward 3 kinesin Kinesin motor domain 5.90E-14
158 LI: 1012467.2:2001 MAY17 27 827 forward 3 pkinase Protein kinase domain 7.30E-76
159 LI: 1 169981.13:2001 MAY17 104 226 forward 2 KRAB KRAB box 1.30E-24
159 LI: 1 169981.13:2001 MAY17 1031 1099 forward 2 zf-C2H2 Zinc finger, C2H2 type 8.60E-07
160 U:1 171553.1 :2001 MAY17 1389 1457 forward 3 zf-C2H2 Zinc finger, C2H2 type 3.80E-08
161 LI: 1 183156.3:2001 MAY17 395 517 forward 2 KRAB KRAB box 1.50E-26
161 LI: 1 183156.3:2001 MAY17 1247 1315 forward 2 zf-C2H2 Zinc finger, C2H2 type 2.40E-07
161 LI: 1 183156.3:2001 MAY17 2034 2102 forward 3 zf-C2H2 Zinc finger, C2H2 type 1 J0E-05
162 LI: 1 188500.6:2001 MAY17 195 782 forward 3 AAA ATPase family associated with various cellular 1.60E-44 activities (AAA)
163 LI: 147333.12:2001 MAY17 1259 1675 forward 2 Dakl Dakl domain 8.60E-07
164 LI: 147523.7:2001 MAY 17 99 554 forward 3 sodcu Copper/zinc superoxide dismutase (SODC) 8.10E-10
165 U:197388.10:2001 MAY17 323 820 forward 2 lactamase_B Metallo-beta-lactamase superfamily 2.90E-35
166 LI:2049216.1 :2001 MAY17 614 712 forward 2 ank Ankyrin repeat 5.60E-09
166 LI:204921ό. l :2001 MAY17 137 499 forward 2 ArfGap Putative GTP-ase activating protein for Arf 1.60E-48
167 U:2051624.2:2001 MAY17 105 1007 forward 3 PALP Pyridoxal-phosphate dependent enzyme 5.00E-65
168 LI:2121838.1 :2001 MAY17 426 494 forward 3 zf-C2H2 Zinc finger, C2H2 type 2.40E-07
169 Ll:2122954.8:2001 MAY17 309 431 forward 3 KRAB KRAB box 1 J0E-18
169 Ll:2122954.8:2001 MAY17 967 1035 forward 1 zf-C2H2 Zinc finger, C2H2 type 1.30E-06
TABLE 3
! ID NO: Template ID Start Stop Frame Pfam Hit Pfam Description E-value
170 Ll:2198064.2:2001 MAY17 96 164 forward 3 zf-C2H2 Zinc finger, C2H2 type 1.50E-06
171 LI:2206583.1 :2001 MAY17 368 436 forward 2 zf-C2H2 Zinc finger, C2H2 type 1.90E-06
171 LI:2206583.1 :2001 MAY17 237 305 forward 3 zf-C2H2 Zinc finger, C2H2 type 9.90E-06
172 LI:235663.6:2001 MAY17 195 767 forward 3 GalactosyLT Galactosyltransferase 7.60E-20
173 LI:236386J:2001 MAY17 1430 1759 forward 2 PX PX domain 3.10E-22
173 U:236386J:2001 MAY17 766 936 forward 1 SH3 SH3 domain 1.20E-1 1
174 U:236654.3:2001 MAY17 816 884 forward 3 zf-C2H2 Zinc finger, C2H2 type 1.20E-04
175 U:256059.46:2001 MAY17 205 741 forward 1 MHCJ Class 1 Histocompatibility antigen, domains 4.20E-13 alpha 1 and 2
176 U:279978.22:2001 MAY17 137 1372 forward 2 AMP-binding AMP-binding enzyme 4.80E-94
177 U:31 1541.6:2001 MAY! 7 2166 2417 forward 3 lectin_c Lectin C-type domain 2.90E-04
177 Ll:31 1541.6:2001 MAY17 273 806 forward 3 SCP SCP-like extracellular protein 2.00E-12
178 LI:346123.1 :2001 MAY17 95 841 forward 2 TIM Triosephosphate isomerase 6.80E-17
179 Ll:38121 1.5:2001 MAY17 626 748 forward 2 KRAB KRAB box 1.60E-22
179 Ll:38121 1.5:2001 MAY17 1281 1349 forward 3 zf-C2H2 Zinc finger, C2H2 type 1.10E-07
179 Ll:38121 1.5:2001 MAY17 2165 2233 forward 2 zf-C2H2 Zinc finger, C2H2 type 1.60E-07
180 Ll:412197.82:2001 MAY17 1331 1819 forward 2 Ribosomal_S5 Ribosomal protein S5 1.90E-63
181 Ll:412936.49:2001 MAY 17 343 435 forward 1 WW WW domain 2.40E-06
182 U:427792.139:2001 MAY17 3 338 forward 3 Peptidase_Cl Papain family cysteine protease 2.20E-05
183 Ll:450229.1 :2001 MAY 17 85 648 forward 1 Ribosomal_S7e Ribosomal protein S7e 4.60E-83
184 Ll:475565.243:2001 MAY17 75 197 forward 3 KRAB KRAB box 2.20E-22
185 UJ64701.8:2001 MAY17 866 1345 forward 2 Peptidase_S26 Signal peptidase 1 4.60E-58
186 Ll:024124.2:2001 MAY17 531 773 forward 3 '9 Immunoglobulin domain 5.40E-06
186 LI:024124.2:2001 MAY17 822 1 106 forward 3 Xlink Extracellular link domain 3.30E-43
187 LI:038252.3:2001 MAY17 2887 3480 forward 1 STAT_bind STAT protein, DNA binding domain 3.60E-76
188 U:056882.1 :2001 MAY17 313 435 forward 1 KRAB KRAB box 1.80E-24
189 U:059530.1 :2001 MAY17 2039 2107 forward 2 Go Loco LGN motif, putative GEF specific for G-alpha 5.20E-08 GTPase
190 U:089950.30:2001 MAY17 1008 1265 forward 3 C2 C2 domain 1.60E-26
191 U:1072906.38:2001 MAY17 890 979 forward 2 WW WW domain 7.30E-08
192 LI: 1 158936.4:2001 MAY 17 280 393 forward 1 WD40 WD domain, G-beta repeat 5.80E-09
193 LI: 1 173412.15:2001 MAY17 1 160 1918 forward 2 UPF0034 Uncharacterized protein family UPF0034 2.50E-09
TABLE 3
SEQ ID NO: Template ID Start Stop Frame Pfam Hit Pfam Description E-value
194 Li: 1 174279.14:2001 MAY17 276 398 forward 3 KRAB KRAB box 3.50E-2
194 LI: 1 174279.14:2001 MAY17 1008 1076 forward 3 zf-C2H2 Zinc finger, C2H2 type 2J0E-0
195 LI: 1 174809.1 2001 MAY 17 657 725 forward 3 zf-C2H2 Zinc finger, C2H2 type 8.60E-0
195 LI: 1 174809.1 2001 MAY 17 431 499 forward 2 zf-C2H2 Zinc finger, C2H2 type 1.20E-0
196 Ll:1 175131.1 2001 MAY17 185 307 forward 2 KRAB KRAB box 6.80E-2
196 Ll: 1 175131.1 2001 MAY 17 842 910 forward 2 zf-C2H2 Zinc finger, C2H2 type 3.60E-0
197 LI: 1 188801.10:2001 MAY17 724 966 forward 1 PDZ PDZ domain (Also known as DHR or GLGF). 1.30E-1
198 LI: 1 189176.27:2001 MAY17 509 577 forward 2 MORN MORN repeat 1.20E-0
199 U: 197739.4:2001 MAY! 7 171 293 forward 3 KRAB KRAB box 1.20E-2
199 LI: 197739.4:2001 MAY 17 768 836 forward 3 zf-C2H2 Zinc finger, C2H2 type 2.50E-0
200 Ll:2049016.1 2001 MAY 17 200 322 forward 2 KRAB KRAB box 1.20E-2
201 LI :2049137.1 2001 MAY 17 260 382 forward 2 KRAB KRAB box 5.90E-2
201 U:2049137.1 2001 MAY 17 875 943 forward 2 zf-C2H2 Zinc finger, C2H2 type 1.90E-0
202 LI :2051907.1 2001 MAY 17 1 17 203 forward 3 efhand EF hand 2.10E-0
202 Ll:2051907.1 2001 MAY! 7 912 1 187 forward 3 mito_carr Mitochondrial carrier protein 1 J0E-3
203 Ll:21 17996.13:2001 MAY17 717 1028 forward 3 GAT GAT domain 2J0E-3
203 Ll:21 17996.13:2001 MAY17 84 515 forward 3 VHS VHS domain 2.90E-6
204 Li:21 18683.15:2001 MAY17 427 774 forward 1 PH PH domain 1.20E-1
204 Ll:21 18683.15:2001 MAY17 1069 1527 forward 1 RhoGAP RhoGAP domain 6.20E-5
204 Ll:21 18683.15:2001 MAY17 241 330 forward 1 WW WW domain 4.30E-0
205 LI:2120312.1 :2001 MAY17 951 1262 forward 3 Ribosomal_L7Ae Ribosomal protein L7Ae/L30e/S12e/Gadd45 1.90E-1 family
206 U:2121328.17:2001 MAY17 432 530 forward 3 ank Ankyrin repeat 2.20E-0
207 U:2121802.5:2001 MAY17 188 310 forward 2 KRAB KRAB box 1.20E-2
207 LI:2121802.5:2001 MAY17 977 1045 forward 2 zf-C2H2 Zinc finger, C2H2 type 3.50E-0
208 Ll:2123406.9:2001 MAY17 406 612 forward 1 CUB CUB domain 4.90E-0
208 U:2123406.9:2001 MAY17 226 396 forward 1 sushi Sushi domain (SCR repeat) 3.50E-0
209 Ll:216129.45:2001 MAY17 1 122 1361 forward 3 UBX UBX domain 4.40E-0
210 U:2186630.1 :2001 MAY17 135 257 forward 3 KRAB KRAB box 1.10E-2
21 1 Ll:2188206.2:2001 MAY17 570 725 forward 3 integrase Integrase DNA binding domain 9.80E-2
212 LI:2199710.9:2001 MAY17 657 1454 forward 3 DEAD DEAD/DEAH box helicase 2.40E-4
212 LL2199710.9 2001 MAY 17 161 1 1802 forward 3 helicase_C Helicase conserved C-terminal domain 4.50E-0
TABLE 3
SEQ ID NO: Template ID Start Stop Frame Pfam Hit Pfam Description E-value
213 U:2209335.2:2001 MAY17 1056 1 154 forward 3 ank Ankyrin repeat 6.80E-0
214 U:230980.13:2001 MAY17 64 162 forward 1 ank Ankyrin repeat 4.50E-10
215 Ll:244421.37:2001 MAY17 3 101 forward 3 zf-CXXC CXXC zinc finger 6.10E-06
216 LI:341998.1 :2001 MAY17 308 598 forward 2 CH Calponin homology (CH) domain 4.40E-13
217 Ll:347931.10:2001 MAY17 905 1 177 forward 2 PH PH domain 1.30E-04
218 U:350771.42:2001 MAY17 793 1083 forward 1 Alpha_adaptin_C Alpha adaptin AP2, C-terminal domain 3.30E-68
219 U:354423.6:2001 MAY17 855 1 166 forward 3 BTB BTB/POZ domain 8.60E-24
220 U:399333.8:2001 MAY17 1235 2398 forward 2 RNB RNB-like protein 9.90E-10
221 LI:445084.36:2001 MAY17 105 551 forward 3 DUF101 Protein of unknown function DUF101 3J0E-12
222 U:454087.3:2001 MAY17 181 303 forward 1 KRAB KRAB box 3.30E-2
222 LI:454087.3:2001 MAY17 754 822 forward 1 zf-C2H2 Zinc finger, C2H2 type 1.80E-0
223 LI:474887.1 :2001 MAY17 2795 3166 forward 2 UQ_con Ubiquitin-conjugating enzyme 9J0E-19
224 LI:745251.1 :2001 MAY17 208 531 forward 1 BTB BTB/POZ domain 2.40E-30
225 LIJ47717.9:2001 MAY17 937 1 1 13 forward 1 ig Immunoglobulin domain 1.50E-07
226 Ll:80621 1.3:2001 MAY17 876 944 forward 3 zf-C2H2 Zinc finger, C2H2 type 4.00E-06
227 LI:815072.1 :2001 MAY17 1 360 forward 1 RibosomalJ Oe Ribosomal L10 1.10E-07
228 Ll:817052.8:2001 MAY17 1084 1206 forward 1 KRAB KRAB box 9.50E-20
228 Ll:817052.8:2001 MAY17 231 1 2379 forward 1 zf-C2H2 Zinc finger, C2H2 type 8.20E-08
229 U:903392.45:2001 MAY17 3 194 forward 3 K etra K+ channel tetramerisation domain 1.60E-0
230 U:013724.1 :2001 MAY17 20 1033 forward 2 V-ATPase_C V-ATPase subunit C 7.50E-12
231 LI:191726.16:2001 MAY17 1360 1716 forward V 20G-Fell_Oxy 20G-Fe(ll) oxygenase superfamily 5.20E-0
232 U:202270.2:2001 MAY17 1500 1829 forward 3 Yippee Yippee putative zinc-binding protein 8.30E-68
233 Ll:21 19352.6:2001 MAY17 358 753 forward 1 20G-Fell_Oxy 20G-Fe(ll) oxygenase superfamily 4.10E-08
234 U:2207776.1 1 :2001 MAY17 592 942 forward 1 ABC1 ABC1 family 2.50E-45
235 LL256442.1 :2001 MAY 17 1466 1717 forward 2 BAF Barrier to autointegration factor 2.90E-30
235 LI:256442.1 :2001 MAY17 1473 1718 forward 3 BAF Barrier to autointegration factor 3.10E-1 1
236 U:330497J:2001 MAY17 61 312 forward 1 PAAD.DAPIN PAAD/DAPIN/Pyrin domain 4.90E-0
237 LI:018494.1 :2001 MAY17 1 1200 forward 1 SSF Sodium:solute symporter family 3.30E-0
238 LL023518.2:2001 MAY17 195 845 forward 3 vATP-synt_AC39 ATP synthase (C/AC39) subunit 1.20E-4
239 U:053488.46:2001 MAY17 1 174 1410 forward 1 PDGF Platelet-derived growth factor (PDGF) 1.80E-51
240 U:058298.27:2001 MAY17 665 1231 forward 2 pkinase Protein kinase domain 3.30E-3
241 LI:1 1 10046.1 :2001 MAY17 84 830 forward 3 MIP Major intrinsic protein 2.60E-56
TABLE 3
SEQ ID NO: Template ID Start Stop Frame Pfam Hit Pfam Description E-value 242 1 166752.1 1 :2001 MAY17 174 296 forward 3 KRAB KRAB box 1.20E-22 242 1 166752.1 1 :2001 MAY17 897 965 forward 3 zf-C2H2 Zinc finger, C2H2 type 1 J0E-07 243 1 173766.1 :2001 MAY17 289 41 1 forward 1 KRAB KRAB box 5.50E-27 243 1 173766.1 :2001 MAY 17 2008 2076 forward 1 zf-C2H2 Zinc finger, C2H2 type 1 JOE-07 244 1 177952.4:2001 MAY17 1257 2003 forward 3 Band_7 SPFH domain / Band 7 family 2.00E-22 244 1 177952.4:2001 MAY17 257 325 forward 2 zf-C2H2 Zinc finger, C2H2 type 1.50E-06 245 1 178064.3:2001 MAY17 274 396 forward 1 KRAB KRAB box 3.80E-10 245 1 178064.3:2001 MAY17 2194 2262 forward 1 zf-C2H2 Zinc finger, C2H2 type 2.20E-06 246 1 183121.1 :2001 MAY17 1080 1 148 forward 3 zf-C2H2 Zinc finger, C2H2 type 6J0E-07 247 1 190431.13:2001 MAY17 1873 2073 forward 1 sushi Sushi domain (SCR repeat) 7.20E-21 248 199121.14:2001 MAY17 1347 1577 forward 3 disintegrin Disintegrin 2J0E-21 248 199121.14:2001 MAY17 318 668 forward 3Pep_M12B_propep Reprolysin family propeptide 8.00E-57 248 199121.14:2001 MAY17 714 1298 forward 3 Reprolysin Reprolysin (M12B) family zinc metalloprotease 4.50E-10 249 202630.5:2001 MAY17 986 1726 forward 2 7tm_l 7 transmembrane receptor (rhodopsin family) 1.40E-30 250 2034488.1 :2001 MAY17 278 346 forward 2 zf-C2H2 Zinc finger, C2H2 type 2J0E-04 251 2051434.8:2001 MAY17 847 1599 forward 1 carb_anhydrase Eukaryotic-type carbonic anhydrase 2.40E-16 251 2051434.8:2001 MAY17 60 830 forward 3 carb_anhydrase Eukaryotic-type carbonic anhydrase 3.80E-13 252 21 18475.9:2001 MAY17 712 957 forward 1 UPAR_LY6 u-PAR/Ly-6 domain 2.30E-32 253 218849.24:2001 MAY17 482 1669 forward 2 OATP_C Organic Anion Transporter Polypeptide (OATP) 8.60E-21 family, C-terminus
253 Ll:218849.24:2001 MAY17 1898 2380 forward 2 OATP_N Organic Anion Transporter Polypeptide (OATP) 1.00E-67 family, N-terminus
254 U:2199824.5:2001 MAY17 480 1 151 forward 3 Tropomyosin Tropomyosin 1.50E-58 254 U:2199824.5:2001 MAY17 458 1 189 forward 2 Tropomyosin Tropomyosin 6.20E-08 255 Ll:233018.32:2001 MAY17 1 19 334 forward 2 crystall Beta/Gamma crystallin 5J0E-1 1 255 U:233018.32:2001 MAY17 1016 1 144 forward 2 Ricin_BJβctin QXW lectin repeat 5.20E-08 256 U:236295.8:2001 MAY17 439 741 forward 1 IRF Interferon regulatory factor transcription factor 5.00E-20 257 U: 286989.14: 2001 MAY 17 325 807 forward 1 MH1 MH1 domain 6.30E-68 257 LI:286989.14:2001 MAY17 1093 1626 forward 1 MH2 MH2 domain 8.40E-12 258 LI:345320.4:2001 MAY17 665 733 forward 2 zf-C2H2 Zinc finger, C2H2 type 1.80E-0 259 Ll:355693.18:2001 MAY17 2221 2373 forward 1 PSI Plexin repeat 2.20E-17 259 Ll:355693.18:2001 MAY17 841 2166 forward 1 Sema Sema domain 1.10E-12
TABLE 3
SEQ ID NO: Template ID Start Stop Frame Pfam Hit Pfam Description E-value
259 Ll:355693.18:2001 MAY17 3553 3807 forward 1 TIG IPT/TIG domain 2.10E-23
260 U:359876.1 :2001 MAY17 599 1345 forward 2 7tm_l 7 transmembrane receptor (rhodopsin family) 1.20E-28
261 LI:406664.32:2001 MAY17 463 639 forward 1 SRF-TF SRF-type transcription factor (DNA-binding and 2.10E-37 dimerisation domain)
262 LI:410324.1 :2001 MAY17 1655 1930 forward 2 cadherin Cadherin domain 2.30E-19
263 Ll:414376.12:2001 MAY17 1637 2224 forward 2 ionjrans Ion transport protein 6.60E-44
263 U:414376.12:2001 MAY17 976 1272 forward 1 KJetra K+ channel tetramerisation domain 2.40E-46
264 U:452089.1 :2001 MAY! 7 107 268 forward 2 Ribosomal_L5 Ribosomal protein L5 6.10E-26
264 LI:452089.1 :2001 MAY17 278 577 forward 2 Ribosomal_L5_C ribosomal L5P family C-terminus 2.50E-60
265 Ll:481614.43:2001 MAY17 614 1594 forward 2 pkinase Protein kinase domain 3J0E-13
265 LI:481614.43:2001 MAY17 798 1418 forward 3 pkinase Protein kinase domain 2.20E-08
266 LI:809605.2:2001 MAY17 1935 2003 forward 3 zf-C2H2 Zinc finger, C2H2 type 3.60E-05
267 LI:816437.25:2001 MAY17 1753 2580 forward 1 lig_chan Ugand-gated ion channel 5.50E-1 1
268 Ll:817827.5:2001 MAY17 329 538 forward 2 elF-5a Eukaryotic initiation factor 5A hypusine, DNA- 3.40E-36 binding OB fold
268 Ll:817827.5:2001 MAY17 101 325 forward 2 elF-5a_N Eukaryotic initiation factor 5A hypusine, SH3-like 2.30E-50 barrel domain
269 U:002345.15:2001 MAY17 261 527 forward 3 ACBP Acyl CoA binding protein 4.40E-56
270 LI:022629.5:2001 MAY17 281 430 forward 2 zf-C3HC4 Zinc finger, C3HC4 type (RING finger) 4.90E-05
271 Ll:061031.4:2001 MAY17 20 715 forward 2 ionjrans Ion transport protein 4.50E-18
272 LI: 108232.2:2001 MAY17 146 769 forward 2 TatD_DNase TatD related DNase 5.20E-08
273 U:1085493.16:2001 MAY17 10 816 forward 1 A_deaminase Adenosine/AMP deaminase 9.40E-13
274 U: 1085513.2:2001 MAY17 537 1742 forward 3 Na_H_Exchanger Sodium/hydrogen exchanger family 2.40E-18
275 U:l 086797.9:2001 MAY17 501 1790 forward 3 Sema Sema domain 2.00E-17
276 U:1088446.1 :2001 MAY17 71 193 forward 2 KRAB KRAB box 9.60E-24
276 LI: 1088446.1 :2001 MAY 17 1659 1727 forward 3 zf-C2H2 Zinc finger, C2H2 type 7.40E-05
277 LI: 1 133764.3:2001 MAY17 383 706 forward 2 spectrin Spectrin repeat 9.60E-1 1
278 LI: 1 147614.5:2001 MAY17 525 701 forward 3 ig Immunoglobulin domain 1 JOE- 1 1
279 U:1 181710.1 :2001 MAY17 86 154 forward 2 zf-C2H2 Zinc finger, C2H2 type 1.10E-05
280 U: 1 183192.1 :2001 MAY17 992 1060 forward 2 zf-C2H2 Zinc finger, C2H2 type 2.20E-06
281 LI: 1 188786.15:2001 MAY17 1320 1406 forward 3 efhand EF hand 8.60E-06
282 U:145626.1 :2001 MAY17 637 804 forward 1 sushi Sushi domain (SCR repeat) 5.20E-14
TABLE 3
SEQ ID NO: Template ID Start Stop Frame Pfam Hit Pfam Description E-value
282 U:145626.1 :2001 MAY17 1328 1492 forward 2 sushi Sushi domain (SCR repeat) 3J0E-04
283 U:l 47869.3:2001 MAY17 4 1749 forward 1 Patched Patched family 2.00E-07
284 U: 151747.4:2001 MAY17 103 207 forward 1 SAP SAP domain 1.40E-07
284 U: 151747.4:2001 MAY17 1096 1254 forward 1 zf-MIZ MIZ zinc finger 7.60E-35
285 LI: 198296.1 :2001 MAY17 646 783 forward 1 Kelch Kelch motif 5.50E-14
286 LI-.20O1 17.4:2001 MAY17 670 771 forward 1 TPR TPR Domain 8.60E-04
287 LI:200704.1 :2001 MAY17 131 1 1493 forward 3 ig Immunoglobulin domain 3.00E-06
288 U:2049995.3:2001 MAY17 1516 2352 forward 1 pkinase Protein kinase domain 1.90E-68
289 U:2052097.2:2001 MAY17 504 605 forward 3 TPR TPR Domain 1.80E-04
290 LL209351.22:2001 MAY17 300 410 forward 3 WD40 WD domain, G-beta repeat 4.80E-13
291 LI: :2120481.1 :2001 MAY 17 501 842 forward 3 CUB CUB domain 7.10E-14
292 U:2121610.13:2001 MAY17 81 803 forward 3 7tm_l 7 transmembrane receptor (rhodopsin family) 7J0E-19
293 U:2191585.1 :2001 MAY17 424 846 forward 1 Steroid_dh 3-oxo-5-alpha-steroid 4-dehydrogenase 2.90E-39
293 U:2191585.1 :2001 MAY17 513 878 forward 3 Steroid_dh 3-oxo-5-alpha-steroid 4-dehydrogenase 3.80E-05
294 U:2198562.3:2001 MAY17 1263 1688 forward 3 2-Hacid_DH_C D-isomer specific 2-hydroxyacid 5.90E-08 dehydrogenase, NAD binding domain
295 U:2209684.5:2001 MAY17 257 544 forward 2 SCAN SCAN domain 4.50E-73
295 U:2209684.5:2001 MAY17 1628 1696 forward 2 zf-C2H2 Zinc finger, C2H2 type 4.50E-07
296 LI:222795.28:2001 MAY17 1300 1587 forward 1 PH PH domain 8.10E-20
297 U:228273.25:2001 MAY17 404 625 forward 2 mbt mbt repeat 6.60E-45
297 LI:228273.25:2001 MAY17 1400 1594 forward 2 SAM SAM domain (Sterile alpha motif) 7J0E-08
297 LI:228273.25:2001 MAY17 1007 1 102 forward 2 zf-C2HC Zinc finger, C2HC type 3.40E-1 1
298 U:232386.31 :2001 MAY17 1395 1499 forward 3 zf-MYND MYND finger 6.90E-07
299 LI:233089.2:2001 MAY17 309 389 forward 3 zf-CCCH Zinc finger C-x8-C-x5-C-x3-H type (and similar). 5J0E-04
300 Ll:240641.10:2001 MAY17 785 883 forward 2 ank Ankyrin repeat 4.80E-09
301 Ll:243871.4:2001 MAY17 722 1006 forward 2 Ribosomal_L7Ae Ribosomal protein L7Ae/L30e/S12e/Gadd45 4.20E-31 family
302 LI:245597J:2001 MAY17 319 555 forward 1 Ets Ets-domain 8.40E-56
303 U:256009.31 :2001 MAY17 826 1380 forward 1 arf ADP-ribosylation factor family 1.10E-54
303 LI:256009.31 :2001 MAY17 31 1 697 forward 2 arf ADP-ribosylation factor family 4.20E-05
304 LI:262221.1 :2001 MAY17 306 731 forward 3 BTB BTB/POZ domain 8.00E-16
305 U:332957.8:2001 MAY17 579 722 forward 3 Kelch Kelch motif 1.00E-08
TABLE 3
I ID NO: Template ID Start Stop Frame Pfam Hit Pfam Description E-value
306 Ll:335352.13:2001 MAY17 197 844 forward 2 IF4E Eukaryotic initiation factor 4E 1 JOE- 13
307 LI:343844J:2001 MAY17 330 401 forward 3 zf-C2H2 Zinc finger, C2H2 type 5.60E-05
308 U:344528.1 :2001 MAY17 1618 1728 forward 1 zf-MYND MYND finger 6.80E-15
309 U:374578.27:2001 MAY17 493 702 forward 1 rrm RNA recognition motif, (a.k.a. RRM, RBD, or RNP 2J0E-20 domain)
310 Ll:381993.13:2001 MAY17 1477 2013 forward 1 ABCJran ABC transporter 1.40E-44
310 Ll:381993.13:2001 MAY17 5160 5696 forward 3 ABC_tran ABC transporter 1.40E-44
31 1 U:400373.2:2001 MAY17 354 446 forward 3 EGF EGF-like domain 9.40E-05
31 1 U:400373.2:2001 MAY17 1 123 1215 forward 1 EGF EGF-like domain 4.20E-04
312 LI:400963.6:2001 MAY17 882 980 forward 3 ank Ankyrin repeat 3.20E-09
313 LI:404874.8:2001 MAY17 962 1372 forward 2 PAZ PAZ domain 4.30E-51
313 U:404874.8:2001 MAY17 1808 2713 forward 2 Piwi Piwi domain 2.10E-14
314 Ll:405158.18:2001 MAY17 806 904 forward 2 ank Ankyrin repeat 3.20E-07
314 Ll:405158.18:2001 MAY17 1580 1810 forward 2 IBR - IBR domain 3.30E-26
315 LI:405889.22:2001 MAY17 821 919 forward 2 ank Ankyrin repeat 5J0E-08
316 U:41 1 151.31 :2001 MAY17 1861 2031 forward 1 LIM LIM domain 3.90E-14
316 U:41 1 151.31 :2001 MAY17 43 282 forward 1 PDZ PDZ domain (Also known as DHR or GLGF). 1.50E-17
317 U:41 1313.51 :2001 MAY17 1262 1438 forward 2 SH3 SH3 domain 1.10E-04
318 U:417127.1 :2001 MAY17 361 483 forward 1 KRAB KRAB box 2.90E-26
319 Ll:429817.44:2001 MAY17 303 476 forward 3 LIM UM domain 3.30E-19
320 Ll:474134.23:2001 MAY17 780 890 forward 3 ank Ankyrin repeat 1.60E-06
321 LI:475378.3:2001 MAY17 2426 2623 forward 2 FYVE FYVE zinc finger 1.50E-15
321 LI:475378.3:2001 MAY17 2057 2338 forward 2 PH PH domain 4.40E-13
321 LI:475378.3:2001 MAY17 1403 1966 forward 2 RhoGEF RhoGEF domain 2.40E-07
322 UJ49588.15:2001 MAY17 2265 2924 forward 3 GP36 Env gp36 protein (HERV/MMTV type) 3.40E-16
322 LI:749588.15:2001 MAY17 74 193 forward 2 lntegrase_Zn Integrase Zinc binding domain 4.10E-1 1
322 LI:749588.15:2001 MAY17 224 697 forward 2 rve Integrase core domain 1 J0E-30
323 UJ57736.17:2001 MAY17 367 465 forward 1 ank Ankyrin repeat 3.00E-08
324 U:817278.4:2001 MAY17 92 307 forward 2 rrm RNA recognition motif, (a.k.a. RRM, RBD, or RNP 1.30E-22 domain)
325 LI:027320.5:2001 MAY17 158 358 forward 2 SAM SAM domain (Sterile alpha motif) 6.30E-06
326 LI:204635.5:2001 AY17 284 619 forward 2 Rieske Rieske (2Fe-2S) domain 6.20E-07
TABLE 3
SEQ ID NO: Template ID Start Stop Frame Pfam Hit Pfam Description E-value
327 LI:215532.38:2001 MAY17 416 862 forward 2 PAP2 PAP2 superfamily 1.10E-0
328 Ll:228319.6:2001 MAY17 527 748 forward 2 mbt mbt repeat 6.30E-3
329 LI:236589.24:2001 MAY17 599 1885 forward 2 DUF254 SAND family protein 5.80E-27
330 Li:247444.3:2001 MAY17 131 415 forward 2 TB2_DP1_HVA22 TB2/DP1, HVA22 family 9.90E-3
331 U:332404.20:2001 MAY17 1943 2179 forward 2 Cache Cache domain 1.10E-0
332 LG:1088459.4:2001JUN22 422 490 forward 2 zf-C2H2 Zinc finger, C2H2 type 2.60E-0
333 LG:1501495.1 :2001JUN22 109 231 forward 1 KRAB KRAB box 1.20E-2
333 LG:1501495.1 :2001JUN22 868 936 forward 1 zf-C2H2 Zinc finger, C2H2 type 2.80E-0
333 LG: 1501495.1 :2001JUN22 2067 2135 forward 3 zf-C2H2 Zinc finger, C2H2 type 4.10E-0
334 LG:334284.10:2001 JUN22 1 756 forward 1 TTL Tubulin-tyrosine ligase family 6.80E-1
335 LG:345279.19:2001 JUN22 151 585 forward 1 projso erase Cyclophilin type peptidyl-prolyl cis-trans 2.00E-3 isomerase
336 LG:7689681.1 :2001JUN22 1 12 180 forward 1 zf-C2H2 Zinc finger, C2H2 type 1.OOE-0
337 LG:7690093.1 :2001JUN22 456 524 forward 3 zf-C2H2 Zinc finger, C2H2 type 4.80E-0
338 LGJ690175.3:2001 JUN22 155 223 forward 2 zf-C2H2 Zinc finger, C2H2 type 2.90E-0
339 LG:7697128.1 :2001JUN22 125 367 forward 2 ig Immunoglobulin domain 5.00E-0
340 LG:006394.20:2001JUN22 643 1 101 forward 1 RhoGAP RhoGAP domain 6.20E-5
341 LG: 1012069.1 :2001JUN22 430 528 forward 1 ank Ankyrin repeat 2.50E-0
342 LG:104533.1 1 :2001 JUN22 950 1 183 forward 2 death Death domain 2.10E-1
343 LG: 1045853.23:2001 JUN22 109 837 forward 1 Beach Beige/BEACH domain 9.80E-1
344 LG:1081017.8:2001 JUN22 443 541 forward 2 ank Ankyrin repeat 6.20E-0
344 LG:1081017.8:2001JUN22 651 749 forward 3 ank Ankyrin repeat 1.90E-0
345 LG:1090358.6:2001 JUN22 663 779 forward 3 KRAB KRAB box 1.60E-1
346 LG: 1 135312.7:2001 JUN22 86 910 forward 2 aldo_ket_red Aldo/keto reductase family 5.70E-3
346 LG: 1 135312.7:2001 JUN22 154 957 forward 1 aldo_ket_red Aldo/keto reductase family 4.00E-1 1
347 LG: 1328501.2:2001 JUN22 289 41 1 forward 1 KRAB KRAB box 8.60E-2
347 LG: 1328501.2:2001JUN22 934 1002 forward 1 zf-C2H2 Zinc finger, C2H2 type 3.10E-0
348 LG: 133095.1 :2001 JUN22 1296 1364 forward 3 zf-C2H2 Zinc finger, C2H2 type 4.20E-0
349 LG: 135379.5:2001JUN22 358 534 forward 1 vwc von Willebrand factor type C domain 1.30E-0
350 LG:1365581.3:2001JUN22 154 276 forward 1 KRAB KRAB box 2.70E-2
351 LG: 1383156.20:2001JUN22 91 1 141 1 forward 2 PSAP Surfactant associated polypeptide 2.30E-10
352 LG:1501767.18:2001JUN22 666 734 forward 3 zf-C2H2 Zinc finger, C2H2 type 1.90E-0
TABLE 3
SEQ ID NO: Template ID Start Stop Frame Pfam Hit Pfam Description E-value
353 LG: 1501890.8:2001 JUN22 235 516 forward 1 FCH Fes/CIP4 homology domain 7.60E-33
353 LG: 1501890.8:2001 JUN22 1876 2046 forward 1 SH3 SH3 domain 6.60E-13
354 LG:203434.23:2001JUN22 202 1080 forward 1 filament Intermediate filament protein 1.50E-08
355 LG:204724.5:2001JUN22 1 390 forward 1 Adeno_El B_19K Adenovirus El B 19K protein / small t-antigen 5.40E-40 355 LG:204724.5:2001JUN22 59 454 forward 2 Adeno_El B_19K Adenovirus El B 19K protein / small t-antigen 5.00E-08
355 LG:204724.5:2001JUN22 600 1751 forward 3 Adeno_El B_55K Adenovirus EB1 55K protein / large t-antigen 4.80E-26
356 LG:257107.16:2001 JUN22 594 890 forward 3 PH PH domain 6.40E-21
357 LG:353530.4:2001JUN22 2197 2298 forward 1 TPR TPR Domain 8.10E-04
358 LG:7683573.3:2001JUN22 289 41 1 forward 1 KRAB KRAB box 8.20E-22
359 LGJ684224.1 :2001 JUN22 385 561 forward 1 LIM LIM domain 9.60E-17
360 LG:7690365.2:2001JUN22 744 866 forward 3 KRAB KRAB box 2.10E-22
360 LG:7690365.2:2001JUN22 1500 1568 forward 3 zf-C2H2 Zinc finger, C2H2 type 3.60E-05
361 LG:968691.1 :2001JUN22 208 531 forward 1 BTB BTB/POZ domain 2.40E-30
362 LG:98307ό.7:2001JUN22 1235 2398 forward 2 RNB RNB-like protein 3.00E-10
363 LG:986291.1 :2001 JUN22 127 570 forward 1 RibosomalJ δp Ribosomal LI 8p/L5e family 4.10E-74
364 LG:990347.41 :2001JUN22 1791 2132 forward 3 PH PH domain 2.70E-17
365 LG:998305.4:2001JUN22 216 314 forward 3 ank Ankyrin repeat 9.60E-07
366 LG:463420.16:2001JUN22 1873 2427 forward 1 Glyco_transf_25 Glycosyltransferase family 25 (LPS biosynthesis 2.00E-72 protein)
366 LG:463420.16:2001 JUN22 2460 2885 forward 3 Glyco_transf_25 Glycosyltransferase family 25 (LPS biosynthesis 5.00E-19 protein)
367 LG:979059.3:2001JUN22 1 186 2418 forward 1 DUF254 SAND family protein 2.60E-27
368 LG:1045509.22:2001 JUN22 77 1252 forward 2 transmembrane4 Tetraspanin family 2.10E-07
369 LG:246935.4:2001JUN22 85 519 forward 1 Smg4_UPF3 Smg-4/UPF3 family 7.60E-58
370 LG:321069.2:2001JUN22 514 807 forward 1 mito_carr Mitochondrial carrier protein 2.60E-30
371 LG:346724.14:2001JUN22 559 690 forward 1 LEM LEM domain 1.00E-24
372 LG:41 1043.3:2001JUN22 272 1258 forward 2 adh_zinc Zinc-binding dehydrogenase l .OOE-19
373 LG:978620.7:2001JUN22 903 998 forward 3 EGF EGF-like domain 6.10E-06 373 LG:978620.7:2001JUN22 531 650 forward 3 Idl_recept_a Low-density lipoprotein receptor domain class 2.30E-09
373 LG:978620.7:2001JUN22 87 506 forward 3 MAM MAM domain. 2.00E-07
374 LG:982784.1 :2001JUN22 582 650 forward 3 zf-C2H2 Zinc finger, C2H2 type 2.90E-05
375 LG:007574.21 :2001JUN22 1627 2214 forward 1 BAR BAR domain 1.00E-05
TABLE 3
SEQ ID NO: Template ID Start Stop Frame Pfam Hit Pfam Description E-value
375 LG:007574.21 :2001JUN22 1 109 1615 forward 2 RhoGEF RhoGEF domain 5.80E-05
375 LG:007574.21 :2001JUN22 3181 3357 forward 1 SH3 SH3 domain 9.50E-12
376 LG:013856.18:2001JUN22 276 368 forward 3 WW WW domain 1.50E-04
377 LG:027320J:2001JUN22 158 358 forward 2 SAM SAM domain (Sterile alpha motif) 6.30E-06
378 LG:077967.9:200UUN22 1249 2028 forward 1 pkinase Protein kinase domain 1.10E-84
378 LG:077967.9:200UUN22 640 870 forward 1 SH2 SH2 domain 3.20E-31
379 LG:128475.9:2001 JUN22 252 362 forward 3 ank Ankyrin repeat 1.60E-06
379 LG:128475.9:2001 JUN22 25 123 forward 1 ank Ankyrin repeat 1.80E-04
380 LG: 1398104.15:2001JUN22 279 572 forward 3 K retra K+ channel tetramerisation domain 2.80E-27
381 LG: 1454018.10:2001 JUN22 2505 2654 forward 3 KA1 Kinase associated domain 1 4.00E-21 381 LG:1454018.10:2001JUN22 477 1232 forward 3 pkinase Protein kinase domain 3.80E-10
381 LG: 1454018.10:2001JUN22 1290 1409 forward 3 UBA UBA/TS-N domain 8.20E-05
382 LG:221548.14:2001JUN22 785 883 forward 2 ank Ankyrin repeat 4.80E-09
383 LG:227500.5:2001JUN22 869 1042 forward 2 UM LIM domain 5.80E-1 1
© © 384 LG:228273.22:2001JUN22 404 625 forward 2 mbt mbt repeat 6.60E-45 384 LG:228273.22:2001JUN22 1400 1594 forward 2 SAM SAM domain (Sterile alpha motif) 7.70E-08
384 LG:228273.22:2001JUN22 1007 1 102 forward 2 zf-C2HC Zinc finger, C2HC type 3.40E-1 1
385 LG:235432.1 :2001JUN22 343 585 forward 1 SAND SAND domain 3.50E-46
386 LG:236904.20:2001JUN22 537 824 forward 3 PH PH domain 4.00E-21
387 LG:253193.21 :2001JUN22 2297 2539 forward 2 mito_carr Mitochondrial carrier protein 3.30E-07
388 LG:332161.3:2001 JUN22 146 715 forward 2 ras Ras family 2.70E-59
389 LG:332923.5:2001JUN22 2396 2665 forward 2 cadherin Cadherin domain 1.00E-23
390 LG:343500.27:2001JUN22 41 1 695 forward 3 mito_carr Mitochondrial carrier protein 1.70E-20
391 LG:369703.9:2001JUN22 1 12 1788 forward 1 Seel Seel family 8.00E-19
392 LG:415378.3:2001 JUN22 160 552 forward 1 Reeler Reeler domain 7.50E-77
392 LG:415378.3:2001 JUN22 1885 2028 forward 1 tspj Thrombospondin type 1 domain 3.10E-23
393 LG:458583.1 :2001 JUN22 31 141 forward 1 WD40 WD domain, G-beta repeat 4.60E-08
394 LG:7690373.1 :2001JUN22 86 154 forward 2 zf-C2H2 Zinc finger, C2H2 type 1.10E-05
395 LG:898324.13:2001JUN22 184 294 forward 1 notch Notch (DSL) domain 1.10E-04
396 LG:979167.5:2001 JUN22 696 1064 forward 3 cyclin Cyclin, N-terminal domain 3.80E-1 1
TABLE 4
SEQ ID NO Template ID Start Stop Frame Domain Topology
66 LG: 1080918.1 :2001 MAR30 1 788 forward 1 TM Non-Cytosolic
66 LG:1080918.1 :2001 MAR30 789 81 1 forward 1 TM Transmembrane
66 LG: 1080918.1 :2001 MAR30 812 818 forward 1 TM Cytosolic
67 LG: 1093747.15:2001 MAR30 1 14 forward 1 TM Non-Cytosolic
67 LG: 1093747.15:2001 MAR30 15 32 forward 1 TM Transmembrane
67 LG:1093747.15:2001 MAR30 33 43 forward 1 TM Cytosolic
67 LG: 1093747.15:2001 MAR30 44 66 forward 1 TM Transmembrane
67 LG: 1093747.15:2001 MAR30 67 831 forward 1 TM Non-Cytosolic
67 LG: 1093747.15:2001 MAR30 1 9 forward 2 TM Non-Cytosolic
67 LG: 1093747.15:2001 MAR30 10 32 forward 2 TM Transmembrane
67 LG: 1093747.15:2001 MAR30 33 43 forward 2 TM Cytosolic
67 LG: 1093747.15:2001 MAR30 44 66 forward 2 TM Transmembrane
67 LG: 1093747.15:2001 MAR30 67 830 forward 2 TM Non-Cytosolic
68 LG: 1096896.47:2001 MAR30 1 491 forward 2 TM Non-Cytosolic
68 LG: 1096896.47:2001 MAR30 492 514 forward 2 TM Transmembrane
68 LG: 1096896.47:2001 MAR30 515 625 forward 2 TM Cytosolic
68 LG: 1096896.47:2001 MAR30 626 648 forward 2 TM Transmembrane
68 LG:1096896.47:2001 MAR30 649 657 forward 2 TM Non-Cytosolic
68 LG: 1096896.47:2001 MAR30 658 680 forward 2 TM Transmembrane
68 LG: 1096896.47:2001 MAR30 681 729 forward 2 TM Cytosolic
68 LG: 1096896.47:2001 MAR30 730 752 forward 2 TM Transmembrane
68 LG: 1096896.47:2001 MAR30 753 792 forward 2 TM Non-Cytosolic
69 LG: 1098931.39:2001 MAR30 1 430 forward 3 TM Non-Cytosolic
69 LG: 1098931.39:2001 MAR30 431 448 forward 3 TM Transmembrane
69 LG: 1098931.39:2001 MAR30 449 541 forward 3 TM Cytosolic
69 LG: 1098931.39:2001 MAR30 542 564 forward 3 TM Transmembrane
69 LG: 1098931.39:2001 MAR30 565 3052 forward 3 TM Non-Cytosolic
70 LG: 1 100823.1 2001 MAR30 1 31 forward 1 TM Cytosoiic
70 LG: 1 100823.1 2001 MAR30 32 54 forward 1 TM Transmembrane
70 LG: 1 100823.1 2001 MAR30 55 68 forward 1 TM Non-Cytosolic
70 LG: 1 100823.1 2001 MAR30 69 91 forward 1 TM Transmembrane
70 LG: 1 100823.1 2001 MAR30 92 280 forward 1 TM Cytosolic
70 LG: 1 100823.1 2001 MAR30 1 98 forward 2 TM Cytosolic
70 LG: 1 100823.1 2001 MAR30 99 121 forward 2 TM Transmembrane
70 LG: 1 100823.1 2001 MAR30 122 226 forward 2 TM Non-Cytosolic
70 LG: 1 100823.1 2001 MAR30 227 249 forward 2 TM Transmembrane
70 LG: 1 100823.1 2001 MAR30 250 255 forward 2 TM Cytosolic
70 LG: 1 100823.1 2001 MAR30 256 278 forward 2 TM Transmembrane
70 LG: 1 100823.1 2001 MAR30 279 279 forward 2 TM Non-Cytosolic
71 LG: 1 166387.1 2001 MAR30 1 700 forward 1 TM Non-Cytosolic
71 LG: 1 166387.1 2001 MAR30 701 723 forward 1 TM Transmembrane
71 LG: 1 166387.1 2001 MAR30 724 804 forward 1 TM Cytosolic
71 LG: 1 166387.1 2001 MAR30 1 607 forward 3 TM Non-Cytosolic
71 LG: 1 166387.1 2001 MAR30 608 630 forward 3 TM Transmembrane
71 LG: 1 166387.1 2001 MAR30 631 713 forward 3 TM Cytosolic
71 LG: 1 166387.1 2001 MAR30 714 736 forward 3 TM Transmembrane
71 LG: 1 166387.1 2001 MAR30 737 779 forward 3 TM Non-Cytosolic
71 LG: 1 166387.1 2001 MAR30 780 802 forward 3 TM Transmembrane
71 LG: 1 166387.1 2001 MAR30 803 804 forward 3 TM Cytosolic
72 LG: 1383036.4 ?:2001 MAR30 1 226 forward 1 TM Non-Cytosolic c 'o E Q. c 5255 o
Q
■— ,— ,— ,— cO CO CO CO CO CO '— ■— ■— ■— ■— ■— •— •— •— r— r— r- .— .— .— .— ,— ,— ■— ,— .— ,— r— CM CM CM CN CN CM CN CN CN CM CN CN CN C CM CM CM g b b b b b σ b b b b b b b b b b σ b b b b b b b b b b b b b b b b o b o o σ b b b b b b b b b b b b "" .P .0.0.0.0.0.0.q .q .0.0.0 o .p ,o .0.0.0.0.0.0 o .p .p o ,p ,o .0.0.0.P .0 o o o Q ^ ^ ^ £ £ -P £ £ £ v2 >2
0. κ ιv. ^ O r^ ^ ^ C ^ <3 <) C> C O Iv. O O co 3 C ^ rr rr iv. ) L r^ |v, r- r rr co 0 -0 0 <3 0 CM CM -— rr oO i— CO O O CO O 0 r n « ?-^ ^ Ω m < I ^ ) <- ^ 3 i C0 00 O C r rr v0 00 O ^ c0 rr <3 00 θ rr p _ CM rr O O CM -— cO r O -O O ^ O O CM r
CM rr v rv Λ rj, '- («) i> > (> o o θ '- '- Lθ < co co (o (> σ σ o> o- c> 0 0- 0 0 0 0 -— ■— ■— ■— ■— ■— CM CN CO CO LO c c^ r— - CM CM CM cO cO cO CO CO CO CO cO CO cO cO cO cO cO c CO CO CO o rr CM CM CN CM cθ cθ cO cO cO cO cO cθ cO cO cO cθ cθ
CO t rv c io o o o o CD o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o
CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO o CO CO CO CO CO CO CO O CO CO CO CO CO CO CO CO CO CO CO CO
CY CY CY Y CY CY CY CY LY CY CY CY CY CY CY CY CY CY CY CY CY CY CY CY CY CY CY LY CY CY CY CY CY CY CY CY CY CY CY CY CY Y CY LY CY CY CY CY CY LY
< < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
55555555555555555555555555555555555555555555555555
Q o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o
Φ o o o o o o o o o o o o o o o o o o CD o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o
CM CM CM CN CM CM CM CM CN CM CM CM CM CN CN CM CN CM CM CM CM CN CN CN CN CM CM CM CN CN CM CM CN CM CN CM CN CN CN CM CN CN CN CM CM CM CM CM CM CM
O C> ( 0 0 0 0 0 0 rf rf rf ^f rf vf •ζf f rf rf rf rf rf rf rf ^f "i rf f rf rf rf ^f "i ^f ^ rf rf rf rf rf ^f ^ ^ v rf "i vf rf rf rf ^ T ^r vT vf rr rr rr rr
£ <3 o" -d -d • o" o" <3 CO CO CO O CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO
CO CO CO CO CO CO CO CO CO lO LO LO si CO CO CO CO C to LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO lO 3 CO CO CO CO CO CO CO CO CO CO CO CO CO CO
LO to LO LO LO LO LO lO LO LO to LO LO LO LO CO LO LO
,2 O O o o o o o o o CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO
CO CO CO CO CO CO CO CO CO CN CM CM CN CN CM CN CM CM CN CM CN CM CM CM CN CM CM CM CN CN CN CN CM CM CM CM CM CN CN CN CM CN CM CM CN CN CM CM CM CM
00 00 oo oo CO 00 00 00 00 LO LO LO LO LO LO LO LO LO LO LO LO LO lO lO LO LO LO lO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO lO lO LO LO LO LO lO
CO CO CO CO o CO CO CO CO rr rr rr rr ^r <ϊ rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr "=3- rr rr rr vT rr rr " <ϊ vt -vT t T vT vf vT vT T
0 _l0 _J00 —J0 _J0 _l0 _J0 —J0 _l0 _l0 _l00 _l00 _J0 _l00 _l0 _l00 —J0 _l0 —J0 _l0000 _l00 _l0000000000 _l0000000 _100 _l0
CM CM CM CM CN CM CM CN CN CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO rv rv rv rv rv rv r rv v rv rv rv rv rv rv rv rv rv rv r rv rv rv rv rv rv rv rv. rv rv rv rv rv rv r (v. rv rv rv rv rv v rv rv v rv rv iv. rv
TABLE 4
SEQ ID NO Template ID Start Stop Frame Domain Topology
73 LG: 1452353.14:2001 MAR30 3580 3602 forward 2 TM Transmembrane
73 LG: 1452353.14:2001 MAR30 3603 3846 forward 2 TM Cytosolic
73 LG: 1452353.14:2001 MAR30 3847 3869 forward 2 TM Transmembrane
73 LG: 1452353.14:2001 MAR30 3870 3915 forward 2 TM Non-Cytosolic
73 LG: 1452353.14:2001 MAR30 3916 3935 forward 2 TM Transmembrane
73 LG: 1452353.14:2001 MAR30 3936 4031 forward 2 TM Cytosolic
73 LG: 1452353.14:2001 MAR30 4032 4054 forward 2 TM Transmembrane
73 LG: 1452353.14:2001 MAR30 4055 4144 forward 2 TM Non-Cytosolic
73 LG: 1452353.14:2001 MAR30 1 1 14 forward 3 TM Non-Cytosolic
73 LG: 1452353.14:2001 MAR30 1 15 137 forward 3 TM Transmembrane
73 LG: 1452353.14:2001 MAR30 138 202 forward 3 TM Cytosolic
73 LG: 1452353.14:2001 MAR30 203 225 forward 3 TM Transmembrane
73 LG: 1452353.14:2001 MAR30 226 234 forward 3 TM Non-Cytosolic
73 LG: 1452353.14:2001 MAR30 235 257 forward 3 TM Transmembrane
73 LG: 1452353.14:2001 MAR30 258 400 forward 3 TM Cytosolic
73 LG: 1452353.14:2001 MAR30 401 423 forward 3 TM Transmembrane
73 LG: 1452353.14:2001 MAR30 424 437 forward 3 TM Non-Cytosolic
73 LG: 1452353.14:2001 MAR30 438 460 forward 3 TM Transmembrane
73 LG: 1452353.14:2001 MAR30 461 617 forward 3 TM Cytosolic
73 LG: 1452353.14:2001 MAR30 618 637 forward 3 TM Transmembrane
73 LG: 1452353.14:2001 MAR30 638 1535 forward 3 TM Non-Cytosolic
73 LG: 1452353.14:2001 MAR30 1536 1558 forward 3 TM Transmembrane
73 LG: 1452353.14:2001 MAR30 1559 1638 forward 3 TM Cytosolic
73 LG: 1452353.14:2001 MAR30 1639 1661 forward 3 TM Transmembrane
73 LG: 1452353.14:2001 MAR30 1662 3140 forward 3 TM Non-Cytosolic
73 LG: 1452353.14:2001 MAR30 3141 3163 forward 3 TM Transmembrane
73 LG: 1452353.14:2001 MAR30 3164 3174 forward 3 TM Cytosolic
73 LG: 1452353.14:2001 MAR30 3175 3197 forward 3 TM Transmembrane
73 LG: 1452353.14:2001 MAR30 3198 3229 forward 3 TM Non-Cytosolic
73 LG: 1452353.14:2001 MAR30 3230 3252 forward 3 TM Transmembrane
73 LG: 1452353.14:2001 MAR30 3253 3291 forward 3 TM Cytosolic
73 LG:1452353.14:2001 MAR30 3292 3314 forward 3 TM Transmembrane
73 LG: 1452353.14:2001 MAR30 3315 3415 forward 3 TM Non-Cytosolic
73 LG: 1452353.14:2001 MAR30 3416 3438 forward 3 TM Transmembrane
73 LG: 1452353.14:2001 MAR30 3439 3579 forward 3 TM Cytosolic
73 LG: 1452353.14:2001 MAR30 3580 3602 forward 3 TM Transmembrane
73 LG: 1452353.14:2001 MAR30 3603 4144 forward 3 TM Non-Cytosolic
74 LG: 1452435.15:2001 MAR30 1 2028 forward 3 TM Non-Cytosolic
74 LG: 1452435.15:2001 MAR30 2029 2051 forward 3 TM Transmembrane
74 LG: 1452435.15:2001 MAR30 2052 2280 forward 3 TM Cytosolic
75 LG: 1498774.1 :2001 MAR30 1 224 forward 2 TM Non-Cytosolic
75 LG: 1498774.1 :2001 MAR30 225 247 forward 2 TM Transmembrane
75 LG: 1498774.1 :2001 MAR30 248 251 forward 2 TM Cytosolic
76 LG: 197180.1 2001 MAR30 1 1282 forward 1 TM Non-Cytosolic
76 LG: 197180.1 2001 MAR30 1283 1305 forward 1 TM Transmembrane
76 LG: 197180.1 2001 MAR30 1306 131 1 forward 1 TM Cytosolic
76 LG: 197180.1 2001 MAR30 1312 1334 forward 1 TM Transmembrane
76 LG: 197180.1 2001MAR30 1335 1372 forward 1 TM Non-Cytosolic
76 LG: 197180.1 2001 MAR30 1 707 forward 3 TM Non-Cytosolic
76 LG: 197180.1 2001 MAR3O 708 730 forward 3 TM Transmembrane TABLE 4
SEQ ID NO Template ID Start Stop Frame Domain Topology
76 LG: 197180.1 2001 MAR30 731 736 forward 3 TM Cytosolic
76 LG: 197180.1 2001MAR30 737 759 forward 3 TM Transmembrane
76 LG: 197180.1 2001 MAR30 760 1304 forward 3 TM Non-Cytosolic
76 LG: 197180.1 2001 MAR30 1305 1327 forward 3 TM Transmembrane
76 LG: 197180.1 2001 MAR30 1328 1338 forward 3 TM Cytosolic
76 LG: 197180.1 2001 MAR30 1339 1361 forward 3 TM Transmembrane
76 LG: 197180.1 2001 MAR30 1362 1371 forward 3 TM Non-Cytosolic
77 LG: 199489.1 2001 MAR30 1 1505 forward 1 TM Non-Cytosolic
77 LG: 199489.1 2001 MAR30 1506 1528 forward 1 TM Transmembrane
77 LG: 199489.1 2001 MAR30 1529 1534 forward 1 TM Cytosolic
77 LG: 199489.1 2001 MAR30 1535 1552 forward 1 TM Transmembrane
77 LG: 199489.1 2001 MAR30 1553 1566 forward 1 TM Non-Cytosolic
77 LG: 199489.1 2001 MAR30 1567 1589 forward 1 TM Transmembrane
77 LG: 199489.1 2001 MAR30 1590 1595 forward 1 TM Cytosolic
77 LG: 199489.1 2001 MAR30 1596 1618 forward 1 TM Transmembrane
77 LG: 199489.1 2001 MAR30 1619 1627 forward 1 TM Non-Cytosolic
77 LG: 199489.1 2001 MAR30 1628 1650 forward 1 TM Transmembrane
77 LG: 199489.1 2001 MAR30 1651 1656 forward 1 TM Cytosolic
' 77 LG: 199489.1 2001 MAR30 1657 1679 forward 1 TM Transmembrane
77 LG: 199489.1 2001MAR30 1680 1898 forward 1 TM Non-Cytosolic
77 LG: 199489.1 2001 MAR30 1 94 forward 2 TM Cytosolic
77 LG:.199489.1 2001 AR30 95 1 13 forward 2 TM Transmembrane
77 LG: 199489.1 2001 MAR30 1 14 122 forward 2 TM Non-Cytosolic
77 LG: 199489.1 2001 MAR30 123 142 forward 2 TM Transmembrane
77 LG: 199489.1 2001 MAR30 143 154 forward 2 TM Cytosolic
77 LG: 199489.1 2001 MAR30 155 177 forward 2 TM Transmembrane
77 LG: 199489.1 2001 MAR30 178 217 forward 2 TM Non-Cytosolic
77 LG: 199489.1 2001 MAR30 218 240 forward 2 TM Transmembrane
77 LG: 199489.1 2001 MAR3O 241 244 forward 2 TM Cytosolic
77 LG: 199489.1 2001 MAR30 245 267 forward 2 TM Transmembrane
77 LG: 199489.1 2001 MAR30 268 304 forward 2 TM Non-Cytosolic
77 LG: 199489.1 2001 MAR30 305 327 forward 2 TM Transmembrane
77 LG: 199489.1 2001 MAR30 328 347 forward 2 TM Cytosolic
77 LG: 199489.1 2001 MAR30 348 370 forward 2 TM Transmembrane
77 LG: 199489.1 2001 MAR30 371 394 forward 2 TM Non-Cytosolic
77 LG: 199489.1 200'1 MAR30 395 414 forward 2 TM Transmembrane
77 LG: 199489.1 2001 MAR30 415 443 forward 2 TM Cytosolic
77 LG: 199489.1 2001 MAR30 444 461 forward 2 TM Transmembrane
77 LG: 199489.1 2001 MAR30 462 465 forward 2 TM Non-Cytosolic
77 LG: 199489.1 2001 MAR30 466 488 forward 2 TM Transmembrane
77 LG: 199489.1 2001 MAR30 489 548 forward 2 TM Cytosolic
77 LG: 199489.1 2001 MAR30 549 571 forward 2 TM Transmembrane
77 LG: 199489.1 2001 MAR30 572 580 forward 2 TM Non-Cytosolic
77 LG: 199489.1 2001 MAR30 581 600 forward 2 TM Transmembrane
77 LG: 199489.1 2001 MAR30 601 61 1 forward 2 TM Cytosolic
77 LG: 199489.1 2001 MAR30 612 634 forward 2 TM Transmembrane
77 LG: 199489.1 2001 MAR30 635 638 forward 2 TM Non-Cytosolic
77 LG: 199489.1 2001 MAR30 639 658 forward 2 TM Transmembrane
77 LG: 199489.1 2001 MAR30 659 738 forward 2 TM Cytosolic
77 LG: 199489.1 2001 MAR30 739 761 forward 2 TM Transmembrane ,, Φ Φ „ Φ Φ „ Φ Φ „ Φ „ Φ Φ „ Φ Φ ,, Φ Φ ,, Φ Φ „ ,, Φ ,, Φ „ Φ Φ ,, Φ ,, Φ ,. Φ f υ c cz c c .o c c u e υ c c .υ c u e c u e c o e υ c o c o o c u o 2 ϋ 2 o 2 ϋ 2 o 2 ϋ 2 o 2 o o 2 o 2 o 2 υ 2 o 2 0 o 2 ϋ 2 o o 2 ϋ θ 2 ϋ θ 2 ϋ 2 θ ϋ 2 o υ 2 o 2
© σ) <5 O = jO <5 X_ == X_ <5 XJ == 12 n -Ω ^ X2 7; X- £ X- = X2 £ X. = X) £ X2 = X. g = n -° 7^ n -Q ^ -Q n ^ -Q n =S ■£> n -Q
•^ 0 ≤^. Ct O co l2r CC O CO C t 2 tC O CO C t J2 tC O "? tO Γ t: O <5 t J2 t O CO t Jt2 t O CO C t £t Ct Oo C t Jt2 t t « t t <2 t co t t o t t co t t t © O f>- φ θ Φ ^ Φ O Φ /^ Φ O Φ Λ" Φ P ® j2 φ ^ φ O φ ^ φ O φ - φ O Φ Φ O Φ O " ® O Φ " O Φ O φ /^ φ -V E EV E >- £ V E ^- E £ " 7 E >- E V £ >- E Y E E V E E £ V E >-Y E >- E V E V >- E V E
H ^ o c o c= o: o c: c o c o c o c o o_: o: o c c o o c= o c o c o c o c o c 2 z σ o z g D z o z 2 2 z o o z σ g z o oz z o z z 2 z o z o z o α. 1— 1— 1— 1— 1— 1— 1— 1 — 1 — 1 — 1 — 1 — 1 — 1 — 1 — 1— 1— 1— h- 1— 1— 1— c £ 55555555555555555555555555555555555555555555555555 en
C CN CM C (N ( CM CM CM CN CN CM CM C C CO CO CO CO CO C CO C CO C CO CO C CO CO CO CO CO CO CO CN C CN
E b bbb b b b b bb b b b b b b bb b b b b b b b b b b b b b b b b b b b σ b b b b b b b b b b b b p.p o o o o o o o o o o o o o.P.00.P.p o o o o o o p o o.P.0.P. .P.P.P.P.P 0 0.p o o o o o o o o o
TABLE 4
SEQ ID NO: Template ID Start Stop Frame Domain Topology
81 LG:332923.4:2001 MAR30 626 645 forward 1 TM Cytosolic
81 LG:332923.4:2001 MAR30 646 664 forward 1 TM Transmembrane
81 LG:332923.4:2001 MAR30 665 1438 forward 1 TM Non-Cytosolic
81 LG:332923.4:2001 MAR30 1 852 forward 3 TM Non-Cytosolic
81 LG:332923.4:2001 MAR30 853 875 forward 3 TM Transmembrane
81 LG:332923.4:2001 MAR30 876 1 187 forward 3 TM Cytosolic
81 LG:332923.4:2001 MAR30 1 188 1210 forward 3 TM Transmembrane
81 LG:332923.4:2001 MAR30 121 1 1234 forward 3 TM Non-Cytosolic
81 LG:332923.4:2001 MAR30 1235 1257 forward 3 TM Transmembrane
81 LG:332923.4:2001 MAR30 1258 1437 forward 3 TM Cytosolic
82 LG:335276.1 :2001 MAR30 1 493 forward 1 TM Non-Cytosolic
82 LG:335276.1 :2001 MAR30 494 516 forward 1 TM Transmembrane
82 LG:335276.1 :2001 MAR30 517 613 forward 1 TM Cytosolic
82 LG:335276.1 :2001 MAR30 614 636 forward 1 TM Transmembrane
82 LG:335276.1 :2001 MAR30 637 739 forward 1 TM Non-Cytosolic
82 LG:335276.1 :2001 MAR30 740 762 forward 1 TM Transmembrane
82 LG:335276.1 :2001 MAR30 763 802 forward 1 TM Cytosolic
82 LG:335276.1 :2001 MAR30 803 825 forward 1 TM Transmembrane
82 LG:335276.1 :2001 MAR30 826 845 forward 1 TM Non-Cytosolic
83 LG:350272.2:2001 MAR30 1 529 forward 1 TM Non-Cytosolic
83 LG:350272.2:2001 MAR30 530 552 forward 1 TM Transmembrane
83 LG:350272.2:2001 MAR30 553 559 forward 1 TM Cytosolic
84 LG:350921.2:2001 MAR30 1 566 forward 1 TM Non-Cytosolic
84 LG:350921.2:2001 MAR30 567 589 forward 1 TM Transmembrane
84 LG:350921.2:2001 MAR30 590 685 forward 1 TM Cytosolic
84 LG:350921.2:2001 MAR30 686 708 forward 1 TM Transmembrane
84 LG:350921.2:2001 MAR30 709 71 1 forward 1 TM Non-Cytosolic
84 LG:350921.2:2001 MAR30 712 734 forward 1 TM Transmembrane
84 LG:350921.2:2001 MAR30 735 831 forward 1 TM Cytosolic
84 LG:350921.2:2001 MAR30 1 550 forward 2 TM Non-Cytosolic
84 LG:350921.2:2001 MAR30 551 573 forward 2 TM Transmembrane
84 LG:350921.2:2001 MAR30 574 673 forward 2 TM Cytosolic
84 LG:350921.2:2001 MAR30 674 693 forward 2 TM Transmembrane
84 LG:350921.2:2001 MAR30 694 702 forward 2 TM Non-Cytosolic
84 LG:350921.2:2001 MAR30 703 725 forward 2 TM Transmembrane
84 LG:350921.2:2001 MAR30 726 830 forward 2 TM Cytosolic
85 LG:406568.1 :2001 MAR30 1 618 forward 2 TM Non-Cytosolic
85 LG:406568.1 :2001 MAR30 619 636 forward 2 TM Transmembrane
85 LG:406568.1 :2001 MAR30 637 656 forward 2 TM Cytosolic
85 LG:406568.1 :2001 MAR30 657 679 forward 2 TM Transmembrane
85 LG:406568.1 :2001 MAR30 680 693 forward 2 TM Non-Cytosolic
85 LG:406568.1 :2001 MAR30 694 716 forward 2 TM Transmembrane
85 LG:406568.1 :2001 MAR30 717 770 forward 2 TM Cytosolic
86 LG:41 1043.3:2001 MAR30 1 99 forward 1 TM Cytosolic
86 LG:41 1043.3:2001 MAR30 100 122 forward 1 TM Transmembrane
86 LG:41 1043.3:2001 MAR30 123 181 forward 1 TM Non-Cytosolic
86 LG:41 1043.3:2001 MAR30 182 201 forward 1 TM Transmembrane
86 LG:41 1043.3:2001 MAR30 202 436 forward 1 TM Cytosolic
86 LG:41 1043.3:2001 MAR30 437 459 forward 1 TM Transmembrane
86 LG:41 1043.3:2001 MAR30 460 685 forward 1 TM Non-Cytosolic TABLE 4
SEQ ID NO: Template ID Start Stop Frame Domain Topology
87 LG:414376.20:2001 MAR30 1 464 forward 2 TM Non-Cytosolic
87 LG:414376.20:2001 MAR30 465 487 forward 2 TM Transmembrane
87 LG:414376.20:2001 MAR30 488 542 forward 2 TM Cytosolic
87 LG:414376.20:2001 MAR30 543 565 forward 2 TM Transmembrane
87 LG:414376.20:2001 MAR30 566 579 forward 2 TM Non-Cytosolic
87 LG:414376.20:2001 MAR30 580 602 forward 2 TM Transmembrane
87 LG:414376.20:2001 MAR30 603 664 forward 2 TM Cytosolic
87 LG:414376.20:2001 MAR30 665 687 forward 2 TM Transmembrane
87 LG:414376.20:2001 MAR30 688 701 forward 2 TM Non-Cytosolic
87 LG:414376.20:2001 MAR30 702 720 forward 2 TM Transmembrane
87 LG:414376.20:2001 MAR30 721 726 forward 2 TM Cytosolic
87 LG:414376.20:2001 MAR30 727 749 forward 2 TM Transmembrane
87 LG:414376.20:2001 MAR30 750 2000 forward 2 TM Non-Cytosolic
88 LG:457695.1 :2001 MAR30 1 257 forward 1 TM Non-Cytosolic
88 LG:457695.1 :2001 MAR30 258 280 forward 1 TM Transmembrane
88 LG:457695.1 :2001 MAR30 281 282 forward 1 TM Cytosolic
89 LG:902390.2:2001 MAR30 1 178 forward 1 TM Cytosolic
89 LG:902390.2:2001 MAR30 1 178 forward 3 TM Cytosolic
90 LG:903565.20:2001 MAR30 1 1239 forward 2 TM Non-Cytosolic
90 LG:903565.20:2001 MAR30 1240 1262 forward 2 TM Transmembrane
90 LG:903565.20:2001 MAR30 1263 1278 forward 2 TM Cytosolic
90 LG:903565.20:2001 MAR30 1279 1301 forward-2 TM Transmembrane
90 LG:903565.20:2001 MAR30 1302 1345 forward 2 TM Non-Cytosolic
91 LG:978182.4:2001 MAR30 1 819 forward 1 TM Non-Cytosolic
91 LG:978182.4:2001 MAR30 820 842 forward 1 TM Transmembrane
91 LG:978182.4:2001 MAR30 843 877 forward 1 TM Cytosolic
91 LG:978182.4:2001 MAR30 878 896 forward 1 TM Transmembrane
91 LG:978182.4:2001 MAR30 897 910 forward 1 TM Non-Cytosolic
91 LG:978182.4:2001 MAR30 91 1 933 forward 1 TM Transmembrane
91 LG:978182.4:2001 MAR30 934 971 forward 1 TM Cytosolic
91 LG:978182.4:2001 MAR30 972 994 forward 1 TM Transmembrane
91 LG:978182.4:2001 MAR30 995 1008 forward 1 TM Non-Cytosolic
91 LG:978182.4:2001 MAR30 1009 1031 forward 1 TM Transmembrane
91 LG:978182.4:2001 MAR30 1032 1410 forward 1 TM Cytosolic
91 LG:978182.4:2001 MAR30 141 1 1428 forward 1 TM Transmembrane
91 LG:978182.4:2001 MAR30 1429 1429 forward 1 TM Non-Cytosolic
91 LG:978182.4:2001 MAR30 1 819 forward 2 TM Non-Cytosolic
91 LG:978182.4:2001 MAR30 820 842 forward 2 TM Transmembrane
91 LG:978182.4:2001 MAR30 843 848 forward 2 TM Cytosolic
91 LG:978182.4:2001 MAR30 849 871 forward 2 TM Transmembrane
91 LG:978182.4:2001 MAR30 872 899 forward 2 TM Non-Cytosolic
91 LG:978182.4:2001 MAR30 900 922 forward 2 TM Transmembrane
91 LG:978182.4:2001 MAR30 923 966 forward 2 TM Cytosolic
91 LG:978182.4:2001 MAR30 967 989 forward 2 TM Transmembrane
91 LG:978182.4:2001 MAR30 990 998 forward 2 TM Non-Cytosolic
91 LG:978182.4:2001 MAR30 999 1018 forward 2 TM Transmembrane
91 LG:978182.4:2001 MAR30 1019 1202 forward 2 TM Cytosolic
91 LG:978182.4:2001 MAR30 1203 1225 forward 2 TM Transmembrane
91 LG:978182.4:2001 MAR30 1226 1429 forward 2 TM Non-Cytosolic
91 LG:978182.4:2001 MAR30 1 904 forward 3 TM Non-Cytosolic 'o 555555555555555 55555555 o
Q n t n n n o o '- '- '- '- '- '- '- '- '- '- C W N W '- ^ ^ n n n n n coon n n r- r- r- r- ^ r- ^ ^ oi cN W N rj p)
PbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPσPσPbPbPoPoPbPbPbPbPbPbPbPbPbPbPbPb o o o o o o o o o o o o o o o p p p p p o o o o o p p p p p p p p p p p p p p p p p p p p p p p p p rr io OO *- J oN o r O LO CN CM
O co rv <
©
© CN CN CN cO cO cO cO cO cO cO rr rr rr rr rr Lθ Lθ to o -θ ' 3 θ -o 3 iv. rv rv oo co oo co oo o o o o o o o o o o o o o o o o o O O O O O C ( ( < C> 0 0 c^ c cs^ ^ ^ o^ ^ ch ^ ^ i^ ^ ^ ^ ^ ^ c^ ^ c^ c^ c^ ^ ^ o^ c ^ ^ o^ o^ o^
Of
UJ CO
TABLE 4
SEQ ID NO Template ID Start Stop Frame Domain Topology
99 LG: 107976.15:2001 MAR30 2584 2606 forward 3 TM Transmembrane
99 LG: 107976.15:2001 MAR30 2607 2625 forward 3 TM Cytosolic
99 LG: 107976.15:2001 MAR30 2626 2645 forward 3 TM Transmembrane
99 LG: 107976.15:2001 MAR30 2646 2686 forward 3 TM Non-Cytosolic
100 LG: 1080096.1 :2001 MAR30 1 6 forward 2 TM Cytosolic
100 LG: 1080096.1 :2001 MAR30 7 29 forward 2 TM Transmembrane
100 LG: 1080096.1 :2001 MAR30 30 51 forward 2 TM Non-Cytosolic
100 LG: 1080096.1 :2001 MAR30 52 74 forward 2 TM Transmembrane
100 LG: 1080096.1 :2001 MAR30 75 172 forward 2 TM Cytosolic
100 LG:1080096.1 :2001 MAR30 173 195 forward 2 TM Transmembrane
100 LG:1080096.1 :2001 MAR30 196 676 forward 2 TM Non-Cytosolic
100 LG: 1080096.1 :2001 MAR30 677 699 forward 2 TM Transmembrane
100 LG: 1080096.1 :2001 MAR30 700 719 forward 2 TM Cytosolic
100 LG:1080096.1 :2001 MAR30 720 737 forward 2 TM Transmembrane
100 LG:1080096.1 :2001 MAR30 738 111 forward 2 TM Non-Cytosolic
100 LG:1080096.1 :2001 MAR30 778 191 forward 2 TM Transmembrane
100 LG: 1080096.1 :2001 MAR30 798 928 forward 2 TM Cytosolic
100 LG: 1080096.1 :2001 MAR30 1 6 forward 3 TM Cytosolic
100 LG: 1080096.1 :2001 MAR30 7 29 forward 3 TM Transmembrane
100 LG: 1080096.1 :2001 MAR30 30 48 forward 3 TM Non-Cytosolic
100 LG: 1080096.1 :2001 MAR30 49 71 forward 3 TM Transmembrane
100 LG: 1080096.1 :2001 MAR30 72 lib forward 3 TM Cytosolic
100 LG: 1080096.1 :2001 MAR30 777 799 forward 3 TM Transmembrane
100 LG: 1080096.1 :2001 MAR30 800 818 forward 3 TM Non-Cytosolic
100 LG: 1080096.1 :2001 MAR30 819 841 forward 3 TM Transmembrane
100 LG: 1080096.1 :2001 MAR30 842 927 forward 3 TM Cytosolic
101 LG: 1080275.1 :2001 MAR30 1 252 forward 1 TM Cytosolic
101 LG: 1080275.1 :2001 MAR30 253 275 forward 1 TM Transmembrane
101 LG: 1080275.1 :2001 MAR30 276 380 forward 1 TM Non-Cytosolic
102 LG: 1090358.10:2001 MAR30 1 3 forward 1 TM Non-Cytosolic
102 LG: 1090358.10:2001 MAR30 4 26 forward 1 TM Transmembrane
102 LG: 1090358.10:2001 MAR30 27 30 forward 1 TM Cytosolic
102 LG: 1090358.10:2001 MAR30 31 53 forward 1 TM Transmembrane
102 LG: 1090358.10:2001 MAR30 54 597 forward 1 TM Non-Cytosolic
102 LG: 1090358.10:2001 MAR30 1 3 forward 2 TM Non-Cytosolic
102 LG: 1090358.10:2001 MAR30 4 26 forward 2 TM Transmembrane
102 LG: 1090358.10:2001 MAR30 27 32 forward 2 TM Cytosolic
102 LG: 1090358.10:2001 MAR30 33 55 forward 2 TM Transmembrane
102 LG: 1090358.10:2001 MAR30 56 597 forward 2 TM Non-Cytosolic
103 LG: 1095833.9:2001 MAR30 1 1721 forward 1 TM Non-Cytosolic
103 LG: 1095833.9:2001 MAR30 1722 1744 forward 1 TM Transmembrane
103 LG: 1095833.9:2001 MAR30 1745 1763 forward 1 TM Cytosolic
103 LG: 1095833.9:2001 MAR30 1764 1786 forward 1 TM Transmembrane
103 LG: 1095833.9:2001 MAR30 1787 1923 forward 1 TM Non-Cytosolic
103 LG: 1095833.9:2001 MAR30 1924 1943 forward 1 TM Transmembrane
103 LG: 1095833.9:2001 MAR30 1944 2097 forward 1 TM Cytosolic
103 LG: 1095833.9:2001 MAR30 2098 2120 forward 1 TM Transmembrane
103 LG: 1095833.9:2001 MAR30 2121 2165 forward 1 TM Non-Cytosolic
103 LG: 1095833.9:2001 MAR30 2166 2188 forward 1 TM Transmembrane
103 LG: 1095833.9:2001 MAR30 2189 2207 forward 1 TM Cytosolic φ Φ Φ Φ Φ φ Φ Φ φ 0) Φ φ 0) φ φ 0) Φ u Cl) Φ φ 0) 0) (1) φ φ c u C c u c c u c c CZ c υ c c υ c c u C c u c c o υ c c o Z C u c r u C C
>- 2 o σ o σ o σ ,, o o o Ω 0 o σ Ω σ o 0 Ω o o o Ω σ o o Ω σ o 0 Ω σ 0 0 0 Ω σ o 0 Ω 0 O σ Ω D O O ., O
© cop o XJ o X o Ω = Ω X! XJ X. X J X. o XJ X. o X. X. X. Ω X. o o XJ XJ Ώ Ω = XJ ° F F F 5 E 8 E F O F 2 F o F F o F F O F o o Ω
F F O X © υ Φ Φ υ Φ > F F F O F F O F 5 F O
U φ F υ Φ Φ Φ q Φ φ E δ E υ Φ υ φ Φ -+ υ— Φ Φ -+ υ- Φ Φ -+ υ— φ φ υ Φ
°- P . υ υ υ p φ
(_ F >
( 1 F l_ £ E F _» F F >- F F >• F υ F - F υ F F υ F >- F F F υ Φ Φ
F F υ Φ O Φ F F υ Φ E £
^ c g υ ^ (_ υ c_ _ C_ n O 1_ υ !_
C_ n C_ O !_ c
C_ Ω C_ u C_
C_ Ω C_ υ C_ o o C_ υ L. I
Ω « n C_ C_ n C_ L. o C_ C_ Ω _. o C_ Ω t_ O <
H C_ Ω £ O U u 7 υ o o o o O o o 7 o o 7 o o V o o 7 o o z z o o z o o O o a o α. g "o £ 555555555555555 5555555555555555555555 o
Q
— — — — — — — ,— ,— ,— -_ -_ _ ,_ _- _- ,_. _- __ _. ,_ _- __ __ __ __ __ __ ,_ ,_ ,_ _. _. _. CM CM CM CM CN CM CM CN CN CN CM CM CM CM CM CM
?EPbPPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPb'DbΌb'Db
C_ O cO cO cO cO C LO C> C -- rr CN O C> CN C> C |v. O ) C> OO Iv. rv O C> CN ( lO L^ n « ω o ( ' Lθ s n ) oD θ <) oo oθ '- w oo s o o c ' ) oo -- n <) co o <) oo ) co oo ) -) ^ ( N- c -θ oo o ( oo o o n - CN CN CO CO CO cO c rr rr rr LO LO LO LO ) 3 -O rv oO OO OO OO OO OO C> C> C> C> 0 0 0 -- ■— ■— rv rv rv oO O O -- -- -- ■— CM CN CN CO CO CO
CO CN CM CN CN CN CN CN CN CN CN CN C CM CN CN ( CN CN CN CM ( C CN C CN CM CN CN CO cO cO CO CO C^ co _: CO -- rr rr rr rr <y3 ) O cO C iO cO -- O cO O cO CO -- rv O C OO CO -- O cO cO 3 <) C> C LO CO 3 rv CD •— rr θ C -- CD CN iO rr rr cθ
< π θ n α) θ N ^ ιn N 3 <) (o o o α ^ ) iD θ o n 'ϊ -o iD r- ^ <) co o <) m 'θ oo _ ) oo o> N (N "τ n ) θ- o « co o o
4_ CN C C c0 cθ c0 c0 C0 rr rr rr L0 i0 i0 L0 ) ) 3 rv 00 00 C0 00 00 C0 C> C> C> ( O O O -- r- ^ r rv rv oo o o- -- ■— ■— ■— CM CN CN CO CO CO C C (N C CN C C C CN CN C C CN CM C CN CN CM C C ( <N CN CN CM CN CN CM CM CO CO CO CO CO ■— ■— -- ■— — -- CM CM CN CM CM CM CN CN CM
O O o o o o
CO CO o CO oCO o CO oCO CO CO CO CO o coocoocoocooco coo cooocoocoocoocoocoocoocoocoocoocoocoocoocoocoocoocoocoocoocoocoocoocoocoocoocooco cooocoocoocoocoocooco
CY CY CY CY CY CY rv rv rv rv rv rv cv rv rv rv rv rv rv rv OL OL OL rv rv rv rv rv rv rv rv rv ■ V l .V .V .V fV .V .V .V .V fV .V .V .V fV .V fV
< < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <<<<<<<<<<<<<<<<< φ o O O O CD o ("3 o o
03 0 f") C) 03 03 C3 03 03 C3 03 03 C3 C3 C3 C 3 C 3 C 3 C 3 C 3 C3 C 3 CD C 3 C 3 C 3 C ) C3 C3 o CM CN CM CN CN CN CM CM CM CM CM CM CM CM CM CM CM 8 CM CM CM CM CN CN CN CN CN CN CN CN CN CN CM CM CM CM CN CN CN CM CM CN CN CN CN CM CM CM CM CM CM
O O O O O O O O O* O O O O O O O O O O O O O O O O O O O* o O O O O O O α O- O O O Ch O* O O* Ch O Ch o O Ch
CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO φ CO CO CO CO CO CO CO CO CO CO CO CO O CO CO CO
00 CO 00 OO oo OO OO OO CO oo oo oo s CO CO CO CO CO CO CO CO CO CO C3 CO CO CO CO C) CO CO C3 C3 C3 CO CO C3 C) C) C3 C3 C3 C3 CO CO CO C
00 oo oo oo oo CO oo β3 α) CO OO OO CO α> α> CO OO CO CC3 OO CO CO CO 00 O) 00 CO CO CO CO OO CO CO as CO 00 a>
Lf3 Lf3 LC3 Lf3 LO LO LC3 103 Lf3 LC3 LC3 U3 if) LO U3 LO LO LO LO LO U) LO LO LO IO LO LO LO LO LO if) U) m in LC3 LO LC3 m LO LO LO IO U) IO m if) LO LO IO LO
Ch Ch Ch Ch Ch Ch C3- (> ( <> ( O* ( < <> C3- C>- C3- ( ( >~ ( (>- C (h (>- ( >• O- ()- ( ( ( ( C C h (h (h C> Ch Ch h (h (h (h (h
CD C_3 CD C_3 CD CD CD CD CD CD CD CD CD CD CD CD CD CD CD CD CD CD CD o CD CD
00000000000000000000000000000000000000000000000000 r-
©
© - ( ^ n n c t < ( o n^ n ( n n !^ o (^n n (^ o o oc^ n c c^c ! n n n n c n [ n c^ n ! ( n (,) n (,) ( l,) o QQJ o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- -o- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o-- o--
UJ CO
Ctyos - Ctyos -
-- tθ rv rv oo -- ιO co O O ιO co cθ -- '— rr o c to N' ' θ W ( O N C> '- « ω θ N tθ ' <i ω -) o> o - - - - - - oj ι (,) o o N- N' N' β -_ CN CN C CN <N CN CN CN CN CN CN CN CN CM CN CN CN co _: -- o o cM iθ rr rv o rr o θ '— rr o o o cN >— rr o cM CO O 3 0 0 0 0 OO CN CN CO O OO CO O CN -O O -- -- , O O CM CN LO >— O < π (^ LO O u3 ^ (^ -- n ^ c^ O ( ( LO O- ( ' ^ ' _ '- n to ^ ιn ^ α o c C N' O C ^ ^ ^ ^ o co o J l 3 ) ^ ^
^ Ω l ' ) ) ) N N N eO ffl OO ffl ffl O> 0' (> O O N N N OO (0 00 ()> σ θ> 0 0 - - - - '- '- W N ( (1 0 - - ' N' cn CN CM CN CM CM CM CM CM CN CN CN CM CM CN CN CN CN CN CN cO cO -- -- -- -- -- -- -- -- -- -- CN CM CM CM CM CM CM CM CN CM CM CN CN CN CN CM CN CN
©
© Q _ (OnOnOnOoO(OoOnOιO(Oo nOoOnO cO nOtO<OoO«OnOoO nO(O nOnOnOnO nOoO oOnOnOnOnO nO nOtO oO(OnOtO nO tO(O cO(OOnO nOnO O Q - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
LU co
Table 5
2604-2862; 2622-3122; 2630-2892; 2630-3177; 2633-2861; 2660-3166; 2674- 3099; 2684-3196; 2701-2948 2704-3189; 2713-3104; 2718-3197; 2722-2960 2722-2968; 2760-3210; 2770 3209; 2773-3015; 2779-3170; 2783-3210; 2796 3030; 2801-3206; 2812-3215 ; 2815-3199; 2816-3087; 2822-3212; 2823-3210 2824-3203; 2826-3212; 2830-3206; 2853-3115; 2855-3209; 2864-3204; 2864 3201; 2864-3210; 2864-3209 ; 2866-3212; 2884-3078; 2878-3209; 2889-3209 2905-3209; 2907-3199; 2907-3170; 2915-3210; 2915-3173; 2920-3204; 2930- 3209; 2937-3206; 2957-3210 ; 2960-3215; 2965 3184; 2967-3204; 2969-3209 2970-3196; 2990-3209; 2995-3209; 3013-3196; 3018-3212; 3032-3208; 3054- 3189; 3061-3206; 3067-3214 3092-3209; 3158 3450 130/ G: 332027.6 :2001 AR30 I I 1-539; 379-847; 392-608; 394-1148; 398-967; 422-1064; 428-787; 642-1264; 690-888; 838-1296; 897-1080; 982-1632; 1066- 1632; 1104-1457; 1164-1453 ; 1370-1459; 1373-1619; 1495-1736; 1545-2138; 1575-1899; 1578-1765; 1618-1775; 1891-2407; 2032-2268; 2075-2447; 2082- 2446; 2119-2523; 2126-2446 ; 2314-2550; 2491 2755; 2491-2889; 2503-2715; 2586-2953; 2586-2808; 2661 -2929; 2674-2860; 2804-3042; 2870-3120; 2880- 3286; 2929-3408; 2929-3128 ; 2949-3197; 2951 3195; 2973-3425; 2973-3116; 3023-3338; 3028-3267; 3067 -3328; 3070-3304; 3120-3347; 3194-3417; 3195- 3417; 3218-3368; 3223-3372 ; 3226-3368; 3234-3368; 3251-3417; 3279-3370; 3302-3370; 3315-3368; 3325 -3456; 3373-3456 131/LG: 336998.1:2001MAR30 I I 1-5526; 1-11708 30-516; 30-512; 30 471; 30- 353; 30-156; 30-477; 30-465; 31-260; 39-651; 96-530; 98-534; 106-527; 107- 412; 120-462; 131-609; 157 384; 182-373; 224 489; 261-396; 296-610; 413- 556; 455-606; 448-707; 448 664; 463-839; 609 1104; 632-948; 692-1273; 889- 1349; 897-1365; 916-1474; 929-1367; 963-1509 1022-1410; 1052-1475; 1127- 1489; 1161-1426; 1202-1771 ; 1279-1668; 1284 735; 1309-1852; 1355-1759; 1408-1680; 1408-1643; 1543-1999; 1571-2182; 576-1747; 1609-1993; 1611- 1997; 1627-1838; 1642-2110 ; 1653-1993; 1731 997; 1733-1994; 1747-1997; 1751-1993; 1866-2290; 1882-2427; 1968-2265; 971-2417; 1975-2417; 2045- 2417; 2142-2402; 2208-2706 ; 2268-2809; 2431- 955; 2439-2688; 2504-2793; 2532-2671; 2570-3071; 2605-3199; 2605-2689 623-3058; 2682-3082; 2727- 2979; 2750-3088; 2788-3398 ; 29-50-3434; 2955- 437; 2954-3225; 2984-3437; 2992-3437; 3046-3265; 3044-3195; 3046-3437; 059-3264; 3080-3437; 3091- 3437; 3167-3438; 3173-3419 ; 3187-3457; 3233- 556; 3450-3867; 3745-6783; 3846-4092; 3964-4354; 4059-4418; 4077-4369; 135-4350; 4144-4354; 4330- 4762; 4861-5175; 5364-5865 ; 5589-6148; 5721 290; 5815-6398; 6191-6796; 6255-6859; 6280-6825; 6504-7063; 6531-6850; 543-6850; 6552-6850; 6556- 6847; 6580-6851; 6595-6850 ; 6611-6848; 6630 853; 6701-7376; 7013 -7651; 7526-8129; 7627-8020; 7717-8020; 7833-8020; 837-8492; 7887-8143; 7916- 8184; 8289-8881; 8434-8984 ; 8501-9044; 8526 080; 8586-8830; 8669-9231; 8782-9184; 8794-9184; 8814-9110; 9008-9559; 024-9238; 9050-9401; 9047- 9280; 9131-9484; 9137-9480 ; 9347-9484; 9471 741; 9646-10042; 9850-10451; 9849-10320; 9850-10441; 9898-10176; 10126-10 41; 10439-10927; 10439-10867; 10459-10739; 10461-10712; 10487-10727; 10586 10780; 10853-11006; 10938-
11341 10990-11491; 11113- 11388; 11155-11381 11181-11725; 11216-11860; 11260 11793; 11264-11707; 11266-11550; 11269 11731; 11689-11952; 11748- 12262 11897-12132; 11990- 12583; 12017-12281 12125-12684; 12125-12638;
12125-12377; 12128-12643; 12136-12718; 12214 12499; 12230-12446; 12245-
12889 12251-12394; 12251-12453; 12323-12548 12326-12576; 12400-12915; 12398 12704; 12418-12850; 12493-12636; 12541 12731; 12611-13040; 12616- 12912 12617-12790; 12619-13154; 12635-12979 12702-13152; 12718-12969; 12730 13049; 12865-13167; 12948-13164; 12955 13560; 12965-13253; 13023- 13285 13027-13222; 13030 13489; 13077-13357 13104-13440; 13114-13399;
13115-13378; 13130-13545; 13134-13461; 13142 13458; 13152-13744; 13153-
13455 13169-13553; 13175- 13633; 13198-13455 13204-13492; 13213-13478;
13216-13511; 13235-13481; 13252-13728; 13252 13497; 13309-13571; 13316-
13520 13347-13562; 13370-13611; 13394-13452 13400-13694; 13404-13982;
13443-13666; 13455-13947; 13461-14005; 13485 14055; 13485-13756; 13529-
14137 13540-14150; 13543-13767; 13546-13873 13583-13829; 13589-13874;
13589-13740; 13592-14132; 13606-13687; 13609 13864; 13613-14123; 13622- TABLE 4
SEQ ID NO: Template ID Start Stop Frame Domain Topology
105 LG:1386609.2:2001 MAR30 1327 1345 forward 2 TM Non-Cytosolic
105 LG: 1386609.2:2001 MAR30 1346 1368 forward 2 TM Transmembrane
105 LG: 1386609.2:2001 MAR30 1369 1380 forward 2 TM Cytosolic
105 LG: 1386609.2:2001 MAR30 1381 1403 forward 2 TM Transmembrane
105 LG: 1386609.2:2001 MAR30 1404 1417 forward 2 TM Non-Cytosolic
105 LG: 1386609.2:2001 MAR30 1418 1440 forward 2 TM Transmembrane
105 LG: 1386609.2:2001 MAR30 1441 1452 forward 2 TM Cytosolic
105 LG: 1386609.2:2001 MAR30 1453 1475 forward 2 TM Transmembrane
105 LG: 1386609.2:2001 MAR30 1476 1750 forward 2 TM Non-Cytosolic
105 LG: 1386609.2:2001 MAR30 1751 1773 forward 2 TM Transmembrane
105 LG: 1386609.2:2001 MAR30 1774 1824 forward 2 TM Cytosolic
105 LG: 1386609.2:2001 MAR30 1825 1847 forward 2 TM Transmembrane
105 LG: 1386609.2:2001 MAR30 1848 2529 forward 2 TM Non-Cytosolic
105 LG: 1386609.2:2001 MAR30 2530 2552 forward 2 TM Transmembrane
105 LG: 1386609.2:2001 MAR30 2553 2756 forward 2 TM Cytosolic
105 LG: 1386609.2:2001 MAR30 2757 2779 forward 2 TM Transmembrane
105 LG: 1386609.2:2001 MAR30 2780 3077 forward 2 TM Non-Cytosolic
105 LG: 1386609.2:2001 MAR30 1 1600 forward 3 TM Non-Cytosolic
105 LG: 1386609.2:2001 MAR30 1601 1623 forward 3 TM Transmembrane
105 LG: 1386609.2:2001 MAR30 1624 1754 forward 3 TM Cytosolic
105 LG: 1386609.2:2001 MAR30 1755 1777 forward 3 TM Transmembrane
105 LG: 1386609.2:2001 MAR30 1778 2315 forward 3 TM Non-Cytosolic
105 LG: 1386609.2:2001 MAR30 2316 2338 forward 3 TM Transmembrane
105 LG: 1386609.2:2001 MAR30 2339 2374 forward 3 TM Cytosolic
105 LG: 1386609.2:2001 MAR30 2375 2397 forward 3 TM Transmembrane
105 LG: 1386609.2:2001 MAR30 2398 2722 forward 3 TM Non-Cytosolic
105 LG: 1386609.2:2001 MAR30 2723 2742 forward 3 TM Transmembrane
105 LG: 1386609.2:2001 MAR30 2743 2754 forward 3 TM Cytosolic
105 LG: 1386609.2:2001 MAR30 2755 2774 forward 3 TM Transmembrane
105 LG: 1386609.2:2001 MAR30 2775 3076 forward 3 TM Non-Cytosolic
106 LG: 1398465.1 :2001 MAR30 1 1 1 1 forward 1 TM Cytosolic
106 LG: 1398465.1 :2001 MAR30 1 12 134 forward 1 TM Transmembrane
106 LG: 1398465.1 :2001 MAR30 135 169 forward 1 TM Non-Cytosolic
106 LG: 1398465.1 :2001 MAR30 170 192 forward 1 TM Transmembrane
106 LG: 1398465.1 :2001 MAR30 193 204 forward 1 TM Cytosolic
106 LG: 1398465.1 :2001 MAR30 205 227 forward 1 TM Transmembrane
106 LG: 1398465.1 :2001 MAR30 228 246 forward 1 TM Non-Cytosolic
106 LG:1398465.1 :2001 MAR30 247 269 forward 1 TM Transmembrane
106 LG: 1398465.1 :2001 MAR30 270 275 forward 1 TM Cytosolic
106 LG:1398465.1 :2001 MAR30 276 298 forward 1 TM Transmembrane
106 LG: 1398465.1 :2001 MAR30 299 384 forward 1 TM Non-Cytosolic
106 LG: 1398465.1 :2001 MAR30 385 407 forward 1 TM Transmembrane
106 LG:1398465.1 :2001 MAR30 408 449 forward 1 TM Cytosolic
106 LG: 1398465.1 :2001 MAR30 450 472 forward 1 TM Transmembrane
106 LG:1398465.1 :2001 MAR30 473 521 forward 1 TM Non-Cytosolic
106 LG: 1398465.1 :2001 MAR30 522 544 forward 1 TM Transmembrane
106 LG:1398465.1 :2001 MAR30 545 630 forward 1 TM Cytosolic
106 LG: 1398465.1 :2001 MAR30 631 653 forward 1 TM Transmembrane
106 LG: 1398465.1 :2001 MAR30 654 657 forward 1 TM Non-Cytosolic
106 LG: 1398465.1 :2001 MAR30 658 675 forward 1 TM Transmembrane TABLE 4
ID NO Template ID Start Stop Frame Domain Topology
106 LG: 1398465.1 2001 MAR30 676 695 forward 1 TM Cytosolic
106 LG: 1398465.1 2001 MAR30 696 718 forward 1 TM Transmembrane
106 LG: 1398465.1 2001 MAR30 719 748 forward 1 TM Non-Cytosolic
106 LG: 1398465.1 2001 MAR30 749 771 forward 1 TM Transmembrane
106 LG: 1398465.1 2001 MAR30 772 791 forward 1 TM Cytosolic
106 LG: 1398465.1 2001 MAR30 792 814 forward 1 TM Transmembrane
106 LG: 1398465.1 2001 MAR30 815 823 forward 1 TM Non-Cytosolic
106 LG: 1398465.1 2001 MAR30 824 846 forward 1 TM Transmembrane
106 LG: 1398465.1 2001 MAR30 847 1087 forward 1 TM Cytosolic
106 LG: 1398465.1 2001 MAR30 1088 1 1 10 forward 1 TM Transmembrane
106 LG: 1398465.1 2001MAR30 1 11 1 11 13 forward 1 TM Non-Cytosolic
106 LG: 1398465.1 2001 MAR30 1 1 14 1 136 forward 1 TM Transmembrane
106 LG: 1398465.1 2001 MAR30 1 137 1 152 forward 1 TM Cytosolic
106 LG: 1398465.1 2001 MAR30 1 205 forward 2 TM Non-Cytosolic
106 LG: 1398465.1 2001 MAR30 206 228 forward 2 TM Transmembrane
106 LG: 1398465.1 2001 MAR30 229 374 forward 2 TM Cytosolic
106 LG: 1398465.1 2001 AR30 375 397 forward 2 TM Transmembrane
106 LG: 1398465.1 2001 MAR30 398 443 forward 2 TM Non-Cytosolic
106 LG: 1398465.1 2001 MAR30 444 466 forward 2 TM Transmembrane
106 LG: 1398465.1 2001 MAR30 467 633 forward 2 TM Cytosolic
106 LG: 1398465.1 2001 MAR30 634 656 forward 2 TM Transmembrane
106 LG: 1398465.1 2001 MAR30 657 696 forward 2 TM Non-Cytosolic
106 LG: 1398465.1 2001 MAR30 697 719 forward 2 TM Transmembrane
106 LG: 1398465.1 2001 MAR30 720 725 forward 2 TM Cytosolic
106 LG: 1398465.1 2001 MAR30 726 743 forward 2 TM Transmembrane
106 LG: 1398465.1 2001 MAR30 744 746 forward 2 TM Non-Cytosolic
106 LG: 1398465.1 2001 MAR30 747 769 forward 2 TM Transmembrane
106 LG: 1398465.1 2001 MAR30 770 808 forward 2 TM Cytosolic
106 LG: 1398465.1 2001 MAR30 809 831 forward 2 . TM Transmembrane
106 LG: 1398465.1 2001 AR30 832 859 forward 2 TM Non-Cytosolic
106 LG: 1398465.1 2001 MAR30 860 882 forward 2 TM Transmembrane
106 LG: 1398465.1 2001 MAR30 883 954 forward 2 TM Cytosolic
106 LG: 1398465.1 2001 MAR30 955 977 forward 2 TM Transmembrane
106 LG: 1398465.1 2001 MAR30 978 1060 forward 2 TM Non-Cytosolic
106 LG: 1398465.1 2001 MAR30 1061 1082 forward 2 TM Transmembrane
106 LG: 1398465.1 2001 MAR30 1083 1 152 forward 2 TM Cytosolic
106 LG: 1398465.1 2001 MAR30 1 520 forward 3 TM Non-Cytosolic
106 LG: 1398465.1 2001 MAR30 521 543 forward 3 TM Transmembrane
106 LG: 1398465.1 2001 MAR30 544 583 forward 3 TM Cytosolic
106 LG: 1398465.1 2001 MAR30 584 606 forward 3 TM Transmembrane
106 LG: 1398465.1 2001 MAR30 607 627 forward 3 TM Non-Cytosolic
106 LG: 1398465.1 2001 MAR30 628 650 forward 3 TM Transmembrane
106 LG: 1398465.1 2001 MAR30 651 658 forward 3 TM Cytosolic
106 LG: 1398465.1 2001 MAR30 659 681 forward 3 TM Transmembrane
106 LG: 1398465.1 2001 MAR30 682 700 forward 3 TM Non-Cytosolic
106 LG: 1398465.1 2001 MAR30 701 718 forward 3 TM Transmembrane
106 LG: 1398465.1 2001 MAR30 719 724 forward 3 TM Cytosolic
106 LG: 1398465.1 2001 MAR30 725 747 forward 3 TM Transmembrane
106 LG: 1398465.1 2001 MAR30 748 789 forward 3 TM Non-Cytosolic
106 LG: 1398465.1 2001 MAR30 790 812 forward 3 TM Transmembrane TABLE 4
SEQ ID NO Template ID Start Stop Frame Domain Topology
106 LG: 1398465.1 2001 MAR30 813 831 forward 3 TM Cytosolic
106 LG: 1398465.1 2001 MAR30 832 851 forward 3 TM Transmembrane
106 LG: 1398465.1 2001 MAR30 852 865 forward 3 TM Non-Cytosolic
106 LG: 1398465.1 2001 MAR30 866 888 forward 3 TM Transmembrane
106 LG: 1398465.1 2001 MAR30 889 1 103 forward 3 TM Cytosolic
106 LG: 1398465.1 2001 MAR30 1 104 1 126 forward 3 TM Transmembrane
106 LG: 1398465.1 2001 MAR30 1 127 1 152 forward 3 TM Non-Cytosolic
107 LG: 1453417.10:2001 MAR30 1 2349 forward 2 TM Non-Cytosolic
107 LG: 1453417.10:2001 MAR30 2350 2372 forward 2 TM Transmembrane
107 LG: 1453417.10:2001 MAR30 2373 2384 forward 2 TM Cytosolic
107 LG: 1453417.10:2001 MAR30 2385 2404 forward 2 TM Transmembrane
107 LG: 1453417.10:2001 MAR30 2405 2407 forward 2 TM Non-Cytosolic
107 LG: 1453417.10:2001 MAR30 2408 2430 forward 2 TM Transmembrane
107 LG:1453417.10:2001 MAR30 2431 2450 forward 2 TM Cytosolic
107 LG:1453417.10:2001 MAR30 2451 2470 forward 2 TM Transmembrane
107 LG: 1453417.10:2001 MAR30 2471 2489 forward 2 TM Non-Cytosolic
107 LG: 1453417.10:2001 MAR30 2490 2512 forward 2 TM Transmembrane
107 LG: 1453417.10:2001 MAR30 2513 2531 forward 2 TM Cytosolic
107 LG: 1453417.10:2001 MAR30 2532 2554 forward 2 TM Transmembrane
107 LG: 1453417.10:2001 MAR30 2555 3920 forward 2 TM Non-Cytosolic
108 LG: 147869.3:2001 MAR30 1 88 forward 1 TM Non-Cytosolic
108 LG: 147869.3:2001 MAR30 89 106 forward 1 TM Transmembrane
108 LG: 147869.3:2001 MAR30 107 1 14 forward 1 TM Cytosolic
108 LG: 147869.3:2001 MAR30 1 15 137 forward 1 TM Transmembrane
108 LG: 147869.3:2001 MAR30 138 146 forward 1 TM Non-Cytosolic
108 LG: 147869.3:2001 MAR30 147 169 forward 1 TM Transmembrane
108 LG: 147869.3:2001 MAR30 170 189 forward 1 TM Cytosolic
108 LG: 147869.3:2001 MAR30 190 212 forward 1 TM Transmembrane
108 LG: 147869.3:2001 MAR30 213 226 forward 1 TM Non-Cytosolic
108 LG: 147869.3:2001 MAR30 227 249 forward 1 TM Transmembrane
108 LG: 147869.3:2001 MAR30 250 315 forward 1 TM Cytosolic
108 LG: 147869.3:2001 MAR30 316 338 forward 1 TM Transmembrane
108 LG: 147869.3:2001 MAR30 339 513 forward 1 TM Non-Cytosolic
108 LG: 147869.3:2001 MAR30 514 536 forward 1 TM Transmembrane
108 LG: 147869.3:2001 MAR30 537 540 forward 1 TM Cytosolic
108 LG:147869.3:2001 MAR30 541 563 forward 1 TM Transmembrane
108 LG: 147869.3:2001 MAR30 564 572 forward 1 TM Non-Cytosolic
108 LG: 147869.3:2001 MAR30 573 595 forward 1 TM Transmembrane
108 LG: 147869.3:2001 MAR30 596 607 forward 1 TM Cytosolic
108 LG:147869.3:2001 MAR30 608 630 forward 1 TM Transmembrane
108 LG:147869.3:2001 MAR30 631 644 forward 1 TM Non-Cytosolic
108 LG: 147869.3:2001 MAR30 645 667 forward 1 TM Transmembrane
108 LG:147869.3:2001 MAR30 668 713 forward 1 TM Cytosolic
108 LG:147869.3:2001 MAR30 1 564 forward 2 TM Non-Cytosolic
108 LG: 147869.3:2001 MAR30 565 587 forward 2 TM Transmembrane
108 LG: 147869.3:2001 MAR30 588 613 forward 2 TM Cytosolic
108 LG:147869.3:2001 MAR30 614 636 forward 2 TM Transmembrane
108 LG:147869.3:2001MAR30 637 645 forward 2 TM Non-Cytosolic
108 LG: 147869.3:2001 MAR30 646 665 forward 2 TM Transmembrane
108 LG: 147869.3:2001 MAR30 666 685 forward 2 TM Cytosolic TABLE 4
SEQ ID NO Template ID Start Stop Frame Domain Topology
108 LG: 147869.3:2001 MAR30 686 708 forward 2 TM Transmembrane
108 LG: 147869.3:2001 MAR30 709 713 forward 2 TM Non-Cytosolic
109 LG: 148485.5:2001 MAR30 1 18 forward 1 TM Cytosolic
109 LG: 148485.5:2001 MAR30 19 36 forward 1 TM Transmembrane
109 LG: 148485.5:2001 MAR30 37 50 forward 1 TM Non-Cytosolic
109 LG: 148485.5:2001 MAR30 51 73 forward 1 TM Transmembrane
109 LG: 148485.5:2001 MAR30 74 189 forward 1 TM Cytosolic
109 LG:148485.5:2001 MAR30 190 212 forward 1 TM Transmembrane
109 LG: 148485.5:2001 MAR30 213 288 forward 1 TM Non-Cytosolic
109 LG: 148485.5:2001 MAR30 289 31 1 forward 1 TM Transmembrane
109 LG:148485.5:2001 MAR30 312 315 forward 1 TM Cytosolic
1 10 LG: 1501818.12:2001 MAR30 1 177 forward 1 TM Cytosolic
1 10 LG:1501818.12:2001 MAR30 178 200 forward 1 TM Transmembrane
1 10 LG: 1501818.12:2001 MAR30 201 571 forward 1 TM Non-Cytosolic no LG: 1501818.12:2001 MAR30 1 446 forward 2 TM Non-Cytosolic no LG: 1501818.12:2001 MAR30 447 469 forward 2 TM Transmembrane no LG: 1501818.12:2001 MAR30 470 481 forward 2 TM Cytosolic no LG: 1501818.12:2001 MAR30 482 501 forward 2 TM Transmembrane no LG: 1501818.12:2001 MAR30 502 510 forward 2 TM Non-Cytosolic no LG: 1501818.12:2001 MAR30 51 1 533 forward 2 TM Transmembrane no LG:1501818.12:2001 MAR30 534 570 forward 2 TM Cytosolic i n LG:1508275.1 :2001 MAR30 1 106 forward 1 TM Cytosolic
1 12 LG:1509771.1 :2001 MAR30 1 134 forward 2 TM Cytosolic
1 12 LG:1509771 .1 :2001 MAR30 135 157 forward 2 TM Transmembrane
1 12 LG:1509771.1 :2001 MAR30 158 159 forward 2 TM Non-Cytosolic
1 13 LG: 1512998.13:2001 MAR30 1 597 forward 1 TM Non-Cytosolic
1 13 LG: 1512998.13:2001 MAR30 598 620 forward 1 TM Transmembrane
1 13 LG: 1512998.13:2001 MAR30 621 777 forward 1 TM Cytosolic
1 13 LG: 1512998.13:2001 MAR30 778 800 forward 1 TM Transmembrane
1 13 LG: 1512998.13:2001 MAR30 801 814 forward 1 TM Non-Cytosolic
1 13 LG: 1512998.13:2001 MAR30 815 837 forward 1 TM Transmembrane
1 13 LG: 1512998.13:2001 MAR30 838 935 forward 1 TM Cytosolic
1 13 LG: 1512998.13:2001 MAR30 936 953 forward 1 TM Transmembrane
1 13 LG: 1512998.13:2001 MAR30 954 1009 forward 1 TM Non-Cytosolic
1 13 LG: 1512998.13:2001 MAR30 1010 1029 forward 1 TM Transmembrane
1 13 LG: 1512998.13:2001 MAR30 1030 1049 forward 1 TM Cytosolic
1 13 LG: 1512998.13:2001 MAR30 1050 1069 forward 1 TM Transmembrane
1 13 LG: 1512998.13:2001 MAR30 1070 1083 forward 1 TM Non-Cytosolic
1 13 LG:1512998.13:2001 MAR30 1084 1 106 forward 1 TM Transmembrane
1 13 LG:1512998.13:2001 MAR30 1 107 1228 forward 1 TM Cytosolic
1 13 LG:1512998.13:2001 MAR30 1 470 forward 2 TM Non-Cytosolic
1 13 LG: 1512998.13:2001 MAR30 471 493 forward 2 TM Transmembrane
1 13 LG: 1512998.13:2001 MAR30 494 523 forward 2 TM Cytosolic
1 13 LG: 1512998.13:2001 MAR30 524 546 forward 2 TM Transmembrane
1 13 LG: 1512998.13:2001 MAR30 547 596 forward 2 TM Non-Cytosolic
1 13 LG: 1512998.13:2001 MAR30 597 619 forward 2 TM Transmembrane
1 13 LG: 1512998.13:2001 MAR30 620 804 forward 2 TM Cytosolic
1 13 LG: 1512998.13:2001 MAR30 805 827 forward 2 TM Transmembrane
1 13 LG: 1512998.13:2001 MAR30 828 934 forward 2 TM Non-Cytosolic
1 13 LG: 1512998.13:2001 MAR30 935 954 forward 2 TM Transmembrane
c "σ ε 5 1—5 1—5 1—5 1—5 1—5 1—5 1—5 1—5 1— 15—5 1—5 1—5 1—5 5555555 5555555 o 1—5 I—5 1—5 1—5 1—5 1—5 1—5 1—5 1—5 1—
Q
C C CΛI CN C CN CN CN CN CN C CN C CN CN CO CO CO C CO C CO C O —
Φ PPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPP bbbbbbbσbb bbbbbbbbbbbbobobσbbbbbbσσbbbbbαbbbbbbbb ooooooooooooooooooooooooopopopppppppppppppppppoooo
O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO C CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO D- _- _- CY C_ C_ _; LY LY LY C^
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _- f_ _ < < < < < < < < < < < < < < < < < < < < < < < < < <
^ φ ^_-_r- _r-_-. _-._ — _ — Σ — _ —_ —_ -- _--_-- -_-_--_--_--_-- _--_-- _ --_--_--_-- O^O ^O O^O O^O O^O O O^O^O O^O O^O O ^O O O^O^O O^O O
-t O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O σ O O O O O O O O O O O O O O O O O O O O O O O O CN CN CN C C CN C C CN CN CN CN CN CM CN CM CN CN CN CN CM CM CM CN CN CN
Φ -o - " ~ - ~o - " ~o " "O " -o v5 ~5 -o -o -o -o ~c> ~o ~ " O - « 5 ~ ~ O* D ^ ~O - -O - -O ~ ~O -O ~O -CΪ ~ -O ^O _) ~ -o ^o ~o __ O O O O O O O O O O O O O O O O O O O O O O O O iv. iv. rv rv rv rv rv rv rv. rv rv rv rv rv rv rv. rv rv rv. rv rv rv rv rv rv. rv.
( ( CN CM CM CN CN CN CN C CN ( C CN CN CN CN CN CM CN C CN C CM 00 00 OO 00 00 00 CO 0O 0O CO CO CO CO CO 0O co co oo oo oo oo oo oo oo co oo oo co oo oo oo oo oo oo oo co oo co co oo oo co oo oo oo oo oo oo oo oo oo oo oo oo oo co oo oo oo co oo oo oo oo o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o
00^0^ 00^00000^00^0000000000 r-
© o ιO U) U3 U3 tO -) tO lO tO U) lO ) ιO U) ιn u) U) ) ιn -) ) lO ιO ιn <) ) -O O O <) O <) ) O ) ) ) 'O -0 -0 -0 ) '0 -0 ) '0 '0
© o o UJ co
TABLE 4
SEQ ID NO Template ID Start Stop Frame Domain Topology
116 LG: 198876.13:2001 MAR30 561 726 forward 3 TM Non-Cytosolic
116 LG: 198876.13:2001 MAR30 727 749 forward 3 TM Transmembrane
116 LG: 198876.13:2001 MAR30 750 1190 forward 3 TM Cytosolic
116 LG: 198876.13:2001 MAR30 1191 1210 forward 3 TM Transmembrane
116 LG: 198876.13:2001 MAR30 1211 1224 forward 3 TM Non-Cytosolic
116 LG: 198876.13:2001 MAR30 1225 1247 forward 3 TM Transmembrane
116 LG: 198876.13:2001 MAR30 1248 1404 forward 3 TM Cytosolic
117 LG:200704.1:2001MAR30 1 425 forward 1 TM Non-Cytosolic
117 LG:200704.1:2001MAR30 426 448 forward 1 TM Transmembrane
117 LG:200704.1:2001MAR30 449 559 forward 1 TM Cytosolic
117 LG:200704.1:2001MAR30 560 582 forward 1 TM Transmembrane
117 LG:200704.1:2001MAR30 583 626 forward 1 TM Non-Cytosolic
117 LG:200704.1:2001MAR30 627 646 forward 1 TM Transmembrane
117 LG:200704.1:2001MAR30 647 733 forward 1 TM Cytosolic
118 LG:206593.3:2001 MAR30 1 464 forward 2 TM Non-Cytosolic
118 LG:206593.3:2001MAR30 465 484 forward 2 TM Transmembrane
118 LG:206593.3:2001MAR30 485 516 forward 2 TM Cytosolic
119 LG:223970.11 2001MAR30 1 90 forward 1 TM Cytosolic
119 LG:223970.11 2001MAR30 91 113 forward 1 TM Transmembrane
119 LG:223970.11 2001MAR30 114 1376 forward 1 TM Non-Cytosolic
119 LG:223970.11 2001MAR30 1377 1399 forward 1 TM Transmembrane
119 LG:223970.11 2001MAR30 1400 1461 forward 1 TM Cytosolic
119 LG:223970.11 2001MAR30 1462 1484 forward 1 TM Transmembrane
119 LG:223970.11 2001MAR30 1485 1509 forward 1 . TM Non-Cytosolic
119 LG:223970.11 2001MAR30 1510 1532 forward 1 TM Transmembrane
119 LG:223970.11 2001MAR30 1533 1687 forward 1 -• TM Cytosolic
119 LG:223970.11 2001MAR30 1688 1710 forward 1 . TM Transmembrane
119 LG:223970.11 2001MAR30 1711 1724 forward 1 TM Non-Cytosolic
119 LG:223970.11 2001MAR30 1725 1747 forward 1 TM Transmembrane
119 LG:223970.11 2001MAR30 1748 2013 forward 1 TM Cytosolic
119 LG:223970.11 2001MAR30 20142036 forward 1 TM Transmembrane
119 LG:223970.11 2001MAR30 2037 2341 forward 1 TM Non-Cytosolic
119 LG:223970.11 2001 MAR30 1 868 forward 2 TM Non-Cytosolic
119 LG:223970.11 2001MAR30 869 891 forward 2 TM Transmembrane
119 LG:223970.11 2001MAR30 892 903 forward 2 TM Cytosolic
119 LG:223970.11 2001MAR30 904 923 forward 2 TM Transmembrane
119 LG:223970.11 2001MAR30 924 927 forward 2 TM Non-Cytosolic
119 LG:223970.11 2001MAR30 928 950 forward 2 TM Transmembrane
119 LG:223970.11 2001MAR30 951 1265 forward 2 TM Cytosolic
119 LG:223970.11 2001MAR30 1266 1288 forward 2 TM Transmembrane
119 LG:223970.11 2001MAR30 1289 1302 forward 2 TM Non-Cytosolic
119 LG:223970.11 2001MAR30 1303 1325 forward 2 TM Transmembrane
119 LG:223970.11 2001MAR30 1326 1401 forward 2 TM Cytosolic
119 LG:223970.11 2001MAR30 1402 1424 forward 2 TM Transmembrane
119 LG:223970.11 2001MAR30 1425 1443 forward 2 TM Non-Cytosolic
119 LG:223970.11 2001MAR30 1444 1466 forward 2 TM Transmembrane
119 LG:223970.11 2001MAR30 1467 1498 forward 2 TM Cytosolic
119 LG:223970.11 2001MAR30 1499 1516 forward 2 TM Transmembrane
119 LG:223970.11 2001MAR30 1517 1528 forward 2 TM Non-Cytosolic
119 LG:223970.11 2001MAR30 1529 1551 forward 2 TM Transmembrane TABLE 4
SEQ ID NO Template ID Start Stop Frame Domain Topology
119 LG:223970.11 2001MAR30 1552 1677 forward 2 TM Cytosolic
119 LG:223970.11 2001MAR30 1678 1700 forward 2 TM Transmembrane
119 LG:223970.11 2001MAR30 1701 2341 forward 2 TM Non-Cytosolic
119 LG:223970.11 2001MAR30 1 622 forward 3 TM Non-Cytosolic
119 LG:223970.11 2001MAR30 623 645 forward 3 TM Transmembrane
119 LG:223970.11 2001MAR30 646 705 forward 3 TM Cytosolic
119 LG:223970.11 2001MAR30 706 728 forward 3 TM Transmembrane
119 LG:223970.11 2001MAR30 729 870 forward 3 TM Non-Cytosolic
119 LG:223970.11 2001MAR30 871 893 forward 3 TM Transmembrane
119 LG:223970.11 2001MAR30 894 899 forward 3 TM Cytosolic
119 LG:223970.11 2001MAR30 900 922 forward 3 TM Transmembrane
119 LG:223970.11 2001MAR30 923 927 forward 3 TM Non-Cytosolic
119 LG:223970.11 2001MAR30 928 950 forward 3 TM Transmembrane
119 LG:223970.11 2001MAR30 951 962 forward 3 TM Cytosolic
119 LG:223970.11 2001MAR30 963 985 forward 3 TM Transmembrane
119 LG:223970.11 2001MAR30 986 1024 forward 3 TM Non-Cytosolic
119 LG:223970.11 2001MAR30 1025 1047 forward 3 TM Transmembrane
119 LG:223970.11 2001MAR30 1048 1250 forward 3 TM Cytosolic
119 LG:223970.11 2001MAR30 1251 1273 forward 3 TM Transmembrane
119 LG:223970.11 2001MAR30 1274 1303 forward 3 TM Non-Cytosolic
119 LG:223970.11 2001MAR30 1304 1326 forward 3 TM Transmembrane
119 LG:223970.11 2001MAR30 1327 1330 forward 3 TM Cytosolic
119 LG:223970.11 2001MAR30 1331 1353 forward 3 TM Transmembrane
119 LG:223970.11 2001MAR30 1354 1460 forward 3 TM Non-Cytosolic
119 LG:223970.11 2001MAR30 1461 1483 forward 3 TM Transmembrane
119 LG:223970.11 2001MAR30 1484 1495 forward 3 TM Cytosolic
119 LG:223970.11 2001MAR30 1496 1518 forward 3 TM Transmembrane
119 LG:223970.11 2001MAR30 1519 1522 forward 3 TM Non-Cytosolic
119 LG: 223970.11 2001MAR30 1523 1545 forward 3 TM Transmembrane
119 LG:223970.11 2001MAR30 1546 1568 forward 3 TM Cytosolic
119 LG:223970.11 2001MAR30 1569 1591 forward 3 TM Transmembrane
119 LG:223970.11 2001MAR30 1592 2022 forward 3 TM Non-Cytosolic
119 LG:223970.11 2001MAR30 2023 2045 forward 3 TM Transmembrane
119 LG:223970.11 2001MAR30 2046 2227 forward 3 TM Cytosolic
119 LG:223970.11 2001MAR30 2228 2250 forward 3 TM Transmembrane
119 LG:223970.11 2001 AR30 2251 2299 forward 3 TM Non-Cytosolic
119 LG:223970.11 2001MAR30 2300 2322 forward 3 TM Transmembrane
119 LG:223970.11 2001MAR30 2323 2341 forward 3 TM Cytosolic
120 LG:227500.5:2001MAR30 1 855 forward 1 TM Non-Cytosolic
120 LG:227500.5:2001MAR30 856 875 forward 1 TM Transmembrane
120 LG:227500.5:2001 MAR30 876 1071 forward 1 TM Cytosolic
120 LG:227500.5:2001MAR30 1072 1094 forward 1 TM Transmembrane
120 LG:227500.5:2001MAR30 1095 1120 forward 1 TM Non-Cytosolic
120 LG:227500.5:2001MAR30 1121 1138 forward 1 TM Transmembrane
120 LG:227500.5:2001 MAR30 1139 1152 forward 1 TM Cytosolic
121 LG:227722J:2001MAR30 1 249 forward 1 TM Cytosolic
121 LG:227722J:2001MAR30 250 272 forward 1 TM Transmembrane
121 LG:227722J:2001MAR30 273 628 forward 1 TM Non-Cytosolic
122 LG:229105.1:2001MAR30 1 184 forward 3 TM Cytosolic
122 LG:229105.1:2 001MAR30 185 207 forward 3 TM Transmembrane f
© ©
H α. c £ 55555555555555555555555555555555555555555555555555
___ co oo co co oo -- -- -- —- ■— N w w n o n o n n w ( ( i (N C C θi n o n c n c n n (« n ( ( < n - - - - ι- ( n n r?PPPPPPPPPPPPPPPPPPP E b σ b b b b b b b b b σbb b b b b b
"" O— O— NO— HO— 4O— 4O— 4O— 4O— 4O— 4O— 4O— 4O— 4O— 4O— 4O— 4O— 4O— 4O— 4O— y- CO -O rv O CM O CN CN CM rv rr rv rv O O LO LO O CM p cO LO OO -- O vT rv O — LO iO rv LO . lO - rv ιo ~ rv oo O CM CM CM CO CO OO OO OO O O CO CO o rv co oo CO o
S? t oo rr rv co ■— O co co co tO 00 rr rv 3 O O c0 rr rv rr rv o CN rr cM oo — rr rv o co cN Lo cN o rr rv < D o n lo co - - Lθ rv o >— ■— lO rv — L rv io rv o -- rv o rv o - r "v o _ cO LO to co oo O LO rv co o — - co t -o - m - o oo co o 0 0 — •— ι<3 " - -- _- -- — - •— 55 CN CN CN CN CO 00 00 00 0 00 co rv rv o CN. C-N- C-N- C-M- CO lO- LO SlO SiO --
r- O
„ CN C ( ( C cO cO cθ cθ cO cθ cθ cθ cθ cθ cθ cθ c cθ c rr rr rr rr rr rr rr rr rr r^ CN CN CN CN CN CN CN C (N CN CN CN CN CN CN CN CN CN CN C\I C C (>J CN CN CN CN CN CN C^ o G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
TABLE 4
SEQ ID NO: Template ID Start Stop Frame Domain Topology
125 LG:236056.27:2001MAR30 720 742 forward 3 TM Transmembrane
125 LG:236056.27:2001MAR30 743 746 forward 3 TM Non-Cytosolic
125 LG:236056.27:2001MAR30 747 769 forward 3 TM Transmembrane
125 LG:236056.27:2001MAR30 770 859 forward 3 TM Cytosolic
126 LG:253889.31:2001MAR30 1 621 forward 1 TM Non-Cytosolic 126 LG:253889.31:2001MAR30 622 644 forward 1 TM Transmejnbrane 126 LG:253889.31:2001MAR30 645 871 forward 1 TM Cytosolic 126 LG:253889.31:2001MAR30 872 894 forward 1 TM Transmembrane 126 LG:253889.31:2001MAR30 895 903 forward 1 TM Non-Cytosolic 126 LG:253889.31 :2001 MAR30 904 926 forward 1 TM Transmembrane 126 LG:253889.31:2001MAR30 927 946 forward 1 TM Cytosolic 126 LG:253889.31:2001MAR30 947 969 forward 1 TM Transmembrane 126 LG:253889.31:2001MAR30 970 1284 forward 1 TM Non-Cytosolic 126 LG:253889.31:2001MAR30 1 574 forward 2 TM Non-Cytosolic 126 LG:253889.31:2001MAR30 575 597 forward 2 TM Transmembrane 126 LG:253889.31:2001MAR30 598 865 forward 2 TM Cytosolic 126 LG:253889.31 :2001 MAR30 866 888 forward 2 TM Transmembrane 126 LG:253889.31:2001MAR30 889 946 forward 2 TM Non-Cytosolic 126 LG:253889.31:2001MAR30 947 969 forward 2 TM Transmembrane 126 LG:253889.31:2001MAR30 970 1074 forward 2 TM Cytosolic 126 LG:253889.31:2001MAR30 1075 1097 forward 2 TM Transmembrane 126 LG:253889.31:2001MAR30 1098 1139 forward 2 TM Non-Cytosolic 126 LG:253889.31:2001MAR30 1140 1162 forward 2 TM Transmembrane 126 LG:253889.31:2001MAR30 1163 1221 forward 2 TM Cytosolic 126 LG:253889.31:2001MAR30 1222 1244 forward 2 TM Transmembrane 126 LG:253889.31:2001MAR30 1245 1284 forward 2 TM Non-Cytosolic 126 LG:253889.31:2001MAR30 1 357- forward 3 TM Non-Cytosolic 126 LG:253889.31:2001MAR30 358 380 forward 3 TM Transmembrane 126 LG:253889.31:2001MAR30 381 401 forward 3 TM Cytosolic 126 LG:253889.31:2001MAR30 402 424 forward 3 TM Transmembrane 126 LG:253889.31:2001MAR30 425 574 forward 3 TM Non-Cytosolic 126 LG:253889.31:2001MAR30 575 597 forward 3 TM Transmembrane 126 LG:253889.31:2001MAR30 598 617 forward 3 TM Cytosolic 126 LG:253889.31:2001MAR30 618 640 forward 3 TM Transmembrane 126 LG:253889.31:2001MAR30 641 867 forward 3 TM Non-Cytosolic 126 LG:253889.31:2001MAR30 868 890 forward 3 TM Transmembrane 126 LG:253889.31:2001MAR30 891 1089 forward 3 TM Cytosolic 126 LG:253889.31:2001MAR30 1090 1112 forward 3 TM Transmembrane 126 LG:253889.31:2001MAR30 1113 1126 forward 3 TM Non-Cytosolic 126 LG:253889.31:2001MAR30 1127 1149 forward 3 TM Transmembrane 126 LG:253889.31 :2001 MAR30 1150 1150 forward 3 TM Cytosolic 126 LG:253889.31:2001MAR30 1151 1173 forward 3 TM Transmembrane
126 LG:253889.31:2001MAR30 1174 1284 forward 3 TM Non-Cytosolic
127 LG:270833.135:2001 MAR30 1 341 forward 1 TM Non-Cytosolic 127 LG:270833.135:2001 MAR30 342 364 forward 1 TM Transmembrane
127 LG:270833.135:2001 MAR30 365 444 forward 1 TM Cytosolic
128 LG:292613.7:2001 MAR30 1 4 forward 1 TM Non-Cytosolic 128 LG:292613.7:2001 MAR30 5 27 forward 1 TM Transmembrane 128 LG:292613.7:2001 MAR30 28 78 forward 1 TM Cytosolic 128 LG:292613.7:2001 MAR30 79 101 forward 1 TM Transmembrane TABLE 4 i lD NO: Template ID Start Stop Frame Domain Topology
128 LG:292613.7:2001 MAR30 102 1272 forward 1 TM Non-Cytosolic
128 LG:292613.7:2001 MAR30 1273 1295 forward 1 TM Transmembrane
128 LG:292613.7:2001 MAR30 1296 1391 forward 1 TM Cytosolic
128 LG:292613.7:2001 MAR30 1392 1414 forward 1 TM Transmembrane
128 LG:292613.7:2001 MAR30 1415 1423 forward 1 TM Non-Cytosolic
128 LG:292613.7:2001 MAR30 1424 1446 forward 1 TM Transmembrane
128 LG:292613.7:2001 MAR30 1447 1514 forward 1 TM Cytosolic
128 LG:292613.7:2001 MAR30 1515 1534 forward 1 TM Transmembrane
128 LG:292613.7:2001 MAR30 1535 1710 forward 1 TM Non-Cytosolic
128 LG:292613.7:2001 MAR30 1 12 forward 2 TM Cytosolic
128 LG:292613.7:2001 MAR30 13 35 forward 2 TM Transmembrane
128 LG:292613.7:2001 MAR30 36 77 forward 2 TM Non-Cytosolic
128 LG:292613.7:2001 MAR30 78 100 forward 2 TM Transmembrane
128 LG:292613.7:2001 MAR30 101 1 12 forward 2 TM Cytosolic
128 LG:292613.7:2001 MAR30 1 13 135 forward 2 TM Transmembrane
128 LG:292613.7:2001 MAR30 136 1586 forward 2 TM Non-Cytosolic
128 LG:292613.7:2001 MAR30 1587 1609 forward 2 TM Transmembrane
128 LG:292613.7:2001 MAR30 1610 1628 forward 2 TM Cytosolic
128 LG:292613.7:2001 MAR30 1629 1651 forward 2 TM Transmembrane
128 LG:292613.7:2001 MAR30 1652 1710 forward 2 TM Non-Cytosolic
128 LG:292613.7:2001 MAR30 1 1 forward 3 TM Cytosolic
128 LG:292613.7:2001 MAR30 2 24 forward 3 TM Transmembrane
128 LG:292613.7:2001 MAR30 25 27 forward 3 TM Non-Cytosolic
128 LG:292613.7:2001 MAR30 28 49 forward 3 TM Transmembrane
128 LG:292613.7:2001 MAR30 50 55 forward 3 TM Cytosolic
128 LG:292613.7:2001 MAR30 56 73 forward 3 TM Transmembrane
128 LG:292613.7:2001 MAR30 74 82 forward 3 TM Non-Cytosolic
128 LG:292613.7:2001 MAR30 83 105 forward 3 TM Transmembrane
128 LG:292613.7:2001 MAR30 106 125 forward 3 TM Cytosolic
128 LG:292613.7:2001 MAR30 126 148 forward 3 TM Transmembrane
128 LG:292613.7:2001 MAR30 149 1 124 forward 3 TM Non-Cytosolic
128 LG:292613.7:2001 MAR30 1 125 1 147 forward 3 TM Transmembrane
128 LG:292613.7:2001 MAR30 1 148 1 167 forward 3 TM Cytosolic
128 LG:292613.7:2001 MAR30 1 168 1 190 forward 3 TM Transmembrane
128 LG:292613.7:2001 MAR30 1 191 1235 forward 3 TM Non-Cytosolic
128 LG:292613.7:2001 MAR30 1236 1258 forward 3 TM Transmembrane
128 LG:292613.7:2001 MAR30 1259 1400 forward 3 TM Cytosolic
128 LG:292613.7:2001 MAR30 1401 1423 forward 3 TM Transmembrane
128 LG:292613.7:2001 MAR30 1424 1467 forward 3 TM Non-Cytosolic
128 LG:292613.7:2001 MAR30 1468 1490 forward 3 TM Transmembrane
128 LG:292613.7:2001 MAR30 1491 1629 forward 3 TM Cytosolic
128 LG:292613.7:2001 MAR30 1630 1652 forward 3 TM Transmembrane
128 LG:292613.7:2001 MAR30 1653 1671 forward 3 TM Non-Cytosolic
128 LG:292613.7:2001 MAR30 1672 1694 forward 3 TM Transmembrane
128 LG:292613.7:2001 MAR30 1695 1709 forward 3 TM Cytosolic
129 LG:331546.2:2001 MAR30 1 1061 forward 1 TM Non-Cytosolic
129 LG:331546.2:2001 MAR30 1062 1079 forward 1 TM Transmembrane
129 LG:331546.2:2001 MAR30 1080 1 150 forward 1 TM Cytosolic
130 LG:332027.6:2001 MAR30 1 12 forward 1 TM Cytosolic
130 LG:332027.6:2001 MAR30 13 35 forward 1 TM Transmembrane TABLE 4
SEQ ID NO: Template ID Start Stop Frame Domain Topology
130 LG:332027.6:2001 MAR30 36 1 12 forward 1 TM Non-Cytosolic
130 LG:332027.6:2001 MAR30 1 13 135 forward 1 TM Transmembrane
130 LG:332027.6:2001 MAR30 136 147 forward 1 TM Cytosolic
130 LG:332027.6:2001 MAR30 148 170 forward 1 TM Transmembrane
130 LG:332027.6:2001 MAR30 171 700 forward 1 TM Non-Cytosolic
130 LG:332027.6:2001 MAR30 701 723 forward 1 TM Transmembrane
130 LG:332027.6:2001 MAR30 724 743 forward 1 TM Cytosolic
130 LG:332027.6:2001 MAR30 744 766 forward 1 TM Transmembrane
130 LG:332027.6:2001 MAR30 767 785 forward 1 TM Non-Cytosolic
130 LG:332027.6:2001 MAR30 786 808 forward 1 TM Transmembrane
130 LG:332027.6:2001 MAR30 809 995 forward 1 TM Cytosolic
130 LG:332027.6:2001 MAR30 996 1018 forward 1 TM Transmembrane
130 LG:332027.6:2001 MAR30 1019 1098 forward 1 TM Non-Cytosolic
130 LG:332027.6:2001 MAR30 1099 1 1 18 forward 1 TM Transmembrane
130 LG:332027.6:2001 MAR30 1 1 19 1 152 forward 1 TM Cytosolic
130 LG:332027.6:2001 MAR30 1 22 forward 2 TM Non-Cytosolic
130 LG:332027.6:2001 MAR30 23 45 forward 2 TM Transmembrane
130 LG:332027.6:2001 MAR30 46 81 forward 2 TM Cytosolic
130 LG:332027.6:2001 MAR30 82 104 forward 2 TM Transmembrane
130 LG:332027.6:2001 MAR30 105 1 13 forward 2 TM Non-Cytosolic
130 LG:332027.6:2001 MAR30 1 14 136 forward 2 TM Transmembrane
130 LG:332027.6:2001 MAR30 137 147 forward 2 TM Cytosolic
130 LG:332027.6:2001 MAR30 148 170 forward 2 TM Transmembrane
130 LG:332027.6:2001 MAR30 171 579 forward 2 TM Non-Cytosolic
130 LG:332027.6:2001 MAR30 580 602 forward 2 TM Transmembrane
130 LG:332027.6:2001 MAR30 603 683 forward 2 TM Cytosolic
130 LG:332027.6:2001 MAR30 684 706 forward 2 TM Transmembrane
130 LG:332027.6:2001 MAR30 707 754 forward 2 TM Non-Cytosolic
130 LG:332027.6:2001 MAR30 755 774 forward 2 TM Transmembrane
130 LG:332027.6:2001 MAR30 775 989 forward 2 TM Cytosolic
130 LG:332027.6:2001 MAR30 990 1012 forward 2 TM Transmembrane
130 LG:332027.6:2001 MAR30 1013 1048 forward 2 TM Non-Cytosolic
130 LG:332027.6:2001 MAR30 1049 1071 forward 2 TM Transmembrane
130 LG:332027.6:2001 MAR30 1072 1091 forward 2 TM Cytosolic
130 LG:332027.6:2001 MAR30 1092 1 1 14 forward 2 TM Transmembrane
130 LG:332027.6:2001 MAR30 1 1 15 1 151 forward 2 TM Non-Cytosolic
130 LG:332027.6:2001 MAR30 1 49 forward 3 TM Cytosolic
130 LG:332027.6:2001 MAR30 50 72 forward 3 TM Transmembrane
130 LG:332027.6:2001 MAR30 73 880 forward 3 TM Non-Cytosolic
130 LG:332027.6:2001 MAR30 881 903 forward 3 TM Transmembrane
130 LG:332027.6:2001 MAR30 904 930 forward 3 TM Cytosolic
130 LG:332027.6:2001 MAR30 931 953 forward 3 TM Transmembrane
130 LG:332027.6:2001 MAR30 954 1002 forward 3 TM Non-Cytosolic
130 LG:332027.6:2001 MAR30 1003 1025 forward 3 TM Transmembrane
130 LG:332027.6:2001 MAR30 1026 1078 forward 3 TM Cytosolic
130 LG:332027.6:2001 MAR30 1079 1 101 forward 3 TM Transmembrane
130 LG:332027.6:2001 MAR30 1 102 1 151 forward 3 TM Non-Cytosolic
131 LG:336998.1 :2001 MAR30 1 714 forward 1 TM Non-Cytosolic
131 LG:336998.1 :2001 MAR30 715 737 forward 1 TM Transmembrane
131 LG:336998.1 :2001 MAR30 738 831 forward 1 TM Cytosolic TABLE 4
SEQ ID NO Template ID Start Stop Frame Domain Topology
131 LG:336998.1:2001MAR30 832 851 forward 1 TM Transmembrane
131 LG:336998.1:2001MAR30 852 865 forward 1 TM Non-Cytosolic
131 LG:336998.1:2001MAR30 866 885 forward 1 TM Transmembrane
131 LG:336998.1:2001MAR30 886 1099 forward 1 TM Cytosolic
131 LG:336998.1:2001MAR30 1100 1122 forward 1 TM Transmembrane
131 LG:336998.1:2001MAR30 1123 1363 forward 1 TM Non-Cytosolic
131 LG:336998.1:2001MAR30 1364 1386 forward 1 TM Transmembrane
131 LG:336998.1:2001MAR30 1387 1542 forward 1 TM Cytosolic
131 LG:336998.1:2001MAR30 1543 1565 forward 1 TM Transmembrane
131 LG:336998.1:2001MAR30 1566 1579 forward 1 TM Non-Cytosolic
131 LG:336998.1:2001MAR30 1580 1602 forward 1 TM Transmembrane
131 LG:336998.1:2001MAR30 1603 1804 forward 1 TM Cytosolic
131 LG:336998.1:2001MAR30 1805 1827 forward 1 TM Transmembrane
131 LG:336998.1:2001MAR30 18285189 forward 1 TM Non-Cytosolic
131 LG:336998.1:2001MAR30 51905212 forward 1 TM Transmembrane
131 LG:336998.1:2001MAR30 52135250 forward 1 TM Cytosolic
131 LG:336998.1:2001MAR30 5251 5273 forward 1 TM Transmembrane
131 LG:336998.1:2001MAR30 52745282 forward 1 TM Non-Cytosolic
131 LG:336998.1:2001MAR30 52835305 forward 1 TM Transmembrane
131 LG:336998.1:2001MAR30 53065311 forward 1 TM Cytosolic
131 LG:336998.1:2001MAR30 53125334 forward 1 TM Transmembrane
131 LG:336998.1:2001MAR30 53355348 forward 1 TM Non-Cytosolic
131 LG:336998.1:2001MAR30 53495371 forward 1 TM Transmembrane
131 LG:336998.1:2001MAR30 53725444 forward 1 TM Cytosolic
131 LG:336998.1:2001MAR30 54455467 forward 1 TM Transmembrane
131 LG:336998.1:2001MAR30 54685700 forward 1 TM Non-Cytosolic
131 LG:336998.1:2001MAR30 1 12 forward 2 TM Cytosolic
131 LG:336998.1:2001MAR30 13 35 forward 2 TM Transmembrane
131 LG:336998.1:2001MAR30 36 5699 forward 2 TM Non-Cytosolic
131 LG:336998.1:2001MAR30 1 4342 forward 3 TM Non-Cytosolic
131 LG:336998.1:2001MAR30 43434365 forward 3 TM Transmembrane
131 LG:336998.1:2001MAR30 43664389 forward 3 TM Cytosolic
131 LG:336998.1:2001MAR30 43904412 forward 3 TM Transmembrane
131 LG:336998.1:2001MAR30 44134436 forward 3 TM Non-Cytosolic
131 LG:336998.1:2001MAR30 44374459 forward 3 TM Transmembrane
131 LG:336998.1:2001MAR30 44604724 forward 3 TM Cytosolic
131 LG:336998.1:2001MAR30 47254747 forward 3 TM Transmembrane
131 LG:336998.1:2001MAR30 47485260 forward 3 TM Non-Cytosolic
131 LG:336998.1:2001MAR30 5261 5283 forward 3 TM Transmembrane
131 LG:336998.1:2001MAR30 52845310 forward 3 TM Cytosolic
131 LG:336998.1:2001MAR30 5311 5333 forward 3 TM Transmembrane
131 LG:336998.1:2001MAR30 53345352 forward 3 TM Non-Cytosolic
131 LG:336998.1:2001MAR30 53535370 forward 3 TM Transmembrane
131 LG:336998.1:2001MAR30 5371 5432 forward 3 TM Cytosolic
131 LG:336998.1:2001MAR30 54335455 forward 3 TM Transmembrane
131 LG:336998.1:2001MAR30 54565499 forward 3 TM Non-Cytosolic
131 LG:336998.1:2001MAR30 55005522 forward 3 TM Transmembrane
131 LG:336998.1:2001MAR30 55235699 forward 3 TM Cytosolic
132 LG:338010.8:2001 MAR30 1 102 forward 2 TM Cytosolic
132 LG:338010.8:2001 MAR30 103 125 forward 2 TM Transmembrane
CM CM CN CN CM CM CM CO CO CO CO CO CO CO -- -- ■— ■— -- -- -- (N C C CN CM CM CN CN CN CN CN CN CN CM CM CN CM CN CO CO CO CO CO i— ■— ■— -- -- --
P P P PPP PP PPP PP P P P P P P P P PP P P P PP P P P P P P P P PPP P P PPP P P P P Ό Ό O DO o σ o D o b b b b b b b b b b b b b b b b σ b b b b b bb b bb b b b bb b b b b bbb b b
.P .P o P P P p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p o o o o o o o o
Q. O CN O cO 3 00 cO -O CN LO rv O OO O CN O CO O O OO CO O OO -- 00 0 0 rr rv o cN oo oo co -- ■— rr rr rv o o rr rr oo -- iv. O o rv O cO O cO iO rv O O O CN O CN cO O O O co CN rr ■— rv -o co o cN rv io rv. rr o co o 3 oo co o cθ Lθ rv — rr rr o rv CN io rv O O CN M CM CN CN CO rv rv O O O rv c0 3 O 3 rv 00 — - — - cθ cθ cθ cθ cθ cθ rr rr ιθ Lθ O LO ιO ιθ Lθ O O — CN CM CN oo ■— CN CN CN CN CO -- -— C ■— ■— CM CM CM CN CN CN CM CM CN CN CN CN CM CM
CQ rv o — rr rv O rr rv o CN (v- O LO CO O c O O CN CN tO CO <— rv. LO CM 00 ■— O < rr rv co o co — - o co
P C co o r o ■— O CN O CN CO O -- — CO C o CN _ O 00 oo rr o rr o o co co o co io -- rr rr o cM io rv o -- ή — — — ON CN CN CN — -— CM CM CN CM rv rv oMorro C LO rv - -O 3 rv ~ -- -- co co co co co co rr rr io iO LO LO LO LO O O — - CN CN
■— ■— -— ■— -— CN CM CM CN CM CN CN CM CM CN CN CN ■— ■— ■— i— ■—
c^
0-_ 0_J 0--J 0_l0_J0_l0_l0_l 0_l 0_l 0_J 0_J0_J
LO LO LO LO LO LO CO CO CO CO CO CO
"o
E 55555555 5555555555 55555555555555 o
Q
φ ε P σ o o
Q. 0 u0u • —— - ι CτO. o rv o st l
UJ CO j .<9 *P RSS O O_ c f O ^ ^ ∞ ∞ OJ ^ O N c δ v CN LO rv. O CO O CN LO S S LO S S ^ CO S
CN - rv oCN rv CO. ^ 5 3 S θ O LO cO ^
CO ■— oo o o O> o α o o α '- - CN oo co co o o o <-, t-, t-' <-, c-, Z C o o - <3 -o o o <3 O O O O CD — -
O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv
<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<
Qφδl lδlδlδlδδllδδlδl lδlδδlδl llll l l l lδlδl l OδOδl l l l l l l ll l l l l ll l l l ll l lllll
-t O O O O O O O O O O O O OδOδOδOδOδOδOδOδO O OδOδOδOδOδOδOoOδOδOδOδOδOδOδOδOδOδOδOδOδOδOδOδOδOδO O CN CN ( CN CN ( CN CN CN CN CN CN C CN CN CN CN CN CN CN CN CN CN CN ( CN CN CN CN CN CN (
Q. rv rv.* rv: rv: rv; rv: rv,' v" rv r rv." rv; v! rv; rv; rv; rv; rv; rv; r; rv rv". r^
C — - —- —- —- —- —- —- —- —- —- —- —- —- —- —- —- —- —- —- —- —- —- —- —- -- —- —- —- —- —- —- —- —- —- —- —- —- —- —- —- — - co co co co co co co co co m co co co co co co co c c co co co co co co co' co co co c^
1_. O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O LO LO LO LO LO LO LO LO IO CN CN CN CN C CN C ( (N CN CN C C CN CN CN C CN ( ( C ( C < CN C CN C^
O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O ' — ■ — ■ — ■ — i — — - ■ — — rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr -- -- -- -- -- -- -- -- -- -^ co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co rr rr rr rr rr rr rr rr rr rr r^
000000^0^0^00000000 r-
© o
© Λ lfl ιO U) LO U) IO U) IO W lO -) W W lO U) -) U) LD lO t U) U0 ιn ιfl ιO ιn ιO ιfi ιn -) tO 'O <) ) ) 'O 'O 'O 'O -O 'O N N N N ϋ α o_- r-- o-- n-- o--n-- o--o-- n--n-- rt-- o-- o-- n-- n-- o-- n-- n-- n-- n-- n- t^ n-- o-- o-- n^ n-- n- n-- o-- --n-- --o-- p-o- n-- n--n-- c-- n-- o-- o-- rt-- t-- n-- c-o- n-- f-- o-- n--
UJ co
CO rπ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ ©
00000000000000000000000000000000000000000000000000 l_ !_i '4_l '4-» '4_ 4_ ϊ_ j_ '4_ 4_ 4->. - - "4- 4_ 4- 4^
00 Go 00 oo Oo 00 Oo G3 oo Oo 00 00 Go OO Go GO OO OO GO 00 GO GO GO G G Go Go G Go Go G Go GO GO GO CO GO GO GO GO CO CO Go Go Go Go C
Go 00 o Oo oo 00 00 Co 00 Oo 00 Go co Go G Oo 00 G G GO GJ G Go G Go Go Go Go G G Go Go GO Go Go Go C G G G 00 Go Go G CO G Ol Ol Ol φ1
J-. 4-» 4- J- J- 4- 4-» J-. _ 4-» 4-» 4_- J_ 4_ - 4- 4- 4- 4- 4- 4- J- 4- 4- 4- 4- 4- 4- 4- 4- 4- 4- 4- 4- 4- 4_- 4-» 4-. .E- 4_- 4_- 4- 4- 4- 4- 4- j -_ _ _ _ o OO CD 00 bo bo 00 00 00 bo bo > 00 00 bo bo bo 00 00 00 00 bo bo 00 00 bo bo 00 00 00 00 00 00 00 00 bo bo bo bo bo bo 00 00 00 00 00 00 GO CO 003 ro rό ro Kb to to ro ro ro ro ro ro ro ro ό rό r ro ro ro ro ro ro ro ro rό rό ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro en en en Ό o o o o CD CD o o o o o o o o O O O o o o o o o o o o o o o o O o o o o o o o o o o o o o o o o ro ro o o o o CD CD o o o o o O ~ O O o o o _ o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o φ
_ _ <
> > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > >
TO TO TO TO TO TO TO 70 70 70 70 70 70 70 70 70 TO 70 O TO TO TO TO 70 70 TO TO TO TO TO TO TO TO TO 70 TO O TO TO TO TO TO TO
Go Co CO CO Go Go Go Go CO Go Go G Go Go G GO Go Go Go Go GO Go CO G CO GJ G CO CO Go CO CO Go Go Go Go GO Go GO GO GO GO GO GO GO > > >
TO O TO
O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O o O O O O O O O O O O O O O O O O Go CO C O O O
_ _ _ _ _ _ _ _ _ _ _ _ r N3 - - -ι - - - - - - - - - - - - - — ' — CO
O O GO 00
O O O en en 4- 4- G . O O O CJi CJi C_ N3 N3 rO rO _. O O vj o O CJ3 C-n 4_ .l-- .^ W W G- Go GO G3 C_3 _l _ 4-» _ ^
00 4- ro o 4- ro r vj
CD t C 3 O 4- o co ro o o o ro 3 vj cn _ ro M ϋi o co o t- t- M oo o - ■ o o o en co ro o vj
4- CD O 00 Ol O CO CO o vj 4- ro ro o vj j_ o vj _ oo en o G o co — - 00000 — ■ Go oo en o o o vj co o 4- — ■ 4- -- ~t C
_ _ _ _ _ _ _ _ _ _ co
CO G0 G0 G0 Go CO G0 4- 4_ 4- S"
•O OO O Cn M M O M M ϋl O en o o ro -O Go o vj co o P
0 O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
^ <! ^ 4 ? ^ ^ ^ ? ξ - ^ ^ fj ξ - ^ ? ^ ^ ξ - ^ ^ ^ ^ ξ - ^ 4 g ξ - i ξ - § ^ ^ ^ ■g * g $
Q Q Q Q Q Q Q Q Q Q Q Q Ω Q Q Q Q Ω Ω Ω Ω Ω Ω Ω Q Q Ω £ Q Ω Q Q Ω Ω 4 g £ g ^
Q Q Q Q Q Q Q Q Ω Ω Ω Ω Ω Ω Ω Ω Ω 4 α αα α α ααα α α αααααααα α _ _ _ _ α _ _ _ _ _ _ α _ Q. _ _ _ _ _ ω ω u - ω ω - ω ω c- ω ω u - ω M i M N) N3 N) i ι ι κ) i 3 w _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ ro ro ro
TABLE 4
SEQ ID NO Template ID Start Stop Frame Domain Topology
138 LG:41 1334.8 2001 MAR30 1718 1737 forward 3 TM Transmembrane
138 LG:41 1334.8 2001 MAR30 1738 2188 forward 3 TM Non-Cytosolic
139 LG:458583.1 2001 MAR30 1 108 forward 2 TM Cytosolic
139 LG:458583.1 2001 MAR30 109 131 forward 2 TM Transmembrane
139 LG:458583.1 2001 MAR30 132 238 forward 2 TM Non-Cytosolic
140 LG:475378.1 2001 MAR30 • 1 1018 forward 2 TM Non-Cytosolic
140 LG:475378.1 2001 MAR30 1019 1041 forward 2 TM Transmembrane
140 LG:475378.1 2001 MAR30 1042 1230 forward 2 TM Cytosolic
140 LG:475378.1 2001 MAR30 1231 1253 forward 2 TM Transmembrane
140 LG:475378.1 2001 MAR30 1254 1267 forward 2 TM Non-Cytosolic
140 LG:475378.1 2001 MAR30 1268 1290 forward 2 TM Transmembrane
140 LG:475378.1 2001 MAR30 1291 1310 forward 2 TM Cytosolic
140 LG:475378.1 2001 MAR30 131 1 1333 forward 2 TM Transmembrane
140 LG:475378.1 2001 MAR30 1334 1378 forward 2 TM Non-Cytosolic
140 LG:475378.1 2001 MAR30 1379 1401 forward 2 TM Transmembrane
140 LG:475378.1 2001 MAR30 1402 1413 forward 2 TM Cytosolic
140 LG:475378.1 2001 MAR30 1414 1436 forward 2 TM Transmembrane
140 LG:475378.1 2001 MAR30 1437 1449 forward 2 TM Non-Cytosolic
141 LG:481572.1 2001 MAR30 1 1 131 forward 1 TM Non-Cytosolic
141 LG:481572.1 2001 MAR30 1 132 1 154 forward 1 TM Transmembrane
141 LG:481572.1 2001 MAR30 1 155 1 185 forward 1 TM Cytosolic
141 LG:481572.1 2001 MAR30 1 186 1208 forward 1 TM Transmembrane
141 LG:481572.1 2001 AR30 1209 1212 forward 1 TM Non-Cytosolic
141 LG:481572.1 2001 MAR30 1213 1235 forward 1 TM Transmembrane
141 LG:481572.1 2001 MAR30 1236 1241 forward 1 TM Cytosolic
141 LG:481572.1 2001 MAR30 1242 1264 forward 1 TM Transmembrane
141 LG:481572.1 2001 MAR30 1265 1725 forward 1 TM Non-Cytosolic
141 LG:481572.1 2001 MAR30 1 1 185 forward 2 TM Non-Cytosolic
141 LG:481572.1 2001 MAR30 1 186 1208 forward 2 TM Transmembrane
141 LG:481572.1 2001 MAR30 1209 1212 forward 2 TM Cytosolic
141 LG:481572.1 2001 MAR30 1213 1232 forward 2 TM Transmembrane
141 LG:481572.1 2001 MAR30 1233 1725 forward 2 TM Non-Cytosolic
142 LG:481704.1 2001 MAR30 1 342 forward 1 TM Non-Cytosolic
142 LG:481704.1 2001 MAR30 343 365 forward 1 TM Transmembrane
142 LG:481704.1 2001 MAR30 366 41 1 forward 1 TM Cytosolic
142 LG:481704.1 2001 MAR30 412 434 forward 1 TM Transmembrane
142 LG:481704.1 2001 MAR30 435 448 forward 1 TM Non-Cytosolic
142 LG:481704.1 2001 MAR30 449 471 forward 1 TM Transmembrane
142 LG:481704.1 2001 MAR30 472 526 forward 1 TM Cytosolic
142 LG:481704.1 2001 MAR30 1 433 forward 2 TM Non-Cytosolic
142 LG:481704.1 2001 MAR30 434 456 forward 2 TM Transmembrane
142 LG:481704.1 2001 MAR30 457 462 forward 2 TM Cytosolic
142 LG:481704.1 2001 MAR30 463 485 forward 2 TM Transmembrane
142 LG:481704.1 2001 MAR30 486 525 forward 2 TM Non-Cytosolic
142 LG:481704.1 2001 MAR30 1 457 forward 3 TM Non-Cytosolic
142 LG:481704.1 2001 MAR30 458 480 forward 3 TM Transmembrane
142 LG:481704.1 2001 MAR30 481 500 forward 3 TM Cytosolic
142 LG:481704.1 2001 MAR30 501 523 forward 3 TM Transmembrane
142 LG:481704.1 2001 MAR30 524 525 forward 3 TM Non-Cytosolic
143 LG:898195.4 2001 MAR30 1 739 forward 1 TM Non-Cytosolic TABLE 4
SEQ ID NO: Template ID Start Stop Frame Domain Topology
143 LG:898195.4:2001 MAR30 740 759 forward 1 TM Transmembrane
143 LG:898195.4:2001 MAR30 760 876 forward 1 TM Cytosolic
143 LG:898195.4:2001 MAR30 877 899 forward 1 TM Transmembrane
143 LG:898195.4:2001 MAR30 900 1 162 forward 1 TM Non-Cytosolic
143 LG:898195.4:2001 MAR30 1 163 1 185 forward 1 TM Transmembrane
143 LG:898195.4:2001 MAR30 1 186 1205 forward 1 TM Cytosolic
143 LG:898195.4:2001 MAR30 1 738 forward 2 TM Non-Cytosolic
143 LG:898195.4:2001 MAR30 739 761 forward 2 TM Transmembrane
143 LG:898195.4:2001 MAR30 762 878 forward 2 TM Cytosolic
143 LG:898195.4:2001 MAR30 879 901 forward 2 TM Transmembrane
143 l_G:898195.4:2001 MAR30 902 1020 forward 2 TM Non-Cytosolic
143 LG:898195.4:2001 MAR30 1021 1043 forward 2 TM Transmembrane
143 LG:898195.4:2001 MAR30 1044 1 130 forward 2 TM Cytosolic
143 LG:898195.4:2001 MAR30 1 131 1 153 forward 2 TM Transmembrane
143 LG:898195.4:2001 MAR30 1 154 1 162 forward 2 TM Non-Cytosolic
143 LG:898195.4:2001 MAR30 1 163 1 185 forward 2 TM Transmembrane
143 LG:898195.4:2001 MAR30 1 186 1204 forward 2 TM Cytosolic
143 LG:898195.4:2001 MAR30 1 516 forward 3 TM Non-Cytosolic
143 LG:898195.4:2001 MAR30 517 539 forward 3 TM Transmembrane
143 LG:898195.4:2001 MAR30 540 637 forward 3 TM Cytosolic
143 LG:898195.4:2001 MAR30 638 660 forward 3 TM Transmembrane
143 LG:898195.4:2001 MAR30 661 738 forward 3 TM Non-Cytosolic
143 LG:898195.4:2001 MAR30 739 761 forward 3 TM Transmembrane
143 LG:898195.4:2001 MAR30 762 780. forward 3 TM Cytosolic
143 LG:898195.4:2001 MAR30 781 803 forward 3 TM Transmembrane
143 LG:898195.4:2001 MAR30 804 874 forward 3 TM Non-Cytosolic
143 LG:898195.4:2001 MAR30 875 897 .forward 3 TM Transmembrane
143 LG:898195.4:2001 MAR30 898 1016 forward 3 TM Cytosolic
143 LG:898195.4:2001 MAR30 1017 1039 forward 3 TM Transmembrane
143 LG:898195.4:2001 MAR30 1040 1058 forward 3 TM Non-Cytosolic
143 l_G:898195.4:2001 MAR30 1059 1081 forward 3 TM Transmembrane
143 LG:898195.4:2001 MAR30 1082 1089 forward 3 TM Cytosolic
143 LG:898195.4:2001 MAR30 1090 1 1 12 forward 3 TM Transmembrane
143 LG.898195.4:2001 MAR30 1 1 13 1 131 forward 3 TM Non-Cytosolic
143 LG:898195.4:2001 MAR30 1 132 1 154 forward 3 TM Transmembrane
143 LG:898195.4:2001 MAR30 1 155 1 160 forward 3 TM Cytosolic
143 LG:898195.4:2001 MAR30 1 161 1 183 forward 3 TM Transmembrane
143 LG:898195.4:2001 MAR30 1 184 1204 forward 3 TM Non-Cytosolic
144 LG:903785.1 :2001 MAR30 1 1456 forward 2 TM Non-Cytosolic
144 LG:903785.1 :2001 MAR30 1457 1479 forward 2 TM Transmembrane
144 LG:903785.1 :2001 MAR30 1480 1483 forward 2 TM Cytosolic
144 LG:903785.1 :2001 MAR30 1484 1501 forward 2 TM Transmembrane
144 LG:903785.1 :2001 MAR30 1502 1541 forward 2 TM Non-Cytosolic
144 LG:903785.1 :2001 MAR30 1542 1564 forward 2 TM Transmembrane
144 LG:903785.1 :2001 MAR30 1565 1570 forward 2 TM Cytosolic
144 LG:903785.1 :2001 MAR30 1571 1593 forward 2 TM Transmembrane
144 LG:903785.1 :2001 MAR30 1594 1602 forward 2 TM Non-Cytosolic
144 LG:903785.1 :2001 AR30 1603 1620 forward 2 TM Transmembrane
144 LG:903785.1 :2001 MAR30 1621 1676 forward 2 TM Cytosolic
145 LG:977454.3:2001 MAR30 1 344 forward 1 TM Non-Cytosolic c "σ
55555 5555555555555 5555555555555555 o
-- -- -- -- CM CM CN CM CN CN CM CN CM — — — — — — — CN CN CM CM CN CN CN CO CO CO CO CO CO CO CO CO CO
Φ P P Ό Ό Ό P Ό Ό Ό Ό Ό Ό Ό Ό Ό Ό P σ o o o o π o π o π O o π π π π o π π o o π π π π π π π π o π O π o π π π π π o π π o π o π π π π π π f5 ^ 5 ? ^ ^ r* r* ^ ^ f5 fϊ ^ ^ ^ ^ ^ ^ ^ f5 ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ f3 ^
^9 o9 o9 o9 o9 o9 o9 o9 O9 o9 o9 o o o o o O o o o o o o o o o o o o O O o o o o o o o o o o o o o o o o ? o o o ? 99 o rr
LU ^ C0 C0 ° ° CN CN C0 C0 C0 C0 C0 ^ __ _I _I _2 _2 ^ _2 __ _ _= _2 ^ __ _2 [_ _ _l
CO O co ■— rr o o CN LO o o CO 3 LO 00 rv o CO o o CN CO r o
< LO 00 CO CO iv. o L rr -O CO O — ■— rr cO LO O cO O CO U) CO HI 1 ∞ _ rr • CO 4) -<) co _. o CN rv CO c CN o r j-> C rv O O cO O CO CO -- co co co rr CN CM CO CO CO CO CO rr 3 o •o o o 3 o o U3 3 3 o <3 rv LO CO CN rr o _ __ __ cM CN CM CN rr rr
r-
© o
© _. ι0 ι0 L0 -0 L0 L0 ι0 ι0 L0 L0 ι0 ι0 L0 3 3 O <3 O O O O -o o O O O O -O rv rv rv oO OO CO OO OO CO CO OO CO CO CO CO OO Q rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr o
LU co
TABLE 4
SEQ ID NO: Template ID Start Stop Frame Domain Topology
148 LG:981795.1:2001MAR30 1 74 forward 2 TM Cytosolic
148 LG:981795.1:2001MAR30 75 97 forward 2 TM Transmembrane
148 LG:981795.1:2001MAR30 98 106 forward 2 TM Non-Cytosolic
148 LG:981795.1:2001MAR30 107 129 forward 2 TM Transmembrane
148 LG:981795.1:2001MAR30 130 224 forward 2 TM Cytosolic
148 LG:981795.1:2001MAR30 225 247 forward 2 TM Transmembrane
148 LG:981795.1:2001MAR30 248 261 forward 2 TM Non-Cytosolic
148 LG:981795.1:2001MAR30 262 282 forward 2 TM Transmembrane
148 LG:981795.1:2001MAR30 283 372 forward 2 TM Cytosolic
148 LG:981795.1:2001MAR30 373 395 forward 2 TM Transmembrane
148 LG:981795.1:2001MAR30 396 414 forward 2 TM Non-Cytosolic
148 LG:981795.1:2001MAR30 415 437 forward 2 TM Transmembrane
148 LG:981795.1:2001MAR30 438 798 forward 2 TM Cytosolic
148 LG:981795.1:2001MAR30 1 4 forward 3 TM Non-Cytosolic
148 LG:981795.1:2001MAR30 5 22 forward 3 TM Transmembrane
148 LG:981795.1:2001MAR30 23 224 forward 3 TM Cytosolic
148 LG:981795.1:2001MAR30 225 247 forward 3* TM Transmembrane
148 LG:981795.1:2001MAR30 248 261 forward 3 TM Non-Cytosolic
148 LG:981795.1:2001MAR30 262 281 forward 3 TM Transmembrane
148 LG:981795.1:2001MAR30 282 372 forward 3 TM Cytosolic
148 LG:981795.1:2001MAR30 373 395 forward 3 TM Transmembrane
148 LG:981795.1 :2001MAR30 396 456 forward 3 TM Non-Cytosolic
148 LG:981795.1 :2001MAR30 457 479 forward 3 TM Transmembrane
148 LG:981795.1 :2001MAR30 480 536 forward 3 TM Cytosolic
148 LG:981795.1:2001MAR30 537 559 forward 3 TM Transmembrane
148 LG:981795.1:2001MAR30 560 797 forward 3 TM Non-Cytosolic
149 LG:982784.1:2001MAR30 1 315 forward 1 TM Non-Cytosolic
149 LG:982784.1:2001MAR30 316 338 forward 1 TM Transmembrane
149 LG:982784.1:2001MAR30 339 358 forward 1 TM Cytosolic
149 LG:982784.1:2001MAR30 359 381 forward 1 TM Transmembrane
149 LG:982784.1:2001MAR30 382 491 forward 1 TM Non-Cytosolic
149 LG:982784.1:2001MAR30 1 359 forward 2 TM Non-Cytosolic
149 LG:982784.1:2001MAR30 360 382 forward 2 TM Transmembrane
149 LG:982784.1:2001MAR30 383 490 forward 2 TM Cytosolic
149 LG:982784.1:2001MAR30 1 227 forward 3 TM Cytosolic
149 LG:982784.1:2001MAR30 228 246 forward 3 TM Transmembrane
149 LG:982784.1:2001MAR30 247 255 forward 3 TM Non-Cytosolic
149 LG:982784.1:2001MAR30 256 278 forward 3 TM Transmembrane
149 LG:982784.1:2001MAR30 279 490 forward 3 TM Cytosolic
150 LG:987322.4:2001MAR30 1 820 forward 1 TM Non-Cytosolic
150 LG:987322.4:2001MAR30 821 843 forward 1 TM Transmembrane
150 LG:987322.4:2001 MAR30 844 862 forward 1 TM Cytosolic
150 LG:987322.4:2001MAR30 863 885 forward 1 TM Transmembrane
150 LG:987322.4:2001 MAR30 886 1048 forward 1 TM Non-Cytosolic
150 LG:987322.4:2001MAR30 1049 1071 forward 1 TM Transmembrane
150 LG:987322.4:2001MAR30 1072 1223 forward 1 TM Cytosolic
150 LG:987322.4:2001 MAR30 1224 1246 forward 1 TM Transmembrane
150 LG:987322.4:2001 MAR30 1247 1277 forward 1 TM Non-Cytosolic
150 LG:987322.4:2001 MAR30 1278 1300 forward 1 TM Transmembrane
150 LG:987322.4:2001 MAR30 1301 1320 forward 1 TM Cytosolic TABLE 4
SEQ ID NO: Template ID Start Stop Frame Domain Topology
150 LG:987322.4:2001 MAR30 1321 1343 forward 1 TM Transmembrane
150 LG:987322.4:2001 MAR30 1344 1352 forward 1 TM Non-Cytosolic
150 LG:987322.4:2001 MAR30 1353 1372 forward 1 TM Transmembrane
150 LG:987322.4:2001 MAR30 1373 1374 forward 1 TM Cytosolic
150 LG:987322.4:2001 MAR30 1 826 forward 2 TM Non-Cytosolic
150 LG:987322.4:2001 MAR30 827 845 forward 2 TM Transmembrane
150 LG:987322.4:2001 MAR30 846 865 forward 2 TM Cytosolic
150 LG:987322.4:2001 MAR30 866 888 forward 2 TM Transmembrane
150 LG:987322.4:2001 MAR30 889 995 forward 2 TM Non-Cytosolic
150 LG:987322.4:2001 MAR30 996 1018 forward 2 TM Transmembrane
150 LG:987322.4:2001 MAR30 1019 1030 forward 2 TM Cytosolic
150 LG:987322.4:2001 MAR30 1031 1053 forward 2 TM Transmembrane
150 LG:987322.4:2001 MAR30 1054 1083 forward 2 TM Non-Cytosolic
150 LG:987322.4:2001 MAR30 1084 1 103 forward 2 TM Transmembrane
150 LG:987322.4:2001 MAR30 1 104 1313 forward 2 TM Cytosolic
150 LG:987322.4:2001 MAR30 1314 1333 forward 2 TM Transmembrane
150 LG:987322.4:2001 MAR30 1334 1352 forward 2 TM Non-Cytosolic
150 LG:987322.4:2001 MAR30 1353 1372 forward 2 TM Transmembrane
150 LG:987322.4:2001 MAR30 1373 1373 forward 2 TM Cytosolic
150 LG:987322.4:2001 MAR30 1 507 forward 3 TM Non-Cytosolic
150 LG:987322.4:2001 MAR30 508 530 forward 3 TM Transmembrane
150 LG:987322.4:2001 MAR30 531 659 forward 3 TM Cytosolic
150 LG:987322.4:2001 MAR30 660 682 forward 3 TM Transmembrane
150 LG:987322.4:2001 MAR30 683 691 forward 3 TM Non-Cytosolic
150 LG:987322.4:2001 MAR30 692 709 forward 3 TM Transmembrane
- 150 LG:987322.4:2001 MAR30 710 812 forward 3 TM Cytosolic
150 LG:987322.4:2001 MAR30 813 835 forward 3 TM Transmembrane
150 LG:987322.4:2001 MAR30 836 1373 forward 3 TM Non-Cytosolic
151 LG:006242J:2001 MAR30 1 608 forward 2 TM Non-Cytosolic 151 LG:006242J:2001 MAR30 609 631 forward 2 TM Transmembrane 151 LG:006242J:2001 MAR30 632 744 forward 2 TM Cytosolic 151 LG:006242J:2001 MAR30 1 585 forward 3 TM Non-Cytosolic 151 LG:006242J:2001 MAR30 586 608 forward 3 TM Transmembrane 151 LG:006242J:2001 MAR30 609 628 forward 3 TM Cytosolic 151 LG:006242J:2001 MAR30 629 651 forward 3 TM Transmembrane
151 LG:006242J:2001 MAR30 652 744 forward 3 TM Non-Cytosolic
152 LG:027320J:2001 MAR30 1 194 forward 2 TM Cytosolic 152 LG:027320J:2001 MAR30 195 217 forward 2 TM Transmembrane 152 LG:027320J:2001 MAR30 218 236 forward 2 TM Non-Cytosolic 152 LG:027320J:2001 MAR30 237 259 forward 2 TM Transmembrane 152 LG:027320J:2001 MAR30 260 375 forward 2 TM Cytosolic 152 LG:027320J:2001 MAR30 376 398 forward 2 TM Transmembrane 152 LG:027320J:2001 MAR30 399 425 forward 2 TM Non-Cytosolic 152 LG:027320J:2001 MAR30 426 448 forward 2 TM Transmembrane 152 LG:027320J:2001 MAR30 449 460 forward 2 TM Cytosolic 152 LG:027320J:2001 MAR30 461 483 forward 2 TM Transmembrane 152 LG:027320J:2001 MAR30 484 486 forward 2 TM Non-Cytosolic 152 LG:027320J:2001 MAR30 1 194 forward 3 TM Cytosolic 152 LG:027320J:2001 MAR30 195 217 forward 3 TM Transmembrane 152 LG:027320J:2001 MAR30 218 248 forward 3 TM Non-Cytosolic c "o 555555555555555555555555555555 o ε 55555555555
CO CO CO CO CO CO CO CO CO CO — •— -- •— — -- ■— i— ■— — — — ■— CN CN C ( ( CN C CN C CN CN CN CN CN CN CN CN CN CN CN CN CN CN CM CN CO CO gbbbbbbbbbbbbbbbbbbbbbbbbbbbbbσbb bbbbbbbbbbbbbbbbb
"" O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
9-rr o o co — — rr rv o io co o rv o rv o o co o co — rr ∞ rr rv o o cN o cN CN -o — o n N io ^ P 3 S g S 2 δ £ |- [_ _. _f ^ C^ '- ^ ) ffl ω ^ » ^ C^ O O C^ N ^ C ^ <) ^ C^ M co C^ ^ O W ιO ^ B O C^I ^ ) M S δ S " " " 2 ^ ™ ^ ^ f" J CN CN ( cθ cθ cθ cθ cθ rr rr co cθ rr rr rT LO ιO LO O O O O ^ co co cθ rr cθ oO cθ cθ cθ O O O O θ ;_ i__ ^ ^ ^ ;_ ^
CO
< "t cr- LO rv O O CN CN LO CO — <T S CO - 00 — — rr — rr CM iO lO oo O O cO — cO co r-v CM — S n o S ^ m o ^ n ^ S S ^ CM
O ' ) ^ 0 '- ^ <) oo oo ^ ^ ^ c o n c^ cι ^ c^ ) ^ c^ •- ) (O O N O N W ^ iD O N ^ ) oo S K S " ^ " 2 ^ f -- ^ CN CN CN cO CO cO CO CO CO rr cO co rr rr rr iO LO tO O O O O m ( - ' C0 CO C0 <D e0 O' σ θ' M> ^- J_ i_ ^ ^ ^ ^ ^ ^ i_ "^
O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O o O o O o o CD o CD n CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO
CO CO CO CO CO CO CO CO CO CO rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv OL OL OL OL r^ fv fv rv rv y fv rv fv fv rv rv rv rv rv rv rv rv rv rv rv f r rv rv rv rv rv r <<<<<<<<<< <<<<<< < < < < < < < < < < < < < < < < < < < < < < <
Q < < < < < < < < < < 55555555J 55555555
Φ 5555555555 O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O o o o o o o o o o o O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O π CN CM CM CN CN CN CN CN CN CM C CN CN CN CN CN CN CN CN CN CN CM CN CM CN CN CM CN CN CN CN CM CM CN CN CN CN CN CN CN
Q. CM CN CN CN CM CM CN CN CM CN ε rv rv rv rv rv rv rv rv rv r-v 5r?r r$r$^5r ^r ^r|r 5rir?r$r r$5r rϊr ^5^5rir r$r$r 5r|5 ^^r5r5r o o o o o o o o o o
CM CN CN CN CM CN CN CN CM CN rr rr rr rr rr r rr rr rr rr rr rr
CO CO CO CO CO CO CO CO CO CO LO LO LO LO LO LO LO LO LO 143 LO LO LO O LO ^ LO LO LO LO LO LO UJ UJ UJ UJ U3 U) rv rv rv. rv rv r rv rv rv v rv rv rv rv rv rv rv v rv iv. iv. rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv v rv rv rv (v. rv rv 3 rv
ON a rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr r
LO LO LO rv rv rv t rvo LO lO io LO LO rv
CN ON OM OM CN CN OM CN CN rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr
O O o o o o o
00000000000000000000000000000000000000000000000000 r-
© o
CM
© ^ CN CM CN C CM C CM C CN C CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO LO LO l LO Lθ Lθ -0 -O LO LO LO LO lO lO lO lO lO LO lO LO Lθ lθ Lθ L l Lθ l^ o a - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
LU co
c σ ε 55555555 o
Q
— — — — — — — — — — — — — — — — — — CN CM CN CM CN CN CN CO CO CO CO CO CO CO CO CO CO CO — — — CN CM CM CM CM CM CO CO CO CM CM gPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPb
^99999999999999999999999999999999999999999999999999 tt θ O t C\| -) ι- N- C ^ ^ O O -) -) ^ N- OO C C 'θ α ra ^ CO C| lO '- N- '- N- ^ ' f ) ffl '- O N O θ n <) <) n ro ,O m '-
O ι- n -) oo θ' '- C> oo o ^ ) oD > -- ^ -) ω <) oD θ ( i- oo θ '- n <) oo s (> o oι -- - oθ '- ιn oD ^ n u3 N y ^ s S -- ^ n o n n n N' N' ' U) <) N N ω ι> ' ' N ω ffl θ> L O <) O ) O N N θ (D ro n ' θ ' -θ 'θ ) J ^ 'θ ™ --
_ < "t oo - — rr cO O CN LO O CO CN LO rr rv O O CN LO O CO Cv O O CN CO <3 CN Lθ CN Lθ CM Lθ rr rv O CM 00 — rr rv __ —.
O co — co io -o co o — rv o co o cN rr o oo o — — o co o o o co — oo o — co o oo rv o o oj — LO CO — LO CO - co co - r^ S — S 55 CN co co co co co co rr rr rr Lθ θ θ -θ rv rv rv co rr rr rv i-v oo oo to -o -o -o -o o rv tv co co co co co co o O "' ^ tu
rv rv r-v |v. rv |v, r rv iv. rv |v. rv |v. rv rv iv. rv rv |v. rv |v. rv rv rv i^ rv rv iv. rv rv rv iv. rv rv iv. rv |v. rv rv rv rv r^ — — — — — — — —
-£φ5-5—5—5—5—5—5—5—5—5—5—5—55555555555555555555 ^
Oooooooooooooo-o-o--o-o-o-oo-o-o-o--o-oo-o-- 5555555-----έ^ oo— —o —o —555 oo-o--oo------ — CDOOOOOOO
O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O OoOoOoOoOoOoOoCMoCNoCMoCMoCNoCMoCMoCM ^ C C C C CN C CN C CN C C CN CN CN CN CN CN ( ( C CN CN CN CN CN CN CN CN CN CN ( C C t — — : ,_ . : L z ^ ^ z z z — Z L I L Z L Z L L L L L L Z IZ L L ZL L — — — cN CN OJ cSi cSJ cSJ rr rr rr rr rr rr cM CM ^ r r r rf rf rf rr' rf rf rf rf rf rf rf rf rf rf rf r rr' r rf rf r rf r r r rf r o o o o o o o o o o o o c c c o o o o o o o o o o o o o o o o o o o o θ ' — < — ■ — ■ — ■ — ■ — co co oo oo co oo o o rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr iO i^
CO OO OO CO CO CO CO CO CO CO CO CO CO CO OO OO OO OO CO OO CO OO CO CO CO CO CO CO CO CO CO OO OO OO CO OO CO CO C^
— OO —O —O — —O —OO — —OO — —OO — —O —OO —O — —O —O —OO — —O —OO —O — —OO — —OO — —OO — —OO —O — —O —OO —O — CON COM CON COM CONOCNOLO LOOOLO LOO lOO lOO tOO lOO
r-
© ό
CM z
© Λ rv iv. v iv. rv rv. |v, rv |v. rv |v. rv iv. |v. rv rv rv rv |v. rv |v. rv iv. rv rv rv iv. rv rv |v. v |v. rv v |v. rv oo co co o oo oo o o o o o o o o
Q co CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO C^ o C>1 CN CN CN CN CM CN C C C ( CN CN CN CN ( ( C C C C CN CN ( CN CN C CN ( CM ( CN C ( CN CN
LU
CO
H α.
C
£ 5555555555555555555555555555555555555555555555555 ____!
ΦPΌΌΌ P Ό Ό ΌΌPPΌP P PPΌΌΌΌΌΌΌ ΌΌ Ό ΌΌPΌΌ
O o o o o o o o o D o o o σ o o o o o o o σ σ o o o o o o o σ o o σ o o o o o σ o σ o o o o σ o o o σ PPPPPPPPP o o o o o o o o o o o o o o o o o o o o p o o oppppppppp o o o o o o
P- r ιv, r 0 f ^ Λ Lθ co - rr o o o o o c <>j uj - — uj co rr iv- o oo oo - — o o o S co — oo — rr S ^ jS v o — rr o CO oo fe 0 N ^ <) θ y 5 K S ,- I,' (>' O M lΛ ' O co o — co o — o — — c CN C NC 0co> Wrr Nrr Cr> 'LOJ -L0O N O - w ιo o < | ^ -- — LO 0to o θLO nL cLO0 Nrv Oco Noo nco Nco 0oo- H^ 'cIM CN nco -c0o |0v "^ Ϊ^: S^ rr rr LO LO LO o CO
< "t CM LO CO - .j-. CN LO rv o rv rv O cO cO O CM CM O rr CO — O CN CN O O O O CN O CN 0 CN LO — r p — — rr o f^ § — co r co — rv o CN rr oo O — rr rv co o — S23— — c0o — CO O —r - io L — rr o v O O _ cO Lo rv o cN rv o rr o rv O — O
CN CN CN CM rr rr rr rr tO LO LO iO to LO rv oo co oo oo o CN CN CO CO — — rr rr LO iO iO O
rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv. rv rv rv rv rv rv rv rv rv rv rv rv rv
>- < < > > > > > > > > > > > > > > > >
Q < <<<<<<<<<<<<<<<<<<< <<<< < < < < < < < < < < < < < < < < < < < < < < 55555555555 555555555555 Φ 5555555555555 5555555555 σ o o o o o o ooo o o o o o o O O O O O O o o O o o o o o o o o o o o o o o O O oO oO O O O O O O O oO oO oO oO oO oO oO oOoO oO O O C_N C _M C _M O O O O O O C.3 CJ C.3 C.3 oo o o o o o o o o o
CN CM CN CM CN CN CM CN CN CN CM CN CN CN CN CM CN CN CN CM CN CM CN CN CN CM CN CN CM CM CM CM C <MM cM cM cM cM cM c c cM cM ε rv' rr rr rr rr rr C COO CO CO <^ ; — ; — ; CN
.φ CO o rrorrorrorrorrorrorrorrorrorrorrorrorr ooorrorrorrorrorr ror ror ror o o o o O O CN 0M OM CN rr oo ) U) U) rv o r o L CN o ooo o o U O O O CN CM CN CN CN CM CM v rv «o CO oooooooooo oo- o rr rr o~ o— oo oo~ rr o o o o o o oo o o o rv rv rv rv rv r ov r ov o- c (> C _) O O ' — ' — ' — ' — ' — ' — • — o o o o o o o o o o o o o o O rv. rv rv rv rrvv cCoO CO CO CO CO CO CO CO CO CO o o rv rv. rv rv rv rv. rv rv rv rv rv rrvv rv rv rv ro co co co co co oo LO O r-
© o
© LO LO LO O O O
Q ' ' ' - ' ' ' ' N' ' ' ' N- N- ' N- ^ N- ' N' N' - ' ' - ' ' N- - ' N' ' ^ N- ' N' N- ^ 'T N' rr rr rr rr rr rr ror o o rr rr o CN CN CN CN C C CN C CN CN C ( CN ( CN CN CN CN C ( CN CN ( CN CN CN CN CN CN (
Q
TABLE 4
SEQ ID NO. Template ID Start Stop Frame Domain Topology
246 1.1:1 183121.1 2001 MAY17 869 891 forward 1 TM Transmembrane
246 U:1 183121.1 2001 MAY 17 892 913 forward 1 TM Non-Cytosolic
246 Ll:l 183121.1 2001 MAY 17 914 936 forward 1 TM Transmembrane
246 Ll:l 183121.1 2001 MAY 17 937 948 forward 1 TM Cytosolic
246 Ll:l 183121.1 2001 MAY 17 949 971 forward 1 TM Transmembrane
246 1.1:1 183121.1 2001 MAY 17 972 101 1 forward 1 TM Non-Cytosolic
246 1.1:1 183121.1 2001 MAY 17 1012 1034 forward 1 TM Transmembrane
246 U: 1 183121.1 2001 MAY 17 1035 1057 forward 1 TM Cytosolic
246 Ll: l 183121.1 2001 MAY 17 1 913 forward 2 TM Non-Cytosolic
246 1.1:1 183121.1 2001 MAY 17 914 936 forward 2 TM Transmembrane
246 LI: 1 183121.1 2001 MAY 17 937 948 forward 2 TM Cytosolic
246 U: 1 183121.1 2001 MAY 17 949 971 forward 2 TM Transmembrane
246 Ll: 1 183121.1 2001 MAY 17 972 1009 forward 2 TM Non-Cytosolic
246 Ll:1 183121.1 2001 MAY! 7 1010 1032 forward 2 TM Transmembrane
246 Ll:l 183121.1 2001 MAY 17 1033 1057 forward 2 TM Cytosolic
246 Ll:l 183121.1 2001 MAY 17 1 573 forward 3 TM Non-Cytosolic
246 Ll: l 183121.1 2001 MAY 17 574 596 forward 3 TM Transmembrane
246 Ll: l 183121.1 2001 MAY 17 597 791 forward 3 TM Cytosolic
246 LI : 1 183121.1 2001 MAY 17 792 809 forward 3 TM Transmembrane
246 U: 1 183121.1 2001 MAY 17 810 873 forward 3 TM Non-Cytosolic
246 Ll: 1 183121.1 2001 MAY 17 874 896 forward 3 TM Transmembrane
246 Ll: 1 183121.1 2001 MAY 17 897 915 forward 3 TM Cytosolic
246 Ll:l 183121.1 2001 MAY 17 916 938 forward 3 TM Transmembrane
246 U:l 183121.1 2001 MAY 17 939 952 forward 3 TM Non-Cytosolic
246 Ll:l 183121.1 2001 MAY 17 953 975 forward 3 TM Transmembrane
246 U: 1 183121.1 2001 MAY 17 976 1056 forward 3 TM Cytosolic
247 LI: 1 1 0431.13:2001 MAY17 1 1983 forward 1 TM Non-Cytosolic
247 Ll: l 190431.13:2001 MAY17 1984 2006 forward 1 TM Transmembrane
247 LI: 1 190431.13:2001 MAY17 2007 2155 forward 1 TM Cytosolic
247 LI: 1 190431.13:2001 MAY17 2156 2175 forward 1 TM Transmembrane
247 LI: 1 190431.13:2001 MAY! 7 2176 2194 forward 1 TM Non-Cytosolic
247 LI: 1 190431.13:2001 MAY17 2195 2217 forward 1 TM Transmembrane
247 LI: 1 190431.13:2001 MAY17 2218 2287 forward 1 TM Cytosolic
247 LI: 1 190431.13:2001 AY17 2288 2307 forward 1 TM Transmembrane
247 U: l 190431.13:2001 MAY17 2308 2461 forward 1 TM Non-Cytosolic
247 LI: 1 190431.13:2001 MAY17 1 1381 forward 2 TM Non-Cytosolic
247 Ll: l 190431.13:2001 MAY17 1382 1404 forward 2 TM Transmembrane
247 LI: 1 190431.13:2001 MAY17 1405 1584 forward 2 TM Cytosolic
247 LI: 1 190431.13:2001 MAY17 1585 1603 forward 2 TM Transmembrane
247 U: l 190431.13:2001 MAY17 1604 2209 forward 2 TM Non-Cytosolic
247 LI: 1 190431.13:2001 MAY17 2210 2232 forward 2 TM Transmembrane
247 LI: 1 190431.13:2001 MAY17 2233 2236 forward 2 TM Cytosolic
247 LI: 1 190431.13:2001 MAY17 2237 2254 forward 2 TM Transmembrane
247 LI: 1 190431.13:2001 MAY17 2255 2461 forward 2 TM Non-Cytosolic
247 LI: 1 190431.13:2001 MAY17 1 2209 forward 3 TM Non-Cytosolic
247 LI: 1 190431.13:2001 MAY17 2210 2232 forward 3 TM Transmembrane
247 LI: 1 190431.13:2001 MAY17 2233 2461 forward 3 TM Cytosolic
248 LI:199121.14:2001 MAY17 1 831 forward 1 TM Non-Cytosolic
248 LI: 199121.14:2001 MAY17 832 854 forward 1 TM Transmembrane
248 LL 199121.14 2001 MAY 17 855 860 forward 1 TM Cytosolic c "σ ε 5555555555 o Q
— — — — CN CN CN C C CN CN CO CO CO CO CO CO CO CO CO CO CO CO CO C CO CN CN C C CN C C CN CN CN C C C
PbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPPbPσPσPoPoPbPbPbPbPbPbPbPbPbPbPbPb o o o o o o o o o o o o o o o o o o o p o o o o o o o o o p pppppppp o p p p p pp p p p pp
r-
©
© CO 00 CO 00 00 00 C0 C0 C0 C0 00 CO C0 CO C0 CO -0 00 00 C0 CO C0 00 00 C0 O O O O O O O O O O O O O O - ■— ■— ■— - - - ■—
Q rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr iO LO LO -O W
O
c 'o 5555555555 o
CO CO — — — CO CO CO — — — — — — — — — — — — — C CN C C C C C C CN CN CN CN CN C CN CN C C CM CN CM CN CN CN CM CN CN CO CO rt^PbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPαPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPb
"" o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o pp op o o o o o opp ppp o o o
P-rr rv CN U5 θ — rr o rv O CO CO cO O O cO LO rr o co CN LO co rr rv rv O cO iO iO cO LO lO co uj O — ιO rv CO — LO rv O — O O CM o o rr rr rr rr rr — 8 O O — — — — — ( CM o n co n co co co co rr rr rr rr
5 t M ) ro O B
<v O j v — co uj - 2 •- 55 o o rr rr
ιv. v v |v. rv iv. rv iv. rv rv rv |v. rv |v. rv v iv. rv rv iv. rv |v, rv rv i^ ιv. rv rv iv. rv |v. rv |v. rv rv |v, rv iv. rv |v. rv |v, rv rv. |v. rv iv. rv iv. rv rv < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
Φ5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5— —55—5—5—5—5—5—5— —55—5—5—5—5—5— —5 —5 —5 —5 —5
fc O O O O O O O O O Q Q O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O ^ CN CN CN CN CN CN CN CN C CM CN CN C CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN cb' c' o o o O O O r r rf rr rf rf rf rf rf rf rf rf r^ C ^ __: ^ ^ ^ ^ ^ ^ CN C CN CN CN CN CN C CN CN C
£ c f . r . | , rv rv rv O O O O O O O O O O O O O ' N' ' ' N' N' N' ' ' ' ^ N' ' ' N' ' N' ' ' ' N' N' ^ ^ N- ' ' ' ' ' ^ ' ' ' ' N' N' N' ^ ' ' ' ' N' N' ' ' ^ N' ' — r- OO CO -O OO CO CO cO CO CO CO OO OO OO CO OO CO OO OO OO cO OO CO CO OO OO CO CO CO CO OO CO OO OO ∞ ∞
LO LO — — — — — — oo co Qj ffl ffl ω co oo M oo oo M ω o oo oo co oo ffl M co ffl ∞ ffl ic ffl co ω oo oo co co Λ co co ω eo oo co oo oo o o -— •— '— ■— -— -— ■— '— ■— ■— •— ■— ■— ■— '— ■— '— '— '— '— ■— '— ■— ■— '— ■— ■— ■ '— '— ■— ,— ■— '-- '— ■— '— '— '— '— ■— r— ,-- ,— ■— ■— ■—
C C C CN C C C CN CN CN CN CN C CN CN CM CN C CN CN C CN CN CN CN CN C r-
© o z
© — — CN C CN CN CN C cO cO CO CO CO cO cO cO cO CO cO cO cO cO CO cO cO cO cO cO CO CO cO cO cO CO CO cO cO
Q _ Lθ lO lΛ lO LO LO Lθ Lθ Lθ LO l lO lO lO lO lO L LO U Lθ lO tO lθ LO Lθ Lθ l lO lO L^
C CN C CN C C CN ( C CN C CN C CN < CN CN ( CN C CN < CN C CM CN CN C CN CN CN C^
G LU CO
Φc 2 p Φ Elo c 1—
^ B 51 — 51 — 15 — 51 — 15 — 51 — 51 — 51 — 51 — 15 — 51 — 15 — 51 — 51 — 51 — 51 — 51 — 51 — 51 — 51 — 51 — 51 — 51 — 51 — 51 — 51 — 51 — 51 — 51 — 51 — 51 — 15 — 15 — 51 — 15 — 51 — 51 — 51 — 51 — 51 — 51 — 15 — 51 — 15 — 51 — 51 — 51 — 51 — 51 — 51 —
(_--
CO CN CN CN CO CO CO — — — — — CN CN CM CN CN CN CN CN CN CO CO CO CO CO CO CO CO CO CO — — — — — — — — — — — — — — — — — CM CM rgPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPb
""££££££££££££££££££££££££££££££££££££££££££££££££££
Pr o rv. u-> c rr rv. oo ( LO rv rv 0^ r^ — r^ _ ^ co o o^ 00 .0 p 9r ; !g cN O — CM rv o o cN ^ oo O Lo v o — 2 S S N- >O O N S ^ -- co o M rv o o cN rv o o o S r^ S ^ SR O — — N r rv
_
< "£ °N m «o CO CO O CO OO Uj cO j CO CN t Sξ tn o o rv o ^. lO rr cO OO — rv 0 r^ 0 0 c 0 co rr r^ co — ? o
j- rr CM rr LO O CO CO O O MO O CO OO O' 0 0 lO iO O O e^ — — CN •O N N MO O- ^ ^ J. ^ ^ ^ CO
r-
© o
CM
© co rr rr LO LO ιθ ιθ L ιθ Lθ Lθ Lθ Lθ Lθ Lθ to ιθ Lθ Lθ 3 θ θ θ θ o rv r rv |v. v v |v. v |v. rv iv, v rv iv. v rv rv r rv o LO LO IO LO LO LO LO LO LO 8 ιθ ιO U) ιO -) -) ιO W W ιO ιO U) U) β ιO -) ιO 3 U) ιO ιO ιO -) ιO -) U3 iO ιO ιO ιO -) ιO ιO -) -) -) ιfi U) U) ιn ιO CN C ( CN C CN CN CN CN CN C C CN ( CN CN C CN C CN CN CN CN CN CN CN ( ( CN C^
C LU O
m r r ι^o ro ro ro s N3 i r N i\ N, r N- i ro ι ι Nj r ι ro ι ι N N3 w (D cri c^ en e ejι erι C3i e^ ejι eji crι crι Cjι erι crι c^ c^ (^ erι C3i cι C3i en e3i erι Ci cjι e3i cjι c^
0300 CD OO C» CO CO (» 03 α! OJ O) α) 0) M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M v o ro ro r ro
CD 00 00 CD
00 00 00 00 o o o o φ
._-. ■ti4-- 4-. 3
N3 ro K3 N3 N3 p C"3 C 3 0 C3
O Q _222 _2222 _S _2 _22 _S 2 Φ
> > > > > > > > > > > > > SSS SS < < < < >
< - > > > > >
M M M M M M M SI M M M S1 M M M M M M M
o O slS <, ( e'I3 o o o o o o o o o o o o o o oo o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o oo o o ..,
Q Q Q Q Q Q Q Ω Ω Ω Ω Q Ω Q Ω Ω Q Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Q Ω Ω Ω Q Ω Ω Ω Ω Ω Q Ω Ω Ω Ω Ω Ω Q Ω Ω q d d d d d d d d ddd d d d ddd dd d d d d d dd d d dddd d d d d ddddd dd dddd d ddφ ro ro ro ro ro - -' -^ -^ -^ -^ ^ ω ) ω u -) ω ω -j -) ω ω c- ω ) _ t- ω ω ω 3 N) N3 N3 N3 M M N3 N) i- N3 N: N3 i N) W N3
D
—1 — 1 — 1 — 1 — 1 — 1 — 1 O S ≤Ξ S S S S S S S S S S S S s __: 22 __; __: __; __: __: __: __: __: _s <Ξ 5_: __: <: <_: __: __: s <?: __: <_: 3 n
D"
TABLE 4
SEQ ID NO Template ID Start Stop Frame Domain Topology
258 U:345320.4:2001 MAY17 1 169 1 191 forward 2 TM Transmembrane
258 U:345320.4:2001 MAY17 1 192 1274 forward 2 TM Non-Cytosolic
258 1.1:345320.4:2001 MAY17 1275 1297 forward 2 TM Transmembrane
258 U:345320.4:2001 MAY17 1298 1431 forward 2 TM Cytosolic
258 1.1:345320.4:2001 MAY17 1432 1454 forward 2 TM Transmembrane
258 U:345320.4:2001 MAY17 1455 1501 forward 2 TM Non-Cytosolic
258 U:345320.4:2001 MAY17 1502 1524 forward 2 TM Transmembrane
258 U:345320.4:2001 MAY17 1525 1649 forward 2 TM Cytosolic
258 U:345320.4:2001 MAY17 1650 1672 forward 2 TM Transmembrane
258 U:345320.4:2001 MAY17 1673 1707 forward 2 TM Non-Cytosolic
258 LI:345320.4:2001 MAY17 1708 1730 forward 2 TM Transmembrane
258 U:345320.4:2001 MAY17 1731 1767 forward 2 TM Cytosolic
258 U:345320.4:2001 MAY17 1768 1790 forward 2 TM Transmembrane
258 U:345320.4:2001 MAY17 1791 2093 forward 2 TM Non-Cytosolic
258 U:345320.4:2001 MAY17 1 6 forward 3 TM Cytosolic
258 1.1:345320.4:2001 MAY17 7 24 forward 3 TM Transmembrane
258 U:345320.4:2001 MAY17 25 1409 forward 3 TM Non-Cytosolic
258 LI:345320.4:2001 MAY17 1410 1432 forward 3 TM Transmembrane
258 LI:345320.4:2001 MAY17 1433 1436 forward 3 TM Cytosolic
258 U:345320.4:2001 MAY17 1437 1459 forward 3 TM Transmembrane
258 LI:345320.4:2001 MAY17 1460 1659 forward 3 TM Non-Cytosolic
258 LI:345320.4:2001 MAY17 1660 1682 forward 3 TM Transmembrane
258 U:345320.4:2001 MAY17 1683 1752 forward 3 TM Cytosolic
258 U:345320.4:2001 MAY17 1753 1775 forward 3 TM Transmembrane
258 LI:345320.4:2001 MAY17 1776 2092 forward 3 TM Non-Cytosolic
259 Ll:355693.18:2001 MAY17 1 1472 forward 1 TM Non-Cytosolic
259 Ll:355693.18:2001 MAY17 1473 1495 forward 1 TM Transmembrane
259 1.1:355693.18:2001 MAY17 1496 2222 forward 1 TM Cytosolic
259 Ll:355693.18:2001 MAY17 2223 2245 forward 1 TM Transmembrane
259 Ll:355693.18:2001 MAY17 2246 2273 forward 1 TM Non-Cytosolic
259 Ll:355693.18:2001 MAY17 2274 2296 forward 1 TM Transmembrane
259 U:355693.18:2001 MAY17 2297 2378 forward 1 TM Cytosolic
259 Ll:355693.18:2001 MAY17 1 2273 forward 3 TM Non-Cytosolic
259 Ll:355693.18:2001 MAY17 2274 2296 forward 3 TM Transmembrane
259 Ll:355693.18:2001 AY17 2297 2378 forward 3 TM Cytosolic
260 LI: 359876.1 200 I M AY 17 1 585 forward 1 TM Non-Cytosolic
260 Ll:359876.1 2001 MAY 17 586 605 forward 1 TM Transmembrane
260 Ll:359876.1 2001 MAY 17 606 630 forward 1 TM Cytosolic
260 Ll:359876.1 2001 MAY 17 631 653 forward 1 TM Transmembrane
260 LI: 359876.1 2001 MAY 17 654 657 forward 1 TM Non-Cytosolic
260 LI: 359876.1 2001 MAY 17 658 677 forward 1 TM Transmembrane
260 Ll:359876.1 2001 MAY 17 678 741 forward 1 TM Cytosolic
260 Ll:359876.1 2001 MAY 17 742 764 forward 1 TM Transmembrane
260 LI: 359876.1 2001 MAY 17 765 913 forward 1 TM Non-Cytosolic
260 LI: 359876.1 2001 MAY 17 1 191 forward 2 TM Non-Cytosolic
260 Ll:359876.1 2001 MAY 17 192 214 forward 2 TM Transmembrane
260 Ll:359876.1 2001 MAY 17 215 225 forward 2 TM Cytosolic
260 Ll:359876.1 2001 MAY 17 226 248 forward 2 TM Transmembrane
260 Ll:359876.1 2001 MAY 17 249 262 forward 2 TM Non-Cytosolic
260 Ll:359876.1 2001 MAY 17 263 285 forward 2 TM Transmembrane TABLE 4
SEQ ID NO Template ID Start Stop Frame Domain Topology
260 Ll:359876.1 2001 MAY 17 286 305 forward 2 TM Cytosolic
260 Ll:359876.1 2001 MAY 17 306 328 forward 2 TM Transmembrane
260 Ll:359876.1 2001 MAY 17 329 361 forward 2 TM Non-Cytosolic
260 Ll:359876.1 2001 MAY 17 362 384 forward 2 TM Transmembrane
260 Ll:359876.1 2001 MAY 17 385 404 forward 2 TM Cytosolic
260 Ll:359876.1 2001 MAY 17 405 427 forward 2 TM Transmembrane
260 Ll:359876.1 2001 MAY 17 428 436 forward 2 TM Non-Cytosolic
260 Ll:359876.1 2001 MAY 17 437 456 forward 2 TM Transmembrane
260 Ll:359876.1 2001 MAY 17 457 534 forward 2 TM Cytosolic
260 Ll:359876.1 2001 MAY17 535 557 forward 2 TM Transmembrane
260 Ll:359876.1 2001 MAY 17 558 585 forward 2 TM Non-Cytosolic
260 Ll:359876.1 2001 MAY 17 586 605 forward 2 TM Transmembrane
260 Ll:359876.1 2001 MAY 17 606 617 forward 2 TM Cytosolic
260 Ll:359876.1 2001 MAY 17 618 637 forward 2 TM Transmembrane
260 Ll:359876.1 2001 MAY 17 638 656 forward 2 TM Non-Cytosolic
260 Ll:359876.1 2001 MAY 17 657 679 forward 2 TM Transmembrane
260 Ll:359876.1 2001 MAY 17 680 739 forward 2 TM Cytosolic
260 Ll:359876.1 2001 MAY 17 740 762 forward 2 TM Transmembrane
260 Ll:359876.1 2001 MAY 17 763 912 forward 2 TM Non-Cytosolic
260 Ll:359876.1 2001 MAY 17 1 368 forward 3 TM Non-Cytosolic
260 Ll:359876.1 2001 MAY 17 369 391 forward 3 TM Transmembrane
260 Ll:359876.1 2001 MAY 17 392 616 forward 3 TM Cytosolic
260 Ll:359876.1 2001 MAY 17 617 639 forward 3 TM Transmembrane
260 Ll:359876.1 2001 MAY 17 640 648 forward 3 TM Non-Cytosolic
260 Ll:359876.1 2001 MAY 17 649 671 forward 3 TM Transmembrane
260 Ll:359876.1 2001 MAY 17 672 705 forward 3 TM Cytosolic
260 Ll:359876.1 2001 MAY 17 706 725 forward 3 TM Transmembrane
260 Ll:359876.1 2001 MAY 17 726 734 forward 3 TM Non-Cytosolic
260 Ll:359876.1 2001 MAY 17 735 757 forward 3 TM Transmembrane
260 Ll:359876.1 2001 MAY 17 758 835 forward 3 TM Cytosolic
260 Ll:359876.1 2001 MAY 17 836 855 forward 3 TM Transmembrane
260 Ll:359876.1 2001 MAY 17 856 869 forward 3 TM Non-Cytosolic
260 Ll:359876.1 2001 MAY 17 870 892 forward 3 TM Transmembrane
260 Ll:359876.1 2001 MAY 17 893 912 forward 3 TM Cytosolic
261 LI:406664.32:2001 MAY17 1 705 forward 1 TM Non-Cytosolic
261 U:406664.32:2001 MAY17 706 728 forward 1 TM Transmembrane
261 LI:406664.32:2001 MAY17 729 951 forward 1 TM Cytosolic
261 LI:406664.32:2001 MAY17 952 974 forward 1 TM Transmembrane
261 LI:406664.32:2001 MAY17 975 977 forward 1 TM Non-Cytosolic
261 U:406664.32:2001 MAY17 978 997 forward 1 TM Transmembrane
261 U:406664.32:2001 MAY17 998 1017 forward 1 TM Cytosolic
261 U:406664.32:2001 MAY17 1018 1040 forward 1 TM Transmembrane
261 U:406664.32:2001 MAY17 1041 1076 forward 1 TM Non-Cytosolic
261 U:406664.32:2001 MAY17 1077 1099 forward 1 TM Transmembrane
261 U:406664.32:2001 MAY17 1 100 1 166 forward 1 TM Cytosolic
261 U:406664.32:2001 MAY17 1 951 forward 2 TM Non-Cytosolic
261 U:406664.32:2001 MAY17 952 974 forward 2 TM Transmembrane
261 LI:406664.32:2001 MAY17 975 1071 forward 2 TM Cytosolic
261 LI:406664.32:2001 MAY17 1072 1094 forward 2 TM Transmembrane
261 Ll:406664.3 2:2001 MAY17 1095 1 1 13 forward 2 TM Non-Cytosolic TABLE 4
SEQ ID NO Template ID Start Stop Frame Domain Topology
261 LI:406664.32:2001 MAY17 1 1 14 1 136 forward 2 TM Transmembrane
261 U:406664.32:2001 MAY17 1 137 1 166 forward 2 TM Cytosolic
261 LI:406664.32:2001 MAY17 1 704 forward 3 TM Non-Cytosolic
261 U:406664.32:2001 MAY17 705 727 forward 3 TM Transmembrane
261 U:406664.32:2001 MAY17 728 910 forward 3 TM Cytosolic
261 U:406664.32:2001 MAY17 91 1 930 forward 3 TM Transmembrane
261 U:406664.32:2001 MAY17 931 1027 forward 3 TM Non-Cytosolic
261 U:406664.32:2001 MAY17 1028 1050 forward 3 TM Transmembrane
261 U:406664.32:2001 MAY17 1051 1069 forward 3 TM Cytosolic
261 LI:406664.32:2001 MAY17 1070 1092 forward 3 TM Transmembrane
261 U:406664.32:2001MAY17 1093 1 1 1 1 forward 3 TM Non-Cytosolic
261 U:406664.32:2001 MAY17 1 1 12 1 134 forward 3 TM Transmembrane
261 LI:406664.32:2001 MAY17 1 135 1 166 forward 3 TM Cytosolic
262 LI :410324.1 2001 MAY 17 1 1308 forward 1 TM Non-Cytosolic
262 LI :410324.1 2001 MAY 17 1309 1331 forward 1 TM Transmembrane
262 LI : 10324.1 2001 MAY 17 1332 1351 forward 1 TM Cytosolic
262 LI :410324.1 2001 MAY 17 1352 1374 forward 1 TM Transmembrane
262 LI :410324.1 2001 MAY 17 1375 1419 forward 1 TM Non-Cytosolic
262 LI :410324.1 2001 MAY 17 1 59 forward 2 TM Cytosolic
262 Ll:410324.1 2001 MAY 17 60 82 forward 2 TM Transmembrane
262 LI :410324.1 2001 MAY 17 83 1006 forward 2 TM Non-Cytosolic
262 LI :410324.1 2001 MAY 17 1007 1029 forward 2 TM Transmembrane
262 LI :410324.1 2001 MAY 17 1030 1 194 forward 2 TM Cytosolic
262 LI :410324.1 2001 MAY 17 1 195 1217 forward 2 TM Transmembrane
262 LI :410324.1 2001 MAY 17 1218 1236 forward 2 TM Non-Cytosolic
262 LI :410324.1 2001 MAY 17 1237 1259 forward 2 - TM Transmembrane
262 LI :410324.1 2001 MAY 17 1260 1335 forward 2 TM Cytosolic
262 LI :410324.1 2001 MAY 17 1336 1358 forward 2 TM Transmembrane
262 LI :410324.1 2001 MAY 17 1359 1419 forward 2 TM Non-Cytosolic
262 LI :410324.1 2001 MAY 17 1 62 forward 3 TM Cytosolic
262 LI :410324.1 2001 MAY 17 63 85 forward 3 TM Transmembrane
262 LI :410324.1 2001 MAY 17 86 1 194 forward 3 TM Non-Cytosolic
262 LI :410324.1 2001 MAY 17 1 195 1217 forward 3 TM Transmembrane
262 LI :410324.1 2001 MAY 17 1218 1335 forward 3 TM Cytosolic
262 LI :410324.1 2001 MAY 17 1336 1358 forward 3 TM Transmembrane
262 LI :410324.1 2001 MAY 17 1359 1361 forward 3 TM Non-Cytosolic
262 LI :410324.1 2001 MAY 17 1362 1384 forward 3 TM Transmembrane
262 LI :410324.1 2001 MAY 17 1385 1418 forward 3 TM Cytosolic
263 Ll:414376.12:2001 MAY17 1 464 forward 2 TM Non-Cytosolic
263 Ll:414376.12:2001 MAY17 465 487 forward 2 TM Transmembrane
263 Ll:414376.12:2001 MAY17 488 542 forward 2 TM Cytosolic
263 U:414376.12:2001 MAY! 7 543 565 forward 2 TM Transmembrane
263 U:414376.12:2001 MAY17 566 579 forward 2 TM Non-Cytosolic
263 Ll:414376.12:2001 MAY17 580 602 forward 2 TM Transmembrane
263 U:414376.12:2001 MAY17 603 664 forward 2 TM Cytosolic
263 Ll:414376.12:2001 MAY17 665 687 forward 2 TM Transmembrane
263 Ll:414376.12:2001 MAY17 688 701 forward 2 TM Non-Cytosolic
263 U:414376.12:2001 MAY17 702 720 forward 2 TM Transmembrane
263 Ll:414376.12:2001 MAY17 721 726 forward 2 TM Cytosolic
263 LI :414376.1 2:2001 MAY17 727 749 forward 2 TM Transmembrane TABLE 4
SEQ ID NO Template ID Start Stop Frame Domain Topology
263 U:414376.12:2001 MAY .7 750 1999 forward 2 TM Non-Cytosolic
264 U:452089.1 2001 MAY 17 1 238 forward 1 TM Non-Cytosolic
264 Ll:452089.1 2001 MAY 17 239 261 forward 1 TM Transmembrane
264 Ll:452089.1 2001 MAY 17 262 312 forward 1 TM Cytosolic
264 Ll:452089.1 2001 MAY 17 1 283 forward 2 TM Non-Cytosolic
264 Ll:452089.1 2001 MAY 17 284 306 forward 2 TM Transmembrane
264 U:452089.1 2001 MAY 17 307 312 forward 2 TM Cytosolic
264 U:452089.1 2001 MAY! 7 1 237 forward 3 TM Cytosolic
264 Ll:452089.1 2001 MAY 17 238 260 forward 3 TM Transmembrane
264 Ll:452089.1 2001 MAY 17 261 283 forward 3 TM Non-Cytosolic
264 Ll:452089.1 2001 MAY 17 284 306 forward 3 TM Transmembrane
264 Ll:452089.1 2001 MAY 17 307 31 1 forward 3 TM Cytosolic
265 U:481614.43:2001 MAY17 1 1525 forward 1 TM Non-Cytosolic
265 U:481614.43:2001 MAY17 1526 1548 forward 1 TM Transmembrane
265 U:481614.43:2001 MAY17 1549 1660 forward 1 TM Cytosolic
266 LI:809605.2:2001 MAY17 1 81 forward 2 TM Non-Cytosolic
266 U:809605.2:2001 MAY17 82 104 forward 2 TM Transmembrane
266 U:809605.2:2001 MAY17 105 137 forward 2 TM Cytosolic
266 LI:809605.2:2001 MAY17 138 160 forward 2 TM Transmembrane
266 LI:809605.2:2001 MAY17 161 880 forward 2 TM Non-Cytosolic
267 Ll:816437.25:2001 MAY17 1 605 forward 1 TM Non-Cytosolic
267 LI:816437.25:2001 MAY17 606 625 forward 1 TM Transmembrane
267 LI:816437.25:2001 MAY17 626 679 forward 1 TM Cytosolic
267 U:816437.25:2001 MAY17 680 702 forward 1 TM Transmembrane
267 U:816437.25:2001 MAY17 703 859 forward 1 TM Non-Cytosolic
267 U:816437.25:2001 MAY17 860 882 forward 1 TM Transmembrane
267 U:816437.25:2001 MAY17 883 1250 forward 1 TM Cytosolic
268 U:817827.5:2001 MAY17 1 244 forward 1 TM Non-Cytosolic
268 Ll:817827.5:2001 MAY17 245 264 forward 1 TM Transmembrane
268 Ll:817827.5:2001 MAY17 265 272 forward 1 TM Cytosolic
268 Ll:817827.5:2001 MAY17 1 240 forward 2 TM Non-Cytosolic
268 Ll:817827.5:2001 MAY17 241 263 forward 2 TM Transmembrane
268 Ll:817827.5:2001 MAY17 264 271 forward 2 TM Cytosolic
268 Ll:817827.5:2001 MAY17 1 235 forward 3 TM Non-Cytosolic
268 U:817827.5:2001 MAY17 236 258 forward 3 TM Transmembrane
268 Ll:817827.5:2001 MAY17 259 271 forward 3 TM Cytosolic
269 Ll:002345.15:2001 MAY17 1 601 forward 1 TM Non-Cytosolic
269 Ll:002345.15:2001 MAY17 602 624 forward 1 TM Transmembrane
269 Ll:002345.15:2001 MAY17 625 946 forward 1 TM Cytosolic
269 Ll:002345.15:2001 MAY17 947 969 forward 1 TM Transmembrane
269 Ll:002345.15:2001 MAY17 970 1282 forward 1 TM Non-Cytosolic
269 Ll:002345.15:2001 MAY17 1283 1300 forward 1 TM Transmembrane
269 Ll:002345.15:2001 MAY17 1301 1307 forward 1 TM Cytosolic
269 Ll:002345.15:2001 MAY17 1 601 forward 2 TM Non-Cytosolic
269 Ll:002345.15:2001 MAY17 602 624 forward 2 TM Transmembrane
269 Ll:002345.15:2001 MAY17 625 636 forward 2 TM Cytosolic
269 Ll:002345.15:2001 MAY17 637 654 forward 2 TM Transmembrane
269 Ll:002345.15:2001 MAY17 655 663 forward 2 TM Non-Cytosolic
269 Ll:002345.15:2001 MAY17 664 681 forward 2 TM Transmembrane
269 Ll:002345.15:2001 MAY17 682 741 forward 2 TM Cytosolic c "o ε 5555555555 555555555555555 o (__
CM CM CN CM CN CM CM CM CN CN CN CM CO CO CO CO co CO CO co co CO co co co co co co CO co co CO CO CO CO CO CO CO CM CM CM φ P P P P P P P P P P P P P P P P P P P P P P "O P X3 P "O "O "O "D "O "O "O "O "O "O "O "O P "O P P P P P P P P P P ε o o D o D o o σ D o o o o o o o o o o o o o o O o O o σ o O π o o o O O O O O α o o o o o o o o o o π
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 5 ^ ^ ^ ^ ^ o o o o o o o O o o o o o o o o o o o o o o o ? ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ r5 ^ ^
O o o o o o o o o o o o o o o o O o o o ? ^ o o ? o ? o o o o
9θ ^ ^ ^ ^ ^ — Q cM rr rv o '^ ∞ '- 'Λ ∞ CD CO rv LO 00 CO CN LO LO 00 LO o rr O CO CM 00 — O CO CO O O ΓV O CO
£_ 9 o o — CM rr o oo δ o v o 00 — L CN — r CO — rr o o cN rr — rr o v?. ∞_ _∞2∞_ 5∞S^- —_, ^(^cc^M^£^c£N^c2oΩ1->rιδoftιoζ ό^- O^^O 00 N ϊ- r o-J^ C rv rv oo oo co co oo c o _ _o rv co ι CN CN CO KΩ O o rv rv rv o — — CN CM O
CO — O CM O O — CO O O O CO O O O m O co io oo — rr O CM O CN O O — — 00 — cO O O CN CN rr O lv- cO O O - CN rr O cO — r — o rv. o o CM — rv o co — rr o — CM rr — rr
LO LO LO O O O O O O rv rv co co co oo co o — — — CM CM lo o o rv v rv — — CN CM
© fM
© O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O ' — ' — ■ — ' — • — ' — ' — • — ' — ' — ■ — ' —
Q $ o o o o o o o o o o o o o o o o o o o o o o o o o o o o rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv o CM CM CM C CN C CN C C C CN CN CN CN ( CN CN C CN C CN CN C CN C CN C C CN CN < C C σ LU co
c 'o ε 55555555555555 555555555555555555 o
Q
— — — — — CM CN CN CN CN CM CN CO CO CO CO CO — — — — — — — C CM CN CN CM CN CM cO CO CO CO cO cO cO cO cO cO cO cO cO cO cO cO cO cO cO gPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPb
^ o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o op oppppp o o o o o c o o cN O co rv o io — — rv o co o rv rv r— rr co -— o cO LO O co o cN c c cOo o Oo Oo ccOo Oo ccOo ttOo Oo Oo Oo itoO rrvv rrvv o o cM co io rv o o cN rv o o co io rv co co oo co o o rv rv rv rv oo — — — CM CM CM CN CN CN CN CN CO CO cO rr rr rr rr rr — O CM o co — 00 — CM CN CO — rr rv oo oo CN LO CN — r -r O _ o __. CO CO O — r o c o o rv o o cM c rov 3 — Lo rv -o- L-o.. r.v- O O C .M- . rv - o O rv co oo or o v _ r io v rv rv — — — CM CM C CM CM CN CN CN CO CO CO rr rr rr rv rv rv rv rv rv rv rv rv rv rv rv
— — — — — — — — — — — — rv rv rv rv rv rv rv fv. rv rv. rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv v rv v rv rv rv rv rv rv rv rv >_ v_ v_ v. >_ >_ >. >. v. v. v. . _ _ _ _ -_ — — — — — — — — — — — — — — — — — — — — — — — — — — — —
— — — — — < << < < < < < < < < > > >- >- > > > > > > >- > >- >- ^φ<_><_≥<_><_><_≥0000000000005—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5—5— —5 —5
+= — — — — — ooo oooooooooooo o o o ooo o o oooooo o o ooooo o o ooooooo
O O O O O O CN CN CN CM CM CN CM CN CM CN CN CN O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O ^ 0 0 0 0 0 ^ ^ - ^ ^ j ^ ^ ^ ^ ^ ^ C C CN CM ( CN CN ( CN CN CN CM C C CN CN CN CN CN C C^ ^- ^ ^. ^ ^ - — — — — — — — — — — — C C (SJ CN ( CN CN CN m ^ ^ ^ ^ ^ c cO rθ cθ c cO c " cO θ cθ" c " c cθ rt 1--. CM CN CN CN CN O O O O O O O O O O O - — ■ — ■ — ■ — ■ — ■ — « — ■ — ■ — ■ — ■ — ■ — ■ — ■ — « — ■ — ■ — ■ — > — ■ — ■ — ■ — ■ — • — — — — — •— ■— — co co co co co rr rr rr rr rr rr rr rr rr rr rr rr iO iO LO LO iO iO u iO iO LO iO LO iO u LO i^
C C CN C CN iO iO uO LO LO iO iO iO LO LO uO iO LO iO iO LO iO iO iO i^
OO OO OO CO CO CO rø CO cO CO CO CO CO CO CO CO CO cO cO OO CO CO OO CO OO OO CO OO CO OO OO OO CO OO CO ∞ o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o
(v
© fM
© CN C N^ ^I W^O O^ O^O O^P^O ^O r^O O ^ n^ ^^^ ^^I '^7 ^^ '^ϊ ^^ '^!l ^ ,ϊ '^ϊ '^;f ^^ ^^^^ ,,,^ϊ ^'!I ,^ϊ ^ ^ ^^ ^^'^ϊ ^^' ^^' ^^ ^^ ^ '^ϊ ^^' ^^' o C C C ( CN CN C CN CN C ( CN CN CM (N ( CN C C C CN ( CN ( ( ( ( CN ( (^
G
2
c "σ ε 55555555555555555555555555555555555555 o a
CO CO CO CO CO CO CO CO CO CO — — — — — — — CN CM CN CN CM CN CN CO CO CO CO CO CO CO CO CO CO CO — — — — — CO CO CO CO CO CO CO CO CM CM
P DPDPOPDPOPDPDP-PbPoP.PDPoPbPDPDPbPDPOPOPDP.PDPDPOP.PDPbPbPbP.PbPbPDPDPOPDPDPDPDPOPDPDPOPOPDP.POPOPD o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^
> > > > > > > > > > > V > > > > > > > > > > > > > > > > > > > > > >
Q < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
55555555555555555555555555555555555555555555555555
£ o o r> o o CD o o o o o o o o o o o CD o CD n CD O o CD o o o o o o CD O O O o o o o O o o CD o O O O
C ) C ) C ) C3 C 3 C 3 o o o o o o o o o o O o o OT 03 03 C3 03 C 3 C3 C3 C 3 O O O C 3 C ) o o C 3 C 3 O O O
Q. CN CN CN CN CN CM CN CN CM CN CN CN CN CN CM CN CN CN CM CN CN CN CM CM CN CN CN CN CM CN CN CN CN CN CN CM CN CN CN CN CN CN CM CN CM CN CM CM CN CM ε CN CN CN CN CN CN CN CN CN CN O O O O O O O O o O O O O o O O O o o O CO CO CO CO CO LO LO to — —
CO CO CO CO CO CO CO CO CO CO rv rv rv rv rv rv rv rv. rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv l-v O O rr rr rr rr rr o o o o o o o o o o c> o o- o (> o O- o o- o o o C C3- o C
LO U3 m U3 if) 3 U) lO U3 rv rv rv rv rv rv rv rv l-v l-v rv rv rv l-v rv r^ l-v rv rv (v. rv l-v rv. fv iv. rr rr v rv S rv3 rr rv rv • o o rv rv
U) U> U) U) U) U) Ki) U> & U3 •o «o o o o o o o o o o • o o «o o o o o o o o o 3 CO C 3 r rr o o o O C3 r O CO CO CO CO CO O CO rv rv rv — —
00 CO CO CO CO 0O CO CO CO «> 00 CO 00 CO oo 00 CO 00 oo CO CO oo oo CO CO CO OO a> 00 00 oo CO CO CO oo 00 CO 00 CO 0O CO CO co co CO rr rr rr co co
CD o o o o o o o o o o o CD o o o o CD o CD o CD o o o o O O O o o
_l —1 _ι —1 _l _l —J —I _l —J _ _l _ι —1 _l _l —I —1 —1 _l —1 _ι _l __l —I - —1 _l —1 —1 —1 —1 _l —1 1 __ι _J
© ό z rr rr rr rr rr rr rr rr rr rr LO UD lO lO lO IO LO UD UD UD UD LO lO UD LO LO lO D LO LO to to LO UD LO O O o o v rv rv rv rv CO 00 CO o o
© Q rv rv rv rv rv rv rv rv rv rv rv r-v rv rv rv rv rv rv rv rv rv rv rv rv (v. rv rv rv l-v rv l-v rv rv rv. r rv rv rv v iv. rv rv rv rv v rv l-v rv rv v
O CM CM CM C CM CM CN CM CM CM CM CM CM CM CM CM CM CM CM CM CM CM CM CM CM CM CM CM CN CM CN CN CM CM CM C CM CM CN CN CN CN CM CM CN CM CM CM CM CM σ LU co
CN CN CM CN — — — — — — — — — — — CN CN CN C CN C C ( ( ( CN C CN CN CN CN CM CM CN CO CO CO CO CO CO C CO CO CO CO C CO CO CO CO
rv |v. rv |v. rv iv. rv rv iv. rv |v. v iv. rv iv. rv rv rv |v. rv rv rv rv iv. rv iv. rv iv. rv rv rv |v. rv iv. v iv. rv rv rv rv rv v rv rv rv rv
— — — — > > > > > < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
^ Φi—i—i—i—lδδllδlδlδlδδlδllδlδlδlδlδlδδllδlδlδlδlδδllδlδlδlδlδδlδllδδllδlδδlll 0δ0δδllδl 00δ00δlδl 00δl 0δl 0δl 0δl 0δl 0δl +1000000000000000000000000000000000000 0
O O O O O CN CN C CN CN CN CN CN C C C C C C C CN CN CN C C CN CN CN CN C CN C C C^ c_^ ^ . ^ L ι L ib ιo ι ι ι Lb ι ι ι_ m_ O — C oN CoN CoN Ooo cOo Oαa Oco Oαa Oco Oco Ooo Ooo oOo oOo Oco Oco O∞ Ooo cOo Oco oOo Oco oOo Oco oOo Oco Ooo oOo Oco Oco Oco oOo cOo Oco cOo cOo O O O O O O O O O O O O O co oo co co co co co oo ra co oo oo oo co oo oo co co oo oo oo co oo oo co ∞ co co oo co co oo co oo ∞
o z
Q o O O O l-v CO CO OO CO CO CO ∞ CO OO CO OO CO CO CO ∞ OO CO OO CO OO CO CO CO CO CO CO CO CO OO OO CO CO CO CO ∞ o C C CM CN CN CN CN ( CN C ( ( CN CN ( C CN CN C C C CN C CN CN CN CN C CN CN CN C^ G
Φ „ Φ ,, Φ Φ „ Φ ., Φ Φ „ Φ Φ „ Φ Φ ,x Φ ., Φ Φ „ Φ Φ , ,, Φ Φ .. Φ Φ ,, Φ Φ „ Φ
C u O c C O u C u e C u e C u e O c C u e C O O C z Z z o CZ cz ϋ CZ
>~ o 2 o 2 o o 2 ϋ 2 θ ϋ 2 o 2 ϋ 2 o 2 ϋ 2 o 2 ϋ 2 o 2 υ o 2 υ 2 o 2 ϋ 2 o o 2 ϋ 2 o 2 υ 2 o 2 ϋ 2 o 2 ra= π OT o _= OT π _= o w -= o OT π = π OT o -= o) w o = o w π -= w π -= π w o = o
O O c £ c O P. £ O c £ O p £ c O p £ p O c £ O c £ c O £ O £ O £ £ O £ O £ c O c £ o o Φ ® £ O Φ £ Φ £ Φ Φ P Φ " Φ £ Φ " Φ O Φ f ^ Φ o , - CD o Φ /^ Φ o Φ O Φ £ Φ Φ £ Φ M Φ £ Φ r Φ
H •- ^ c o c ^ o ^ o c o c ^ c o ^ c o c ^ c o ^ o c ^ c o ^ c o o c ^ c o c ^ o c ^ c o c o z σ Z D o z _ z σ 2 ^ σ 2 z σ σ z σ z p. o z o σ z z σ P. z σ o z o 22 α.
£ 55555555555555555555555555555555555555555555555555 c__
CO CO CO CO CO CN CN CN CN CN — — — — — — — — — — — — — — — — — CN CN CN CN CN CN CN CN CN — — — — — — — — — —
?cPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPPPPPPPPPPP P P P P bbbb bbb b bbb b b b b p o o 0 o o o o p o o o o o o o o o o p o p o o 0.P .P P P P P .P P .P .P .P .P .P .P .P .P .P .P .P .P .P .P o o o S o o CM — — — rr o — — o co rv —. CO O O CM OO CO CM lO p Prr a S £ - ^ S f j -o oLoo rrvr orv. S^ r5£ r —v. c-o rior -cN rrrr o — c rNr Orr o rv o — co io i-v — rv o — — rv o o co o y cO iO O cO cO LO rv O i- O O O -- I .n .Λ . (v O 0' r. _ ^ C (x| rt rt r (>- rr io rv O O O O o :__ t rr LO LO LO LO LO O O O O OO CO CO rv — — CM CN CN CN CN CN
CO t ∞ C UJ ^f ^v cO O OO — Ln OO CM u CM uD O cO rv o CM rr rv — rr — rr O cO CN CM CN UD
O rrr oS So So —'T - O oo rr rv — ^" — cO LO CN rr cM rr rr rv. o_ — co io rv — rv O CN rT LO Iv- - — CM CM - rr co - S ^ 2 co co uD K O O O O — — — CM CM rr rr rT rr LO LO LO LO LO rr rr tO LO LO iO iO O rv O O cO O CM ^. — ?. ?M f rN r_ O O -0 C0 00 O CN C C C C
rv
o O o o o rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rv rr rr
_ J _ι _ι
TABLE 4
SEQ ID NO: Template ID Start Stop Frame Domain Topology
284 LI: 151747.4:2001 MAY17 1296 1299 forward 1 TM Cytosolic
284 LI: 151747.4:2001 MAY17 1300 1322 forward 1 TM Transmembrane
284 LI: 151747.4:2001 MAY17 1323 1366 forward 1 TM Non-Cytosolic
284 LI: 151747.4:2001 MAY17 1367 1386 forward 1 TM Transmembrane
284 LI: 151747.4:2001 MAY17 1387 1392 forward 1 TM Cytosolic
284 LI: 151747.4:2001 MAY17 1393 1415 forward 1 TM Transmembrane
284 LI: 151747.4:2001 MAY17 1416 1434 forward 1 TM Non-Cytosolic
284 LI: 151747.4:2001 MAY17 1435 1457 forward 1 TM Transmembrane
284 LI: 151747.4:2001 MAY17 1458 1535 forward 1 TM Cytosolic
284 LI: 151747.4:2001 MAY17 1 532 forward 2 TM Non-Cytosolic
284 LI: 151747.4:2001 MAY17 533 555 forward 2 TM Transmembrane
284 LI: 151747.4:2001 MAY17 556 575 forward 2 TM Cytosolic
284 LI: 151747.4:2001 MAY17 576 598 forward 2 TM Transmembrane
284 LI: 151747.4:2001 MAY! 7 599 673 forward 2 TM Non-Cytosolic
284 LI: 151747.4:2001 MAY17 674 693 forward 2 TM Transmembrane
284 LI: 151747.4:2001 MAY17 694 845 forward 2 TM Cytosolic
284 LI: 151747.4:2001 MAY17 846 865 forward 2 TM Transmembrane
284 LI: 151747.4:2001 MAY17 866 896 forward 2 TM Non-Cytosolic
284 LI: 151747.4:2001 MAY17 897 919 forward 2 TM Transmembrane
284 LI: 151747.4:2001 MAY17 920 976 forward 2 TM Cytosolic
284 LI: 151747.4:2001 AY17 977 999 forward 2 TM Transmembrane
284 LI: 151747.4:2001 MAY17 1000 1085 forward 2 TM Non-Cytosolic
284 LI: 151747.4:2001 MAY17 1086 1 108 forward 2 TM Transmembrane
284 LI: 151747.4:2001 MAY17 1 109 1206 forward 2 TM Cytosolic
284 LI: 151747.4:2001 MAY17 1207 1229 forward 2 TM Transmembrane
284 LI: 151747.4:2001 MAY17 1230 1238 forward 2 TM Non-Cytosolic
284 LI: 151747.4:2001 MAY! 7 1239 1258 forward 2 ' TM Transmembrane
284 LI: 151747.4:2001 MAY17 1259 1327 forward 2 TM Cytosolic
284 LI: 151747.4:2001 MAY17 1328 1350 forward 2 TM Transmembrane
284 LI: 151747.4:2001 MAY17 1351 1372 forward 2 TM Non-Cytosolic
284 LI: 151747.4:2001 MAY17 1373 1395 forward 2 TM Transmembrane
284 LI: 151747.4:2001 MAY17 1396 1401 forward 2 TM Cytosolic
284 LI: 151747.4:2001 MAY17 1402 1424 forward 2 TM Transmembrane
284 LI: 151747.4:2001 MAY17 1425 1438 forward 2 TM Non-Cytosolic
284 LI: 151747.4:2001 MAY17 1439 1461 forward 2 TM Transmembrane
284 LI: 151747.4:2001 MAY17 1462 1535 forward 2 TM Cytosolic
284 LI: 151747.4:2001 MAY17 1 660 forward 3 TM Non-Cytosolic
284 LI: 151747.4:2001 MAY17 661 683 forward 3 TM Transmembrane
284 LI: 151747.4:2001 MAY17 684 857 forward 3 TM Cytosolic
284 LI: 151747.4:2001 AY17 858 880 forward 3 TM Transmembrane
284 LI: 151747.4:2001 MAY17 881 889 forward 3 TM Non-Cytosolic
284 LI: 151747.4:2001 MAY17 890 912 forward 3 TM Transmembrane
284 LI: 151747.4:2001 MAY17 913 1000 forward 3 TM Cytosolic
284 LI: 151747.4:2001 MAY17 1001 1020 forward 3 TM Transmembrane
284 LI: 151747.4:2001 MAY17 1021 1029 forward 3 TM Non-Cytosolic
284 LI: 151747.4:2001 MAY17 1030 1047 forward 3 TM Transmembrane
284 LI: 151747.4:2001 MAY17 1048 1085 forward 3 TM Cytosolic
284 LI: 151747.4:2001 MAY17 1086 1 108 forward 3 TM Transmembrane
284 LI: 151747.4:2001 MAY17 1 109 1 120 forward 3 TM Non-Cytosolic
284 LI: 151747.4:2001 MAY17 1 121 1 143 forward 3 TM Transmembrane Φ e 2 φ εco D g: £ 55555555555555555555555555555555555555555555555555
Q
CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO — — — — — — — — — — — — — — — — — — — CN CM CM CN CM CM CN CM CM CM CM CM CN CN CN CN rg_PbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPbPb
"" p o o o o o o o o o o o o o o o o o o p p p p p p p p p p p p p p p p p p p p p p p p p p p p o o o rv CM io rv O iO co rr rv — rr O co iO O O — rr O O O CM CO — o P CN. CN O — CN lO rv O O CM rr o rv o co O rr O co o o rv O CN io rv o — CO CO O CN lO CN LO r-i r O cO cO O LO CO O O cO O rr r rr iO O — CM rr CO LO CM CO -- CO LO o — — CN CN cO cO cO cO co rr rr rT r rr in CO o o o o o — — — — CM CN CN CO CO CO rr rr rr y CN g rr c lO N O O lO LO iO LO o rv rv oo oo <Ξ2 2 2 -
^ ^^ ^ ^ ^^^ ^^ ^^ ^ ^^ ^^ ^^ ^^ ^ ^ ^^ ^ ^ ^ ^ ^ ^^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^^ ^ ^^
Q<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<
Q O O O O O O O O O O O O O O O O O O O O O OδOδOδOδOδOδOδOδOδOδOδOδOδOδOδOδOδOδOδOδOδOδOδOδOδOδOδOδO ^ CN C CN C CN C C C C CN CN CN CM C C CN CN C C C CN C CN C C CN CN CN C
^. -^ -^. ^. -^ -^. -^. -^. -^ -^. -^. ^. -^. -^. -^. -^. X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
^ r rvr- irvr!rrvr |rvr; rrvr ir"vrrrvr |rv rv i v | vr_ r r-vr r-v |vr r . rv |v rvrrrvr_ r|vr. rv rvr; rrv rvrNθ ooo o o o
|v. rv |v. rv |v. rv. rv r o< oCN CNoCN oCN oC oCN oCNoCNoCN oCN o( CoNoC oC oC oCN oCN o(^ oo oooo o o o oo o o oo o
- -- - - - -- -- -- - - - -- -- - -- CO CO 00 00 CO C0 C0 CO CO C0 CO 0O CO 0O 0O 00 CO 00 00 C0 00 CO CO CO CO C0 C0 00 00 00 00 C0 00 00 CO lO iO iO LO iO lO LO lO lO LO lO LO uD LO iO O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
© O
CM z
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ Lθ ιO ιO ιO -) Lθ U3 i() ) lO ιO tO U) ιO ιO U5 U) U) ιO ) ιn ιn u) Λ ιO -) -) ) ιO -) Lθ Lθ - ι ιO
© Q co oo co co co oo oo co α3 <x3 oo oo oo oo oo oo co oo oo co co co oo co co co co oo co co co oo co co co co ∞ o C ( CN ( CN CN ( C C C C CN CN CN CN CN ( C CN CN C CN CN CN C C CN CN CN C CN CN C
01 O
Q c 'o ε 555555555555 55555555 o
Q
CN CM CN CN CN CM CM CN CM CN CN CO CO CO CO CO CO CO CO CO O O CO CO CO co co co CO CO CO CO co co CO φ ε P P P P P P P P P P P "O "O Ό P P P P P P P P P P P P P P P P P P P P P "O "O P P "O "O "O P "O "O "O P P P P y σ o o o σ σ o σ O o o π π π π π π o o O O O o O o o o o o o o o o o o o σ σ σ σ o o σ o σ o σ o o π u_ ^ ^ r* ^ ^ ^ ^ ? ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ r5 ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ o o O o o o o o o o o o o o o o o o o o O o o o o o o o o o o o o o o o o o o o o o o o o o o o o o
_ O O O O t0 00 O CM L0 l0 ro _ ^t rv. __ « -.,' O _ oo o o o cM rr rv u. ιo o „-, rr rT CM rr - CO OO O CO O CM UD P - ^ — ^^ —S —— CN CO lO — rr rv O O CN LO S — — o — 0O0 - —_ o r cn - rv. r rr rD-> c rxoi c iv nM- i c co — ( r Ω o r-v o o cM rvN. oC rvv. So ^ u ! —^: 9 rr g rv r ςς S irj ii — — CM CN CN cc rrrr rrrr rrrr Ω^ S^S
LU co CM CN CN c cθ ^f^ D^ ^^ ^^ oO oO -- - CN CCN CCNM CCNN rr rrrr rrr ^ S^ S^ S^ S^ CN U S D u5 r< r^ r K ∞ uo rv o v o o o O O o o
— CM iO — rr CO O rr o C 3 ON o CN CN
— — — CM CM CM CO CO CO rr rr O o 00 _ CN _ O rr rr to J o o CO CO CO CM UD
r-
© fM
© Λ LO lO LO LO l L lθ Lθ l L lO lO LO lO LO lO tO lO lO lθ Lθ lO lθ L LO LO LO L O O O O O
Q oo co co co oo co co oo oo oo oo oo co co co oo oo oo co oo oo oo co oo oo co oo co co co co co co co ∞ o — ( CN ( CN CN C C CN CN C C ( CN CN ( C C C CN CN CN ( CN CN CN ( CN C
G LU CO
TABLE 4
SEQ ID NO: Template ID Start Stop Frame Domain Topology
288 U:2049995.3:2001 MAY17 1454 1476 forward 1 TM Transmembrane
288 LI:2049995.3:2001 MAY17 1477 1504 forward 1 TM Non-Cytosolic
288 U:2049995.3:2001 MAY17 1505 1527 forward 1 TM Transmembrane
288 U:2049995.3:2001 MAY17 1528 1642 forward 1 TM Cytosolic
288 LI:2049995.3:2001 MAY17 1643 1660 forward 1 TM Transmembrane
288 LI:2049995.3:2001 MAY17 1661 1668 forward 1 TM Non-Cytosolic
288 U:2049995.3:2001 MAY17 1 831 forward 2 TM Non-Cytosolic
288 U:2049995.3:2001 MAY17 832 854 forward 2 TM Transmembrane
288 U:2049995.3:2001 MAY17 855 913 forward 2 TM Cytosolic
288 LI:2049995.3:2001 MAY17 914 936 forward 2 TM Transmembrane
288 U:2049995.3:2001 MAY17 937 1061 forward 2 TM Non-Cytosolic
288 U:2049995.3:2001 MAY17 1062 1084 forward 2 TM Transmembrane
288 LI:2049995.3:2001 MAY17 1085 1096 forward 2 TM Cytosolic
288 U:2049995.3:2001 MAY17 1097 1 1 19 forward 2 TM Transmembrane
288 U:2049995.3:2001 MAY17 1 120 1 122 forward 2 TM Non-Cytosolic
288 U:2049995.3:2001 MAY17 1 123 1 145 forward 2 TM Transmembrane
288 U:2049995.3:2001 MAY17 1 146 1635 forward 2 TM Cytosolic
288 LI:2049995.3:2001 MAY17 1636 1658 forward 2 TM Transmembrane
288 U:2049995.3:2001 MAY17 1659 1668 forward 2 TM Non-Cytosolic
288 LI:2049995.3:2001 MAY17 1 1 125 forward 3 TM Non-Cytosolic
288 LI:2049995.3:2001 MAY17 1 126 1 148 forward 3 TM Transmembrane
288 LI:2049995.3:2001 MAY17 1 149 1263 forward 3 TM Cytosolic
288 LI:2049995.3:2001 MAY17 1264 1283 forward 3 TM Transmembrane
288 LI:2049995.3:2001 MAY17 1284 1302 forward 3 TM Non-Cytosolic
288 LI:2049995.3:2001 MAY17 1303 1325 forward 3 TM Transmembrane
288 U:2049995.3:2001 MAY17 1326 1448 forward 3 TM Cytosolic
288 U:2049995.3:2001 MAY17 1449 1471 forward 3 TM Transmembrane
288 U:2049995.3:2001 MAY17 1472 1667 forward 3 TM Non-Cytosolic
289 U:2052097.2:2001 MAY17 1 939 forward 3 TM Non-Cytosolic
289 U:2052097.2:2001 MAY17 940 962 forward 3 TM Transmembrane
289 LI:2052097.2:2001 MAY17 963 982 forward 3 TM Cytosolic
289 LI:2052097.2:2001 MAY17 983 1005 forward 3 TM Transmembrane
289 LI:2052097.2:2001 MAY17 1006 1008 forward 3 TM Non-Cytosolic
289 LI:2052097.2:2001 MAY17 1009 1031 forward 3 TM Transmembrane
289 U:2052097.2:2001 MAY17 1032 1062 forward 3 TM Cytosolic
290 Ll:209351.22:2001 MAY17 1 845 forward 2 TM Non-Cytosolic
290 Ll:209351.22:2001 MAY17 846 868 forward 2 TM Transmembrane
290 Ll:209351.22:2001 MAY17 869 922 forward 2 TM Cytosolic
290 LL209351.22:2001 MAY17 1 730 forward 3 TM Non-Cytosolic
290 LL209351.22:2001 MAY17 731 753 forward 3 TM Transmembrane
290 Ll:209351.22:2001 MAY17 754 853 forward 3 TM Cytosolic
290 LL209351.22:2001 MAY17 854 876 forward 3 TM Transmembrane
290 Ll:209351.22:2001 MAY17 877 922 forward 3 TM Non-Cytosolic
291 LI:2120481.1 :2001 MAY17 1 218 forward 1 TM Non-Cytosolic
291 LI:2120481.1 :2001 MAY17 219 241 forward 1 TM Transmembrane
291 LI:2120481.1 :2001 MAY17 242 252 forward 1 TM Cytosolic
291 U:2120481.1 :2001 MAY17 253 275 forward 1 TM Transmembrane
291 LI:2120481.1 :2001 MAY17 276 284 forward 1 TM Non-Cytosolic
291 LI:2120481.1 :2001 MAY17 285 304 forward 1 TM Transmembrane
291 LI:2120481.1 :2001 MAY17 305 344 forward 1 TM Cytosolic
_5 ε 55555555555555555 555555 5555555555555555 o
Q
CM CN CM — CO CO CO CO CO CO CO CO iO CO CO CN CM CN CO CO CO CM φ P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P Ό P P P P P P P P P P P P P ε o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o σ o o o o o o o o o o o o o o π o
^ ^ ^ ^ ^ o5 ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ r* ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o - rv o o — rr co o rv o — CM uD — o
0 -0 00 0 0 00 0 — CM UO UD CM rT O O o co co rr rr rr rr iO iO iO iO CN c LO LO LO
CO
< t iO oo rv o CM iO rr rv oo — co o o — — rr co — — o — o Λ , 00 CO N O O CO CO O -n _ CM uj — rr uj oo O rr o oo — o oo o — CM UD — CM rr — O rr o rv O CN co io rv co co co rr rr rr rr iO uD iO l iO CO _
— — — — CN CN CN CM CM - c? Ξ 2 o rr o — — co — — rr — O CN co iO O CN _
CM CM CN — — I _ -O ιO ιO LO CO CO
r-
© 0 f
© — CN (N (N CN CN CN CM CN CN CN ( CN ( CN cθ cθ cθ c cθ c cθ cO cθ rr rr rr rr rr rr ιO UD Lθ uD tO UD UD uD
Q o O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O o CM CN CM CN CM CM CM CM CN CN CN CN CM CM CM CN CN CN CM CN CN C CN CN ( CN CN CM (N (N CN CN CN CM ( CN CN CM CN CM C CM CN CN CM CN CM CN CM
LU CO
TABLE 4
SEQ ID NO: Template ID Start Stop Frame Domain Topology
295 U:2209684.5:2001 MAY17 838 860 forward 2 TM Transmembrane
295 LI:2209684.5:2001 MAY17 861 971 forward 2 TM Cytosolic
295 LI:2209684.5:2001 MAY17 972 994 forward 2 TM Transmembrane
295 U:2209684.5:2001 MAY17 995 1033 forward 2 TM Non-Cytosolic
295 LI:2209684.5:2001 MAY17 1034 1056 forward 2 TM Transmembrane
295 LI:2209684.5:2001 MAY17 1057 1068 forward 2 TM Cytosolic
295 LI:2209684.5:2001 MAY17 1069 1091 forward 2 TM Transmembrane
295 LI:2209684.5:2001 MAY17 1092 1 100 forward 2 TM Non-Cytosolic
295 LI:2209684.5:2001 MAY17 1 101 1 123 forward 2 TM Transmembrane
295 U:2209684.5:2001 MAY17 1 124 1527 forward 2 TM Cytosolic
295 LI:2209684.5:2001 MAY17 1528 1550 forward 2 TM Transmembrane
295 LI:2209684.5:2001 MAY17 1551 1601 forward 2 TM Non-Cytosolic
295 LI:2209684.5:2001 MAY17 1602 1619 forward 2 TM Transmembrane
295 U:2209684.5:2001 MAY17 1620 1797 forward 2 TM Cytosolic
295 LI:2209684.5:2001 MAY17 1798 1817 forward 2 TM Transmembrane
295 LI:2209684.5:2001 MAY17 1818 1840 forward 2 TM Non-Cytosolic
295 U:2209684.5:2001 MAY17 1 837 forward 3 TM Non-Cytosolic
295 LI:2209684.5:2001 MAY17 838 860 forward 3 TM Transmembrane
295 LI:2209684.5:2001 MAY17 861 970 forward 3 TM Cytosolic
295 LI:2209684.5:2001 MAY17 971 993 forward 3 TM Transmembrane
295 LI:2209684.5:2001 MAY17 994 1084 forward 3 TM Non-Cytosolic
295 U:2209684.5:2001 MAY17 1085 1 107 forward 3 TM Transmembrane
295 U:2209684.5:2001 MAY17 1 108 1532 forward 3 TM Cytosolic
295 U:2209684.5:2001 MAY17 1533 1555 forward 3 TM Transmembrane
295 U:2209684.5:2001 MAY17 1556 1569 forward 3 TM Non-Cytosolic
295 U:2209684.5:2001 MAY17 1570 1589 forward 3 TM Transmembrane
295 U:2209684.5:2001 MAY17 1590 1600 forward 3 TM Cytosolic
295 LI:2209684.5:2001 MAY17 1601 1623 forward 3 TM Transmembrane
295 U:2209684.5:2001 MAY17 1624 1839 forward 3 TM Non-Cytosolic
296 U:222795.28:2001 MAY17 1 1525 forward 1 TM Non-Cytosolic
296 U:222795.28:2001 MAY17 1526 1548 forward 1 TM Transmembrane
296 LI:222795.28:2001 MAY17 1549 1686 forward 1 TM Cytosolic
297 U:228273.25:2001 MAY17 1 1378 forward 2 TM Non-Cytosolic
297 LI:228273.25:2001 MAY17 1379 1401 forward 2 TM Transmembrane
297 LI:228273.25:2001 MAY17 1402 1501 forward 2 TM Cytosolic
297 LI:228273.25:2001 MAY17 1 45 forward 3 TM Cytosolic
297 LI:228273.25:2001 MAY17 46 68 forward 3 TM Transmembrane
297 LI:228273.25:2001 MAY17 69 659 forward 3 TM Non-Cytosolic
297 LI:228273.25:2001 MAY17 660 682 forward 3 TM Transmembrane
297 LI:228273.25:2001 MAY17 683 694 forward 3 TM Cytosolic
297 U:228273.25:2001 MAY17 695 717 forward 3 TM Transmembrane
297 U:228273.25:2001 MAY17 718 1501 forward 3 TM Non-Cytosolic
298 LI:232386.31 :2001 MAY17 1 1013 forward 1 TM Non-Cytosolic
298 LI:232386.31 :2001 MAY17 1014 1032 forward 1 TM Transmembrane
298 LI:232386.31 :2001 MAY17 1033 1074 forward 1 TM Cytosolic
298 U:232386.31 :2001 MAY17 1075 1097 forward 1 TM Transmembrane
298 U:232386.31 :2001 MAY17 1098 1 153 forward 1 TM Non-Cytosolic
298 LI:232386.31 :2001 MAY17 1 1012 forward 2 TM Non-Cytosolic
298 U:232386.31 :2001 MAY17 1013 1032 forward 2 TM Transmembrane
298 LI:232386.31 :2001 MAY17 1033 1089 forward 2 TM Cytosolic
O 55555555
O ε 5 Q
CM CN CN CM CO CO CO co CO CO CO CO O O co CN CM CM CN CN CM CN CM CN CN CM CO CO CO CO CO
P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P o o o o o o o o o o o o o o o o o o o o σ o σ o o σ o o o o σ o o o
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ c ^ ^ ^ ^ ^ ^ ^ ^ ^ o o o o o o o o o o o o 0 o ? ^ ^ o o o o o o o o o o o o o o o o o 0 o o
_ o CO rr rv o o rv o rr o rv O O — rr rv o rr rv rr - O rr rv — o — LO rv o — CO J CO UJ . O _ OO _ O CM LO rv LO CO CO O LO
00 0 <— — — CM CN CO CO CO CO O O O — — lO uJ oO OO OO O O » o 52 - — - _ £ _ oo - o co rv o
< o o — CM UJ _ ^ LO_ 00 — CO CO O CO CM LO r __ LO 00 to rv rv o o — rr CN iO O oO rv O cO — O CO rv O CM uD cO — J CO π-> — J CO rv o — to rv co o - rf i0 oo _ rv oo θ co tθ rv ιθ oo co 0 _ 0^ - CM rr £ o — — — ~ — co rr uj rv o O — CN r O O — — — CN CN CO CO CO CO O O — — 00 o — — — — rv o o- o- o" 2 - - - u rv o O — —
ιv. rv rv rv rv rv v rv rv rv rv
■— ■— ■— r— i— i— ■— ■— ■— ■— —
Φ ^ ^ - - - - - - - - ^
-O O O O O O O O O O O O
O O O O O O O O O O O O n CM CM CM CN CM CM CN CM CM CM CM C — — — — — — — — — — — t (T5 co co co cq c co co co co co i— o o o o o o o o o o o
OO CO OO OO CO CO OO OO CO OO CO
CO CO CO CO CO CO CO CO CO CO CO
CM CN CN CN CN CN CN CN CN CN CN
CO CO CO CO CO CO CO CO CO CO CO
C CN CN CN C C (N (N CN C CN r- OooO O O O O O O O O O O O O O O O O O o CN CMoCNoC oCMoCMoCMoCNoCNoC ooooooooo
555555 555555555555 555555555555555 5555555555 o
CO O CO CO CO CO co CM CM CN CM CN CN CN CN CN — — — CM CN CM CN CN CM CM CN CM CN CM CO CO CO CO CO CO CO CO CO Φ P P P P P P P _ "2 £ £ "2 "2 "2 "2 £ "2 p p £ £ "σ tP o^ o^ o^ σ^ o o σ bb£bbbbbb£b£b b b b b b b b o b b b b b o o o o o o o o o o o o o o o o o o o o o o o o o o o o p p p p p p p p p p p p p p p p p p p p o o
PrS - O -o S r r^ S ∞ ^ O O Ig - rr o co CN LO LO - rr rr rv CM - cM io io rr rv rv o rr rr o o o rv io - ,-, o CM io co o co o — cN rr o o o cN O co co o — rr iv. n; ^ cM o cM O
£ - cN CN r? r u uD o 9 O ^O uO3 ^ co _2 ∞ 2; _-: ^ _3 S 9; --: ≤ S ^ cS O o - co co co rr o co co co rr rr rr o o CO rr rr c C C CM C C C CO CO rr rr cO l f oV o o r- C I CD cD rD
-t CM iO rv uD O CN O CO
< π -o co — n u) co L N _. - - cN CN rr rr L io - co
r~-
© f
© O o oo o CN CN CN CN CN CN CM CN CM CN CN CM CM CM CN CN CN CM CN CN CN CN CN o __ 0 o_ o _ o _ o _ oo _ oo _ oo _ oo _ oo_ oo_ oo_ o_ o_ o_o_o_o_o_ o_o_o_ o_o_ o_ o_ o_ O_ O_ O_ O _ O _ O _ O _ O_ O_ O_ O_ O _ O O O O O O O O O _ O__ O__
— CN C CN CN CN CN CN CN CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO
G
5— I 5— 5 1— r 5— r 5— ► 5— 555555555555555555555555555555555555
CO CO CO CO CO CO CO CO CO — — ■— i— i— — — — CO CO CO CO CO CO CO CO CO — — •— ■— ■— — ■— ■— ■— — — — — — — — — — — —
Φpppppppppppppppppppppppppppppppppppppppppppppp _ "2 "2 £ £
O o o σ σ o o o o o o o σ o o o o o o o b o b b b o o o o o o o o o p o o o o o o o o o p p o o N C COO OO — ( iO n iO So So ≥rr
rv v v rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv rv iv. rv rv rv rv rv rv rv rv rv rv rv rv rv v l-v rv
> > > > > > > > > > > > > > > > > >
>
Q > > > > > > > > > < < < < < < < < < < < < < < < < < < < < < < < < 5555555 < < < < < < < < < < < < < < < < < 5 5
0) 5 ,— — 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 55 5 5 5 5 5 5 5 5 5 5 5 5 u o o o o o o o o o o o o o o o o CD CD o o o o o o o O o o O o o o O O O o o o o O o O α o o CN CN CN CN CN CN CN O 0) 03 03 C3 C) C3 C3 C 3 C ) C ) C 3 C 3 C 3 C 3 C 3 8 o
C ) C 3 C ) C ) C ) C 3 C ) o o C 3 CJ CJ CD CJ o o o CD CD o C C3 C3
CN CN CN CN CN CM CM CN CN CN CM CN CN CN CM CN CN CM CM CN CN CM CN CM ε CM CN , — , — , — , — , — , — , — CM CM CN CN CN CN CN CN CN CN CN CN CN CM CN CN CM CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO rv rv CO CO CO CO CO CO CO CO CO CO 00 CO 00 00 00 00 00 00 00 00 CO φ
1— r^ rv Ch Ch , — r rv rv v rv rv rv rv rv rv. l-v rv rv rv CN CM CM CM CN CM CN CN CN CN CM CM CN CM CN CN CN CN CN CN CN CN CN CN
(h (h C ) C 3 C ) C ) O C ) C ) CN CN ON U) U) U) U) U) U) u> U) u> U) U) U) U3 U3 lO LO U Uj UJ Uj lO LO LO lO LO UJ UJ U UJ lO UJ UJ UJ UJ UJ UJ UJ U u> U) C ) C 3 C 3 C ) C ) CJ C ) CN CN ON o o o o c> c> o o o Ch ih ih " ih co co co co co co co co co co co co co co co co co co co co co co co co
U) U) o O «o o ) -O O CN CN CN 0M CN CN CN CN CN (N (N CN (N CM (M (M (N LO LO LO UJ Uj LO LO tO UJ lO UJ lO LO lO LO lO UJ LO UJ UJ UJ UJ UJ UJ rr rr U) U3 LO U3 to U3 K O O O CO CO CO CO CO CO CO CO CO CO CO Ci CO CO co co co co co co co co co co co co co co co co co co co co co co co co
CN CN CN CN CN CN CN CM CN CN CN CN CO CO CO CO CO C) CO CO CO CO O CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO r~-
© O z
© coO coO coO coO coo coo cooorr rororrouj UoJ UoJoiO LoO LoO ioO U uj u u u
Q O cooLO cooJ coocoocooj cooou oOoOoO OoOooO OoOoOo ooooo ooooooooo o co co co co co co co co co co co co co co co co co co co co co co co co co co co o o coocoocoocoocoocoocoocoocooco cooocooco coo coo
G LU o
c "o 5555555555555555555 555555555555 o ε 5
Q
— — — CN ( (N CN C C C CN CN C C CN ( CO C CO CO CO CO CO CO CO CO CO CO CO C CO C φpppppppppppppppppppppppppppppppppppppppppppppppppp o σoooooσooooooooσooooσooσooσoσσoσoooooσoσoooooooooo opooooooooooooooooooooooooooooooooooppoooooooooooo
CO O rv o rr CM o rv O O CM CM co co co rr rr rr rr - r rrr ro-v r cvo —o uoj ccoN co co co rr rr rr
r- o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o rv rv rv rv rv rv i-v
Q § O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O o CO co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co c^
G LU co
TABLE 4
SEQ ID NO Template ID Start Stop Frame Domain Topology
308 1.1:344528.1 2001 MAY 17 1 940 forward 1 TM Non-Cytosolic
308 1.1:344528.1 2001 MAY 17 941 963 forward 1 TM Transmembrane
308 U:344528.1 2001 MAY 17 964 1309 forward 1 TM Cytosolic
308 U:344528.1 2001 MAY 17 1310 1332 forward 1 TM Transmembrane
308 Ll:344528.1 2001 MAY 17 1333 1349 forward 1 TM Non-Cytosolic
308 Ll:344528.1 2001 MAY 17 1 853 forward 2 TM Non-Cytosolic
308 1.1:344528.1 2001 MAY 17 854 876 forward 2 TM Transmembrane
308 1.1:344528.1 2001 MAY 17 877 929 forward 2 TM Cytosolic
308 Ll:344528.1 2001 MAY 17 930 952 forward 2 TM Transmembrane
308 Ll:344528.1 2001 MAY 17 953 1349 forward 2 TM Non-Cytosolic
309 1.1:374578.27:2001 MAY17 1 496 forward 1 TM Cytosolic
309 U:374578.27:2001 MAY17 497 519 forward 1 TM Transmembrane
309 1.1:374578.27:2001 MAY17 520 523 forward 1 TM Non-Cytosolic
309 LI:374578.27:2001 MAY17 1 496 forward 2 TM Non-Cytosolic
309 1.1:374578.27:2001 MAY17 497 519 forward 2 TM Transmembrane
309 LI:374578.27:2001 MAY17 520 523 forward 2 TM Cytosolic
309 U:374578.27:2001 MAY17 1 495 forward 3 TM Non-Cytosolic
309 1.1:374578.27:2001 MAY17 496 518 forward 3 TM Transmembrane
309 1.1:374578.27:2001 MAY17 519 523 forward 3 TM Cytosolic
310 Ll:381993.13:2001 MAY17 1 69 forward 1 TM Cytosolic
310 Ll:381993.13:2001 MAY17 70 89 forward 1 TM Transmembrane
310 Ll:381993.13:2001 MAY17 90 103 forward 1 TM Non-Cytosolic
310 Ll:381993.13:2001 MAY17 104 126 forward 1 TM Transmembrane
310 1.1:381993.13:2001 MAY17 127 138 forward 1 TM Cytosolic
310 Ll:381993.13:2001 MAY17 139 161 forward 1 TM Transmembrane
310 U:381993.13:2001 MAY17 162 205 forward 1 TM Non-Cytosolic
310 LI:381993.13:2001 MAY17 206 225 forward 1 TM Transmembrane
310 Ll:381993.13:2001 MAY17 226 394 forward 1 TM Cytosolic
310 Ll:381993.13:2001 MAY17 395 417 forward 1 TM Transmembrane
310 1.1:381993.13:2001 MAY17 418 2098 forward 1 TM Non-Cytosolic
310 1.1:381993.13:2001 MAY17 2099 2121 forward 1 TM Transmembrane
310 1.1:381993.13:2001 MAY17 2122 2239 forward 1 TM Cytosolic
310 U:381993.13:2001 MAY17 2240 2262 forward 1 TM Transmembrane
310 1.1:381993.13:2001 MAY17 2263 2282 forward 1 TM Non-Cytosolic
310 1.1:381993.13:2001 MAY17 1 150 forward 2 TM Cytosolic
310 LI:381993.13:2001 MAY17 151 173 forward 2 TM Transmembrane
310 Ll:381993.13:2001 MAY17 174 177 forward 2 TM Non-Cytosolic
310 LI:381993.13:2001 MAY17 178 195 forward 2 TM Transmembrane
310 U:381993.13:2001 MAY17 196 201 forward 2 TM Cytosolic
310 LI :381993.13:2001 MAY 17 202 224 forward 2 TM Transmembrane
310 LI:381993.13:2001 MAY17 225 1670 forward 2 TM Non-Cytosolic
310 U:381993.13:2001 MAY17 1671 1693 forward 2 TM Transmembrane
310 LI :381993.13:2001 MAY 17 1694 2196 forward 2 TM Cytosolic
310 U:381993.13:2001 MAY17 2197 2216 forward 2 TM Transmembrane
310 LI :381993.13:2001 MAY 17 2217 2239 forward 2 TM Non-Cytosolic
310 U:381993.13:2001 MAY17 2240 2262 forward 2 TM Transmembrane
310 U:381993.13:2001 MAY17 2263 2282 forward 2 TM Cytosolic
310 U:381993.13:2001 MAY17 1 20 forward 3 TM Cytosolic
310 LI:381993.13:2001 MAY17 21 43 forward 3 TM Transmembrane
310 U:381993.13:2001 MAY17 44 102 forward 3 TM Non-Cytosolic TABLE 4
SEQ ID NO: Template ID Start Stop Frame Domain Topology
310 LI:381993.13:2001MAY17 103 125 forward 3 TM Transmembrane
310 U:381993.13:2001MAY17 126 144 forward 3 TM Cytosolic
310 U:381993.13:2001MAY17 145 167 forward 3 TM Transmembrane
310 Ll:381993.13:2001 MAY17 168 1179 forward 3 TM Non-Cytosolic
310 Ll:381993.13:2001 MAY17 1180 1202 forward 3 TM Transmembrane
310 Ll:381993.13:2001 MAY 17 1203 1342 forward 3 TM Cytosolic
310 Ll:381993.13:2001 MAY! 7 1343 1362 forward 3 TM Transmembrane
310 Ll:381993.13:2001 MAY17 1363 1381 forward 3 TM Non-Cytosolic
310 LI :381993.13:2001 MAY 17 1382 1401 forward 3 TM Transmembrane
310 LI :381993.13:2001 MAY 17 1402 1421 forward 3 TM Cytosolic
310 Ll:381993.13:2001 MAY17 1422 1444 forward 3 TM Transmembrane
310 Ll:381993.13:2001 MAY17 1445 1453 forward 3 TM Non-Cytosolic
310 Ll:381993.13:2001 MAY17 1454 1471 forward 3 TM Transmembrane
310 Ll:381993.13:2001 MAY17 1472 1477 forward 3 TM Cytosolic
310 Ll:381993.13:2001 MAY17 1478 1500 forward 3 TM Transmembrane
310 Ll:381993.13:2001 MAY 17 1501 2282 forward 3 TM Non-Cytosolic
311 LI:400373.2:2001MAY17 1 145 forward 1 TM Non-Cytosolic
311 LI:400373.2:2001MAY17 146 168 forward 1 TM Transmembrane
311 LI:400373.2:2001MAY17 169 469 forward 1 TM Cytosolic
311 U:400373.2:2001MAY17 470 492 forward 1 TM Transmembrane
311 LI:400373.2:2001MAY17 493 1295 forward 1 TM Non-Cytosolic
311 LI:400373.2:2001MAY17 1 1245 forward 2 TM Non-Cytosolic
311 LI:400373.2:2001MAY17 1246 1268 forward 2 TM Transmembrane
311 LI:400373.2:2001MAY17 1269 1295 forward 2 TM Cytosolic
311 U:400373.2:2001MAY17 1 850 forward 3 TM Non-Cytosolic
311 U:400373.2:2001MAY17 851 873 forward 3 TM Transmembrane
311 U:400373.2:2001MAY17 874 1049 forward 3 TM Cytosolic
311 U:400373.2:2001MAY17 1050 1072 forward 3 TM Transmembrane
311 U:400373.2:2001MAY17 1073 1231 forward 3 TM Non-Cytosolic
311 U:400373.2:2001MAY17 1232 1254 forward 3 TM Transmembrane
311 U:400373.2:2001MAY17 1255 1258 forward 3 TM Cytosolic
311 U:400373.2:2001MAY17 1259 1281 forward 3 TM Transmembrane
311 LI:400373.2:2001MAY17 1282 1295 forward 3 TM Non-Cytosolic
312 LI:400963.6:2001MAY17 1 1292 forward 2 TM Non-Cytosolic
312 U:400963.6:2001MAY17 1293 1315 forward 2 TM Transmembrane
312 LI:400963.6:2001MAY17 1316 1318 forward 2 TM Cytosolic
313 U:404874.8:2001MAY17 1 1121 forward 2 TM Non-Cytosolic
313 U:404874.8:2001MAY17 1122 1144 forward 2 TM Transmembrane
313 LI:404874.8:2001MAY17 1145 1150 forward 2 TM Cytosolic
313 U:404874.8:2001MAY17 1151 1173 forward 2 TM Transmembrane
313 U:404874.8:2001MAY17 1174 1200 forward 2 TM Non-Cytosolic
313 LI:404874.8:2001MAY17 1201 1223 forward 2 TM Transmembrane
313 U:404874.8:2001MAY17 1224 1245 forward 2 TM Cytosolic
313 LI:404874.8:2001MAY17 1 1029 forward 3 TM Non-Cytosolic
313 LI:404874.8:2001MAY17 1030 1052 forward 3 TM Transmembrane
313 LI:404874.8:2001MAY17 1053 1123 forward 3 TM Cytosolic
313 LI:404874.8:2001MAY17 1124 1146 forward 3 TM Transmembrane
313 LI:404874.8:2001MAY17 1147 1190 forward 3 TM Non-Cytosolic
313 U:404874.8:2001MAY17 1191 1213 forward 3 TM Transmembrane
313 U:404874.8:2001MAY17 1214 1244 forward 3 TM Cytosolic c "σ 5555555555555555555555555555555555 o
Q
— — — — — — — — — — — — — — — — — — — CN C ( (N CN (N ( CN CN CN C C CN C C CN < CN CN CM CN CN CM CN CM CO CO CO CO CO CO
£ O£D£-£.£b£D£O£O£.£D£b£b£o£O£.£D£O£O£-£b£-£O£O£O£O£.£O£D£D£b£D£D£b£D£D£O£O£.£D£b£O£-£O£D£O£D£b£b£D£D o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o opppppppppppppppp o o o uj oo orv c ^
CQ O CM — rr o cM O co rr rv oo — to oo o co o co rv o — rr co - rv o rr rv u co o o co — o co io oo cM iO uj oo < π — u -j co- -rv o - — r -_r. c-o- .u-D. U.-j -rv rr rv i-v O - —— co o co _ o o — co uj oo co — cM rr — co rv o — rr o oo rr o co o cM rr o i_ ~ co co rr rr uj uj o o rv rv. oo co o o O ~ O O O CN CN LO lO rv rv rv cO CO CO O O O O O O O O — — — CM CM CN
CO CM CM CN CN — — — — — — — — — — — — — — CN CN CN CN CM CN CM CN CN CN 5 v rv v iv. rv r rv rv rv rv rv rv rv rv rv rv l-v rv rv rv l-v rv rv. rv r-v r rv rv l-v rv rv rv rv l-v r r-v rv rv rv rv l-v rv rv rv rv. rv rv
Q < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
55555555555555555555555555555555555555555555555555
Φ o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o O o o o o o o o O o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o n CM CN CM CN CN CN CM CM CN CM CM CN CM CM CM ε co oo CO 00 CO 00 00 co CO oo CO co co oo oo 00 CO CO 00 CO CO CO 00 CO 00 CO 00 00 CO 00 00 oo oo oo 00 CO 00 CO 00 00 oo co co co 00 00 00 oo 00 00
£ CO oo co oo co 00 00 00 SB 00 CO 00 00 oo 00 CO 00 00 00 00 00 CO oo 00 CO 00 00 CO CO 00 00 00 00 00 00 00 CO CO CO 00 CO CO oo oo CO UJ UJ UD J UD J J J UJ UD UD J UD J J UJ UJ UJ J J UD UJ UJ J UJ J UJ UJ J UD LO J J UJ UJ UJ UJ UJ UJ J UJ UJ
U UJ J J UJ UJ UJ UJ J J UJ J UJ UD J UJ J UJ UJ UD UJ UJ UJ UJ UJ UJ UJ J LO J UJ UJ UJ J UJ J UJ UJ UJ UJ UJ UJ o o O o o o o o o o o o O o o o O o o o o O O o o o o o o o o O o o o o o o o O O o o o o rr rr rr o rr o rr rr rr rr rr rr 8 rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr r~-
© o f
© o — C CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO
G LU O
o
00 CO co co CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CN CN CN CM CN CM CM CN CN CO CO CO O CO CN CM CM φ ε P P P P P P P P P P P P P P P P P υ o π o o O O O o o o o π o O O π π
_. ^ ^ c* ^ ^ ^ ^ ^ ^ r5 o o o o o o o o o o o o O O O o o αc uj rr rv o oo rv o o co rv o o rv oo — rv o o _ CM rr o ιv. o — rr o oo o cM rr o o co rr
O O O O O O O O O O O — — — CM CM CM
CO — — — — CN CN CN CN CN CN CN CN CN CN CN co -fc UJ CO O UJ oo o o co — — rr oo — o oo o cN < D 5 .. . O CO O — rr θ OO O CN UJ O O cO _ CO O O rv o rr CO o CO CO o o ) CO <>- ON rr O rr O oo _ J CO _
009 o C O ?O O O O O O O O O — — — CM CN o — ON U O — — — — — CM CN CM CN CN CN CN CN CN CM — — rr CM CN CM o CD o 1 rr o
— rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr io uj LO LO u o o o o o o o o o rv rv rv rv rv oo oo co o o o o o o o o o o o o — co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co
G LU CO
u u c u c c- u ω u u u u ω u u c- u u u u u c- c- u u c- c- c- c u c. U l C- U C C- C- U U U U C- C- U U I l U NJ i Nj Nj ro ro isj NJ Nj r w ro i j Nj ro ro NJ Nj ro isj o o r ro o ro ro ro ro ro ro ro ro — — —— — —— — — — — — — — —- o o C-D C D C ~D o o oooooooooooooooooooooo
— ' oo n n ∞ B rTl '^ on 'r_! '__ 'i_! 'i_! j^ '^ * ^ Go Go Go Go O O Oi Cn .fc- .C- .C- .t_. ro ro O O O Oi ^ ^ J- W U C- M I -+
^ ∞ — S 2 < ^ -J ro vj rs ___ v_ [^ c _-. en
- O O --1 - O ^ 8 r v^ _ g: _≤ ^; _ g rθ W Oi G O __. - O vj r C* .|-, -J C O C_ K j_. O CO .C_ - Cn rO O G3 ^ o oo o oo o o cS cS 3 c3 cSκo c5 c5 b O κoh b c5 c3 c3 cS c3 cScScS o o o
Q Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω ddddddddddddddddddddddddddddddddddddddddddddddddddφ
C_3 G C -^ --' -- ^ --' G3 GO W CA3 G3 G3 G0 3 GO GO G CA3 G G G0 03 C_3 C_3 G3 W W W
D o
S2S_S^22?SSSS_S ssssssss ^ Z ^ ^ ^ ^. 3
Ω
c "o ε 555555 555555555555555555 o
Q co co co co — — — — — — — — — C C CM CN CN CN CN CM CM CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CM — — — — — — — — — CN CN CM
££££££££££££££££££££££££££££££££b£b£b£b£b£b£b£b£b£b_bb_ p p b_ p p p bbbbbbbbbbbbb bbbbbbbbbbbbbbbbb b_ o b b b b
£££££££££££££ 000000 000000 000000000 0000000000 000000
Ω. UJ O OO O CM OO — O O — rT - UJ OO O CO CN UJ UJ CO O OO — O co rr rr — rr o o o cO UJ rr O cO tO cO LO OO O O 00 — __ ?? — O
0 oo CN rr i-v o o o cN rr o co io — — co cM rr io rv o — — rr O O O rt- „-, — CN CN UD CO — O rr rv — o — rr co rv. o O CM co _ co _ co - rr ' u io rv rv cN rr rr uj iO uJ uj u o cM uj o o rv iv. oo co o CD — — CN — O CM r o CN rr rr rv CN
- — — CM — — — — — — — — CM 3 C CM CM CN CO — CM CM cO cO CO cO CO rr — CN CN t O C M Iv- O CM UJ O O — rr cO O O O O N — rr UJ UJ CN UJ |v, o rv UJ — —
< CO O N O C
O O OO CN UJ _ rv oO Oo C CM cN τr rv co ιo _ — co cN rr uj iv. o - — rr co uj rr o co uj co o oo o o oo O CM O CO CO O O CN UD CO rv rv. o o O CO O rr uj uj |v. rv ~ rr rr uj uj uj uj uj o rr rr uj uJ O O lv. rv co co o o - — — O CN CO O CN rr rr rv — o —
CM CN CN — CM CM CO CO CO CO CO — CM
r~-
© o
« CN CN CN CN c c cO cθ cO cO cO cO cθ cθ cθ cθ cθ cθ cθ cθ cθ cθ cθ cO cO cO cO c cθ cθ cO cθ cθ
© Q CN CN ( (N <>J C C C C C CN ( C CN C CN CN ( CN CN ( C CN e C^ o — CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO C^
G LU CO
CN CN CN CN CN CN C CO C C ( CN CN CM CM CO CO C CO CO CO CO CO CO CO CO CO CN CN CN — — — — — — — CN CN CN CN CN CN CN CN CN CN CN CM bbbbbbσbbσbbbbbbbbbbbbσbbσbbbbbbbbbbbbbbbbbbbσbbbb
""££££££££££££££££££££££££££££££££££££££££££££££££££
Q-rr o o — o o _* - — lo rr rv co — o vn f . cri ,— Lo c^ o co — cM uj co S J^ ^ t co o cN - rr to ^-, f f-) -f) - rr o cM CN uj rv o rr £ o rv o rr -o cN rr 5. — co o uj rv oo — o ^ g S cN CN rr o o co — co o S £ S — co o c rr o o ≤ g S S o cM CN U — co rr rv ^ J5 CM M CM CO CO ^ CM CM O CM C CM l ^ ^ w ^ ι- -- '- ^ CM I c O ^ |2 ! ^ ^ ^ L0 l0 L0 L0 ^ ^ ^ -- - r0 O ^ ^ ^ ^
_J
"5 "t cM UJ I-v O CM O U-. CN CM UJ cO O CM ,. n r (N O 3 O CN CO O jβ 9 O rr O cO CM UD - l-. _ CN iO O cO cO O OO
< O rr o iv- o rr o - UJ 5R — co — UJ IV. CO - — o o <"N' cs' ' ' r- O co — co — co co — — co o CM rr O — rr rv: _o r>. O CM cθ LO - co rr
•— Jj CM CM CM CO CO CO ^ CM CN CM CM CM CO 0 0 0 _ _ _ CM CM CO CO — — rT rr LO lO LO UD ^ r^ oo ς — — CO CO rr rr rr
r-
© O
© ^. uj uj uj io u uj o o o o o rv rv rv rv rv rv rv rv rv rv rv rv oo oo oo co oo o o o o o o o o o o o o o o o o o o o o o o
Ω C C C C C C C CN C C C C CN CN CN CN CN CN CN CN C C C C CN CN C O — co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co
G
c O
555555 55555555 55555555555 o
Q
CN CN C C CM CO CO CO CO CO CO CO CO CO CO CO CO CO CO CN CM CM CN CN CN CM CM CN — — — — — — — CN CN CN CN CN CN CN CN CN CO CO CO CD CO — gbbbbbbbbbbbbb_b_bbbb_bbb£bbbbbbbbb_£bbb_bbb£b_bbb"2bb_b_"2b£b£bPbbbb u"££££££££££££££££££££££££££££££££££££££££££££££££££
Q-cO O CM LO rr rv O — — UD oO CN i O C rr 2 ιv. r rNi . o ^ ° > C O _ --r cθ — — rr rv f^ ^ ( r. _ O cO O f , ir) CM O O
£ o — CM rr o co o uj rv co Q — n n o o ^ ^ t ^ ^ o α w N " c ^ ^ oo o rv ^ j o — C0 O w « <) 0, fv (, +j ^ u) u ιr) ιo c o ^ ^ ^ Λ U) ) u3 Lθ U32 ° 2 " " " ^ ^ ^ ^ ^ ^ > " " w ^ ^ co » σ n -3 ω α ^
CO
< "t — rr rv cO O CO — CM CM O O CO O O CO ^ Ri <-> o-> v, -> co '-- O c'^ fM io O CM CN UJ r rJ c-J in '— ^ n ^ O W
O rv o — CM r — co O iO (v. co O — co rr o — 1- co io o o O O O CN — <__ iS co O co O — ^ co r r ∞ O — ^ S rv o - + rr rr uj UJ io cO co rr rr rr uj uj uj uD LO — 2 ^ "J ^ ^ co co r rr — " rr rr rr u — c rr rv o -Q - — " co co
Os
© © Oo Oo Oo Oo Oo Oo Oo Oo Oo Oo Oo Orv o
c 'o ε 555555555 5555555555 o
Q
CN CM CM CM CN CN CM CM CM CM CM CO CO CO o CO CO CO CO n CO CO CO CO co co co co co cn φ P P "O "O "O "O "U "O T3 ε P P P P P P P P P P P P P P P P P "O P P P P "O "O P "O U "O P "D "O P τs P P P P P P Ό "O y 0 σ o 0 O 0 o o O o 0 o o o o o o o o o o o o o o o o o o o o o O o O O o O O o o o o o o o o π o o
^ r5 ^ ^ ^ ^ ^ r5 ^ ^ ^ ^ ^ ^ ^ ^ ^ o5 ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ? ^ ^ i* ^ ^ o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o f5 ^ o O O o o o o o o o o o o o o o o ?o o
r-
© O z
© Q oooooooooooooooooooooooooooooooooooooo — — — — — — — — — — — — O co co co co co co co co co co co co co co co co co co co co co co co co co co co co co co c^
G LU co
TABLE 4
SEQ ID NO: Template ID Start Stop Frame Domain Topology
371 LG:346724.14:2001 JUN22 1038 1090 forward 1 TM Non-Cytosolic
371 LG:346724.14:2001 JUN22 1 1 1 forward 2 TM Cytosolic
371 LG:346724.14:2001JUN22 12 34 forward 2 TM Transmembrane
371 LG:346724.14:2001JUN22 35 497 forward 2 TM Non-Cytosolic
371 l_G:346724.14:2001JUN22 498 520 forward 2 TM Transmembrane
371 LG:346724.14:2001JUN22 521 783 forward 2 TM Cytosolic
371 LG:346724.14:2001JUN22 784 801 forward 2 TM Transmembrane
371 LG:346724.14:2001JUN22 802 879 forward 2 TM Non-Cytosolic
371 LG:346724.14:2001JUN22 880 902 forward 2 TM Transmembrane
371 LG:346724.14:2001 JUN22 903 1090 forward 2 TM Cytosolic
372 LG:41 1043.3:2001 JUN22 1 121 forward 3 TM Cytosolic
372 l_G:41 1043.3:2001JUN22 122 144 forward 3 TM Transmembrane
372 LG:41 1043.3:2001JUN22 145 203 forward 3 TM Non-Cytosolic
372 LG:41 1043.3:2001JUN22 204 223 forward 3 TM Transmembrane
372 LG:41 1043.3:2001 JUN22 224 458 forward 3 TM Cytosolic
372 LG:41 1043.3:2001 JUN22 459 481 forward 3 TM Transmembrane
372 LG:41 1043.3:2001 JUN22 482 707 forward 3 TM Non-Cytosolic
373 LG:978620.7:2001JUN22 1 490 forward 2 TM Non-Cytosolic
373 LG:978620.7:2001JUN22 491 513 forward 2 TM Transmembrane
373 LG:978620.7:2001JUN22 514 515 forward 2 TM Cytosolic
373 LG:978620J:2001JUN22 1 351 forward 3 TM Non-Cytosolic
373 LG:978620J:200UUN22 352 374 forward 3 TM Transmembrane
373 LG:978620J:200UUN22 375 514 forward 3 TM Cytosolic
374 LG:982784.1 :200UUN22 1 315 forward 1 TM Non-Cytosolic
374 LG:982784.1 :200UUN22 316 338 forward 1 TM Transmembrane
374 LG:982784.1 :200UUN22 339 358 forward 1 TM Cytosolic
374 LG:982784.1 :200UUN22 359 381 forward 1 TM Transmembrane
374 LG:982784.1 :2001 JUN22 382 682 forward 1 TM Non-Cytosolic
374 LG:982784.1 :2001JUN22 683 705 forward 1 TM Transmembrane
374 LG:982784.1 :2001JUN22 706 715 forward 1 TM Cytosolic
374 LG:982784.1 :2001JUN22 1 359 forward 2 TM Non-Cytosolic
374 LG:982784.1 :2001JUN22 360 382 forward 2 TM Transmembrane
374 LG:982784.1 :2001JUN22 383 715 forward 2 TM Cytosolic
374 LG:982784.1 :2001JUN22 1 227 forward 3 TM Cytosolic
374 LG:982784.1 :2001JUN22 228 246 forward 3 TM Transmembrane
374 LG:982784.1 :2001JUN22 247 255 forward 3 TM Non-Cytosolic
374 LG:982784.1 :2001JUN22 256 278 forward 3 TM Transmembrane
374 LG:982784.1 :2001JUN22 279 358 forward 3 TM Cytosolic
374 LG:982784.1 :2001JUN22 359 376 forward 3 TM Transmembrane
374 LG:982784.1 :2001JUN22 377 398 forward 3 TM Non-Cytosolic
374 LG:982784.1 :2001JUN22 399 421 forward 3 TM Transmembrane
374 LG:982784.1 :2001JUN22 422 433 forward 3 TM Cytosolic
374 LG:982784.1 :2001JUN22 434 456 forward 3 TM Transmembrane
374 LG:982784.1 :2001JUN22 457 475 forward 3 TM Non-Cytosolic
374 LG:982784.1 :2001JUN22 476 498 forward 3 TM Transmembrane
374 LG:982784.1 :2001JUN22 499 715 forward 3 TM Cytosolic
375 LG:007574.21 :2001JUN22 1 6 forward 3 TM Cytosolic
375 LG:007574.21 :2001JUN22 7 29 forward 3 TM Transmembrane
375 LG:007574.21 :2001JUN22 30 38 forward 3 TM Non-Cytosolic
375 LG:007574.21 :2001JUN22 39 56 forward 3 TM Transmembrane TABLE 4
SEQ ID NO: Template ID Start Stop Frame Domain Topology
375 LG:007574.21 :2001JUN22 57 89 forward 3 TM Cytosolic
375 LG:007574.21 :2001JUN22 90 1 12 forward 3 TM Transmembrane
375 LG:007574.21 :2001JUN22 1 13 1684 forward 3 TM Non-Cytosolic
376 LG:013856.18:2001JUN22 1 1 178 forward 1 TM Non-Cytosolic
376 LG:013856.18:2001JUN22 1 179 1201 forward 1 TM Transmembrane
376 LG:013856.18:2001JUN22 1202 1222 forward 1 TM Cytosolic
376 LG:013856.18:2001 JUN22 1 898 forward 2 TM Non-Cytosolic
376 LG:013856.18:2001 JUN22 899 921 forward 2 TM Transmembrane
376 LG:013856.18:2001 JUN22 922 1 172 forward 2 TM Cytosolic
376 LG:013856.18:2001 JUN22 1 173 1 195 forward 2 TM Transmembrane
376 LG:013856.18:2001 JUN22 1 196 1221 forward 2 TM Non-Cytosolic
376 LG:013856.18:2001 JUN22 1 1 1 forward 3 TM Cytosolic
376 LG:013856.18:2001 JUN22 12 34 forward 3 TM Transmembrane
376 LG:013856.18:2001JUN22 35 1221 forward 3 TM Non-Cytosolic
377 LG:027320.7:2001JUN22 1 194 forward 2 TM Cytosolic
377 LG:027320.7:2001JUN22 195 217 forward 2 TM Transmembrane
377 LG:027320.7:2001JUN22 218 236 forward 2 TM Non-Cytosolic
377 LG:027320.7:2001JUN22 237 259 forward 2 TM Transmembrane
377 LG:027320.7:2001JUN22 260 375 forward 2 TM Cytosolic
377 LG:027320.7:2001JUN22 376 398 forward 2 TM Transmembrane
377 LG:027320.7:2001JUN22 399 423 forward 2 TM Non-Cytosolic
377 LG:027320.7:2001JUN22 424 446 forward 2 TM Transmembrane
377 LG:027320.7:2001JUN22 447 457 forward 2 TM Cytosolic
377 LG:027320.7:2001JUN22 458 475 forward 2 TM Transmembrane
377 LG:027320.7:2001JUN22 476 484 forward 2 TM Non-Cytosolic
377 LG:027320.7:2001JUN22 485 507 forward 2 TM Transmembrane
377 LG:027320.7:2001JUN22 508 527 forward 2 TM Cytosolic
377 LG:027320.7:2001JUN22 1 194 forward 3 TM Cytosolic
377 LG:027320.7:2001JUN22 195 217 forward 3 TM Transmembrane
377 LG:027320.7:2001JUN22 218 248 forward 3 TM Non-Cytosolic
377 LG:027320.7:2001JUN22 249 264 forward 3 TM Transmembrane
377 LG:027320.7:2001JUN22 265 276 forward 3 TM Cytosolic
377 LG:027320.7:2001JUN22 277 299 forward 3 TM Transmembrane
377 LG:027320.7:2001JUN22 300 318 forward 3 TM Non-Cytosolic
377 LG:027320.7:2001JUN22 319 341 forward 3 TM Transmembrane
377 LG:027320.7:2001JUN22 342 361 forward 3 TM Cytosolic
377 LG:027320.7:2001JUN22 362 384 forward 3 TM Transmembrane
377 LG:027320.7:2001JUN22 385 387 forward 3 TM Non-Cytosolic
377 LG:027320.7:2001JUN22 388 410 forward 3 TM Transmembrane
377 LG:027320.7:2001JUN22 41 1 527 forward 3 TM Cytosolic
378 LG:077967.9:2001JUN22 1 1041 forward 1 TM Non-Cytosolic
378 LG:077967.9:2001JUN22 1042 1064 forward 1 TM Transmembrane
378 LG:077967.9:2001JUN22 1065 1078 forward 1 TM Cytosolic
378 LG:077967.9:2001JUN22 1 757 forward 2 TM Non-Cytosolic
378 LG:077967.9:2001JUN22 758 780 forward 2 TM Transmembrane
378 LGO77967.9:2001JUN22 781 1078 forward 2 TM Cytosolic
379 LG:128475.9:2001JUN22 1 315 forward 2 TM Non-Cytosolic
379 LG:128475.9:2001JUN22 316 338 forward 2 TM Transmembrane
379 LG:128475.9:2001JUN22 339 391 forward 2 TM Cytosolic
379 LG:128475.9:2001JUN22 392 414 forward 2 TM Transmembrane TABLE 4
SEQ ID NO: Template ID Start Stop Frame Domain Topology
379 LG: .28475.9:2001 JUN22 415 474 forward 2 TM Non-Cytosolic
379 LG:128475.9:2001JUN22 475 497 forward 2 TM Transmembrane
379 LG:128475.9:2001JUN22 498 508 forward 2 TM Cytosolic
379 LG: 128475.9:2001JUN22 509 531 forward 2 TM Transmembrane
379 LG:128475.9:2001JUN22 532 777 forward 2 TM Non-Cytosolic
379 LG: 128475.9:2001JUN22 778 800 forward 2 TM Transmembrane
379 LG: 128475.9:2001JUN22 801 812 forward 2 TM Cytosolic
379 LG: 128475.9:2001JUN22 813 830 forward 2 TM Transmembrane
379 LG:128475.9:2001 JUN22 831 1065 forward 2 TM Non-Cytosolic
379 LG: 128475.9:2001JUN22 1 495 forward 3 TM Non-Cytosolic
379 LG:128475.9:2001 JUN22 496 518 forward 3 TM Transmembrane
379 LG: 128475.9:2001 JUN22 519 524 forward 3 TM Cytosolic
379 LG:128475.9:2001 JUN22 525 547 forward 3 TM Transmembrane
379 LG: 128475.9:2001 JUN22 548 1064 forward 3 TM Non-Cytosolic
380 LG:1398104.15:2001JUN22 1 744 forward 2 TM Non-Cytosolic
380 LG: 1398104.15:2001JUN22 745 767 forward 2 TM Transmembrane
380 LG:1398104.15:2001JUN22 768 794 forward 2 TM Cytosolic
380 LG:1398104.15:2001JUN22 1 746 forward 3 TM Non-Cytosolic
380 LG:1398104.15:2001JUN22 747 769 forward 3 TM Transmembrane
380 LG:1398104.15:2001JUN22 770 794 forward 3 TM Cytosolic
381 LG: 1454018.10:2001JUN22 1 1296 forward 1 TM Non-Cytosolic
381 LG: 1454018.10:2001JUN22 1297 1319 forward 1 TM Transmembrane
381 LG:1454018.10:2001JUN22 1320 1331 forward 1 TM Cytosolic
381 LG: 1454018.10:2001 JUN22 1332 1351 forward 1 TM Transmembrane
381 LG: 1454018.10:2001 JUN22 1352 1472 forward 1 TM Non-Cytosolic
381 LG: 1454018.10:2001 JUN22 1 1288 forward 2 TM Non-Cytosolic
381 LG: 1454018.10:2001 JUN22 1289 131 1 forward 2 TM Transmembrane
381 LG: 1454018.10:2001JUN22 1312 1331 forward 2 TM Cytosolic
381 LG: 1454018.10:2001 JUN22 1332 1354 forward 2 TM Transmembrane
381 LG: 1454018.10:2001 JUN22 1355 1472 forward 2 TM Non-Cytosolic
382 LG:221548.14:2001JUN22 1 608 forward 1 TM Non-Cytosolic
382 LG:221548.14:2001JUN22 609 631 forward 1 TM Transmembrane
382 LG:221548.14:2001JUN22 632 650 forward 1 TM Cytosolic
382 LG:221548.14:2001JUN22 651 670 forward 1 TM Transmembrane
382 LG:221548.14:2001 JUN22 671 2297 forward 1 TM Non-Cytosolic
382 LG:221548.14:2001JUN22 2298 2320 forward 1 TM Transmembrane
382 LG:221548.14:2001JUN22 2321 2381 forward 1 TM Cytosolic
382 LG:221548.14:2001 JUN22 2382 2404 forward 1 TM Transmembrane
382 LG:221548.14:2001 JUN22 2405 2413 forward 1 TM Non-Cytosolic
382 LG:221548.14:2001 JUN22 2414 2436 forward 1 TM Transmembrane
382 LG:221548.14:2001JUN22 2437 2498 forward 1 TM Cytosolic
382 LG:221548.14:2001JUN22 2499 2518 forward 1 TM Transmembrane
382 LG:221548.14:2001JUN22 2519 2689 forward 1 TM Non-Cytosolic
382 LG:221548.14:2001JUN22 2690 2712 forward 1 TM Transmembrane
382 LG:221548.14:2001JUN22 2713 2865 forward 1 TM Cytosolic
382 LG:221548.14:2001JUN22 2866 2888 forward 1 TM Transmembrane
382 LG:221548.14:2001JUN22 2889 2990 forward 1 TM Non-Cytosolic
382 LG:221548.14:2001JUN22 2991 3013 forward 1 TM Transmembrane
382 LG:221548.14:2001JUN22 3014 3076 forward 1 TM Cytosolic
382 LG:221548.14:2001JUN22 1 1672 forward 3 TM Non-Cytosolic TABLE 4
SEQ ID NO Template ID Start Stop Frame Domain Topology
382 LG:221548.14:2001JUN22 1673 1695 forward 3 TM Transmembrane
382 LG:221548.14:2001JUN22 1696 1715 forward 3 TM Cytosolic
382 LG:221548.14:2001JUN22 1716 1735 forward 3 TM Transmembrane
382 LG:221548.14:2001JUN22 1736 2124 forward 3 TM Non-Cytosolic
382 LG:221548.14:2001JUN22 2125 2147 forward 3 TM Transmembrane
382 LG:221548.14:2001 JUN22 2148 2299 forward 3 TM Cytosolic
382 LG:221548.14:2001JUN22 2300 2322 forward 3 TM Transmembrane
382 LG:221548.14:2001JUN22 2323 3075 forward 3 TM Non-Cytosolic
383 LG:227500.5:2001JUN22 1 855 forward 1 TM Non-Cytosolic
383 LG:227500.5:2001JUN22 856 875 forward 1 TM Transmembrane
383 LG:227500.5:2001JUN22 876 1071 forward 1 TM Cytosolic
383 LG:227500.5:2001JUN22 1072 1094 forward 1 TM Transmembrane
383 LG:227500.5:2001JUN22 1095 1 120 forward 1 TM Non-Cytosolic
383 LG:227500.5:2001JUN22 1 121 1 138 forward 1 TM Transmembrane
383 LG:227500.5:2001JUN22 1 139 1218 forward 1 TM Cytosolic
383 LG:227500.5:2001JUN22 1219 1238 forward 1 TM Transmembrane
383 LG:227500.5:2001JUN22 1239 1241 forward 1 TM Non-Cytosolic
384 LG:228273.22:2001JUN22 1 1379 forward 1 TM Non-Cytosolic
384 LG:228273.22:2001JUN22 1380 1402 forward 1 TM Transmembrane
384 LG:228273.22:2001JUN22 1403 1539 forward 1 TM Cytosolic
384 LG:228273.22:2001JUN22 1 45 forward 3 TM Cytosolic
384 LG:228273.22:2001JUN22 46 68 forward 3 TM Transmembrane
384 LG:228273.22:2001JUN22 69 659 forward 3 TM Non-Cytosolic
384 LG:228273.22:2001JUN22 660 682 forward 3 TM Transmembrane
384 LG:228273.22:2001JUN22 683 694 forward 3 TM Cytosolic
384 LG:228273.22:2001JUN22 695 717 forward 3 TM Transmembrane
384 LG:228273.22:2001JUN22 718 1539 forward 3 TM Non-Cytosolic
385 LG:235432.1 2001JUN22 1 610 forward 1 TM Non-Cytosolic
385 LG:235432.1 2001JUN22 61 1 633 forward 1 TM Transmembrane
385 LG:235432.1 2001JUN22 634 780 forward 1 TM Cytosolic
385 LG:235432.1 2001JUN22 1 610 forward 3 TM Non-Cytosolic
385 LG:235432.1 2001JUN22 61 1 633 forward 3 TM Transmembrane
385 LG:235432.1 2001JUN22 634 779 forward 3 TM Cytosolic
386 LG:236904.20:2001JUN22 1 1425 forward 3 TM Non-Cytosolic
386 LG:236904.20:2001JUN22 1426 1443 forward 3 TM Transmembrane
386 LG:236904.20:2001JUN22 1444 1463 forward 3 TM Cytosolic
386 LG:236904.20:2001JUN22 1464 1486 forward 3 TM Transmembrane
386 LG:236904.20:2001JUN22 1487 1520 forward 3 TM Non-Cytosolic
386 LG:236904.20:2001JUN22 1521 1543 forward 3 TM Transmembrane
386 LG:236904.20:2001JUN22 1544 1570 forward 3 TM Cytosolic
387 LG:253193.21 :2001JUN22 1 6 forward 1 TM Cytosolic
387 LG:253193.21 :2001JUN22 7 29 forward 1 TM Transmembrane
387 LG:253193.21 :2001JUN22 30 920 forward 1 TM Non-Cytosolic
387 LG:253193.21 :2001JUN22 1 159 forward 2 TM Non-Cytosolic
387 LG:253193.21 :2001JUN22 160 182 forward 2 TM Transmembrane
387 LG:253193.21 :2001JUN22 183 259 forward 2 TM Cytosolic
387 LG:253193.21 :2001JUN22 260 282 forward 2 TM Transmembrane
387 LG:253193.21 :2001JUN22 283 920 forward 2 TM Non-Cytosolic
388 LG:332161.3:2001JUN22 1 631 forward 2 TM Non-Cytosolic
388 LG:332161.3 2001JUN22 632 654 forward 2 TM Transmembrane TABLE 4
SEQ ID NO: Template ID Start Stop Frame Domain Topology
388 LG:332161.3:2001 JUN22 655 674 forward 2 TM Cytosolic
388 LG:332161.3:2001JUN22 675 697 forward 2 TM Transmembrane
388 LG:332161.3:2001 JUN22 698 1 121 forward 2 TM Non-Cytosolic
388 LG:332161.3:2001 JUN22 1 628 forward 3 TM Non-Cytosolic
388 LG:332161.3:2001 JUN22 629 651 forward 3 TM Transmembrane
388 LG:332161.3:2001 JUN22 652 679 forward 3 TM Cytosolic
388 LG:332161.3:2001 JUN22 680 702 forward 3 TM Transmembrane
388 LG:332161.3:2001 JUN22 703 1 121 forward 3 TM Non-Cytosolic
389 LG:332923.5:2001JUN22 1 1513 forward 1 TM Non-Cytosolic 389 LG:332923.5:2001JUN22 1514 1536 forward 1 TM Transmembrane 389 LG:332923.5:2001JUN22 1537 1556 forward 1 TM Cytosolic 389 LG:332923.5:2001JUN22 1557 1579 forward 1 TM Transmembrane 389 LG:332923.5:2001JUN22 1580 1644 forward 1 TM Non-Cytosolic 389 LG:332923.5:2001JUN22 1645 1667 forward 1 TM Transmembrane 389 LG:332923.5:2001JUN22 1668 1850 forward 1 TM Cytosolic 389 LG:332923.5:2001JUN22 1851 1873 forward 1 TM Transmembrane 389 LG:332923.5:2001JUN22 1874 2015 forward 1 TM Non-Cytosolic 389 LG:332923.5:2001JUN22 2016 2038 forward 1 TM Transmembrane 389 LG:332923.5:2001JUN22 2039 2041 forward 1 TM Cytosolic 389 LG:332923.5:2001JUN22 1 1042 forward 2 TM Non-Cytosolic 389 LG:332923.5:2001JUN22 1043 1065 forward 2 TM Transmembrane 389 LG:332923.5:2001JUN22 1066 1449 forward 2 TM Cytosolic 389 LG:332923.5:2001JUN22 1450 1472 forward 2 TM Transmembrane 389 LG:332923.5:2001JUN22 1473 1555 forward 2 TM Non-Cytosolic 389 LG:332923.5:2001JUN22 1556 1578 forward 2 TM Transmembrane 389 LG:332923.5:2001JUN22 1579 1632 forward 2 TM Cytosolic 389 LG:332923.5:2001JUN22 1633 1655 forward 2 TM Transmembrane 389 LG:332923.5:2001JUN22 1656 2041 forward 2 TM Non-Cytosolic 389 LG:332923.5:2001JUN22 1 791 forward 3 TM Non-Cytosolic 389 LG:332923.5:2001JUN22 792 814 forward 3 TM Transmembrane 389 LG:332923.5:2001JUN22 815 834 forward 3 TM Cytosolic 389 LG:332923.5:2001JUN22 835 853 forward 3 TM Transmembrane 389 LG:332923.5:2001JUN22 854 1326 forward 3 TM Non-Cytosolic 389 LG:332923.5:2001JUN22 1327 1346 forward 3 TM Transmembrane 389 LG:332923.5:2001JUN22 1347 1508 forward 3 TM Cytosolic 389 LG:332923.5:2001JUN22 1509 1528 forward 3 TM Transmembrane 389 LG:332923.5:2001JUN22 1529 1556 forward 3 TM Non-Cytosolic 389 LG:332923.5:2001JUN22 1557 1579 forward 3 TM Transmembrane 389 LG:332923.5:2001JUN22 1580 1633 forward 3 TM Cytosolic 389 LG:332923.5:2001JUN22 1634 1656 forward 3 TM Transmembrane
389 LG:332923.5:2001JUN22 1657 2040 forward 3 TM Non-Cytosolic
390 LG:343500.27:2001JUN22 1 42 forward 2 TM Cytosolic 390 LG:343500.27:2001JUN22 43 65 forward 2 TM Transmembrane
390 LG:343500.27:2001JUN22 66 321 forward 2 TM Non-Cytosolic
391 LG:369703.9:2001JUN22 1 1 133 forward 1 TM Non-Cytosolic 391 LG:369703.9:2001JUN22 1 134 1 156 forward 1 TM Transmembrane 391 LG:369703.9:2001JUN22 1 157 1 157 forward 1 TM Cytosolic 391 LG:369703.9:2001JUN22 1 224 forward 2 TM Cytosolic 391 LG:369703.9:2001JUN22 225 247 forward 2 TM Transmembrane 391 LG:369703.9:2001JUN22 248 1 156 forward 2 TM Non-Cytosolic TABLE 4
SEQ ID NO: Template ID Start Stop Frame Domain Topology
392 LG:415378.3:2001JUN22 1 1251 forward 3 TM Non-Cytosolic
392 LG:415378.3:2001JUN22 1252 1274 forward 3 TM Transmembrane
392 LG:415378.3:2001 JUN22 1275 1355 forward 3 TM Cytosolic
392 LG:415378.3:2001JUN22 1356 1378 forward 3 TM Transmembrane
392 LG:415378.3:2001JUN22 1379 1417 forward 3 TM Non-Cytosolic
392 LG:415378.3:2001 JUN22 1418 1440 forward 3 TM Transmembrane
392 LG:415378.3:2001 JUN22 1441 1491 forward 3 TM Cytosolic
392 LG:415378.3:2001 JUN22 1492 1514 forward 3 TM Transmembrane
392 LG:415378.3:2001 JUN22 1515 1851 forward 3 TM Non-Cytosolic
393 LG:458583.1 :2001JUN22 1 108 forward 2 TM Cytosolic
393 LG:458583.1 :2001JUN22 109 131 forward 2 TM Transmembrane
393 LG:458583.1 :2001JUN22 132 323 forward 2 TM Non-Cytosolic
394 LGJ690373.1 :2001 JUN22 1 95 forward 2 TM Cytosolic
394 LG:7690373.1 :2001JUN22 96 1 18 forward 2 TM Transmembrane
394 LG:7690373.1 :2001JUN22 1 19 219 forward 2 TM Non-Cytosolic
395 LG:898324.13:2001 JUN22 1 225 forward 1 TM Non-Cytosolic
395 LG:898324.13:2001JUN22 226 248 forward 1 TM Transmembrane
395 LG:898324.13:2001 JUN22 249 276 forward 1 TM Cytosolic
395 LG:898324.13:2001 JUN22 1 189 forward 2 TM Non-Cytosolic
395 LG:898324.13:2001JUN22 190 212 forward 2 TM Transmembrane
395 LG:898324.13:2001JUN22 213 224 forward 2 TM Cytosolic
395 LG:898324.13:2001 JUN22 225 247 forward 2 TM Transmembrane
395 LG:898324.13:2001 JUN22 248 276 forward 2 TM Non-Cytosolic
396 LG:979167.5:2001JUN22 1 252 forward 1 TM Non-Cytosolic
396 LG:979167.5:2001 JUN22 253 272 forward 1 TM Transmembrane
396 LG:979167.5:2001JUN22 273 344 forward 1 TM Cytosolic
396 LG:979167.5:2001JUN22 345 362 forward 1 TM Transmembrane
396 LG:979167.5:2001JUN22 363 366 forward 1 TM Non-Cytosolic
396 LG:979167.5:2001JUN22 367 386 forward 1 TM Transmembrane
396 LG:979167.5:2001JUN22 387 627 forward 1 TM Cytosolic
396 LG:979167.5:2001JUN22 628 647 forward 1 TM Transmembrane
396 LG:979167.5:2001JUN22 648 661 forward 1 TM Non-Cytosolic
396 LG:979167.5:2001JUN22 662 684 forward 1 TM Transmembrane
396 LG:979167.5:2001JUN22 685 708 forward 1 TM Cytosolic
396 LG:979167.5:2001 JUN22 709 731 forward 1 TM Transmembrane
396 LG:979167.5:2001 JUN22 732 1 174 forward 1 TM Non-Cytosolic
396 LG:979167.5:2001 JUN22 1 175 1 194 forward 1 TM Transmembrane
396 LG:979167.5:2001JUN22 1 195 1210 forward 1 TM Cytosolic
396 LG:979167.5:2001JUN22 1 623 forward 3 TM Non-Cytosolic
396 LG:979167.5:2001 JUN22 624 646 forward 3 TM Transmembrane
396 LG:979167.5:2001JUN22 647 652 forward 3 TM Cytosolic
396 LG:979167.5:2001JUN22 653 675 forward 3 TM Transmembrane
396 LG:979167.5:2001JUN22 676 1209 forward 3 TM Non-Cytosolic Table
1/LG: 036272. 1:2 1MAR30 I I 2390-2842; 2 435-2838; 2523-2 834; 2501- 2834; 2531-2833; 2477 834; 2656 2833; 2490-2834; 2467-2833; 2582-2833; 2406 2834; 2381-2833 2409-2832 2371-2833, 2463-2832 ; 2414- 2832; 2447 -2832 2251-2830; 2415 832; 2718 2832; 2550- 832; 2709-2832; 2524-2832; 2389 2832; 2468-2832 2488-2832 2362-2832; 2359-2832 ; 2394- 2832; 2374 2831 2539-2830; 2424 832; 2432 2832; 2424-2830; 2442-2830; 2561-2830; 2543 2826; 2423-2828 2532-2830 2390-2826; 2636-2821 ; 2437- 2821; 2518 2821 2351-2813; 2358 815; 2550-2805; 2524- 804; 2531-2795; 2461-2794; 2513 2793; 2146-2793 2445-2792 2445-2791; 2229-2786 ; 2233- 2785; 2361 2784 2461-2766; 2497 764; 2301-2764; 2456- 762; 2414-2758; 2332-2747; 2461 2734; 2416-2720 2495-2719 2464-2703 ; 2442-2667 ; 2077- 2647; 2505 2649 2405-2609; 2025 597; 2297 2566; 2273- 504; 1885-2484; 2133-2456; 1885 2446; 2217-2416 1902-2347 2029-2305; 2057-2303 ; 2057- 2293; 2085 2279 1812-2238; 1618 250; 2043 2211; 1968- 198; 1919-2182; 2024-2165; 1697 2148; 1834-2129 1843-2093 1823-2060; 1770-2052 ; 1770- 2036; 1825 2015 1866-2018; 1547 986; 1652-1882; 1650- 835; 1549-1794; 1066-1597; 535- 163; 141-763; 141-64 1-218 2 /LG: 093337.3:2 1MAR30 I I 1-257; 1-507; 20-487; 29-254; 211-815; 213-475; 309-943; 444-93 473-1032; 555-986 3/LG: 1049927.6: 01MAR30 I I 1-323; 16-199; 16-570; 19-664; 20-93; 21-93 22-93; 176-761; 80-371; 262-842; 282-849; 314-839; 548-943 4/LG:1051891.34 001MAR30 I I 1-491; 325-957; 338-901; 415-901; 420-1016 435-1017; 461-1 3; 577-892 ; 694-849; 803-1377; 892-1334; 897-1161; 105 1- 1308; 1078-1330 5/LG:1089626 1: 200 1MAR30 I I 1-210; 1 -514; 1-3 64; 137-689; 13 7-607; 162-700; 187-775; 243 695; 251-775; 277-775; 295-703; 296 556; 296-519; 298 384; 427-624; 429 800; 484-580; 502-757; 625-967; 627 791; 647-1251; 822-103 3; 832-1276; 834-931; 925-1437 ; 946-138 4; 946-10 48; 946-1426; 957-1248; 992- 1487; 1004-1486 ; 1014-1317; 1017-159 2; 1016-1 561; 1017-1536; 1058-1488 1059-1565; 1076-1365; 1076-1501; 107 7-1639; 1 087-1568; 1087-1428; 1136 1619; 1136-1616 ; 1137-1620; 1164-161 0; 1169-1 610; 1217-1610; 1223-1481 1228-1581; 1236-1504; 1248-1619; 124 8-1621; 1 264-1619; 1304-1944; 1299 1944; 1319-1599 ; 1319-1566; 1328-162 0; 1388-1 539; 1594-1846; 1594-2082 1700-2050; 1817-1905; 1898 2427; 194 4-2500; 2 296-2469; 2319 2537 6/LG: 1101416.6: 2001MAR30 I 10-442; 1-175; 8- 362; 1-409; 8-4 74; 10 -273 9- 256; 10-597; 9-262 ; 9-251; 9-250; 11 -310; 13- 398; 9-467; 10- 164; 1 1-166 13-275; 11-266; 11-295; 12-263; 11-1 72; 16-26 7; 12-195; 12-2 58; 11 -284 13- 340; 13-140 13 -20 13-113 15-253 15-302 13-482; 13-236 16-26 0 15-
267 14-277 14-28 17-191 17-568 16-572 15-308; 17-633 17-28 8 17-
276 16-244 16 17 15-270 16-508 18-168 20-254; 19-367 19-29 1 17-
438 20-272 20 26 20-256 20-531 23-277 28-299; 29-309 29-28 4 31-
347 34-278 41 28 42-322 44-316 69-216 71-312; 71-293 81-28 2 80-
366 84-596 85 29 89-299 90-352 98-268 139- 346 141-39 147 -598
148-347 159-426 159-384; 160-412 172-644 175-412 179-51 181 -460
215-423 222-630 223-634; 230-633 242-633 253-556 261-63 277 -571
277-531 281-525 292-538; 286-547 322-671 335-603 339-63 341 -633
345-615 350-630 355-582; 358-640 361-634 372-633 373-63 375 -629
380-635 387-633 396-596; 396-657 404-637 406-633 435-63 440 -631
440-656 440-897 455-649; 456-629 460-631 462-633 466-63 466 -633
472-633 474-633 476-634; 476-631 479-633 478-633 480-63 487 -631
488-632 488-631 488-633; 488-654 492-640 488-634 504-63 504 -633
505-638 512-633 537-1058; 556-633; 559-643; 745-1259; 1010 -1261; 348- 626;
17-349; 376-627 ; 360-605; 385-622; 385-578; 399-626; 351-579 : 374-599; 375-
594; 22-239; 346-561; 393-597; 379-580; 9-209 ; 383-579; 10-2 !05; 16-209; 11-
203; 441-625 ; 8-198; 21-208 ; 11-197; 23-208; 15-198; 9-183; 9-165; 12-186;
19-189; 14-184; 12-180; 11-179; 8-162; 414-558; 35-182; 28-1 L73; 54-196;
393-536 ; 12-143 ; 17-146; 9-137; 9-135; 17-132 ; 21-132; 46-124
7/LG:1295974.1: 2001MAR30 I I 414-840; 451-838; 488-838; 550-8 .38; 47 7-836;
516-837 ; 541-836; 555-836 417-835; 731-835; 468-834; 606-83 S2; 407-822; Table 5 450-822; 473-817; 476-817; 565-814; 461-806; 531-808; 351-724; 341-717; 344-548; 205-466; 49-284; 1-260
8/LG: 1400572.2 :2001MAR30 || 1-499; 1-470; 1-385; 1-368
9/LG: 1446621.1:2001MAR30 jj 1-592; 224-609; 266-587; 279-575; 282-674; 284- 698; 284-691; 534-670; 542-671; 551-674
10/LG: 1499752.1:2001 AR30 || 1-456; 1-355; 24-106; 22-245; 9-225; 7-204; 27-222; 6-199; 55-185; 6-124; 6-67
11/LG: 1503044.7 :2001MAR30 || 1-605; 8-547; 21-290; 50-645; 127-452; 365- 1118
12/LG: 1503588.1:2001MAR30 || 1-296; 12-383
13/LG:1503589.2:2001MAR30 || 1-477; 5-246; 139-290; 367-1012; 377-616; 390- 618; 424-884; 479-717; 626-1119; 716-980; 773-1188; 830-1226 14/LG:1506339.4:2001MAR30 || 1-86; 1-674; 1-241; 1-578; 1-140; 1-254; 22- 638; 358-443
15/LG: 220648.6 :2001MAR30 || 1-256; 1-99; 17-312; 17-331; 35-541; 45-413; 81-647; 81-638; 189-482; 236-574; 272-505; 588-777
16/LG:236654.1:2001MAR30 || 1-192; 5-330; 6-304; 6-303; 13-98; 14-549; 23- 474; 93-372; 239-505; 293-738; 293-511; 369-849; 371-582; 409-918; 528-724; 651-1142; 727-1192; 739-1154; 753-1194; 772-1195; 806-1155; 806-1192; 806- 1044; 806-1075; 806-1158; 846-1192; 913-1193; 951-1184; 1087-1193 17/LG: 237699.26 :2001 AR30 || 1-262; 1-265; 21-253; 21-327; 21-311; 21-310; 21-299; 24-243; 21-186; 21-279; 22-281; 23-276; 22-279; 23-263; 23-259; 23- 258; 23-265; 24-259; 25-278; 25-266; 25-248; 25-302; 26-290; 27-280; 27- 162; 27-307; 27-268; 27-254; 28-286; 29-228; 30-290; 33-410; 33-305; 33- 243; 35-309; 36-282; 36-265; 37-267; 39-306; 38-300; 39-282; 39-280; 42- 698; 42-312; 42-263; 42-258; 42-248; 47-252; 51-281; 56-220; 71-318; 76- 538; 77-291; 77-259; 83-194; 111-312; 114-388; 123-328; 135-424; 155-350; 159-797; 219-505; 243-467; 246-491; 256-501; 278-397; 305-578; 353-534; 403-564; 453-632; 465-734; 492-737; 637-847; 650-859; 726-1145; 726-851; 747-1261; 770-844; 793-851; 993-1399; 993-1359; 993-1352; 993-1249; 993- 1183; 993-1163; 993-1353; 1000-1245; 1086-1403; 1105-1364; 1131-1405; 1176- 1332; 1219-1403; 1301-1403; 1324-1402
18/LG:311541.16:2001MAR30 || 1-599; 23-618; 266-920; 427-892; 428-659; 613- 910; 613-919; 614-910; 651-901; 652-812; 794-1072; 822-1112; 833-1094; 848- 1044; 918-1375; 998-1229; 1008-1414; 1030-1322; 1179-1642; 1185-1640; 1201- 1640; 1206-1509; 1215-1470; 1232-1507; 1240-1592; 1248-1534; 1256-1491; 1343-1598; 1401-1655; 1409-1975; 1600-2055; 1650-1949; 1796-2015; 1802-2055 19/LG:335923.7:2001MAR30 || 304-724; 148-591; 145-590; 213-588; 178-586; 234-585; 165-584; 106-582; 154-581; 290-582; 188-581; 163-582; 121-582; 224-581; 142-581; 134-581; 191-580; 253-578; 128-578; 220-374; 1-349 20/LG: 350342.14 :2001MAR30 || 1-264; 4-158; 6-3089; 25-405; 25-521; 79-683; 294-552; 318-600; 361-607; 394-1011; 398-648; 408-910; 451-927; 502-983; 507-1021; 514-748; 567-658; 595-683; 612-763; 746-992; 747-1002; 749-1029; 762-1237; 806-983; 914-1163; 916-1487; 922-1585; 1057-1531; 1057-1308; 1078-1143; 1085-1322; 1198-1343; 1219-1285; 1220-1491; 1242-1797; 1246- 1700; 1246-1446; 1328-1573; 1397-1824; 1536-2184; 1537-2042; 1554-2092; 1579-1980; 1596-2211; 1634-2118; 1646-2245; 1671-2235; 1701-2272; 1704- 2258; 1711-2281; 1712-2282; 1717-2308; 1738-2223; 1737-1970; 1743-2015; 1743-2216; 1744-2109; 1746-2006; 1747-2052; 1747-2194; 1752-2330; 1752- 2081; 1752-1995; 1752-2027; 1846-2372; 1899-1985; 1902-2061; 1911-2167; 1922-2167; 1933-2180; 1949-2244; 1954-2185; 1955-2192; 1975-2185; 1978- 2088; 1992-2273; 2005-2220; 2013-2098; 2016-2302; 2018-2268; 2018-2195; 2079-2336; 2079-2325; 2079-2312; 2081-2266; 2091-2272; 2100-2590; 2109- 2618; 2128-2404; 2160-2744; 2164-2544; 2172-2450; 2172-2407; 2172-2398; 2187-2537; 2188-2434; 2192-2378; 2232-2431; 2243-2323; 2258-2511; 2257- 2515; 2299-2501; 2301-2568; 2338-2551; 2350-2557; 2364-2617; 2367-2634; 2385-2921; 2386-2641; 2398-2917; 2449-2996; 2471-2975; 2490-2789; 2490- 2715; 2504-3010; 2520-2891; 2590-2941; 2633-3070; 2651-3102; 2657-2955; 2657-2940; 2668-2915; 2686-3095; 2697-2836; 2700-2911; 2714-3093; 2732- 3093; 2744-3089; 2751-3098; 2760-3063; 2764-3060; 2776-3093; 2786-3052; Table 5
2790-3086 ; 2795-3084; 2799-3089; 2815-305 7; 2853-3070; 2853-3091; 2885-
3450; 2885-3097; 2902-3089; 2905-3098; 2933-3092; 2957-3089; 2963-3093;
2965-3195 3005-3094; 3034-3090; 3060-3216; 3064-3203
21/LG:369301.32 :2001MAR30 || 8-475; 2-388 ; 1-197; 42-594; 62-329; 112-574;
147-403; 155-631; 167-766; 182-494; 219-400; 305-556; 428-1003; 448-1038;
382-435; 419-660; 499-1071; 494-751; 507-688; 534-1134; 552-792; 567-866;
572-814; 584-862; 614-866; 628-1080; 641-1081; 667-1103; 698-1142; 699-886;
717-1127; 717-1204; 717-976; 814-1392; 846-1099; 851-1069; 912-1175; 895-
1309; 870 1077; 942-1517; 931-1066; 892-1055; 939-1027; 960-1217; 969-1525;
983-1254; 1005-1209; 1015-1552; 1015-1561 ; 1015-1259; 1022-1456; 1065-1444;
1065-1340 1070-1319; 1082-1261; 1102-1420; 1140-1284; 1141-1605; 1215-
1352; 1134-1306; 1166-1319; 1156-1445; 1162-1596; 1179-1359; 1179-1570;
1190-1598 ; 1197-1568; 1208-1490; 1209-1491; 1210-1503; 1211-1458; 1206-
1598; 1206-1534; 1206-1501; 1208-1602; 1224-1587; 1229-1603; 1248-1854;
1257-1598 ; 1286-1524; 1287-1497; 1290-1870; 1293-1598; 1310-1598; 1314-
1477; 1366-1598; 1385-1896; 1433-1865; 1444-1677; 1444-1675; 1452-1602;
1456-1598 ; 1540-1884; 1595-1777; 1597-1874; 1597-1777; 1600-1883; 1613-
1903; 1634-1874; 1635-1874; 1668-1884; 1738-1874; 1763-1876; 1785-1897;
1823-2121 ; 1953-2297; 1992-2215; 1995-2246; 2007-2332; 2030-2337; 2037-
2334; 2037-2304; 2037-2324; 2037-2094; 2037-2093; 2037-2296; 2037-2299;
2037-2269 ; 2037-2209; 2037-2189; 2037-2300; 2044-2296; 2134-2719; 2136-
2378; 2146-2370; 2202-2703; 2229-2471; 2282-2610; 2284-2740; 2299-2610;
2301-2528 ; 2307-2610; 2327-2576; 2333-2444; 2333-2715; 2340-2716; 2340-
2749; 2340-2708; 2340-2624; 2340-2610; 2340-2621; 2344-2714; 2348-2677;
2378-2677 ; 2387-2610; 2415-2610; 2436-2962; 2467-2610; 2552-2610; 2571-
2810; 2602-2742; 2647-2745; 2761-2870; 2786-3434; 3120-3657; 3140-3662;
3172-3434 3281-3766; 3294-3827; 3433-3711; 3549-4156; 3603-3840; 3673-
4284; 3787-4039; 3802-4039; 3806-4039; 3858-4425; 4116-4709; 4132-4647;
4168-4644
22/LG:452 089.1:2001MAR30 1-497; 35-576; 66-313; 236-685; 376-781
23/LG:454087.3 :2001MAR30 1-540; 8-537; 13-528; 251-778; 283-735; 339-
717; 700-1272; 704-1254; 829-1387; 897-1445; 1309-1876; 1375-1739; 1394-
1687; 1394-1624
24/LG:466 302.1:2001MAR30 | | 1-52 9; 16-10 7; 18 -542; 24-131; 101-542
25/LG:474267.1:2001MAR30 j j 1-27 3; 7-275 195 -382; 195-408 : 195-435 ; 197-
463 197-458; 200-486; 202-588 201-426 201- 429 202-455 202-719 204- 494 203-481; 203-499; 208-469 209-493 209 436 210-475 212-478 215- 500 215-478; 218-403; 218-419 219-468 219- 634 222-428 223-376 225- 767 225-473; 226-515; 227-395 226-477 227 477 230-466 230-454 230- 481 231-475; 233-462; 232-546 234-499 234 560 234-885 236-484 237- 497 237-826; 237-853; 240-700 237-827 240 440 241-526 241-496 255- 744 247-477; 247-527; 248-516 252-670 252 606 251-593 254-520 256- 655 260-503; 261-551; 265-676 264-495 264- 493 265-636 273-518 279- 751 288-473; 292-747; 296-532 349-469 371- 853 373-851 373-604 373- 808 373-617; 377-589; 389-865 396-859 396- 852 398-853 398-852 400- 662 403-853; 404-823; 407-870 411-856 413- 855 415-852 418-854 421- 855 420-500; 431-852; 434-853 442-853 453- 856 463-853 465-914 466- 782 467-855; 468-865; 469 858 469-914 469 724 483-853 484-858 487- 856 486-861; 489-851; 490-915 494-914 495 858 532-851 533-853 543- 858 544-820; 547-853; 545-647 549-854 555 819 566-853 600-836 616- 773 618-914; 704-912; 722-825 729-853 26/LG:995613.10:2001MAR30 | I 1-5 90; 1-53 7; 437-1051; 480-1051; 521-1112; 521-1015; 521-1113; 521-1020; 10 14-1359; 1014-1276; 1040-1252; 1040-1423; 1147-1378; 1158-1409; 1349-1615; 1447-2021; 1514-1994; 1518-1730; 1603-1775 27/LG: 011843.5 :2001MAR30 || 1-518; 448-1156; 847-1432; 954-1502; 1109-1502; 1170-1270; 1185-1499; 1402-1654; 1465-1695; 1513-1766; 1513-1761; 1518- 1766; 1556-2188; 1556-2190; 1556-1875; 1960-2149 28/LG: 075904.32 :2001MAR30 | I i-i60; 26-3 68; 18-471; 26-491; 26-351; 26-454; 26-452; 26-342; 26-224; 26- 118; 26-313; 86-546; 175-369; 264-463; 308-910; 347-1026; 383-625; 385-1082 ; 433-742; 441-1127; 471-714; 490-763; 563-816; Table 5 588-972 ; 573 -829 ; 649-1022 ; 833-1460 ; 831-13 84 ; 1030-1210 ; 1015-1258 ; 1174- 1689 ; 1225-1550 ; 1270-1624 ; 1270-1484 ; 1214- 1323 ; 1371-1799 ; 1451-1753 ; 1647-2104 ; 1691-1752 ; 1724-1800 ; 2013 -2586 ; 2273-2893 ; 2323 -2635 ; 2390- 2601 ; 2513-2796 ; 2598-2881 ; 18-573 ; 519-763 29 /LG : 1004781 . 3 : 2001MAR30 | | 1-462 ; 145-456 ; 145-709; 573-1138; 573-1124; 593 -942 ; 838-1227 ; 852 -1481 ; 852-1385 ; 972-1258 30 /LG : 1041807 . 8 : 2001MAR30 | | 1-468 ; 1-508 ; 1 -459; 1-231; 1-227; 1-349; 1- 80 ; 1-53 ; 1-229 ; 1-115 ; 17-192 ; 1-166 ; 1-155 ; 1-79; 1-57; 19-96; 1-230; 1- 171 ; 1-289 ; 1-151 ; 1-450 ; 1-242 ; 1-485 ; 1-527; 1-389; 1-538; 1-510; 1-590; 25-319 ; 44-117 ; 39-190 ; 129 -688 ; 128-626 ; 129-638; 185-372; 185-317; : 147-
589 192-347 203-441 216-510; 192-793; 203 -420; 239-503, 205-469 2 25511-- 516 214-773 257-657 250-773; 216-432; 279 -708; 315-580; 317-559 333399-- 777 342-799 342-580 342-578; 300-451; 306 -387; 350-603, 369-680 336677-- 623 394-841 379-533 401-642; 412-939; 416 -738; 425-692; 478-849 448822-- 703 489-616 494-765 494-761; 501-800; 535 -1152; 503-796; 544-1146; 519- 811 529-813 530-812 568-833; 555-802; 561 -814; 567-812; 581-816 604- 804 607-816; 643-1207 : 612-812 : 624-774 : 67 2-1101; 695-826; 698-1226; 738- 812 780-948; 747-804; 783-959; 804-948; 869 1334; 981-1430; 1104-1378;
1244-1665; 1246-1528; 1246-1316; 1331-1541; 1363-1636; 1383-1677; 1422- 1696; 1570-1679; 1578-1833; 1635-2197; 1665 2279; 1730-2016; 1741-2002; 1876-2168; 1877-2390; 1944-2192; 2053-2189; 2055-2201 31/LG: 1044448.2 :2001MAR30 || 1-578; 92-526; 291-932; 326-748; 333-770; 470- 958; 480-1044; 522-780; 522-937; 572-813; 584-983; 624-1256; 629-876; 659- 1025; 659-905; 675-913; 693-1011; 746-841; 772-1344; 899-1111; 917-1476; 1047-1411; 1072-1523; 1072-1317; 1134-1654; 1136-1246; 1187-1623; 1249-
1312; 1445-2016; 1516-1943 1551-1911 1723- 2346 1743-2375 1795-2057
1795-2149; 1862-1991; 1907-2154; 1911-2016 1951 2395; 1987 2100; 1987-
2369; 1991-2227; 2013-2237 2051-2283 2052- 2266 2061-2286 2061-2449
2094-2350; 2101-2354; 2104-2354; 2093-2402; 2089 2516; 2111 2314; 2099-
2175; 2101-2359; 2082-2346 2104-2775 2089-2329 2090-2335 2091-2359
2104-2735; 2095-2322; 2116-2401; 2107 2370; 2103 2345; 2110-2371; 2112-
2410; 2135-2401; 2156-2228 2184-2471 2200 2381 2212-2608 2197- 2479
2217-2795; 2218-2474; 2227-2471; 2270 2803; 2274 2795; 2285 2588; 2303
2543; 2303-2562; 2312-2616 2312-2514 2317 2863 2334-2762 2335- 2815
2337-2804; 2338-2545; 2339-2685; 2346 2611; 2337 2583; 2346 2675; 2340-
2587; 2354-2535; 2357-2595 2346-2576 2359 2820 2380-2432 2379- 2856 2390-2859; 2398-2551; 2399 2858; 2401 2854; 2403-2860; 2391 2500; 2403 2856; 2405-2859; 2408-2855 2407-2857 2412- 2856 2416-2723 2427- 2852 2414-2610; 2434-2856; 2439 2852; 2441 2855; 2444-2780; 2455 2856; 2461 2856; 2458-2856; 2459-2860 2459-2720 2459 2856 2460-2857 2465- 2856 2466-2814; 2467-2855; 2468 2860; 2470 2854; 2480-2856; 2472 2714; 2486 2856; 2487-2724; 2497-2853 2501-2862 2504 2856 2504-2857 2505- 2855
2506-2859; 2507-2753; 2510-2856; 2512 2855; 2526-2856; 2522 2862; 2524
2859; 2524-2861; 2527-2855 2528-2856 2529 2799 2530-2856 2529- 2787 2525-2856; 2539-2859; 2547 2858; 2551 2769; 2551-2860; 2551 2856; 2553 2856; 2553-2858; 2554-2856 2560-2818 2560 2858 2560-2817 2566- 2855
2581-2857; 2585-2856; 2605-2817; 2614 2858; 2623-2858; 2625-2857; 2626-
2858; 2627-2852; 2629-2856 2631-2835 2642 2856 2644-2838 2647-2862 2652-2813; 2661-2856; 2678 2856; 2689 2855; 2693-2818; 2696-2856; 2699- 2856; 2753-2857; 2773-2855 2779-2856 2791- 2860; 2804-2862 32 /LG: 1080598.9 :2001MAR30 I 1-431; 1 163; 1-611; 1-305; 13-555; 14-562
14-292; 39-740; 39-519; 41-193; 44-292; 48-310; 49-513; 51-643; 56-765; 61- 450; 71-673; 76-794; 76-377; 78-185; 186-804 ; 186-369; 186-334; 203-827; 205-466; 291-1096; 337-912; 339-608; 348-622 ; 419-1021; 419-937; 624-1164; 624-939; 634-716; 635-1020; 640-942; 643-930 ; 697-882; 720-969; 728-1353; 729-984; 739-1384; 759-1052; 778-1350; 797-1039; 814-1420; 835-1349; 848- 1153; 876-1422; 945-1350; 1090-1647; 1090-1655; 1090-1670; 1110-1404; 1116- 1357; 1126-1755; 1148-1755; 1171-1705; 1188-1685; 1189-1750; 1202-1707; 1223-1423; 1253-1334; 1296-1685; 1353-1703; 1360-1806; 1360-1613; 1360- 1742; 1366-1811; 1375-1823; 1377-1808; 1379-1805; 1395-1805; 1404-1805; Table 5
1433-1808; 1449-1742; 1495 1755; 1497-1750; 1 500-1805; 1545-1800; 1554- 1805; 1646-2081; 1652-2115 1650-2052; 1781-2241; 1838-2320; 1838-2005; 1846-2115; 1847-2115; 1850 2379; 1850-2432; 1953-2100; 2007-2256; 2191- 2397; 2191-2503; 2296-2371 2320-2372 33 /LG: 1081017.1:2001 AR30 I 1-354; 1-581; 32 0-804; 3 20-791; 320- 796; 320- 764; 320-462; 321-621; 330 757; 329-896; 331-896; 334-896; 344-791; 352- 760; 467-666; 576-763; 578 849; 585-851; 585-837; 585-877; 598-1163; 598- 918; 602-1089; 605-841; 60 5-875; 650-1201; 650-1129; 648-1177; 654-1294; 671-941; 692-1177; 705-143 8; 705-1177; 706-1187; 706-1078; 712-1092; 725- 1212; 725-972; 752-1359; 7 92-1177; 806-1369; 803-1333 ; 824-1296; 835-1235; 840-1317; 842-1053; 852-13 33; 880-1348; 874-1333; 923-1025; 931-1194; 923- 1276; 936-1333; 940-1363; 949-1131; 958-1333; 965-1333; 965-1189; 980-1089; 985-1089; 986-1089; 999-13 33; 1008-1333; 1014 1333; 1018-1333; 1005-1333; 1027-1333; 1039-1366; 1041 1333; 1053-1363; 1053-1333 ; 1053-1316; 1062- 1333; 1083-1333; 1091-1395 1091-1355; 1091-1333; 1092-1333; 1097-1333; 1124-1369; 1146-1369; 1193 1472; 1239-1333; 1244-1333 ; 1248-1333; 1247- 1333; 1255-1333; 1258-1333 1262-1334; 1271-1333; 1409-1473; 1429-1983; 1463-1553; 1463-1584; 1463 1515 34/LG : 1083120.2 :2001MAR30 I 1-684; 26-587; 2 6-260; 59-694; 270-833; 300- 833
35/LG : 1097492.12 :2001MAR30 II i- 664; 7 -492; 84-56 2; 104 -614; 107-3 73; 109- 702; 237-692; 406-630; 409 -467; 414-636; 425 -691; 428-8 80; 453-617 ; 489- 972; 520-955; 521-1177; 574-780; 635-825; 63 1-1204; 723 -1263 ; 823- 1089; 1024-1213; 1027-1561; 1027-1301; 1027-1300; 1029-1608; 1084-1647; 1137- 1243; 1188-1692; 1188-1690 ; 1205-1442; 1255- 1453 1287- 1963 1319- 1727; 1318-1526; 1372-1928; 1377-1669; 1423-1652; 1478-2056; 1484-1719; 1513- 1834; 1534-2189; 1561-2164 ; 1590-1852; 1610- 2130 1686 2280 1694- 1918; 1680-1968; 1719-1798; 1765-1979; 1844-2063; 1855 2038; 1891-2204; 1891- 2090; 1891-2060; 1954-2232 ; 1968-2173; 1981- 2169 2028 2226 2068 2316; 2090-2336; 2132-2352; 2143-2351; 2195-2775; 2205-2507; 2208-2821; 2243- 2538; 2244-2523; 2267-2823 ; 2279-2815; 2371- 2896 2369- 2559 2381 2986; 2389-2914; 2414-2660; 2444-2731; 2452-2565; 2468 2808; 2475 2732; 2481- 2715; 2491-2886; 2539-2744 ; 2558-3030; 2598- 2824 2608- 2868 2631 2952; 2631-2874; 2658-2764; 2666-3161; 2737-2981; 2741 3375; 2747 3303; 2830- 3245; 2850-3123; 2875-3129 ; 2887-3101; 2877- 3108 2899- 3426 2903 3181; 2926-3211; 2928-3217; 2958-3192; 2983-3243; 2978 3253; 3039 3583; 3040- 3280; 3056-3297; 3052-3324 ; 3070-3374; 3068- 3324 3087- 3365 3117 3620; 3137-3359; 3155-3386; 3155-3538; 3177-3432; 3184 3735; 3181 3388; 3181- 3514; 3206-3719; 3206-3735 ; 3230-3429; 3257- 3517 3299- 3770 3326 3575; 3342-3793; 3328-3981; 3363-3940; 3361-3613; 3359 3473; 3368 3602; 3368- 3611; 3372-3612; 3370-3940 ; 3391-3658; 3426- 3948 3465- 3745 3465 3739; 3485-3737; 3484-4052; 3486-3738; 3491-3731; 3503 4040; 3512 3780; 3512- 3789; 3529-3787; 3527-3764 ; 3526-4034; 3534- 4041 3553- 4041 3563 4038; 3577-3860; 3577-4078; 3579-4078; 3582-4095; 3583 4039; 3593 4058; 3593- 3809; 3602-4041; 3605-3968 ; 3605-3808; 3605- 3831 3612- 3834 3617 3855; 3618-4078; 3622-4081; 3623-4079; 3635-3969; 3639 3945; 3650 4040; 3670- 4041; 3670-4038; 3672-4085 ; 3672-4078; 3682- 4043 3684- 4078 3694 4079; 3697-4084; 3703-4080; 3715-4061; 3722-3912; 3729 4029; 3730 4076; 3732- 4084; 3736-3946; 3739-4037 ; 3740-4079; 3743- 4078 3751- 4078 3752 4079; 3752-4061; 3754-4053; 3755-4035; 3756-4078; 3756 3840; 3765 3992; 3767- 4040; 3772-3994; 3778-4076 ; 3784-3988; 3815- 4076 3827- 4053 3899 4078; 3951-4040; 3976-4055 36/LG: 118834.9 :2001MAR30 | I 1367-1825; 1370-1611; 1255-1539; 1147-1482; 1332-1477; 1021-1420; 862-1383; 889-1322; 1079-1269; 835-1226; 936-1182; 722-1176; 838-1175; 712-1173; 832-1172; 766-1172; 762-1166; 861-1153; 854- 1043; 464-1033; 320-770; 417-728; 467-712; 1-643; 322-599; 1-562; 322-521; 1-128
37/LG: 1227408.25 :2001MAR30 || 1-532; 257-786; 276-822; 298-860; 412-521; 433-505; 539-1095; 539-1122; 539-1112; 539-1106; 539-1162; 539-1205; 539- 1129; 539-1146; 539-1163; 539-1156; 539-744; 539-1135; 539-1172; 539-1093; Table 5 539-1101; 539-1144; 539-1143; 539-1136; 539-1192; 539-1182; 539-1159; 544- 812; 545-778; 641-874; 783-864
38/LG:1326953.1:200lMAR30 || 1-147; 32-489; 36-304; 153-375; 153-290; 153- 383; 153-359; 161-529
39/LG: 1397821.17 :2001MAR30 || 1-266; 15-266; 16-555; 19-287; 19-238; 20- 279; 30-134; 444-1012; 460-820; 470-822; 480-795; 490-744; 512-819; 512- 884; 512-794; 515-968; 627-1000; 634-879; 816-1361; 817-1058; 1093-1653; 1206-1758; 1206-1446; 1206-1412; 1206-1409; 1207-1701; 1235-1845; 1255- 1694; 1261-1904; 1272-1801; 1281-1861; 1284-1851; 1312-1483; 1313-1512; 1317-1933; 1335-1867; 1339-1505; 1343-1625; 1368-1639; 1381-1870; 1381- 1951; 1389-1664; 1405-1648; 1408-1938; 1415-1875; 1410-1942; 1417-1930; 1418-1661; 1422-1647; 1426-1713; 1440-1881; 1444-1686; 1454-1811; 1456- 1716; 1461-1978; 1462-1672; 1475-2057; 1480-1714; 1486-1766; 1493-1978; 1493-1940; 1493-1691; 1510-1970; 1516-1970; 1516-1940; 1520-1980; 1530- 1978; 1529-1943; 1530-1981; 1532-1974; 1534-1976; 1540-1976; 1563-1812; 1565-1940; 1568-1817; 1568-1736; 1593-1940; 1597-1983; 1612-1905; 1615- 1833; 1616-1819; 1624-1974; 1628-1855; 1628-1843; 1632-1976; 1642-1940; 1661-1788; 1686-1794; 1695-1850; 1722-1978; 1797-1879; 1839-1984 40/LG:1512507.1:2001MAR30 || 1-578; 1-589; 48-674
41/LG:196583.5:2001MAR30 |j 1-604; 375-911; 391-739; 450-1000; 543-1034; 560-666; 623-749; 725-1286; 758-1332; 811-1129; 909-1330; 1020-1640; 1075- 1444; 1080-1254; 1080-1409; 1080-1232; 1155-1416; 1306-1901; 1331-1947; 1362-1920; 1500-2068; 1508-1939; 1508-1777; 1508-1775; 1508-1761; 1508- 1768; 1508-2058; 1508-2091; 1508-1988; 1538-1869; 1540-1775; 1599-2130; 1603-1872; 1624-2084; 1661-2015; 1673-1904; 1875-2458; 1880-2170; 2124- 2378; 2153-2847; 2187-2847; 2283-2513; 2283-2646; 2302-2538; 2325-2846; 2330-2876; 2330-2504; 2330-2523; 2350-2937; 2383-2842; 2386-2891; 2387- 2674; 2387-2661; 2387-2663; 2387-2659; 2387-2692; 2388-2689; 2389-2627; 2394-2685; 2406-2951; 2428-2915; 2477-2913; 2481-2911; 2491-2951; 2522- 2950; 2571-2957; 2572-2951; 2587-2848; 2600-2910; 2607-2968; 2610-2829; 2685-2951; 2703-2882; 2703-2950; 2703-2945
42/LG:198669.1:2001MAR30 || 1-264; 15-656; 15-596; 28-525; 29-413; 29-245; 34-444; 34-380; 34-286; 34-223; 39-434; 39-290; 119-380; 267-805; 589-991; 598-914; 596-806; 692-914; 696-914; 726-979; 722-1152; 779-1199; 785-871; 786-1328; 784-1056; 799-945; 828-1372; 837-1120; 875-947; 903-1179; 913-
1391 928-1420; 929-1108; 946-1230; 976-1597; 981-1180; 1007-1218; 1015 1579 1031-1618; 1042-1280; 1067-1178; 1070-1345; 1082-1344; 1092-1687
1107-1331; 1119-1353; 1121-1621; 1121-1296; 1129-1430; 1148-1394; 1186
1446 1187-1504; 1186-1457; 1188-1369; 1193-1628; 1193-1639; 1195-1625
1216-1451; 1216-1422; 1245-1434; 1251-1480; 1254-1577; 1255-1577; 1294-
1555 1294-1440; 1309-1580; 1343-1865; 1354-1598; 1413-1639; 1423-1778
1423-1508; 1435-2072; 1479-2042; 1478-1703; 1480-1848; 1519-1743; 1520
1779 1525-1613; 1551-1980; 1551-1780; 1555-2097; 1558-1841; 1571-1723
1576-1836; 1586-1857; 1615-1867; 1619-1862; 1619-1860; 1625-2107; 1634
2048 1638-2054; 1667-1927; 1680-1945 1697-2038; 1697-1904; 1709-1930 1715 2232; 1717-2010; 1744-2409; 1749 2328; 1755-2039; 1771-2220; 1771 1914 1779-2021; 1807-1982; 1828-2058 1834-2122; 1837-2089; 1841-2124 1872 2160; 1873-2365; 1880-2271; 1879 2061; 1883-2141; 1883-2006; 1883 2145 1883-2116; 1890-2167; 1956-2568 1955-2271; 1955-2202; 1969-2205 1978 2255; 1991-2476; 1994-2289; 2001 2641; 1998-2221; 2005-2251; 2014 2641 2013-2271; 2017-2583; 2021-2230 2023-2256; 2023-2323; 2027-2187
2029-2268; 2035-2336; 2043-2276; 2043-2186; 2056-2222; 2066-2137; 2080
2332 2080-2330; 2085-2293; 2101-2484; 2101-2321; 2109-2356; 2120-2359 2153 2430; 2177-2448; 2179-2365; 2195-2715; 2192-2438; 2209-2356; 2211 2501 2212-2275; 2213-2281; 2243-2344; 2259-2508; 2263-2371; 2295-2813 2311 2833; 2314-2889; 2318-2602; 2320-2772; 2324-2583; 2327-2945; 2340 2417 2358-2595; 2361-2851; 2369-2691; 2396-2628; 2402-2807; 2408-2651 2411 2865; 2426-2543; 2429-2852; 2440-2939; 2449-2818; 2457-2909; 2469- 2913 2471-2894; 2471-2724; 2476-2726; 2478-2730; 2493-2945; 2493-2850
2496-2755; 2498-2607; 2502-2560; 2511-2743; 2512-2740; 2533-2952; 2534- Table 5 2946; 2531-2939; 2542-2936; 2549-2965; 2552-2937; 2558-2970; 2566-3066; 2566-2937; 2571-2938; 2571-2944; 2579-2678; 2579-2937; 2598-2935; 2586- 2842; 2594-2946; 2595-2930; 2599-2896; 2615-2937; 2614-2938; 2619-2960; 2622-2935; 2624-2912; 2640-2935; 2641-2848; 2658-2923; 2661-2963; 2664- 2952; 2669-2952; 2669-2946; 2670-2936; 2671-2935; 2684-3076; 2687-2936; 2696-2937; 2701-2936; 2706-2940; 2713-2852; 2714-2938; 2724-2962; 2739- 2963; 2741-2816; 2766-2946; 2791-2893; 2840-2960; 2854-2920; 2876-2963; 2902-3276; 2902-3160; 3024-3157
43/LG:202943.1:200lMAR30 || 1-467; 66-523; 109-604; 187-604; 204-719; 307- 586; 350-844; 349-937; 379-655; 623-900; 690-1338; 931-1169; 1065-1675; 1171-1802; 1185-1272; 1228-1495; 1228-1496; 1233-1500; 1285-1788; 1363- 1591; 1401-1810; 1401-1645; 1407-1647; 1469-2019; 1610-2115; 1742-1924; 1851-2412; 2045-2453; 2068-2697; 2172-2584; 2202-2382
44/LG: 204724.3 :2001MAR30 || 1-272; 1-313; 1-455; 1-288; 2-300; 2-272; 3- 290; 4-312; 5-316; 5-286; 7-229; 7-202; 16-308; 17-303; 17-105; 17-338; 31- 263; 31-153; 76-712; 76-530; 385-947; 648-790; 659-793; 718-959; 875-1165; 889-1183; 945-1321; 948-1149; 954-1079; 968-1273; 985-1279; 1052-1289; 1086-1513; 1086-1332; 1103-1411; 1124-1663; 1273-1586; 1356-1601; 1358- 1665; 1366-1623; 1395-1559; 1409-1715; 1508-1816; 1562-1851 45/LG: 206425.10 :2001MAR30 || 1-271; 105-232; 218-327; 224-613; 338-955; 354-681; 354-602; 368-574; 368-632; 390-667; 396-451; 420-1049; 472-921; 580-676; 832-1433; 844-1396; 970-1352; 1026-1298; 1031-1513; 1056-1281; 1145-1330; 1146-1752; 1369-1774; 1432-1700; 1641-1923; 1736-2373; 1787- 2221; 1788-2033; 1821-2140; 1823-2102; 1832-2220; 1998-2181; 2072-2186 46/LG:208190.2:2001MAR30 || 1-568; 23-547; 31-455; 34-319; 45-101; 76-243; 99-495; 193-843; 201-440; 201-673; 318-618; 334-837; 382-628; 411-864; 411- 796; 521-631; 772-1381; 954-1368; 958-1114; 981-1434; 1115-1473; 1115-1448; 1115-1311; 1177-1473; 1243-1476; 1332-1413; 1372-1721; 1456-1738; 1493- 1667; 1531-1694; 1531-1971; 1531-2014; 1906-2013
47/LG: 222927.2 :2001MAR30 || 1-570; 68-596; 193-732; 301-905; 404-702; 404- 965; 404-623; 457-739; 496-761; 533-1154; 538-1244; 574-866; 658-1046; 674- 866; 723-1099; 757-1177; 806-1418; 885-1375; 901-1155; 911-1340; 960-1179; 1010-1373; 1022-1360; 1074-1468; 1074-1234; 1074-1329; 1109-1254; 1147- 1555; 1149-1670; 1148-1341; 1167-1244; 1243-1670; 1378-1578; 1387-1613; 1387-1728; 1438-1889; 1444-1971; 1444-1693; 1463-1765; 1465-1993; 1517- 1841; 1520-1789; 1521-1791; 1527-1831; 1564-1688; 1569-1735; 1587-1742; 1587-2008; 1608-1697; 1609-1867; 1638-1822; 1646-1920; 1646-1873; 1653- 1959; 1657-2078; 1662-1901; 1665-2085; 1685-1805; 1693-2087; 1709-1980; 1729-2287; 1746-2085; 1751-2085; 1787-2221; 1787-1897; 1819-2091; 1822- 1956; 1848-2062; 1863-1973; 1876-2110; 1912-2008; 1915-2367; 1957-2580; 1964-2206; 1966-2218; 2026-2311; 2072-2568; 2072-2359; 2080-2440; 2080- 2327; 2080-2280; 2085-2581; 2085-2327; 2090-2292; 2121-2348; 2128-2341; 2131-2279; 2131-2288; 2148-2606; 2151-2712; 2150-2426; 2155-2318; 2161- 2673; 2165-2465; 2169-2696; 2170-2439; 2202-2457; 2206-2642; 2206-2428; 2213-2622; 2215-2510; 2217-2683; 2227-2712; 2222-2383; 2237-2481; 2241- 2646; 2268-2526; 2277-2640; 2287-2746; 2287-2611; 2287-2481; 2302-2508; 2312-2710; 2312-2698; 2314-2706; 2312-2380; 2323-2708; 2331-2752; 2331- 2540; 2348-2755; 2347-2610; 2347-2550; 2351-2646; 2361-2589; 2409-2756; 2412-2626; 2433-2670; 2453-2711; 2475-2752; 2521-2744; 2523-2750; 2528- 2751; 2566-2803; 2600-2752; 2602-2751; 2623-2749; 2627-2758; 2637-2753; 2643-2749; 2671-2746; 2675-2746; 2702-3123
48/LG:228046.5:2001MAR30 || 1-471; 54-6211; 189-720; 670-1229; 670-904; 686-1164; 686-933; 756-947; 1200-1654; 1726-2284; 1737-2331; 1907-2503; 1927-2353; 1936-2400; 2098-2593; 2274-2845; 2308-2955; 2342-2472; 2342- 2548; 2344-2904; 2345-2485; 2377-2592; 2377-2598; 2418-2646; 2603-2864; 2603-2995; 2672-2898; 2686-3214; 3003-3257; 3008-3289; 3044-3578; 3060- 3299; 3092-3562; 3094-3354; 3094-3268; 3094-3239; 3094-3413; 3136-3636; 3136-3373; 3140-3563; 3154-3297; 3168-3561; 3215-3561; 3244-3561; 3242- 3532; 3262-3561; 3262-3479; 3262-3507; 3284-3818; 3279-3458; 3281-3407; 3350-3901; 3377-3872; 3439-3563; 3449-3925; 3457-3915; 3468-3942; 3472- Table 5
3941; 3481 3941; 3502-3799 3505-3798; 3505- 3780 3505- 3797; 3513 -3942 3536-4003; 3537-3860; 3537-3941; 3540-3 948; 3551 3949; 3558-3936; 3561 3942; 3564 3948; 3581-4040 3586-3941; 3606- 4004 3621- 3944; 3632 -3942 3636-3945; 3641-3836; 3693-3940; 3746-3 930; 3760 4036; 3837-4044; 3843 3941; 3899 4040; 3918-4040 3959-4548; 3975- 4040 4362- 4450; 4377 -4785 4372-4838; 4373-4439; 4381 4454; 4388-4 638; 4416 4940; 4417-4539; 4445 4744; 4445 4988; 4472-4731 4527-4784 4542- 5053 4542- 4727; 4575 -4784 4615-5105; 4628-5198; 4636 4900; 4658-4 907; 4664 4914; 4710-4999; 4733 5206; 4802 5033; 4850-4966 4854-5089; 4864- 5031 4893- 5413; 4912 -5125 4912-5416; 4920-5582; 4935-5258; 4978-5 505; 4980 5212; 5004-5447; 5006 5270; 5033-5214; 5052-5660 5082-5352; 5087- 5521 5086- 5356; 5090 -5372 5128-5377; 5126-5237; 5130 5358; 5140-5 646; 5190-5384; 5225-5384; 5300 5687; 5306-5500; 5317-5563 5362-5928; 5363- 5814 5413- 5643; 5425 -5703 5437-5817; 5490-5757; 5502 5793; 5504-6 099; 5516-6000; 5551-6054; 5551 5791; 5560-5796; 5615-6164 5615 5817; 5616- 5899 5627- 6173; 5645 -5881 5645-5885; 5645-5858; 5664 6168; 5667-5 959; 5689 6210; 5689-5953; 5689 5938; 5696-5958; 5698-6173 5715-6162; 5717- 6197 5734- 6211; 5737 -6034 5740-6211; 5753-5988; 5762 6214; 5777-6 213; 5783 6173; 5783-6214; 5805 6211; 5820-6213; 5822-6211 5881-6176; 5881- 6110 5886- 6209; 5889 -6170 5896-6125; 5896-6216; 5898-6167; 5919-6 170; 5930 6214; 5968-6471; 5977 6213; 5978-6293; 5983-6212 5983-6165; 5983- 6211 6003- 6142; 6016 -6507 6042-6212; 6093-6367; 6245-6682; 6257-6 678; 6260 6642; 6263-6678; 6351 6682; 6359-6682; 6472-6603 6499-6683 49/LG:230980.1:2001MAR30 I 1-464; 1-26 9; 1-522; 14-182 ; 29-487; 59-644; 224-613; 297-571 497-1027 833-1414; 856-1445; 867-1121; 1001-1526; 1125- 1486; 1135-1551; 1162-1487 1164-1488 1170-1362; 1186-1488; 1300-1639; 1333-1642; 1334-1642 50/LG:236976.2:2 001MAR30 I I 1-47 8; 1-566; 65-497; 183-514; 183-439; 199- 683; 202-478; 272-721; 416-637 51/LG:238322.6:2001MAR30 I I 1-60 5; 57 -317 ; 67-17 5; 104-7 28; 148-7 79; 164- 700; 196-849; 314-477; 439-1085; 508- 817; 527-1162; 825- 1264; 1028-1284; 1210-1714; 1235-1767; 1418-1908; 1610 -2193; 1614-2204; 1 676-3446; 1712- 1907; 1711-1968; 1713-1906 1714-1973 ; 1713-1964 ; 1715-1 964; 1801-2128; 1881-2489; 1899-2409; 2233 2577; 2465 -2966; 2639-2929; 2 640-2929; 2706- 3055; 2731-2943; 2737-2834 2759-3013 ; 2773-3339 ; 2806-3 091; 2807-3072; 2808-3188; 2865-3116; 2904 3540; 2930 -3374; 2952-3210; 2 994-3446; 2995- 3472; 2995-3246; 3013-3220 3030-3263 ; 3038-3229 ; 3054-3 388; 3097-3450; 3128-3412; 3131-3260; 3142 3281; 3164 -3446; 3230-3416; 3 239-3744; 3248- 3439; 3263-3494; 3263-3451 3263-3675 ; 3265-3740 ; 3291-3 552; 3322-3753; 3318-3692; 3343-3797; 3378 3794; 3380 -3676; 3381-3760; 3 408-3800; 3417- 3821; 3422-3814; 3440-3790 3451-3750 ; 3455-3724 ; 3510-3 793; 3531-4012; 3547-3787; 3562-3765; 3562 3739; 3562 -3767; 3573-3748; 3 614-3781; 3645- 3790; 3782-4264; 3782-4059 3792-4388 ; 3800-3983 ; 3805-4 352 52/LG:341461.1:2001MAR30 I I 1-639; 88 -611 ; 94-311; 105-2 97; 105-3 09; 108- 280; 108-532; 108-351; 119-625; 119-3 03; 395-870 ; 402-48 4; 539-948; 564- 946; 608-816; 656-949; 668-1082; 896- 1328 53/LG:354088.1:2001 AR30 I I 1-525; 24 5-45 5; 451-945; 599-791; 662-1314; 809-1347; 809-910; 1154-1399; 1154-15 96; 1172-1766; 1192-1467; 1192-1705; 1258-1820; 1262-1555; 1282-1555; 1282 -1706; 1307-1667; 1307-1952; 1307- 1664; 1314-1551; 1457-1570; 1539-1664 ; 1574-1665 54/LG:376275.1:2001MAR30 I I 1-671; 8- 389; 412-981; 491-667; 589-805 55/LG:399281.3:2001MAR30 j j 1-456; 48 -221 ; 48-605; 48-365; 51-241; 108-377; 215-687; 305-867 ; 380-605; 399-725; 3 99-608; 401-614; 406-956; 672-1248; 862-1299; 863-1299; 863-1080; 1181-17 72; 1273-1853; 1518-1996; 1519-1996; 1531-2009; 1528-1831; 1542-2124; 1667 -2233; 1842-2358; 1848-2270; 1854- 2335; 1911 2019; 2092-2656; 2142-2439 ; 2157-2656; 2214-2612; 2531-2612 56/LG:404921.10: 2001MAR30 | I 1-342; 1 9-656; 23-225; 24-476; 30-595; 30-503; 163-512; 170-463 ; 429-690; 429-928; 5 92-1104; 857-1242; 908-1179; 1172- 1753; 1202-1639; 1243-1517; 1455-1695 ; 1455-1863; 1630-1904; 1629-2014; 1880-2115; 1882-2208; 1895- 2450; 1908 -2117; 1935-2364; 1935-2217; 2001- Table 5 2632; 2298-2490; 2334-2603; 2330-2623; 2440-2666; 2466-2571; 2481-2732; 2486-2723; 2564-2693; 2575-2853; 2578-2823; 2598-2832; 2716-2957; 2763- 3210; 2763-2982; 2833-3148; 2860-3135; 2952-3149; 2971-3068; 2984-3480; 2999-3391; 3018-3337; 3042-3576; 3045-3518; 3059-3325; 3105-3229; 3111- 3664; 3116-3381; 3122-3304; 3124-3597; 3128-3473; 3135-3462; 3156-3492; 3163-3434; 3163-3425; 3187-3779; 3202-3480; 3202-3408; 3220-3778; 3226- 3532; 3279-3518; 3304-3598; 3305-3545; 3305-3544; 3379-3662; 3392-3682; 3430-3677; 3507-3645; 3543-3611
57/LG:444677.34:200lMAR30 || 1-261; 29-306; 51-341; 51-243; 53-361; 53-470; 53-531; 152-695; 190-445; 356-896; 356-753; 356-765; 356-913; 356-876; 356- 928; 356-934; 541-1032; 573-1005; 594-665; 757-1171; 761-1054; 763-921; 765-1018; 823-1063; 823-1061; 938-1337; 1144-1332
58/LG:968691.1:2001 AR30 || 1-230; 1-649; 3-238; 192-248; 192-354; 202-641 59/LG:983862.1:200lMAR30 jj 1-2668; 1712-2303; 1770-2274; 1771-1930; 1811- 2056; 1857-2181; 1865-2300; 1865-2087; 1867-2383; 1867-2136; 1947-2258; 1959-2181; 2087-2547; 2133-2305; 2185-2383; 2221-2585; 2221-2690; 2221- 2486; 2256-2504; 2274-2780; 2293-2506; 2306-2798; 2396-2710; 2404-2702; 2404-2802; 2468-2779; 2496-2749; 2515-2770; 2556-2811; 2656-2806; 2709- 3108; 2820-3352; 2950-3504; 2954-3197; 2998-3601; 3030-3111; 3054-3609; 3070-3466; 3070-3321; 3083-3386; 3093-3608; 3116-3560; 3144-3621; 3152- 3244; 3166-3525; 3185-3649; 3189-3647; 3190-3645; 3195-3645; 3202-3645; 3221-3646; 3234-3646; 3240-3652; 3252-3646; 3255-3605; 3257-3644; 3278- 3646; 3315-3653; 3315-3564; 3322-3646; 3322-3663; 3336-3587; 3342-3648; 3366-3646; 3375-3646; 3387-3644; 3405-3646; 3475-3650; 3476-3644; 3480- 3644; 3550-3645; 3550-3635
60/LG:984130.1:2001MAR30 || 1-519; 72-338; 104-659; 243-441; 253-897; 324- 781; 423-926; 455-660; 468-1070; 520-973; 523-781; 529-782; 567-789; 567- 810; 622-754; 657-949; 721-996; 761-1001; 980-1370; 1014-1370; 1014-1522; 1071-1370; 1126-1623; 1214-1406; 1231-1652; 1236-1496; 1273-1527; 1303- 1370; 1309-1851; 1345-1593; 1352-1576; 1448-1593; 1472-1973; 1474-2177; 1495-2016; 1518-1593; 1694-2076; 1714-1940; 1714-2060; 1721-1919; 1788- 2302; 1801-2320; 1932-2360; 1984-2284; 2046-2228; 2088-2362; 2174-2365; 2271-2364
61/LG: 986291.1 : 2001MAR30 || 1-164; 1-736; 1-358; 1-66; 1-269; 1-612; 1-621; 227-891; 257-894; 274-889; 523-806
62/LG:045210.8:2001MAR30 || 951-1385; 884-1248; 670-1246; 832-1243; 787- 1242; 832-1238; 1013-1208; 776-1238; 862-1236; 978-1218; 759-1057; 751- 1048; 670-920; 431-896; 462-853; 612-827; 436-724; 274-650; 162-606; 343- 601; 144-599; 365-599; 347-599; 236-599; 352-599; 215-599; 184-598; 177- 591; 84-538; 153-538; 101-538; 131-538; 66-538; 65-538; 100-538; 1-520; 1- 515; 326-504; 155-500; 73-428; 1-345; 18-253; 79-204
63/LG:229284.39:200lMAR30 || 1-363; 1-260; 1-386; 1-319; 1-294; 1-218; 1- 140; 4-188; 9-550; 9-552; 19-149; 438-961; 471-538; 509-685; 550-1231; 563- 1177; 576-1177; 575-1123; 630-1172; 684-1291; 709-1078; 712-976; 786-1291; 885-1044; 935-1210; 1047-1544; 1069-1384; 1071-1334; 1074-1362; 1088-1627; 1088-1571; 1130-1378; 1141-1742; 1143-1376; 1231-1711; 1250-1741; 1250- 1374; 1271-1829; 1274-1500; 1275-1452; 1290-1879; 1308-1743; 1319-1737; 1345-1900; 1380-1956; 1435-1995; 1464-1783; 1472-1991; 1472-1965; 1482- 1729; 1483-1754; 1496-2030; 1529-2071; 1538-1726; 1540-1849; 1552-2122; 1558-2036; 1563-1821; 1607-1842; 1654-2218; 1652-1951; 1677-1757; 1686- 2271; 1729-2329; 1742-2298; 1756-2214; 1768-2250; 1823-2329; 1824-2315; 1845-2331; 1901-2542; 1910-2505; 1925-2312; 1992-2310; 2040-2313; 2062- 2339; 2069-2365; 2161-2688; 2172-2447; 2172-2397; 2173-2832; 2203-2440; 2220-2481; 2262-2474; 2278-2531; 2284-2523; 2287-2531; 2294-2523; 2321- 2827; 2331-2586; 2386-2952; 2464-2991; 2476-2635; 2579-3015; 2585-2836; 2635-2887; 2711-2998; 2720-2952; 2719-3285; 2731-2969; 2733-2919; 2758- 3010; 2770-3129; 2776-3294; 2807-3021; 2858-3014; 1840-2322 64/LG:337810.20:2001 AR30 || 1-506; 9-476; 24-263; 27-245; 104-671; 104- 701; 104-221; 104-705; 104-740; 105-710; 192-477; 211-494; 239-667; 239- 439; 244-453; 294-519; 293-720; 349-901; 350-638; 355-413; 371-660; 376- Table 5
627; 398- -644; 4533-- -770099;; 455-774 ; 485-566 ; 518-1140 ; 536-1146 ; 561-708 ; 564-
805; 564- -785; 571- -1047 581-1128 ; 594-1055 ; 595-813 ; 608-893 ; 616-890 ; 622-
812; 622- -825; 631- -1144 646-817 ; 646-1149 ; 656-979 ; 659-928 ; 666-1168 ; 689-
777; 690- -972; 698- -1168 703-953 ; 724-896 ; 742-1203 ; 741-1204 ; 745-954 ; 745-
984; 745- -976; 745- -962; 745-986 ; 745-991 ; 745-988 ; 747-954 ; 745-992 ; 745-
983; 745- -997; 745- -989; 747-1204 ; 754-1148 ; 760-1208 ; 773-1227 ; 772-987 ;
778-121 2; 773-1211 ; 772-989 ; 778-1205 ; 780-1208 ; 785-1203 ; 794-1211 ; 788- 1206; 803-1106; 804-1205 ; 805-1169 ; 809-1205 ; 810-1030 ; 817-1088 ; 819-1212 ; 824-1203; 829-1110 ; 834-1203 ; 836-1205 ; 838-1211 ; 840-1211 ; 848-1208 ; 852- 1213; 855-1212; 854-1159 ; 873-1203 ; 876-1205 ; 878-1205 ; 884-1141 ; 886-1129 ; 891-1208; 892-1205 ; 893-1138 ; 911-1203 ; 918-1211 ; 919-1205 ; 920-1205 ; 920- 1177; 921-1210; 924-1158 ; 935-1091 ; 935-1168 ; 943-1204 ; 947-1201 ; 948-1215 ; 953-1207; 956-1213 ; 1001-1203 ; 1020-1186 ; 1029-1212 ; 1032-1211 ; 1039-1203 ; 1040-1205; 1078- 1204 ; 1094-1218 ; 1094-1205 65/LG:463420.1:2 001MAR30 || 1-143; 1-540; 1-469; 32-523; 47-371; 114-651; 111-433 ; 135-331 258-733; 299-644; 333-572; 363-851; 379-938; 382-636; 429-655 ; 443-957 577-1148; 587-969; 616-1146; 625-947; 627-861; 648-1130; 685-1161; 698-1149; 698-1132; 751-1146; 758-1130; 764-1130; 765-1130; 785- 1026; 791-1130; 806-1130; 853-1130; 854-1130; 863-1130; 874-926; 874-1130; 874-959 ; 881-1130; 999-1130; 1000-1130; 1015-1146; 1034-1593; 1094-1146; 1178-1733; 1271-1560; 1428-1677; 1428-1956; 1431-2014; 1437-1799; 1437-
1798 1437- 1692 1437- 1589 1437- 1498 1443- 1707 1446- 1793 1454-1689 1454 1651; 1457 1662; 1470 -2001; 1477 1703; 1495 1595; 1501 2015; 1505 1954 1515- 1779 1526- 1769 1531- 2066 1532- 2028 1572- 2091 1613-1899 1628 2165; 1640 2057; 1640 2178; 1668 2177; 1668 2163; 1675 2226; 1683 2231 1688- 2188 1695- 1800 1707- 2088 1710- 2088 1740- 2235 1751-2275 1760 2214; 1794 2432; 1811 -2082; 1814 -2405; 1818 2075; 1826 2081; 1828 2220 1828- 2417 1826- 2092 1828- 2259 1846- 2338 1858- 2443 1861-2144 1868 2148; 1870 2116; 1870 2114; 1878 2423; 1880 2152; 1891 2194; 1898 2160 1899- 2291 1903- 2454 1983- 2478 1983- 2248 2005- 2564 1929-2297 1938 2362; 1942 2359; 1964 2230; 1970 2144; 1969 2477; 1974 2194; 1976 2214 1979- 2231 1985- 2275 1987- 2197 1989- 2240 1992- 2531 2005-2294 2011 2317; 2021 2617; 2022 2252; 2029 2628; 2030 2517; 2092 2344; 2104 2601 2128- 2571 2082- 2497 2081- 2386 2084- 2322 2088- 2593 2088-2688 2088 2673; 2088 2675; 2088 -2655; 2088 -2653; 2107 -2328; 2127 2410; 2127 2398 2128- 2374 2129- 2369 2141- 2771 2142- 2733 2163- 2325 2173-2401 2176 2793; 2183- 2312; 2195-2651; 2205 2592; 2207-2789; 2205 2442; 2206 2467 2207- 2449 2209-2624 2215-2480 2232-2774 2233-2779 2232-2524 2247 2800; 2253 2404; 2253-2458; 2254-2465; 2259 2826; 2260-2799; 2270- 2712 2267- 2536 2277-2519 2284-2842 2290-2499 2291-2822 2301-2532 2302 2537; 2306 2512; 2316-2892; 2321-2866; 2334-2439; 2338-2939; 2340- 2639 2346- 2621 2351-2612 2351-2557 2353-2845 2358-2629 2363-2606 2363 2546; 2363 2498; 2364-2680; 2366-2610; 2378 2628; 2378-2587; 2380 2536 2383- 2882 2383-2609 2384-2506 2389-2634 2389-2618 2403-2911 2407 2870; 2407 2674; 2407 2636; 2412-2738; 2411 2513; 2419 2866; 2421- 2635 2422- 2654 2423-2981 2450-2722; 2450-2711 2460-2712 2474-2836 2474 2838; 2456 3008; 2494 2975; 2494-2738; 2495 2748; 2495-2747; 2516- 2682 2485- 3014 2507-3072 2508-2729 2423-3024 2517-2779 2517-2767
2508-3106; 2527 2732; 2512 2784; 2536 2808; 2534 3203; 2548 2651; 2550
3066 2554- 2805 2537-3104 2574-3100 2578-2829 2583-3153 2583-2838 2585 3205; 2584 2821; 2588-2739; 2598-3115; 2582 3205; 2588-3207; 2596- 3205 2601- 3205 2600-3205 2602-3205 2602-3235 2620-3207 2604-3205 2623 2710; 2606 3205; 2638 2931; 2615 3205; 2615 3207; 2616-3205; 2617 3207 2621- 3205 2623-3205 2627-3205 2625-3205 2628-3205 2630-3205 2631 3205; 2648 3205; 2652 3205; 2635 3205; 2633 3205; 2657 2880; 2640- 3205 2643- 3205 2648-3207 2649-3205 2651-3205 2685-2968 2654-2867 2657 3205; 2656 3205; 2657 2866; 2661 3205; 2662 3205; 2663 3205; 2662- 2974 2667- 3205 2669-3205 2689-3215 2694-3144 2678-3205 2712-2954 2689 3205; 2692 3205; 2696 2866; 2711 3214; 2712-3214; 2712 3073; 2712 3213 2722- 3205 2700-3206 2719-3205 2732-3214 2702-3205 2702-3207 Table 5
2703-3205; 2724- 3214; 2713 3205; 2711-3207; 2741-3 009; 2747 3000; 2739-
3214 2724- -3205; 2725- 3205 2727 -3205 2744- 3214 2723- 3205 2745 -3214; 2747 3204; 2731-3032; 2731 3107; 2765-3214; 2747 205; 2768 3215; 2749- 3205 2749- -3207; 2767- 3214 2750 •3205 2774- 3213 2761- 3205 2794 -3027;
2785-3214; 2765-3189; 2797 3032; 2768 3196; 2769 207; 2792 3214; 2771-
3205 2790 -3214; 2773- 3215 2773 ■3196 2780- 3207 2794- 3213 2800 -3215; 2810 3053; 2781-3205; 2788 3207; 2814 3105; 2820 064; 2810 3198; 2810- 3204 2793 -3205; 2797- 3214 2817 •3205 2820- 3214 2819- 3114 2801 -3205;
2836-3089; 2825-2937; 2810 3205; 2811 3205; 2831 215; 2815 3205; 2851-
3214 2843 -3209; 2852- 3205 2836 ■3010 2840- 3152 2846- 3118 2850 -3203;
2874-3214; 2876-3205; 2888 3127; 2879 3214; 2898-3 158; 2895 3214; 2916-
3214 2907- -3214; 2930- 3193 2998 •3205 2999- 3205 3012- 3205 3014 -3205; 3034 3154; 3038-3145; 3095 3352; 3094 3353; 3117 617; 3121 3723; 3189- 3774 3207- -3704; 3207- 3694 3207 ■3687 3207- 3686 3207- 3646 3207 -3660; 3209 3710; 3208-3703; 3216 3425; 3215 3523; 3216-3 804; 3216 3739; 3216- 3707 3216- -3678; 3216- 3676 3216 ■3621 3216- 3371 3217- 3750 3216 -3645; 3216 3657; 3217-3790; 3221 3657; 3217 3632; 3232 487; 3237 3501; 3243- 3787 3247 -3834; 3246- 3696 3246 ■3382 3255- 3725 3264- 3774 3282 -3800; 3283 3520; 3285-3815; 3286 3817; 3288-3379; 3294 813; 3292 3577; 3300- 3816 3314- -3579; 3315- 3603 3320 ■3568 3328- 3565 3333- 3586 3339 -3794; 3357 3823; 3359-3817; 3359 3815; 3363 3826; 3375-3 819; 3379 3816; 3383- 3621 3385 -3644; 3385- 3816 3390 ■3785 3390- 3571 3403- 3656 3395 -3645; 3402 3777; 3408-3815; 3418 3639; 3427-3821; 3431 817; 3438 3730; 3438- 3626 3438- -3624; 3463- 3718 3472 ■3707 3481- 3816 3482- 3821 3482 -3794;
3499-3775; 3515-3756; 3531 3799; 3591-3821; 3598 812; 3661 3815; 3723-
3783 3168 -3441; 3547- 3814 3542 ■3814 3211- 3482 3515- 3794 3531 -3810; 3500 3789; 3530-3814; 3208 3497; 3254-3564; 3462-3 813; 3427 3786; 3434- 3814 3419 -3814; 3225- 3639 3493 •3805 1957- 2216 3577- 3814 3576 -3814; 3569 3806; 3587-3812; 3593 3814; 3603 3814; 3612 814; 3614 3814; 3615- 3814 3618 -3814; 3618- 3809 3620 ■3814 3619- 3812 3618- 3810 3623 -3814;
3211-3396 66/LG:1080 918.1: 2001MAR30 I 2050-2459; 2118-2459; 2163-2456; 1901-2262; 1712-2227; 1317-1890; 1050 -1715; 1051-1715; 1066-1702; 1399-1604; 1317- 1510; 834- 1368; 1002-1298; 525-1094; 834-1077; 649-1048; 529-923; 269-815; 218-815; 2 05-802 1-639 67/LG:1093 747.15 2001MAR30 II i -626; 6 1-735 ; 98-56 1; 98 -751; 98-649; 103- 350; 119-3 74; 167-383; 188 418; 188-582; 20 9-456; 231-888; 164-439; 227- 495; 255-5 07; 331-590; 415 591; 385-825; 39 0-823; 634-886; 634-916; 636- 914; 658-9 02; 759-1364; 78 2-1028; 878-1134; 897-15 10; 916-1135; 919-1287; 1054-1306; 1242-1502; 1246 -1502 ; 1249-1661; 1249-1 529; 1261-1864; 1322- 1582; 1323 -1599; 1324-1609 1516-1841 1516 1943; 1519-1807; 1522-2050; 1528-1815; 1576-2099; 1576 -1837 ; 1586 1852; 1586-2 013; 1617-2169; 1641- 1902; 1674 -1919; 1690-1933 1830-2281 1829 2362; 1830-2443; 1830-2398; 1836-2422; 1839-2427; 1844 2350 ; 1852 2456; 1868-2 441; 1879-2493; 1888- 2370; 1943 -2209; 1961-2390 2040-2489 2106 2494; 2113-2493; 2120-2495; 2184-2497; 2234-2497; 2292 -2493 ; 2352-2490; 2353-2 493; 2369-2493; 2381-2489 68/LG:1096 896.47 :2001MAR30 II i-573; 399-1062; 502 -1081 502-1044; 532- 1161; 563- 1123; 581-1022; 854-1164; 897-1457; 954- 1384; 1100-1497; 1363- 1934; 1385 -1502; 1428-1873 ; 1428-1502; 1749-1967; 1760-2258; 1810-2379; 1839-2076; 1905-2187; 2149-2306 ; 2150-2308; 2150-2 240 69/LG:1098 931.39 :2001MAR30 1-191; 120-836; 196- 7210; 467-1084; 523-1073; 531-1056; 723-1016; 1417-1 76i; 1440-1798; 1803-239 7; 1850-2384; 2041-2606; 2321-2731; 2815-3441; 2950 3532 ; 3420-3704; 3869-4 460; 3874-4290; 4386- 4555; 4672 -5034; 4680-4898 4870-5316; 4957-5438; 4970-5037; 4983-5145; 5077-5218; 5199-5817; 5529 5845 ; 5674-6147; 5674- 963; 5728-5805; 5853- 6322; 5879 -6309; 6149-6336 6153-6425; 6192-6641; 6352-6610; 6403-6910; 6413-6539; 6433-6518; 6584 6894 ; 6627-6851; 6632- 928; 6637-6889; 6652- 6894; 6675 -7239; 6710-6983 6735-7258; 6771-7321; 6833 7394; 6834-7419; 6837-7170; 6837-6971; 6843 7114 ; 6894-7516; 6915- 396; 6916-7189; 6922- 7215; 6953 -7341: 6958-7160 6986-7392; 7201-7738; 7235-7570; 7243-7737; Table5
7284-7755; 7285-7755; 7351- 7662; 7366- -7753; 7439- -7753; 7439- -7687; 7472-
7768 7480-7659; 7499-7753; 7528- -7845, 7627- -8182, 7644 -7755 7649- -7945;
7686-7753; 7771-8047; 7772- 8045; 7801- -7886; 7892- -8162; 7892- -8158; 8062-
8410 8072-8332; 8075-8274; 8085- -8328, 8090- -8357, 8097 -8319 8100- -8539;
8101-8372; 8111-8340; 8114- 8395; 8119- -8438; 8119- -8201; 8119- -8484; 8119-
8320 8119-8309; 8119-8301; 8119- -8286, 8119- -8282, 8119 -8280 8119- -8265;
8119-8251; 8119-8223; 8119- 8224; 8119- -8220; 8119- -8194; 8119- -8182; 8141-
8417 8155-8459; 8159-8428; 8172- -8457, 8180- -8662, 8180 -8407 8182- -8407;
8182-8567; 8186-8417; 8186- 8272; 8202- -8665; 8199- -8713; 8202- -8359; 8209-
8729 8227-8577; 8230-8490; 8241- -8490; 8248- -8641, 8248 -8626 8263- -8467;
8274-8536; 8280-8840; 8283- 8574; 8333- -8581; 8355- -8850; 8372- -8621; 8384-
8793 8394-8616; 8403-8799; 8406- -9014; 8416- -8682, 8457 -8727 8470- -9137; 8472 8784; 8561-8871; 8566- 9106; 8607- -9178; 8645- -9132; 8660- -8908; 8662- 9138 8663-8940; 8673-9139; 8675- -9096; 8680- -9139, 8682 -9139 8688- -8929; 8691 9135; 8693-9144; 8701- 9101; 8699- -9136; 8707- -9158; 8715- -9100; 8722- 9136 8722-8950; 8725-8970; 8725- -8904, 8728- -9100, 8738 -9070 8739- -9002; 8742 8999; 8749-9140; 8754- 9139; 8759- -9139; 8761- -9139; 8761- -9135; 8761- 8821 8765-9139; 8768-9135; 8775- -9145, 8771- -9139, 8778 -9139 8785- -9135; 8786 9139; 8786-9088; 8789- 8963; 8799- -8994; 8799- -9142; 8801- -9076; 8803- 9139 8806-9100; 8815-9138; 8819- -9058; 8820- -9144, 8821 -9143 8820- -9032; 8822 9139; 8826-9135; 8832- 9117; 8832- -9066; 8841- -9139; 8847- -9134; 8847- 9119 8854-9139; 8865-9139; 8899- -9140, 8902- -9139, 8909 -9093 8912- -9151; 8918 9144; 8941-9143; 8943- 9134; 8950- -9088; 8962- -9140; 8971- -9139; 8974- 9129 8974-9084; 8980-9139; 9009- -9135, 9030- -9139, 9037 -9125 9078- -9135; 4- 596; 667-1054
70/LG:1100 823.1:2001MAR30 | | 1-565; 2C 1-459; 20-320; 20 -268; 332-667; 403- 839; 448-839; 526-840; 598- 839 71/LG:1166387.1:2001MAR30 | | 1-435; 2- '-497; 96-497; 131-341 137-387; 139- 373; 156-383; 163-435; 181- 410; : L94-412; 207-360, 232-' 770; 232-838; 283- 519; 295-496; 303-682; 309- 828; 309-557; 312-605, 329- 945; 332-398; 383- 1043; 403-503; 409-674; 413- -1055 418- -1050; 453-1047; < 152-711; 519-1044; 549-840; 587-1057; 600-1162; ; 653 -1089, 653-897; 693-1203; 693-1089; 693- 1184; 693-1234; 693-1108; 6? 93-1258; 693-1298; 69Z 1-1293 ; 693- -1287; 693-1278; 693-1149; 693-1251; 693-108* 6; 695-1295 >; 695- -1260, 695- 1237; 693-1046; 696- 1080; 721-814; 716-935; 748- -1294 748- -951; 772-1421; 772-1361; 778-1304; 791-1288; 798-1090; 814-108( 6; 827-1074; 830- -1455, 841- 1073; 844-1142; 848- 1237; 858-1387; 861-1397; 8( 67-1271; 867-1049; 90" '-1310 ; 907- -1494; 922-1345; 936-1141; 954-1144; 967-119 4; 983-153_ »; 999- -1277, 1000 -1277, 1001- -1274; 1001-1246; 1005-1238; 1020- 1316; 1021- -1264; 1033- -1109; 1043- -1645; 1043- 1250; 1043-1325; 1073-1310; 1146 -1385, 1148- -1400, 1150 -1367 1158- -1382; 1216-1462; 1227-1496; 1234- 1513; 1235- -1425; 1261- -1596; 1264- -1576; 1274- 1816; 1275-1823; 1275-1870; 1293 -1817, 1313- -1465, 1317 -1668, 1323- -1778; 1323-1543; 1346-1628; 1349- 1592; 1354- -1633; 1365- -1605; 1365- -1667; 1367- 1615; 1400-1683; 1403-1579; 1435- -1645, 1445- -1729, 1482 -1750, 1485- -1718; 1502-2034; 1501-1761; 1512- 1920; 1523- -1816; 1523- -1808; 1532- -1841; 1534- 2078; 1534-2050; 1536-1826; 1565 -2011, 1567- -1706, 1583 -2059, 1593- -2038; 1592-1894; 1592-1721; 1605- 2168; 1629- -1896; 1634- -1884; 1634- -1833; 1635- 1914; 1646 2169; 1652-1878; 1671 -1922, 1675- -2161, 1675 -1911, 1677- -1916; 1677-1893; 1677-1887; 1679- 1953; 1679- -1943; 1686- -1922; 1691- -2130; 1691- 1953; 1693 1928; 1693-1917; 1704 -2210, 1710- -2054, 1711 -2192, 1711- -1961; 1716-1870; 1718-2153; 1733- 2226; 1733- -1991; 1733- -1930; 1735- -2015; 1735- 1979; 1738 2212; 1746-2171; 1749 -2210, 1752- -2210, 1754 -2213, 1754- -2210; 1754-2212; 1760-2210; 1761- 2207; 1763- -2207; 1765- -2056; 1766- -2203; 1770- 2211; 1770 2213; 1770-2207; 1770- -2210, 1773- -2213, 1778 -2030, 1781- -2210; 1784-2210; 1784-2033; 1790- 2034; 1796- -2211; 1797- -2210; 1797- -2212; 1803- 2216; 1802 2210; 1804-2143; 1806- -2212; 1809- -2206, 1828 -2212, 1828- -2207; 1830-2210; 1831-2171; 1834- 2214; 1834- -2210; 1847- -2170; 1850- -2210; 1855- 2210; 1866 2103; 1874-2038; 1880- -2164; 1889- -2170; 1890 -2209, 1892- -2211; 1893-2211; 1893-2210; 1897- 2210; 1897- -2208; 1898- -2169; 1897- -2106; 1897- 2105; 1896-2210; 1913-2212; 1914- -2156; 1913- -2053, 1913 -1974, 1922- -2211; Table 5
1947-2213; 1948- 2211; 1949 -2210; 1968-2212; 1977 -2207; 1989-2210; 1989- 2200; 1989 2178; 1991-2169 ; 1998-2210; 2000-2210 ; 2004-2210; 2014-2210; 2014-2247; 2020-2210; 2020 -2196; 2021-2182; 2023-2210; 2024-2210; 2040- 2210; 2044 2210 2050-2210 ; 2061-2210; 2067-2205 ; 2083-2414; 2091-2210; 2102-2213; 2117-2211; 2147 -2202; 2206-2411 72/LG:1383036.49 :2001MAR30 I I 1-536; 326-578; 32 6-943; 347- 938; 4 01-823; 501-998; 553-815 ; 598-826; 731-1193; 735-967; 79 6-1050; 898 -1117; 898-1141; 986-1251; 1067-1637; 1077- 1208; 1119-1680; 1195- 1680; 1222- 1680; 1242-1856; 1251-1680; 1253 1745; 1255 1680; 1275-1689; 1280 -1540; 1295 -1588; 1299-
1624 1317-1680 1316-1587 1321-1503 1336-1679 1358-1615 1376-1647; 1415 1680; 1446 1855; 1471 -1680; 1474-1680; 1481 -1986; 1506 1680; 1506- 1681 1507-1680 1509-1680 1519-1764 1522-1674 1537-1600 1544-1823; 1552 1755; 1565-1748; 1563 -1680; 1564-2060; 1565 1690; 1566 2112; 1572- 2112 1577-1646 1587-1667 1603-2087 1608-1684 1610-2087 1618-1686;
1621-1689; 1631-1867; 1640 -1895; 1654-1895; 1656 -2142; 1658 1920; 1737-
1894 1756-2187 1766-2065 1800-2017 1904-2300 1947-2166 1996-2268; 2007 2535; 2009-2257; 2061 -2255; 2151-2274; 2185 -2806; 2261 2393; 2311- 2534 2333-2564 2335-2597 2335-2631 2335-2568 2335-2636 2335-2582; 2336 2603; 2336-2632; 2335-2579; 2337 2580; 2337 -2538; 2338 2623; 2339- 2596 2340-2615 2340-2555 2340-2926 2341-2632 2341-2564 2343-2566; 2343 2631; 2345-2505; 2345 2657; 2345 2540; 2349 -2574; 2348 2594; 2349- 2682 2349-2553 2350-2686 2350-2571 2351-2595 2350-2585 2350-2643; 2351 2532; 2352 2825; 2351 2617; 2351 2600; 2351 -2565; 2351 2579; 2352- 2611 2351-2614 2353-2610 2353-2633 2353-2594 2353-2543 2353-2613; 2353 2553; 2353 2634; 2353 2522; 2353 2574; 2355 2614; 2355 2612; 2357- 2889 2356-2655 2355-2626 2357-2829 2353-2839 2357-2586 2354-2830; 2357 2881; 2357-2594; 2357 2627; 2360-2663; 2357 -2632; 2357 -2600; 2357- 2617 2360-2623 2359-2616 2360-2626 2360-2605 2360-2609 2361-2926; 2362 2876; 2362 2600; 2361 2606; 2362 2616; 2363 -2613; 2364 -2634; 2364- 2614 2364-2653 2364-2609 2364-2625 2366-2913 2370-2704 2370-2847; 2371 2615; 2370 2580; 2370 2620; 2370 2609; 2370 2633; 2371 2658; 2372- 2748 2372-2635 2373-2633 2376-2614 2376-2591 2378-2646 2379-2647; 2380 2825; 2380 2838; 2382 2622; 2386-2489; 2388 2655; 2389 2631; 2392- 2681 2392-2880 2399-2664 2407-2621 2413-2658 2412-2673 2414-2649; 2413 2653; 2413-2669; 2415 -2673; 2420-2653; 2431 -2746; 2435 -2508; 2435- 2613 2436-2671 2441-2723 2447-2654 2449-2593 2462-2783 2462-2796;
2469-2749; 2470 2716; 2471 2752; 2477-2661; 2477 3045; 2485 -2730; 2509-
2754 2509-2996 2540-2962 2564- 2843 2576- 2836 2589-2761 2596-2877; 2603 2854; 2611-3060; 2611 2873; 2611 2815; 2611 -2691; 2616 -2816; 2630- 2842 2642-2919 2672-3143 2673- 2916 2685- 2917 2694-2933 2698-2994; 2710 3265; 2719-3302; 2726 -3263; 2753 2913; 2751 -3026; 2753 -3128; 2757- 3120 2758-2952 2759-2990 2768- 2917 2768- 2861 2781-2917 2791-3054;
2807-3204; 2808-3167; 2810 3076; 2809 2994; 2825 3302; 2831 -3055; 2831-
3085 2835-3272 2837-3113 2839- 3305 2842- 3068 2843-3261 2846-3272; 2848 3302; 2849 3302; 2852 3097; 2852 3120; 2855 3305; 2856 3303; 2867- 3303 2866-3309 2868-3087 2872- 3108 2873- 3272 2874-3101 2879-3302; 2880 3303; 2880 3302; 2882 -3302; 2885 3302; 2889 3302; 2895 -3272; 2895- 3161 2899-3303 2900-3300 2903- 3048 2903- 3304 2907-3272 2909-3302; 2910 3302; 2914 3307; 2919 3302; 2921 3309; 2924 3309; 2922 -3302; 2924- 3307 2924-3302 2926-3302 2927- 3304 2931- 3302 2934-3302 2936-3065; 2944 3302; 2947 3303; 2955 3272; 2962 3196; 2970 3272; 2975 -3207; 2977- 3272 2995-3221 2999-3300 3020- 3272 3030- 3307 3033-3281 3036-3304; 3053 3272; 3059-3272; 3067 3302; 3074 3272; 3079 3290; 3104 3274; 3106- 3272 3120-3390 3147-3272 3153- 3239 3158- 3263 3158-3244 3160-3271;
3165-3290; 3184 3272; 3203 3272; 3230 3302; 1413 1685; 1350 1682; 1316-
1682 1319-1686 1319-1680 1267- 1681 2351- 2963 1339-1680 1443 -1682;
786-1017; 1454-1680; 787-1 005; 401-607; 937-1143 853-1054; 1511-1680; 1242-1406; 912-1066 73/LG:1452353.14 2001MAR30 || 1-8958; 133-322; 838-909; 1214-8945; 1460- 2119; 1841-2020; 2361-2885 2344-2874; 2437-2492; 2570-2814; 2964-3586; Table 5
2996-3424; 3022-3322; 3037 -3236; 3070-3322; 3263 -3519; 3266- -3778; 3339- 3769; 3479-4961; 3482-3761 ; 3579-4109; 3600 4000 3679- -3984 3692-4022; 3912-4465; 4048-4312; 4375 -4691; 4377-4631; 4392 -4617; 4474- -5126; 4514- 4957; 4728-4947; 4844-5468 ; 5237-5519; 6149 6533 6165- -6412 6167-6456; 6202-6600; 6517-6994; 6835 -8846; 6882-7132; 7196 -7748; 7218- -7560; 7236- 7797; 7343-7872; 7905-8280 ; 7918-8284; 7966- 8328 8025- -8292 8029 8319; 8231-8696; 8242-8485; 8242 -8695; 8286-8887; 8346 -8823; 8440- -8739; 8450- 8683; 8458-8823; 8559-9069 ; 8568-9141; 8702- 9046 8874 -9139 8873 9350; 8875-8927; 9280-9533; 9284 -9534; 9286-9827; 9288 -9520; 9289- -9536; 9290- 9538; 9294-9764; 9295-9595 ; 9295 9527; 9295- 9481 9296 -9520 9300 9630; 9301-9520; 9331-9747; 9378 -9609; 9410-9655; 9468 -9609; 9546- -10152 9548- 9808; 9569-9797; 9591-9881 ; 9593 9876; 9598- 10099; 9603-10180; 9609-9834; 9613-10077; 9655-10294; 96 54-9898; 9675-1033 0; 9681-9951; 9685-9810; 9709- 9965; 9737-9831; 9745-9837 ; 9765 10031; 9785 -10230; 9803-10065; 9821-12139; 9868-10340; 9876-10338; 98 76-10106; 9878-103 24; < 3878-10135; 9890-10108; 9898-10170; 9905-10344; 99 08-10192; 9910-103 34; 9912-10348; 9911-10292 9929-10344; 9929-10340; 99 31-10340; 9936-103 38; ! .936-10405; 9938-10337 9939-10190; 9953-10349; 99 49-10340; 9974-101 96; ! .982-10249; 9987-10340 10021-10188; 10042-10341; 10047 10341; 10052 -10340; 10080-10562; 10100
10703; 10133- 10703 10174- 10348 10186-10549 10206- 10340 10223-10454 10259-10725; 10304 10563; 10338 10605; 10347 -12139; 10373 10477; 10373 10547; 10373- 10616 10384- 10653 10417-10736 10431- 10842 10504-10829 10513-10953; 10529 10944; 10600 11101; 10605 -10863; 10642 10957; 10642 10952; 10654- 11164 10654- 10981 10655-10813 10702- 11240 10709-11230 10727-10978; 10729 10973; 10760 10998; 10769 -11022; 10810 11088; 10820 11070; 10822- 11047 10887- 11092 10901-11106 10904- 11177 10911-11127 10911-11176; 10935 11249; 10939-11128; 10971 -11222; 10991 11358; 10991 11407; 10991- 11290 10991- 11224 10997-11304 11001- 11154 11022-11340
11022-11343; 11022-11180; 11022 11169; 11022 -11230; 11053-11601; 11090
11394; 11103-11274 11110- 11372 11114-11625 11114-11393 11141- 11390 11141-11383; 11154 11557; 11154 11725; 11167 -11628; 11169 11450; 11174 11438; 11191-11697 11191- 11270 11196-11675 11200-11294 11205- 11690 11213-11658; 11219 11366; 11221 11483; 11237 -11625; 11257 11507; 11264 11487; 11284-11489 11310- 11864 11319-11662 11325-11586 11336- 11575
11339-11628; 11390-11856; 11397-11660; 11400 -11855; 11409-11853; 11411
11858; 11431-11671 11445- 11649 11479-11689 11480-11770 11484- 11716
11500-11757; 11541-11788; 11550-11985; 11588 -12130; 11592-12038; 11597-
11831; 11608-11837 11646- 11829 11666-11949 11666-11832 11669-11969
11717-12151; 11721-12139; 11724-11956; 11725 -11859; 11729-12139; 11733-
12139; 11737-12139 11738- 12139 11743-12138 11743-12151 11745- 12139
11754-12139; 11775-12139; 11778-12049; 11778 -12139; 11781-12139; 11785-
12139; 11786-12139 11788- 12019 11798-12139 ; 11808-12139 11810-12141 11810-12139; 11810 12189; 11812 12055; 11812-12139; 11842 12139; 11846 12139; 11849-12145 11856- 12148 11856-12139 ; 11858-12182 11859-12185
11860-12188; 11864-12111; 11866 12127; 11868-12184; 11869 12139; 11873
12192; 11875-12189 11875- 12181 11889-12139 ; 11893-12187 11899-12174
11899-12139; 11904-12184; 11903 12124; 11906-12161; 11906 12139; 11918
12139; 11920-12182; 11923- 12144 11924-12139 ; 11928-12068 11930-12139 11932-12188; 11931-12139; 11937 12139; 11946-12183; 11947 12139; 11960 12180; 11962-12139; 11987- 12139 11997-12185 ; 12000-12179 12006-12139 12008-12139; 12031-12185; 12041 12169; 12057 -12139; 12070-12185; 12071 12434; 12080-12139 74/LG: 1452435.15 :2001MAR30 || 1-6193; 826-1462; 1735-2257; 4834-5302; 4834- 5062; 4834-5060; 4854-5122 ; 4953-5258; 4977-5198; 5009-5253; 5057-5327; 5060-5283; 5059-5344; 5485-5937; 5701-6107; 5711-6198; 5741-6200; 5862- 6354; 5857-6188; 5857-6229 ; 5865-6196; 5864-6194; 5871-6194; 5872-6194; 5886-6198; 5897-6207; 5905-6165; 5955-6234; 6005-6185; 6087-6198; 6123- 6535; 6124-6593; 6124-6458 ; 6124-6365; 6133-6601; 6136-6507; 6212-6266; 6218-6367; 6219-6365; 6248-6738; 6397-6807; 6406-6807; 6436-6700; 6438- 6703; 6438-6691; 6438-6683 ; 6438-6678; 6439-6697; 6439-6704; 6439-6689; Table 5
6439-6673; 6446-6807; 6454- 6741 ; 6455-6802 ; 6462 - 6807; 6475-6807; 6475- 6819; 6533-6802; 6538-6806; 6543 -6802 ; 6544-6802 ; 6607-6812; 6609-6843 75/LG:1498774.1:2001 AR30 | I 1-602 ; 1-296 ; 7-460 ; 8-663; 11-382; 51-694; 91-695; 200-638; 648-756 76/LG:197180.1:200lMAR30 || 1-286; 22 0-425; 223-4 26; 257- 521; 258- 427; 300- 923; 313-467; 315-577; 331-604; 331-503; 336-511 336-514 361-453 ; 360- 460; 381-515; 387-450; 412 496; 413-556; 423-484 430-570 433-583 ; 524- 625; 524-691; 543-672; 547-688; 553-695; 574-701 578-667 632-849 ; 628- 805; 654-1104; 667-1076; 733-1042; 750-892; 742-1 031; 766-1029; 772-1013; 778-1025; 783-948; 794-1066 ; 799-934; 809-1039; 8 00-985; 800-999; 806-1151; 808-1139; 807-910; 814-1021 ; 814-1038 ; 815-1081; 822-902; 819-959; 823- 1091; 821-904; 824-1073; 825-914; 825-1021; 825-9 16; 830-1015; 828-1127; 837-1035; 842-1051; 842-957 ; 846-1080 ; 848-1108; 849-1109 ; 861-1081; 875- 1335; 861-1079; 862-1059; 861-1014; 862-1061; 867 -1064; 867-1077; 869-1042; 855-1107; 882-970; 903-1261 ; 897-1006 ; 904-1005; 906-1067 ; 907-1091; 907- 1089; 907-1216; 907-1083; 910-1014; 915-995; 927- 1063; 922-995; 923-1130; 922-1084; 943-1338; 945-1025; 961-1496; 951-1030; 944-1407; 952-1084; 963- 1508; 946-1049; 967-1203; 977-1536; 985-1175; 991 -1311; 991-1207; 989-1099; 986-1538; 993-1536; 1058-1191; 1056-1143; 1080-15 08; 1076-1534; 1086-1529; 1104-1509; 1095-1536; 1102-1520; 1093-1483; 1097- 1351; 1108-1536; 1111-
1508; 1121-1542 1126-1537 1129-1536 ,- 1130-1536; 1131-1536 1132- 1536; 1134-1536; 1142 1450; 1141 1443; 1141-1506; 1133- 1529; 1135-1536; 1152- 1508; 1141-1536 1140-1536 1154-1537 ; 1142-1377; 1153-1388 1159- 1536; 1170-1540; 1155 1391; 1157 1536; 1156-1529; 1177- 1508; 1178-1519; 1166- 1420; 1166-1447 1176-1513 1166-1440 ; 1176-1529; 1191-1536 1177- 1509; 1168-1344; 1178 1508; 1169-1427; 1170-1536; 1184-1536; 1173 1508; 1184- 1542; 1187-1537 1182-1536 1188-1554 ; 1187-1536; 1181-1445 1195- 1536;
1195-1541; 1196-1557; 118 1539; 1195-1452; 1197-1529; 1198 1464; 1200-
1500; 1206-1536 1198-1510 1190r1483 ; 1194-1518; 1203-1510 1196- 1450; 1197-1538; 1169 1424; 1196 1465; 1207-1536; 1208-1490; 1209 1472; 1209- 1529; 1199-1492 1209-1542 1210-1504 ; 1210-1465; 1211-1493 1203- 1490;
1211-1465; 1212-1477; 1213 1489; 1213-1510; 1215- 1540; 1215-1539; 1214-
1538; 1215- 1541 1214 -1446 1216-1527 ,- 1217-1539; 1217-1537 1209-1536; 1217- 1509; 1218 1538; 1218 1536; 1219-1538; 1219-1540; 1218 1465; 1219- 1537; 1220- 1529 1221 -1453 1221-1536 ; 1221-1529; 1221-1477 1222-1539; 1222- 1542; 1222 1484; 1223 1477; 1216-1539; 1223-1475; 1223 1480; 1224- 1471; 1225- 1488 1225 -1537 1224-1480 ; 1226-1537; 1224-1536 1226-1487; 1227-1517; 1228 1513; 1228 1539; 1227-1469; 1220-1536; 1227 1468; 1228- 1536; 1230- 1509 1230 -1536 1230-1538 ; 1222-1537; 1232-1464 1231-1499; 1230-1530; 1232 1544; 1233 1511; 1232-1511; 1234-1487; 1234 1534; 1235- 1456; 1235- 1473 1235 -1537 1234-1452 ; 1236-1497; 1236-1481 1236-1508; 1237-1497; 1237 1538; 1230 1442; 1240-1481; 1242- 1394; 1242-1503; 1243- 1486; 1243- 1539 1243 -1509 1243-1511 ; 1235-1459; 1245-1542 1245- 1535; 1245-1504; 1246 1529; 1247- 1540; 1247-1509; 1246- 1442; 1247-1503; 1246- 1466; 1247- 1507 1247 -1487 1247-1513 ; 1248-1538; 1248-1508 1250- 1537;
1250-1520; 1250-1541; 1250 1498; 1253-1530; 1254- 1478; 1252-1502; 1244-
1540; 1254-1465 1253-1536 1254-1471 ; 1254-1489; 1254- -1513 1254-1484;
1255-1526; 1258-1548; 1257 1542; 1260-1538; 1261- 1517; 1262 1495; 1263-
1452, 1262- -1510 1263 -1539 1263-1529 ,- 1264-1507; 1263 -1431 1265-1515;
1265- -1540; 1267 1536; 1267 1533; 1266-1506; 1268- 1499; 1268 1541; 1269-
1500, 1269- -1529 1268 -1507 1269-1537 ; 1270-1458; 1272 -1540 1273-1512;
1273- -1537; 1272 1498; 1273 1513; 1273-1435; 1273- 1458; 1274 1519; 1274-
1499, 1274- -1525 1275 -1433 1273-1491 ; 1276-1492; 1275 -1537 1277-1539;
1277- -1490; 1278 1533; 1280 1521; 1280-1522; 1279- 1529; 1281 1473; 1282-
1487, 1274- -1488 1283 -1516 1285-1520 ,- 1286-1460; 1277 -1513 1286-1433;
1285- -1461; 1288 1531; 1288 1529; 1289-1536; 1287- 1469; 1289 1543; 1290-
1529, 1289- -1531 1281 -1536 1291-1529 ; 1290-1521; 1291 -1423 1291-1538;
1292- -1529; 1282 1529; 1293 1498; 1293-1521; 1293- 1536; 1294 1536; 1293-
1529, 1294- -1529 1294 -1487 1294-1522 ; 1294-1537; 1294- -1563 1294-1508;
1295-1536; 1295-1527; 1287-1508; 1294-1429; 1296- 1520; 1296-1529; 1295- Table 5
1464 1288 -1516 1297 -1529 1296 -1531 1296 -1492 ^.298 -1509 1298 -1529;
1298- -1534; 1290- -1536; 1298- -1533; 1299- -1480; 1298- -1520; 1300- -1522; 1300-
1536 1301 -1541 1294 -1503 1294 -1534 1304 -1539 1301 -1554 1294 -1439;
1306- -1543; 1306- -1560; 1305- -1518; 1298- -1538; 1307- -1532; 1309- -1538; 1300-
1529 1310 -1542 1309 -1529 1300 -1503 1309 -1530 1309 -1520 1310 -1540;
1311- -1437; 1303- -1529; 1312- -1536; 1312- -1474; 1313- -1537; 1313- -1501; 1314-
1529 1314 -1513 1315 -1529 1307 -1529 1316 -1517 1315 -1503 1315 -1575;
1317- -1524; 1318- -1529; 1319- -1510; 1319- -1529; 1319- -1536; 1320- -1475; 1317-
1498 1320 -1502 1321 -1539 1321 -1479 1321 -1541 1313 -1529 1323 -1542;
1322- -1453; 1324- -1504; 1314- -1538; 1325- -1537; 1326- -1529; 1317- -1517; 1327-
1540 1319 -1454 1320 -1536 1330 -1488 1330 -1536 1330 -1490 1331 -1536;
1331- -1479; 1324- -1536; 1324- -1533; 1336- -1541; 1328- -1434; 1338- -1522; 1339-
1539 1340 -1539 1341 -1538 1342 -1534 1341 -1502 1344 -1589 1345 -1535;
1321- -1536; 1344- -1528; 1348- -1538; 1347- -1529; 1348- -1536; 1340- -1529; 1349-
1529 1349 -1503, 1351 -1538 1349 -1533 1349 -1511 1350 -1525, 1351 -1523;
1352- -1513; 1342- -1539; 1354- -1536; 1354- -1508; 1354- -1507; 1355- -1536; 1357-
1529 1348 -1535 1357 -1519 1358 -1521 1357 -1536 1358 -1538, 1359 -1536;
1360- -1464; 1355- -1529; 1363- -1535; 1358- -1536; 1357- -1439; 1367- -1533; 1369-
1473 1360 -1491 1370 -1529 1370 -1522 1361 -1532 1370 -1539, 1371 -1529;
1372- -1528; 1366- -1529; 1376- -1488; 1377- -1529; 1376- -1522; 1375- -1503; 1379-
1537 1373 -1536 1383 -1538 1384 -1489 1386 -1538 1386 -1536, 1388 -1529;
1388- -1541; 1391- -1536; 1390- -1537; 1392- -1532; 1395- -1529; 1396- -1538; 1396-
1681 1396 -1494 1396 -1521 1397 -1486 1397 -1539 1402 -1529, 1399 -1517;
1405- -1487; 1406- -1485; 1406- -1510; 1422- -1537; 1413- -1538; 1426- -1585; 1426-
1503 1418 -1536 1426 -1529 1433 -1536 1432 -1529 1434 -1520, 1433 -1529;
1426- -1536; 1436- -1539; 1436- -1536; 1428- -1536; 1437- -1536; 1434- -1536; 1435-
1534 1445 -1542 1446 -1540 1460 -1536 1461 -1536 1473 -1536, 1541 -1800;
1587- -2070; 1670- -1914; 1686- -1927; 1725- -1871; 1744- -1969; 1762- -2039; 1763-
2030 1765 -1974 1784 -2113 1823 -2445 1824 -2299 1834 -2126, 1846 -2247;
1852- -2135; 1888- -2023; 1954- -2224; 1963- -2242; 1993- -2437; 1995- -2446; 2004-
2217 2013 -2475 2017 -2439 2033 -2436 2033 -2277 2057 -2465 2084 -2299;
2093- -2330; 2132- -2475; 2132- -2393; 2147- -2299; 2150- -2416; 2171- -2431; 2214-
2475 2225 -2459 2338 -2449 2338 -2458 2339 -2518 2387 -2449 2388 -2947;
2577- -3045; 2672- -2876; 2686- -2972; 2707- -3167; 2707- -3173; 2709- -2934; 2715-
2996 2716 -3163 2721 -3033 2722 -3169 2722 -2806 2722 -2960 2723 -2806;
2722- -3024; 2723- -2866; 2738- -2886; 2738- -3002; 2738- -2794; 2738- -3074; 2783-
3300 2786 -3262 2789 -3255 2808 -3071 2812 -3151 2813 -3102 2829 -3035;
2839- -3262; 2846- -3071; 2846- -3302; 2863- -3309; 2868- -3136; 2879- -3300; 2884-
3302 2887 -3306 2889 -3304 2890 -3308 2894 -3302 2902 -3302 2909 -3316;
2912- -3302; 2932- -3305; 2933- -3308; 2943- -3291; 2944- -3302; 2947- -3176; 2953-
3310 2957 -3305 2957 -3095 2960 -3214 2962 -3302 2968 -3305 2971 -3258;
2982- -3224; 2995- -3198; 2995- -3173; 3001- -3302; 3005- -3300; 3006- -3302; 3013-
3279 3016 -3307 3017 -3302 3026 -3316 3039 -3305 3045 -3303 3054 -3302;
3054- -3307; 3055- -3302; 3064- -3153; 3128- -3304; 3196- -3291; 3244- -3487; 3351-
3935 3719 -4108 3719 -4113 3719 -4031 3720 -4034 3721 -3997 3722 -3999;
3730- -3879; 3890- -4108; 3890- -4117; 4012- -4114; 780-1059; 1183-1534; 1229-1409
1235- -1536; 1136- -1403; 1266- -1534; 943-1211; 726-987; 917-1185; 983 -1252;
1260- -1529; 1165- -1434; 1006- -1275; 1317- -1529; 1267- -1409; 1015- -1286; 1037-
1308 943- 1214; 1068- 1339; 1263- 1409; 1269- L409; 230-504; 1240-1516; 1242-
1518 1146 -1422 1097 -1374 1009 -1284 1032 -1311 1205 -1484 1148 -1427;
1249- -1528; 924-1203; 1057-1337; 1162-1443; L021-1302; 1070-1352; 920-1202;
805-1087; 920-1203; 1151-1435; 807-1094; 1157-1445; 1078-1367; 1242-1533;
942-1234; 1248-1413; 1103-1397; 977-1270; 757-1053; 1245-1413; 1238-1533;
925-1224; 1231-1533; 1234-1409; 748-1053; 1227-1534; 1224-1534; 1200-1508;
1225- -1534; 1157- -1447; 1225- -1407; 1068- -1380; 1222- -1536; 1236- -1533; 1218-
1534 1221 -1413 1222 -1413 1216 -1533 1049 -1367 1220 -1413, 922- 1240;
1032- -1357; 1140- -1464; 1207- -1533; 906-1233; L177-1413; 1195-1529; 1189-1529
1186- -1529; 854-1193; L184-1529; L161-1413; . L187-1529; L190-1413; L189-1409
1159- -1413; 791-1127; L185-1533; L184-1534; . L174-1413; L168-1519; L186-1409
1192- -1534; 1180- -1533; 815-1170; L183-1413; . L185-1409; L178-1529; L171-1529 Table 5 1182-1413; 1177-1534; 1176-1409; 815-1173; 1147-1413; 1172-1407; 1165-1529; 825-1190; 728-1085; 1160-1534; 1161-1409; 1159-1409; 1151-1529; 1160-1413; 1163-1413; 1156-1409; 1153-1413; 1142-1526; 1134-1516; 1146-1533; 1156- 1413; 1140-1529; 953-1343; 1139-1533; 1140-1534; 1140-1409; 1145-1413; 1137-1533; 1140-1413; 1136-1409; 1129-1529; 1137-1409; 1133-1534; 1129- 1526; 1132-1533; 1134-1409; 1129-1533; 1129-1534; 1133-1409; 1131-1409; 1130-1409; 1128-1409; 1127-1409; 1126-1409; 1128-1413; 1125-1537; 1126- 1413; 1122-1409; 1123-1409; 1123-1413; 1125-1413; 1118-1534; 1121-1409; 1124-1413; 1125-1409; 1119-1409; 1122-1413; 1121-1413; 1118-1409; 1110- 1530; 1110-1409; 1112-1533; 1112-1409; 1108-1409; 1118-1413; 1102-1409; 1097-1533; 1093-1533; 1069-1413; 1113-1413; 1225-1413; 2856-3302; 1089- 1534; 983-1409; 1086-1409; 1082-1533; 1075-1522; 1075-1534; 1079-1413; 1009-1471; 1075-1409; 216-680; 1052-1528; 989-1470; 993-1310; 957-1475; 1005-1520; 989-1527; 983-1516; 993-1454; 968-1531; 968-1536; 267-506; 1212- 1533; 1218-1413; 1193-1529; 1143-1488; 1162-1409; 1151-1409; 1149-1409; 832-1225; 1141-1409; 1133-1533; 2900-3302; 1115-1536; 1092-1409; 1109-1409; 1085-1533; 1068-1529; 955-1510; 926-1533; 1096-1387; 1238-1409; 351-622; 1222-1409; 1184-1413; 1189-1413; 793-1156; 805-1134; 1116-1409; 771-1206; 754-1247; 1046-1313; 1245-1511; 948-1213; 990-1255; 953-1218; 226-491; 1271-1532; 1074-1338; 1273-1409; 731-993; 242-505; 988-1251; 902-1165; 1274-1536; 1274-1409; 1014-1276; 1276-1536; 1243-1503; 949-1209; 957-1216; 1269-1528; 1055-1314; 1277-1409; 1145-1403; 947-1205; 740-997; 1089-1347; 1321-1514; 989-1245; 675-912; 1282-1413; 1504-1759; 222-477; 1032-1285; 727-980; 723-974; 1144-1396; 897-1149; 1282-1526; 263-514; 1146-1397; 1098- 1350; 293-543; 978-1227; 1091-1340; 1280-1529; 915-1164; 1022-1270; 1227- 1474; 965-1212; 1291-1537; 1246-1493; 871-1118; 1148-1393; 1147-1393; 1138- 1384; 1143-1389; 988-1234; 1288-1533; 1089-1334; 1292-1536; 1075-1319; 239- 482; 999-1241; 987-1230; 1187-1429; 761-1002; 1164-1405; 1239-1479; 1096- 1336; 1000-1240; 1041-1281; 1164-1404; 1044-1283; 1006-1244; 1164-1402; 1298-1409; 1148-1386; 1299-1536; 1149-1385; 1295-1531; 1006-1242; 957-1193; 271-507; 1044-1280; 263-500; 1274-1509; 1307-1537; 1178-1410; 1001-1233; 1254-1413; 1305-1409; 1302-1533; 1006-1236; 253-481; 1309-1407; 1008-1236; 1311-1409; 1285-1413; 1294-1520; 1114-1339; 776-1000; 1298-1524; 1009-1233: 257-481; 1291-1514; 1277-1500; 1310-1533; 1236-1459; 1314-1409; 1314-1536; 926-1147; 873-1094; 874-992; 1302-1521; 1311-1529; 805-1023; 1046-1263; 1068-1283; 1276-1491; 1320-1534; 1319-1533; 807-1018; 1152-1364; 1006-1218; 984-1195; 1323-1533; 985-1195; 1312-1521; 1018-1227; 1181-1389; 1328-1409 821-1027; 1320-1526; 985-1191; 1330-1409; 1024-1229 1050-1255; 846-1050; 1307-1510; 1331-1533; 725-927; 13.38-1409; 1194-1396 1335-1409; 1146-1347 842-1042; 1321-1521; 1337-1409; 1325-1396; 931-1130 1336-1409; 972-1100; 959-1156; 1001-1196; 1104-1300; 1291-1487; 895-1090 1343-1409; 1343-1536 1147-1338; 1338-1529; 1185-1374 854-1044; 1347-1536; 1037-1228; 1473-1537 1000-1189; 1157-1343; 1074-1255 1029-1214; 725-908; 1333-1517; 987-1170; 1002-1184; 1357-1520; 1281-1461 1051-1226 745-913; 1356-1529; 1093-1263; 1364-1529; 1369-1534; 1369-1533 1207-1372 1016-1179; 757-920; 807-965;
849-1005; 318-470; 1379-1529; 1307-1455; 903-1051; 953-1089 : 720-863; 1263 1404; 1474-1536; 273-412; 1369-1508; 976-1104; 1379-1508; 35-7-513; 41-111; 1420-1537; 1420-1536; 367-481; 388-501; 984-1096; 1439-1536 : 1193-1289; 1442-1537; 1433-1523; 1452-1537; 1442-1529; 938-1020; 7-85; 1217-1296; 1338-1414; 1463-1536; 650-709
77/LG:199489.1:200lMAR30 || 1-496; 1-493; 1-477; 15-468; 19-264; 32-316 79-500; 79-521; 79-477; 79-466; 79-453; 79-436; 79-366; 80-422; 79-149; 80- 465; 80-441; 81-441; 80-494; 99-389; 126-531; 127-428; 167-602; 170-2146; 199-614; 206-597; 245-768; 534-1175; 541-758; 612-1172; 666-1124; 860-1477 928-1429; 1117-1720; 1176-1575; 1222-1754; 1265-1731; 1535-2097; 1636-2216 1692-2010; 1692-1937; 1692-2169; 1692-2178; 1692-2219; 1692-2148; 1692- 2070; 1692-2069; 1692-1832; 1723-2178; 1986-2388; 1986-2271; 1986-2259; 2001-2561; 2006-2151; 2097-2386; 2126-2239; 2146-2377; 2304-2757; 2420- 2819; 2436-2949; 2578-2699; 2685-3183; 2774-3214; 2790-3214; 2799-3329; 2804-3351; 2869-3454; 3013-3116; 3102-3313; 3171-3326; 3244-3524; 3246- Table 5
3688; 3246 -3524 3246- 3518; 3355 -3608; 3523- 3805; 3568- 3961; 3568- -3993; 3708-3939; 3797 4366; 4032-4153; 4047-4361; 4051-4271; 4108-4504; 4120- 4723; 4247 -4499 4290- 4447; 4359 -4596; 4359- 4579; 4359- 4504; 4510- -4743; 4526-4742; 4583 4815; 4619-5038; 4651-5058; 4652-4922; 4661-4936; 4659- 4950; 4732 -4994 4779- 5027; 4820 -5080; 4855- 5162; 4867- 5405; 4869- -5113; 4872-5130; 4883-5232; 4891-5371; 4891-5339; 4891-5174; 4891-5134; 4906- 5291; 4907 -5362 5017- 5234; 5060 -5234; 5077- 5344; 5098- 5356; 5150- -5263; 5151-5247; 5185 5443; 5217-5427; 5229-5662; 5230- 5662; 5244-5606; 5259- 5503; 5259 -5463 5286- 5539; 5288 -5511; 5308- 5666; 5306- 5508; 5324- -5508; 5331-5593; 5335 5666; 5394-5666; 5391-5692; 5411- 5521; 5438-5665; 5446- 5642; 5453 -5716 5462- 5692; 5466 -5694; 5495- 5694; 5498- 6088; 5500- -5662; 5502-5666; 5504-5666; 5550-5666; 5558-5666; 5567-5662; 5573-5662; 5573- 5663; 5589 -5666 78/LG:2019 08.3: 001MAR30 I I 1-5 45; 25 -4594 ; 31-545; 1 05-247 ; 105- 195; 130 433; 190-7 00; 2 1-562; 295-747; 362-587; 367-672; 432-661; 679-13 37; 896- 1527; 896- 1439; 927-1513; 937-1158; 937-1396; 1056-1609; 11 59-161 0; 1242- 1581; 1250 -1837 1252-1536 1385-1612 ; 1390-2094; 1421-1812 1421 -1607; 1421-1636; 1876 2557; 1907 2539 ; 1907-2149 ; 1945-2421 ; 1945 2520; 2050- 2599; 2102 -2288 2105-2218 2105-2557 ; 2123-2793; 2123-2665 2168 -2427; 2266-2486; 2284 2675; 2359 2668 ; 2347-2581 ,- 2365-2557 ; 2396 -2952; 2440- 2939; 2441 -2915 2453-2843 2481-2949 ; 2497-2824; 2500-2902 2528 -2993; 2537-2799; 2538 2985; 2549 2752 ; 2552-3001 ; 2553-2985 ; 2573 2926; 2578- 2985; 2584 -2985 2596-2995 2622-2971 ; 2628-2984; 2632-2993 2634 -2995; 2641-2993; 2655 2939; 2655 2916 ; 2690-2988 ; 2690-2985 ; 2805 2982; 2812- 3267; 2812 -3431 2812-3056 2812-3093 ; 2875-3336; 2935-2995 3143 -3794; 3242-3791; 3379 3850; 3452 3708 ; 3456-3969 ; 3456-3681 ; 3494 -3936; 3521- 4054; 3536 -4015 3536-4245 3543-3673 ; 3690-4177; 3690-3920 3694 -4305; 3716-4127; 3724 3943; 3727 4492 ; 3735-4064 ; 3736-4168 ; 3736 3954; 3896- 4521; 3919 -4351 3956-4522 3969-4229 ; 3969-4342; 4021-4592 4049 -4560; 4082-4549; 4124 4594; 4124-4597 ; 4127-4594 ; 4133-4597 ; 4142 4594; 4143- 4594; 4145 -4594 4150-4595 4151-4594 ; 4163-4594; 4172-4597 4171 -4369; 4211-4387; 4220 4594; 4225 4597 ; 4231-4594 ; 4231-4598 ; 4261 4594; 4299- 4553; 4376 -4594 4391-4594 4465-4594 ; 4479-4594 79/LG-.2472 45.26 2001MAR30 I i-425; 280-606; 426-1151 ; 426-848; 459-798; 459-774; 5 82-12 3; 611-871 646-1235; 669-1258; 670-1295; 669-1233; 794- 1235; 835- 1292; 866-1429; 1187-1563; 1190-1467; 1200-1396; 1205-1459; 1238- 1321; 1244 -1812 1398-1942 1459-1693 ; 1494-1942; 1625-1883; 1629-1942; 1645-2045; 1656 1942; 1683 1852 ; 1692-1942 ; 1739-1962 ; 1746-2349; 1749- 1901; 1806 -1942 1847-2290 1884-2144 ; 2066-2321; 2124-2316; 2127-2272; 2128-2519; 2128 2321; 2128 2457 ,- 2128-2190 ; 2128-2318 ; 2129-2311; 2150- 2439; 2193 -2293 2194-2281 2205-2321 ; 2205-2254; 2223-2318; 2234-2478; 2240-2318 80/LG:2563 65.2: 2001MAR3 0 I I 1- 470; 48-563; 255-821; 255-753; 328-682; 564- 820; 728-1 010; 765-1362 ; 848-1399; 905-1162; 977-1248; 1011-1465; 1116- 1344; 1272 -1865 ; 1280-1 532; 1429-1654; 1433-1653; 1464-1722; 1716-2029; 1719-2156; 1721 -1923; 2 053-2186; 2063-2331; 2063-2325; 2089-2358; 2212- 2358; 2212 -2387 ; 2213-2 358 81/LG:3329 23.4: 2001 AR3 0 II 1- 3812; 11 6-719 ; 117 -643; 117-7 1; 13 1-793; 291-689; 5 83-89 6; 615-1 167 629-850; 629-1135; 6 80-1167; 688-1201 ; 688- 1323; 805- 1518; 858-112 3; 915-1173; 947-1346; 94 7-1213 ; 1302-1919 ; 1416- 1902; 1416 -1644 1442-1 684 1450-1868 1522-1813 1523-1712 1523-1865; 1523-1863; 1543 1904; 1 673 2140; 1673 2013; 1673 2132; 1812 2172; 1814- 2107; 1815 -2076 1932-2 182 1976-2135 2000-2613 2045-2178 2075-2613; 2174-2330; 2181 2669; 2 226 2726; 2239 2632; 2241 2512; 2242 2668; 2270- 2720; 2297 -2720 2304-2 705 2327-2705 2359-2712 2367-2708 2375-2708; 2381-2708; 2441 -2712; 2 444 3010; 2446 2708; 2454 2720; 2454 2847; 2577- 3103; 2623 -2683 2675-2 885 2687-3007 2687-2932 2687-2933 2740-3018; 2781-3002; 2795 3516; 2 925 3117; 3120 3404; 3210 3465; 3217 3470; 3217- 3712; 3245 -3690 3247-3 490 3315-3774 3328-3776 3353-3751 3379-3634; 3408-3813; 3419 3812; 3 443-3812; 3477 3892; 3478 4030; 3484 3791; 3529- Table 5 4017; 3553-3806; 3606-4055; 3632-4015; 3648-3812; 3649-3812; 3700-3791; 3848-4314
82/LG:335276.1:200lMAR30 || 1-523; 214-692; 217-434; 219-434; 222-784; 223- 787; 652-911; 735-1330; 1004-1642; 1110-1231; 1178-1331; 1230-1778; 1232- 1471; 1286-1505; 1442-1700; 1444-1863; 1447-1729; 1608-1866; 1708-1941; 1724-2235; 1735-2233; 1811-2004; 1882-2439; 1880-2009; 1947-2436; 1963- 2232; 1967-2222; 1975-2539; 2046-2500; 2060-2492; 2105-2532; 2291-2504; 2296-2528; 2296-2497; 2296-2535; 2390-2457
83/LG:350272.2:2001MAR30 || 1-395; 164-734; 280-938; 294-647; 347-620; 356- 619; 356-705; 395-1012; 421-679; 479-928; 480-689; 480-728; 483-777; 498- 927; 570-975; 575-890; 576-976; 596-1056; 612-1039; 623-726; 624-1059; 627- 909; 633-975; 663-941; 707-1041; 714-1085; 714-1005; 714-988; 718-1000; 722-992; 739-1012; 749-974; 756-997; 769-1306; 771-1017; 771-1022; 780- 1090; 788-952; 816-1043; 817-1328; 843-1039; 910-1426; 910-1369; 934-1039; 952-1039; 958-1039; 982-1535; 982-1043; 1169-1478; 1182-1638; 1186-1397; 1186-1402; 1186-1635; 1186-1281; 1186-1269; 1186-1673; 1186-1508; 1195- 1276; 1195-1284; 1196-1246; 1195-1286; 1197-1635; 1198-1676; 1206-1673; 1206-1638; 1221-1508; 1222-1667; 1224-1662; 1239-1671; 1255-1673; 1258- 1679; 1271-1679; 1288-1679; 1298-1675; 1299-1673; 1320-1676; 1327-1673; 1337-1670; 1341-1679; 1340-1673; 1347-1667; 1349-1543; 1340-1571; 1368- 1674; 1393-1639; 1406-1679; 1406-1508; 1420-1639; 1421-1573; 1429-1508; 1431-1673; 1432-1673; 1463-1659; 1471-1673; 1475-1544; 1490-1673; 1492- 1680; 1492-1673; 1506-1674; 1509-1631; 1587-1673; 1589-1667; 1611-1673 84/LG:350921.2:2001MAR30 || 1-592; 165-433; 344-536; 344-516; 475-1077; 617-883; 617-1169; 691-1300; 691-1156; 949-1555; 1006-1251; 1206-1719; 1484-2130; 1518-1868; 1823-2179; 1823-2146; 1823-2080; 1857-2192; 1860- 2133; 1893-2180; 1943-2493; 2026-2186; 2029-2175; 2052-2186
85/LG:406568.1:2001MAR30 || 1-602; 19-607; 16-623; 36-359; 35-327; 35-301; 36-474; 36-301; 41-295; 46-323; 47-317; 53-690; 72-588; 210-321; 210-414; 281-474; 304-840; 381-646; 399-856; 536-872; 536-827; 564-1112; 580-984; 601-1243; 630-906; 671-1297; 715-1207; 758-1150; 832-1378; 836-1091; 943- 1155; 981-1385; 1095-1346; 1095-1297; 1141-1323; 1154-1378; 1157-1379; 1160-1385; 1208-1370; 1315-1853; 1345-1571; 1384-1686; 1407-1968; 1404- 1776; 1404-1491; 1403-1616; 1403-1614; 1404-1644; 1404-1595; 1406-1631; 1407-1504; 1406-1547; 1406-1565; 1410-1617; 1413-1679; 1413-1700; 1420- 1538; 1417-1665; 1420-1912; 1420-1914; 1430-1725; 1432-1672; 1437-1525; 1471-1744; 1506-1727; 1508-1640; 1518-2013; 1518-1814; 1526-1654; 1544- 1885; 1546-1748; 1552-1822; 1579-1811; 1581-1881; 1620-1864; 1624-1923, 1622-1954; 1628-1830; 1642-1954; 1706-2104; 1709-1980; 1729-1958; 1737- 1920; 1737-1955; 1754-2003; 1754-2020; 1770-2055; 1770-2056; 1776-1962, 1795-2210; 1795-2174; 1795-2092; 1798-2225; 1796-2084; 1798-1967; 1797- 2058; 1849-2045; 1855-2041; 1857-2140; 1857-2055; 1867-2151; 1883-2057; 1908-2200; 1919-2234; 1920-2245; 2039-2232; 2044-2311; 2049-2245; 2079-223? 86/LG: 411043.3 :2001MAR30 || 1-497; 45-314; 45-288; 54-265; 57-592; 66-560; 69-652; 72-339; 342-610; 434-694; 453-950; 525-957; 591-827; 598-1222; 599- 865; 857-1266; 858-1060; 858-1292; 873-1161; 899-1137; 901-1489; 953-1308; 1138-1433; 1287-1641; 1293-1608; 1294-1624; 1352-1608; 1358-1608; 1362- 1610; 1366-1610; 1399-1997; 1463-1620; 1552-1630; 1564-2024; 1566-1734; 1586-1971; 1661-1748; 1713-1977; 1781-2056; 1821-2056; 1853-2056; 1876- 2056; 1909-2056; 1916-2071; 1983-2044
87/LG:414376.20:2001MAR30 || 1-4252; 172-812; 1338-1907; 1362-1918; 2094- 2582; 2358-2773; 3011-3253; 3058-3347; 3069-3685; 3299-3715; 3379-3746; 3381-3963; 3640-4115; 3703-4236; 3807-4354; 3900-4109; 4166-4392; 4166- 4427; 4175-4555; 4222-4506; 4509-4677; 4585-5019; 4602-5203; 4625-5083; 4627-4871; 4738-5046; 4740-5012; 4834-4900; 4919-5441; 4995-5346; 5006- 5499; 5050-5480; 5098-5525; 5121-5719; 5123-5377; 5126-5209; 5162-5388; 5181-5388; 5438-5961; 5442-5668; 5465-5707; 5536-6001; 5804-6000 88/LG:457695.1:2001MAR30 || 1-570; 1-482; 57-281; 354-848
89/LG:902390.2:2001MAR30 jj 1-507; 1-536; 1-158; 5-248; 7-484; 10-467; 9- 257; 14-274; 21-507; 20-507; 35-507; 197-251; 385-441 Table 5 90/LG:903565.20:200lMAR30 || 1-4027; 847-949; 1001-1541; 1224-1589; 1224- 1557; 1782-2337; 1812-2008; 1815-2020; 1924-2017; 1944-2505; 2019-2250; 2139-2367; 2174-2441; 2178-2346; 2213-2349; 2219-2518; 2380-2862; 2479- 2728; 2557-2812; 2620-3173; 2630-3144; 2654-3197; 2654-3196; 2687-2891; 2758-3338; 2758-3217; 2758-3023; 2765-3044; 2770-3024; 2770-3015; 2780- 3030; 2883-3217; 2883-3384; 2883-3228; 2883-3159; 2896-3152; 2932-3324; 2934-3222; 2949-3400; 2949-3415; 2952-3204; 2976-3228; 2987-3306; 2989- 3228; 3006-3318; 3019-3396; 3032-3151; 3036-3315; 3040-3641; 3048-3340; 3048-3277; 3100-3255; 3112-3372; 3156-3444; 3156-3430; 3157-3431; 3159- 3702; 3169-3431; 3210-3452; 3238-3575; 3239-3471; 3239-3641; 3253-3456; 3319-3564; 3331-3561; 3345-3611; 3347-3565; 3371-3845; 3394-3821; 3396- 3882; 3429-3991; 3441-3983; 3443-3675; 3467-3705; 3481-3787; 3507-3988; 3511-3831; 3519-3738; 3532-3990; 3532-3988; 3547-3788; 3568-4030; 3574- 4014; 3576-4027; 3575-3831; 3586-4032; 3593-4031; 3593-3842; 3599-3841; 3606-3863; 3632-4032; 3634-3980; 3637-4036; 3651-3916; 3667-4031; 3664- 4034; 3670-4034; 3681-3990; 3688-3984; 3690-4037; 3690-4036; 3692-4027; 3700-4024; 3706-4024; 3722-4027; 3753-4009; 3768-4000; 3771-4035; 3772- 4025; 3778-4016; 3806-4025; 3814-4022; 3831-4032; 3846-4036; 3866-4018; 3891-4032; 3959-4028; 3965-4032
91/LG:978182.4:2001MAR30 || 1-605; 15-568; 18-311; 18-2556; 36-487; 41-597; 55-475; 57-281; 161-424; 188-2253; 365-744; 450-725; 457-729; 744-999; 763- 1314; 806-997; 893-1090; 926-1212; 942-1403; 1030-1542; 1082-1408; 1164- 1546; 1167-1423; 1198-1429; 1243-1712; 1298-1717; 1358-1755; 1358-1666; 1439-2003; 1480-1746; 1499-1712; 1512-2051; 1512-1776; 1512-1711; 1512- 1710; 1535-1789; 1556-1881; 1566-1800; 1590-1712; 1665-2102; 1691-1887; 1773-2045; 1817-2116; 1828-2403; 1828-2060; 1828-2036; 1960-2537; 1971- 2474; 1976-2250; 2010-2259; 2028-2530; 2052-2536; 2067-2328; 2104-2432; 2087-2411; 2089-2548; 2100-2401; 2112-2558; 2122-2576; 2125-2388; 2147- 2505; 2156-2773; 2159-2566; 2164-2575; 2165-2575; 2172-2576; 2180-2571; 2189-2556; 2243-2539; 2268-2515; 2275-2576; 2275-2532; 2275-2554; 2304- 2558; 2306-2714; 2308-2575; 2315-2518; 2361-2575; 2392-2843; 2431-2564; 2481-2713; 2482-2761; 2668-2909; 2749-2945; 2773-3370; 3066-3304; 3168- 3673; 3318-3861; 3334-3702; 3336-3513; 3364-3651; 3482-3921; 3482-3675; 3603-4046; 3604-4047; 3625-4035; 3629-4035; 3650-4062; 3652-4019; 3660- 3895; 3680-4046; 3702-4046; 3710-4007; 3742-4060; 3756-4046; 3772-4020; 3794-4040; 3947-4044; 3973-4289
92/LG: 986827.1:2001MAR30 || 1-460; 257-710; 258-546; 553-1064; 583-1136; 631-1161; 631-1130; 632-1140; 632-1125; 632-1146; 633-1102; 632-1089; 633- 1204; 633-1175
93/LG:013792.1:2001MAR30 || 1-379; 1-609; 381-728; 384-792; 398-631; 689- 1253; 692-952; 694-976; 699-1364; 801-1064; 856-1569; 1287-1617 94/LG:018258.1:200lMAR30 || 1-622; 83-256; 126-378; 126-393; 265-735; 265- 497; 309-614; 500-657
95/LG:023126.3:2001 AR30 || 1-511; 342-605; 379-612; 379-723; 386-880; 568- 1005; 567-1059; 573-722; 648-859; 648-987; 648-985; 699-1115; 757-1005; 771-1154; 775-1154; 880-1122; 1090-1591; 1100-1364; 1100-1307; 1100-1343; 1129-1299; 1168-1410; 1213-1443; 1213-1431
96/LG:023618.1:2001MAR30 || 2-528; 1-597; 140-599; 193-593; 236-490; 270- 869; 280-641; 371-777; 377-605; 625-1064; 659-1233; 675-1113; 677-979; 707- 1194; 790-1031; 790-893; 1106-1600; 1131-1725; 1131-1510; 1240-1769; 1300- 1415; 1310-1548; 1377-1459; 1604-1800; 1604-2071; 1605-1843; 1685-1746; 1685-2193; 1809-2014; 1830-2314; 1837-2197; 1893-2354; 1914-2301; 1943- 2175; 1942-2449; 1943-2378; 1943-2328; 1943-2196; 2017-2594; 2039-2341; 2131-2371; 2147-2377; 2167-2378; 2521-2995; 2588-3052; 2692-2857; 2895- 3416; 2912-3115; 3109-3364; 3312-3855; 3312-3916; 3368-3631; 3372-3508; 3377-3927; 3378-3492; 3385-4007; 3411-3644; 3445-3697; 3653-4056; 3747- 3928; 3830-4089; 3981-4408; 3983-4247; 4219-4363; 4232-4797; 4255-4384; 4275-4799; 4387-4799; 4387-4585; 4485-4719; 4500-4767; 4622-4808; 4622- 4799; 4625-5257; 4643-4824; 4650-4751; 4663-4918; 4667-4906; 4700-4927; 4705-5039; 4714-5043; 4728-4978; 4796-5051; 4801-4919; 4806-5081; 4847- Table 5
5146; 4870-5134; 4917-5474 ; 4932 -5155, 4973 -5222 4973-5467; 4973-5277; 4983-5198; 4997-5274; 5001 -5210; 5001- -5167; 5014 5245; 5023-5228; 5030- 5296; 5032-5547; 5073-5483 ; 5081 -5560, 5094 -5353 5096-5256; 5104-5323; 5105-5292; 5112-5560; 5116 -5491; 5117- -5560; 5150-5533; 5158-5560; 5156- 5560; 5185-5477; 5205-5406 ; 5249 -5467, 5265 -5503 5346-5555; 5374-5560; 5403-5831; 5429-5560; 5583 -6218; 6123- -6463; 6262 6397; 6283-6695 97/LG: 030999.1:2001MAR30 | | 2157 -2648, 2184 -2543 2017-2311; 1808-2209; 1806-2093; 1808-2009; 1522 -1981; 1521- -1666; 1530-1651; 1470-1636; 1-1636; 1319-1636; 1335-1636; 1475 -1636; 1391- -1636; 1416-1636; 1378-1636; 1376- 1636; 1368-1636; 1397-1611 ; 1053 -1585, 1062 -1558 ; 926-1235; 899-1232; 516- 910; 582-661
98/LG:103508.1:200lMAR30 | I 1-203; 13-329; 19-54 8; 20-133; 65-439; 83-485; 123-584; 144-439; 135-691; 143-584; 394-681; 518-1235; 675-1123; 676-923; 751-1167; 773-1339; 777-13 95; 795-1382; 823-1095 ; 823-1093; 844-1095; 981- 1095; 1066-1119; 1066-1249 99/LG:107976.15:2001MAR30 | 1 1-562; 136-751 252- -6258; 271-696; 721-867; 730-989; 1603-1851; 2384-2 690; 2477-2628; 2477-2606; 2597-7897; 2674-3122; 2674-2943; 2722-3004; 2726 -3186; 2814- -3051; 2975- -3445; 2975- -3234; 3107-
3644 3644-3918; 3856-4437 ; 4014- -4326, 4134 -4400 4272 -4536, 4395 -4636; 4515 4921; 4517-4772; 4530 -4798; 4847- -5128; 4847- -5109; 4847- -5110; 4866- 5128 4870-5401; 5006-5376 ; 5006 -5199, 5015 -5243 5034 -5434, 5079 -5278; 5083 5267; 5097-5389; 5112 -5388; 5112- -5322; 5120- -5259; 5149- -5358; 5160- 5322 5169-5358; 5186-5643 ; 5211- -5362, 5217 -5722 5217 -5564, 5217 -5535; 5217 5458; 5217-5433; 5224 -5440; 5224- -5405; 5240- -5317; 5248- -5397; 5272- 5531 5274-5535; 5279-5511 ; 5281 -5571 5300 -5564 5305 -5576, 5317 -5567; 5388 5652; 5389-5658; 5408 -5979; 5415- -5936; 5471- -5879; 5483- -5622; 5541- 5972 5549-5833; 5542-5754 ; 5554 -6067 5545 -5778 5549 -5791 5573 -6042;
5554-5705; 5575-6185; 5565 -5821; 5601- -6209; 5612- -6197; 5620- -5886; 5639-
5983 5677-5886; 5706-5920 ; 5713 -5840 5707 -5955 5714 -5957 5718 -6025;
5722-6209; 5740-5957; 5728 -5949; 5733- -6209; 5752- -6202; 5767- -5986; 5760-
5916 5778-6201; 5775-5955 ; 5775- -6014, 5800 -6263 5807 -6260, 5807- -6258; 5833 6058; 5822-6203; 5835 -6198; 5834- -6161; 5834- -6258; 5835- -6261; 5835- 6096 5839-6197; 5842-6258 ; 5843- -6258, 5845 -6258 5850 -6198, 5855 -6258; 5857 6258; 5862-6259; 5864 -6262; 5875- -6124; 5888- -6258; 5891- -6198; 5892- 6007 5893-6261; 5898-6263 ; 5873- -6266, 5910 -6258 5910 -6255, 5910 -6137; 5912 6263; 5913-6258; 5913 -6151; 5915- -6258; 5946- -6258; 5945- -6263; 5945- 6257 5948-6196; 5949-6238 ; 5953 -6260 5953 -6259 5963 -6258, 5964 -6258;
5973-6196; 5989-6432; 5990 -6252; 5995- -6239; 6009- -6258; 6010- -6580; 6022-
6189 6040-6249; 6045-6264 ; 6045 -6198 6011 -6266 6030 -6266, 6074 -6258; 6080 6762; 6082-6179; 6108 -6258; 6095- -6340; 6095- -6331; 6097- -6258; 6122- 6264 6107-6618; 6108-6231 ; 6113 -6261 6119 -6258 6152 -6202 6203 -6485; 6190 6726; 6198-6258; 6222 -6560; 6222- -6467; 6227- -6510; 6244- -6861; 6251- 6807 6326-6553; 6437-7030 ; 6440 -6872 6441 -6961 6477 -6993 6477 -6846;
6502-7026; 6515-6730; 6499 -6704; 6618- -6809; 6619- -7163; 6633- -6861; 6707-
7061 6734-7256; 6766-7266 ; 6783- -7127, 6782 -7102 6782 -7059, 6782- -7052;
6782-6955; 6783-7157; 6783 -7142; 6813- -7066; 6835- -7085; 6840- -7087; 6860- 7072; 6883-7404; 6887-7417 ; 6887 -7151, 6941 -7492 7008 -7416, 7008- -7255; 7012-7250; 7014-7285; 7025 -7313; 7038- -7294; 7086- -7550; 7126- -7552; 7126- 7342; 7199-7415; 7206-7468 ; 7249- -7523, 7289 -7544 7309 -8062, 7367- -7842; 7390-7859; 7432-7897; 7447 -7732; 7485- -7904; 7486- -7725; 7488- -7829; 7491- 7903; 7517-7896; 7520-7903 ; 7575 -7858, 7578 -8056 7576 -7817, 7591 -7894; 7598-7897; 7620-7897; 7639 -7859; 7642- -7730; 7747- -7894; 7751- -8065; 7771- 7893; 7771-8066; 7806-7858 100/LG: 1080096.1:2001MAR30 I I 1-763; 8-596; 11-6 10; 245-698; 369-974; 363- 564; 384-978; 425-997; 426-1033; 426-873; 463-970; 465-724; 653-897; 755- 1329; 934-1530; 995-1576; 997-1238; 1046-1336; 1056-1308; 1056-1492; 1067- 1566; 1101-1367; 1138-1376 ; 1146-1582; 1155-1480 ; 1155-1754; 1163-1520; 1168-1432; 1178-1674; 1398-1695; 1413-2002; 1473 -1706; 1491-2058; 1606- 2159; 1609-1897; 1607-2076 ; 1624-2036; 1626-1812 ; 1644-1908; 1668-2108; 1669-1915; 1885-2077; 1894-2384; 1894-2119; 1899-2425; 1964-2449; 1976- Table 5
2223; 2014-2428 ; 2014-2453; 2017-2320; 2019-2474; 2021-2314; 2043-2437 2110-2474; 2109-2474; 2114-2474; 2127-2413; 2127-2452; 2160-2426; 2164 2474; 2176-2688 ; 2196-2281; 2203-2376; 2259-2474; 2266-2474; 2271-2627 2301-2660; 2309-2474; 2317-2473; 2329-2475; 2343-2474; 2370-2474; 2371 2474; 2372-2474 ; 2415-2678; 2415-2474; 2415-2683; 2415-2475; 2423-2785 2418-2474; 2531-2679; 2568-2743; 2599-2667 101/LG:1080275. 1:2001MAR30 || 1-359; 1-265; 128-638; 128-808; 199-527; 287- 899; 517-992; 577-843; 584-1122; 678-899; 684-1126; 697-1126; 721-948; 775- 1126; 775-1052; 805-1022; 913-1141; 931-1126; 935-1088; 947-1459; 1006-1126 102/LG:1090358.10:2001MAR30 || 1-573; 2-279; 346-572; 354-564; 354-543; 410-1047; 530-788; 530-1118; 530-1047; 527-1079; 546-860; 568-1064; 592- 1002; 665-1118; 683-968; 689-1118; 691-1123; 700-1121; 703-1313; 721-1333; 733-940; 754-1118; 861-1076; 861-1118; 866-937; 924-1018; 1123-1555; 1129- 1793; 1552-1778 103/LG:1095833. :2001MAR30 II i- 6046; 339-5 63; 3 43-595 ; 499- 1090; 569-4936; 699-896; 761-10 5; 779-102 ; 875-1495; 971- 1143; 1152-1682; 1179-1734; 1181-1469; 1622 2166; 1681 2269; 1755-1919; 1799-2069; 1850-2326; 1850- 2115; 2201-2451 2201-2673 2201-2455; 2205-2311 ; 2362-4960; 2607-3156; 2634-2889; 2859 3277; 2868 3277; 2893-3127; 3310-5014; 3516-3760; 3823- 4267; 3831-4316 3890-4300 3892-4300; 3913-4210 ; 4402-4635; 4471-4778 4502-4753; 4589 4892; 5031 5308; 5065-5535; 5508-5919; 5552-5756; 5564 5746; 5565-6046 5608-6046 5632-5927; 5637-6042 ; 5647-5981; 5703-6042 5719-6042; 5723 6038; 5728 6042; 5781-6046; 5898-6148; 5907-6511; 5980- 6046; 5990-6499 6145-6630 6145-6703; 6176-6404 ; 6186-6359; 6262-6483 6443-6970; 6443 6515; 6443 6621; 6584-7093; 6629-7027; 6629-7029; 6885- 7403; 6888-7445 6912-7499 7006-7330; 7042-7477 ,- 7046-7558; 7046-7759 7079-7460; 7082 7339; 7117 7444; 7140-7351; 7142-7423; 7198-7552; 7201- 7511; 7202-7483 7246-7840 7552-7938; 7552 -7816 ; 7756-8283; 7756-8299 7764-8244; 7928 8681; 7966 8390; 7985-8399; 8097-8680; 8137-8681; 8144 8704; 8260-8607 8413-8695 8444-8723; 8458-8626 ; 8462-8609; 8462-8593 8467-9052; 8521 8950; 8531 9103; 8552-9265; 8572-9119; 8837-9331; 8864 9421; 8879-9554 8868-9151 8883-9003; 8883 -9079 ; 8883-9069; 8896-9186 9186-9540; 9258 9529; 9351 9534 104/LG:1383121. 5:2001 AR3 II 1 -508; 27-298; 37 459; 39-143; 213-697; 255- 498; 316-573; 5 2-1058; 58 -799; 704- 97; 704-1133; 705-1414; 900-1395; 974-1133; 977-1 33; 1017-1 83; 1056-1 02; 1076-1486; 1079-1133; 1263-1747; 1527-1936; 1520 2064; 1526 1707; 1709 1973; 1709-2008; 1711-2000; 1716- 2007; 1718-1992 1720-2070 1721-1982 1725-1980 ; 1732-2003; 1732-1973; 1732-1923; 1735 1960; 1735 2002; 1737 1985; 1751-1991; 1762-1982; 1770- 1979; 1770-1965 1784-2003 1786-1992 1800-2036 ; 1802-1952; 1877-1983; 1893-2008; 1906 2422; 1752 2038; 314- 74; 257-486; 232-418; 2097-2263; 1860-2014; 1892 2039; 1838 1945; 1845 1928 105/LG:1386609. :2001MAR30 II i-387; -643; 46-3 33; 52 -324; 181-5 87; 181- 440; 208-357; 3 9-898; 407 6519; 538- 15; 648-1080; 69 0-884; 728-1230; 791- 1339; 1155-1271 1157-1405 1206-1470 1272-1540 ; 1272 -1691; 1370-1669; 1372-1647; 1785 2107; 1785 1989; 1823 2098; 1869-2124; 2077-2259; 2077- 2351; 2107-2616 2109-2388 2206-2617 2385-2642 ; 2457-2567; 2499-2577, 2502-3062; 2519 2707; 2531 3075; 2619 3119; 2737-2906; 2737-3183; 2787- 3035; 2887-3523 2944-3337 2953-3522 3212-3803 ; 3469-3784; 3513-3842, 3513-3821; 3513 3754; 3719 4001; 3799 3967; 3822-4052; 3844-4214; 3854- 3984; 3982-4309 3986-4214 4002-4209 4043-4283 ; 4109-4285; 4203-4517, 4294-4674; 4294 4683; 4305 4757; 4400 4644; 4471-4926; 4472-4928; 4473- 4928; 4512-4927 4590-4869 4602-4927 4635-4921 ; 4636-4926; 4661-5042, 4676-4927; 4694 4927; 4764 4923; 4770 4918; 4778-4926; 4825-5131; 4985- 5224; 4985-5363 5002-5255 5017-5443 5057-5275 ; 5076-5281; 5079-5275; 5120-5475; 5119 5275; 5136 5275; 5170 5363; 5363-5737; 5383-5679; 5389- 5781; 5431-5868 5433-5719 5451-5719 5498-5719 ; 5550-6124; 5649-6282; 5668-5848; 5684 6111; 5684 5828; 5694 6226; 5720-5916; 5720-6125; 5763- 6021; 5763-6113 5807-6095 5835-6093 5919-6262 ; 5926-6281; 5926-6481, 5926-6271; 5942 6481; 5944 6479; 5958 6479; 6014-6324; 6047-6478; 6051- Table 5
6519; 6056-6620; 6096-6477 6098-6343; 6103 6519; 6105- 6519 6110- -6522; 6110-6521; 6112-6523; 6120 6518; 6149-6519; 6151-6517; 6161 6519; 6186- 6479; 6189-6515; 6210-6710 6269-6519; 6290 6830; 6309- 6517 6310 -6519; 6368-6522; 6391-6525; 6421 6517; 6535-7153; 6541-6828; 6569 7161; 6746- 7055; 6749-6997; 6896-7082 6918-7190; 7024 7248; 7107- 7397 7173 -7287; 7186-7382; 7188-7650; 7201 7722; 7219-7436; 7301-7750; 7305-7605; 7334- 7685; 7334-7736; 7365-7611 7410-7627; 7438 7702; 7442- 7713 7442 -7684; 7477-7820; 7477-7711; 7523-7686; 7610-7848; 7609-7853; 7610 7871; 7614- 7864; 7694-8243; 7694-8247 7709-7876; 7754 8053; 7784- 8233 7805 -8033; 7812-8072; 7812-8252; 7829 8253; 7842-8134; 7860-8255; 7864-8229; 7878- 8243; 7912-8233; 7916-8274 7942-8254; 7942- 8216; 7983- 8252 8036 -8342; 8057-8255; 8109-8580; 8140 8243; 8163-8254; 8163-8450; 8185 8454; 8314- 8612; 8314-8545; 8327-8463 8317-8650; 8318- 8560; 8318- 8543 8318 -8727; 8319-8572; 8319-8766; 8319 8772; 8347-8585; 8366-8657; 8381 8647; 8390- 8944; 8395-8690; 8400-8680 8402-8868; 8406- 8639; 8496- 8761 8516 -8788; 8517-8999; 8517-8787; 8521 8757; 8522-8990; 8530-8819; 8531 8758; 8535- 8769; 8542-8707; 8589-8841 8589-8861; 8662- 8837; 8726- 9208 8729 -9046; 8733-9177; 8743-8955; 8742-8989; 8754-9047; 8776-9228; 8804 9210; 8816- 9224; 8826-9216; 8834-9227 8842-9072; 8842- 9118; 8844- 9129 8847 -9220; 8878-9213; 8878-9216; 8880 9227; 8891-9218; 8909-9227; 8923-9184; 8929- 9199; 8929-9227; 8937-9207 8963-9209; 8968- 9219; 8980- 9233 8997- -9208; 9010-9184; 9011-9223; 9096 9232; 9098-9227 106/LG:1398465.1 :2001MAR30 II i-574; 35-687; 144- 583; 221-496; 22 8-549; 353-914; 360-828 ; 345-601; 357-629; 358-628; 400- 922; 430-540; 44 6-692; 446-675; 451-682 ; 462-680; 462-728; 556-984; 574- 711; 601-893; 62 9-891; 648-886; 657-857 ; 658-1214 703-973; 753-964 ; 753 -992; 762-1344 770-1324; 778-1037; 779-1100; 802-97 7; 814-1096; 816-9 64; 8 91-1105; 905-118 4; 930-
1174 934-1364; 943-1364; 939-1215; 965-1364 ; 965 -1250 ; 970-1242; 975-1593;
1007-1236; 1015- 1252; 1025 1283; 1025-1285;- 1025- 1364; 1063-1332; 1078-
1364 1099-1325 1099-1256 1105 1394 1124- 1364; 1129-1369; 1143 -1779; 1145 1381; 1164-1680; 1166-1489; 1167 1369; 1181-1472; 1188-1364; 1197- 1742 1249-1745 1289-1714 1299-1821 1393- 1540; 1393 -1867; 1393 -1844; 1393 1829; 1394 1633; 1400 1872; 1400 1633; 1400-1614; 1400-1610; 1400- 1572 1399-1740 1401-1565 1402-1772 1402- 1633; 1403-1739; 1407 -1633; 1408 2016; 1413 1822; 1418 1523; 1435 1704; 1437-1633; 1442-1575; 1443- 1565 1443-1849 1442-1790 1443-1702 1447- 1719; 1456-1911; 1457 -1732; 1463 1633; 1475 1928; 1475 1735; 1498-1585; 1497-1747; 1501-2014; 1499- 1635 1502-1672 1522-1633 1533 -1984 1533- 1739; 1539-1775; 1543 -1782;
1543-1809; 1549 1820; 1560 2046; 1560 1888; 1560-1765; 1559-1775; 1559-
1713 1562-1828 1569-2023 1573 -1819 1570- 1635; 1581-1880; 1584 -1656; 1610 1887; 1611 2202; 1617 2158; 1620-1827; 1629-1892; 1629-1873; 1636- 2043 1638-2145 1639-2021 1642 -2204 1654- 2119; 1654-2010; 1654 -1995;
1685-1907; 1688 1955; 1694-1987; 1695 2158; 1701-2157; 1703-2157; 1704-
2171 1705-2005 1709-2157 1709-1957 1711 2011; 1713-1938; 1728 -1985;
1729-1980; 1730 1965; 1738 2021; 1752 1983; 1753-2043; 1756-2091; 1758-
1840 1764-2378 1768-2162 1769-2115 1781 2437; 1782-2050; 1789 -2131;
1790-2158; 1798 2157; 1797 2387; 1804 2378; 1805-2157; 1809-2158; 1810-
2157 1812-2162 1824-2390 1828-2120 1833 2317; 1833-2083; 1833 -2070; 1835 2387; 1839-2382; 1838 2158; 1851 2173; 1854-2138; 1859-2465; 1859- 2397 1859-2390 1864-2130 1866-2423 1869 2144; 1880-2154; 1883 -2162; 1887 2158; 1894 2158; 1903 2158; 1907 2172; 1906-2300; 1913-2154; 1917- 2158 1920-2384 1921-2345 1930-2208 1946- 2158; 1948-2158; 1951 -2377;
1953-2335; 1953 2265; 1953 2238; 1967 2382; 1965-2158; 1976-2192; 1974-
2153 1980-2158 1988-2158 1995-2241 2001 2272; 2013-2452; 2015 -2265; 2017 2163; 2021 2398; 2021 2240; 2021 2282; 2028-2259; 2031-2377; 2037- 2528 2039-2259 2040-2622 2040-2278 2043- 2589; 2045-2287; 2050 -2326; 2060 2299; 2073 2326; 2073 2306; 2073 2259; 2080-2282; 2106-2605; 2107- 2437 2119-2342 2123-2655 2121-2724 2123- 2404; 2124-2368; 2131 -2754;
2131-2378; 2136 2394; 2138 2423; 2157-2384; 2159-2692; 2159-2507; 2164-
2230 2167-2713 2173-2468 2172 -2433 2178- 2453; 2180-2410; 2202 -2582; Table 5
2204-2469; 2205-2 661; 2205 2456; 2214-2480 ; 2219-2460; 2224 -2748; 2223- 2463; 2227-2745; 2235 2711 2236 -2768; 2236-2508; 2238-2433 ; 2237 -2426; 2241-2712; 2242-2486; 2248-2520; 2251-2408; 2255-2846; 2264 -2495; 2285- 2840; 2285-2548; 2287 2647 2290 -2518; 2292-2564; 2293-2572 ; 2294 -2471; 2304-2454; 2318-2580; 2323-2910; 2332-2622; 2332-2576; 2344 -2854; 2344- 2564; 2344-2529; 2355 2544 2365 -2586; 2364-2542; 2376-2511 ; 2343 -2460; 2385-2937; 2390-2584; 2393 2653; 2392-2484; 2411-2644; 2427 -2645; 2445- 2728; 2446-2703; 2453-2858 2454 -2951; 2453-2719; 2454-2737 ; 2455 -2703; 2456-2695; 2469-2771; 2481 2845; 2481-2868; 2481-2871; 2481 -2625; 2482- 2766; 2491-2745; 2497-2745 2503 -2757; 2503-2754; 2521-2684 ; 2526 -2819; 2534-2807; 2535-2714; 2538-2785; 2543-2796; 2547-2810; 2549 -2852; 2550- 2714; 2566-2807; 2587-2770 2624 -2888; 2658-2732; 2665-2848 ; 2740 -2988; 2782-2982; 2783-3040; 2796-2963; 2802-3011; 2827-3360; 2830 -3110; 2841- 3148; 2851-2946; 2879-3398 2908 -3131; 2915-3140; 2924-3177 ; 2934 -3076; 2949-3198; 2957-3212; 2964 3458; 3003-3408; 3000-3259; 3001 -3090; 3001- 3247; 3001-3113; 3005-3249 3020 3310; 3091-3320 107/LG:1453417.10 :2001MAR30 || 1 10383; 1460-10383; 2021-26 09; 27 31-2944; 2828-3245; 2914-3418; 3779-4059; 4753-5024; 4823-5239; 4888 -5151; 4898- 5468; 4913-5488; 4925-5480 5054 5462; 5077-5344; 5378-5924 ; 5543-6059; 5622-6129; 5653-5879; 6004 6316; 6291-6817; 6666-6963; 6668 -6959; 6669- 6959; 6674-6992; 6712-7161 6725 6916; 6829-7092; 6835-7103 ; 6857-6983; 6859-7106; 6875-7379; 6935-7447; 7017-7111; 7017-7232; 7070 -7379; 7762- 8228; 7828-8334; 7849-8272 7854 8329; 7854-8395; 7947-8472 ; 8002-8237; 8038-8300; 8044-8614; 8073 8141; 8172-8733; 8172-8599; 8177 -8519; 8238- 8817; 8257-8526; 8265-8720 8323 8467; 8363-8606; 8564-8692 ; 8615-8873; 8665-8945; 8698-8982; 8781 8899; 8788-9430; 8822-8905; 8845 -9096; 8850- 9141; 8883-9353; 8888-9126 8937 9103; 8975-9286; 8975-9293 ; 8985-9181; 9016-9587; 9019-9236; 9065-9348; 9113-9613; 9113-9628; 9134 -9566; 9166- 9375; 9171-9473; 9209-9556 9222 9476; 9243-9787; 9290-9525 ; 9297-9573; 9316-9778; 9383-9645; 9384-9636; 9389-9692; 9393-9671; 9397 -9979; 9474- 9733; 9504-9618; 9510-9720 9510 9708; 9517-10011; 9517-977 7; 9529-9740; 9550-9798; 9551-9737; 9572-9871; 9574-10125 ; 9603-10048; 96 09-9878; 9686- 10257; 9718-9943; 9718-10196; 97 39-9959; 9743-9852; 9744-10 022; 9752-10002; 9766-10033; 9789-10059; 9800-100 22; 9804-10275; 9819-10066; 9834-10342; 9846-10244; 9861-10141; 9930-102 41; 9935-10388; 9957-10237; 9971-10229; 9985-10330; 10006-10390; 10055-1 0329; 10056-10329; 10083-10 349; 10088- 10329; 10115-10353; 10214-10782 10228-10333; 10241-10333; 10242-10333; 10318-10877; 10385-10671; 10428 10762; 10503-10721; 10520- 1133; 10596- 10729; 10719-11000; 10729-11050 10952-11133; 11013-11262; 11117-11394; 11120-11396; 11145-11600; 11145 11396; 11146-11410; 11217- 1754; 11220- 11452; 11263-11505; 11263-11529 11404-11727; 11449-11730; 11465-11762; 11472-11730; 11472-11699; 11481- 11730; 11481-11734; 11499-1 1730; 11602- 11730
108/LG:147869 3:2 001 AR30 || 1-386; 1-592; 1-642; 281-960; 492-1082; 602- 931; 854-1074 905-1471; 905-1207; 1156-1300; 1229-1394; 1371-1668; 1499- 2141
109/LG:148485.5:2 001MAR30 || 1-671; 1-542; 168-276; 316-779; 334-779; 335- 844; 335-556; 367-536; 492-923; 629-754; 808-947 110/LG:1501818.12 :2001MAR30 || 1-556; 1-216; 19-293; 24-285; 24-263; 31- 311; 31-324; 31-261; 32-233; 33-654; 35-312; 44-320; 46-302; 47-256; 52- 324; 56-321; 57-341; 57-333; 57-307; 60-435; 59-335; 59-324; 60-365; 60- 333; 64-355; 67-334; 89-527; 73-293; 76-363; 77-314; 81-394; 78-369; 78- 330; 78-328; 83-391; 86-520; 92-294; 146-469; 185-393; 229-846; 250-467; 250-557; 256-792 274-664; 311-588; 331-459; 335-484; 343-601; 363-535; 380-672; 380-639 402-601; 408-669; 412-969; 413-718; 414-504; 434-685; 434-678; 456-685 469-740; 568-1089; 583-762; 590-826; 600-827; 638-883; 636-866; 636-853 699-966; 718-1185; 723-1300; 735-1044; 765-1027; 765- 1026; 764-1273; 763-1175; 784-1291; 777-1055; 796-939; 790-1061; 791-1056; 801-1103; 820-1171; 803-975; 813-985; 831-1070; 835-1107; 835-1056; 843- 983; 885-1340; 887-1340; 892-1339; 902-1339; 925-1198; 913-1339; 935-1341; Table 5
941-1198; 946-1 163; 947-11 68; 949-1347; 969- 1343; 975- 1342; 1035-1499; 1035-1171; 1037 -1341 ; 1042-1302; 1047-1171; 1048-1338; 1061-1304; 1064 1343; 1071-1315 1083-1343 ; 1093-1292; 1108- 1337; 1120-1350 ,- 1154-1340 1156-1351; 1167 1352 1180 1574; 1202-1663; 1218-1341; 1234-1658; 1281 1661; 1281-1662 1297-1707 1300-1710; 1373- 1706; 1373-1709 ,- 1373-1714 1373-1481; 1380 1662 ; 1388 1679; 1387-1665; 1389-1638; 1402-1659; 1411 1659; 1411-1707 1411-1667 1411-1661; 1411- 1641; 1469-1704 ; 1470-1614 1496-1708; 1543 -1713 ; 1564 1711; 1557-1659; 1574-1713; 1574-1707; 1574 1684; 1574-1668 1577-1655 1598-1710; 1602- 1659; 1610-1707 ; 1613-1694 1613-1695; 1627 -1707 ; 1088 1263 111/LG:1508275. 1:2001MAR30 11 ι-3 20; 1-243 112/LG:1509771. 1:2001MAR30 I I 1-479; 1-398 113/LG:1512998. 13:2001MAR3 1 565; 326-6 20; 425 -710; 425-474; 4 55-924; 514-1073; 519-7 67; 589-832 ; 589-1153; 652-1020; 651-857; 1029-1395 ; 1140- 1771; 1163-1527 1178-1716 ; 1203 1527; 1214-1865; 1285-1668; 1338- 1698; 1366-1710; 1407 1658 ; 1407-1794; 1427-1751; 1488- 869; 1624-1824; 1688- 1934; 1749-2177 1758-2004 ; 1758 1998; 1772-1959; 1811-2094; 1938- 2062; 1943-2511; 1945 2507 ; 1949-2213; 1978-2573; 2051- 177; 2051-2617; 2307- 2903; 2312-2785 2334-2611 ; 2369 2618; 2390-3027; 2393-2850; 2454- 2681; 2469-2890; 2482 2890 ; 2493 -2867; 2508-2752; 2516-2703; 2575-2785; 2586- 2779; 2597-2892 2631-2848 ; 2745 3011; 2810-3284; 2836-3040; 2874- 3128; 2883-2991; 2902 2991 ; 2911-2998; 2952-3366; 2965- 045; 2984-3245; 3040- 3308; 3068-3327 3074-3254 ; 3074 3306; 3074-3347; 3166-3589; 3101- 3298; 3124-3453; 3130 3323 ; 3186-3386; 3217-3446; 3244-3364; 3272-3560 3343- 3542; 3428-3685 114/LG:198251.7 :2001MAR3 0 I I 1-50 9; 6 532; 278-5 85; 4 69-982 ; 517- 763; 518- 757; 552-714; 5 82-1126; 592-1070; 607 796; 697-7 96; 702-1172; 702-1133; 703-799; 722-11 75; 720-796; 732-999; 735-948; 73 8-1071; 738-961; 748-1249; 751-1133; 757-1 175; 769-1091; 775-906 784-1171; 804-1334; 810-1177; 826- 1183; 855-1362; 910-1171 ; 928-1179; 934-1175; 94 5-1494; 988-1171; 1024- 1585; 1116-1572 1127-1809; 1154-1342 1170-1730 1171-1708 1176-1279; 1181-1355; 1183 1531; 1183-1463; 1204 1410; 1229 -1517 ; 1290 1812; 1343- 1593; 1347-1738 1347-1729; 1358-1823 1363-1686 1409-1895 1412-1686; 1435-1752; 1436 1865; 1469-1974; 1472 1790; 1487 1943 ; 1489 1674; 1548- 2042; 1553-1791 1553-1661; 1569-1709 1602-1973 1608-2115 1634-1818;. 1640-2017; 1640 1861; 1640-1858; 1697 2229; 1703 2274 ,- 1767 2273; 1824- 2381; 1837-2095 1849-2247; 1849-2101 1860-2057 1878-2115 1895-1972; 1909-2443; 1927 -2447; 1927-2432; 1928 2206; 1931 2191 ; 1936 2485; 1948- 2342; 1959-2418 1961-2217; 1970-2505 1983-2337 1985-2115 1993-2513; 2004-2282; 2014 -2073; 2063-2361; 2078 2365; 2118 -2189 ; 2131 2660; 2133- 2429; 2133-2417 2135-2599; 2135 2390 2135-2254 2135-2267 2145-2624; 2145-2307; 2166 2505; 2166-2399; 2176 2767; 2180 -2326 ,- 2188 2480; 2188- 2472; 2226-2577 2226-2439; 2235 2434 2239-2495 2239-2498 2245-2827; 2246-2540; 2272 2599; 2298-2488; 2312 2602; 2314 -2591 ; 2343 2916; 2357- 2611; 2360-2618 2384-2719; 2378-2821 2391-2657 2391-2645 2391-2640; 2387-2640; 2400 -2649; 2433-3105; 2442 2746; 2459 2964 ; 2458 2960; 2469- 2757; 2484-2806 2503-2759; 2521 2813 2551-2986 2572-2837 2573-2783; 2579-2813; 2580 -2851; 2590-2865; 2591 2864; 2591 2863 ; 2592 2822; 2595- 2765; 2603-2889 2612-2755; 2617-3113 2617-2845 2620-3166 2642-3048; 2640-3185; 2647 2858; 2653-2908; 2657 2923; 2657 -2902 ; 2657 2873; 2678- 2963; 2689-2951 2738-3110; 2740-3033 2751-3018 2762-3288 2762-2989; 2779-3377; 2779 -2980; 2784-3052; 2789 3020; 2792 3052 ; 2811-3061; 2812- 3113; 2807-3016 2807-2977; 2807-2891 2815-3070 2815-3004 2818-3034; 2820-3318; 2821 -3106; 2821-3093; 2822 3092; 2820 3014 ; 2828 3449; 2840- 3379; 2845-3081 2846-2971; 2867 3302 2869-3300 2870-3133 2883-3189; 2893-3162; 2892 -3104; 2914-3481; 2914 3522; 2925 3189 ; 2928 3204; 2948- 3520; 2948-3211 2951-3515; 2956 3389 2969-3210 2971-3300 2972-3223; 2975-3283; 2980 3194; 2982-3194; 2989-3512; 2993 -3232 ; 2996 3471; 3000- 3273; 3004-3522 3007-3554; 3012 3196 3013-3264 3033-3331 3037-3289; 3043-3245; 3045 3295; 3050-3255; 3064-3292; 3070 -3502 ; 3078 3519; 3084- Table 5
3307; 3089-3364; 3090- 3553; 3095 -3553; 3101- 3553; 3102- 3558 3102- 3320; 3106-3560; 3114-3508; 3113-3560; 3124-3479; 3123-3539; 3123-3383; 3125- 3553; 3126-3376; 3127- 3553; 3133 -3553; 3134- 3375; 3136- 3553 3143- 3556; 3145-3553; 3146-3556; 3151-3397; 3155-3554; 3155-3408; 3163 3553; 3184- 3553; 3189-3553; 3209- 3555; 3208 -3455; 3209- 3466; 3217- 3559 3221- 3515; 3224-3526; 3234-3553; 3234- 3508; 3234-3461; 3234-3460; 3237 3553; 3237- 3358; 3238-3482; 3244- 3558; 3254 -3558; 3257- 3509; 3254- 3507 3254- 3492; 3257-3472; 3259-3387; 3261-3503; 3263-3531; 3265-3558; 3266 3559; 3266- 3553; 3266-3452; 3282- 3527; 3290 -3551; 3303- 3543; 3318- 3543 3318- 3534; 3322-3553; 3331-3556; 3336-3559; 3346-3540; 3358-3558; 3361-3553; 3361- 3545; 3449-3547 115/LG:198296.1: 2001 AR30 | | 1-2 00; 4 289; 139-362; 13 9-647; 139-504; 195- 500; 227-489; 318-501; 422-628; 479-7 18; 549-763; 573- 809; 656-1123; 694- 815; 728-976; 740-1246; 760-1269 769 -1057; 803-1353; 810-1114; 846-1176; 881-1063; 881-1385; 913-1348; 934-140 7; 940-1443; 951- 1313; 994-1445; 1000- 1445; 1007-1541; 1028-1267; 1042-1269 1053-1376; 1056 1444 1059-1450; 1073-1422; 1073-1349; 1144-1445; 1156 -1444; 1164-1517; 1167 1429; 1213- 1445; 1238-1445; 1238-1443; 1254-1348 1342-1443; 1355 1441 1361-1794; 1379-1462; 1430-1698; 1534-1781; 1534 -1820; 1539-1808; 1549 1814; 1579- 1859; 1609-1839; 1609-2128; 1623 -1867 1647-1899; 1649 2084 1661-1860; 1693-2009; 1747-2003; 1756-1895; 1788 -2084; 1805-1980; 1806 2413; 1826- 2084; 1874-2084; 1892-1985; 1907-2084 1925-2084; 1951 2161 2011-2084; 2044-2093; 2298-2574; 2301-2559; 2301 2569; 2301-2714; 2301-2360; 2338- 2878; 2449-2878; 2453-2921; 2466-2917 2474-2856; 2474 2877 2474-2733; 2527-2914; 2529-2693; 2588-3255; 2599 2866; 2623-2921; 2681 2770; 2695- 3384; 2716-3259; 2839-2917; 2934-3380 2972-3371; 2992 -3565 3030-3377 116/LG:198876.13 :2001MAR30 | | 1-533; 37-291 ; 63-339; 1 16-405 122-380; 147- 1473; 268-1454; 301-783; 405-657 ; 411 -703; 432-825; 43 2-550 453-730; 517- 1035; 552-748; 587-1115; 644-796 ; 666 -859; 673-848; 68 8-996 691-969; 722- 1330; 722-946; 744-982; 751-817; 768- 1073; 769-1027; 8 03-1367; 834-1114; 861-1105; 862-1432; 863-1361; 863-110 0; 901-1456; 903- 1146; 913-1400; 946- 1553; 946-1157; 955-1313; 970-1435; 9 72-1391; 972-1360 ; 984-1355; 984-1351; 997-1394; 999-1582; 1008-1308; 1013-1 357; 1019-1625; 1 017-1460; 1037-1296; 1040-1312; 1052-1457; 1068-1456; 1080 -1456; 1093-1456; 1093 1437; 1095- 1459; 1099-1456; 1103-1456 1105-1456 1119 -1664 1142 -1601 1143-1402; 1154-1410; 1156- 1334; 1169-1456; 1179 1434; 1190 1454; 1244 1419; 1246- 1427; 1258-1462; 1288-1580 1301-1575 1306-1842 1324 -1435 1358-1634; 1358-1598; 1438- 1634; 1449-1634; 1454 1634; 1460 1634; 1471 1617; 1495- 1612; 1503-2036; 1532-2109 1553-2092 1577-1814 1664 -2170 1664-2127; 1664-1991; 1665- 1741; 1704-1998; 1712 2066; 1732 1832; 1777 2043; 1777- 2124; 1826-2103; 1833-2090 1850-2454 1857-2405 1885 -2143 1897-2421; 1911-2172; 1911- 2133; 2001-2211; 2001 2061; 2050 2301; 2054 2298; 2068- 2304; 2099-2395; 2100-2723 2111-2524 2118-2320 2140 -2726 2140-2733; 2221-2775; 2231- 2287; 2233-2481; 2233 2451; 2240-2519; 2243 2571; 2243- 2304; 2273-2809; 2286-2422 2292-2563 2292 -2542 2307 -2625 2307-2573; 2313-2502; 2323- 2562; 2329-2523; 2335 -2933; 2375 2611; 2392-2819; 2405- 2621; 2458-2881; 2457-2804 2462-3029 2477 -2800 2482 -2907 2482-2691; 2483-3051; 2488- 2735; 2511-2756; 2511 -2749; 2514-2961; 2515 2956; 2517- 2589; 2518-2698; 2518- 2764 2524-2812 2523 -2840 2524 -2720 2544-2996; 2544-2761; 2620-2849; 2632 3115; 2641 3189; 2657 2897; 2658 2927; 2661- 3219; 2665-3202; 2670- 2921 2683-2998 2717 -3219 2717 -3201 2716-2942; 2782-3221; 2782-3049; 2786 3402; 2831 3365; 2845-3425; 2856 3425; 2866- 3371; 2873-3157; 2873- 3105 2878-3131 2878 -3119 2879 -3143 2894-3009; 2914-3165; 2923-3418; 2932 3159; 2934 -3203; 2941-3327; 2963-3160; 2992- 3158; 2994-3214; 2999- 3264 2999-3250 3020 -3295 3020 -3141 3021-3310; 3026-3303; 3033-3247; 3037 3379; 3040 -3148; 3046 3208; 3052-3331; 3054- 3485; 3054-3291; 3066- 3585 3078-3343 3096 -3366 3106 -3224 3117-3434; 3159-3395; 3163-3519; 3166 3447; 3170 3451; 3180 3275; 3181 3308; 3203- 3756; 3226-3509; 3228- 3470 3229-3463 3233 -3479 3238 -3496 3237-3786; 3244-3461; 3244- 3509; 3261-3501; 3266 3412; 3268-3501; 3270 3442; 3277- Table 5
3720 3284 -3532 3293-3543 3293 -3508 3295-3523 ; 3302 3895 3308 3556; 3313 3673; 3336 3598; 3336 3516; 3345 3787; 3354-3785; 3352-3565; 3352- 3640 3353-3623 3352-3597 3355 -3584 3353-3597 ; 3357 3644 3401 3597; 3401 3689; 3411 3691; 3413 3685; 3414 3695; 3414-3657; 3420-4055; 3426- 3577 3436-3702 3450-3679 3454 -3786 3456-3942 ; 3456 3705 3466 3736; 3466 3690; 3468 3673; 3512 3756; 3520 3790; 3530-3888; 3557-4047; 3557- 3933 3556-3770 3556-3718 3557 -3778 3559-4166 ; 3568- 3836 3568 3732; 3578 3772; 3582 -3773; 3588 3801; 3594-3817; 3600-3690; 3600 4190; 3599- 4077 3600-3852 3599-3830 3621 -4064 3623-3880 ; 3623- 3865 3623 3999; 3623 4115; 3630 -3975; 3636 4208; 3631 3898; 3634-3916 3638-3945; 3638- 3910 3649-4170 3649-4148 3648 -3916 3652-4159 ; 3674- 3924 3676 3907; 3683 4208; 3680 -4169; 3684 3965; 3687-4177; 3687-3864; 3693 4208; 3693- 3956 3692-3920 3707-3971 3709 -3924 3711-3969 ; 3717- 3950 3728 3998; 3729 3860; 3730 -4031; 3730 3986; 3730 3906; 3731-4008; 3733 3880; 3734- 4215 3741-4211 3744-4212 3746 -4212 3747-4208 ; 3748- 4208 3750 4084; 3748 4214; 3755 -4214; 3754-3841; 3755 4022; 3756-4208; 3756 4077; 3756- 3885 3757-3992 3759-4212 3767 -4198 3767-4150 ; 3773 4020 3782 4215; 3786 4173; 3788 4214; 3788 4208; 3793-4212; 3793-4208; 3795 4212; 3796- 4048 3796-4208 3796-4206 3800 -4208 3806-4212; 3812- 4040 3812 4176; 3812 3985; 3812 -3977; 3812-3989; 3814-4208; 3816-4211; 3818 4213; 3820- 4211 3826-4087 3830-4208 3831 -4210 3832-4205; 3833- 3968 3837 4214; 3840 4089; 3853-4206; 3855-4043; 3856-4113; 3860 4180; 3862 4147; 3862- 4129 3862-4127 3864-4050 3865 -4022 3865-4017 3867- 4028 3869 4098; 3879 4105; 3884 4184; 3884-4164; 3884-4099; 3885 4143; 3884 4202; 3890- 4202 3890-4127 3891-4122 3935 -4166 3940-4202 3940- 4039 3949 4208; 3950 4141; 3963 4207; 3970 4208; 3972 4215; 3974 4214; 4005 4203; 4011- 4210 4013-4213 4027-4204 4036 -4208 4040-4208 4044- 4103 4091 4208;
3941-4123; 3811 4110; 3631-3717; 3905 4123; 3741-3933 3904 4123; 3891-
4212 3866-4123 3797-4123 3843 -4123 3835-4123 ; 3829- 4123 3816-4123; 3811 4123; 3809 -4123; 3813-4123; 3808-4123; 3792-4123; 3756 4123; 3758- 4123 3916-4123 3848-4123 3820-4123; 3851-4123 ; 3914- 4173 3962 -4123;
3969-4123; 54-2 97; 3901-4128; 3812-4003; 3990-4123; 363 1-3696; 4000-4123;
3974-4123; 3749 -3930; 3797-3889; 4004-4123; 4038 4123; 4043 4214; 4045-
4123; 4032-4175 ; 4140-4208; 4140-4213; 3922-3971
117/LG:200704.1 :2001MAR30 | I I"5 64; 307-910; 314-1046; 912-1146; 959-1250;
959-1307; 1069- 1686; 1221-1547; 1224-1536; 1301-1845; 1399-1782; 1405-1782;
1517-1734; 1760 -2194; 1761-2050; 1788-2201; 1893-2148
118/LG:206593.3 :2001MAR30 1-537; 13-376; 16-229; 310-770; 451- 538; 451-
649; 456-652; 4 86-650; 550-868; 567-731; 606-757; 601-1290; 644-1311; 643-
1108; 722-1290; 879-1139; 879-1410; 882-1179; 934-1328; 945-1211; 946-1448;
1004-1549; 1075 -1256; 1101-1519; 1138-1266; 1148-1549
119/LG:223970.1 1:2001MAR30 II i-262; 37-2802; 59-238; 101-258; 750-1131;
842-1078; 895-9 68; 1160-162 9; 1217-1672; 1242-1767; 1258-1664; 1266-1781;
1264-1664; 1330 -1783; 1337-1626; 1344-1783; 1363-1914; 1386-1715; 1404-
1979; 1579-1745 1706-2010; 1859-2452; 1865-2498; 1876-2127; 1876-2109;
1891-2199; 1912 2167; 2027- 2199; 2050-2191; 2099-2676; 2164-2493; 2239-
2395; 2242-2473 2246-2451; 2278-2738; 2290-2460; 2324-2527; 2396-2895;
2496-2976; 2549 2713; 2551- 3012; 2567-2754; 2649-3127; 2672-3117; 2769-
3236; 2780-2984 2780-3237; 2825-3348; 2827-2986; 2865-3264; 2867-3393;
2867-3381; 2875 -3188; 2895-3324; 2924-3001; 2962-3301; 3008-3368; 3012-
3389; 3014-3291 3018-3236; 3020-3133; 3065-3407; 3099-3236; 3099-3195;
3100-3345; 3233 -3726; 3233-3780; 3279-3335; 3471-3626; 3500-3846; 3500-
4108; 3519-4034 3524-3655; 3524-3862; 3524-3645; 3524-3622; 3565-3837;
3563-4025; 3565 3947; 3565-3715; 3593-3844; 3634-4159; 3730-4008; 3814-
4051; 3826-4154 3868-4106; 3869-4135; 3899-4081; 3937-4439; 3941-4154;
3977-4423; 3978 4450; 3980-4443; 3981-4450; 3982-4160; 3984-4453; 3989-
4450; 3991-4450 3992-4449; 3994-4449; 3994-4154; 3994-4450; 3999-4149;
4001-4450; 4005 4453; 4006-4154; 4009-4449; 4010-4453; 4015-4449; 4016-
4620; 4024-4464 4028-4420; 4037 -4477; 4041-4449; 4045-4450; 4049-4576;
4060-4552; 4067 4489; 4073-4454; 4077-4449; 4081-4451; 4089-4482; 4087- Table 5
4335 4101 -4429, 4198 -4482, 4198 -4489 4198 -4453, 4198 -4451 4213 -4449;
4233- -4693; 4233- -4481; 4265- -4453; 4267- -4443; 4270- -4449; 4278- -4489; 4278-
4401 4285 -4483, 4294 -4820 4305 -4800 4347 -4870, 4350 -4579 4354 -4863;
4357- -4488; 4390- -4441; 4397- -4473; 4397- -4482; 4474- -4562; 4477- -4717; 4482-
4934 4517 -4672, 4517 -4753 4517 -4678 4546 -4817 4596 -5087 4602 -5060;
4607- -4984; 4643- -5094; 4743- -5058; 4745- -5017; 4750- -5086; 4790- -5101; 4799-
5033 4875 -5053, 4889 -5460 4955 -5421 4957 -5054, 5021 -5095 5031 -5287;
5141- -5602; 5151- -5212; 5151- -5349; 5153- -5315; 5157- -5422; 5193- -5356; 5193-
5449 5193 -5540, 5193 -5336, 5193 -5357 5199 -5396, 5206 -5265 5208 -5440;
5229- -5451; 5234- -5492; 5243- -5471; 5255- -5805; 5255- -5522; 5256- -5544; 5270-
5517 5270 -5559, 5279- -5488, 5287 -5555 5289 -5547, 5290 -5556 5326 -5473;
5336- -5616; 5351- -5666; 5355- -5736; 5371- -5623; 5372- -5620; 5374- -5641; 5375-
5631 5379 -5716, 5403- -5653, 5424 -5690 5435 -5698, 5457 -5715 5472 -5755;
5477- -5720; 5499- -5656; 5506- -5613; 5510- -5672; 5517- -5772; 5552- -6082; 5564-
5832 5583 -5805, 5585- -5766, 5587 -5783 5606 -5869, 5607 -5858 5608 -5842;
5641- -5938; 5655- -5942; 5656- -5897; 5658- -5865; 5661- -5942; 5661- -5941; 5673-
5973 5689 -5941, 5699- -6193, 5699 -6186 5702 -5977, 5737 -5938 5737- -6005;
5738- -6028; 5746- -5821; 5747- -6037; 5752- -6019; 5755- -6035; 5755- -5996; 5763-
5990 5789 -6107, 5794- -5978, 5799 -6321 5806 -6159, 5807 -6192 5829- -6089;
5829- -6082; 5839- -6117; 5848- -6029; 5849- -6131; 5860- -6228; 5863- -6412; 5873-
5984 5881 -6491, 5881- -6262, 5883 -6141 5888- -6157, 5888 -6121 5894- -6153;
5899- -6123; 5899- -6130; 5903- -6170; 5908- -6133; 5918- -6107; 5918- -6138; 5920-
6199 5926 -6489, 5926- -6175, 5926 -6185 5935- -6220, 5934 -6264 5942- -6367;
5947- -6198; 5947- -6222; 5950- -6199; 5962- -6167; 5965- -6178; 5965- -6202; 5965-
6263 5965 -6190, 5965- -6198, 5965 -6220 5965- -6213, 5967 -6197 5970- -6418;
5970- -6496; 5979- -6520; 5982- -6250; 5995- -6224; 6029- -6309; 6030- -6254; 6054-
6257 6057 -6501, 6072- -6381, 6074 -6366 6075- -6362, 6079 -6496 6102- -6200;
6103- -6479; 6106- -6492; 6109- -6333; 6109- -6487; 6109- -6332; 6109- -6269; 6111-
6348 6111 -6358, 6114- -6340, 6114 -6310 6126- -6367, 6128 -6388 6128- -6375;
6132- -6389; 6134- -6522; 6135- -6352; 6145- -6385; 6147- -6333; 6172- -6420; 6182-
6472 6189 -6430, 6189 -6414, 6195 -6494 6218- -6489, 6221 -6757 6234- -6475;
6252- -6676; 6266- -6492; 6269- -6646; 6274- -6515; 6288- -6586; 6288- -6770; 6288-
6527 6295 -6634, 6309 -6550, 6316 -6579 6331- -6496, 6351 -6796 6358- -6648;
6358- -6599; 6371- -6859; 6376- -6621; 6377- -6822; 6377- -6636; 6380- -6607; 6385-
6821 6405 -6860, 6405 -6510, 6419 -6656 6435- -6857, 6437 -6857 6437- -6687;
6438- -6857; 6439- -6857; 6444- -6797; 6448- -6860; 6449- -6863; 6449- -6858; 6450-
6857 6461 -6702, 6461- -6684, 6462 -6735, 6462- -6835, 6464- -6858 6470- -6857;
6473- -6702; 6473- -6857; 6476- -6857; 6481- -6704; 6483- -6857; 6496- -6855; 6499-
6703 6505 -6860, 6512 -6648, 6515 -6664, 6519- -6858, 6520- -6863 6521- -6862;
6527- -6860; 6529- -6858; 6529- -6857; 6530- -6857; 6531- -6739; 6532- -6857; 6535-
6763 6536 -6855, 6539 -6861, 6539 -6857, 6546- -6857, 6549- -6856 6552- -6857;
6554- -6863; 6555- -6857; 6557- -6739; 6577- -6652; 6608- -6829; 6640- -6875; 6665-
7025 6686 -7027, 6718- -6857, 6719 -6854 6722- -7031, 6753- -7032 6777- -6983;
6784- -7025; 6791- -6857; 6827- -7014; 6834- -7025
120/LG:227500.5 2001MAR30 | 1-198; 36-297; 82-317; 87- -644; 89-719; 91-371
103-511; 239-482 !; 259 -802; 272-801; 270-802 297- -802; 313-454; 313-647;
313-451; 316-801; 450 -681; 450-817; 521-871 615- -1142; 620-1217; 635-1217;
692-1234; ' 757-906; 809-130' '; 809 -1335, 809-: L414; 809-1398; 809-1363; 876-
1204 924- L255; 924-1194; 924-1035; 944-1262; 98 )-1199 991- -1464; 1176-
1385 1193 -1690, 1320 -1549, 1323 -1943, 1484- -2071, 1575- -2099 1635- -1806;
1695- -2016; 1698- -1945; 1698- -2222; 1726- -1852; 1733- -1847; 1751- -2357; 1757-
2189 1758 -2020, 1775- -2112, 1818 -2410, 1828- -2000, 1851- -2319, 1853- -2424;
1855- -2412; 1982- -2236; 2177- -2237; 2311- -2582; 2332- -2588; 2335- -2588; 2340-
2665 2359 -2588, 2375- -2934, 2375- -2551, 2389- -2588; 2389- -2677, 2407- -2588;
2463- -2704; 2463- -2588; 2490- -2746; 2497- -2780; 2516- -2760; 2623- -3125; 2623-
3018 2623 -3073, 2647- -3013, 2648 -3056, 2662- -3041; 2683- -3279, 2733- -2819;
2817- -3308; 2877- -3272; 2877- -3087; 2877- -3344; 2890- -3504; 2891- -3344; 2893-
3344 2894 -3015, 2906- -3345, 2916- -3344, 2917- -3344; 2924- -3344, 2945- -3344;
2947- -3135; 2951- -3344; 2958- -3344; 2998- -3162; 3008- -3231; 3049- -3367; 3069-
3351 3078 -3291, 3105- -3320, 3106- -3344, 3191- -3457 Table 5
121/LG:227722 .7 : 2001 AR30 | | 1472-1886 ; 1299-1625 ; 1153-1589 ; 1481-1586 ; 823-1368; 791-1206 ; 569-934 ; 638-932 ; 347-931 ; 711-827 ; 101-657 ; 1-515 ; 4- 255
122/LG:229 105.1 :2001MAR30 | | 1-454; 14 -620; 130-633; 1 77-23 8; 214 -699; 214- 454; 223-486; 232-488; 311-603; 316-830; 343-698; 343- 676; 404-958; 409- 674; 409-916; 479-733; 496-746; 603-1055; 666-925; 666 -1177 ; 681-1203; 703- 966; 703-950; 801-1086; 817-1088; 824-1055; 824-1214; 861-1092; 885-1297; 900-1000; 947-1209; 972-1324; 972-1217 ; 1033-1334; 103 3-1215; 1061-1285; 1070-1315; 1168-1397; 1149-1401; 1181-1648; 1282-1882; 1282-1893; 1290- 1513; 1299-1414 ; 1363-1960; 1371-1691 1413-1971; 1396-1960 1399-1960; 1400-1642; 1400-1766; 1414-1960; 1432-1912; 1444-1960; 1468-1738; 1477- 1952; 1482-1916 ; 1492-1822; 1511-1777 1552-2042; 1636-1874 1635-1692; 1665-1908; 1717-1959; 1718-2129; 1718-1976; 1807-2366; 1812 2108; 1828- 2368; 1846-2323 ; 1849-2366; 1853-2368 1854 2107; 1854-2398 1863-2352; 1881-1977; 1916-2392; 1917-2362; 1942 2052; 1979-2401; 1991-2193; 2001- 2358; 2013-2402 ; 2020-2408; 2025-2402 2026 2402; 2031-2173 2045-2390; 2045-2391; 2048-2401; 2067-2321; 2067 2380; 2067-2368; 2083-2402; 2096- 2274; 2103-2404 ; 2110-2398; 2111-2397 2115 2350; 2115-2392 2131-2405; 2137-2406; 2162-2397; 2184-2402; 2259 2352; 2259-2392; 2278-2402; 2314- 2416; 2322-2408 123/LG:233761.4 :2001MAR30 || 1-534; 66-287; 307-872; 334-773; 335-787; 343- 969; 343-839; 345-917; 367-646; 368-793; 368-806; 368-664; 368-818; 368- 561; 368-620; 368-508; 368-768; 368-803; 396-766; 399-711; 410-843; 438- 1017; 455-1016; 581-842; 620-885; 620-886; 550-791; 620-1122; 655-859; 690- 952; 800-1001; 820-1173; 851-937; 898-1176; 940-1372; 984-1168; 1087-1378; 1088-1443; 1066-1301; 1074-1282; 1099-1358; 1099-1410; 1236-1484; 1229- 1724; 1217-1402 ; 1247-1504; 1247-1821; 1250-1512; 1256-1530; 1264-1466; 1305-1912; 1361-1653; 1367-1669; 1397-1639; 1448-1923; 1448-1657; 1467 1935; 1474-1881 ,- 1494-1749; 1528-1837; 1538-2149; 1538-1602; 1563-1831 1593-2007; 1646-1894; 1657-2218; 1657-1885; 1657-2225; 1661-2208; 1688- 1974; 1712 -1885 ; 1741-2263; 1755-1981; 1820-2076; 1820-2087; 1829-2075 1867-2153; 1875-2109; 1881-2121; 1882-2123; 1905-2171; 1911-2451; 1930- 2207; 1941-2194 ; 1951-2067; 1951-2193; 1974-2251; 2028-2181; 2033-2289 2062-2225; 2105-2353; 2109-2369; 2114-2391; 2122-2367; 2175-2358; 2202 2380; 2202-2463 ; 2210-2802; 2223-2805; 2230-2454; 2275-2480; 2276-2512 2277-2528; 2292-2524; 2325-2590; 2332-2614; 2333-2543; 2368-2839; 2372 2790; 2374-2745 ; 2378-2795; 2383-2839; 2389-2843; 2416-2679; 2417-2839 2418-2720; 2422-2686; 2424-2788; 2426-2842; 2427-2683; 2441-2798; 2444 2657; 2450-2844 ; 2451-2683; 2454-2836; 2480-2839; 2480-2793; 2481-2785 2483-2839; 2506-2796; 2508-2608; 2541-2728; 2571-2787; 2602-2839; 2620 2794; 2641-2856 2656-2833; 2668-2839; 2674-2791; 2710-2841; 2718-2851 2728-2873; 2736 2803; 2788-2839 124/LG:234326.67:2001MAR30 || 1-4628; 1-237; 98-180; 149-561; 270-487; 516- 1057; 757-1160; 1036-1524; 1071-1588; 1098-1649; 1135-1373; 1151-1450; 1176-1525; 1238 1841; 1260-1628; 1458-1576; 1605-2123; 1641-1968; 1681- 2054; 1772-2098 1776-2301; 1869-2110; 1884-2145; 1891-2212; 1921-2319; 2026-2293; 2081 2356; 2117-2325; 2193-2367; 2209-2412; 2216-2334; 2568- 3084; 2581-2840 2586-2918; 2691-3038; 2706-2923; 2706-3108; 2715-3055; 2719-3092; 2733 3185; 2733-2944; 2795-3074; 2804-3228; 2916-3124; 2916- 3127; 2923 -3486 2956-3165; 3042-3278; 3110-3366; 3166-3459; 3176-3437; 3187-3457; 3193 3427; 3204-3456; 3228-3488; 3233-3485; 3309-3421; 3329- 3427; 3425-3677 3440-3690; 3468-3667; 3502-3765; 3512-3764; 3521-3746; 3807-4002; 3856 4158; 3877-4125; 3883-4093; 3882-4130; 3889-4381; 3901- 4140; 3903 -4004 3904-4140; 3912-4194; 3925-4002; 3928-4179; 3930-4178; 3943-4167; 3945 4128; 3945-4184; 3946-4236; 3946-4266; 3946-4096; 3951- 4264; 3951-4120 3969-4240; 3986-4258; 4027-4566; 3995-4213; 4013-4322; 4019-4334; 4019-4248; 4020-4301; 4023-4267; 4023-4174; 4023-4180; 4023- 4190; 4023-4240 ; 4023-4281; 4023-4264; 4023-4196; 4023-4241; 4023-4251; 4023-4198; 4023-4243; 4023-4250; 4023-4114; 4023-4284; 4023-4257; 4023- 4138; 4023-4242 ; 4027-4209; 4027-4286; 4028-4116; 4029-4291; 4030-4258; Table 5
4031- -4285; 4042- -4262; 4044- -4293; 4050- -4626; 4052- -4286; 4056- -4291; 4060-
4325, 4060 -4607, 4060- -4347 4066- -4318, 4067- -4419, 4067 -4250, 4071 -4288;
4085- -4347; 4104- -4346; 4109- -4334; 4111- -4367; 4111- -4381; 4128- -4373; 4129-
4438 4139 -4425, 4144- -4412 4161- -4633 4164- -4420, 4165 -4633, 4167 -4413;
4168- -4628; 4169- -4628; 4175- -4628; 4175- -4335; 4176- -4454; 4177- -4630; 4178-
4628 4179 -4429, 4179- -4633 4181 -4628 4181- -4627, 4182 -4428 4183 -4314;
4185- -4632; 4186- -4426; 4186- -4428; 4187- -4628; 4188- -4636; 4189- -4424; 4199-
4469 4200 -4482, 4201- -4628 4202 -4452 4203- -4628, 4206 -4435 4207 -4628;
4207- -4464; 4222- -4443; 4222- -4628; 4228- -4475; 4229- -4468; 4231- -4483; 4231-
4487, 4236 -4628, 4241- -4511 4242- -4628, 4246- -4627, 4248 -4446, 4248 -4628;
4249- -4634; 4250- -4523; 4252- -4629; 4252- -4503; 4257- -4631; 4259- -4527; 4261-
4512, 4265 -4627, 4269- -4507 4274 -4632, 4282- -4514, 4290 -4630, 4290 -4626;
4293- -4579; 4293- -4512; 4297- -4557; 4300- -4518; 4301- -4531; 4303- -4628; 4305-
4586 4308 -4596, 4330- -4628 4325 -4628, 4325- -4548, 4331 -4634, 4335 -4542;
4338- -4595; 4341- -4629; 4345- -4629; 4343- -4588; 4344- -4631; 4349- -4611; 4349-
4498 4349 -4605, 4351- -4628 4351 -4596 4352- -4628, 4353 -4596, 4356 -4608;
4360- -4616; 4366- -4541; 4372- -4589; 4376- -4616; 4378- -4461; 4381- -4631; 4392-
4633 4392 -4628 4393- -4445 4395 -4628 4397- -4628, 4403 -4630, 4406 -4627;
4406- -4632; 4418- -4628; 4452- -4628; 4454- -4628; 4454- -4632; 4455- -4628; 4459-
4630 4472 -4628 4491- -4698 4503 -4628 4511- -4626 4539 -4671 4201 -4545;
3412- -3677; 4022- -4217; 3475- -3719; 3477- -3689; 3569- -3775; 3798- -4004; 3522-
3723 493- 583; 3522-3616; 4566-4626; 4023-4088
125/LG:236056.27:2001MAR30 II i-- 139; 44-614 508- -1056; 508-1055; . 313-729;
514-756; 518-999; 518- -777; 607-1273; 631-1071; 667-1318; 667-1308 ; 710-
1308 713- 1308; 723-1074; 722-1093; 724-1246; 733-1308 ; 738- -1267; 742-1205;
750-1329; 751-1254; 757-1040; 760-1396; 795- -1104, 836- L198; 838-1150; 889-
1122 894- 1168; 913-1179; 914-1121; 915-1126; 918-1171 ; 922- -1198; 903-1308;
931-1209; 937-1523; 937-1159; 949-1548; 952- -1573 952- L238; 953-1232; 967-
1174 991- 1314; 995-1216; 998-1484; 1002-1561; 1007-1193; 1007-1280; 1008-
1236 1034 -1345 1038 -1285 1057 -1288 1062- -1308 1062 -1295 1064 -1302;
1064- -1224; 1068- -1308; 1069- -1308; 1070- -1308; 1072- -1308; 1085- -1292; 1086-
1310 1088 -1331 1100- -1355 1114 -1354 1122- -1602, 1131 -1338, 1158 -1424;
1182- -1308; 1196- -1473; 1203- -1680; 1203- -1478; 1203- -1311; 1246- -2578; 1270-
1662 1315 -1834 1309- -1866 1315 -1626 1315- -1906, 1315 -1815, 1315 -1872;
1316- -1765; 1316- -1735; 1315- -1582; 1315- -1528; 1317- -1588; 1317- -1555; 1321-
1709 1327 -1419 1330- -1597 1332 -1640 1337- -1583 1365 -1555, 1368 -1611;
1367- -1539; 1372- -1588; 1386- -1578; 1403- -1631; 1406- -1786; 1411- -1694; 1425-
1638 1427 -1741 1437 -1991 1438 -1708 1456- -1894 1456 -1716 1464 -1683;
1464- -1671; 1473- -2063; 1473- -1725; 1475- -1689; 1487- -1717; 1495- -1779; 1511-
1774 1528 -1703 1512 -2086 1535 -1725 1543 -1855 1556 -2154 1557 -2105;
1561- -2109; 1574- -2123; 1582- -2148; 1592- -2151; 1592- -1831; 1599- -1851; 1606-
1964 1606 -1850 1612- -1814 1629 -2025 1629- -2241, 1645 -1914, 1632 -1734;
1657- -2184; 1657- -1879; 1657- -1848; 1659- -1825; 1668- -1922; 1671- -2236; 1671-
1932 1677 -1884 1689- -1854 1700 -1950 1703- -2014, 1712 -2383, 1733 -2006;
1748- -2024; 1748- -1985; 1751- -2012; 1760- -1983; 1744- -2086; 1754- -2002; 1788-
2163 1811 -2268 1813 -2246 1815 -2072 1815- -2085, 1822 -2104, 1825 -2358;
1834- -2016; 1835- -2120; 1844- -2042; 1847- -2091; 1851- -2002; 1854- -2384; 1858-
2080 1862 -2102 1863 -2153 1871 -2085 1873 -2106 1875 -2132 1878 -2471;
1880- -2135; 1879- -2201; 1885- -2304; 1918- -2446; 1933- -2416; 1945- -2537; 1974-
2234 1987 -2266 1988 -2269 1991 -2234 1995 -2475 1996 -2527 2000 -2289;
2003- -2263; 2007- -2257; 2016- -2277; 2017- -2263; 2022- -2539; 2022- -2540; 2028-
2574 2027 -2399 2029 -2285 2031 -2460 2039 -2322 2053 -2520 2068 -2576;
2070- -2481; 2081- -2504; 2080- -2472; 2080- -2291; 2111- -2582; 2116- -2582; 2123-
2387 2125 -2575 2126- -2575 2129 -2583, 2132- -2582, 2139 -2575, 2140- -2534;
2144- -2579; 2151- -2407; 2152- -2577; 2160- -2576; 2164- -2351; 2167- -2578; 2167-
2427 2167 -2581 2170 -2379 2175 -2325, 2176- -2567, 2177 -2578, 2177- -2418;
2188- -2450; 2191- -2581; 2191- -2415; 2194- -2433; 2197- -2554; 2199- -2420; 2206-
2443 2213 -2582 2216 -2576 2217 -2575, 2217- -2480, 2217 -2428, 2218- -2541;
2218- -2498; 2218- -2516; 2223- -2485; 2223- -2409; 2233- -2578; 2236- -2463; 2237-
2580 2246 -2559 2248 -2434 2250 -2501, 2250- -2465, 2250 -2600, 2252- -2577; Table 5
2253-2576; 2261- 2447; 2261 -2541; 2262-2539; 2263-2549; 2263-2581; 2265 2585; 2266-2511; 2270-2580 ; 2270-2579; 2269-2542; 2272-2575; 2274-2578 2276-2581; 2276-2575; 2277-2566; 2289-2576; 2305-2575; 2306-2583; 2312 2575; 2317-2465; 2326-2567 ; 2330-2575; 2336-2581; 2341-2575; 2352-2541 2356-2581; 2365-2575; 2377-2528; 2379-2575; 2397-2579; 2417-2573; 2418 2576; 2424-2579; 2432-2542 ; 2456-2579; 2455-2567; 2461-2579; 2468-2577 2480-2575; 2499-2582; 2512-2575 126/LG:253889.31 2001MAR30 II i- 584; 73-1809; 74- -617; ' 189-1 035; 504-782; 508-776; 563-789 566-1002 ; 566- 812; 607-1040; 628-861 703-1030; 708-1081; 735-1081; 753-1072; 762-999; 783 -1036, 790-934; 811-1075; 814-930; 816- 1071; 827-1048; 832-940; 877-132 4; 890-1161 902- -1332; 912-1150; 933-1198; 945-1024; 961-1510; 983-1252; 99 6-1215; 1023-1580; 1032-1110; 1043-1268; 1068-1337; 1094-1204; 1096-1362; 1109- -1567; 1123- -1224; 1135-1381; 1154- 1412; 1167-1409; 1177-1442 ; 1202 -1318, 1202- -1441, 1230 -1409 1248-1462; 1249-1450; 1257-1501; 1271-1569; 1282- -1832; 1282- -1779; 1287 1795; 1299- 1502; 1291-1522; 1308-1779 ; 1317 -1821, 1317- -1587, 1332 -1811 1333-1820; 1341-1629; 1346-1811; 1355-1823; 1358- -1823; 1366- -1777; 1368 1821; 1370- 1820; 1376-1850; 1378-1820 ; 1378 -1516 1381- -1820, 1381 -1814 1382-1832; 1383-1850; 1387-1820; 1394-1820; 1398- -1823; 1404- -1814; 1406 1854; 1407- 1814; 1408-1821; 1412-1821 ; 1413 -1829 1417 -1854 1417 -1814 1416-1727; 1416-2016; 1418-1641; 1420-1792; 1418- -1799; 1422- -1836; 1423 1814; 1422- 1591; 1423-1831; 1425-1832 ; 1425 -1811, 1426- -1820, 1433- -1832 1441-1832; 1449-1973; 1449-1820; 1452-1832; 1452- -1823; 1451- -1782; 1453 1850; 1453- 1827; 1458-1856; 1458-1821 ; 1459 -1821, 1459- -1820, 1460- -1821 1460-1820; 1461-1811; 1462-1810; 1462-1818; 1466- -1821; 1469- -1762; 1469 1717; 1469- 1708; 1472-1775; 1474-1773 ; 1475 -1836, 1480 -1833, 1480 -1766 1480-1744; 1481-1855; 1483-1855; 1483-1820; 1486- -1854; 1486- -1832; 1487 1814; 1494- 1818; 1507-1796; 1515-1835 ; 1515 -1811, 1543 -1821, 1538 -1704 1546-1820; 1559-1777; 1577-1822; 1578-1814; 1578- -1811; 1580- -1820; 1602 1789; 1602- 1762; 1610-1814; 1610-1830 ; 1627 -1811, 1629 -2138, 1649 -2236 1658-1818; 1680-2236; 1688-1899; 1716-2130; 1719- -2006; 1719- -1985; 1738 1820; 1793- 2289; 1807-2047; 1812-2285 ; 1818 -2353, 1825- -2073, 1841- -2133 1857-2115; 1857-2109; 1867 2084; 1906-2108; 1907- -2134; 1929- -2150; 1935-2473; 1955- 2494; 1969-2447; 1995-2291 ; 1995 -2589, 1995- -2236, 2010 -2259 2016-2504; 2023-2286; 2026-2501; 2026-2300; 2034- -2237; 2037- -2261; 2040 2545; 2046- 2296; 2057-2514; 2061-2299 ,- 2094 -2291, 2103- -2356, 2110 -2540 2112-2542, 2113-2545; 2126-2542; 2130-2547; 2132- -2350; 2136- -2364; 2136 2360; 2141- 2540; 2145-2447; 2152-2540 ; 2157 -2539, 2175- -2284, 2193 -2613 2198-2543; 2196-2352; 2226-2544; 2260-2517; 2296- -2540; 2344- -2624; 2410 2613; 2413- 2613; 2413-2524; 2418-2542 ; 2486 -2881, 2486 -2742, 2501 -3051 2501-2631; 2647-2796; 2652-3126; 2653-3074; 2654- -3086; 2682- -3217; 2669-2920; 2672- 2842; 2682-3194; 2682-3223 ,- 2685 -2952, 2717- -2986, 2718- -3302 2740-2956; 2784-2993; 2807-3271; 2807-3027; 2814- -3320; 2814- -3043; 2819 3001; 2822- 3301; 2822-3279; 2822-3090 ; 2845 -3005, 2868- -3103, 2869- -3123 2956-3202; 2968-3146; 2970-3271; 2974-3468; 2996- -3156; 2997- -3097; 3003 3229; 3042- 3227; 3057-3301; 3080-3337 ; 3094 -3556, 3111- -3625, 3111 -3338 3111-3436; 3127-3373; 3128-3374; 3154-3555; 3171- -3438; 3201- -3766; 3207 3729; 3216- 3590; 3228-3457; 3232-3556 ; 3252 -3519, 3256 -3467, 3260 -3431 3266-3729; 3271-3436; 3347-3771; 3348-3766; 3356- -3623; 3366- -3753; 3374 3767; 3425- 3664; 3450-3703; 3453-3691 ; 3469 -3555, 3491 -3766, 3493 -3585 3531-3732; 3536-3768; 3536-3766; 3542-3766; 3556- -3823; 3586- -3727; 3620 3854; 3646- 3765; 3660-3766; 3681-3854 ; 3712 -3800, 3756- -3854, 3768- -3854 1413-1820; 1411-1820; 2034-2274 127/LG:270833.13 5:2001MAR3 0 || 1-515; 1-251; 206-844; 375-867; 375-653 397-867; 630-968 ; 709-1019 ; 754-1301; 776-828; 788-1015; 816-1094; 1063 1331; 1063-1314; 1068-1310 ; 1068-1328; 1080-1330; 1099-1315; 1101-1310 1109-1315; 1110-1315; 1110-1313; 1115-1315; 1115-1310; 1117-1317; 1118 1319; 1130-1322; 1133-1332 ; 1133-1299; 1156-1313; 1159-1316; 1158-1279 1170-1315; 1180-1315; 1192-1315; 1195-1317; 1198-1313; 1199-1313; 1199 Table 5
1317; 1201-1317; 1203-1315 ; 1210-1315 ; 1210 -1313 1221 -1315; 1224-1317; 1247-1315; 1249-1313; 1249 -1315 ; 1263 -1317 ; 538-778 128/LG:292613.7: 2001MAR30 I I 1-562 ; 1-270 ; 1-246 481- 905; 496-908 825 1372; 838-1283; 838-1061; 841-1041 ; 920-1200; 96 8-1140 ; 1029-1223; 1056 1332; 1113-1343; 1119-1697 1119- 1448 1119-1377 1139-1654 1192 1850 1193-1711; 1192-1424; 1193 -1461; 1195 1469; 1265 1379; 1286 1756; 1362 1698; 1389-1692; 1495-1784 1507- 1809 1571-1692 1698-2269 1700 1972 1706-1930; 1808-2076; 1832 2285; 1869 2124; 1887 2064; 1887 2047; 1887 1988; 1925-2025; 1941-2373 1960- 2218 1994-2392 2002-2260 2013 2208 2036-2565; 2039-2179; 2071 -2318; 2074 2285; 2097 2339; 2121 2371; 2138 2358; 2173-2633; 2193-2664 2201- 2532 2269-2521 2314-2601 2333 2585 2337-2553; 2361-2626; 2368 -2891; 2368 2612; 2368 2571; 2380 2640; 2389 2881; 2429-3046; 2439-2677 2439- 2560 2447-2735 2463 -2715 2480 2878 2493-2742; 2494-2781; 2496 -2779; 2526 3000; 2533 -3003; 2587 2866; 2597- 2835; 2629-2881; 2631-2906 2633- 2863 2653-3156 2695-3156 2695-3155 2695-3153; 2710-3208; 2729 -3156; 2774 3044; 2774 -2918; 2775 2991; 2776- 3155; 2781-3023; 2788-3156 2834- 3047 2837-3269 2837-3047 2841 3156 2848-3156; 2849-3070; 2855 -3145; 2880 3117; 2889 -3269; 2889 3155; 2892- 3428; 2892-3092; 2921-3191 2937- 3105 2953-3375 2954-3371 3003 3379 3038-3324; 3038-3319; 3123 3434; 3156 3371; 3166 -3482; 3190 3651; 3190- 3401; 3201-3480; 3273-3469 3282- 3870 3282-3523 3288-3911 3296 3572 3299-3866; 3318-3607; 3322 3639; 3345-3772 3345 3561; 3372 3913; 3373 3604; 3389-3874; 3397-3913 3421 -3944 3446-3910 3452-3681 3454 3913 3453-3910; 3463-3913; 3496 3940; 3497 3942; 3500 3773; 3516 3916; 3511 3914; 3524-3918; 3547-3911 3553 -3908 3553 -3904 3555-3984 3557 3873 3558-3908; 3562-3660; 3589 3844; 3590 3798; 3591 3794; 3613 -3972; 3616 4064; 3616-3912; 3620-3908 3621 -3908 3641-3982 3686-3909 3689 3972 3738-4015; 3751-3910; 3760 4216; 3773 3915; 3774 4028; 3778 3879; 3779 3913; 3786-4318; 3816-3913 3834 -4186 3848-3913 3848-3931 3847 3937 3908-4098; 3984-4393; 3984 4207; 4044 4321; 4044 4302; 4068 4306; 4120 4387; 4155-4432; 4174-4423 4175 -4568 4175-4379 4181-4393 4181 4430 4202-4502; 4202-4441; 4238 4819; 4367 4633; 4402 4687; 4434 4887; 4438 4699; 4481-4936; 4482-4706 4484 -4603 4532-5044 4559-5094 4560 5131 4566-4926; 4579-4825; 4581 4799; 4632 5094; 4632 -4899; 4683-5134; 4704 4944; 4717-5131; 4725-5131 4730 -5132 4729-4928 4735-4979 4736 5131 4747-5113; 4747-5094; 4747 -5047; 4747-5041; 4760 -5131; 4783-5038; 4787 5127; 4849-5132; 4987-5131 129/LG:331546.2: 2001MAR30 I I I-5 37; 1 0-582; 16-3 105; 34-397 ; 39-3 06; 39- 357; 43-491; 39-416; 39-28 0; 39- 300; 43-617 ; 39-374; 45-629 ,- 42-531; 44- 562; 53-187; 50-316; 50-23 4; 54- 234; 75-342 ; 143 -649; 178-737; 191-399; 467-1075; 489-854; 494-777 ; 517- 1039; 537-1110; 553-811; 560-788; 614-1124; 639-1160; 671-1214; 786-98 1; 808 -1373 811-1419; 830-1332; 851-1324; 881- 1154; 919-1379; 966-1201; 984-15 88; 996-1238; 1005-1242; 1024-1253; 1040- 1247; 1105-1306; 1119-1379 1122 -1512 1148-1397 ; 1279-1527 1313-1572; 1394-1965; 1465-1734; 1505 1783; 1522 1778; 1537-1653; 1560-1827; 1590- 1840; 1602-1702; 1604-1830 1604-1935 1657-2067 ; 1665-2227 1677-2042; 1678-1885; 1692-1886; 1704 -2054; 1708 2223; 1713-1993; 1718-2278; 1760- 1920; 1780-1950; 1780-2213 1788-2362 1842 -2250 ; 1845-2426 1847-1935; 1858-2369; 1898-2267; 1898 -2109; 1918-2163; 1938-2117; 1955 2067; 1956- 2192; 1965-2169; 1990-2456 2043-2214 2043 -2305 ,- 2082-2331 2099-2570; 2104-2359; 2108-2350; 2113 2599; 2115 2214; 2117-2309; 2119 2288; 2121- 2363; 2119-2192; 2124-2682 2131-2352 2131-2587 ; 2185-2441 2208-2374; 2212-2467; 2216-2480; 2213 2374; 2224-2504; 2251-2519; 2256 2805; 2276- 2563; 2290-2677; 2289-2712 2294-2750 2297-2574 ; 2332-2594 2347-2808; 2349-2710; 2359-2751; 2362 2702; 2361-2626; 2371-2988; 2371-2933; 2377- 2657; 2377-2624; 2380-2952 2389-2795 2396-2935 ,- 2404-2757 2404-2689; 2409-2667; 2411-2874; 2418 2671; 2423-2626; 2427-2625; 2469-3030; 2474- 2956; 2472-2712; 2487-2747 2491-2704 2508-2758 ; 2515-3010 2517-2813, 2517-2606; 2517-2803; 2517 -2821; 2521-2822; 2523-2925; 2536 2959; 2546- 2772; 2547-2778; 2553 -2755 2559-3158 2567-2861 ; 2579-2890 2595-2856; Table 5
2604-2862; 2622-3122; 2630-2892; 2630-3177; 2633-2861; 2660-3166; 2674- 3099; 2684 3196; 2701-2948; 2704-3189; 2713-3104; 2718-3197; 2722-2960; 2722-2968; 2760-3210; 2770-3209; 2773-3015; 2779-3170; 2783-3210; 2796- 3030; 2801-3206; 2812-3215; 2815-3199; 2816-3087; 2822-3212; 2823-3210; 2824-3203; 2826-3212; 2830-3206; 2853-3115; 2855-3209; 2864-3204; 2864- 3201; 2864-3210; 2864-3209; 2866-3212; 2884-3078; 2878-3209; 2889-3209; 2905-3209; 2907-3199; 2907-3170; 2915-3210; 2915-3173; 2920-3204; 2930- 3209; 2937-3206; 2957-3210; 2960-3215; 2965-3184; 2967-3204; 2969-3209; 2970-3196; 2990-3209; 2995-3209; 3013-3196; 3018-3212; 3032-3208; 3054- 3189; 3061-3206; 3067-3214; 3092-3209; 3158-3450 130/LG:332027.6:2 001MAR30 || 1-539; 379-847; 392-608; 394-1148; 398-967; 422-1064; 428-787 ; 642-1264; 690-888; 838-1296; 897-1080; 982-1632; 1066- 1632; 1104-1457; 1164-1453; 1370-1459; 1373-1619; 1495-1736; 1545-2138; 1575-1899; 1578-1765; 1618-1775; 1891-2407; 2032-2268; 2075-2447; 2082- 2446; 2119-2523; 2126-2446; 2314-2550; 2491-2755; 2491-2889; 2503-2715; 2586-2953; 2586-2808; 2661-2929; 2674-2860; 2804-3042; 2870-3120; 2880- 3286; 2929-3408; 2929-3128; 2949-3197; 2951-3195; 2973-3425; 2973-3116; 3023-3338; 3028-3267; 3067-3328; 3070-3304; 3120-3347; 3194-3417; 3195- 3417; 3218-3368; 3223-3372; 3226-3368; 3234-3368; 3251-3417; 3279-3370; 3302-3370; 3315-3368; 3325-3456; 3373-3456 131/LG:336998.1:2 001MAR30 || 1-5526; 1-11708; 30-516; 30-512; 30-471; 30- 353; 30-156; 30-477; 30-465; 31-260; 39-651; 96-530; 98-534; 106-527; 107- 412; 120-462; 131-609; 157-384; 182-373; 224-489; 261-396; 296-610; 413- 556; 455-606; 448-707; 448-664; 463-839; 609-1104; 632-948; 692-1273; 889- 1349; 897-1365; 916-1474; 929-1367; 963-1509; 1022-1410; 1052-1475; 1127- 1489; 1161-1426; 1202-1771; 1279-1668; 1284-1735; 1309-1852; 1355-1759; 1408-1680; 1408-1643; 1543-1999; 1571-2182; 1576-1747; 1609-1993; 1611- 1997; 1627-1838; 1642-2110; 1653-1993; 1731-1997; 1733-1994; 1747-1997; 1751-1993; 1866-2290; 1882-2427; 1968-2265; 1971-2417; 1975-2417; 2045- 2417; 2142-2402; 2208-2706; 2268-2809; 2431-2955; 2439-2688; 2504-2793; 2532-2671; 2570-3071; 2605-3199; 2605-2689; 2623-3058; 2682-3082; 2727- 2979; 2750-3088; 2788-3398; 2950-3434; 2955-3437; 2954-3225; 2984-3437; 2992-3437; 3046-3265; 3044-3195; 3046-3437; 3059-3264; 3080-3437; 3091- 3437; 3167-3438; 3173-3419; 3187-3457; 3233-3556; 3450-3867; 3745-6783; 3846-4092; 3964-4354; 4059-4418; 4077-4369; 4135-4350; 4144-4354; 4330- 4762; 4861-5175; 5364-5865; 5589-6148; 5721-6290; 5815-6398; 6191-6796; 6255-6859; 6280-6825; 6504-7063; 6531-6850; 6543-6850; 6552-6850; 6556- 6847; 6580-6851; 6595-6850; 6611-6848; 6630-6853; 6701-7376; 7013-7651; 7526-8129; 7627-8020; 7717-8020; 7833-8020; 7837-8492; 7887-8143; 7916- 8184; 8289-8881; 8434-8984; 8501-9044; 8526-9080; 8586-8830; 8669-9231; 8782-9184; 8794-9184; 8814-9110; 9008-9559; 9024-9238; 9050-9401; 9047- 9280; 9131-9484; 9137-9480; 9347-9484; 9471-9741; 9646-10042; 9850-10451; 9849-10320 ; 9850-10441; 9898-10176; 10126-10441; 10439-10927; 10439-10867; 10459-10739; 10461-10712; 10487-10727; 10586-10780; 10853-11006; 10938-
11341 10990-11491; 11113-11388; 11155-11381; 11181-11725; 11216-11860;
11260-11793; 11264-11707; 11266-11550; 11269-11731; 11689-11952; 11748-
12262 11897-12132; 11990-12583; 12017-12281; 12125-12684; 12125-12638; 12125 12377; 12128-12643; 12136-12718; 12214-12499; 12230-12446; 12245- 12889 12251-12394; 12251-12453; 12323-12548; 12326-12576; 12400-12915; 12398 12704; 12418-12850; 12493-12636; 12541-12731; 12611-13040; 12616- 12912 12617-12790; 12619-13154; 12635-12979; 12702-13152; 12718-12969;
12730-13049; 12865-13167; 12948-13164; 12955-13560; 12965-13253; 13023-
13285 13027-13222; 13030-13489; 13077-13357; 13104-13440; 13114-13399; 13115 13378; 13130-13545; 13134-13461; 13142-13458; 13152-13744; 13153- 13455 13169-13553; 13175-13633; 13198-13455; 13204-13492; 13213-13478; 13216 13511; 13235-13481; 13252-13728; 13252-13497; 13309-13571; 13316- 13520 13347-13562; 13370-13611; 13394-13452; 13400-13694; 13404-13982; 13443 13666; 13455-13947; 13461-14005; 13485-14055; 13485-13756; 13529- 14137 13540-14150; 13543-13767; 13546-13873; 13583-13829; 13589-13874;
13589-13740; 13592-14132; 13606-13687; 13609-13864; 13613-14123; 13622- Table 5
14131 13622- 14155 13622- 13860 13624-13935 13629- 13832 13641- 14029 13642 13928; 13647 13966; 13649 13885; 13651 13995; 13662 13837; 13669 13888 13680- 13955 13683- 13773 13713-14178 13719- 14205 13725- 13960 13759 14232; 13767 14241; 13769 14242; 13769 14023; 13776 14249; 13778 14083 13781- 14243 13781- 14247 13790-14241 13790- 14054 13790- 14249 13803 14045; 13805 14059; 13805 14054; 13805 14045; 13805 14035; 13807 14070 13807- 14025 13808-•14241 13810-14243 13810- 14242 13814- 14242 13814 14245; 13821 14249; 13824 14242; 13830 14243; 13829 14246; 13833 13902 13851- 14242 13862- 14232 13871-14132 13880- 14232 13902- 14413 13902 14489; 13909 14232; 13930 14243; 13932 14155; 13937 14242; 13938 14243 13967- 14242 13977- 14232 13985-14215 14016- 14239 14019- 14277 14023 14097; 14026 14592; 14050 14232; 14051 14232; 14052 14231; 14059 14318 14067- 14243 14076- 14170 14082-14246 14083- 14176 14143- 14627 14153 14232; 14259 14578; 14259 14516; 14259 14480; 14276 14573; 14298 14584 14296- 14918 14305- 14525 14318-14488 14332- 14830 14335- 14573 14343 14970; 14355 14636; 14357 14568; 14417 14894; 14422 14643; 14448 15011 14457- 14625 14458- 14585 14526-14782 14532- 14802 14534- 14630 14536 14815; 14537 14841; 14537 14757; 14538 14735; 14538 14717; 14544 14835 14548- 14897 14548- 14810 14554-15119 14554- 14837 14556- 14964 14574 15091; 14569 14722; 14571 15039; 14585 14814; 14585 15134; 14585 14846 14591- 15127 14608- 14848 14615-15060 14613- 14846 14619- 14913 14621 15136; 14634 15130; 14654 15131; 14658 14927; 14660 14755; 14665 15133 14666- 15133 14681- 14945 14681-14932 14682- 15128 14684- 15132 14690 15128; 14693 15128; 14701 15152; 14703 15126; 14714 15181; 14723 15130 14725- 15139 14729- 15130 14730-15129 14734- 15126 14733- 15050 14735 15129; 14734 14857; 14740 15130; 14743 15130; 14742 15130; 14744 15280 14744- 15009 14752- 15130 14754-15130 14756- 15011 14760- 15035 14763 15289; 14770 15128; 14770 15054; 14775 15129; 14786 15123; 14787 15139 14790- 15128 14790- 15129 14790-15010 14793- 15130 14796- 15123 14801 15094; 14812 15180; 14830 15030; 14830 14920; 14856 15182; 14872 15130 14872- 15069 14872- 14986 14875-15094 14887- 15130 14897- 15128 14903 15010; 14904 15129; .14934 15079; 14940 15199; 14964 15211; 14964 15118 14969- 15137 14975- 15133 14977-15129 15004- 15256 15035- 15128 15061 15184; 15064 15304; 15072 15302; 15091 15302; 15161 15386; 15163 15412 15165- 15309 15165- 15406 15165-15391 15166- 15434 15169- 15417 15171 15302; 15173 15302; 15216 15302; 15231 15468; 15238 15374; 15240 15793 15240- 15518 15247- 15498 15315-15583 15323- 15645 15327- 15590 15327 15490; 15327 15567; 15327 15533; 15327 15504; 15363 15550; 15373 15631 15377- 15638 15379- 15641 15392-15661 15396- 15630 15422- 15681 15427 15621; 15429 15700; 15446 15587; 15500 15858; 15505 15765; 15505 15883 15508- 15725 15508- 15991 15534-16075 15534- 15779 15537- 15939 15538 15795; 15548 15848; 15550 16057; 15550 15796; 15550 15780; 15556 15811 15559- 15821 15559- 15835 15561-15839 15561- 15835 15562- 16111 15562 15799; 15581 15824; 15581 15806; 15606 15715; 15611 15850; 15613 15906 15616- 15937 15616- 15776 15624-15905 15624- 15862 15624- 15751 15635 15933; 15638 16124; 15637 15875; 15644 16223; 15647 15954; 15649 15913 15661- 16277 15665- 15944 15671-15891 15681- 15994 15689- 16115 15700 15873; 15691 16114; 15715 15963; 15716 16111; 15738 15955; 15769 16118 15774- 16006 15780- 16045 15786-16118 15783- 15958 15797- 15980 15814 16068; 15814 16064; 15816 16050; 15828 16031; 15836 16081; 15846 16081 15855- 16115 15857- 16086 15863-16123 15869- 16111 15893- 16321 15903 16196; 15905 16356; 15914 16368; 15921 16360; 15921 16111; 15923 16373 15923- 16222 15930- 16374 15931-16123 15937- 16199 15945- 16209 15949 16360; 15950 16204; 15951 16371; 15952 16123; 15958 16121; 15988 16111 15996- 16222 16005- 16324 16005-16233 16007- 16368 16023- 16369 16030 16258; 16030 16206; 16034 16358; 16037 16243; 16044 16272; 16050 16341 16052- 16362 16054- 16368 16129-16317 16134- 16354 16137- 16313 16142 16368; 16142 16329; 16142 16315; 16142 16366; 16169 16360; 16184 16368 16185- 16360 16188- 16362 16208-16368 16213- 16367 16212- 16336 16220 16320; 16220 16305; 16288 16363; 16302 16647; 16309 16757; 16312 Table 5
16680; 164 69-16794; 16480 17100; 14839-15130 ; 14259-14689 ; 10792 -11181 ;
4330-4872; 13529-14157; 30-270
132/LG:338010.8:2001 AR30 11 1-4 34; 1 231; 1-165 8-114; 46 -305; 50-569;
60-332; 60-607; 66-292; 66 -277; 267-5 1; 273-545 334-423; 338-806; 392-
654; 420-682; 529-769; 534 816; 544-9 0; 631-118 8; 711-1103 ; 766-1197
133/LG:344597.1:2001MAR30 I I-5 628; 52-625; 28 7- 799; 387- 947; 7 56-1289;
974-1284; 1020-1469; 1269-1881; 1399 651; 1404- 1866; 1630- 2065; 1638-2030;
1638-1995; 1640-1855; 1666 1914; 1777 2171; 1816 2015; 1914 -2506; 1915-
2262; 2054-2507; 2061-2507 ,- 2193-2507 2320 2848 2353-2500 ,- 2421-2842;
2480-2943; 2488-3037; 2521-2659; 2582 2998; 2610 -2941; 2860 -3064; 2943-
3182; 3118-3421; 3114-3382 ; 3120-3368 3150-3711 3180-3715 ; 3222-3777;
3244-3609; 3360-3903; 3412-3673; 3451 3826; 3516 -3617; 3547 -4043; 3563-
3803; 3644-3784; 3704-3873 ; 3760-4011 3860-4360 3878-4243 ; 3964-4445;
3977-4085; 3981-4490; 3980-4200; 3984 4445; 4022 -4563; 4044 -4341; 4053-
4640; 4055-4289; 4078-4445 ; 4140-4641 4164-4428 4173-4532 ; 4202-4401;
4213-4394; 4309-4521; 4320-4429; 4320 4566; 4320 -4683; 4377 -4755; 4378-
4661; 4379-4553; 4379-4452 ; 4382-4523 4398-4688 4398-4553 ; 4422-4642;
4439-4775; 4452-4780; 4493-4565; 4571 4771; 4593 -4776; 4709 -5114; 4709-
4868; 4709-4982; 4717-4988 ; 4726-5029 4749-5000 4762-5000 ; 4764-4943,
4778-5087; 4787-5110; 4834-5076; 4844 5100; 4865-5060; 4891 -5114; 4891-
5112; 4891-5380; 4916-5076 ; 5016-5082 5041-5234 5122-5593 ; 5128-5380;
5128-5402; 5127-5357; 5127-5599; 5128 5595; 5128-5597; 5128 -5572; 5129-
5571; 5130-5587; 5129-5313 ; 5129-5622 5129-5306 5130-5385 ; 5131-5524;
5130-5487; 5151-5628; 5165-5493; 5166 5594; 5168-5631; 5211 -5636; 5220-
5628; 5225-5405; 5260-5423 ; 5278-5627 5293-5625 5291-5628 ; 5290-5526;
5311-5615; 5331-5628; 5341-5494; 5359 5595; 5365 609; 5370 -5625; 5393-
5633; 5393 -5631; 5404-5628 ; 5419-5636 5446-5634 5475-5636 ; 5505-5628;
5510-5628
134/LG:347 361.2 2001 AR30 II ι-4 80; 14-3433 ; 22- 156; 2 3-565 ; 22-2 45; 26-
562; 41-586; 24-6005; 45-2 69; 73 -691; 145-710; 3 70-629 370 -697; 431-761;
555-1200; 673-6245; 678-1321; 697-1063; 936-1535 946- 1206; 977-1237; 1047-
1603 1076-1381 1076-1315 1076-1320; 1254-1655 1631 -1760 ; 2139-2759;
2139-2681; 2505 3051; 2640 3243; 2710-3441; 2808 -3233; 2911 -3441; 2961-
3226 3019-3569 3041-3325 3063-3264; 3091-3563 3101 -3480 ; 3152-3609; 3230 3691; 3252-3782; 3286-3509; 3345-3966; 3362 -3949; 3382 -3975; 3536- 3908 3538-3791 3687-4296 3689-3956; 3691-4252 3789 -3980 ; 3963 -4107; 4000 4500; 4060-4657; 4211-4603; 4252-4510; 4359 4645; 4396 -4640; 4396- 4926 4398-4617 4399-4727 4405-4624; 4412-4770 4438 4655 ; 4458-4658; 4457 4654; 4458-4704; 4465 4742; 4465-4745; 4494 -5051; 4504 -5074; 4614- 5157 4634-5156 4646-5003 4680-5160; 4688-5156 4699 5160 ; 4718-5156; 4738 5113; 4763-5126; 4777 5051; 4786-5382; 4811 5376; 4872 -5161; 4918- 5328 4930-5226 4932-5225 4962-5126; 4965-5180 4972 5251 ; 4981-5251; 4987 5254; 4988-5251; 5045 5380; 5067-5336; 5089 5675; 5089 -5642; 5089- 5332 5100-5293 5136-5388 5140-5251; 5141-5419 5236 5740 ; 5255-5494; 5269 5744; 5276 5787; 5286 5576; 5411-6046; 5415 5944; 5420 -6007; 5444- 5841 5472-5730 5480-5637 5523-6032; 5524-5850 5574 5860 ; 5582-5836; 5623 5833; 5642-5871; 5661 6211; 5660-5870; 5685 5923; 5702 -5959; 5702- 6250 5705-6071 5731-5966 5731-6180; 5737-5993 5741 -5958 ; 5760-6193; 5767 5952; 5797 6424; 5835 6245; 5889-6537; 5894 -6151; 5909 -6009; 5916- 6178 5922-6168 5924-6308 5935-6232; 5955-6203 5961 6369 ; 5963-6252; 5969 6574; 5975 6153; 6012-6318; 6022-6307; 6031 6285; 6068 -6563; 6068- 6334 6091-6343 6104-6468 6106-6375; 6126-6376 6153 -6403 ; 6153-6449;
6172-6780; 6185-6392; 6188 6774; 6189-6330; 6192 6465; 6203 -6421; 6209-
6302 6218-6473 6230-6486 6233-6681; 6233 -6398 6264 -6513 ; 6289-6512;
6307-6850; 6322 6513; 6329 6607; 6346-6528; 6361 6604; 6382 -6625; 6399-
6513 6428-6680 6460-6703 6517-6762; 6538-6770 6538 -6723 ; 6557-6705;
6556-7079; 6587 6858; 6593 7168; 6593-7017; 6593 7113; 6604 -6890; 6622-
6808 6631-7139 6642-6781 6644-6894; 6647-6832 6651 -6895 ; 6653-6912;
6664-6923; 6677 7215; 6683 6950; 6688-7181; 6689 -6934; 6688 -6924; 6691-
6948 6708-6939 6714-6869 6718-6999; 6718-6956 6721 -6954 ; 6721-7010; Table 5
6727-6956; 6732-6941; 6733-6997; 6759- -7053; 6758- -7293; 6762- -7006; 6764- 6983; 6767-6986; 6768-7004; 6785 -7398 6793 -6850, 6792 -7030 6801 -7078; 6814-7375; 6834-7070; 6838-7089; 6839- -7388; 6848- -7383; 6884- -7122; 6885- 7179; 6887-7499; 6906-7084; 6910 -7097 6911 -7470, 6916 -7114 6940 -7412; 6962-7412; 6970-7437; 6971-7227; 6971- -7220; 6977- -7287; 6981- -7418; 6981- 7469; 6982-7218; 6986-7160; 6989 -7274, 6991- -7220, 7005 -7260 7007- -7413; 7007-7415; 7008-7494; 7020-7221; 7021- -7494; 7022- -7496; 7023- -7492; 7024- 7412; 7028-7494; 7035-7491; 7035 -7495, 7039- -7495, 7042 -7496 7045- -7329; 7046-7488; 7046-7306; 7050-7351; 7051- -7452; 7052- -7492; 7055- -7325; 7056- 7494; 7058-7498; 7058-7491; 7065 -7341, 7068- -7494, 7071 -7368 7071- -7494; 7071-7337; 7072-7494; 7076-7300; 7077- -7497; 7078- -7415; 7079- -7494; 7086- 7374; 7078-7494; 7086-7457; 7086 -7382, 7086- -7498, 7086 -7494 7089 -7494; 7091-7415; 7101-7456; 7106-7308; 7109- -7414; 7118- -7501; 7127- -7492; 7126- 7497; 7131-7297; 7130-7297; 7131 -7383, 7134- -7494, 7140 -7355 7141- -7298; 7152-7499; 7155-7500; 7155-7397; 7156- -7499; 7166- -7499; 7168- -7325; 7173- 7494; 7173-7491; 7190-7413; 7215 -7494, 7216- -7412, 7224 -7412 7230 -7479; 7231-7494; 7245-7495; 7252-7378; 7256- -7492; 7268- -7501; 7269- -7417; 7276- 7454; 7332-7494; 7335-7490; 7335 -7407, 7342- -7468, 7341 -7492 7384 -7491; 7412-7624; 7412-7626; 7414-7624; 7454- -8049; 7459- -8004; 7525- -8083; 7681- 8150; 7832-8379; 7855-8272; 8041 -8174, 8045- -8284, 8113 -8270 8261 -8885; 8406-8924; 8679-8924; 8689-9074; 8820- -8920 135/LG:349293.17:2001MAR30 || 2- 2758; 1-462 2-263; 2- 369; 3-415; 11-223; 12-599; 12-577; 49-291; 70-408; 109-364; 197-734, 197- 132; 231-2758; 458- 990; 449-953; 584-953; 601-1062; 698-1351; 713-1033; 773-917; 773 -1312; 842-1062; 885-1130; 921-1143; 95 0-1224; 995 -1293 1059 -2501 1058 -1582; 1058-1266; 1080-1244; 1083-1194; 1083- -1587; 1105- -1298; 1169- -1378; 1222-
1430; 1328-1765 1362-1631; 1361- -1561, 1376- -1947, 1430 -1956 1433- -1638; 1447-1983; 1455 2037; 1493-1954; 1581- -2032; 1595- -1796; 1616- -1936; 1628- 2199; 1633-1893 1640-1913; 1658- -2226, 1770- -1993, 1793 -2042 1818- -2492; 1842-2490; 1844 2334; 1912-2039; 1919- -2486; 1921- -2241; 1926- -2485; 1939- 2468; 1953-2287 1966-2255; 1969- -2212, 1979- -2243, 1980 -2288 1995- -2245;
2004-2236; 2004-2248; 2013-2297; 2034- -2264; 2072- -2285; 2072- -2242; 2102-
2288; 2139-2425 2140-2321; 2169- -2418, 2170- -2720, 2170 -2601 2177- -2601;
2170-2614; 2202-2467; 2209-2598; 2233- -2604; 2248- -2475; 2274- -2517; 2314-
2553; 2315-2759 2324-2604; 2328- -2606, 2357- -2459, 2357 -2568 2361- -2758; 2375-2480; 2382 2710; 2393-2752; 2485- -2705; 2505- -2756; 2532- -2722; 2541- 2747; 2599-2736 2659-3256; 2706- -3032, 2706- -3076, 2706 -3165 2708- -3108; 2712-3176; 2729 2902; 2802-2859; 2813- -3249; 2813- -3995; 2815- -3078; 2818- 3101; 2818-3081 2893-3182; 2908- -3160, 2949- -3153 2978 -3112 2987- -3185; 3000-3271; 3009 3551; 3027-3336; 3029- -3334; 3043- -3273; 3045- -3288; 3053- 3265; 3061-3303 3075-3335; 3080- -3334, 3101- -3463 3107 -3511 3105- -3411;
3119-3299; 3119-3388; 3160-3403; 3190- -3895; 3206- -3466; 3241- -3762; 3244-
3826; 3265-3387 3274-3409; 3278- -3506 3282 -3545 3308 -3993 3322- -3934; 3333-3523; 3329 3538; 3338-3841; 3340- -3538; 3343- -3538; 3382- -3857; 3382- 3622; 3429-3953 3453-3728; 3453- -3988 3453 -3711 3468 -3679 3556- -3998;
3560-3706; 3565-3995; 3569-3995; 3569- -3998; 3570- -3999; 3571- -4004; 3578-
3999; 3607-3994; 3610-3995; 3614- -3998, 3615- -3867, 3616 -3997 3622- -3995;
3622-4001; 3644--3995; 3644-3836; 3662- -3995; 3667- -3998; 3679- -3956; 3697-
3998; 3709-3998; 3710-3946; 3734- -3995, 3739- -3947, 3741 -3995, 3755- -3995;
3757-3991; 3758-394! 3787-3998; 3814- -3997; 3815- -3998; 3872- -3995; 3884-
3998; 3894-3994
136/LG:410595.19:2001MAR30 || 1- 360; 1-389; 1-161; 163 -797; 175-797; 283- 619; 388-956; 400-666; 403-957; 405-577; 474-720, 539- L069; 592-777; 739- 976; 741-845; 745-1281; 782-1231, ; 785- -1059; 808-1099; 337-1114; 837-1355; 889-1535; 900-1022; 872-1116; 90f 6-111" '; 890- -1088, 893- L274; 893-1118; 926 1211; 900-1106; 937-1133; 921-14f 66; 949-1064; 971-1220 ; 991- -1114; 1019- 1486; 1091-1536; 1102-1571; 1104- -1575, 1197- -1582, 1202 -1451, 1250- -1536; 1251-1543; 1254-1447; 1309-1894; 1309- -1536; 1316- -1607; 1322- -1536; 1416- 1916; 1492-1888; 1508-1959; 1511- -1962, 1521- -1958, 1585 -1967, 1648- -1914; 1720-2190; 1725-1966; 1744-1964; 1745- -1946; 1752- -1957; 1757- -1964; 1757- Table 5
1926; 1757-1923 ; 1757 -1919 1757 -1906 1757 -1908 1757 -1966 1757 -1960; 1757-1865; 1757 -1855; 1757- -1818; 1757- -1809; 1757- -1806; 1757- -1959; 1757- 1928; 1757-1956 ; 1758 -1967 1759 -1928 1759 -1944 1759 -1959 1759 -1888; 1759-1965; 1766 -2210; 1771- -1964; 1775- -1967; 1777- -2036; 1833- -2034; 1882- 2098; 1908-2146 ; 1914- -2173, 1960 -2139, 2049- -2173, 2102 -2173 137/LG:411151.3 5:2001MAR30 II i- 537; 12-460 41-613; 41-593 46-560; 51- 3923; 58-482; 1 06-405 116- -391; L68-379; 222-460, 282- 586; 282-629; 286- 393; 290-734; 2 90-582 360- -515; . 368-419; 374-892, 451- 549; 524-629; 754- 995; 807-1057; 1091-1591; 1123-1686; 1231-1661; 1372-1766; 1429-1904; 1436 1722; 1437-1738 ; 1483- -1744, 1516 -2094 1518 -2001, 1553 -2151 1561 -1949; 1557-2009; 1574 -1763; 1646- -1890; 1727- -1995; 1792- -2399; 1820- -2028; 1862- 2477; 1870-2476 ; 1898 -2181 1914 -2380 1922 -2204, 1991 -2398 1995 -2478; 2011-2171; 2013 -2612; 2071- -2370; 2077- -2342; 2130- -2620; 2135- -2636; 2136- 2667; 2138-2382 ; 2156 -2437, 2170 -2454 2176 -2422, 2194 -2771 2260 -2828; 2271-2646; 2284 -2370; 2331- -2836; 2334- -2593; 2361- -2833; 2385- -2569; 2398- 2909; 2412-2631 ; 2414 -2901, 2414 -2668 2444 -2641, 2466 -2756 2468 -2719; 2472-2697; 2502 -2842; 2552- -3027; 2641- -2845; 2683- -2856; 2684- -2942; 2687- 2901; 2714-2984 ; 2725 -3017 2742 -3296 2755 -3033, 2760 -3137 2775 -2933; 2788-3043; 2807 -3072; 2864- -3105; 2896- -3447; 2949- -3199; 2953- -3519; 2960- 3245; 2979-3056 ; 3008 -3641 3080 -3341 3129 -3653 3129 -3343 3158 -3374; 3190-3274; 3195 -3244; 3210- -3654; 3217- -3878; 3277- -3424; 3279- -3476; 3381- 3917; 3438-3841 ; 3440 -3713 3465 -3917 3474 -3652 3540 -3636 3582 -4133; 3580-3786; 3636 -3979; 3694- -3923; 3703- -4131; 3729- -3958; 3746- -4168; 3806- 4263; 3806-4078 ; 3911 -4167 3927 -4177 3928 -3979 4017 -4309 4020 -4271; 4020-4171; 4022 -4171; 4022- -4170; 4022- -4162; 4022- -4139; 4022- -4132; 4022- 4118; 4022-4173 ; 4022- -4145, 4029 -4330, 4049 -4190, 4059 -4250 4071 -4394; 4077-4162; 4079 -4171; 4080- -4371; 4085- -4350; 4104- -4428; 4122- -4419; 4173- 4399; 4197-4279 ; 4197- -4261, 4198 -4433 4207- -4419, 4216 -4372 4220 -4419; 4230-4419; 4290 -4419; 4313- -4419; 4319- -4419; 4357- -4419; 4362- -4419; 4364- 4419; 4369-4419 138/LG:411334.8 :2001MAR30 | 1-229; 1- -529; . L70-786; 206-5853; 251 -798; 856 1071; 923-1347; 1173-. L412; 1858-. 2081; 1931-; _370; 3252-: 3720; 3256-: 3507; 3321-3420; 3372 -3508; 3425- -3595; 3437- -4048; 3437- -3704; 3507- -3975; 3619- 4163; 3638-3892 ; 3687 -3995 3692 -4010 3699 -4049, 3930 -4094 3949 -4010; 3983-4216; 4092 -4347; 4168- -4660; 4200- -4274; 4228- -4555; 4238- -4425; 4262- 4760; 4355-4809 ; 4410 -4811 4415 -4794 4431 -4556 4464 -4686 4474 -4703; 4504-4810; 4504 -4824; 4551- -4698; 4648- -4894; 4820- -5374; 4810- -5363; 4822- 4986; 4882-5168 ; 4928 -5129 4942 -5342 4977 -5186 4978 -5230 4986 -5351; 5016-5284; 5017 -5354; 5020- -5351; 5086- -5321; 5093- -5354; 5141- -5354; 5146- 5354; 5156-5342 ; 5166 -5342 5176 -5342 5182 -5354 5183 -5357 5184 -5751; 5184-5853; 5193 -5384; 5201- -5351; 5229- -5354; 5231- -5354; 5239- -5354; 5240- 5351; 5568-5637 ; 5568 -5709 5568 -5706 5568 -5806 5568 -5649 5568 -5772; 5568-5638; 5568 -5977; 5568- -5679; 5568- -5820; 5568- -5780; 5570- -6167; 5574- 5881; 5577-5975 ; 5584 -6038 5588 -5739 5590 -5791 5592 -5857 5598 -5802; 5600-5739; 5603 -5808; 5638- -6155; 5638- -5904; 5661- -5896; 5697- -5936; 5697- 5904; 5702-6141 ; 5725 -5934 5729 -6000 5752 -6041 5771 -6021 5773 -5980; 5773-6016; 5809 -6078; 5814- -6416; 5815- -6076; 5824- -6476; 5857- -6127; 5859- 6110; 5859-6166 ; 5859 -6117, 5861 -6217 5869 -6131, 5869 -6087 5870 -6367; 5870-6078; 5915 -6494; 5915- -6489; 5927- -6369; 5933- -6279; 5935- -6202; 5946- 6169; 5954-6327 ; 6006 -6246, 6006 -6194 6015 -6242, 6024 -6519, 6024- -6250; 6051-6309; 6076 -6556; 6087- -6330; 6099- -6519; 6108- -6478; 6108- -6453; 6108- 6357; 6112-6566 ; 6117 -6552, 6117 -6300 6117 -6283, 6123 -6565 6123- -6379; 6126-6557; 6128 -6438; 6143- -6557; 6147- -6526; 6148- -6397; 6155- -6461; 6156- 6557; 6161-6565 ; 6164 -6401 6176 -6368 6177 -6565, 6179 -6557, 6189- -6442; 6196-6421; 6198 -6497; 6205- -6519; 6214- -6460; 6221- -6468; 6225- -6502; 6225- 6566; 6227-6565 ; 6236 -6557, 6239 -6565, 6242 -6552, 6267 -6444, 6273- -6557; 6279-6543; 6282 -6550; 6284- -6535; 6285- -6528; 6285- -6546; 6288- -6568; 6289- 6477; 6289-6549 ,- 6292 -6565 6304 -6546, 6304 -6553, 6309 -6549, 6313- -6565; 6318-6552; 6326 -6568; 6331- -6565; 6331- -6776; 6351- -6557; 6352- -6552; 6381- 6565; 6394-6557 ,- 6394 -6528 6394 -6565, 6394- -6537, 6417 -6565, 6458- -6552 Table 5
139/LG:458583.1 2001 AR30 | 1-303; 125-680 - 125- -335; 383-715
140/LG:475378.1 2001MAR30 j 1-530; 1- -589; 55-587; 155 -476; 195-530; 255
530; 321-869; 332-926 534- -1000; 571-1133; 572-1077; 752-1028; 799-1235;
816-1340; 360-1162; 876-1160; 985-1211; 1001-1180; 1045-1305; 1046-1434;
1046- -1428; 1046- -1323; 1050- -1411; 1147- -1399; 1257- -1658; 1338- -1615; 1340-
1759, 1340- -1533, 1393- -1680, 1410- -1699, 1511- -2115, 1542- -1823, 1548- -1823;
1570- -2107; 1587- -1796; 1594- -2115; 1601- -1822; 1601- -1651; 1665- -1875; 1679-
1858, 2037- -2365, 2082- -2331 2141- -2705, 2174- -2668, 2219- -2370, 2267- -2540;
2274- -2831; 2292- -2560; 2293- -2490; 2375- -2646; 2394- -2790; 2410- -2695; 2484-
2551, 2497 -2857, 2503- -2900 2505- -2879, 2506- -2887, 2509- -2900, 2521- -2888;
2521- -2653; 2524- -2888; 2539- -2894; 2538- -2826; 2540- -2894; 2544- -2804; 2544-
2752, 2544 -2748, 2547- -2826 2559- -3072, 2569- -2969, 2575- -2819, 2582- -2893;
2586- -2849; 2595- -2895; 2595- -2744; 2604- -2869; 2610- -2790; 2619- -2890; 2633-
2890, 2695 -2968, 2696- -2905 2701- -2888, 2718- -2890, 2791- -2888, 2801- -2889;
2814- -2893; 2865- -3158; 2914- -3201; 2919- -3339; 2919- -3173; 2921- -3143; 2943-
3163, 2968 -3415, 2968- -3419 2968- -3235, 2978 -3327, 2984 -3074, 3001- -3248;
3035- -3233; 3039- -3572; 3042- -3249; 3043- -3273; 3045- -3322; 3061- -3541; 3071-
3210 3074 -3202, 3077- -3322 3077 -3314, 3096 -3561, 3101 -3385, 3109 -3636;
3121- -3391; 3142- -3711; 3142- -3399; 3164- -3727; 3200- -3573; 3208- -3444; 3237-
3498 3251 -3852 3261 -3503 3278 -3603, 3298 -3750, 3323 -3745, 3320 -3601;
3326- -3839; 3348- -3618; 3359- -3841; 3360- -3691; 3360- -3645; 3360- -3803; 3360-
3634 3373 -3798 3379 -3644 3380 -3603 3390 -3848, 3392 -3842, 3409 -3594;
3429- -3843; 3446- -3629; 3465- -3841; 3470- -3760; 3478- -3956; 3490- -3917; 3493-
3798 3502 -3712 3519 -3843 3529 -3841 3559 -3956, 3565 -3834, 3564 -4020;
3564- -3958; 3571- -4020; 3579- -3829; 3590- -3841; 3591- -3845; 3595- -3959; 3602-
3841, 3608 -3841, 3621- -3838, 3656- -3800, 3679- -3833, 3679- -3956, 3688- -3956;
3714- -3954; 3804- -4024; 3826- -3956; 3953- -4350
141/LG:481572.1 2001MAR30 | 1-533; 16-5246 • 194: 1-2268 194: 1-2267 3175-
3690 3252 -3676, 3513- -3775 3519 -4030, 3532- -3904, 3559- -3848, 3620 -3880;
3623- -3880; 3636- -3771'; 3670- -4042; 3747- -4044; 3775- -3904; 3791- -4043; 3851-
4125 3879 -4075 3871 -3979 3878 -4049, 3894 -4454, 3896- -4125, 3896- -4426;
3897- -4058; 3907- -4134; 3908- -4348; 3907- -4384; 3908- -4377; 3908- -4149; 3910-
4319 3909 -4044 3910 -4080 3910 -4079, 3910 -4106, 3910 -4052, 3910- -4308;
3910- -4292; 3910- -4172; 3910- -4091; 3910- -4086; 3910- -4057; 3910- -4068; 3910-
4046 3910 -4045 3910 -4042 3910 -4038, 3910 -4035, 3910 -4033, 3910 -4034;
3910- -4031; 3910- -4026; 3910- -4029; 3910- -4023; 3910- -4022; 3910- -4015; 3910-
4012 3910 -4000 3910 -3995 3910 -3981 3910 -3980, 3910 -3979, 3910 -3976;
3910- -3964; 3910- -3963; 3910- -4073; 3910- -3961; 3915- -3999; 3929- -4471; 3916-
4179 3935 -4413 3935 -4274 3928 -4176 3930 -4203, 3933 -4185, 3933 -4174;
3936- -4221; 3941- -4139; 3950- -4257; 3967- -4270; 3971- -4043; 3959- -4529; 3959-
4083 3965 -4542 3978 -4407 3968 -4210 3980 -4252, 3968 -4207, 3981 -4291;
3978- -4239; 4006- -4283; 4038- -4486; 4038- -4298; 4040- -4168; 4052- -4333; 4041-
4306 4042 -4223 4060 -4279 4049 -4484 4051 -4360, 4053 -4280 4060 -4577;
4077- -4311; 4079- -4396; 4071- -4354; 4087- -4370; 4080- -4339; 4083- -4360; 4096-
4330 4093 -4331 4097 -4695 4099 -4432 4110 -4386, 4101 -4333, 4102 -4343;
4133- -4392; 4135- -4449; 4122- -4387; 4124- -4323; 4124- -4248; 4139- -4387; 4143-
4416 4144 -4413 4145 -4404 4146 -4425 4135 -4700, 4141- -4451, 4151- -4663;
4171- -4283; 4176- -4380; 4176- -4428; 4201- -4449; 4204- -4522; 4192- -4510; 4193-
4408 4195 -4447 4219 -4457 4220 -4538 4209 -4781, 4221 -4496, 4213- -4496;
4228- -4516; 4221- -4403; 4235- -4470; 4225- -4578; 4225- -4448; 4225- -4404; 4247-
4482 4266 -4381 4255 -4852 4255 -4469, 4259 -4844, 4277 -4451, 4274- -4514;
4284- -4519; 4285- -4497; 4292- -4561; 4297- -4700; 4300- -4713; 4303- -4516; 4307-
4581 4314 -4578 4348 -4884 4348 -4967 4348 -4937, 4348 -4789, 4357- -4631;
4359- -4545; 4361- -4515; 4365- -4639; 4365- -4640; 4366- -4826; 4366- -4650; 4366-
4677 4387 -4660 4390 -4594 4390 -4583 4400 -4635, 4403 -4826, 4419- -4828;
4421- -4850; 4421- -4834; 4421- -4668; 4422- -4808; 4432- -4787; 4436- -4700; 4436-
4680 4445 -4913 4438 -4684 4441 -4704, 4458 -4704, 4460 -4738, 4462- -4703;
4463- -4850; 4463- -4638; 4465- -5002; 4471- -4696; 4469- -4534; 4475- -4692; 4492-
4829 4501 -4902 4503 -4826 4503 -4769, 4511 -4647, 4513 -4790, 4513- -4772;
4513- -4696; 4516- -4856; 4521- -4759; 4536- -4775; 4543- -5016; 4546- -4807; 4555- Table 5
5016; 4558-4794; 4561-5016 ; 4563 -5016; 4564- 5017 4566- 4850; 4572- 4976 4572-5016; 4572-4851; 4582 -5022; 4596-5020; 4612 4834; 4596-5012; 4602 5017; 4606-5014; 4612-4760 ; 4606 -5017; 4607- 4826 4611- 5018; 4612- 4748 4611-5016; 4612-4921; 4613 -4846; 4612-4816; 4612 4854; 4614-4819; 4616 4850; 4618-5019; 4632-5016 ; 4635 -5015; 4637- 4912 4641- 4834; 4643- 4927 4642-4856; 4648-5018; 4649 -5016; 4651-4920; 4650-4768; 4653-5016; 4660 5014; 4660-4991; 4660-4972 ; 4660 -4925; 4661- 5016 4670- 5016; 4675- 5016 4675-4986; 4675-4985; 4687 -5022; 4688-4831; 4695-5021; 4700-4948; 4713 4842; 4711-5016; 4716-5016 ; 4717 -4992; 4718- 5004 4719- 5016; 4727- 5014 4729-5176; 4729-5142; 4736 -5016; 4738-5016; 4744-4914; 4745-4826; 4750 5016; 4758-5018; 4758-5016 ; 4786 -5016; 4795- 5016 4797- 5005; 4798- 5012 4806-5017; 4815-5016; 4822 -5017; 4832-5023; 4836-5016; 4861- 5016; 4891 5016; 4969-5023 142 /LG: 481704.1:2001MAR30 | | 117 2-158 1; 1158 -1578 911- -1541; 1421 -1517; 1092-1481; 1092-1385; 1094 -1373; 897-1298; 9 98-1271; 694-1188; 838-1167; 876-1106; 718-1105; 671-11 05; 637-1050; 385- 754; 1-577 143 /LG: 898195.4 :2001 AR30 II ι-545; 10-635; 23-622; 41 -242; 57-25 7; 60-622; 61-2285; 77-432; 77-2285; 90-344 ; 90-640; 93 -372 96-378; 125-655 ; 130-215; 141-424; 156-402; 170-748; 233-448; 314-810; 449-1015; 468-1037; 573-805; 630-1122; 669-1237; 728-11 96; 854-1420; 919-1068 981-1110; 984-1545; 1094- 1209; 1151-1714; 1157-1624 ; 1181-1671 ; 1225 1459 1237-1486; 1237-1468; 1253-1686; 1268-1523; 1310 -1595; 1382-1935; 1383-1779; 1447-2027; 1499 1820; 1500-2052; 1504-1788 ; 1544 1835 ; 1595-1920 1654 1909; 1661-2053 1661-1888; 1672-2200; 1739 -1938; 1773 -2246; 1780 2055; 1818-2376; 1834 2288; 1841-2087; 1847-2290 ; 1877-2284 ; 1893-2301 1912-2285; 1913-2156 1916-2282; 1927-2078; 1932 -2421; 1932-2480; 1949-2168; 1949-2375; 1949 2285; 1974-2285; 1974-2454 ; 1989-2282 ; 1986-2220 1986-2199; 2011-2432 2019-2459; 2036-2532; 2036 -2526; 2033 -2481; 2037-2268; 2061-2526; 2067- 2285; 2068-2286; 2075-2526 ; 2077-2339 ; 2083-2487 2098-2379; 2099-2389 2107-2526; 2121-2353; 2125 -2526; 2237-2627; 2252 2771; 2252-2471; 2253 2526; 2294-2874; 2303-2518 ; 2362-2518 ; 2382-2928 2410-2637; 2418-2841 2418-2681; 2418-2672; 2425 -2645; 2429-2526; 2458 2993; 2527-2778; 2541 2820; 2543-2733; 2543-2811 ; 2544-2834 ; 2553-2794 2553-2732; 2563-3145 2563-3106; 2570-2791; 2594 -2755; 2606-2841; 2615 3006; 2620- 2931; 2650 3042; 2734-2994; 2746-2981 ; 2773-3021 ; 2782-2994 2793-3060; 2807-3064 2815-2882; 2853-3358; 2921 -3154; 2923-3178; 2936-3185; 2951-3325; 2955 3171; 3008-3492; 3016-3467 ; 3042-3253 ; 3076-3443 3099-3351; 3105-3367 3106-3501; 3133-3604; 3137 -3603; 3159-3464; 3172-3482; 3189-3477; 3198 3477; 3209-3607; 3227-3606 ; 3228-3615 ; 3248-3561 3271-3464; 3278-3544 3289-3423; 3289-3449; 3289 -3491; 3305-3476 3373-3442; 3380-3479; 3402 3610; 3433-3605 144/LG: 903785.1:2001MAR30 I I 1-537 ; 147-456; 194- 5654; 228-4 30; 34 5-936; 1324-1593; 1365-1943; 1399 -1784; 1457-1947; 1461-1961; 1783-2025; 2074- 2248; 2118-2400; 2161-2595 2241-2439; 2281- 2370 2379 -2746; 2389- 2670; 2432-2680; 2602-3119; 2624 2914; 2682-3236; 2696 3090; 2742-3311; 2745- 2892; 2746-3057; 2757-3265 2864-3098; 2867- 3096 2941 -3179; 2955- 3445; 2987-3336; 3011-3231; 3016 -3316; 3020-3411; 3043 3550; 3234-3764; 3240- 3345; 3246-3757; 3256-3487 3258-3633; 3268- 3668 3269 -3529; 3273- 3754; 3283-3432; 3283-3700; 3355 3757; 3361-3638; 3381-4103; 3387-3757; 3393- 3757; 3408-3757; 3411-3757 3423-3757; 3431- 3757 3438 -3757; 3448 3757; 3471-3757; 3497-3757; 3509 3757; 3511-3757; 3573-3757; 3574-3669; 3588- 3757; 3643-4079; 3648-4241 3657-3757; 4029- 4597 4240 -4507; 4411- 4851; 4469-4671; 4469-4757; 4602 -5028; 4602-4997; 4604 4911; 4711-5029 4800- 5021; 4899-5029 145/LG : 977454.3 :2001MAR30 || 1-469; 1-280; 15-229; 280-731; 292-807; 359- 829; 437-966; 465-966; 486-950; 491-760; 491-753; 598-1169; 623-1039; 632- 1033; 635-1036; 637-1006; 641-1040; 643-1038; 644-1010; 645-1004; 645-799; 645-756; 645-794; 645-775; 645-1048; 658-1031; 660-1004; 660-907; 660-1033; 660-848; 660-828; 660-831; 664-958; 665-906; 672-1130; 673-1033; 679-976; 680-1172; 685-1033; 689-1005; 689-1026; 715-978; 726-1106; 726-981; 727- Table 5
1168; 72 7-1269; 731-995 ; 752-1174 ; 773-1175 ; 780- 1194; 808-1025; 823-1137; 828-1156 ; 828-9 6 ; 828-999 ; 828-940 ; 846-1177 ; 850-1033; 853-1166; 881- 1133; 898-1088; 927-1141 ; 927-1146 ; 927-1145 ; 927-1140; 927-1147; 934-1174; 934-1357 ; 934-1 82 ; 937-1182 ; 985-1281 ; 996-1173 ; 998-1472; 1075-1182; 1138-1334; 1284 1552 ; 1410-1685 ; 1453 -2022 ; 1455-1728; 1483-1738; 1527- 1818; 1527-2062 1677-1916; 1678-2228; 1749-2016; 1749-1987; 1750-2280; 1751-1983; 1874 2163; 2075-2332; 2075-2499; 2086-2282; 2121-2430; 2186- 2402; 2255-2881 2257-2483; 2270-2553; 2302-2525; 2307-2694; 2528-2926; 2530-2826; 2545 3021; 2676-2923; 2675-3021; 2713-2985; 2723-2984; 2741- 2866; 2741-3219 2757-3039; 2760-3001; 2761-3046; 2816-3052; 2816-3021; 2829-2985; 2920 2985; 2923-2985 146/LG:977724.1 :2001MAR30 || 1-530; 30-338; 57-3 06; 6 5-378; 64-5 54; 66- 305; 71-658; 71 388; 75-2406; 91-708; 93-263; 97-669; 97-662 ; 98-629; 112- 395; 177 419; 3 9-583; 534-920; 575-878; 669-909; 821-1375; 826-999; 961-
1227 975- 1066; 1021-5202; 1142-1410; 1167-1670; 1170-1350; 1235-1302; 1239 1339; 1242 1603; 1310-1389; 1365-1817; 1544-1699; 1544-2053; 1601- 1854 1643 -2146 1668-2096; 1668-2180 1668-1908; 1675-1924 1678-1859; 1752 1979; 1765 -2130; 1815-2369; 1816-2099; 1816 2046; 1816 1928; 1816- 2047 1845 -2361 1877-2405; 1940-2364 1944- 2027; 1946-2163 1968-2403; 2006 2406; 2047 -2334; 2047-2514; 2064 2406; 2090- 2402; 2116 2335; 2174- 2351 2217 -2397 2232-2348; 2270-2407 2273- 2846; 2291-2401 2335-2911; 2364 2974; 2441 -2581; 2702-2928; 2746 2948; 2817- 3197; 2847 3216; 2850- 3172 3009 3175 3009-3231; 3017-3332 3017- 3175; 3037-3129 3037-3263; 3219 3501; 3226 -3513; 3256-3486; 3272 3531; 3297- 3582; 3313 3598; 3377- 3842 3377 3630 3377-3916; 3446-3698 3446- 4002; 3466-4029 3581-3819; 3592 3869; 3607 -3858; 3661-4086; 3724 3986; 3725-4246; 3737 4128; 3753- 4009 3753 4033 3755-4244; 3754-3996 3755- 3979; 3762-4216 3773-4073, 3779 4074; 3814 -4312; 3814-4042; 3828 4019; 3869- 4059; 3869 4073; 3876- 4124 3883 4093 3946-4286; 4064-4302 4143- 4371; 4149-4562 4198-4538;
4198-4441; 4199 -4443; 4247-4662; 4261 4457; 4264-4513; 4269 4503; 4269-
4393 4278-4662 4294-4662; 4298-4662 4383- 4650; 4383-4662 4386-4604;
4395-4630; 4415-4799; 4415-4872; 4415-4826; 4417 4662; 4419 4662; 4421-
4613; 4445-4807 4468-4662; 4490-4662 4492-4662, 4495-4662 4500-4866; 4546-4662; 4567 -5010; 4584-5161; 4599-4875; 4612 4872; 4682 5153; 4682- 4928; 4682-4953 ; 4681-4784; 4682-5162; 4683-4895; 4698-5161 4699-5164; 4706-5146; 4708-5158; 4717-4944; 4741-5192; 4743-5199; 4754 5204; 4754- 5198; 4763-5197 ; 4771-5036; 4828-5141; 4835-5197; 4842-5117 4849-5100; 4861-5199; 4869-5199; 4870-5072; 4880-5132; 4901-5202; 4909 5206; 4921- 5152; 4922-5201 ; 4928-5161; 4939-5149; 4955-5176; 4979-5199 5067-5200; 5080-5179; 5104-5205; 5111-5205; 5115-5199 147/LG:978215.19:2001MAR30 || 1-378; 238-778; 340 -587; 559- 789; 6 69-1082; 686-1291; 792-1046; 935-1346; 934-1515; 1006-1283 ; 1023-1242; 1068-1596; 1090-1372; 1090-1277; 1097-1263; 1134-1704; 1179-1436; 1179-1431; 1183- 1345; 1207-1437 ; 1268-1654; 1280-1485; 1440-1722 1470-1683 ; 1536-2077; 1653-2067; 1653-1922; 1675-1777; 1714-2254; 1732 1964; 1733 -1962; 1740- 1989; 1744-1820 ; 1760-2004; 1792-2096; 1797-2043 1797-1930 ; 1842-2372; 1850-2092; 1850-2155; 1863-2049; 1860-2452; 1863 2237; 1893 -2140; 1918- 2047; 1925-2442 ; 1934-2481; 1933-2172; 1958-2219 1965-2263 ; 1972-2227; 1996-2184; 1998-2280; 2014-2230; 2014-2464; 2025 2374; 2049-2437; 2081- 2260; 2093-2284 ,- 2105-2719; 2113-2706; 2124-2312 2135-2701 ; 2139-2421; 2145-2411; 2145-2410; 2150-2361; 2161-2377; 2163-2719; 2176-2713; 2180- 2384; 2192-2383 ; 2194-2719; 2211-2717; 2211-2341 2216-2719 ; 2241-2727; 2235-2474; 2242-2669; 2282-2729; 2292-2719; 2302 2729; 2302-2698; 2300- 2669; 2305-2719 ,- 2333-2697; 2340-2669; 2371-2669 2375-2719 ; 2372-2710; 2384-2669; 2388-2719; 2388-2630; 2393-2719; 2394-2719; 2397-2719; 2398- 2670; 2405-2629 ,- 2411-2544; 2418-2730; 2416-2669 2422-2669 ; 2428-2676; 2442-2669; 2454-2669; 2458-2584; 2526-2669; 2565-2669; 2606-2669 148/LG:981795.1 :2001MAR30 || 1849-2395; 1825-2330 ; 1591-1978; 159 1-1946; 1787-1928; 1455-1926; 1452-1897; 1269-1819; 1457-1749; 1115-1554; 862-1541; 1185-1511; 1324-1510; 1209-1505; 996-1505; 1081-1505; 1101-1508; 1297-1479; Table5
770-1371; 1037-1306; 470-1057; 1-1022; 448-888; 596-876; 190-829; 553-826; 166-719; 553-654; 118-612; 62-539; 118-345
149/LG: 982784.1:2001MAR30 || 850-1473; 959-1177; 769-1062; 691-993; 693- 988; 679-987; 526-986; 600-986; 677-986; 683-984; 716-981; 497-941; 490- 933; 570-927; 750-892; 222-872; 605-871; 282-834; 673-795; 307-695; 383- 677; 1-581; 84-574; 137-324; 84-240
150/LG:987322.4:2001MAR30 || 1-443; 30-4114; 49-443; 342-4114; 376-995; 394-701; 500-712; 707-1214; 827-1090; 963-1208; 963-1367; 1019-1334; 1035- 1579; 1111-1588; 1111-1672; 1115-1345; 1126-1395; 1135-1790; 1143-1427; 1146-1382; 1161-1710; 1323-1601; 1369-1588; 1374-1559; 1401-1932; 1457- 1689; 1497-1739; 1509-1860; 1606-1903; 1663-2126; 1663-1890; 1703-1784; 1758-2046; 1820-2086; 1832-2259; 1847-2047; 1912-2108; 2023-2216; 2023- 2250; 2022-2538; 2023-2429; 2023-2226; 2023-2461; 2055-2325; 2132-2387; 2159-2476; 2174-2404; 2226-2506; 2237-2510; 2315-2523; 2350-2454; 2350- 2523; 2356-2624; 2443-2635; 2469-2625; 2535-2823; 2535-3083; 2551-3004; 2589-2722; 2590-2876; 2609-2847; 2623-2991; 2643-3070; 2643-2877; 2651- 3096; 2648-3066; 2656-2910; 2657-2850; 2657-2912; 2662-2944; 2669-3107; 2733-3001; 2818-3094; 2849-3184; 2884-3044; 2890-3125; 2890-3475; 2903- 3195; 2917-3495; 2917-3138; 2917-3345; 2929-3137; 2958-3463; 2983-3099; 3073-3629; 3073-3147; 3088-3359; 3100-3367; 3110-3361; 3110-3300; 3153- 3744; 3165-3453; 3168-3429; 3182-3462; 3187-3445; 3219-3580; 3219-3476; 3251-3505; 3262-3442; 3266-3705; 3332-3600; 3350-3555; 3375-3606; 3378- 3923; 3384-3659; 3398-3768; 3408-3665; 3421-4064; 3450-3668; 3463-3961; 3458-3747; 3462-3729; 3463-3941; 3493-3630; 3513-3699; 3520-3709; 3528- 4063; 3535-3802; 3539-4087; 3541-3783; 3551-4082; 3574-3819; 3583-4077; 3633-3982; 3630-4089; 3650-4119; 3653-4074; 3658-4121; 3659-4117; 3661- 4122; 3663-4107; 3666-3905; 3669-4069; 3672-4116; 3679-3925; 3679-4116; 3688-4106; 3691-4080; 3700-4076; 3702-3947; 3709-4075; 3713-4068; 3713- 4109; 3717-4121; 3723-4090; 3752-4120; 3764-4030; 3766-4116; 3768-4123; 3777-4037; 3777-4027; 3782-4048; 3810-4070; 3812-3944; 3812-4062; 3826- 4044; 3824-4096; 3832-4116; 3832-4073; 3839-4091; 3872-4076; 3903-4063; 3911-4102; 3942-4127; 3983-4117; 3990-4122; 3997-4115; 4021-4116; 4028-4103 151/LG: 006242.7 :2001MAR30 || 1-2218; 1-218; 78-340; 83-302; 196-621; 215- 466; 215-464; 232-455; 309-639; 329-551; 342-600; 346-579; 350-620; 353- 551; 358-683; 373-655; 386-658; 406-610; 411-871; 506-802; 519-871; 523- 665; 556-1102; 677-871; 728-981; 734-984; 747-1273; 747-1001; 763-1018; 791-1023; 805-1171; 819-1050; 922-1113; 922-1096; 922-1090; 922-1086; 922- 1085; 922-991; 933-1327; 933-1165; 947-1089; 976-1301; 981-1295; 984-1292; 984-1260; 984-1255; 984-1213; 993-1233; 1011-1490; 1011-1311; 1013-1237; 1014-1227; 1041-1242; 1048-1300; 1056-1348; 1058-1252; 1059-1349; 1059- 1289; 1060-1210; 1068-1341; 1083-1272; 1089-1258; 1135-1260; 1146-1470; 1163-1379; 1169-1419; 1171-1457; 1172-1428; 1181-1435; 1183-1447; 1191- 1583; 1196-1512; 1200-1724; 1198-1442; 1203-1472; 1207-1453; 1220-1651; 1227-1461; 1234-1508; 1246-1678; 1246-1516; 1246-1352; 1251-1504; 1261- 1580; 1260-1641; 1260-1565; 1260-1560; 1260-1467; 1260-1434; 1266-1562; 1276-1470; 1284-1490; 1291-1716; 1317-1627; 1326-1600; 1332-1613; 1332- 1588; 1334-1391; 1338-1640; 1356-1597; 1358-1600; 1357-1521; 1363-1601; 1376-1679; 1376-1557; 1398-1667; 1403-1514; 1432-1700; 1441-1627; 1442- 2042; 1455-2085; 1464-1883; 1474-1723; 1484-1753; 1493-1782; 1494-1731; 1496-1732; 1500-1558; 1524-1862; 1527-1773; 1540-2030; 1569-1831; 1577- 2034; 1578-1784; 1583-1835; 1594-1782; 1615-2127; 1630-2179; 1630-1871; 1634-2108; 1638-2101; 1642-1919; 1644-1896; 1651-2130; 1651-1921; 1654- 1941; 1669-2219; 1669-1918; 1685-1935; 1686-1938; 1688-1904; 1694-1945; 1694-1798; 1694-2181; 1696-1947; 1719-2205; 1720-2197; 1719-1979; 1724- 1916; 1726-2177; 1732-1946; 1737-1949; 1742-1983; 1751-2221; 1752-1937; 1752-1824; 1754-2222; 1758-2215; 1756-2218; 1759-2013; 1762-2221; 1765- 2224; 1768-2221; 1769-2225; 1769-2217; 1770-2225; 1775-2221; 1776-2223; 1776-2220; 1778-2225; 1779-2208; 1781-1902; 1790-2031; 1789-1902; 1791- 2223; 1804-2218; 1807-2224; 1813-2209; 1814-2235; 1816-2208; 1819-2219; 1822-2222; 1825-2057; 1826-2220; 1839-2006; 1841-2206; 1843-2217; 1844- Table5
2218; 1844 -2095; 1845-2125 1849-2179; 1849-2089; 1854-2219 1871-2120 1874-2210; 1878-2084; 1880 215; 1896-2216; 1894-2218; 1896 2218; 1899 2218; 1899-2114; 1903-2218 1908-2205; 1909-2225; 1912-2148 1914-2206 1932-2218; 1941-2219; 1945 222; 1947-2218; 1947-2195; 1952-2218; 1953- 2206; 1954-2218; 1954-2206 1954-2170; 1956-2218; 1959-2218 1961-2216 1962-2206; 1998-2203; 2000 218; 2000-2192; 2002-2201; 2004 2110; 2011 2218; 2011-2222; 2012-2208 2013-2218; 2022-2218; 2028-2218 2028-2206 2033-2215; 2059-2151; 2102 173; 2158-2215 152/LG:027320.7:2001MAR30 1-303; 1-571; 120-503; 234-668 246-668; 261- 773; 427-659; 569-1006; 88 1178; 907-1459; 952-1301; 973-1267; 985-1406; 1063-1350; 1138-1411 153/LG:147541.44:2001MAR30 II i 586; 4-112; 6-276; 12- 259; 13-259; 14-274; 129-378; 276-779; 273-933 274-5 65; 274-554 ; 299- -551; 303-595; 310-858; 310-657; 310-815; 310-804 310-7 50; 310-590 ; 310- -450; 310-425; 310-470; 314-867; 316-566; 320-943 338-8 14; 354-691 ; 373- -484; 378-583; 393-750; 404-613; 413-748; 433-1028 ; 453- 971; 459-76 9; 503-917; 506-1066; 556-879; 556-1186; 573-1096; 567-11 65; 57 8-826 ,- 581- 825; 581-956; 591-2738; 592- 1092; 599-1092; 604-905; 6 08-118 0; 606-1099 ; 608- -880; 583-856; 612-865; 614-806; 620-870; 623-1104 639- 896; 642-11 04; 648-1047; 650-1094; 655-901; 677-1089; 690-933; 697-858 678- 1248; 717-9 86; 723-1001; 747-1003; 787-994; 837-1085; 837-1084; 841-1065; 86 1-1092; 861 -1018, 907-1159; 975-1218; 1011-
1403 1013-1253; 1018-1299 1031 -1317 ; 982- 1187; 1041-1272; 1115-1602;
1136-1587; 1136-1264; 1140 1462; 1141-1406; 1147- -1599; 1146-1414; 1146-
1275 1146-1502; 1151-1403 1162 -1399 ; 1173 -1679 1169 -1417 1172-1417
1184-1715; 1188-1453; 1208 1456; 1210-1509; 1211 1537; 1213 1434; 1243
1453 1248-1438; 1250-1513 1255 1542 ; 1258 -1541 1260 -1854 1269-1412 1272 1550; 1278-1648; 1278 1583; 1286-1693; 1290 1368; 1305-1865; 1305 1594 1309 1843; 1312-1399 1312 -1798 ; 1314 -1549 1315 1319-1885 1332 1851; 1332-1554; 1349 1892; 1348-1547; 1601; 1356- 1636 1378-1625; 1385-1621 1388 -1518 ; 1391 -1576 1393- 1396-1644
1417-2059; 1418-1697; 1432 1797; 1432-1737; 1449-1693; 1727; 1470
1692 1470-1719; 1482-1649 1517 -1762 ; 1519 -1762 1520 1522-1719 1521 1718; 1522-1800; 1528 1825; 1531-1793; 1539 1811; 2093; 1557 1745 1560-1855; 1565-1826 1577 -1835 ; 1577 -1832 1578 1581-1865
1582-1840; 1584-1819; 1587-1734; 1643-1855; 1645 1880; 1648-1916; 1650-
2161 1650-1889; 1651-1920 1653 -2160 ; 1653 -1849 1655-1940 1655-1887 1658 1907; 1666-1943; 1668 1975; 1680-1920; 1681 1811; 1707-2248; 1711- 2151 1709-1956; 1729-2350 1731 -1919 ; 1737 -2324 1736-2037 1745-1949 1748 2159; 1748-2011; 1748 1900; 1750-2020; 1753-2179; 1760-2168; 1763- 2022 1763-2009; 1765-2059 1770 -2041 ; 1780 -2194 1787 -2043 1788- 2028 1789 2054; 1804-2086; 1807 1914; 1809-2053; 1812-2063; 1816 2386; 1819- 2091 1842-2411; 1844-2086 1846 -2350 ; 1849 -2408 1855-2145 1860- 1956 1865 2141; 1865-2134; 1883-2350; 1873-2123; 1873-2115; 1878 2416; 1880 2160 1889-2182; 1899-2139 1908 -2350 ; 1901 -1988 1905-2193 1917- 2079 1917 2042; 1918-2188; 1919 2158; 1919-2132; 1922 2396; 1922 2173; 1937 2103 1937-2413; 1937-2194 1937 -2186 ; 1938 -2154 1937-2102 1938- 2075 1937 2168; 1939-2223; 1945 2185; 1961-2198; 1961-2282; 1962 2207; 1963 2221 1964-2197; 1968-2208 1973 -2205 ; 1971 -2210 1972-2196 2003- 2435 1998 2255; 2001-2350; 2004 2208; 2010-2300; 2013 2244; 2014 2248; 2015 2239 2038-2299; 2039-2292 2040 -2101 ; 2040 -2282 2044-2332 2044- 2413 2046 2337; 2056-2282; 2061 2294; 2062-2262; 2061 2200; 2085 2552; 2086 2552 2093-2357; 2097-2400 2097 -2366 ; 2103 -2365 2105-2695 2105- 2363 2106 2666; 2106-2413; 2106 2279; 2106-2262; 2109-2277; 2111 2350; 2121 2543 2123-2601; 2123-2273 2124 2643 ; 2129 -2591 2137-2325 2139- 2425 2147 2421; 2147-2239; 2150 2702; 2156-2407; 2157-2447; 2158 2350; 2161 2563 2170-2425; 2182-2413 2185 2426 ; 2184 -2413 2186-2375 2205- 2730 2212 2701; 2212-2413; 2216 2413; 2220-2324; 2220 2413; 2222 2513; 2222- 2424 2222-2702; 2225-2660 2227 2501 ; 2229 -2647 2231-2413 2231- 2723 2237 2815; 2240-2647; 2241 2506; 2249-2651; 2254 2653; 2263 2736; 2266- 2718 2269-2503; 2264-2340 2266 2655 ; 2269 -2648 2269-2611 2269- 2523 Table 5
2270- -2541; 2270- -2 490; 2274-2738 2274-2736; 2274-2647; 2270- 2412; 2279-
2738 2280 -2739 2282-2561; 2287-2739; 2293 2533; 2294 -2493; 2294- 2426;
2294- -2532; 2294- -2 610; 2294-2512 2295-2738; 2310-2769; 2307-2643; 2331-
2738 2329 -2573 2331-2629; 2333-2610; 2338 2809; 2341 -2769; 2346- 2594;
2346- -2575; 2348- -2 648; 2350-2741 ; 2357-2741; 2357-2735; 2356-2744; 2355-
2738 2357 -2648, 2359-2738; 2359-2647; 2409- 2504; 2426 -2811; 2428- 2704;
2431- -2813; 2431- -2 808; 2431-2653 ; 2431-2623; 2432-2667; 2432-2745; 2433-
2664 2433 -2653, 2435-2808; 2435-2745; 2436- 2740; 2438 -2719; 2439- 2808;
2441- -2742; 2441- -2 730; 2441-2813 ; 2441-2809; 2441-2808; 2441-2772; 2441-
2688 2441 -2677, 2441-2663; 2441-2664; 2441- 2653; 2441 -2646; 2441- 2624;
2441- -2613; 2441- -2 552; 2441-2745 ; 2441-2717; 2454-2610; 2454-2687; 2454-
2647 2460 -2706, 2460-2647; 2469-2771; 2469- 2568; 2469 -2564; 2474- 2672;
2475- -2647; 2478- -2 707; 2484-2694 ; 2484-2676; 2487-2766; 2487-2786; 2492-
2702 2507 -2808, 2508-2808; 2511-2740; 2517- 2739; 2539 -2808; 2542- 2810;
2543- -2740; 2546- -2 808; 2554-2808 ; 2563-2803; 2568-2810; 2571-2740; 2575-
2727 2575 -2797, 2586-2738; 2590-2858; 2595- 2815; 2611 -2740; 2614- 2808;
2622- -2745; 2626- -2 770; 2626-2808 ; 2631-2746; 2661-2808; 2692-2808; 2696-
2966 2709 -2808 2726-2808; 2841-3114; 3030- 3529; 3037 -3594; 3041- 3575;
3044- -3654; 3065- -3 301; 2441-2648 ; 2459-2738; 2441-2738; 2441-2740; 2431-
2738 2432 -2739 2239-2413; 1368-1682; 2222- 2413; 1568 -1906; 2441- 2810;
2435- -2738; 1332- -1 831; 2473-2740 ; 1545-1811; 1995-2249; 2489-2739; 1606-
1855 1365 -1610 2495-2738; 2430-2646; 1534- 1736; 2449 -2645; 2595- 2738;
1652- -1775; 2579- -2 699; 1426-1542 ; 2463-2526; 2683-2738
154/LG:228319.2 2 001MAR30 I I 1-359; 62-330; 165-450; 1 65-660; 391-940; 419-
737; 468-737; 480 -1098; 486-931 ; 535-1192; 8 16-1384
155/LG:238754.19: 2001MAR30 | | 1 550; 1-438; 1-371; 8-5 56; 2 4-191; 9 2-375;
34-581; 36 -238; 9 4-530; 45-224; 51-575; 71-3 08; 103-646; 103-357; 1 30-554;
1 13300--, 2 .3344;; 119-448; 130-341; 131- 635 193-266 196-487 203-295; 206 365 208- 617; 206-362 211-477; 212- 430 212-482 212-506 213-4 74; 213- 466 223- 837; 217-456 216-397; 225 512 230-773 237-825 239-5 09; 244 780 244- 474; 244-460 244-455; 244- 454 279-825 277-473 291-6 11; 291- 559 296- 550; 304-601 303-524; 316 596 317-588 320-817 320-5 68; 329- 789 329- 575; 337-858 401-702; 337- 640 343-836 345-578 346-5 79; 359- 533 366- 622; 356-500 378-697; 394- 623 403-991 395-716 399-6 50; 401- 528 407- 846; 412-937 411-676; 409- 551 412-665 418-636 424-9 08; 427- 906 427- 673; 433-944 434-940; 433- 676 433-1008 ; 434-674 440- 879 441 -905; 455- 741; 452-680 452-553; 455 729 453-665 454-699; 457-6 79; 459- 819 469- 905; 471-711 479-738; 481 715 490-869 488-735; 497-9 04; 497- 776 496- 775; 496-772 497-717; 498 739 504-789 503-726; 503-7 93; 503- 766 504- 800; 510-676 509-777; 480- 1180; 478-585 ; 528-774; 530- 878 530 -772; 533- 789; 534-919 534-739; 542- 1087; 504-835 ; 543-769; 546- 693 553 -868; 559- 838; 594-1095 604-1047; 66 0-916 ; 662-89 0; 663-884 ; 610 -1104; 6 10-879; 668- 937; 623-1112 534-714; 625 -1093 ; 589-85 1; 639-1110; 63 9-879; 6 03-845; 603- 842; 646-1104 621-696; 669 -834; 653-110 6; 655-1109; 65 7-1080; 594-876; 661- 1107 ; 661-110 ; 575-844; 66 4-1111; 600-8 69; 600-849; 666-1107; 606-882; 609- 883; 676-1108 638-863; 619 -776; 643-859 ; 625-883; 692-923; 630 -883; 697- 827; 698-1109 701-1104; 70 9-1108; 710-1 111; 710-914; 712-1113; 712-
1108; 647-882; 67 -833; 651-845 ; 690-831; 68 8-815; 668-851; 668-820 ; 669- 883; 696-855; 674 858; 741-827; 743-1108; 74 5-827; 747-1112 ; 747-11 08; 757- 1089; 769-1113; 7 71-1109; 779-1 013; 713-883; 795-1108; 795-1062; 79 6-869; 733-882; 735-880; 786-1087; 786 -1086 ; 844-11 10; 798-1099; 800-1087; 806- 1086; 806-1087; 8 08-1090; 767-8 83; 813-1088; 813-1087; 819-1089; 82 3-1090; 825-1090; 817-107 5; 821-1075; 8 23-1077; 823- 1035; 818-901; 881-1118 ; 842- 1077; 815-1048; 8 44-1077; 845-1 072; 846-1127 ; 831-901; 848-1079; 85 0-1074; 855-1071; 858-107 5; 860-1075; 8 68-1082; 872- 1066; 880-1079; 881-108 2; 886- 1077; 887-1077; 8 95-1078; 897-1 080; 898-1077 ,- 940-1573 ; 1041-1133; 104! 1135; 1049-1136; 1050-1135; 106 0-1273; 1144- 1818; 1712-2293 156/LG:405751.12: 2001MAR30 | | 1 -457; 1-333; 32-310; 68-378; 68-308; 108- 375; 110-647; 110 365; 119-558; 117-370; 117 399; 118 386; 118-346; 119- 369; 119-363; 120 357; 120-353; 122 528; 123 413; 127-381; 126-372; 129- Table 5
402; 136-564 136-627; 135-621; 136-338; 138-279; 138- 415; L35-380; 138-
324; 141-382 140-371; 141-381; 151-650; 147-273; 149- 406; L50-730; 150-
724; 151-410 150-286; 152-371; 153-434; 154-582; 157- 413; L57-426; 157-
408; 157-388 158-417; 158-385; 159-412; 165-801; 168- 803; L70-564; 169-
447; 170-468 173-549; 174-423; 184-423; 188-789; 189- 787; L91-1754; 259-
711; 281-558 280-517; 304-558; 307-564; 327-531; 353- 1014; 356-590; 386-
1053 435-623; 450-738; 465-1038 ; 466-851; 465-732; 48 9-601 ; 495-764; 496-
745; 523-992; 555-691; 592-1060; 605-799; 628-897; 643 -961; 659-1196; 666-
893; 685-946; 692-931; 730-928; 735-910; 737-991; 744- 1006; 774-999; 783-
1059 783-1057; 783-997; 795-980 ; 798-1046; 809-1360; 811-1058; 818-1050;
820-: L057; 813-997; 829-1403; 830-1045; 838-1120; 842-1 124; 346-1144; 856-
1088 861-1203; 863-1123; 870-1113; 878-1116; 904-1149 ; 910 -1181; 911-1483
912-: L456; 911-1158; 911-1147; 947-1159; 962-1165; 973- 1212; 1008-1220;
1010- -1245; 1010-1274; 1011-1254; 1016-1269; 1016-1191; 1018 -1269; 1039-
1315 1050-1198; 1059-1322; 1065-1309; 1075-1369; 1079 -1278 • 1120-1411
1123- -1364; 1129-1428; 1145-1470; 1147-1291; 1154-1429; 1167 -1366; 1167
1447 1168-1419; 1169-1419; 1171-1398; 1196-1436; 1199 -1450 1218-1498
1219- -1505; 1222-1494; 1224-1451; 1237-1390; 1237-1494; 1237 -1470; 1237
1468 1237-1464; 1237-1457; 1237-1431; 1239-1439; 1275 -1542 ; 1278-1542
1279- -1570; 1304-1544; 1312-1551; 1314-1553; 1320-1546; 1324 -1585; 1348
1568 1555-1754; 1593-2123; 1603-1754; 1675-1828; 1679 -1854 ; 1681-1853
1773- -2233; 1773-2226; 1773-2131; 1773-1998; 1773-1980; 1773 -1978; 1773
1986 • 1773-1954; 1773-1927; 1773-1919; 1775-2093; 1775 -2069 ; 1775-1893
1776 -1993; 1777-1971; 1781-2027; 1782-1988; 1794-2043; 1796 -1892; 1799
1880 1817-2078; 1817-1867; 1830-2003; 1834-2045; 1841 -2127 ; 1866-2332
1871 -2092; 1871-2075; 1873-2069; 1878-2065; 1879-2101; 1882 -2113; 1887
2113 1887-2134; 1887-1938; 1918-2099; 1938-2332; 1960 -2189 ; 1983-2218
1989 -2111; 1994-2309; 1999-2207; 2054-2334; 2056-2329; 2099 -2661; 2288-
2811 2322-2590; 2364-2833; 2391-2562; 2393-2556; 2413 -2736 - 2496-2743
157/LI: 011822.6 :2001 AY17 || 2081-2375; 2081-2365; 210 0-2355; 2194-2348;
2021- -2315; 1697-2311; 1922-2312; 1960-2198; 1922-2189; 1703 -1949; 1274-
1920 1469-1852; 1245-1794; 1211-1777; 1061-1759; 1211 -1741 1510-1740;
1200- -1706; 961-1662; 1045-1646; 958-1637; 1163-1628; 1 371-1620; 1197-1603;
813-. L540; 908-1517; 891-1476; 845-1477; 1220-1450; 802 -1422 725-1418; 704-
1320 720-1281; 722-1235; 698-1230; 698-1229; 402-1059 ; 821 -974; 261-874;
281-1 348; 254-843; 671-776; 342-729; 78-702; 22-669; 78 -661; 21-635; 1-621;
1-614; 449-596; 22-573; 22-559; 21-538; 99-405; 28-328 ; 21-, _58
158/LI:1012467.2:2001MAY17 || 180-621; 471-620; 24-620 ; 40- 520; 419-620; 1-
620; 1-618; 14-615; 53-615; 3-665; 20-620; 200-620; 18 0-920 ; 212-916; 183-
906; 277-896; 191-895; 286-896; 341-897; 416-896; 279- 896; . 287-896; 394-
896; 172-880; 174-1015; 279-968; 220-927; 272-931; 260 -927; 309-931; 176-
921; 231-925 151-615; 143-615; 116-620; 44-620; 297-6 20; 89-544; 121- 512;
123-475 159/LI:1169981.1 3:2001 AY17 || 32-348; 33-259; 123-742; 158-611; 391-1119; 666-938; 870-1106; 1016-1331; 1-523; 1-285; 10-656; 25-726; 24-719; 33-631; 33-719; 33-583; 33-506; 33-491; 39-587; 104-708; 109-355; 123-378; 124-702; 124-227; 115-707 ; 123-512; 126-379; 144-607; 163-680; 204-356; 336-612; 363-971; 375-790 428-1088; 536-759; 582-1249; 608-938; 668-977; 684-1086; 702-1119; 762-1043; 941-1340; 941-1331; 997-1272; 1010-1282; 1114-1288; 1116-1320 160/LI:1171553.1 :2001MAY17 || 1856-2144; 1856-2103; 1865-2157; 1903-2505; 1925-2076; 1785-2158; 1801-2156; 1785-2156; 1841-2481; 1836-2481; 1-206; 24-581; 31-348; 31-507; 31-317; 38-568; 59-323; 58-177; 63-287; 222-457; 342-938; 379-501 ; 402-527; 493-1012; 533-1113; 538-901; 538-747; 626-833; 628-1219; 621-1220; 674-1226; 674-1144; 684-1272; 699-1237; 724-1312; 751- 966; 780-1232; 788-1312; 814-1312; 832-1240; 833-1093; 833-1056; 835-921; 837-1023; 905-1510; 921-1237; 926-994; 964-1161; 966-1337; 999-1548; 1021- 1117; 1039-1294; 1073-1631; 1098-1697; 1118-1568; 1162-1504; 1164-1328; 1211-1789; 1359-1570; 1369-2007; 1369-1813; 1371-1468; 1404-1733; 1443- 1995; 1462-1974; 1469-2013; 1483-1585; 1483-1963; 1483-1921; 1494-1785; Table 5 1541-2023; 1551-1854; 1554-2129; 1553-2098; 1554-2073; 1595-2025; 1596- 2136; 1597-2165; 1613-1902; 1613-2038; 1614-2176; 1624-2105; 1674-2157; 1673-2173; 1673-2153; 1701-2147; 1706-2147; 1740-2056; 1754-2147; 1753- 2055; 1760-2018; 1765-2118; 1773-2041; 2114-2655; 2115-2581; 2131-2383; 2135-2283; 2237-2587; 2354-2442; 2435-2968; 2481-3041; 2550-3062; 2860-3078 161/LI: 1183156.3 :2001MAY17 || 46-465; 279-774; 297-763; 297-1006; 330-597; 700-989; 818-1373; 825-1470; 892-1438; 892-1518; 892-1336; 892-1456; 892- 1387; 1066-1699; 1121-1314; 1213-1697; 1231-1782; 1257-1824; 1268-1527; 1305-1867; 1307-1856; 1514-2133; 1919-2537; 1933-2537; 2147-2537; 2170- 2537; 1-603; 909-1175; 1233-1824; 1346-1829; 2283-2899
162/LI:1188500.6:2001MAY17 || 540-1227; 591-1260; 601-1307; 1-576; 1-600; 96-719; 96-692; 96-687; 275-833; 284-838; 288-844; 390-981; 508-1106; 517- 724; 523-1125; 538-1099; 617-1125; 624-1304; 647-1191; 676-1398; 756-1413; 786-1487; 790-1505; 836-1486; 859-1478; 891-1486; 893-1509; 909-1486; 912- 1467; 913-1491; 922-1505; 928-1486; 936-1524; 996-1501; 1040-1503 163/LI:147333.12:2001 AY17 || 1096-1739; 1-506; 28-165; 270-533; 296-797; 495-808; 495-1046; 495-1048; 509-759; 582-1016; 776-1152; 776-1049; 819- 1160; 824-1306; 826-1279; 833-1260; 927-1275; 1143-1641; 1184-1260; 1184- 1580; 1184-1663; 1184-1490
164/LI: 147523.7 :2001MAY17 || 301-779; 374-778; 353-778; 94-777; 188-779; 258-779; 257-779; 413-779; 225-778; 326-778; 152-762; 308-760; 197-715; 324-698; 170-662; 1-651; 1-615; 1-593; 1-583; 1-550; 1-487; 1-485; 198-466; 1-298; 1-261
165/LI:197388.10:2001MAY17 || 1170-1400; 1185-1340; 1189-1415; 1190-1422; 1243-1402; 1245-1415; 940-1215; 975-1422; 1169-1415; 1-479; 51-665; 36-602; 36-589; 89-378; 142-351; 165-867; 157-403; 157-415; 195-451; 184-274; 189- 418; 210-401; 242-684; 245-684; 281-566; 303-904; 295-578; 322-1141; 338- 589; 406-1137; 395-491; 450-1278; 919-1171; 919-1134; 500-1121; 598-828; 612-883; 604-896; 647-933; 647-934; 673-833; 680-771; 685-771; 715-1419; 724-1433; 756-1434; 775-1343; 775-1003; 785-1231; 821-1413; 844-1010; 845- 959; 855-1128; 854-1124; 868-1105; 885-1128; 868-1104; 1290-1415; 1315- 1415; 1320-1400
166/LI:2049216.1:2001MAY17 || 1-611; 64-471; 164-783; 235-729 167/LI:2051624.2:2001MAY17 jj 779-1263; 675-1249; 628-1160; 836-1159; 674- 1161; 550-1158; 324-1100; 339-1062; 322-1046; 241-948; 308-919; 154-896; 283-873; 3-811; 1-787; 314-716; 504-689; 43-574; 61-498; 2-476; 1-359; 1- 202; 596-1264
168/LI:2121838.1:2001MAY17 || 1-361; 1-349; 1-338; 4-252; 121-584; 187-487; 206-464; 331-610; 375-622
169/LI:2122954.8:2001MAY17 || 516-1102; 571-1085; 702-1084; 712-1084; 654- 1084; 577-1084; 529-1084; 488-1084; 565-1047; 587-985; 28-803; 1-553; 1- 522; 1-227
170/LI:2198064.2:2001MAY17 || 1-401; 50-293 171/LI:2206583.1:2001MAY17 jj 231-629; 1-360
172/LI:235663.6:2001MAY17 |j 1-552; 1-603; 1-456; 1-392; 1-432; 32-565; 61- 555; 182-522; 222-587; 245-597; 287-911; 302-665; 391-1014; 398-915; 396- 893; 422-861; 456-972; 470-884; 479-698; 505-1016; 526-1092; 535-808; 575- 1257; 607-1068; 646-1029; 647-1133; 670-1136; 684-1133; 692-1010; 707-918; 726-839; 786-1004; 875-1444; 1023-1488; 1048-1251
173/LI:236386.7:2001MAY17 || 2898-3229; 2898-3119; 2899-3433; 2899-3229; 2904-3365; 2927-3358; 2928-3365; 2938-3308; 2957-3214; 2957-3299; 2962- 3546; 2962-3027; 2971-3521; 2972-3549; 2989-3228; 3008-3585; 3028-3228; 3028-3227; 3059-3232; 3065-3369; 3071-3705; 3084-3578; 3099-3350; 3113- 3608; 3116-3413; 3119-3403; 3121-3209; 3134-3418; 3136-3401; 3136-3192; 3136-3644; 3137-3371; 3136-3431; 3142-3644; 3166-3456; 3163-3432; 3161- 3384; 3171-3382; 3179-3427; 3189-3644; 3197-3431; 3196-3441; 3209-3539; 3242-3465; 3245-3751; 3245-3504; 3245-3469; 3249-3535; 3284-3644; 3299- 3902; 3306-3475; 3312-3833; 3312-3739; 3312-3571; 3320-3920; 3335-3599; 3363-3648; 3373-3640; 3373-3620; 3386-3612; 3416-3918; 3420-3642; 3470- 3922; 3484-3880; 3492-3742; 3493-3908; 3499-3917; 3505-3741; 1671-2214; Table 5
1679- -2086; 1685-1953; 1685- -2003; 1864-1967; 1874- -2487; 1874- -2225; 1882-
2329, 1944-2002; 1943-2319, 2092-2555; 2149- -2638, 2149-2590 2149-2418;
2149- -2604; 2209-2565; 2220- -2450; 2220-2448; 2307- -2550; 2323- -2404; 2340-
2682 2357-2877; 2410-2927, 2457-2958; 2464- -3075, 2493-2653 2536-2959;
2537- -3021; 2537-3020; 2540- -2885; 2540-3070; 2540- -2998; 2546- -3123; 2546-
2757 2546-2746; 2576-3000 2586-3028; 2603- -3191, 2612-3089 2625-3047;
2627- -2927; 2664-2859; 2674- -3214; 2683-2934; 2730- -3169; 2732- -3213; 2735-
2874 2747-3211; 2745-3111 2745-3016; 2745- -3015, 2779-3308 2779-3010;
2791- -3223; 2797-3434; 2806- -3279; 2803-3332; 2803- -3229; 2803- -3145; 2824-
3084 2825-3027; 2843-3377 2853-3420; 2863- -3502, 2885-3111 2898-3362;
2898- -3330; 2898-3272; 1-627; 19-230; 155-788; 479-1214; 519- -883; 532-724;
779-1224; 791-1290; 866-1656; 870-1544; 872- -1478, 871-1556; 910-1360; 939-
1408 990-1503; 1004-1403; 1010-1404; 1050-1679; 1118-1398; 1120-1641;
1128- -1460; 1131-1430; 1152- -1260; 1186-1552; 1201- -1797; 1208- -1786; 1228-
1845 1339-1476; 1355-1858, 1389-1984; 1418- -1663, 1419-1833 1434-1885;
1458- -2076; 1466-2042; 1483- -2103; 1544-2109; 1556- -1998; 1557- -2004; 1558-
1792 1634-1815; 3509-3912, 3529-3912; 3542- -3813, 3548-3912 3554-3920;
3558- -3873; 3574-3906; 3575- -3920; 3608-3917; 3610- -3912; 3614- -3920; 3617-
3900 3629-3917; 3630-3895, 3632-3912; 3665- -3917, 3678-3907 3689-3917;
3689- -3919; 3691-3922; 3698- -3920; 3701-3904; 3703- -3877; 3721- -3863; 3742-
3869 3784-3912; 3789-3912 3814-3920; 3814- -3923, 3819-4174 3819-4168;
3832- -3912; 4119-4416; 4138- -4416
174/LI: 236654.3 :2001MAY17 | 1-326; 9-94; 10-545, 19-470; 89-368; 235-501;
289-734; 289-507; 365-845; 367-578; 405-914 524- -720; 647-1138; 723-1188;
735-1150; 749-1190; 768-1191; 802-1040; 802- -1188 802-1071; 802-1151; 802-
1154 842-1188; 909-1189; 947-1180; 1083-1189
175/LI: 256059.46 :2001MAY17 | | 1-278; 1-261; 5-179; 6-231; 7- -196; 9-236; 10
238; 12-291; 17-117; 16-299; 17-309; 17-243 16-401; 17-230 17-237; 17-
426; 18-295; 18-568; 19-298; 24-480; 38-472 161- -401; 200-335; 342-761;
444-688; 473-566; 522-1106, 659-957; 929-1196; 969-1599; 982-1544; 1010-
1148 1027-1148; 1063-1148, 1066-1574; 1081- -1148, 1491-1677 1490-1552;
1500- -1677; 1779-2000; 1525- -1677; 1528-1677; 1531- -1677; 1536- -1677; 1537-
1677 1549-1677; 1550-1677 1565-1760; 1564- -1677, 1568-1912 1568-1900;
1592- -1677; 1593-1677; 1595- -1677; 1598-1677; 1608- -1677; 1611- -1677; 1613-
1677 1615-1677; 1621-1677 1627-1677; 1779- -2047, 1801-1890 1825-2228;
1825- -1881; 1825-1920; 1825- -2226; 1925-2320; 1979- -2338; 2036- -2320; 2045-
2306 2048-2320; 2048-2317 2090-2272; 2122- -2317 2164-2320 2164-2293;
2191- -2305; 2201-2315; 2201- -2317; 2201-2329; 2201- -2316; 2201- -2265; 2229-
2765 2246-2331; 2262-2316 1491-1707; 1825- -1971 1500-1565 2224-2320;
1491- -1697; 23-393; 256-633 29-418; 17-448
176/LI =279978.22 :2001MAY17 | | 1-287; 2-232; 20-629; 138-628 145-312; 222-
596; 275-711; 275-833; 424- -817; 427-690; 490-993 642-903; 672-764; 721-
1021 778-950; 817-1377; 825-1418; 839-1482 843- -1399; 845-1358; 851-1088;
846-1522; 847-1643; 848-1306; 826-1012; 774- -916; 888-1546; 869-1439; 899-
1681 933-1246; 945-1299; 957-1159; 1008-1696; 981-1674; 1001-1256; 1019-
1495 1019-1356; 1029-1229, 1124-1685; 1124- -1390, 1153-1679 1203-1470;
1220- -1810; 1157-1574; 1251- -1806; 1247-1767; 1264- -1878; 1522- -1703; 1529-
1744 1532-1744; 1536-1957, 1571-1976; 1577- -1652, 1588-1917 1591-1821;
1606- -1735; 1698-1793; 1730- -1952; 1767-1892; 1790- -2090; 1806- -1946; 1439-
1945 1443-1838; 1477-1840, 1479-1840; 1531- -1820, 1308-1567 1333-1808;
1332- -1733; 1346-1902; 1374- -1988; 1362-1828; 1368- -1684; 1373- -1738; 1388-
1810 1381-1832; 1428-1688, 1452-1932; 1253- -1843, 1264-1879 1296-1513;
1286- -1836; 1277-1634
177/LI : 311541.6 : 2001MAY17 | 2446-2813; 2464-2750; 2606-2859; 1-399; 12-
353; 216-640; 288-854; 588- -957; 588-803; 627-777, 767-1445; 1094-1564;
1385- -1604; 1389-1678; 1391- -1697; 1403-1689; 1420- -2005; 1457- -1835; 1457-
1656 1500-1724; 1565-1772 1567-1670; 1635- -2266, 1644-1932 1679-1883;
1679- -1880; 1713-2271; 1756- -2017; 1810-2065; 1810- -2073; 1810- -2401; 1829-
2289 1890-2050; 1952-2461, 1980-2310; 2025- -2305, 2054-2120, 2122-2402;
2144- -2693; 2151-2609; 2180- -2837; 2258-2858; 2270- -2857; 2278- -2870; 2303- Table 5
2856; 2310-2750; 2327-2873; 2395 -2858; 2399-2819; 2401-2856; 2405-2859; 2413-2863; 2417-2856; 2420-2819; 2422-2679; 2432-2856; 2436-2607; 2448- 2723; 2456-2808; 2454-2753; 2459 -2818; 2472-2707; 2478-2691; 2559-2814; 2560-2857; 2600-2819; 2635-2863 178/LI:346123.1:2001MAY17 || 8-4 95; 8-52 9; 8-5 69; 8 -428; 31-536; 42-532; 1- 568; 8-478; 42-528; 42-495; 42-424; 42-2 51; 42 -662; 42-691; 42-714; 42-547; 42-601; 42-496; 42-494; 42-474; 42-434; 42-298 ; 42-140; 42-683; 42-570; 42- 598; 42-659; 42-480; 51-144; 160-662; 19 5-712; 276-867; 330-882; 567-1068; 570-968; 606-877; 614-1017; 635-871; 673 -850 179/LI:381211.5:2001MAY17 || 1-546; 112- 355; 1 15-33 9; 1 17-40 1; 210 572; 213-691; 214-708; 220-446; 221-742; 221 699; 221-73 3; 2 21-523; 221 389; 221-463; 225-303; 352-822; 352-741; 387 741; 418-74 1; 4 32-757; 437-635; 476-741; 510-1097; 520-741; 525-741; 568 -741; 569-7 72; 572-1084; 586-1235; 586-741; 688-775; 716-1235; 766-1291; 12 14-1732 ; 14 70-1 951; 1472-1592;
1475-1760; 1475-1711 ; 1535-2039; 11553: 388--2200 9999;; 115553 -17 37; 1682-2066; 1814- 1935; 1948-2473; 194 8-2531; 1948--22554455;; 11 994488--225530 ; 1 948- 2553; 1948 2180; 1955-2536; 1955-2493 ; 2009-2470; 22000099--2255 5522;; 220010-22 47; 3151-3595; 3157- 3596; 3146-3598; 314 9-3598; 3138--33559988;; 33 113388--335591 ; 2 640- 2920; 2038 2453; 2070-2535; 2076-2534 ; 2375-2569; 22338888--2299 1133;; 223388-26 46; 2413-2704; 2508- 2822; 2518-2854; 252 7-2806; 2528-22778844;; 22 558822--228811 ; 2 585- 2832; 2622 3133; 2687-3273; 2845-3446 ; 2884-3516; 22992277--3355 5566;; 229929-34 90; 2939-3483; 2936- 3175; 2936-3556; 293 6-3296; 2941-33448833;; 22 995599--334493 ; 2 973- 3545; 2987 3519; 2996-3391; 3020-3286 ; 3022-3247; 33002244--3355 9955;; 330084-35 52; 3122-3365; 3171- 3595; 3177-3598; 319 5-3595; 3200-33444444;; 33 221166--336600 ; 3 222- 3596; 3222 3580; 3239-3591; 3300-3591 ; 3351-3591; 33339955--3355 9955 180/LI:412197.82:200 1MAY17 | | 17--229944;; 1177 --227711;; 17-28 4-325; 17- 203 ; 17- 235; 17-275; 17-274; 17-249; 17-226688;; 1177-- 225566;; 118-290 18-258; 8-160 ; 19-275 ; 20-246; 22-848; 8-27 6; 22-241; 166--226699;; 11 66--225533;; 16 -2 ; 16-213; 18-247 ; 25- 272; 25-218; 11-195; 13-227; 22-667766;; 1166-- 8899;; 1177 -237 ; 6-217; 16-223 ; 16-90 ; 16-185; 17-254; 17-1 52; 17-176; 1177--117733;; 1177--116611 ; 17 - 7; 17-233; 17 -175 ; 17- 261; 32-272; 17-227 17-385; 17-112277;; 1177- 111133;; 118-232 17-131; 18- 266 ; 17- 253; 17-263; 18-236 15-231; 19-168 1 199--1 16622; 2 20-241 21-258; 21- 228 ; 20- 204; 22-172; 22-239 25-259; 25-157 2255-222233; 225-273 29-295; 30- 174 ; 30- 127; 43-686; 43-136 80-136; 86-146 1 144--223311; 1166-35 178-739; 14-256 ; 15- 227; 15-242; 15-261 15-207; 16-212 1155--222211; 115-223 15-253; 203 -623 ; 216- 427; 379-565; 446-62 7; 564-1308; 747-13500;; 1122773 -179 1300-1535 ; 15-254 ; 15-258; 15-267; 16-2 14; 16-262; 16-257; 1435-1701 ; 04 -1959 ; 17 -248 ; 1- 274; 1-165; 17-107; 22-686; 23-99; 17-145; 17- 122 ; -160 ; 19 -119 ; 22 -618 ; 13-253; 1-653; 17-23 4; 19-285; 22-753; 23-265; 25-2 ; 30-290 ; 126-874 ; 296-577; 831-1393; 2 2-626 181/LI:412936.49:200 1MAY17 || 1-3 39933;; 66--228811;; 2255-285 ; 40-283 ; 44-234 ; 49-311 ; 54-311; 69-196; 175 653; 404-649;; 777788--11006677;; 11--529 ; 1-590 ; 1-566 ; 1-314 ; 1- 223; 9-666; 14-269; 13-270; 15-23311;; 2255--228877;; 2255-268 ; 29 -137 ; 32-227 ; 38-302 ; 42-146; 42-327; 42-3 15; 43-306; 4477--224488;; 4488--228899 ; 48 -183 ; 48 -308 ; 50-162 ; 48- 130; 52-331; 53-315; 53-252; 54-222222;; 5566--333322;; 556-161 ; 56-321 ; 59-347 ; 84- 649; 89-293; 111-793 ; 166-816; 22277--446600;; 225544--77554 ; 264-765 ; 291-600 ; 332-649 ; 466-960; 682-1055; 6 82-790; 719-11006633;; 779944--11006677 ; 796 -1067 ; 841-1067 ; 847 - 1067
182/LI:427792.139:20 01MAY17 | | 71 177--992200;; 7 71188-- -99663; 732-924; 734- -932; 743-911 748-921; 753-914; 77 0-1343; 806-9 97722;; 881199--992255;; 819-920; 830-959; 835-1182; 836-1107; 837-1112; 842-1163; 844 4--992200;; 8 84466--991144; 868-1109; 983- -1371 ; 990- 1384; 1016-1114; 103 7-1180; 1037- -11559988;;'' 1 1004422-- -111178 106S )-1265; 1263- 1383; 1263-1378; 1270-1390 ; 1278-1343; 1 1228811--11338833;; 1 12281- -1341; 1283-1340; 1283- 1342; 1283-1343; 128 3-1356; 1283- -11338866;; 1 1228833-- -113371 1283 -1372; 1283- 1383; 1283-1375; 1283-1389 ; 1283-1385; 1 1228833--11338844;; 1 12285- -1383; 1290-1383; 1305- 1383; 1309-1383; 131 6-1383; 1323- -1133'7 788;; 7 71111--886622; 1-236; 62- -343 296 -448;
297 -547 ; 307 -554 ; 422 -986 ; 430-9C 02; 505 -826 533- -885; 533- -897 533 -926;
534-775 ; 545-834 ; 557 -927 ; 594-9] 12; 598 -926 600- -898; 612- -893 617 -914;
620 -844 ; 621-920 ; 622 -879 ; 624-9( 01; 627 -903 629- -871; 629- -926, 629 -920;
644-920 ; 644-914 ; 648-923 ; 647 -9. 20; 655 -889 655- -903; 663- -914, 665 -913; Table 5 667-902; 669-921; 669-891; 670-920; 670-918; 671-914; 6 79-893; 678-880; 678-905; 682-924; 685-915; 699-1128; 699-914; 703-926; 707-925; 707-850; 709-879; 711-920; 924-1182; 734-920; 704-920; 936-1178; 838-1178; 478-822; 787-1186; 703-1166; 475-1018
183/LI:450229.1:2001MAY17 | | 1-583; 1-474; 1-567; 1-565 ; 1-608; 1-589; 1- 708; 1-509; 1-367; 1-600; 1-836; 1-678; 1-588; 1-677; 15-303; 40-634; 118- 715; 207-820; 319-841
184/LI:475565.243:2001MAY17 | | 1-728; 1-746 185/LI: 764701.8 :2001MAY17 | | 1059-1565; 1101-1556; 1093 -1549; 1160-1549; 1151-1549; 1112-1549; 1239-1549; 1468-1549; 1196-1549; 1211-1549; 1040- 1542; 799-1479; 789-1477; 1093-1472; 796-1468; 797-1465 ; 986-1447; 830- 1448; 1276-1444; 781-1433; 1333-1410; 888-1375; 936-1348; 1174-1378; 1135- 1371; 757-1295; 752-1295; 1131-1240; 816-1216; 483-1048 ; 490-966; 485-748; 343-740; 600-701; 1-587; 343-567; 1-266
186/LI: 024124.2 :2001MAY17 | | 1360-1872; 1566-1766; 1330 -1761; 1467-1 761; 1541-1759; 1335-1759; 1680-1757; 1222-1755; 1286-1752; 1619-1752; 10 67- 1758; 1298-1747; 1296-1744; 1219-1736; 1600-1735; 1566-1717; 1612-17 08; 1051-1666; 1262-1638; 1276-1585; 1157-1493; 966-1542; 942-1475; 1040 -1454; 912-1455; 1219-1485; 925-1451; 913-1451; 913-1452; 1193 -1527; 949-14 50; 946-1431; 1319-1466; 1180-1466; 1304-1466; 978-1431; 1465-1532; 1361 -1466; 1309-1466; 1310-1452; 1301-1383; 817-1310; 1027-1258; 1001-1243; 113 2-1311; 1008-1155; 497-947; 517-825; 668-793; 176-780; 516-761; 1-562; 1-99 187/LI: 038252.3 :2001MAY17 | | 2056-2646; 2067-2648; 2083-2457; 2084-2 653; 2094-2342; 2096-2386; 2099-2425; 2099-2282; 2107-2381; 2118-2497; 21 32-
2318 2141-2648; 2145-2651 2152-2425; 2171-2710 2171- 2693 2171-26 91; 2179-2703; 2183-2409; 2186 2378; 2192-2451; 2201 2656; 2203 2476; 22 17-
2688 2222 2456; 2226-2687 2231-2690; 2237-2685 2237- 2426 2241-26 98; 2248 2690; 2249-2699; 2254 2701; 2262-2647; 2266 2687; 2276-2618; 22 92- 2618 2298 2514; 2301-2350 2305-2532; 2307-2693 2310- 2693 2319-26 86; 2325 2692; 2333-2688; 2337-2695; 2339-2587; 2342 2693; 2356 2699; 23 57- 2699 2358 -2442; 2361-2645 2367-2689; 2367-2688 2373- 2693 2375-26 87-; 2381 2689 2399-2684; 2401-2699; 2410-2683; 2422 2693; 2422 2686; 10 59- 1338 1074 -1691; 1087-1745 1091-1754; 1091-1768 1098- 1825 1109-14 95; 1109 1659; 1117-1646; 1127 1694; 1134-1682; 1136 1840; 1157 1815; 11 65- 1327 1166 1327; 1169-1767 1180-1380; 1178-1651 1185- 1402 1185-14 14; 1185 1689; 1185-1451; 1185 1736; 1188-1719; 1211 1428; 1211 1465; 12 22- 1849 1221 1689; 1225-1859 1222-1689; 1227-1964 1229- 1842 1238-16 95;
1248-1757; 1248-1834; 1249 1719; 1252-1828; 1260 1956; 1268 1803; 12 92-
1919; 1299-1963; 1316-1712 1322-1641; 1339-1945 1341- 1575 1344-19 60;
1343-1937; 1346-1639; 1364-2009; 1366-1512; 1387 1788; 1390 1967; 13 94-
1627; 1400-1880; 1401-1873 1460-1729; 1460-1945 1467- 2206 1518-17 41; 1539-1807; 1556-1836; 1557 2251; 1562-2104; 1575 2162; 1580 2122; 15 90- 1599-1946; 1630-2272 1634-1894; 1642-1941 1652- 2019 1652-19 07; 1670-2199; 1680-2189; 1704 1856; 1707-1987; 1716 2176; 1723-1877; 17 31- 1975; 1740-2282; 1741-2343 1741-2003; 1749-2279 1754- 2306 1753-23 17;
1752-2053; 1759-2231; 1764-2503; 1769-1871; 1774 2336; 1781 2056; 17 81-
2071 1785-1902; 1803-1902 1804-2096; 1807-1902 1807- 2191 1815-20 63;
1817-2098; 1819-2130; 1819-2092; 1833-2194; 1834 2330; 1839 2451; 18 55-
2123; 1858-2447; 1862-2087 1879-2191; 1905-2136 1906- 2377 1911-23 77; 1914-2376; 1949-2316; 1953 2469; 1954-2307; 1953 2490; 1956 2525; 19 67- 2553; 1965-2398; 1965-2441 1975-2162; 1971-2526 1981- 2339 1991-26 08; 2003-2388; 2003-2351; 2005 2298; 2010-2221; 2010 2446; 2029 2431; 20 49- 2547; 2441-2685; 2449-2696 2451-2686; 2452-2630 2453- 2668 2461-26 1E 2474-2688; 2476-2618; 2484 2618; 2487-2695; 2490 2618; 2490-2663; 25 68- 3010; 2568-2972; 2568-2973 2568-2962; 2568-3014 2568- 2959; 2570-26 96;
2917-3340; 2987-3555; 3120-3378; 3215-3515; 3221-3554; 3290-3534; 33 39-
3487 1-59 9; 178-720; 179-408; 183-408; 184-760; 184-658; 188-462; 1 88-750;
189-478; 1 92-408; 193-408; 194-686; 196-764; 196-334; 197-754; 199-7 93; 1055-1298; 198-674; 198-388; 205-770; 204-408; 204-478; 205-408; 203 -532; 205-547; 2 08-804; 210-391; 211-409; 213-408; 220-513; 299-881; 369-9 18; Table 5 418-647; 443-1013; 480-744; 568-1121; 621-781; 634-1226; 741-1002; 741- 1403; 741-1084; 741-1281; 743-996; 753-1324; 790-1268; 808-1093; 848-1584; 855-1349; 857-1565; 897-1346; 897-1186; 947-1523; 958-1500; 968-1626; 995- 1506; 1011-1609; 1028-1589; 1029-1590; 1032-1684; 1053-1680; 1048-1293; 1051-1514
188/LI: 056882.1:2001MAY17 || 1-573; 150-492; 181-397
189/LI: 059530.1:2001MAY17 jj 2-593; 1-553; 167-580; 325-581; 453-823; 744- 982; 755-1059; 755-1328; 755-1211; 755-1092; 755-1150; 755-1219; 755-1313; 755-1236; 755-1374; 755-1270; 755-1395; 755-1358; 755-951; 757-1048; 755- 1216; 755-1418; 768-1357; 777-1040; 785-875; 869-1029; 940-1407; 984-1337; 1051-1599; 1166-1685; 1182-1620; 1194-1884; 1211-1707; 1241-1654; 1256- 1788; 1261-1646; 1399-1608; 1449-1553; 1530-2261; 1587-2150; 1600-2206; 1594-1854; 1603-1828; 1605-2180; 1603-2220; 1610-2166; 1685-2066; 1689- 2191; 1821-2358; 1900-2182; 1900-2271; 1902-2362; 1905-2029; 1906-2402; 1985-2290; 1986-2245; 2031-2282; 2062-2274; 2077-2271
190/LI:089950.30:2001MAY17 || 438-988; 479-1092; 687-1161; 1285-1804; 1742- 1918; 2041-2259; 1-209; 8-665; 15-283; 15-281; 14-510; 17-884; 17-174; 17- 669; 17-600; 17-321; 25-262; 27-321; 32-488; 34-284; 41-284; 42-316; 41- 513; 42-282; 49-321; 49-295; 54-353; 60-329; 61-549; 66-380; 67-325; 67- 355; 68-313; 74-316; 99-685; 114-739; 122-737; 133-275; 145-554; 144-555; 188-786; 191-771; 213-908; 233-463; 235-465; 252-512; 308-567; 322-860; 336-834; 370-618; 378-1042; 391-1105; 424-1080; 440-1043; 447-677; 456- 1144; 464-618; 481-832; 510-1056; 546-736; 595-671; 782-1331; 824-1477; 848-1479; 1113-1364; 1128-1389; 1324-1463; 1385-1665; 1530-1805; 1647-2004; 1762-2027; 1972-2236; 1984-2253; 2001-2354; 2056-2283; 2082-2354 191/LI:1072906.38:2001MAY17 || 1-528; 301-862; 301-847; 306-987; 310-800; 310-717; 310-559; 310-538; 323-780; 356-970; 361-540; 367-617; 389-983; 404-674; 407-914; 435-521; 443-526; 444-538; 458-961; 465-879; 506-1051; 558-810; 598-893; 598-790; 730-846; 771-821; 771-840; 923-1390; 925-1373; 935-1385; 950-1250; 995-1373; 996-1207; 1017-1605; 1184-1547; 1216-1504; 1220-1505; 1358-1608; 1386-1872; 1422-1695; 1426-1686; 1429-1703; 1430- 1587; 1432-1694; 1440-1694; 1453-1915; 1554-1846; 1563-1910; 1571-1871; 1591-1900; 1644-1899; 1670-1785; 1672-1933; 1718-2209; 1726-2107; 1833- 2069; 1840-2069; 1892-2136; 1899-2160; 1917-2169; 1957-2083; 1974-2184; 2062-2130; 2128-2246; 2137-2425; 2151-2363; 2154-2592; 2154-2615; 2152- 2390; 2154-2551; 2155-2633; 2155-2363; 2298-2423; 2302-2942; 2410-2836; 2412-2489; 2416-2844; 2426-2847; 2432-2608; 2435-2692; 2449-2847; 2449- 2701; 2450-2843; 2457-2642; 2465-2656; 2473-2851; 2484-2843; 2486-2576; 2495-2696; 2543-2815; 2543-2816; 2573-2820; 2573-2816; 2591-2842; 2602- 3216; 2606-2821; 2644-2933; 2655-2896; 2849-2922
192/LI: 1158936.4 :2001MAY17 || 1-581; 167-777; 207-587; 213-842; 241-770; 247-362; 264-625; 290-363; 315-891; 417-919; 475-946; 526-934; 746-1175; 759-870; 806-1176; 837-963; 851-1176; 937-1176; 989-1625; 1007-1176; 1020- 1074; 1052-1175
193/LI:1173412.15:2001MAY17 || 251-366; 259-426; 267-395; 409-650; 474- 1068; 567-832; 696-1310; 870-1363; 1017-1588; 1-344; 194-462; 227-456; 239-
388 ; 237 - -331 ; 238-447; 239-432; 239-453; 244-780; 244-482; 244-710; 248-
832 ; 248 - -798 ; 248-542; 248-523; 248-410; 247-354; 249-440; 251-889; 251-
800 ; 254- -893 ; 255-513; 256-521; 264-515; 259-523; 264-517; 265-496; 267-
512 ; 306- -2483 : 334-966; 371-818; 404-953; 409-718; 417-676; 435-713; 453-
748 ; 461- -726 ; 497-690; 503-990; 508-1132; 561-709; 569-894; 582-793; 635-
945 ; 645- -1311 : 710-1190; 814-1272; 814-1065; 831-1356; 859-1497; 928-1175; 975-1227; 994-1409; 1015-1256; 1041-1448; 1040-1533; 1054-1275; 1060-1365; 1063-1642; 1072-1547; 1082-1222; 1095-1299; 1122-1366; 1149-1355; 1171- 1404; 1176-1408; 1185-1319; 1200-1481; 1241-1528; 1254-1546; 1263-1585; 1275-1340; 1278-1437; 1283-1546; 1283-1497; 1285-1580; 1297-1464; 1294- 1420; 1297-1534; 1313-1557; 1317-1562; 1319-1588;' 1333-1570; 1333-1544; 1397-1631; 1396-1969; 1478-2052; 1725-2269; 1789-2278; 1794-2278; 1801- 2278; 1802-2083; 1835-2278; 1848-2259; 1864-2279; 1885-2242; 1886-2278; 1931-2175; 1943-2242; 1944-2277; 1947-2199; 1950-2468; 1960-2207; 1986- Table 5 2278; 2005-2278; 2046-2278; 2074-2269; 2091-2195; 2115-2279; 2129-2483; 2129-2279; 2177-2471; 2180-2485; 2181-2266; 2202-2483; 2227-2485; 2271- 2472; 2271-2471; 2271-2468; 2271-2464; 2271-2460; 2271-2458; 2271-2427; 2272-2471; 2271-2466; 2280-2471; 2280-2856; 2281-2773; 2280-2744; 2289- 2478; 2290-2458; 2296-2472; 2296-2458; 2311-2458; 2320-2458; 2321-2483 194/LI:1174279.14:2001MAY17 || 192-807; 603-1268; 1027-1253; 1030-1220; 560-1044; 543-1041; 597-1030; 328-904; 172-787; 135-741; 316-613; 1-607; 162-597; 171-595; 160-592; 136-592; 332-592; 225-592; 436-588; 173-582; 132-593; 395-592; 332-550; 24-538; 1-521; 398-492; 74-476; 154-494; 154- 442; 215-422; 215-429; 150-374; 130-331; 6-331; 1-259
195/LI:1174809.1:2001MAY17 || 481-1052; 444-1043; 639-1033; 578-992; 1-533 196/LI:1175131.1:2001MAY17 j| 724-1285; 836-1352; 995-1631; 1104-1511; 1308-1912; 1576-2172; 1743-2178; 1974-2177; 2073-2199; 1-597; 18-550; 18- 413; 29-208; 44-609; 48-345; 128-309; 194-447; 219-493; 226-752; 229-529; 246-590; 290-613; 343-854; 349-614; 446-683; 593-1216; 639-1278; 724-917; 729-1319; 782-1379; 782-1174; 836-1453; 955-1563; 962-1657; 959-1501; 1006- 1312; 1006-1268; 1039-1286; 1087-1705; 1105-1790; 1202-1796; 1232-1507; 1234-1472; 1241-1507; 1324-1896; 1515-2213; 1542-2198; 1547-2063; 1582- 1861; 1580-2030; 1622-1920; 1729-2178; 1767-2196; 1783-2176; 1781-2213; 1905-2177; 1925-2203; 2007-2173; 2022-2178; 2034-2170; 2034-2217; 2082-2177 197/LI:1188801.10:2001MAY17 || 547-1166; 578-1024; 592-1073; 601-805; 601- 1000; 621-769; 628-1235; 630-1140; 742-1333; 757-1013; 757-983; 769-1413; 833-1068; 889-1346; 889-1462; 916-1503; 941-1434; 956-1419; 986-1462; 989- 1628; 1014-1172; 1016-1569; 1083-1593; 1150-1615; 1210-1721; 1337-1580; 1370-1634; 1359-1899; 1359-1743; 1359-1890; 1359-1970; 1359-1648; 1359- 1845; 1360-1576; 1376-1768; 1400-1668; 1400-1732; 1401-1865; 1408-1602; 1430-1904; 1444-1722; 1455-1622; 1456-2018; 1512-1641; 1511-1769; 1582- 1858; 1593-1787; 1604-1902; 1623-1950; 1761-2226; 1775-2221; 1803-2213; 1830-2223; 1876-2225; 1884-2225; 1904-2219; 1930-2209; 1964-2224; 1965- 2222; 1985-2224; 2180-2259; 1562-2013; 1704-1950; 1848-2184; 1927-2226; 2134-2223; 1-527; 1-552; 1-274; 12-280; 45-210; 61-244; 318-958; 332-916; 442-974; 447-985; 459-574; 527-1073; 1-2231; 263-752; 527-778; 1359-1702; 1366-1870; 1408-1593; 1452-1571
198/LI:1189176.27:2001MAY17 || 56-620; 689-744; 1-294; 10-233; 375-829; 646-1057; 647-910; 685-1127; 791-1019
199/LI:197739.4:2001MAY17 || 590-1037; 347-942; 369-1021; 357-1038; 444- 1037; 457-1037; 461-1065; 472-1037; 488-1038; 490-1038; 505-640; 581-1037; 1-274; 25-331; 26-305; 42-102; 59-467; 67-301; 67-593; 67-723; 101-351; 125-285; 123-334; 178-919; 178-651; 229-749; 253-314; 333-499; 599-785; 634-974; 640-1037; 700-1030
200/LI: 2049016.1:2001MAY17 || 1-412; 22-260; 58-509; 61-503; 325-738; 326- 734; 326-739
201/LI:2049137.1:2001MAY17 || 330-704; 233-690; 663-1251; 120-551; 79-310; 1-217; 663-1220; 500-1119; 206-807; 87-664; 386-639; 393-690; 257-690; 232- 679; 314-725; 316-721
202/LI:2051907.1:2001MAY17 || 1-577; 1-630; 54-543; 183-778; 237-763; 264- 943; 295-527; 295-826; 386-819; 381-718; 376-962; 392-997; 394-1012; 479- 1044; 477-1052; 503-938; 582-1125; 520-1006; 522-1043; 533-955; 584-1061; 573-1164; 610-1287; 601-1266; 630-1164; 649-1290; 678-1371; 717-1312; 744- 1293; 743-1323; 783-1308; 803-1305; 829-1323; 840-1301; 848-1294; 853-1471; 870-1293; 896-1470; 910-1544; 945-1489; 981-1748; 1100-1640; 1101-1622; 1156-1691; 1174-1662; 1177-1782; 1188-1625; 1202-1304; 1236-1844; 1361- 1781; 1385-1780; 1517-1781
203/LI:2117996.13:2001MAY17 || 1-649; 338-797; 560-1028; 838-1349; 1-548; 3-567; 31-728; 88-742; 210-751; 254-950; 256-371; 372-990; 379-917; 524- 942; 529-1072; 632-993; 744-1420; 759-1422; 758-1331; 822-1401 204/LI:2118683.15:200lMAY17 || 1368-1966; 1297-1966; 1316-1966; 1324-1965; 1337-1966; 1342-1966; 1330-1966; 1352-1966; 1360-1966; 1348-1966; 1342- 1964; 1275-1965; 1351-1963; 1567-1964; 1298-1959; 1274-1911; 1263-1935; 1631-1851; 1690-1844; 1640-1810; 1174-1806; 1111-1780; 1111-1775; 1111- Table 5 1769; 1127-1760; 1130-1751; 1205-1747; 1111-1747; 1111-1736; 1111-1733; 1111-1730; 1114-1727; 1111-1725; 1244-1727; 1111-1715; 1174-1638; 1140- 1638; 1205-1638; 1217-1638; 1250-1638; 1276-1638; 1298-1638; 1319-1638; 1328-1638; 1330-1638; 1432-1638; 1443-1638; 1463-1637; 1216-1638; 1134- 1637; 1448-1637; 1202-1637; 1242-1629; 1295-1629; 1365-1629; 1134-1628; 1187-1628; 1111-1623; 1156-1620; 1163-1620; 1434-1620; 1253-1620; 1238- 1617; 1003-1612; 1147-1609; 1215-1609; 1198-1609; 1239-1609; 1353-1609; 1159-1606; 1319-1602; 1338-1599; 1365-1596; 1187-1592; 1110-1585; 1111- 1550; 1111-1541; 1003-1541; 1111-1536; 1126-1530; 1111-1518; 1111-1515; 1111-1510; 985-1503; 1043-1501; 1138-1501; 1009-1405; 1003-1404; 1208-1322; 886-1147; 511-1149; 560-1117; 692-1052; 780-1034; 855-1023; 327-894; 302- 894; 471-871; 463-852; 720-844; 555-810; 492-805; 483 -805 ; 439-788 ; 122- 696; 1-497; 1-260; 1-207
205/LI:2120312.1:2001MAY17 || 1-232; 1-246; 1-306; 163 -571 , : 163 -805 ; 163 728; 163-832; 163-456; 163-703; 191-874; 210-573; 260-895 ; 341-640 ; 374- 1073; 426-1127; 622-1088; 618-1358; 716-1263; 743-1378; 744-1370; 753-1276; 805-1373; 861-1306; 863-1317; 897-1302; 948-1353
206/LI:2121328.17:2001MAYl7 || 716-808; 716-807; 716-811; 718-841; 717-810; 1-528; 1-348; 1-574; 20-348; 19-404; 69-817; 84-808; 126-808; 137-808; 140- 820; 143-819; 145-809; 141-348; 151-815; 170-827; 175-879; 178-816; 179- 809; 181-824; 207-760; 207-808; 222-973; 224-811; 244-848; 246-815; 260- 921; 275-837; 310-808; 325-812; 433-820; 540-810; 635-809; 711-814; 279- 814; 595-1112; 716-813; 717-815
207/LI:2121802.5:2001MAY17 || 1-583; 28-528; 21-673; 20-601; 20-618; 21- 557; 16-687; 20-535; 20-130; 20-483; 20-576; 20-658; 61-658; 87-536; 128- 693; 131-787; 167-500; 210-617; 210-733; 210-600; 211-663; 210-535; 242- 577; 242-714; 247-875; 298-633; 298-739; 317-725; 332-932; 332-593; 350- 787; 378-849; 400-714; 400-813; 400-868; 401-849; 406-848; 409-927; 411- 1004; 418-926; 420-927; 445-924; 459-927; 459-1010; 487-849; 487-927; 488- 849; 498-958; 514-1059; 513-1057; 514-1068; 514-973; 514-883; 515-933; 515- 1007; 515-814; 518-849; 541-1028; 554-927; 568-1157; 583-1004; 612-927; 625-1043; 645-1088; 981-1346
208/LI:2123406.9:2001MAY17 || 5-608; 334-619; 444-615; 444-612; 445-616; '444-616; 403-616; 269-616; 269-615; 428-615; 1-615; 9-615; 3-615; 354-608; 407-611; 444-611; 428-609; 269-522
209/LI:216129.45:200lMAY17 || 977-1461; 1154-1410; 1183-1437; 1011-1437; 1015-1433; 1023-1279; 1023-1296; 1035-1473; 1034-1286; 1034-1280; 1040- 1519; 1045-1683; 1045-1363; 1054-1378; 1061-1576; 1058-1479; 1061-1478; 1061-1434; 1064-1417; 1078-1592; 1077-1658; 1093-1606; 1094-1501; 1095- 1356; 1097-1384; 900-1402; 909-1449; 929-1439; 941-1288; 946-1037; 966- 1495; 970-1553; 977-1348; 998-1706; 1002-1202; 1018-1465; 1014-1511; 1119- 1550; 1122-1383; 1139-1367; 1152-1770; 1154-1398; 1165-1466; 1173-1453; 1176-1345; 1178-1455; 1099-1340; 1109-1746; 1112-1353; 1183-1405; 1184- 1459; 1193-1472; 1197-1480; 1195-1431; 1202-1460; 1208-1503; 1209-1455; 1210-1666; 1340-1960; 1366-1496; 1372-1620; 1213-1473; 1213-1465; 1224- 1418; 1229-1461; 1231-1466; 1246-1556; 1252-1480; 1252-1482; 1375-1543; 1292-1474; 1332-1493; 1332-1464; 1337-1684; 1385-1676; 1404-1673; 1423- 1676; 1493-1731; 1-284; 53-367; 118-372; 126-740; 129-582; 172-408; 561- 867; 648-1235; 690-1359; 694-1331; 707-1291; 768-849; 785-1240; 820-1474; 828-1038; 830-1306; 836-1474; 837-1425; 838-1509; 845-1171; 860-1427; 876- 1513; 891-1623; 895-1526 210/LI:2186630.1:2001MAY17 || 1-590
211/LI:2188206.2:2001MAY17 jj 484-738; 163-743; 104-421; 1-329; 32-195; 19- 461; 1-457; 74-446; 343-445; 375-428; 116-421; 793-979; 562-940 212/LI:2199710.9:2001MAY17 || 1194-1358; 1195-1608; 1194-1621; 1203-1635; 1203-1795; 1203-1781; 1203-1745; 1203-1471; 1209-1806; 1212-1632; 1194- 1415; 1229-1613; 1233-1691; 1235-1616; 1240-1683; 1243-1687; 1206-1664; 1237-1452; 1240-1575; 1242-1342; 1243-1442; 1251-1506; 1254-1646; 1256- 1517; 1257-1662; 1257-1611; 1256-1485; 1255-1339; 1256-1408; 1266-1580; 1267-1482; 1273-1876; 1273-1680; 1273-1507; 1257-1677; 1311-1900; 1312- Table 5 1456; 1333-1561; 1339-1578; 1300-1575; 1315-2096; 1373-1933; 1385-1697; 1407-1637; 1421-1597; 1454-1708; 1458-1588; 1473-1777; 1476-2053; 1479- 2077; 1488-2019; 1493-1660; 1501-2063; 1513-2095; 1527-1799; 1553-1809; 1579-2182; 1687-2241; 1607-1744; 1619-1848; 1627-2182; 1653-1937; 1664- 2246; 1701-1947; 1729-2030; 1744-2024; 1752-2249; 1752-2038; 1762-2182; 1718-1967; 1794-2088; 1800-2298; 1797-2059; 1816-2288; 1823-2364; 1823- 2366; 1908-2242; 1845-2394; 1846-2313; 1853-2290; 1856-2139; 1871-2306; 1946-2304; 1962-2366; 1901-2366; 1904-2405; 1976-2202; 1909-2578; 1927- 2299; 1998-2178; 2016-2120; 2029-2366; 2051-2366; 1981-2366; 2053-2337; 2053-2317; 2069-2366; 2028-2199; 2029-2305; 2108-2337; 2068-2317; 2125- 2366; 2126-2366; 2152-2382; 2169-2495; 2122-2298; 2165-2317; 2167-2317; 2182-2333; 2233-2333; 2237-2319; 2239-2367; 2243-2317; 2225-2302; 2263- 2352; 2-65; 1-243; 1-457; 23-557; 19-236; 26-209; 23-327; 23-648; 23-224; 31-198; 151-514; 286-872; 382-1008; 382-1021; 483-1043; 578-1192; 606-895; 714-1200; 715-1201; 740-1175; 836-1201; 835-1201; 906-1500; 941-1192; 1193- 1618; 1193-1587; 1194-1628; 1194-1609; 1194-1572; 1194-1563; 1194-1560; 1194-1539; 1194-1461; 1193-1385; 1195-1693; 1194-1685; 1194-1629; 1194- 1650; 1194-1618; 1194-1544; 1194-1523; 1194-1459; 1194-1454; 1194-1429; 1194-1412; 1194-1380
213/LI:2209335.2:2001MAY17 || 671-967; 695-896; 701-1296; 702-1224; 704- 1251; 704-1362; 704-1321; 698-1347; 719-1191; 704-1332; 720-1306; 747-1427; 755-1347; 799-1299; 800-1451; 846-1415; 868-1216; 1039-1316; 1068-1361; 1134-1621; 1302-1809; 1-480; 1-508; 392-788; 704-1333; 747-1333; 1029-1416; 1535-1853
214/LI:230980.13:2001MAY17 || 1-522; 50-701; 150-784; 173-814; 350-880; 367-952; 401-1088; 466-1223; 486-1223; 536-1257; 597-1259; 602-1348; 607- 1339; 647-1351; 665-1302; 665-1178; 686-1267; 705-1327; 709-1298; 713-1245; 772-1483; 844-1339; 911-1341; 908-1800; 978-1339; 973-1367; 988-1404; 1015- 1340; 1017-1341; 1023-1215; 1039-1341; 1042-1719; 1091-1784; 1153-1492; 1186-1495; 1187-1495; 1276-1976
215/LI:244421.37:2001MAY17 || 1-554; 1-350; 1-244; 65-323; 91-554; 232-728; 591-1337; 601-1336; 600-1312; 643-1233; 648-1228; 648-1325; 648-1243; 648- 1215; 648-908; 648-1376; 725-1442; 763-1352; 768-1492; 914-1560; 922-1314; 1050-1807; 1135-1578; 1173-1703; 1257-1576; 1344-1867; 1384-1661; 1423- 1679; 1433-2184; 1451-1747; 1446-2091; 1497-1672; 1584-2091; 1614-2158; 1616-2155; 1620-2177; 1623-2148; 1628-1901; 1636-2086; 1642-2145; 1651- 2079; 1693-2161; 1693-1925; 1704-1914; 1713-1955; 1873-1962; 1981-2173; 650-1272
216/LI:341998.1:2001MAY17 || 1-606; 1-592; 22-593; 181-592; 181-621; 209- 558; 286-582
217/LI:347931.10:2001MAY17 || 788-1406; 789-973; 796-1300; 809-1083; 848- 1126; 886-1097; 887-1470; 890-1502; 926-1498; 997-1652; 1017-1469; 1019- 1473; 1015-1760; 1057-1468; 1065-1496; 1084-1784; 1092-1235; 1126-1729; 1129-1839; 1141-1641; 1167-1574; 1193-1412; 1215-1962; 1267-1863; 1275- 1741; 1343-1920; 1347-1832; 1352-1799; 1365-2002; 1380-1629; 1397-1981; 1405-1950; 1434-1672; 1452-1906; 1453-2147; 1498-1950; 1498-1693; 1504- 2054; 1540-1902; 1549-2264; 1564-2110; 1553-1645; 1569-2224; 1567-2253; 1582-2090; 1598-2229; 1632-1719; 1644-2222; 1649-1975; 1658-2270; 1670- 2201; 1676-2369; 1704-2265; 1707-2089; 1712-2114; 1716-2273; 1729-2236; 1754-2230; 1740-2368; 1774-2361; 1776-2356; 1785-2292; 1803-2376; 1803- 2349; 1830-2419; 1836-2085; 1856-2350; 1862-2394; 1862-2228; 1862-2117; 1871-2514; 1912-2060; 1924-2185; 1950-2516; 1950-2645; 1968-2475; 1960- 2031; 1963-2418; 1981-2183; 1984-2478; 1992-2276; 1996-2278; 2027-2177; 2041-2547; 2042-2539; 2042-2444; 2042-2374; 2042-2117; 2050-2555; 2057- 2338; 2065-2552; 2076-2562; 2111-2657; 2117-2747; 2137-2367; 2158-2486; 2150-2738; 2149-2613; 2157-2395; 2157-2723; 2167-2676; 2234-2518; 2248- 2715; 2310-2842; 2313-2847; 2340-2743; 1257-1519; 1-658; 5-711; 29-455; 29- 179; 41-254; 65-497; 65-219; 162-2239; 226-792; 234-824; 239-857; 254-930; 256-469; 262-932; 260-516; 263-909; 283-959; 330-880; 348-822; 360-788; 393-901; 392-1104; 401-1038; 399-580; 430-998; 429-1000; 430-1000; 443-993; Table 5 445-936; 445-1201; 459-626; 469-727; 500-1062; 508-866; 560-1065; 560-845; 556-1098; 557-951; 571-1081; 571-1082; 583-844; 595-1221; 628-1135; 681- 1101; 682-1419; 722-1381; 787-1184; 2341-2831; 2348-2901; 2356-2544; 2364- 2801; 2376-2638; 2383-2853; 2398-2581; 2397-2593; 2400-2890; 2403-2880; 2405-2594; 2433-2908; 2440-2877; 2442-2904; 2444-2875; 2451-2875; 2451- 2868; 2453-2888; 2482-2882; 2486-2905; 2499-2901; 2529-2914; 2536-2901; 2542-2863; 2558-2908; 2558-2882; 2578-2902; 2593-3098; 2593-2857; 2602- 2882; 2609-2784; 2652-2911; 2656-2908; 2655-2887; 2833-2882; 3001-3422, 3001-3452; 3029-3577; 3333-3888; 3423-3850; 3575-4122; 3575-4019; 3575- 4012; 3791-4096; 3861-4144; 3907-4491; 4068-4535; 4127-4534; 4236-4754; 4236-4533; 4252-4713; 4349-4713; 4614-4713; 1218-1666; 1438-1578; 2621- 2879; 1257-1520; 1808-2188; 1855-2285; 1275-1710; 1643-2163; 1183-1717; 1283-1821; 1208-1739; 1068-1606; 679-1222; 679-1227; 1197-1751; 1176-1736; 3680-4239; 1032-1592; 1026-1592; 2285-2864; 896-1479; 896-1480; 641-1261; 1562-2203; 822-1469; 1563-2204; 1196-1841; 642-1313; 1069-1759; 844-1526 218/LI:350771.42:2001MAY17 || 935-1045; 1-545; 89-613; 148-338; 155-303; 158-403; 172-431; 204-287; 207-412; 290-668; 289-412; 292-380; 562-1110; 564-771; 846-1092; 850-1068; 856-1044; 857-1089; 861-1119; 863-1128; 864- 1129; 864-1048; 865-1119; 868-1120; 871-1110; 871-1003; 889-1020; 910-1113; 915-1115; 915-1096; 966-1166
219/LI: 354423.6 :2001MAY17 || 268-532; 699-880; 775-1215; 930-1640; 1359- 1754; 1448-1569; 1-481; 135-413; 357-647; 363-666; 390-957; 395-652; 591- 896; 763-1369; 764-1218; 767-1216; 775-1304; 783-1044; 783-1183; 784-1044; 845-1043; 1066-1739; 1104-1176; 1114-1715; 1359-1488; 1359-1527; 1359-1713; 1359-1677; 1431-1550; 1445-1664; 1459-1677; 1459-1793; 1481-1753; 1517- 1693; 1566-1833; 1581-1827; 1581-1796; 1649-1947; 1649-1837; 1651-1826; 1682-1764; 1709-1855; 1721-2091; 1713-1899; 1728-2062; 1773-1983; 1810- 2387; 1852-2028; 1857-2055
220/LI:399333.8:2001MAY17 || 1-482; 77-351; 106-726; 106-711; 106-353; 115- 660; 185-533; 222-625; 225-953; 312-548; 484-986; 688-1162; 709-854; 741- 832; 741-1219; 765-1291; 819-1349; 841-1112; 868-1456; 895-1126; 926-1554; 959-1576; 1000-1623; 1016-1627; 1138-1339; 1170-1681; 1170-1422; 1185-1602; 1229-1372; 1231-1486; 1311-1444; 1263-1643; 1263-1487; 1270-1876; 1345- 1631; 1378-1582; 1426-1985; 1426-1880; 1437-2078; 1515-2070; 1535-2161; 1624-2127; 1661-1914; 1664-2052; 1668-1788; 1693-2167; 1715-2341; 1788- 2400; 1916-2460; 2036-2543; 2036-2552; 2036-2339; 2063-2728; 2077-2231; 2103-2353; 2122-2379; 2124-2610; 2135-2567; 2137-2424; 2143-2447; 2183- 2709; 2188-2754; 2224-2775; 2248-2466; 2289-2761; 2290-2531; 2291-2537; 2238-2425; 2318-2885; 2356-2831; 2356-2605; 2371-2644; 2413-2659; 2430- 2933; 2481-2698; 2481-2644; 2554-2798; 2630-2754
221/LI:445084.36:2001MAY17 || 438-555; 1-253; 12-145; 64-296; 154-553; 196- 626; 196-465; 202-552; 229-561; 270-552; 291-539; 266-543; 404-555; 444- 552; 500-555
222/LI:454087.3:2001MAYl7 || 829-1387; 1-540; 8-537; 13-528; 251-778; 283- 735; 339-717; 615-1136; 700-1272; 704-1254; 897-1450
223/LI:474887.1:2001MAYl7 || 1-318; 305-845; 1120-1591; 1277-1944; 1865- 1998; 2135-2790; 2463-2823; 2540-3221; 2756-3419; 2866-3006; 1-596; 12-254; 12-111; 83-676; 119-483; 123-386; 386-956; 428-665; 429-680; 441-680; 456- 1070; 702-1075; 835-1297; 901-958; 1013-1384; 1052-1591; 1075-1352; 1139- 1508; 1231-1591; 1229-1590; 1260-1944; 1293-1591; 1310-1591; 1515-1591; 1865-2218; 1892-2322; 1933-2199; 2130-2443; 2132-2377; 2134-2374; 2225- 2775; 2461-2807; 2464-2882; 2454-2935; 2457-2706; 2463-2849; 2465-2873; 2532-2771; 2578-2831; 2570-2828; 2570-3255; 2663-3218; 2749-3419; 2784- 3419; 2795-3419; 2848-3006; 2866-2991; 2868-3006
224/LI:745251.1:2001MAY17 || 1-649; 1-230; 4-713; 3-238; 192-248; 192-354; 202-641; 367-1046
225/LI:747717.9:2001MAY17 || 462-1213; 580-1140; 371-1051; 222-1046; 589- 968; 209-940; 1-884; 284-881; 198-879; 38-818; 4-786; 41-777; 294-763; 38- 683; 38-667; 38-632; 39-625; 39-570; 39-538; 39-521; 39-488 Table 5 226/LI:806211.3:2001MAY17 || 1-383; 9-505; 1 1-209; 35-521; 35-325; 35-134; 35-446; 35-443; 35-163; 62-144; 62-252; 62-117; 415-994; 453-913; 602-905; 602-900; 832-1062 227/LI : 815072.1 : 2001 AY17 || 36-304; 153-383; 153-375; 153-359; 153-290; 161-530; 1-147; 32-519 228/LI: 817052.8 :2001MAY17 I I 752-850; 752-13 28; 1 -576; 157-24 72; 237-750; 300-761; 413-645; 429-715 565-826; 607-676; 708-1272; 726-1130; 748-1109; 2040-2484; 2042-2448; 2049-2483; 2052-2458; 2068-2444; 2078-2415; 2086- 2415; 2097-2415; 2130-2430; 2132-2415; 2142 2290; 2155 2451; 2155-2415; 2158-2473; 2161-2458; 2171-2473; 2171-2466; 2172- 2464; 2172-2324; 2189- 2458; 2240-2473; 2240-2449; 2247-2550; 2250-2323; 2303-2411; 756-1293; 759- 1048; 763-1389; 848-1366; 1949-2220; 881-1133; 1949-2217; 896-1519; 925- 1487; 925-1209; 1987-2415; 951-1198; 1992-2415; 1998-2458; 977-1470; 1999- 2249; 992-1219; 1109-1267; 1112-1334; 1115-1606; 1116-1395; 2002-2415; 2008-2458; 1116-1610; 1123-1713; 1146-1606; 1189-1473; 1198-1887; 1226- 1490; 1227-1785; 1230-1507; 1246-1409; 1278-1862; 1278 1877 1295-1922; 1323-1690; 1361-1752; 1361-1746; 1385-1902; 1385-1614; 1394 954; 1411- 1706; 1423-1695; 1450-1620; 1473-1866; 1531-1927; 1531 1777 1554-1780; 1631-1863; 1635-1930; 1636-1895; 1638-1744; 1655-1950; 1684 153; 1692- 2317; 1700-1933; 1724-2177; 1729-2006; 1766-2078; 1768 1959 1808-2172; 1810-2073; 1867-2324; 1867-2150; 1881-2473; 1915-2473; 1915 979; 1923- 2473; 1930-2474; 2018-2473; 2020-2483 229/LI: 903392.45 :2001MAY17 || 2-513; 3-649; 1-3 47; 1-34 5; 9- 588; 1 3-412; 17-388; 22-398; 39-354; 54-157; 56-730; 82-5 74; 86-509; 91-584; 12 4-616; 128-584; 150-718; 182-805; 169-715; 173-722 177-438; 2 08-437; 208 -745;
224-795; 217-594; 226-789; 228-739; 260-941 262-816; 2 73-538; 292 -816;
292-537; 301-847; 321-610; 323-854; 329-593 331-988; 3 38-760; 338 -806;
357-588; 387-531; 389-955; 392-641; 416-1142 ; 431-677; 456-936; 46 5-1034;
473-1089; 490-777;; 519-1145; 522-1070; 533-9 51; 539-990 556-1190; 611-861;
611-1262; 637-840;: 640-910; 724-935; 780-976 ; 784-875 806-1070; 645-777 230/LI:013724.1:2001MAY17 || 1-358; 7-362; 7 -381; 7-357 ; 7-384; 7-361; 12- 657; 106-793; 163-586; 235-352; 325-473; 408 -1011; 468- 1033; 563-1051; 1099-1735; 1-363; 7-363; 7-383; 12-260; 12-3 59; 12-149; 22-292; 25 -258; 3- 593; 8-463; 12-463; 12-595; 12-602; 11-295; 12-604; 12 486; 12-532 ; 12-564; 12-557; 12-555; 51-610; 12-538; 12-537; 12-6 23; 12-473; 12-517; 14-468; 14- 457; 14-545; 14-524; 14-425; 14-356; 18-320; 18-529; 18 469; 18-580; 18-
604; 26-352; 31-334; 36-715; 40-682; 46-793; 51-400; 51 470; 100-296; 105- 164; 127-764 ; 129-428; 129-357; 133-447; 167 -614; 149-8 28; 227-800 ; 200- 755; 232-462 ; 255-813; 256-838; 294-420; 294 -599; 297-7 53; 330-966 ; 329- 712; 383-606 ; 372-1071; 438-612; 424-884; 42 6-878; 432- 944; 480-905; 519- 1131; 521-765; 543-864; 553-1150; 593-1151; 825-945; 82 3-1420; 833-1053; 1115-1720; 1123-1364; 1326-1896; 1369-1638 231/LI:191726.16:2001MAY17 || 780-1612; 770- 1063; 806- 1003; 795-1332; 823- 1170; 805-1271; 810-1524; 808-1511; 810-1482 ; 827-1586 ; 871-1365; 849- 1391; 861-1151; 874-1555; 870-1636; 879-1391; 887-1521; 866-iθ89; 885-1455; 887- 1351; 882-1627; 898-1617; 924-1644; 925-1530 ; 923 -1638 ; 956-1445; 924- 1550; 925-1554; 943-1368; 946-1539; 955-1469; 956-1463; 966-1462; 978-1520; 977- 1447; 990-1708; 1011-1622; 1018-1689; 1037-1686; 1042-1698; 1033-1466; 1046-1547; 1055-1281; 1082-1648; 1073-1558; 1075-1786; 1161-1843; 1234 1456; 1239-1460; 1248-1458; 1254-1830; 1254-1460; 1305-1392; 1306-1645 1312-1842; 1375-1784; 1392-1915; 1354-1698; 1364-1579; 1364-1575; 1412 1633; 1446-1777; 1459-1715; 1459-1673; 1489-1754; 1605-1843; 1662-2248 1921-2165; 2012-2170; 21-474; 1-632; 1-724; 1-428 1-798; 1-660; 1-459 ; 1- 787; 1-680; 88-483; 191-958; 169-318; 222-1088; 211-932; 204-921; 175- 813; 221-1135; 283-723; 285-817; 285-804; 298-985 ; 324-807; 349-809; 357-90 9; 358-933; 360-1048; 365-802; 369-1011; 376-842; 338-1213; 385-837; 396- 1050; 438-857; 439-831; 446-955; 448-976; 412-639; 460-1051; 462-905; 469-11 60; 468-916; 471-1028; 474-1144; 481-1136; 499-989; 512-931; 496-1311; 505 1274; 505-1226; 557-1077; 574-1071; 538-1431 ; 559 1301 ; 603-927; 565-1 270; 588-1218; 638-1298; 631-1270; 648-1385; 677-1143; 655-1225; 681-1401; 714- Table 5
1130; 682-1107; 685-1165; 695-1192; 717-928; 716-1374; 749-1149; 734-1390;
736-1299; 775-1103; 796-1529; 764-1445; 767-1289; 768-1257; 767-1453; 776-
1497
232/LI:202 270.2 :2001MAY17 || 1811-2091; 1871-235 8; 1980-225 6; 2057-2653;
2148-2749; 2260-2728; 2329-2752; 2383-2764; 2454-2654; 1-376; 1-414; 1-595;
152-300; 188-872; 301-597; 403-1006; 405-1021; 881-1472; 1220-1767; 1230-
1507; 1281-1557; 1305-1544; 1345-1608; 1493-1816 1504-1763 ; 1535-1889;
1535-1807; 1606-1893; 1751-2035; 1782-2377; 1803-1954; 1826-2061; 1839-
2100; 1857-2123; 1857-2141; 1857-2208; 1872-2124 1890-2015 ; 1905-2084;
1909-2155; 2012-2545; 2024-2250; 2040-2463; 2042 2626; 2098-2251; 2127-
2743; 2138-2404; 2140-2372; 2149-2539; 2189-2453 2199-2531 ; 2199-2442;
2199-2763; 2284-2565; 2279-2748; 2306-2764; 2309-2758; 2329-2532; 2336-
2764; 2342-2689; 2380-2472; 2395-2764; 2402-2753 2431-2714 ; 2454-2764;
2455-2664; 2454-2713; 2455-2751; 2456-2648; 2456-2717; 2457-2684; 2457-
2701; 2457-2686; 2463-2761; 2509-2753; 2565-2796 2645-2750
233/LI:2119352.6:2001MAY17 || 807-979; 330-975; 401-975; 67 3-967; 656-965;
749-965; 571-964; 566-963; 670-963 803-962; 539-961; 662-961; 785-961;
330-959 97-960 530-960; 773-960 534-958; 544-959; 545-959; 626-959;
651-959 20-957 511-958; 500-958 505-959; 530-958; 537-958; 562-958;
566-958 90-958 672-958; 677-958 689-958; 719-958; 748-958; 788-958;
792-958 06-958 619-957; 646-957 673 -957; 668-958; 702-957; 822-957;
824-957 47-956 726-956; 776-954 666-948; 688-918; 820-916; 432-852; 21-
833; 21-83 5; 297-713; 25-669; 260-613; 3-568 38-574; 245-563; 380-553;
403-542; 215-536; 14-534; 1-524; 13-507 ; 396-469 ,- 21-459; 180-392; 179-390;
127-384; 32-330; 25-290; 31-283; 53-283 ; 14-279; 27-271; 34-262; 12-258;
80-252; 14-238; 1-237; 98-235; 56-229; 21-221; 60-222; 15-214; 21-196; 13-
193; 40-125
234/LI:220 7776.11:2001MAY17 || 1-631; 1 3-554; 14-73; 1 08-5 51; 11 5-691; 207-
592; 232-650; 245-763; 277-643; 283-785 ; 311-879; 319- 942; 468-8 38; 482-
640; 488-653; 619-1134; 704-974; 729-1036; 842-1456; 8 89-1128; 9 66-1202;
1011-1577; 1097-1449; 1119-1590; 1127-1300; 1135-1368; 1160-1463 ; 1196-
1445; 1198-1838; 1230-1675; 1250-1857; 1255-1490; 1279 -1909; 129 9-1417;
1342-1593; 1342-1787; 1342-1864; 1342-1591; 1367-1861; 1354-1942 ; 1383-
2006; 1410-1982; 1419-1663; 1456-1725; 1459-1951; 1459 1697; 146 7-1973;
1479-2012; 1469-1639; 1470-1970; 1473-1939; 1492-1756; 1501-1769 ; 1519-
1756; 1528-1639; 1550-1639; 1558-2015; 1584-1825; 1587 -2012; 158 0-2007;
1603-2008; 1588-1855; 1616-2012; 1629-2016; 1610-2008; 1631-2012 ; 1647-
2017; 1639-2012; 1660-2012; 1663-2012; 1657-2012; 1665 1893; 169 8-2008;
1700-1854; 1689-1976; 1709-2012; 1773-2012; 1830-2008; 1815-2007 ; 1859-
2012; 1872-2012; 1874-2012; 1877-2008; 1891-2009; 1914 2008; 193 8-1997
235/LI:256442.1:2001MAY17 || 1451-2137; 1-375; 38-547; 47-547; 9 9-691; 603-
1008; 814-1084; 945-1525; 1426-1527; 1443-1595 ; 1447-1 857; 1630- 2158
236/LI:330497.7:2001MAY17 || 1-511; 1-522; 15-586; 1-4 62; 15-435 ; 33-574
237/LI:018494.1:2001MAY17 |j 1-242; 49-355; 283-736; 6 10-1351; 6 03-1096;
603-1137; 603-1153; 604-846; 606-859; 1-390; 603-1333; 861-1332; 845-1712;
859-1359; 868-1378; 923-1388; 1067-1593 ; 1022-1761; 10 62-1681; 1158-2014;
1252-1490; 1313-2034; 1353-1932; 1387-1741; 1388-1958; 1412-1952 ; 1430-
1547; 1430-1698; 1432-1578; 1497-2206; 1490-2156; 1472 -1990; 1493-2009;
1506-2195; 1558-2186; 1546-1998; 1672-2309; 1680-2311; 1769-2315 ; 1853-
2252; 1856-2454; 1907-2337; 1908-2337; 1905-2769; 1905 -2727; 1946-2513,
1954-2214; 1971-2577; 1994-2462; 2039-2642; 2057-2649; 2085-2556 ; 2084-
2245; 1775-2315; 1790-2265; 1790-2182; 1803-2305; 1814 -2553; 2101-2622;
2111-2477; 2216-2562; 2266-2712; 2309-2752; 2315-2746; 2502-2749 ,- 2615-
2751; 2617-2751; 2622-2755
238/LI:023518.2 :2001MAY17 || 731-1224; 877-1224 ; 879-1224 ; 893-1224 ; 899-
1224; 905-1224; 898-1224; 447-1193; 1093 -1224 ; 1103 -1224 ; 844-1219 ; 977-
1216; 774-1193; 525-1178; 752-1163; 582 -1150 ; 497-1056 ; 977-1224 ; 890-1729 ;
1070-1641; 979-1636; 884-1615; 822-1552 ; 859-1434 ; 612-1242 ; 890-1231 ; 918-
1231; 1047-1231; 832-1226; 422-1007; 260-969 ; 335-963 ; 277-961 ; 388-949 ; Table 5 490-944; 668-944; 388-939; 584-927; 228-871; 395-817; 263-800; 240-798; 256-789; 153-737; 1-644; 1-563; 178-519; 1-468
239/ I: 053488.46 :2001MAY17 || 1885-1975; 1-195; 1-498; 10-449; 10-244; 10- 240; 10-242; 14-514; 13-505; 14-303; 14-288; 15-498; 15-154; 15-142; 17- 209; 18-498; 19-244; 19-249; 29-293; 30-469; 33-225; 35-331; 38-257; 40- 452; 44-234; 45-643; 49-129; 79-255; 91-158; 91-223; 91-225; 162-225; 163- 443; 183-817; 206-499; 293-829; 310-498; 315-580; 324-498; 366-947; 398- 893; 421-1044; 514-790; 583-1235; 695-1246; 726-1225; 801-1329; 811-1306; 811-1234; 813-1391; 822-1291; 824-1364; 826-1186; 838-1075; 875-2031; 899- 1427; 933-1418; 1002-1294; 1096-1398; 1098-1433; 1336-1947; 1416-1672; 1460-1702; 1465-1737; 1527-1779; 1617-1902; 1699-1946; 1726-1994; 1758- 1946; 380-498; 1637-1923; 973-1294; 1461-1923; 1497-2026; 1486-2031 240/LI: 058298.27 :2001MAY17 || 538-1288; 781-1246; 751-1246; 588-1281; 1090- 1271; 688-1249; 646-1246; 599-1247; 798-1246; 819-1246; 785-1246; 579-1249; 708-1246; 881-1246; 633-1247; 738-1197; 480-1187; 498-1119; 513-1158; 616- 1111; 447-1092; 338-1036; 365-963; 190-930; 319-924; 24-766; 12-711; 1-710; 1-692
241/LI:1110046.1:2001MAY17 || 931-1360; 732-1194; 638-1095; 528-1071; 697- 1027; 412-1009; 364-1008; 478-974; 660-934; 192-866; 319-961; 300-880; 365- 831; 250-828; 196-763; 616-730; 5-520; 1-548; 1-507; 36-388; 36-352; 23- 353; 22-353; 149-350; 84-292; 21-284; 1-247; 482-1112; 693-1194; 1324-1830; 1539-1815; 1429-1811; 1514-1807; 1673-1806; 1393-.1806; 1259-1806; 1502- 1803; 1312-1702; 1243-1701; 1110-1695; 1336-1689; 1261-1444; 877-1416; 895- 1369
242/LI:1166752.11:2001MAYl7 || 545-948; 838-1384; 913-1562; 1000-1661; 1058-1696; 1137-1644; 1171-1447; 1265-1527; 1425-1707; 1-507; 1-588; 12- 556; 3-441; 3-440; 3-411; 58-436; 58-451; 428-665; 454-966; 464-848; 466- 692; 556-859; 723-904; 724-1207; 832-1273; 846-1544; 866-1441; 865-1435; 903-1303; 910-1409; 951-1542; 970-1531; 973-1341; 991-1582; 1018-1710; 1028-1412; 1038-1581; 1055-1600; 1080-1603; 1085-1282; 1088-1744; 1124- 1745; 1128-1707; 1146-1548; 1147-1452; 1152-1698; 1169-1680; 1190-1696; 1197-1595; 1197-1357; 1265-1766; 1283-1696; 1297-1906; 1357-1724; 1388- 1708; 1397-1582; 1562-1708; 1598-1736; 1615-1734
243/LI:1173766.1:200lMAY17 || 6-379; 5-637; 8-504; 7-301; 7-96; 7-303; 11- 359; 16-272; 26-291; 26-613; 215-333; 400-843; 26-620; 26-541; 26-693; 559- 612; 674-1280; 690-1284; 731-1303; 732-1339; 732-1179; 769-1291; 26-225; 26-388; 26-701; 771-1030; 959-1203; 27-592; 27-337; 1061-1635; 1240-1836; 1303-1544; 1352-1642; 1362-1798; 1362-1614; 1444-1682; 27-350; 26-292; 29- 481; 40-572; 74-271; 92-616; 94-243; 125-280; 172-484; 1461-2060; 1469- 1826; 1474-1738; 1484-1980; 1651-1941; 1704-2001; 1719-2282; 1779-2012; 1797-2364; 1461-1786; 1912-2465; 1913-2382; 1915-2203; 1929-2346; 1932- 2118; 1950-2214; 1974-2414; 1975-2221; 1995-2279; 2191-2383; 2200-2690; 2200-2425; 2205-2731; 2270-2755; 2282-2529; 2320-2759; 2322-2734; 2323- 2626; 2325-2780; 2327-2620; 2349-2743; 2416-2780; 2415-2780; 2420-2780; 2433-2719; 2433-2758; 2466-2732; 2470-2780; 2482-2994; 2502-2587; 2509- 2682; 2565-2780; 2577-2933; 2607-2966; 2615-2780; 2649-2780; 2671-2780; 2677-2780; 2678-2780; 2676-2780; 2721-2984; 2721-2989; 2721-2781; 2721- 2780; 2729-3091; 2837-2985; 2874-3049; 2905-2973; 2635-2781; 2724-2780; 2572-2780; 1-225; 1-466; 4-259; 5-589
244/LI:1177952.4:2001MAYl7 || 1-599; 1-608; 131-756; 209-572; 212-572; 328- 879; 328-630; 350-616; 433-691; 535-688; 572-825; 589-1213; 617-1286; 635- 766; 731-1432; 763-1390; 771-1435; 784-1451; 791-1466; 793-1469; 820-1404; 809-1072; 821-1506; 818-1425; 835-1425; 846-1533; 879-1267; 879-1036; 887- 1522; 920-1469; 920-1539; 928-1454; 930-1538; 929-1495; 960-1608; 960-1362; 984-1608; 990-1621; 998-1617; 1013-1669; 1082-1335; 1085-1235; 1120-1395; 1140-1656; 1135-1522; 1160-1776; 1146-1527; 1160-1644; 1161-1482; 2148- 2259; 1054-1713; 1069-1351; 1081-1464; 2015-2211; 2014-2154; 2091-2253; 1046-1578; 1054-1475; 1162-1385; 1179-1801; 1206-1856; 1214-1455; 1235- 1841; 1260-1794; 1265-1934; 1265-1816; 1298-2000; 1311-1970; 1311-1824; 1310-1550; 1314-1789; 1350-1624; 1360-2057; 1371-2039; 1379-1874; 1389- Table 5
1906; 1413-1940 ; 1429 -1695, 1431-1696; 1434-1752 1439 -2106; 1444-1706; 1484-1729; 1507 -2108; 1522- -2121; 1522-1733; 1529- -2133; 1533-2177; 1537- 1777; 1599-2227 ; 1600 -2319, 1598-2149; 1612-2154 1600 -2157; 1621-2145; 1624-2115; 1626 -2076; 1646- -2204; 1647-2212; 1647- -2149; 1654-1851; 1688- 2148; 1688-2243 ; 1698- -2211, 1691-2004; 1726-2154 1741 -2149; 1717-2149; 1749-2236; 1758 -2154; 1771- -2222; 1802-2253; 1812- -2149; 1837-2256; 1845- 2225; 1906-2256 ; 1909 -2149, 1928-2154; 1955-2262 1989 -2125; 2004-2236 245/LI:1178064. 3:2001 AY17 | | 2812-3267; 2875-3336; 3428-3978; 3536-4245; 3690-4177; 3727 -4492; 3782- -4253; 3967-4371; 4077- -4603; 4142-4594; 4150- 4595; 4220-4594 ; 4261 -4594, 4479-4594; 1-545; 25- -4594; 31-545; 99-743; 105 195; 113-247; 1 30-433 - 190- -700; 242-713; 271-562 295- 747; 362-587; 364- 878; 432-661; 6 13-1237; 896-1527; 896-1439; 928-1493; 327-1513; 937-1403; 937-1158; 1056- 1609; : L064-1598; 1159-1610; 1242-1581; L250-1837; 1250-1785 1252-1536; 1385 -1612; 1390- -2094; 1421-1812; 1421- -1636; 1421-1624; 1421- 1607; 1622-2159 ; 1697- -2309, 1845-2590; 1876-2557 1907 -2539; 1907-2149; 1945-2520; 1945 -2421; 2050- -2599; 2102-2288; 2105- -2557; 2105-2218; 2108- 2750; 2108-2703 ; 2123- -2793, 2123-2665; 2168-2427 2266 -2486; 2284-2675; 2359-2668; 2347 -2581; 2365- -2557; 2374-2975; 2396- -2952; 2431-2958; 2441- 2915; 2449-2643 ; 2453 -2843, 2481-2949; 2500-2959 2497 -2824; 2500-2902; 2528-2993; 2537 -2799; 2538- -2985; 2549-2875; 2552- -3001; 2553-2985; 2578- 2985; 2584-2985 ; 2596 -2995, 2622-2971; 2628-2984 2632 -2993; 2634-2995; 2641-2993; 2655 -2939; 2655- -2916; 2690-2988; 2690- -2985; 2805-2982; 2812- 3431; 2812-3056 ; 2812 -3093, 2812-2864; 2935-2995 3237 -3599; 3242-3791; 3230-3881; 3452 -3708; 3456- -3973; 3456-3681; 3494- -3936; 3521-4054; 3536- 4015; 3543-3673 ; 3644 -4137 3683-4182; 3690-3920 3694 -4305; 3716-4127; 3724-3943; 3735 -4064; 3736- -4168; 3736-3954; 3763- -4364; 3799-4335; 3896- 4521; 3919-4351 ; 3942 -4454, 3956-4522; 3969-4342 3969 -4229; 4021-4592; 4049-4560; 4082 -4549; 4124- -4594; 4124-4597; 4127- -4594; 4133-4597; 4143- 4594; 4145-4594 ; 4151- -4594, 4163-4594; 4171-4369 4172 -4597; 4211-4387; 4220-4611; 4225 -4597; 4231- -4594; 4231-4598; 4299- -4553; 4376-4594; 4391- 4594; 4465-4594 246/LI:1183121. 1:2001MAY17 || 2953-3264; 2786-3179; 2952-3172; 2942-3172; 2996-3172; 2952 -3156; 2952- -3147; 1512-2159; 1509- -2094; 1539-2080; 1390- 2031; 1735-2030 ; 1323 -2027, 1580-2024; 1753-2019 1453 -2018; 1670-1998; 1345-1993; 1355 -1992; 1386- -1990; 2669-3014; 2909- -3001; 2232-2738; 2203- 2733; 2261-2686 ; 2031 -2685, 2170-2675; 2200-2675 2028 -2540; 1978-2506; 2027-2506; 2002 -2506; 2448- -2506; 1390-1987; 1385- -1978; 1349-1970; 1390- 1961; 1286-1952 ; 1312 -1946, 1414-1948; 1290-1922 1221 -1916; 1358-1889; 1311-1883; 2168 -2501; 2361- -2506; 2266-2506; 2148- -2501; 2185-2506; 1826- 2492; 2092-2456 ; 2185 -2447, 1797-2438; 1687-2361 2073 -2358; 1718-2320; 1801-2298; 1663 -2279; 1789- -2280; 1594-2225; 1407- -1861; 1227-1853; 1275- 1848; 1616-1840 ; 1282 -1802, 1092-1764; 1226-1768 1110 -1742; 1195-1738; 1086-1723; 1439 -1725; 1227- -1714; 1143-1713; 1088- -1704; 1199-1683; 1006- 1630; 952-1627; 1031- L621; 1047-1611; 939-1604; 1006-1591; 988-1567; 1018- 1560; 968-1552; 892-1531; 1141-1504; 1049-1488; 805-1458; 763-1446; 915- 1438; 1554-2216 ; 1637 -2191 1498-2197; 1669-2181 1230 -1431; 1145-1413; 773-1397; 1070- 1332; ( 598-1326; 690-1316; 1070-1309; 1159-1307; 687-1248; 559-1162; 613-1 138; 676-1098; 401-1087; 425-1069, 469-. LOU; 682-887; 250- 864; 311-834; 4 83-797 - 262- -703; 248-637; 1-590; 195-517; 116-515; 1522- 2183; 1597-2234 ; 1681 -2077, 1765-2332; 1927-2539, 2062 -2522; 2169-2506; 2217-2738; 2367 -3012; 2388- -3017 247/1.1:1190431. 13:2001MAY17 || 6452-6850; 6453-6850; 6460-6853; 6465-6855; 6465-6853; 6478 -6870; 6489- -6855; 6484-6855; 6493- -6855; 6517-7224; 6533- 6767; 6545-6853 ,- 6586 -6855, 6598-6837; 6612-6875, 6618 -6855; 6642-7239; 6649-7238; 6653 -7304; 6676- -7250; 6692-6853; 6701- -7281; 6705-6855; 6708- 6855; 6712-6855 ; 6737 -6855, 6743-6850; 6779-6855, 6781- -6850; 2-294; 1-271; 2-292; 2-271; 2 -236; : 2-234, 4-6853; 104-2248; 897-1475 1535-6853; 1748- 2284; 1748-2005 ; 2215 -2265, 2311-2379; 3266-3648, 4156- -4710; 4437-4926; 4839-5409; 4971 -5417; 5065- -5645; 5110-5251; 5350- -5891; 5414-5555; 5531- 5853; 5779-6489 ; 5779 -6269, 5779-6247; 5779-6041, 5792- -6409; 5891-6565; Table 5
5928-6496; 5995-6440; 5993 -6634; 6004- -6579; 6012- -6718; 6011- -6722; 6056- 6639; 6073-6619; 6080-6640 ; 6102- -6393, 6117- -6755, 6119 -6461 6123 -6416; 6124-6632; 6139-6305; 6147 -6709; 6151- -6841; 6155- -6762; 6191- -6736; 6193- 6867; 6203-6638; 6204-6439 ; 6206- -6455, 6231- -6853, 6240 -6467 6240 -6465; 6244-6609; 6249-6468; 6249 -6469; 6252- -6684; 6259- -6451; 6262- -6848; 6269- 6461; 6278-6573; 6280-6799 ; 6286- -6856; 6286- -6775, 6292- -6736, 6340- -6850; 6350-6878; 6372-6853; 6375 -6784; 6393- -6586; 6403- -6853; 6413- -6855; 6428- 6853; 6429-6853; 6435-6850 ; 6433- -6855; 6441- -6855, 6445- -6855, 7140- -7385; 7181-7381; 7181-7346; 7190 -7455; 7190- -7381; 7190- -7379; 7190- -7374; 7190- 7276; 7235-7391 248/LI: 199121.14 :2001MAY17 | | 1-519; . 5-3843 303- -504; 406-939; 431-3841; 446-993; 481-1303; 481-131 8; 481- -1170, 481-1269; 483-753; 503-790 536- 1329; 560-1098; 660-895; 6 63-1167; 731-1031 810- -1448; 858-1028; i 384-1122; 934-1195; 955-1263; 975-16 17; 1014-1593; 1068-1348; 1071-1263; 1151-1230; 1283-1835; 1354-1857; 1446 -2096; 1455- -1652; 1467- -1988; 1467- -1902; 1497-
1745 1507-1751; 1578-2148; ; 1607- -2080, 1630- -2137, 1639 -2137, 1649 -1891;
1716-1914; 1776-2544; 1847- -2304; 1855- -2396; 1855- -2397; 1864- -2394; 1897-
2147 1914-2482; 1920-2207 ; 1923 -2257, 1923- -1997, 1973 -2247, 1985 -2595; 1991 2190; 2002-2596; 2022 -2580; 2074- -2290; 2046- -2588; 2077- -2359; 2101- 2341 2127-2226; 2129-2321 ; 2132 -2391, 2152- -2350, 2163 -2448 2171 -2419; 2195 2775; 2208-2748; 2222 -3038; 2220- -2615; 2221- -2504; 2301- -3013; 2317- 3229 2340-2550; 2351-3125 ; 2352 -3181, 2376- -3153, 2383 -2992 2424 -3044; 2450 2709; 2482-3042; 2503 -3097; 2503- -2980; 2515- -3024; 2550- -2840; 2610- 2797 2615-2669; 2617-2739 ; 2617 -2859, 2639 -2879, 2639 -3020 2639 -2943;
2639-2859; 2662-2871; 2683- -2898; 2684- -2910; 2716- -2885; 2720- -3224; 2722-
2986 2719- 3231; 2740- 3224; ; 2761- -3251, 2781- -3033, 2789- -3023, 2797- -3085; 2805 3067; 2817-3095; 2833- -3084; 2843- -3074; 2844- -3131; 2846- -3078; 2876- 3134 2889- 3555; 2889- 3465; ; 2889 -3148, 2889- -3209, 2890 -3137, 2892- -3173; 2913 3205; 2916-3185; 2918- -3167; 2926- -3160; 2939- -3224; 2953- -3218; 2991- 3228 2993- 3233; 3004- 3616; ; 3009 -3258, 3020- -3224, 3021 -3249, 3024- -3224; 3033 3224; 3041-3224; 3051- -3224; 3054- -3224; 3058- -3224; 3062- -3616; 3061- 3837 3066- 3224; 3075- 3224; ; 3076 -3224, 3081- -3224, 3091 -3224, 3101 -3224; 3111 3224; 3140-3740; 3143- -3224; 3161- -3224; 3173- -3775; 3305- -3609; 3357- 3859 3381- 3645; 3383- 3797; ; 3386 -3845, 3388- -3839, 3389 -3649 3390 -3834; 3393 3549; 3394-3693; 3399- -3843; 3405- -3661; 3408- -3827; 3409- -3804; 3409- 3745 3409- 3574; 3409- 3806; ; 3409 -3860, 3409 -3796, 3409 -3519 3409 -3541; 1832 2085; 1871-2479; 1951- -2518; 2016- -2286; 2124- -2286; 3409- -3688; 3409- 3836 3409- 3581; 3409- 3653; ; 3408 -3682, 3409 -3522, 3409 -3514 3409 -3605; 3409 3559; 3409-3696; 3409- -3530; 3409- -3492; 3409- -3681; 3409- -3485; 3409- 3542 3409- 3859; 3409- 3713; ; 3409 -3496, 3409 -3567 3409 -3549 3409 -3572; 3409 3614; 3409-3478; 3409- -3491; 3417- -3566; 3418- -3672; 3417- -3671; 3420- 3828 3423-•3569; 3427- 3843; ; 3427 -3687 3428 -3657 3430 -3843 3432 -3626;
3432-3820; 3434-3843; 3434- -3628; 3436- -3845; 3437- -3842; 3438- -3679; 3440- 3835; 3444-3666; 3444-3843; ; 3445 -3850 3448 -3844 3448 -3699 3451 -3804; 3462-3716; 3469-3843; 3469- -3842; 3496- -3849; 3496- -3760; 3496- -3843; 3498- 3655; 3504-3749; 3511-3775; ; 3512 -3777 3516 -3697 3534 -3843 3541 -3835; 3544-3842; 3548-3843; 3554- -3842; 3560- -3842; 3563- -3658; 3563- -3849; 3563- 3846; 3563-3825; 3597-3843; ; 3603 -3766, 3621 -3823, 3632 -3846, 3633- -3841; 3635-3856; 3643-3842; 3646- -3802; 3647- -3742; 3696- -3846; 3717- -3817 249/LI: 202630.5 :2001MAY17 || 1091-1862; 1134-1809; 1142-1553; 1142-1552; 1138-1595; 1144-1644; 1141- -1592; 1160- -1702; 1137- -1304; 1144- -1312; 1177- 1480; 1155-1397; 1183-1675; ; 1159 -1387, 1200 -1711 1210 -1612 1205- -1446; 1184-1719; 1211-1814; 1220- -1449; 1208- -1733; 1214- -1353; 1256- -1658; 1259- 1714; 1265-1715; 1268-1643; ; 1249 -1881, 1347- -1531 1367 -1542, 1363 -1637; 1364-1953; 1372-1583; 1422- -2014; 1435- -1988; 1436- -1911; 1494- -2039; 1509- 2104; 1624-1869; 1625-1978; ; 1627 -1729, 1635 -1835 1655 -1838 1648- -1892; 1650-1890; 1678-1768; 1723- -1870; 1717- -1947; 1751- -1913; 1792- -2221; 1-605; 87-606; 139-798; 283-858; 438-679; 438-675; 438-665; 440-673; 450- -1099; 450-1026; 450-860; 450-103: 1; 450 -913; 450-963; 450-888 ; 452- -1012; 517-608; 560-1262; 559-729; 573-859; ; 571- 706; 683-806; 681-862; 758-939; 758-971; Table 5 758-1094; 775-1034; 810-1441; 834-1388; 834-1436 ; 842-1465; 839-1446; 845- 1395; 879-1510; 884-1296; 906-967; 936-1537; 959-1569; 962-1611; 935-1517; 983-1545; 991-1486; 1001-1500; 1012-1626; 998-1287; 1013-1342; 1013-1241; 1014-1675; 1025-1768; 1029-1612; 1040-1512; 1018-1201; 1033-1695; 1039- 1572; 1055-1555; 1058-1580; 1060-1665; 1081-1416 ; 1100-1765; 1064-1438; 1068-1663; 1103-1631; 1072-1628; 1080-1417; 1086-1662; 1088-1743; 1076- 1307; 1106-1342; 1116-1648
250/LI: 2034488.1:2001MAY17 || 689-1275; 652-1220 ; 316- 961; 365-935; 558- 927; 312-871; 516-858; 312-823; 51-781; 318-752; 241-753; 6- -667; 1-664 251/LI:2051434.8:2001MAY17 || 239-624; 389-766; 456-940; 488-1048 ; 560- 1255; 586-1056; 621-1087; 709-1195; 790-1330; 88 1-946; 881-: 1404; 891-1458; 914-1582; 1080-1294; 1268-1775; 1419-1667; 1494- 1999; 1-292 24-599; 24- 383; 24-270; 25-387; 29-401; 31-573; 31-224; 31- 222; 31-277 31-561; 31- 565; 31-477; 31-577; 31-164; 31-358; 31-590; 31- 166; 44-260 57-439; 61- 666; 223-400; 235-498; 261-766; 267-501; 295-863 ; 287- 720; 362-765; 404- 716; 435-1023; 443-765; 454-791; 458-1085; 458-1 075; 476-999; 477 -1134; 500-1065; 513-940; 540-1056; 558-1214; 548-781; 560-1033; 561-987 ; 574- 1064; 589-1155; 576-987; 594-1278; 596-1051; 597 -1289; 624-1200; 562-1134; 659-1328; 683-1235; 707-1174; 709-1070; 800-1390 ; 789- 1401; 807-1326; 814- 1521; 832-1415; 835-1458; 843-1401; 884-1460; 89 4-1324 ; 885- -1411; 885-1341; 885-1062; 913-1197; 891-1480; 891-1370; 891-1405 ; 908- 1466; 891-1421; 906- 1678; 950-1562; 969-1200; 1004-1182; 1079-1350; 1082-1468; 1101-1765; 1241- 1804; 1256-1721; 1275-1970; 1275-1947; 1292-1841 ; 1297 -1772 1359 -1923; 1452-1707; 1444-2023; 1448-2092; 1506-1657; 1505 -2012; 1522- -1769 252/LI:2118475.9:200lMAYl7 || 1-675; 25-79; 113- 310; 213-466; 318 -967; 406- 864; 432-1089; 493-1088; 517-1082; 718-1113; 809 -1113; 890-1414; 952-1113; 1-451; 1-609; 1-630; 1-607; 1-434; 1-287; 5-514; 16-604; 16- -531; 113-290; 113-1039; 113-683; 113-515; 127-294 ;.185-390 ; 20 9-491; 210-i 395; 220-668; 267-955; 288-838; 316-902; 331-1021; 369-574; 36 9-620; 369-686; 383-888; 407-624; 412-847; 417-865; 420-1033; 433-1088; 4 58-683 ; 452- -955; 192-1088; 538-1088; 569-854; 605-1075; 633-1060; 682-807; 692-1306; 720-1321; 763- 1113; 781-1322; 793-1395; 826-1382; 824-1013;' 85 2-1089 ; 873- -1001; 876-1040; 916.-1063; 914-1365; 928-1113; 933-1113;. 975-1063 ; 1002 -1370 1018 -1116; 1030-1113; 1045-1113
253/LI:218849.24:2001MAY17 || 2807-3432; 2807-34 96; 2815-3440; 2829-3277; 2825-3260; 2848-3238; 2839-3387; 2845-3036; 2843 -3402; 2870- -3503; 2863-
3237; 2866-3097 2879-3125; 2869-3111; 2874-3515 ; 2876 -3048 2883 -3167; 2885-3162; 2889 3175; 2890-3572; 2892-3547; 2905 -3289; 2923- -3637; 2923- 3500; 2937-3567 2934-3543; 2937-3489; 2948-3190 ,- 2948 -3360 2948 -3205;
2948-3200; 2952-3440; 2952-3543; 2952-3572; 2954 -3199; 2955- -3149; 2966-
3555; 2988-3361 2988-3306; 2988-3234; 3012-3489 ; 3021 -3167 3037 -3269;
3057-3655; 3070-3356; 3071-3163; 3071-3322; 3076 -3337; 3079- -3467; 3102-
3547; 3079-3489 3079- 3314; 3086- 3321 3101 -3368 ; 3102 -3397 3098 -3375; 3103-3303; 3107 3603; 3109-3709; 3120 3440; 3121 -3435; 3129- -3301; 3139- 3424; 3142-3406 3143- 3378; 3160- 3640 3167 -3320 ; 3191 -3419 3195 -3405; 3199-3476; 3221 3390; 3223-3456; 3227-3526; 3233 -3649; 3232- -3504; 3232- 3438; 1285-1502 1315- 1738; 1315- 1861 1321 -1738 ; 1424 -1742 1431 -1992; 1484-2091; 1557 2374; 1611-2221; 1714-1957; 1733 -2011; 1739- -2269; 1851- 2343; 1843-2028 1883- 2128; 1886- 2081 1896 -2147 ; 1915 -2133 1916 -2088; 1918-2114; 1942 2703; 1979-2699; 2014 2867; 2025 -2263; 2028- -2652; 2027- 2321; 2027-2512 2030- 2512; 2037- 2695 2048 -2756 ; 2080 -2684 2088 -2336; 2090-2332; 2101 2301; 2146-2459; 2157 2774; 2153 -2330; 2156- -2781; 2158- 2659; 2181-3024 2204- 2424; 2205- 2415 2210 -2980 ; 2211 -2907 2247 -2858;
2246-3007; 2254-2750; 2269-2919; 2281-2753; 2281 -2897; 2292- -2959; 2307-
2661; 2328-2870 2366-2930; 2378-3119; 2386-2934 ; 2395 -2860 2434 -2996;
2428-3037; 2448-2997; 2453-2637; 2523-3241; 2529 -3266; 2538- -3312; 2541-
3197; 2541-3192 2545-2953; 2544-3265; 2552-2824 ,- 2570 -3365 2573 -3185; 2579-2832; 2581 3157; 2582-2873; 2582-2870; 2586 -2825; 2585- -2965; 2587- 3157; 2591-3169 2593-2820; 2603-2860; 2609-3032 ; 2626 -3181 2624 -3458;
2629-2896; 2645-3479; 2664-3312; 2653-3187; 2664 -3227; 2679- -3275; 2671- Table 5
3537; 2689-3039; 2692-3265; 2703 -2913 ; 2704-3001 2708 -3322 2712-3517;
2712-3408; 2717-3340; 2717-3235; 2724-3229 ; 2728 3424; 2732 3355; 2742-
3015; 2743-3359; 2746-3264; 2743 -3367 ; 2763-3504 2778-3426 2784-3050;
2796-3337; 1-292 ; 4-576; 11-441; 9-651 ; 21-4088 ; 21-516; 22-498; 21-296;
23-558; 23-590; 25-503; 24-370; 27-487 ; 26-222 ; 39-484 ; 39 300; 43-583; 63-
702; 63-515; 109 2462; 167-796; 224-738 ; 276-979 ; 299-618; 308-630; 307-
782; 356-625; 363-609; 366-694; 372-731 ; 384-517 ; 385 729; 388-551; 422-
730; 371-599; 442-614; 484-1100; 490-926 ; 531-83 3; 554-1088 ; 637-1033; 667-
917; 678-1236; 700-1166; 814-1388 ; 834-1439 ; 851 -1475; 910-1520; 940-1455;
940-1502; 940-1388; 946-1445; 946-1423 ; 946-1386 946-1415; 946-1100; 953-
1088 1016-1202; 1016-1113; 1016-1562 1016-1508 1016-1476 1016-1485; 1016 1505; 1024-1502; 1073-1318; 1073 1308; 1073 1763; 1078 1542; 1078- 1309 1119-1501; 1118-1695; 1139-1313 1142-1656 1149-1573 1149-1617; 1149 1314; 1155-1445; 1193-1588; 1198-1677; 1208 1686; 1208 1698; 1220- 1577 1264-2076; 1286-1804; 3253-3520 3261-3766 3261-3745; 3267 3569; 3268-3532; 3269-3487; 3270-3552; 3272 3524; 3270 3505; 3274- 3456 3276-3551 3284- 3549 3298 -3636 3297-3475 3302-3522 3302-3511;
3314-3458; 3322-3613; 3324 3562; 3323 3536; 3334 3600; 3357 3894; 3358-
3615; 3359-3604 3361- 3580 3362 -3610 3374-3841 3374-3630 3385-3735;
3398-3913; 3396 3683; 3397 3667; 3397-3607; 3407 3669; 3407 -3613; 3426-
4043; 3441-3713 3442- 3947 3444 -3919 3445-4050 3447-4045 3469-3908;
3477-4049; 3528 3947; 3534 3635; 3549-3797; 3553 3823; 3553 -3978; 3554-
3908; 3559-4030 3569- 3745 3570 3945 3571-3942 3571-3961 3574-3950;
3575-3932; 3575 3825; 3582 3944; 3585 4191; 3587 3849; 3587 -4172; 3589-
3847 3593-3994 3606- 3908 3607-3935 3610-3927 3615-4097 3624-4086;
3624 3853; 3632-4060; 3634 4091; 3634 4026; 3637 3853; 3641 4091; 3644-
3890 3648-3931 3647- 3913 3647-3948 3651-3909 3650-3897 3650-3797;
3651 3944; 3659-3930; 3676 4086; 3676 4085; 3687 -4089; 3688 3906; 3693-
4226 3694-3942 3770- 3935 3773-3937 3777-4049 3787-4096 3789-4050; 3794-4199; 3794 4086; 3806-4036; 3814-4090; 3810 -3943; 3815 -4235; 3822-
4235 3826-4075 3826-4037 4026 4232 4048- 4235 4097-4214 4152-4230;
3828-4241; 3830 4035; 3830-3938 3831 4235; 3849 -4086; 3856 -4086; 3871- 4117; 3874-4034 3876-4287 3882 3945 3896- 4163 3896-4036 3897-4088; 3899-4480; 3901 4088; 3908 4092; 3909 4233; 3909 -4196; 3909 4193; 3909- 4226; 3909-4163 3910-4036 3915 4142 3942- 4236 3937-4083 3938-4088: 3945-4217; 3949 4167; 3955-4092; 3961 4028; 3974 -4163; 3991 -4235; 3991- 4233; 3994-4228 4003-4235 4021 4326 4024- 4235 1-157; 11 55-1616; 1208- 1758; 2779-3342 3736-3926 3743 4094 3744- 4069 3747-3980 ; 3748-4088; 3749-4097; 3753 4090; 3757-4053; 3758 4088; 3759 -3952; 3765 -4091; 3728- 4088; 3696-4142 3722-4087; 3722 4046 2750- 2879 562-839; 1073-1489; 984- 1537; 1168-1710 1168-1718; 1909 2488 254/LI:2199824.5 :2001MAY17 I I 1- 470; 48-563 ; 255 -821; 255-7 53; 328 -682; 569-820; 728-1010; 765-1362; 847 -1421 ; 905-1162; 977-1248; 1011-14 65; 1116- 1344; 1272-1772; 1272-1872; 1280 -1532 ; 1429-1654 1433-1653 ; 1464- 1722 255/LI:233018.32 :2001MAY17 I I 29 94-33 82; 2999-3217; 3003-3247; 302 7-3460; 3041-3460; 3074-3316; 3123-3368; 3138 -3463; 3139 -3486; 3148-3382; 3158- 3412; 3189-3643; 3241-3801; 3346 -3620 3397-3643 3443-3758 ; 3477- 3549; 3549-4120; 3579-4240; 3631-4246; 3621 -4240; 3631 -4142; 3631-4202; 3682- 3937; 3695-4262; 3726-4262; 3724 -4262 3729-3924 3733-4016 ; 3751- 4048; 3760-4013; 3796-4002; 3812-3919; 3834 -4262; 3841 -4117; 3847-4023; 3863- 4116; 3865-4014; 4008-4262; 4025 -4262 2530-2807 2542-2962 ; 2550- 2860; 2571-2962; 2572-2871; 2580-2811; 2586 3249; 2588 -2880; 2590-2961; 2592- 3137; 2593-2982; 2596-2968; 2612 -2802 2621-2824 2628-2887 ; 2655- 2925; 2642-2961; 2646-2866; 2658-2900; 2666 -3248; 2681 -2964; 2688-2932; 2690- 2962; 2697-2956; 2699-2977; 2710 -3111 2715-3147 2739-2978 ; 2743- 2982; 2760-3206; 2759-3160; 2767-3008; 2768 2925; 2778 -3032; 2807-2884; 2792- 2968; 2793-3262; 2794-3038; 2795 -3043 2803-2917 2804-3135 ; 2806- 2975; 2807-3061; 2807-2965; 2808-2961; 2812 3291; 2813 -2923; 2820-3267; 2822- 3382; 2829-2981; 2832-3455; 2832 -3417 2833-3398 2832-2967 ; 2833- 3080; 2847-3119; 2849-2981; 2855-2956; 2863 2956; 2887 -3382; 2887-3007; 2894- Table 5
3169; 2898-3420 2900-3127 2904 2961; 2915 3130; 2943 3130 ; 1395 1978; 1407-1581; 1408 1607; 1418-1909; 1419-2004; 1421-1685; 1445-2023; 1450- 1723; 1459-1741 1457-1954 1457-1687; 1501 1750; 1511 1755 ,- 1524 2130; 1515-1782; 1524 1803; 1546-1793; 1550-1778; 1546-1802; 1551-1827; 1643- 2012; 1675-2140 1677-2140 1702-1958; 1732 2215; 1738 1966 ; 1747 2024; 1779-2040; 1813 2101; 1820 2056; 1841-2474; 1867-2107; 1888-2107; 1934- 2454; 1933-2601 1944-2194 1948-2519; 2008 2637; 2040 2308 ; 2043 2313; 2081-2334; 2093 2330; 2119 2746; 2122-2729; 2123- 2411; 2123-2395; 2140- 2757; 2145-2656 2146-2706 2157-2442; 2163 2587; 2164 -2257 ; 2169 2457; 2173-2766; 2180 2394; 2207-2440; 2208-2441; 2221-2730; 2245-2539; 2229- 2530; 2233-2423 2242-2794 2245-2410; 2244 2691; 2245 -2532 ; 2248 2548; 2249-2583; 2249 2489; 2253-2442; 2249-2375; 2250-2653; 2269-2868; 2272- 2835; 2284-2772 2286-2797 2285-2714; 2289-2858; 2290 -2521 ; 2295 2736; 2295-2476; 2299 2573; 2302-2798; 2302-2781; 2308-2513; 2312-2779; 2313- 2753; 2317-2517 2319-2586 2320-2555; 2331-2892; 2332 -2661 ; 2340 2616; 2346-2911; 2388 2982; 2376 2817; 2375-2609; 2379-2640; 2396-2900; 2405- 2941; 2421-2964 2405-2586 2408-2932; 2429-2683; 2447 -2998 ; 2438 2595; 2459-2669; 2498 2620; 2485 2942; 2499-3124; 2495-2956; 2516-2982; 2503- 2957; 2516-2756 2523-2861 1-639 ; 1-622; 1-741; 1-728 ; 1-678; 14-696; 122- 720; 227-588; 2 7-629; 227-691; 227-669; 227-688; 227- 732; 228-826 227- 849; 266-486; 3 7-647; 419-684; 430-1052; 447-875 ; 471 -843; 471-713; 515- 1086; 550-1084; 550-1214; 560-1089; 560-942 ; 577-1088; 628-1271; 665-1278; 719-1179; 744-1 65; 745-1345; 746-1263; 749-1360; 750- 1301; 754-1349; 758- 1389; 784-1316; 782-1328; 820-1199; 820-1085; 849-1285 ; 835-1381; 836-1082; 838-1474; 853-1 82; 892-1194; 927-1457; 949-1502; 956- 1321; 988-1175; 1018- 1616; 1035-1631 1056-1661 1057-1651; 1063 -1606; 1075 -1698 ; 1087-1349; 1139-1878; 1141 1877; 1152 1745; 1152-1584; 1156-1878; 1167-1389; 1169- 1878; 1175-1433 1180-1878 1187-1878; 1192 -1878; 1190 -1710 ; 1186-1744; 1212-1435; 1243 1581; 1256 1741; 1256-1804; 1275-1581; 1283-1560; 1270- 1826; 1280-1379 1316-1597 1328-1902; 1327-1578; 1330 -1613 ; 1352-1594; 1361-1702; 1373 1970; 1392-1943; 2123-2592; 1188-1839; 2364-2924; 2391- 3015; 2410-2655 2472-2959 2501-2957; 35-345; 2242-25 89; 2157-2762; 1-679; 9-719
256/LI:236295.8 2001MAY17 || 697-1227; 1-608; 134-764; 697-12 91; 979- 1239 257/LI:286989.14:2001MAY17 j| 1-530; 1-474; 1-168; 181-554; 1 82-532; 182- 671; 182-672; 186-1895; 191-672; 197-640; 193-2128; 198-658; 206-502; 2991- 3230; 2994-3269 3005-3266 3097-3273; 3102-3423; 3112-3265; 3124-3272, 3133-3273; 3197-3377; 3340 3609; 2426-2907; 2426-2835; 2446-2 614; 2450- 2919; 2452-2720 2482-2920 2490-2731; 2500-2956; 2500-2799; 2508-2770 2560-2778; 2595-3077; 2588-3002; 2600-2937; 2599-2907; 2599-3 079; 259 9- 3050; 2599-3025 2599-3026 2599-3020; 2599-3002; 2605-3050; 2615-290 9 2619-2781; 2622 -2901; 2625 2830; 2636-2829; 2637-2915; 2644-2 924; 266 1 3130; 2661-3246 2673-2849 2683-2912; 2688-3228; 2708-2954; 2708-290 7 2718-2953; 2722 3234; 2738 2975; 2739-2998; 2746-3251; 2752-3 269; 277 8- 3227; 2795-3019 2812-3013 2820-3265; 2823-3266; 2825-3266; 2825-327 1 2847-3266; 2859 3266; 2872 3112; 2876-3273; 2876-3266; 2887-3 068; 289 1- 3122; 2897-3138 2900-3272 2908-3410; 2908-3320; 2914-3273; 2952-313 7; 2952-3213; 2967 3272; 2968 3220; 2972-3275; 2974-3266; 2975-3 205; 298 0- 3273; 2983-3266 2987-3253 992-1361; 996-1169; 1023-1289; 10 56-1604; 1139- 1519; 1147-1566 1153-1644 1208-1446; 1231-1834; 1244-1750; 1260-1477, 1276-1522; 1276 1702; 1282 1881; 1283-1825; 1286-1776; 1293-1 921; 1311- 1765; 1337-1593 1338-1825 1353-1884; 1393-1638; 1394-1658; 2378-2835; 2379-2588; 1402 -1700; 1421 1802; 1430-1699; 1440-1710; 1465-1 712; 1491- 1578; 1700-1842 1825-1895 1806-2528; 1860-2129; 1860-2348; 1881-2749; 1903-2110; 1903 -2282; 1913 2275; 1920-2195; 1941-2196; 1941-2 187; 1956- 2276; 1958-2180 1984-2184 2000-2230; 2036-2272; 2040-2271; 2044-2283; 2093-2280; 2153 -2481; 2191 2340; 2199-2447; 2305-2591; 2315-2 722; 2333- 2722; 2336-2663 2364-2722 2378-2682; 2378-2928; 2378-2796; 2378-2722; 2378-2810; 2378-2593; 206-458; 237-541; 257-1851; 268-507; 30 2-783; 337- 775; 337-907; 398-907; 403-1022; 407-1022; 407-1001; 412-1020 ; 423-1022; Table 5
421-1022; 426-1022; 428-1022; 433-979; 431- 900; 437-1022; 447-1022; 448-
1022; 447-729; 449-1022; 452-1022; 455-1022 ; 460-1022; 461-1022; 469-1022;
471-1021; 483-1022; 494-838; 496-1022; 511-1022; 514-1022; 515-1022; 518-
1022; 524-1022; 526-1099; 531-851; 531-1008 ; 535-1022; 538-839; 547-791;
548-1022; 552-1014; 555-1022; 562-839; 573-1022; 579-771; 587-1011; 633-
1091; 636-875; 652-1022; 694-1231; 701-966; 701-1203; 716-998; 737-952;
769-1001; 785-1246; 807-988; 807-1225; 807-1072; 842-1048; 855-1090
258/LI:345320.4:2001MAY17 || 1-1798; 70-3502; 155-402; 163-294; 194-588;
272-838; 311-864; 312-865; 312-897; 391-942 396-702; 404-835; 432-945;
435-836; 444-738; 483-995; 574-1084; 569-1082; 582-1079; 604-1084; 1200-
1574 143 5-1929 1948- 2236 1958- -2174; ; 1961 2189 2000- 2236 2109- 2297; 2149 2413 ; 2283 2879; 2294 2605; 2338- -2484; 2469 2813; 2501 2769; 2503- 3179 2503-2757 2558- 2830 2563- -2715;r 2659 2984 2659- 2966 2665- 2900; 2784 3172 ; 2878 3401; 2925 3415; 2928- -3156; 3025 3648; 3114 3630; 3118- 3502 3125-3307 3165- 3477 3186- -3508; : 3265 3502 3282- 3502 3296- 3534; 3296 3546 ; 3317 3521; 3323 3502; 3324- -3729; 3358 3477; 3375 3502; 3379- 3502 3380-3502 3382- 3502 3389- -4005; : 3399-3502 3409- 3502 3420- 3985; 3420 4003 ; 3452 3502; 3561 3831; 3656- -3866; 3681 3947; 3687 4299; 3687- 4109 3687-3871 3687- 3860 3687- -3837; : 3687-3813 3687- 3761 3687- 3754; 3702 4417 ; 3759 4009; 3810 4110; 3836- -3951; 3855 4026; 3857 4132; 3858- 4163 3858-4107 3886- 4132 3892- -4323; : 3897-4321 3899- 4146 3913- 4176; 3920 4148 ; 3932 4515; 3932 4341; 3932- -4177; 3932 4163; 3948 4203; 3959- 4479 3973-4197 3978- 4483 4027- -4501; : 4075-4313 4081- 4496 4083- 4501;
4098-4368 ; 4103 4463; 4108 4507; 4109- -4371; 4188 4495; 4220 4432; 4237-
4908 4301-4892 4308- 4513 4308- -4569; : 4330-4467 4334- 4505 4347- 4593;
4349-4625 ; 4371 4764; 4371 4531; 4376- -4623; 4420 4975; 4458-4673; 4475-
4975 4482-5145 4485- 4701 4498- -4678; : 4508-4746 4552-4893 4571-4933; 4589 5171 ; 4594 4931; 4605 4933; 4616- -4874; 4633 4904; 4677 5135; 4677- 4916 4678-4831 4698- 5007 4700- -5006; : 4704-4955 4730-5253 4730-5024; 4746 4889 ; 4785 5046; 4791 5047; 4809- -5069; 4844 5089; 4845-4924; 4855- 5113 4863-5138 4872- 5130 4922- -5150; : 4997-5405 5008-5320 5016-5410;
5031-5304; 5047 5350; 5047 5251; 5050- -5354; 5089 5511; 5089 5400; 5068-
5577 5092-5346 5092- 5334 5092- -5366; : 5093-5340 5093-5327 5090-5487;
5090-5511 ; 5114 5355; 5090 5612; 5132- -5399; 5146 -5354; 5162-5246; 5167
5310 5145-5437 5159- 5620 5163- -5419; ; 5165-5626 5166-5614 5174-5618; 5182 5622 ; 5190 5613; 5188 5564; 5207- -5453; 5225 5574; 5223 5352; 5224- 5611 5230-5612 5230- 5567 5242- -5355; : 5245-5616 5288-5575 5311-5614; 5328 5622 ; 5330 5614; 5330 5546; 5359- -5602; 5375 5611; 5393 5622; 5408- 5612 5447-5614 5456- 5612 5475- -5622; : 5483-5697 5484-5979 5546-6158; 5593 5799 ; 5614 5724; 5633 5871; 5633- -5856; 5693 5850; 5721 5997; 5722- 6013 5794-6235 5794- 6156 5830- -6280; ; 5889-6259 5898-6224 5898-6262; 5898 6153 ; 5909 6262; 5916 6147; 5936- -6262; 5939 6277; 5942 6259; 5952- 6176 6004-6259 6009- 6235 6016- -6273; : 6019-6273 6035-6273 6094-6254
259/LI: 355693.18 :2001MAY17 | | 1-364; 645-920; 93 7-1546; 1473-1936; 1605-
1847 192 9-2531 2421-2551 2627- -3008; : 3729-4005 4111-5418 4487-4949; 4666 4905 ; 4996 5325; 5139 5671; 5253- -5554; 5295 5771; 5408-6010; 5458- 6131 6217-6802 6245-6799 6267- -6821; : 6294-6862 6308-6805; 6353-6631;
6367-6759 ; 6379- -6643; 6392- -6638; 6423- -6811; 6-255; 22-610; 108-686; 110- 679; 361- 1008; 434-857; 497-6759 ; 592- -1076; 738-1312; 751-1314; 751-1323; 935-1415; 938-1076; 1042-1550; 1158-1770; 1164-1678; 1167-1616; 1483-2037; 1483-1737 ; 1553- -1901; 1577- -1853; 1609- -1895; 1633-1892; 1660-1895; 1705- 1896; 195 0-2554; ; 2043- -6027; 2184- -2377; : 2192-2300 ; 2228-2858; 2571-2984; 2627-3111 ; 2627- -3053; 2627- -3030; 2627- -2831; 2639-3001; 2706-3303; 2717- 3192; 275 3-3250; : 2787- -3377; 2957- -3462; : 2957-3213 ; 3008-3241; 3155-3774; 3182-3539 ; 3319- -3774; 3298- -3846; 3315- -3979; 3408-3991; 3421-3925; 3504- 3774; 365 6-4101; ; 3781- -4339; 3868- -4142; : 3894-4241 ; 3934-4523; 4006-4506; 4117-4634 ; 4205- -4768; 4358- -4736; 4487- -4642; 4487-4708; 4504-4753; 4539- 5050; 457 5-4843; : 4801- -5347; 4806- -5253; : 4974-5526 ; 4974-5212; 4996-5242; 5040-5292 ; 5059- -5331; 5087- -5684; 5115- -5665; 5149-5674; 5154-5525; 5174- 5806; 519 5-5541; : 5264- -5879; 5280- -5932; 5276-5838 ; 5279-5576; 5297-5902; Table 5 5313-5581; 5324-5840; 5325-5901; 5394-6010; 5412-5588; 5440-5998; 5446- 6071; 5453-6052; 5473-5649; 5486-5732; 5489-6048; 5514-5772; 5503-5704; 5505-6064; 5536-6091; 5562-6125; 5586-6211; 5603-5850; 5630-6245; 5607- 5894; 5611-6166; 5622-6296; 5640-6228; 5638-6143; 5666-5948; 5681-6224; 5682-6284; 5702-6253; 5708-6263; 5710-6324; 5712-5839; 5727-5858; 5754- 6190; 5755-6097; 5781-6124; 5780-6320; 5781-5880; 5798-6472; 5817-6109; 5823-5988; 5828-6379; 5856-6351; 5875-6127; 5880-6121; 5887-6430; 5901- 6492; 5923-6072; 5935-6464; 5940-6546; 5943-6477; 5955-6515; 5955-6200; 5979-6236; 5979-6339; 5978-6620; 5979-6212; 5989-6560; 5997-6545; 6003- 6272; 6003-6232; 6003-6476; 6012-6465; 6043-6690; 6053-6670; 6065-6356; 6068-6340; 6071-6256; 6071-6242; 6077-6614; 6105-6621; 6105-6555; 6111- 6630; 6112-6369; 6114-6361; 6115-6218; 6122-6403; 6132-6405; 6134-6300; 6150-6421; 6150-6411; 6150-6395; 6167-6704; 6150-6420; 6196-6445; 6199- 6803; 6205-6724; 6213-6448; 6222-6804; 6226-6458; 6226-6762; 6236-6521; 6251-6787; 6253-6757; 6260-6508; 6249-6762; 6250-6822; 6276-6722; 6283- 6885; 6282-6770; 6296-6565; 6296-6551; 6300-6842; 6297-6506; 6286-6824; 6318-6765; 6336-6918; 6336-6759; 6343-6806; 6357-6939; 6356-6614; 6365- 6670; 6366-6762; 6372-6809; 6372-6767; 6374-6573; 6353-6774; 6379-6724; 6380-6752; 6386-6762; 6389-6641; 6389-7001; 6395-6771; 6397-6722; 6403- 6808; 6402-6707; 6428-6804; 6448-6812; 6449-6666; 6475-6777; 6503-6722; 6512-6962; 6512-6864; 6515-6942; 6523-6751; 6533-6963; 6560-6814; 6563- 6963; 6567-6805; 6619-6795; 6621-6805; 6639-6790; 6700-6963; 6735-6958; 6869-7102; 6897-6958; 6986-7136
260/LI:359876.1:200lMAYl7 || 552-1274; 552-1279; 552-1069; 552-1366; 2116- 2703; 552-1216; 1421-2005; 44-758; 151-758; 1241-1870; 1327-1855; 1219- 1807; 1099-1670; 941-1655; 552-1341; 553-1306; 866-1220; 552-1035; 552- 1012; 555-810; 552-779; 1211-1775; 552-1083; 950-1618; 1550-2394; 2176- 2813; 2438-2739; 1840-2706; 1583-2427; 2063-2277; 1266-2122; 1517-2053; 560-1070; 592-1341; 2253-2717; 928-1476; 2170-2705; 1842-2702; 552-1037; 1- 717; 552-1079; 1155-1841; 1212-2055; 2094-2700; 552-1315; 557-1288 261/LI:406664.32:2001MAY17 || 2590-2915; 1-260; 129-379; 150-397; 161-698; 173-616; 196-464; 222-498; 224-453; 230-631; 229-481; 240-495; 247-442; 271-3026; 359-3048; 518-824; 619-830; 666-872; 936-1670; 928-1627; 998- 1271; 1005-1261; 1008-1283; 1107-1262; 1156-1364; 1147-1311; 1158-1337; 1429-1874; 1593-2113; 1592-1935; 1641-2069; 1686-1905; 1704-1931; 1878- 2362; 1910-2368; 1922-2399; 1992-2568; 1995-2293; 2001-2435; 2057-2425; 2102-2578; 2147-2605; 2166-2642; 2202-2875; 2253-2717; 2257-2858; 2269- 2876; 2334-2892; 2391-2867; 2391-2808; 2391-2657; 2398-2614; 2405-2719; 2436-2701; 2446-2718; 2481-2748; 2509-2752; 2530-2889; 2530-2763; 2596- 2867; 2597-2705; 2679-3312; 2691-2916; 2691-2911; 2695-2974; 2705-3108; 2969-3487; 2977-3500; 2166-2569; 2293-2568; 162-756; 919-1541 262/LI:410324.1:2001MAY17 || 1267-1919; 3202-3547; 1-633; 568-855; 777- 1031; 916-1044; 927-1064; 947-3346; 1609-2097; 2243-2345; 2516-2797; 3197- 3322; 3209-3308; 3244-3707; 3246-3491; 3263-3405; 3394-3852; 3425-3589; 3448-3960; 3503-4115; 3749-4158; 3749-4030; 3804-4236; 3806-4103; 3840- 4065; 4091-4258
263/LI: 414376.12 :2001 AY17 || 5181-5388; 5282-5899; 5438-5961; 5442-5668; 5465-5707; 5513-5999; 3379-3746; 3381-3963; 5123-5377; 5126-5209; 5162- 5388; 5180-5776; 4738-5046; 4740-5012; 4804-5490; 4830-5399; 4834-5422; 4834-4900; 4872-5367; 4891-5406; 4897-5429; 4901-5406; 4919-5441; 4925- 5602; 4948-5413; 4951-5446; 4963-5602; 4995-5346; 5006-5499; 5042-5447; 5042-5446; 4644-5319; 4627-4871; 4625-5116; 5045-5579; 5045-5554; 5050- 5480; 5052-5688; 5055-5688; 5085-5650; 5098-5525; 5121-5719; 5612-6163; 5676-6016; 3640-4115; 3703-4236; 3807-4354; 1-4252; 4625-5056; 5517-5999; 5527-6002; 5536-6001; 5545-5999; 5558-5999; 5595-5827; 5611-6121; 3058- 3347; 3069-3685; 3299-3715; 4625-5070; 4625-5162; 4625-5104; 4625-5202; 4625-5083; 172-812; 1338-1907; 1362-1918; 2094-2582; 2358-2773; 3011-3253; 4625-4677; 4602-5203; 4625-5071; 4625-5120; 4585-5019; 4668-5147; 4667- 5147; 4676-5172; 3900-4109; 4166-4428; 4166-4392; 4175-4555; 4222-4506; 4509-4677 Table 5
264/LI:452 089.1:2001 AY17 | 1-497; 20-514; 20-5 16; 20-515; 20-487; 20-485; 20-85; 20-77; 35-555; 35-47 35-708; 35-700; 35-576; 35-455; 35-466; 35- 685; 35-319; 36-179; 44-578 66-313; 120-615; 206-753; 236-682; 321-804; 321-920; 337-956; 339-613; 354-937; 376-817; 442-920; 447-936 265/LI:481614.43:2001MAY17 I I 3382-3618; 3399-3655; 3410-3683; 3410-3622; 3415-4042; 3417-3638; 3417 3704; 3432-3690; 3438 3727; 3441-3971; 3452-
3717 3462-3943; 3471-3714 3482-3721; 3498-3732 3507-3765; 3519-4037; 3532 3763; 3534-4105; 3552-3792; 3550-3791; 3579 3871; 3583-3958; 3601- 3655 3602-3871; 3617-4177 3627-4096; 3629-3873 3653-3916; 3659-4189;
3672-3883; 3684-4192; 3684 3956; 3699-3907; 3709 3938; 3714-4214; 3745-
3967 3752-3995; 3771-3936 3759-4018; 3777-3922 3780-4054; 3775-4032; 3774 3954; 3777-3888; 3783 3989; 3797-4035; 3796 3943; 3810-4059; 3811- 4056 3813-4093; 3821-4452 3813-4095; 3813-4069 3829-4070; 3850-4406; 3854 4099; 3868-4106; 3870 4117; 3870-3975; 3885 4145; 3885-4439; 3893- 4112 3895-4350; 3906-4430 3903-4187; 3904-4139 3904-4143; 3923-4281; 3947 4199; 3959-4211; 3960-4613; 3968-4542; 3983 4484; 3992-4160; 3994- 4135 4000-4586; 4001-4296 4014-4220; 3921-4358 3921-4220; 4418-4567; 4245 4713; 4245-4682; 4259 4667; 4277-4575; 4284-4545; 4285-4556; 4291- 4716 4290-4675; 4292-4675 4266-4556; 4271-4715 4178-4616; 4180-4436;
4188-4714; 4202-4675; 4205 4713; 4205-4712; 4208-4675; 4206-4497; 4207-
4491 4234-4666; 4231-4729 4236-4674; 4239-4498 4213-4674; 4221-4447;
4233-4390; 4245-4740; 4117 4652; 4123-4375; 4124-4385; 4124-4300; 4125-
4421 4129-4696; 4129-4392 4139-4715; 4143-4479 4156-4424; 4162-4470;
4070-4652; 4154-4632; 4066-4546; 4067-4659; 4067-4419; 4069-4321; 4069-
4269 4092-4652; 4086-4713 4092-4575; 4006-4285 4011-4555; 4011-4502; 4014 4226; 4015-4263; 4021 4231; 4023-4275; 4024-4308; 4036-4224; 4039- 4628 4045-4648; 4047-4259 4051-4355; 4059-4682 4062-4641; 4066-4717; 4069 4667; 3905-4100; 3918 4055; 3907-4085; 3913 4510; 3914-4301; 4351- 4497 4357-4756; 4359-4627 4365-4675; 4357-4666 4321-4669; 4317-4726;
4320-4753; 4328-4496; 4328-4756; 4330-4753; 4330-4748; 4337-4753; 4344-
4758 4345-4752; 4344-4604 4346-4751; 4346-4753 4346-4671; 4349-4675;
2651-2965; 2651-2892; 2688-2910; 2713-2945; 2727-2993; 2738-2993; 2738-
2995 2749-2869; 2776-3046 2781-2911; 2792-3065 2827-3107; 2828-3016; 2829 2934; 2839-3128; 2852 3433; 2852-3090; 2858-3068; 2899-3445; 2907- 3188 2925-3413; 2929-3147 2930-3233; 2945-3442 2945-3171; 2946-3044;
2953-3511; 2957-3201; 2982 3224; 2983-3218; 3007 3281; 3012-3253; 3041-
3275 3042-3285; 3053-3127 3071-3457; 3081-3293 3105-3675; 3105-3265;
3111-3382; 3137-3405; 3138-3690; 3148-3707; 3147 3642; 3163-3468; 3178-
3380 3185-3436; 3185-3445 3194-3318; 3207-3794 3210-3735; 3224-3562; 3225 3542; 3240-3488; 3248-3334; 3272-3528; 3272 3416; 3276-3514; 3276- 3444 3285-3545; 3285-3521 3286-3510; 3308-3612 3331-3557; 3332-3563;
3346-3854; 3352-3876; 3352-3872; 3364-3567; 3369-3674; 3376-3618; 2993-
3541 785-929; 787-948; 810 1122; 880-1136; 958-1119; 1039-1780; 1145-1452; 1233 1778; 1329-1908; 1334-1582; 1350-1939; 1373-1939; 1374-1615; 1378- 1903 1721-1939; 1911-2491 1905-2463; 1926-2159 ; 1928-2201; 1940-2320; 1940 2173; 1940-2200; 1942 2062; 1946-2215; 1946-2201; 1947-2186; 1947- 2511 1953-2519; 1947-2472 1954-2339; 1963-2210 ; 1967-2491; 1963-2235; 1980 2374; 1985-2532; 2006-2281; 2013-2347; 2022-2236; 2022-2379; 2067- 2264 2098-2494; 2104-2427 2143-2640; 2178-2429 ; 2178-2414; 2188-2738; 2212 2435; 2263-2782; 2267-2512; 2270-2623; 2314-2487; 2322-2729; 2370- 2672 2370-2702; 2374-2669 2392-3070; 2394-2838 ; 2403-2965; 2410-2847; 2430 2944; 2539-2608; 2576 2845; 2585-2808; 2590-2940; 2599-2867; 2605- 2738 2614-2862; 2621-2714 2631-2973; 2633-2993 ; 2633-2905; 1-338; 1-261;
6-209; 198-529; 240-579; 241-372; 252-472; 260-357; 277-765; 277-529; 294- 520; 393-4753; 400-667; 403 832; 403-946; 404-706; 447-899; 447-913; 455- 648; 475-619; 475-599; 481-573; 492-924; 494-593 ; 561-1098; 598-1163; 597- 842; 631-1137; 630-977; 684 915; 693-804; 739-1012; 749-996; 771-1121; 4298-4713; 4297-4754; 4293-4600; 4299-4643; 4304-4749; 4311-4675; 4314- 4751; 4314-4553; 4377-4533; 4386-4647; 4391-4753 ,- 4393-4757; 4392-4541; 4393-4752; 4397-4662; 4412 4753; 4402-4753; 4405-4753; 4407-4748; 4410- Table 5 4753; 4422-4542; 4445-4710; 4479-4566; 4487-4926; 4659-4754; 4695-4905; 4745-4982; 4374-4751; 4516-4753; 4549-4682; 4231-4578; 4256-4641; 1546- 1909; 1946-2374; 3935-4391; 4105-4562; 2344-2861; 4231-4753; 4146-4657; 4132-4651; 2756-3302; 1926-2486; 1946-2507; 2173-2734; 4009-4600; 1946- 2562; 4020-4683
266/LI:809605.2:200lMAY17 || 1-542; 3-284; 3-151; 13-253; 50-244; 54-290; 119-591; 120-453; 520-1134; 570-998; 594-1134; 846-1086; 921-1090; 1003- 1214; 1003-1279; 1011-1598; 1011-1281; 1011-1247; 1052-1670; 1052-1266; 1052-1271; 1112-1649; 1120-1391; 1132-1478; 1144-1392; 1144-1664; 1148- 1672; 1184-1648; 1340-1604; 1396-1879; 1419-1983; 1440-2031; 1482-2042; 1522-2046; 1490-1982; 1516-2030; 1538-1855; 1580-2160; 1599-2031; 1601- 1869; 1602-1872; 1624-2097; 1626-2071; 1657-2259; 1657-1932; 1671-1921; 1685-2112; 1689-2275; 1689-2128; 1725-2007; 1732-1891; 1790-2292; 1798- 2132; 1815-2333; 1819-2033; 1819-2198; 1875-2105; 1875-2119; 1984-2409; 1984-2522; 1984-2633; 1994-2562; 1997-2194; 1997-2394; 2014-2595; 2059- 2455; 2080-2588; 2084-2333; 2172-2627; 2183-2291; 2223-2637; 2264-2595; 2294-2633; 2337-2631; 2346-2646; 2348-2614; 2354-2637; 2354-2641; 2356- 2631; 2417-2632; 2467-2634
267/LI:816437.25:2001MAY17 || 1-3058; 124-350; 327-912; 427-638; 628-1258; 644-1192; 658-1234; 699-1019; 716-1235; 812-1387; 816-1077; 810-1019; 812- 1364; 973-1234; 1032-1625; 1105-1617; 1108-1272; 2140-2420; 2183-2302; 2263-2752; 2251-2893; 2287-2875; 2331-2922; 2350-2538; 2370-2821; 2410- 2642; 2412-2580; 2414-3051; 2420-2762; 2422-2685; 2432-2691; 2452-2511; 2453-3057; 2464-2918; 2463-2603; 2483-2620; 2503-2656; 2510-3218; 2522- 3289; 2524-3198; 2546-3255; 2584-2795; 2586-2822; 2583-3088; 2590-2794; 2590-3208; 2609-3333; 2617-2889; 2619-2926; 2640-2923; 2644-2939; 2674- 3021; 2683-3064; 2687-3236; 2739-2933; 2739-2924; 2714-2892; 2747-2921; 2804-3030; 2821-3011; 2886-3160; 3065-3165; 3050-3393; 3100-3259; 3087- 3539; 3094-3665; 3100-3660; 3105-3383; 3163-3496; 3188-3671; 3180-3382; 3209-3451; 3209-3460; 3245-3658; 3255-3645; 3290-3671; 3354-3454; 3383- 3649; 3423-3538; 3432-3637; 714-839; 968-1019; 3350-3454; 1122-1496; 1128- 3750; 1199-1729; 1224-1528; 1284-1403; 1275-1789; 1319-1709; 1436-2073; 1440-1885; 1566-2129; 1602-1806; 1634-2183; 1641-1737; 1698-2281; 1735- 2157; 1934-2539; 1934-2538; 1934-2537; 2066-2450; 2093-2189; 2116-2876 268/LI: 817827.5 :2001 AY17 || 1-602; 1-531; 1-495; 1-488; 1-296; 1-286; 1- 420; 7-460; 8-663; 11-382; 51-694; 91-695; 183-816; 200-692; 203-810; 257- 790; 493-814; 494-814; 648-756; 707-816
269/LI:002345.15:2001MAY17 || 2749-3417; 2767-2943; 2768-3345; 2806-2919; 2863-3341; 3070-3336; 3097-3521; 3192-3614; 3197-3428; 3203-3580; 3205- 3258; 3205-3255; 3209-3501; 3212-3465; 3212-3481; 3216-3592; 3217-3288; 3217-3311; 3217-3296; 3217-3298; 3218-3523; 3218-3789; 3218-3542; 3218- 3536; 3218-3535; 3218-3525; 3218-3622; 3218-3557; 3218-3548; 3218-3573; 3218-3848; 3218-3423; 3218-3544; 3218-3414; 3218-3471; 3218-3415; 3218- 3588; 3218-3468; 3218-3361; 3218-3351; 3218-3347; 3218-3277; 3218-3331; 3218-3338; 3218-3315; 3218-3289; 3218-3327; 3218-3317; 3229-3797; 3218- 3618; 3228-3740; 3228-3417; 3228-3482; 3230-3445; 3237-3391; 3237-3381; 3237-3350; 3243-3841; 3246-3545; 3246-3417; 3248-3731; 3254-3444; 3266- 3898; 3261-3476; 3277-3761; 3287-3565; 3293-3404; 3300-3580; 3315-3918; 3332-3912; 3491-3879; 3498-3908; 3507-3762; 3509-3920; 3511-3873; 3516- 3766; 3522-3918; 3529-3923; 3530-3920; 3540-3923; 3549-3901; 3550-3777; 3553-3845; 3555-3845; 3560-3880; 3567-3851; 3574-3821; 3581-3801; 3588- 3912; 3593-3895; 3594-3920; 3597-3918; 3601-3879; 3616-3923; 3621-3918; 3628-3915; 3644-3880; 3650-3915; 3655-3914; 3670-3912; 3674-3897; 3676- 3923; 3689-3924; 3690-3918; 3699-3918; 3699-3844; 3700-3918; 3709-3918; 3716-3923; 3726-3922; 3726-3870; 3726-3912; 3726-3875; 3729-3897; 3728- 3874; 3731-3875; 3775-3918; 3809-3909; 3835-3933; 1445-2095; 1584-1880; 1607-2121; 1621-1867; 1643-2040; 1647-2045; 1647-1974; 1648-2045; 1648- 2247; 1676-2133; 1695-2133; 1695-2273; 1701-1928; 1702-2116; 1715-1946; 1721-2324; 1771-2096; 1780-2064; 1796-2119; 1800-2123; 1811-2045; 1833- 2077; 1889-2136; 1918-2225; 1918-2160; 1955-2580; 1969-2616; 1975-2498; Table 5 1978-2133; 2006-2292; 2090-2363; 2189-2699; 2191-2436; 2 194-2313; 2222- 2459; 2358-2576; 2386-2690; 2391-2959; 2417-2919; 2420-2698; 2427-2731; 2445-2944; 2447-2709; 2456-2916; 2451-2919; 2457-2766; 2485-2749; 2486- 2917; 2509-2754; 2510-2752; 2558-2919; 2587-2882; 2589-2850; 2604-2919; 2610-2919; 2616-2766; 2629-2911; 2627-2919; 2627-2921; 2628-2912; 2664- 2907; 2689-2821; 2682-2919; 2715-2919; 2726-2919; 2742-2919; 1-579; 21-171; 22-649; 29-570; 29-482; 33-392; 37-171; 39-625; 512-980; 548-792; 640-907; 922-1600; 1065-1411; 1099-1799; 1123-1543; 1242-1929; 1312-1949; 1418-2016; 3349-3666; 3345-3878; 3350-3622; 3355-3637; 3365-3909; 3368-3650; 3372- 3626; 3399-3478; 3398-3877; 3402-3632; 3408-3628; 3407-3877; 3410-3901; 3432-3671; 3431-3685; 3432-3876; 3432-3894; 3439-3691; 3439-3700; 3447- 3918; 3457-3728; 3463-3917; 3464-3702; 3469-3610; 3467-3742; 3466-3918; 3475-3916; 3490-3761 270/LI : 022629.5 : 2001MAY17 I 163 -499 ; 150 -496 ; 688 -938 ; 348 -941 ; 419 -940 ; 329-941; 356-938; 367-924 363 -92 4; 362-943; 362-934; 375-865; 600-885
767-873; 371-866 525-866 565 -86 ( 6; 496-850; 368-851; 626-851; 385-850 412-850; 207-848 610-848 566 -842 3; 624-843; 296-808; 362-779; 375-770 408-770; 401-770 462-770 171 -77 C 0; 163-766; 345-746; 101-670; 162-691 163-689; 161-689 163-685 166 -68. 2; 372-676; 163-673; 146-652; 163-653 163-652; 227-646 163-635 163 -607 ; 163 -586 ; 163 -580 ; 163 - 560 ; 1 -463 ; 163 - 454; 166-437; 163 -397 163-377; 163-376; 164-376; 165-344; 163-334; 163- 327; 15-293 271/LI:0 61031.4:2 001MAY1 7 || 9 31-1391; 936-11 82; 9 35-1571; 974-1634; 1214- 1777; 1699-2374; 1673-23 03; 1686-2358; 1-590; 245-862; 245-861; 469-863; 469-862; 1728-2277; 1791 -2086; 1774-2376; 1876-2042; 1946-2277; 2058-2548; 2058-2524; 2071-2221; 23 04-2634; 2307-2440; 2308-2675; 2311-2520; 2318- 2544; 2363-2675; 2387-26 38; 2494-2675; 2507-2675; 2516-2675 ; 2529-2675; 2550-2710; 2614-2675; 26 25-2675; 1669-2277; 469-860; 547-861; 663-863; 707 863; 707-862; 707-860; 7 25-1277; 916-1603; 931-1426; 931-1532; 931-1635; 931-1518 931-1548; 931- 1445; 931-1405; 1247-1458; 1246-1456; 1246-1357; 1247-1357; 1246-1832; 12 47-1832; 1281-1832; 1342-1847; 1399-1832; 1428- 2114; 1428-2118; 1454-21 14; 1464-2156; 1488-2115; 1487-2221 ; 1533-2115; 1525-2156; 1527-2224; 16 09-2277; 1639-2306; 1619-2277; 1648-2178; 1662- 2361; 1664-2264; 1657-22 77; 1229-2022; 1238-1832; 1247-1984 ; 1247-2004; 1247-1844; 1247-1847; 12 47-1840; 1246-1844; 1247-1920; 1247-1824; 1251- 1845; 1247-1930 272/LI:l08232.2:2 001MAY17 1 -45 4; 1-230; 92-676; 106-818; 106-678; 100-
797 106-787; 107 -713 107 -731 ; 1 06-597; 107-640 106-694; 107-809; 107- 645 108-422; 111 -676 109-708; 10-661; 128-510 136-443; 152-392; 156- 435 191-716; 216 -879 246-531; 78-881; 289-859 350-934; 378-933; 527- 841 531-840; 683-934; 777-934; 91-934; 799-934 826-934; 862-1516; 876- 934
273/LI:1085493.16:2001MAYl7 || 10 09-164 0; 1022-1 630; 11 01-17 18; 11 26-1726; 1281-1679; 1291-1926; 1508-1912; 1527-1665; 1527-1720; 1527-1696; 1527- 1637; 1540-1643; 1560-1694; 1560- 1697; 1561-2069 ; 1563-1961; 1578- 2218; 1597-1908; 1599-1725; 1603-2253; 1602-2192; 1619-1691; 1624-1686; 1624- 1730; 1624-1980; 1624-1680; 1624- 1708; 1624-1738 ; 1624-1917; 1627- 1694; 1642-1694; 1806-2191; 1831-2212; 1831-2193; 1831-2191; 1835-1926; 1835- 1901; 1838-2193; 1836-2115; 1844- 2190; 1872-2128 ; 1924 2191; 1937- 2154; 1950-2108; 1960-2191; 1967-2191; 2019-2615; 2041-2191; 2051-2191; 2069- 2191; 2076-2191; 2087-2191; 2100- 2574; 2130-2191 ; 2132 2191; 2101- 2191; 2102-2191; 2130-2749; 2138-2654; 2491-2729; 2494-2940; 2498-2938; 2499- 3001; 2499-3004; 2499-2596; 2514- 3008; 2514-2569 ; 2514-2963; 2522- 2672; 2551-2809; 2554-2890; 2566-2781; 2566-2720; 2574-3040; 2611-3040; 2627- 3048; 2626-3045; 2635-2851; 2648- 3038; 2659-2913 ; 2677-3043; 2701- 3040; 2741-3040; 2775-3040; 2779-3042; 2779-3040; 2779-3044; 2776-3037; 2791- 2959; 2812-3040; 2825-3040; 2849- 2998; 2862-3040 ,- 2914-3044; 2993- 3046; 204-784; 207-809; 207-455; 214-83 6; 226-843; 261-564; 300-865; 307 -566 314-852; 373-712; 375-638; 379-87 0; 374-505; 394-898; 408-652; 417 -750 434-641; 439-1124; 451-1049; 1-65 0; 9-185; 451-689; 457-1004 472- 1019 Table 5
512-802; 572-819 592-970; 12-502; 56-580; 62-665; 653-816; 715-1183; 884- 1182; 63-283; 85 697; 95-675; 95-682; 143-794; 149-762; 191-699; 57-211; 123-391; 207-342 252-827; 374-654; 405-637 ; 450-793; 564-858; 765-858; 2645-2916; 2716 3016; 2779-3025; 2825-3045 274/LI:1085513.2 :2001MAY17 || 1475-1872; 15 21-1797; 1581-2191; 1677-1879; 1757-2143; 1806-2270; 1962-2521; 2040-2576; 1-534; 10- 216; 242-928; 334- 599; 433-832; 547-1073; 575-714; 579-1166; 588-848; 588-819 602-1020; 628 1120; 708-1253; 773-965; 794-1061; 801-1439 ; 803- -1447; 920-1481; 945-1533; 1010-1676; 1012-1519; 1033-1564; 1038-1390; 1038- -1384; 1040- -1364; 1040- 1465; 1041-1149; 1048-1602; 1050-1279; 1066 -1544, 1129 -1447 1102-1489; 1193-1563; 1150-1757; 1170-1471; 1219-1491; 1234- -1838; 1270- -1507; 1270- 1554; 1280-1783; 1282-1554; 1353-1876; 1428 -1870, 1429 -2049 1443-1690; 1446-2026; 1478-2100; 1482-1890; 1520-1788; 1457- -1669; 1457- -1618; 1557- 1943; 1533-1994; 1572-2187; 1514-1729; 1582 -2218, 1578 -1999 1641-2178; 1605-1900; 1656-2077; 1659-2181; 1705-1980; 1691- -1963; 1693- -1994; 1752- 2087; 1774-2382; 1778-1996; 1822-2356; 1806 -2015, 1803 -2009 1821-2058; 1880-2224; 1931-2159; 1959-2168; 1993-2464; 1995- -2100; 2021- -2408; 2028- 2584; 2042-2200; 2105-2369; 2113-2686; 2191 -2621, 2191 -2482 2191-2635; 2201-2661; 2208-2688; 2258-2684; 2269-2638; 2267- -2639; 2291- -2623; 2293- 2566; 2322-2649; 2325-2523; 2347-2684; 2349 -2684, 2344 -2682 2417-2684; 2440-2673; 2440-2633; 2450-2684; 2596-2688 275/LI:1086797.9 :2001MAY17 || 4223-4755; 42 50-4504; 4258-4705; 4941-5291; 4300-4682; 4397 4890; 5016-5557; 5200-5553; 5278- -5835; 4410- -4585; 4410- 4894; 4433-4704 4548-4758; 4580-4758; 4691 -5274, 4704 -4758 4802-5214; 4802-5054; 4802 4878; 5279-5823; 5283-5886; 5283- -5832; 5283- -5830; 5304- 5780; 5304-5403 5307-5857; 5308-5698; 5307 -5560, 5304 -5404 5311-5799; 5331-5587; 5431 5713; 5445-5521; 4802-4952; 4802- -5209; 4802- -5201; 5531- 6106; 5529-5807 5555-5783; 5574-5838; 4813 -5293, 4835 -5104 4935-5270; 4940-5120; 4941 5286; 6422-6602; 6426-6553; 6426- -6630; 6427- -6593; 6429- 6630; 6458-6624 6472-6630; 6544-6631; 6192 -6592, 6259 -6349 6297-6519; 6363-6630; 6414-6630; 6511-6635; 3411-3642; 3946- -4526; 4216- -4745; 4835- 5273; 4950-5120 5282-5861; 5304-5650; 5311 -5857, 5470 -5975 5622-5874; 5996-6528; 6045 6355; 6065-6417; 6079-6590; 6120- -6579; 5646- -5949; 5660- 6067; 5670-6215 5684-6083; 5724-6172; 5724 -5993, 5971 -6539 5724-6289; 5729-5860; 5745 6271; 5991-6515; 5995-6251; 5997- -6262; 5997- -6229; 6003- 6263; 6011-6539 6045-6283; 6064-6527; 6065 -6520, 6065 -6485 6065-6526; 6065-6518; 6065 6525; 6064-6296; 6075-6339; 6085- -6592; 5756- -6228; 5768- 6027; 5797-6036 5845-6065; 5845-6478; 5890 -6130, 5895 -6187 5903-6131; 5907-6159; 5939-6498; 5944-6294; 5944-6266; 6087- -6597; 6098- -6344; 6107- 6334; 6131-6388 6133-6390; 6152-6368; 6159 -6416, 6201 -6440 6216-6630; 6218-6466; 6223-6593; 6223-6627; 6268-6537; 6268- -6528; 6279- -6564; 6285- 6645; 6324-6631 6332-6630; 6341-6631; 6353 -6627, 6365 -6631 6365-6634; 6386-6589; 6405-6627; 5945-6069; 5949-6447; 5964- -6528; 1-189; 15-232; 101- 401; 102-593; 103-365; 329-931; 440-734; 59 6-218: 1; 645 -1164 672-1218; 946 1565; 1018-1465; 1066-1491; 1128-1704; 1797 -2081, 1797 -2354 1797-2184; 1899-6632; 1986- 2401; 2070-2629; 2261-2630; 2322- -2851; 2322- -2993; 2416- 2975; 2442-2669; 2759-3409; 2787-3440; 2788 -3298, 2795 -3414 2895-3411; 4189-4714; 2905- 3414; 2970-3346; 3003-3582; 3196- -3670; 3229- -3800; 3301- 3824; 3394-3824; 3410-3935; 3531-3788; 3671 -4046, 3666 -4207 3666-4191; 3945-4538; 4025-4516; 4043-4538; 4220-4758; 4090- -4436 276/LI:1088446.1 :2001MAY17 || 510-790; 637- 1276; 817-1467; 919-1214; 1022- 1654; 1236-1818; 1397-1997; 1683-1948; 1934 -2485, 1-621; 1-395; 74-600; 74 479; 74-458; 247-938; 303-938; 318-941; 388 -1057, 479-. 345; 506-1075; 512- 1035; 517-1041; 526-953; 596-1162; 650-978; 652-1308; ' 711-1337; 760-1068; 828-1259; 856-1406; 879-1477; 878-1329; 880 -1421, 950-. 1580; 950-1372; 952- 1547; 1002-1542; 1022-1689; 1133-1714; 1165 -1783, 1200 -1729 1229-1663; 1353-2003; 1369-2031; 1373-2029; 1392-1780; 1460- ■1747; 1576- -1950; 1667- 1986; 1676-1987; 1683-2045; 1700-1896; 1771 -1963; 1890- -2309, 1891-2091 277/LI:1133764.3 2001MAY17 I I 513-1033; 817 -1398; 1144- -1778, 1284-1678; 1568-2198; 2114 2299; 1919-2303; 1886-2300; 2064- -2300; 1574- -2235; 1526- Table 5
2206 ; 1247 -199 2 ; 1374-1986 ; 1318-1979 ; 1227 -1936 ; 1077-1837 ; 1278-1807 ; 1175-1792 ; 1277 -1788 ; 940-1733 ; 1041-1610 ; 917 -1570 ; 425-1150 ; 803 -1135 ; 448 -1085 ; 515- 1075 ; 484-1063 ; 359-1060 ; 217 -979 ; 525-925 ; 622 -923 ; 1-860 ; 235-799 278 /LI : 1147614 .5:200 1MAY17 II I"4 06; 3-552; 1-47 20-578; 15-539 ; 20-497; 20-675 ; 20-270 ; 20-6 13; 20-593; 20-136; 20-610; -289; 46 377; 1 06-789; 192 -784 ; 217-732; 23 4-481; 241-345; 254-305 ; 254 06; 275-9 13; 32 8-528; 330-819 ; 342 -986; 37 8-819; 383-1005; 423-681; 43 1107; 444 1013; 466-1014; 483 -1139 ; 483 -709; 4 83-1066; 483-834; 483-1035; 5-895; 51 8-675; 521-595; 568-1213 ; 570 -1032; 608-1250; 641-1227; 649-749; 55-851; 6 67-1401; 680-
1232 679-1273 ; 688- 1393; 769-1328; 814-1455; 82 907; 804- 1455; 827-1396;
831-1463; 846- 1277; 851-1455; 853-1405; 875-1449 861-1454; 960-1616; 1027-
1689 1035- 173 107 2-1592 1075- 1664 1097-1576 1261-1897 1310-1951; 1321 1870; 134 1455 ; 1343 1817; 1351 1908; 1351 917; 1374 1928; 1385 1928 1387- 192 139 8-1928 1405-1928 1405-1940 1481-2047 1500-1902 1492 2066; 148 2225 ; 1500 2059; 1500 1901; 1500 889; 1500 1890; 1500 1995 1502- 206 150 4-2155 1513-2078 1557-1794 1518-1928 1532-2253 1536 2113; 155 2066 ; 1560 2170; 1607 1847; 1574 015; 1623 -1861; 1592 1889 1628- 228 162 4-2220 1624-1984 1623-2154 1626-1822 1634-2281 1656 1753; 172 1902 ; 1714 2253; 1716 2340; 1723 066; 1723 1899; 1723 1927 1723- 188 172 3-2275 1723-2321 1708-2417 1723-1996 1723 -1801 1724 2223; 173 1805 ; 1739 2223; 1754 2340; 1768 439; 1766 -1946; 1797 2454 1779- 224 179 6-2420 1779 2316 1784-2275 1790-2433 1781-2284 1838 2419; 183 9-2340; 1811 2389; 1848 2401; 1866 453; 1844 2241; 1875 2154 1946- 247 π 1932-2170 1932-2572 1957-2340 1938-2524 1945-2537
1946-2616; 1945 2603 ; 1945 2457; 1945 2283; 1958 494; 1945 -2304; 1945 2015; 1970-2567 1945-2206 1967-2623 1980-2503 1984-2428 2039-2588 2086-2695; 2106 2602 ,- 2092 2474; 2098 2462; 2092 677; 2092 -2679; 2096 2801; 2096-2700 2121-2723 2123-2599 2131-2773 2135-2386 2139-2745 2146-2712; 2149 2396 ; 2150 2379; 2154 2393; 2163 361; 2166 2399; 2185 2698; 2189-2408 2192-2838 2204-2721 2214-2724 2214-2770 2219-2925
2220-2440; 2226-2791 ; 2229 2638; 2227 2840; 2234 846; 2237 -2748; 2235
2286 2272-2743; 2280-2854 2301-2831 2316-3021 2319-2758 2320-2740 2349 2819; 2318-2861 ; 2345 2985 2350 2591; 2368 592; 2330 2989; 2354 2901 2364-3005; 2329-3009 2376-3023 2395-2595 2408-3098 2395-2645 2408 2880; 2445-3103 ; 2445 3098; 2440 3095; 2450 933; 2445 3138; 2461 3178 2482-306 57 2488-2975 2495-2873 2500-2692 2492-3108 2495-3044
2530-2954; 2493 3091 ; 2521-3097; 2539 2804; 2539 803; 2554 -2802; 2555 2995; 2564-2803 2566-3128 2589-2844 2569-2898 2558-3050 2583-2836 2585-2824; 2596-2875 ; 2595-3097; 2614 2873; 2595 985; 2618 -2926; 2618
3095; 262 2-307 2670-2895 2665-3057 2681-2880 2681-2917 2681-3104 2681-2928 2684-3095; 2688 3098; 2690 3090; 2695 091; 2720 3046; 2698 3092; 2713-297 2741-3095 2763-2961 2748-2962 2748-2993 2753 -2957 2763-3097 277 2936 ; 2772-2935; 2763 2968; 2788 085; 2801 -3083; 2806- 3101; 2817-309 2801-3069 2820-3097 2879-3045 2886-3091 2882 -3093 2919-3097 ; 2903-3099 ; 2965 3090 279/LI:ll81710.1:2001MAY17 II 1-2 52; 28-577; 28-234; 28-191 28-112; 149- 668; 345-497; 354-488 280/LI:ll83192.1:200 1MAY17 || 1-155; 52-656; 84-379; 89-313; 148-654; 149- 663; 149-698; 149-700; 152-411; 145-410; 169-684; 175-695; 244-791; 180- 737; 180-672; 257-472; 312-956; 313-940; 324-886; 342-892; 345-987; 375- 942; 390-859; 418-1020; 427-1034; 407-1033; 433-1043; 443-1031; 426-1075; 505-1123; 509-1192; 510-1107; 557-1206; 558-954; 561-973; 570-1158; 576- 1256; 576 -1086 ,- 613-1274; 637-1273; 647-975; 664-1223; 664-1181; 698-1324; 710-1323; 735-1347; 759-1431; 805-1347; 785-1049; 828-1538; 906-1497; 941- 1591; 1032-1569; 1039-1680 ; 1039-1542; 1132-1573; 1144-1573; 1169-1395; 1229-1870 ; 1223-1573 ; 1223-1499; 1253-1469; 1351-1827; 1360-1588; 1378- 1573; 1382-1535; 1395-1661 ; 1394-1906; 1453-1573; 1476-1944; 1476-1670; 1437-1658 Table 5 281/LI: 1188786.15 :2001 AY17 || 2564-2793; 2570-3027; 2570-2713; 2581-3032; 2581-2798; 2587-2845; 2587-2969; 2594-2825; 2594-2827; 2651-2830; 2659- 3340; 2675-2964; 2704-2770; 2738-2951; 2741-2983; 3295-3503; 2795-3174; 2803-3479; 2879-3125; 2881-3092; 2894-2963; 3302-3742; 3323-3882; 3333- 3729; 3336-3738; 3498-3742; 3499-3736; 3514-3738; 2895-3129; 3548-3737; 2925-3135; 3575-3721; 3581-3740; 3629-3742; 2925-3299; 2936-3693; 2971- 3252; 2985-3276; 2988-3256; 3035-3239; 3039-3631; 3143-3378; 3153-3404; 3178-3764; 3178-3451; 3228-3703; 3239-3480; 3239-3700; 3258-3761; 3286- 3489; 3286-3742; 762-1327; 762-1121; 764-866; 762-1064; 789-1324; 789-1323; 909-1480; 917-1150; 953-1501; 1029-1522; 1077-1482; 1083-1731; 1089-1600; 1127-1590; 1172-1380; 1178-1708; 1210-1650; 1210-1466; 1218-1460; 1240- 1749; 1273-1516; 1304-1754; 1304-1757; 1382-1954; 1382-1800; 1393-1800; 1400-1610; 2562-2997; 1412-1800; 1429-1804; 2562-2731; 1444-1800; 1512- 1800; 1518-1994; 1531-1731; 1542-1994; 1580-1800; 1587-1775; 1698-1800; 1703-2223; 2563-2636; 1733-2240; 1759-2230; 1765-2273; 1765-2476; 1766- 2259; 1765-2240; 1765-2224; 1765-2490; 1765-2547; 1767-2015; 1765-2230; 1794-2019; 1796-2230; 1907-2235; 1989-2725; 2069-2823; 2081-2230; 2078- 2790; 2095-2235; 2106-2230; 2109-2235; 2176-2234; 2174-2751; 2265-2765; 2546-3070; 2557-2798; 2557-2906; 2559-2712; 2562-2820; 1-571; 99-477; 107- 642; 109-615; 116-545; 116-484; 131-448; 132-501; 135-525; 135-576; 135- 442; 135-588; 135-589; 135-487; 135-478; 213-756; 212-883; 261-760; 550- 1031; 684-1271; 762-1250; 762-1420; 135-432; 199-772; 677-944; 1781-2130; 2063-2625; 2109-2240; 2517-2613; 2562-2703; 2563-2713
282/LI:145626.1:2001MAY17 || 593-942; 972-1258; 1819-2125; 1819-2398; 1819- 2188; 1821-1987; 2064-2490; 2356-2882; 1-558; 1-462; 145-456; 145-709; 573- 1138; 774-1325; 838-1227; 852-1479; 852-1386; 979-1575; 1483-2035; 1575- 2165; 1668-1956; 1819-2423; 1819-2378; 1819-2335; 1819-2323; 1819-2317; 1819-2362; 1819-2356; 1819-2376; 1819-2387; 1819-2251; 1819-2090; 1819- 2408; 1873-2447; 1877-2152; 1883-2150; 1979-2570; 2116-2713; 2229-2785; 2230-2706; 2247-2847; 2306-2529; 2369-2950; 2362-2509; 2370-2706; 2378- 2966; 2378-3004; 2384-3117; 2443-2910; 2442-2910; 2451-2948; 2561-2945; 2812-3102
283/LI:147869.3:2001MAYl7 || 1217-1859; 1089-1386; 623-1189; 874-1112; 874- 1018; 623-925; 210-800; 572-792; 1-678; 320-649
284/LI:151747.4:2001MAY17 || 1-57; 1-334; 1-365; 1-610; 1-401; 1-387; 1- 587; 6-121; 69-490; 69-375; 69-371; 69-289; 69-610; 85-607; 82-607; 79- 1944; 79-1797; 99-695; 115-739; 134-607; 158-390; 174-597; 174-345; 180- 417; 198-590; 206-672; 206-749; 256-402; 260-781; 267-792; 320-759; 367- 705; 382-631; 407-922; 398-996; 399-741; 418-915; 428-669; 449-997; 472- 1025; 502-685; 514-769; 540-1022; 562-1204; 606-1231; 631-876; 620-1209; 622-848; 635-892; 649-1159; 644-1141; 693-886; 709-907; 734-1187; 737-1204; 759-1391; 777-1385; 786-1263; 775-1078; 775-1383; 776-1126; 808-1437; 817- 1079; 858-1308; 875-1112; 869-1447; 904-979; 968-1235; 968-1073; 972-1437; 971-1421; 1059-1266; 1077-1310; 1117-1335; 1130-1531; 1134-1457; 1174-1426; 1190-1732; 1221-1658; 1227-1680; 1231-1786; 1265-1558; 1273-1787; 1345- 1726; 1377-1450; 1404-1639; 1449-1728; 1437-1825; 1447-1827; 1462-1822; 1485-1749; 1516-1826; 1536-1822; 1544-1822; 1549-2005; 1550-2001; 1549- 1997; 1559-2001; 1643-2213; 1645-2131; 1696-2016; 1696-1880; 1698-1908; 1695-1803; 1694-1752; 1733-1789; 1776-2277; 1886-2277; 1913-2288; 1914- 2271; 1931-2295; 1952-2425; 1952-2219; 1955-2289; 1961-2309; 2031-2182; 2033-2242; 2034-2297; 2034-2271; 2036-2292; 2042-2100; 2050-2309; 2060- 2231; 2067-2292; 2147-2414; 2185-2428; 2187-2741; 2199-2491; 2203-2472; 2247-2720; 2320-2704; 2325-2674; 2376-2703; 2395-2497; 2427-2706; 2434- 2509; 2470-3086; 2495-3169; 2534-2787; 2567-2706; 2610-2957; 2621-2887; 2621-2783; 2664-2886; 2732-3020; 2742-3195; 2755-2877; 2878-3097; 2879- 3087; 2883-3087; 2912-3087; 2923-3090; 2928-3122; 2932-3427; 2943-3090; 2958-3096; 2961-3098; 2961-3212; 2970-3097; 2972-3113; 2996-3108; 3009- 3249; 3019-3339; 3060-3298; 3102-3560; 3119-3562; 3119-3541; 3119-3374; 3133-3381; 3134-3411; 3136-3623; 3139-3445; 3150-3388; 3188-3382; 3238- 3736; 3243-3453; 3321-3712; 3321-3556; 3321-3449; 3346-3584; 3359-3486; Table 5
3381-3779; 3406-3615; 3409-3616; 3415-3616; 3424-3720; 3428-3730; 3474- 3930; 3483-3616; 3492-3770 ; 3506-3616; 3522-3594; 3534-3916; 3537-3630 3549-3893; 3620-3942; 3623-3939; 3633-4068; 3634-4087; 3636-3931; 3640 3931; 3655-4064; 3708-4103 ; 3800-4070; 3816-3875; 3970-4315; 4047-4555 4046-4588; 4046-4607; 4046-4343; 4046-4220; 4100-4602; 4103-4322; 4138- 4314; 4138-4302; 4141-4322 ; 4188-4306; 4197-4593; 4210-4839; 4255-4593 4462-4529
285/LI: 198296.1:2001MAY17 I 965- 1602; 970- 1621; 994-1445; 1000-1445; 1007- 1541; 1028-1267; 1042-1269 1053-1376; 1056-1444 1059-1450; 1073-1422; 1073-1349; 1144-1445; 1156 1444; 1164-1517; 1167-1429; 1213-1445; 1238- 1445; 1238-1443; 1-207; 4 289; 139-362; 139-647; 139-504; 195-500; 227-489; 1254-1348; 1342-1443; 318-501; 1355-1441; 422-628; 479-718; 1361-1804; 1379-1462; 549-763; 573-809; 656-1123; 1430-1698 ; 1534-1781; 694-815; 1534- 1820; 1539-1808; 1579-1859 ; 1609-2128; 740-1246; 760-1269; 1609-1839; 1623- 1867; 769-1057; 803-1353; 810-1124; 809-1385; 846-1176; 881-1063; 881-1385; 913-1348; 1649-2084; 934-1407; 1661-1860; 1693-2009; 940-1443; 951-1313; 1747-2003; 1788-2084; 1805-1980; 1806-2413; 1826-2084; 1874-2084; 1907- 2084; 1925-2084; 1951-2161 2011-2084; 2298-2574 ; 2301-2360 2301-2569; 2301-2559; 2338-2878; 2449 2878; 2453-2921; 2466-2917; 2474 2877; 2474- 2856; 2527-2914; 2529-2693 2588-3255; 2623-2921 ; 2681-2770 2695-3384; 2716-3259; 2839-2917; 2934 3380; 2972-3371; 1549-1814; 1647 1899; 1756- 1895; 1892-1985; 2044-2093 2301-2714; 2474-2733 ; 2599-2866 2730-2821; 2992-3565; 3725-4174; 3963 4242; 3030-3377; 3186-3700; 3190 3802; 3353- 4115; 3496-4052; 3515-4170 3554-4134; 3612-4090 ; 3725-3957 3771-3844; 3771-4370; 3898-4017; 3906-4154 286/LI:200117.4:2001MAY17 I I 1-23 3; 55 -145; 71-312 ; 80-388; 9 0-279; 90-365; 93-362; 100-352; 103-386; 134-540 ; 136-409; 340-901; 364-673; 399-1045; 417-1109; 465-775; 469-723 ; 471-611; 470-838 ; 487-938; 504-771; 550-818; 569-1022; 592-988; 631-1137; 631-828; 642-1077; 643-890; 647-855; 650-1110; 655-829; 665-1118; 667-1110; 672-1127; 673-1117; 675-1122; 679-1084; 680- 1084; 686-985; 696-1117; 697-1117 ; 703-1118; 704-1110; 721-1117; 722-1117; 731-1118; 730-1204; 736-1117; 742-1089 ; 765-1117; 772-1108; 773-1005; 818- 1107; 827-1117; 828-1117; 839-1078; 848-1117 ; 853-1074; 855-1371; 853-1108; 880-1118; 943-1110; 967-1232; 974-1257 ; 974-1082; 1088-1325 287/LI:200704.1:2001MAYl7 I I 746-1350; 1069-1765; 1352-1586; 1423-2047; 1634-2201; 1661-2231; 1661-2021; 1661-2224; 1700-2242; 2200-2634; 1-703; 3- 496; 4-773; 6-348; 8-196; 119-872 ; 146-868; 159-871; 162-873; 257-872; 267- 871; 272-872; 746-1413; 745-1373; 746-1315; 746-1514; 753-1486; 981-1471; 1053-1695; 1152-1727; 1163 1848; 1169-1797; 1203-1922; 1374-1987; 1387- 2004; 1399-1690; 1399-1747 1480-2225; 1509- 2126; 1554-2101; 1554-2268; 1586-2139; 1639-2229; 1655 2111; 1661-2226; 1661-2247; 1661-2236; 1661- 2223; 1661-2346; 1661-2237 1661-2127; 1662- 2251; 1664-1976; 1663-2267; 1661-2232; 1662-2224; 1707 2229; 1711-2007; 1726-2182; 1726-2183; 1726- 2244; 1733-2131; 1733-2007 1733-2129; 1733- 2184; 1733-2232; 1735-2183; 1737-2183; 1741-2285; 1733 2182; 1835-2225; 1835-2416; 1839-2222; 1845- 2222; 1921-2183; 1957-2174 2009-2561; 2186- 2486; 2201-2490; 2228-2641; 2333-2588
288/LI : 2049995.3 : 2001MAY17 I I 163 7-1943; 1861-2350; 2070-2659; 2555-3005; 2562-2613; 2562-2662; 2593-2850; 2637-2936; 2737-2851; 3608-4063; 3627- 3858; 3636-4007; 3645-3772 ; 3680-4062; 3706-4175; 3718-4172; 3739-4071; 3755-4170; 3773-4161; 3825-4042; 3847-4170; 3877-4320; 3946-4159; 3983- 4093; 3998-4170; 4060-4344 ; 4151-4344; 4570-4759; 1-2733; 49-4170; 190-521; 246-627; 259-709; 341-865; 499-837; 693-1275; 781-1074; 796-2460; 803-949; 954-1389; 1035-1187; 1255-1473; 1282-1555; 1282-1552; 1398-1884; 1470-1806; 1470-1693; 1470-1936; 1522-1748; 1551-2013; 1642-2222; 1653-2195; 1656- 2156; 1799-2107; 1930-2484 1996-2529; 2029-2299; 2043-2645; 2088-2529; 2117-2690; 2157-2758; 2272 2664; 2299-2663; 2555-2986; 2556-2990; 2561- 2991; 2562-2816; 2562-2939 2562-3025; 2562-2737; 2562-2954; 2565-3009; 2574-3022; 2583-3070; 2588 2811; 2610-2871; 2632-2885; 2633-3113; 2636- 2912; 2652-2922; 2668-2947 2674-3185; 2676-2879; 2716-3230; 2744-3258; Table 5
2753 -2959 ; 2753 -2984 ; 2762 -3307 ; 2762 -3011 ; 2763- 3199; 2762 3210; 2796
3125 2796-3121; 2807-3105; 2833-3114 2839-3059; 2839 -3108 2867- 3426 2871 3125; 2876-3163; 2902- 3126; 2929-3185; 2962-3227; 2973 3235; 2995 3252 3007-3265; 3008-3293; 3029- 3432 3028 3267; 3028 -3437 3033- 3482
3039-3146; 3059-3324; 3070- 3588; 3095 3408; 3108-3356; 3139 3387; 3155
3427 3160-3413; 3181-3474 3184- 3708 3192 3766; 3196 -3444 3201-■3501 3200 3450; 3222-3486; 3235- 3479; 3243 3526; 3244- 3494; 3245 3439; 3247 3518 3247-3513; 3251-3516 3267- 3492 3268-3508; 3283 -3581 3313- 3578
3324-3578; 3334-3610; 3345 3814; 3357 3639 3377-3629; 3379 3651; 3395
4048 3406-3944; 3406-3616 3408- 3873 3408-3632; 3436 -3517 3446-■3740 3450 3719; 3454-3682; 3468 3703; 3466 4040; 3461-3955; 3503 3758; 3526 3762 3534-3741; 3550-4090 3555- 4060 3574 3915; 3576 -3856 3596- 4055
3605-4063; 3607-4063; 3608 4020; 3611 4025; 3617-4062; 3618 4132; 3626
4054 3628-3895; 3628-3765 3630- 4021 3630 3935; 3638 -3904 3639-•3914
3644-4025; 3645-4061; 3667-4055; 3670-3926; 3687-3974; 3693 4062; 3703
4055 3705-4057; 3696-4170; 3709-4167 3711- 4164; 3713 -4170 3715- 4165
3718-4170; 3724-4173; 3728-4171; 3732-4065; 3744-4163; 3747 4005; 3748
4179; 3750-4170; 3762-4173 3769-4125 3769- 4159; 3772 -4055 3775- 4055 3777-4008; 3787-3986; 3790 -4170; 3791-4172; 3793-4065; 3795 4129; 3809 4140; 3813-4064; 3833-4075 3841-4096 3841- 4170; 3841 -4055 3844- 4290 3852-4170; 3858-4170; 3857 -4064; 3872-4341; 3880-4347; 3888 4173; 3895 4170; 3905-4320; 3949-4320 3952-4053 3965- 4062; 3972 -4158 3984- 4212 3994-4340; 3994-4055; 3996 -4348; 3999- -4172; 4004-4124; 4005 4170; 4007 4056; 4051-4344; 4075-4338 ; 4081 -4172 4082-4170; 4123 -4172 4217- 4765 4227-4503; 4367-4636; 4402 -4636; 4590- -5005; 4628-5005 289/LI: 2052097.2 :2001MAY17 II ι-< 189; 27-578; 365-635; 366-7 90; 40 9-975; 433-691; 455-917; 458-719; 564-844; 564-1085 ; 602-875; 622-1159; 627-944; 812-1438; 916-1493; 918-14 94; 1117-1565; 1127-1361; 12 99-1551; 13 85-2069; 1460-1986; 1503-2070; 1521 -2097; 1520- -1713; 1527-1932; 1691-1962; 1737- 2142; 1816-2374; 1819-2065 ; 1769 -1883 1857-2164; 1903 -2126 ; 1931-2061; 1922-2073; 2053-2152; 2116 -2686; 2122- -2774; 2140-2638; 2212-2658; 2253- 2859; 2309-2847; 2311-2863 ; 2320 -2865 2324-2860; 2349 -2846 ; 2519-3113; 2566-2694; 2579-2845; 2579 -2984; 2590- -2984; 2718-3190; 2721-3126 290/LI: 209351.22 :2001MAY17 | | 1047-1726; 1048-1732; 10 48-1665; 1- 511; 41- 510; 283-592; 291-1127; 35 9-901; 372-765; 408-902 ; 422 -1298 ; 447-1351; 481- 1307; 479-1045; 482-1184; 488-1095; 505-1154 ; 604-1295 ; 606-948; 604-803; 606-1418; 650-1437; 663-14 32; 724-1432; 777-1753; 750- 1146; 771-1629; 782- 1580; 776-1370; 792-1612; 819-1370; 815-1103 ; 859-1220 ; 909 -1605; 889-1556; 914-1152; 934-1707; 934-11 64; 949-1116; 976-1733; 996- 1647; 1006-1692; 1015-1702; 988-1507; 1048- 1736; 1014-1769; 1081-1819; 1100- 1455; 1111-1903; 1131-1710; 1135-1602; 1118 -1938; 1144- -1941; 1146-1664; 1181 -1349; 1203- 1323; 1252-1787; 1278-1818 ; 1306 -1689 1306-1719; 1336 -1753 1348-1863, 1356-2115; 1445-1778; 1453 -1820; 1466- -2325; 1505-2172; 1507-1778; 1510 1749; 1510-1966; 1583-1975 ; 1604 -2141 1604-2142; 1643 -2021 1655-1921 1682-2190; 1686-2281; 1731 -1953; 1743- -2159; 1759-2148; 1750-2696; 1781- 2016; 1789-2370; 1806-2091 ; 1824 -2366 1847-2123; 1848 -2080 1015-1805 1048-1757; 1051-1359; 1051 -1742; 1075- -1664; 1060-1320; 1849 2029; 1847 2572; 1861-2101; 1936-2565 ; 1961 -2578 1961-2067; 1947 -2224 1961-2557 1961-2626; 1961-2702; 1961 -2764; 1961- -2580; 1961-2184; 1991-2746; 1990 2326; 2024-2528; 2031-2723 ; 2031 -2642 2029-2408; 2031 -2267 2031-2253 2050-2741; 2069-2573; 2073 -2660; 2071- -2297; 2088-2343; 2119-2398; 2120 2361; 2124-2211; 2133-2481 ; 2143 -2736 2153-2757; 2154 -2741 2157-2721 2158-2430; 2165-2714; 2170 -2405; 2196- -2761; 2211-2541; 2231 2709; 2264 2489; 2264-2407; 2279-2644 ; 2316 -2603 2304-2669; 2310 -2758 2311-2769 2312-2756; 2329-2721; 2334 -2756; 2341- -2590; 2343-2761; 2344 2756; 2350 2755; 2350-2934; 2357-2756 ; 2358 -2727, 2368-2467; 2377 -2761 2403-2754 2411-2602; 2412-2760; 2412 -2650; 2419- -2536; 2420- 2761; 2453 2759; 2471- 2741; 2473-2761; 2488-2729 ; 2489 -2717, 2504-2763; 2504 -2759 2511-2761 2511-2661; 2541-2764; 2601 -2767 Table 5 291/LI:2120481.1:2001MAY17 || 1192-1924; 1545-1654; 1563-1654; 1302-1649; 1320-1649; 1149-1612; 869-1604; 775-1586; 1059-1580; 913-1565; 1270-1544; 1012-1537; 1068-1535; 904-1506; 937-1493; 945-1482; 1196-1445; 810-1424; 527-1417; 797-1396; 1063-1292; 1012-1268; 927-1239; 939-1216; 621-1180; 623-1203; 659-1165; 321-1009; 735-1002; 344-980; 299-942; 363-882; 142-868; 660-854; 462-785; 234-763; 108-694; 1-682; 203-670; 291-669; 365-634; 1- 438; 65-428
292/LI:2121610.13:2001MAY17 || 170-825; 198-631; 391-830; 441-602; 565-820; 364-950; 377-943; 371-941; 472-939; 620-859; 441-833; 227-832; 177-830; 227-830; 178-831; 158-830; 83-830; 148-830; 89-830; 147-831; 565-831; 565- 830; 450-830; 139-830; 565-828; 83-723; 41-704; 72-663; 33-651; 23-637; 88- 629; 1-602; 1-603; 41-607; 36-602; 7-603; 1-604; 11-602; 441-603; 186-603; 66-603; 426-603; 66-602; 123-602; 435-602; 26-604; 52-601; 173-602; 35-602; 38-598; 56-578; 41-557; 22-518 293/LI: 2191585.1:2001MAY17 || 1-720; 328-894
294/LI: 2198562.3 :2001 AY17 jj 2345-2721; 2347-2596; 2051-2416; 24-276; 243- 393; 254-393; 258-465; 275-769; 334-551; 520-843; 527-1036; 537-846; 542- 943; 570-869; 583-1071; 592-795; 666-854; 677-1268; 724-1203; 771-1174;
771-1082; 781-1213; 796-1154; 950-1569; 964-1704; 1000-1594 1017-1672 1037-1447; 1038-1754; 1055-1563; 1055-1560; 1061-1308; 1064 1723; 1073 1416; 1076-1540; 1090-1712; 1090-1815; 1106-1647; 1115-1717 1130-1542
1160-1775; 1160-1743; 1164-1852; 1164-1859; 1165-1901; 1160-1968; 1189
1890; 1189-1358; 1192-1712; 1196-1711; 1202-1747; 1242-1744 1243-1776 1250-1779; 1257-1744; 1266-1958; 1271-1666; 1301-1753; 1302 1739; 1319- 1980; 1327-1810; 1332-1896; 1341-2040; 1349-1981; 1373-1940 1383-1891
1388-1990; 1389-1906; 1390-1928; 1396-1838; 1407-1861; 1417-2032; 1434-
1997; 1457-1949; 1458-2003; 1467-2165; 1483-2186; 1499-2058 1502-1923
1503-1654; 1511-2202; 1513-2129; 1533-2045; 1539-2112; 1534-1650; 2130 2500; 2190-2682; 2290-2682; 2296-2722; 2324-2720; 2051-2297; 2094-2382 2096-2319; 1-465; 1541-2210; 1543-2024; 1545-2123; 1559-2249; 1572-2011; 1604-2317; 1617-2285; 1633-2111; 1639-2122; 1642-2213; 1644-2150; 1647- 2217; 1652-1953; 1660-2315; 1691-2384; 1703-2408; 1708-2324; 1715-2315; 1719-2176; 1735-2172; 1738-2340; 1741-2317; 1749-2371; 1775-2202; 1784- 2053; 1844-2401; 1878-2517; 1877-2456; 1937-2406; 1945-2377; 1945-2363; 1969-2197; 2355-2719; 2384-2719; 2393-2677; 2455-2749; 2465-2719; 2558- 2719; 2564-2720
295/LI:2209684.5:2001MAY17 || 2276-2622; 3861-4472; 3982-4501; 4017-4779; 4213-4640; 4449-4800; 4705-5225; 5134-5521; 5135-5527; 1-5491; 3106-3727; 3695-4249; 3698-4371; 3699-4357; 3812-4620; 3957-4379; 3982-4598; 3982- 4194; 3982-4419; 4011-4596; 4011-4264; 4011-4552; 4012-4537; 4041-4721; 4065-4743; 4100-4567; 4101-4589; 4157-4805; 4245-4800; 4314-4572; 4345- 4816; 4358-4805; 4465-4802; 4490-4567; 4571-5296; 4586-4823; 4615-5213; 4943-5485; 5083-5431; 5126-5484; 5126-5471; 5135-5370; 5135-5480; 5134- 5457; 5135-5348; 5135-5443; 5135-5483; 5135-5360
296/LI:222795.28:2001MAY17 || 3975-4032; 3956-4515; 548-650; 551-1057; 680- 976; 681-1297; 782-1331; 764-1434; 796-1351; 798-1439; 835-1526; 849-1556; 868-1373; 900-1169; 888-1613; 1052-1599; 1063-1603; 1123-1263; 1140-1607; 1170-1375; 1170-1446; 1205-1483; 1228-1745; 1236-1777; 1245-1497; 1253- 1538; 1269-1556; 1290-1758; 1307-1572; 1323-1594; 1358-1596; 1340-1518; 1372-1806; 1365-1528; 1412-1998; 1438-1926; 1492-1756; 1506-1729; 1507- 1959; 1507-1758; 1507-1759; 1536-1746; 1569-1778; 1613-1878; 1648-1889; 1650-1935; 1655-1902; 1657-1741; 1658-2245; 1664-1926; 1664-1791; 1678- 2121; 1685-2002; 1698-2247; 1700-2285; 1710-2335; 1748-2338; 1754-2317; 1769-2341; 1807-2168; 1810-2020; 1807-1948; 1810-1987; 1866-2140; 1903- 2337; 1905-2364; 1919-2408; 1925-2343; 1966-2184; 1974-2093; 1966-2668; 1969-2563; 1969-2582; 1992-2216; 2019-2615; 2038-2180; 2040-2235; 2044- 2251; 2054-2367; 2042-2592; 2065-2339; 2069-2329; 2057-2622; 2108-2367; 2076-2682; 2090-2632; 2102-2637; 2124-2591; 2141-2380; 2169-2749; 2145- 2244; 2153-2397; 2169-2734; 2186-2650; 2183-2609; 2188-3920; 2197-2525; 2219-2686; 2223-2653; 2236-2841; 2245-2732; 2246-2349; 2285-2755; 2286- Table 5
2717; 2283- 2542; 2321-2581 ; 2321-2589; 2332 -2737 ; 2327 -2646 ; 1-543; 38 0- 566; 395-93 7; 400-1065; 428-1009; 496-761; 528-1095; 3582-3 917; 3579-3843; 3578-3920; 3581-3719; 3581-3820; 3588-3845; 3587-3714; 3588 3892; 3589
3836 3589 3920 3590-3920 3592- 3800 3593-3920 ; 3598-3920 3606-3920 3607 3919; 3607 3869; 3611 3923; 3611-3889; 3599-3917; 3612-3859; 3612 3917 3614 3926 3615-3921 3613- 3920 3618-3918 ; 3620-3919 3621-3807 3622 3831; 3621 3928; 3622 3919; 3608-3916; 3623-3920; 3626 3931; 3625 3920 3624 3884 3619-3904 3627- 3920 3620-3822 ; 3642-3926 3644-3878 3645 3856; 3648 3920; 3645-3861; 3651 3926; 3658-4225; 3657 3920; 3662 3951 3648 3869 3666-3856 3656 3918 3677-4029 ; 3678-3764 3661-3922 3663 3917; 3683 3920; 3684-3910; 3685-3922; 3673-3920; 3689-3917; 3692 3917 3695- 3882 3695-3917 3700- 3947 3697-3920 ; 3684-3861 3707-3917 3710 3920; 3694 3873; 3717 3918; 3724-3883; 3707-3766; 3728 3920; 3728 3917 3743- 3922 3747-3879 3742- 3923 3758-3922 ; 3767-3920 3749-3919 3753 3918; 3754 3920; 3760 3917 3762-3920; 3765-3920; 3793 3921; 3795 3920 3812- 3917 3795-3896 3801- 3920 3802-3892 ; 3820-3922 3829-3923 3840 3918; 3843 3918; 3847 4272; 3853-3919; 3857-3920; 3866 3924; 3909 4231 3962- 4483 4126-4363 4126- 4355 4126-4218 ; 4210-4731 4206-4518 4238 4837; 4253 4515; 4362-4643; 4414-4981; 4592-4950; 4625 5183; 4764 4920 4776 4950 3465-3746 3466- 3919 3466-3921 ; 3467-3922 3467-3920
3469-3682; 3468 3921; 3468 3929; 3470-3725; 3471-3687; 3476 3920; 3479
3921 3481- 3673 3485-3694 3485- 3730 3488-3920 ; 3487-3920 3489-3920
3496-3920; 3496 3919; 3498 3703; 3499 3917; 3502-3920; 3504-3927; 3503
3923 3502- 3933 3504-3740 3504-3920 3506-3840 ; 3507-3920 3508-3918 3511 3920; 3513 3791; 3516-3875; 3513-3918; 3514-3919; 3515 3920; 3516 3681 3515- 3921 3520-3921 3520- 3853 3521-3921 ; 3523-3775 3523-3920 3525 3920; 3529 3926; 3526 3920; 3530 3659; 3531-3920; 3531 3921; 3534 3921 3532 3920 3538-3920 3534-3920 3541-3770 ; 3553-3999 3548-3747 3549 3799; 3555 3917; 3547 3765; 3565 3921; 3571-3913; 3570 3920; 3570 3927 3571- 3920 3574-3835 3577-3757 3578-3938 ; 3577-3923 3123-3495
3128-3496; 3164 3398; 3164 3399; 3171 3432; 3192-3578; 3200 3357; 3200
3690 3210 3465 3229-3807 3234-3367 3236-3819 ; 3236-3821 3261-3785 3257 3878; 3264 3881; 3280 3769; 3281 3435; 3292-3443; 3294 3897; 3297 3517 3353- 3895 3354-3883 3345-3882 3363 -3880 ; 3372-3894 3372-3782 3372 3733; 3372 3617; 3372 3602; 3372-3883; 3372-3695; 3372 3878; 3379 3622 3386- 3792 3396-3927 3383- 3631 3385-3547 ; 3372-3472 3393-3491 3396 3842; 3404 3627; 3406 3726; 3406 3937; 3410-3681; 3422 3790; 3416 3688 3423 3878 3424-3882 3423-3920 3428-3882 ; 3435-3920 3437-3888 3439 3917; 3443 3681; 3445 3924; 3449 3919; 3453-3724; 3459 3519; 3460 3921 3464 3921 3464-3919 3464-3917 3475-3926 ; 3465-3920 3466-3920 4781 4950; 4820 4950; 4830 4951; 4928 5060; 2329-2580; 2342 2575; 2353 2633 2355 2885 2357-2781 2362-2925 2373-2733 ; 2373 -2623 2373-2640 2371 2569; 2395-2955; 2398 2655; 2406 2509; 2408-2477; 2413 2688; 2420 2799 2424 2954 2478-3128 2482-2550 2487-2756 ; 2510-3070 2520-2766 2524 3056; 2547-3106; 2543 -2788; 2544 2828; 2547-2799; 2553 2796; 2580 3320 2618 2835 2628-3188 2629-3163 2686-2979 ; 2697-3185 2722-2979 2736 2996; 2737-2957; 2738 3009; 2743-3019; 2767-3067; 2768-3264; 2770 2964 2777 3010 2799-3150 2807- 3359 2815-3079 ; 2815-3067 2835-3369 2841 3063; 2854 3329; 2855 3099; 2857 2914; 2857-3346; 2867 3107; 2873 3044 2874- 3037 2876-3191 2887-3475 2890-3072 ; 2890-3080 2894-3153 2944 3251; 2946 3537; 2956 3475; 2956-3442; 2982-3469; 2978-3229; 2983 3065 2991 3212 3010-3115 3018- 3231 3028-3309 ; 3035-3245 3039-3352 3049 3332; 3050-3308; 3052 3325; 3108-3351; 3101-3301; 3101-3351; 3121 3350 3140 3351 3130-3263 3108- 3732 3149-3351 ; 3121-3491 3121-3496 3153 3355; 1289-1729; 2839 3272; 2613 3113; 2815-3351; 2794-3351; 2800 3351 2373- 2941 2519-3132 2518-3159 2376-3055 297/LI:2282 73.25 :2001MAY17 I I 351 8-3714; 3501-36 05; 3525-4113; 3536-3811; 3538-3739; 3544 4012; 3561-4181; 3549-3744; 3571-3706; 3606-4230; 3613- 3867; 3615- 4311 3613-4181 ; 3660-4359; 3654-4121 ; 3673-4240; 3687-4228; 3685-4128; 3685-3905; 3704-4270; 3698-4239; 3728-4139; 1-4323; 1420-1978; Table 5
1434-1861; 1423 1990; 1424 1868; 1426-2023 ; 1432 -1855; 1433 1672; 1433
1763 1433- 1838 1433-2038 1433 -1855 1433-2057 1433 2098 1471- 1888 1544 1991; 1736 2339; 1751 2190; 1751 2224; 1826 -2271; 1905 2487; 1907 2478 1919- 2483 1955-2616 1991 -2441 2008-2655 2010 2249 2010- 2390 2023 2088; 2030 2518; 2036 2474; 2070-2629; 2070 -2591; 2135-2220; 2161 2635 2161- 2670 2175-2239 2178 -2841 2179-2923 2202 2713 2220- 2537 2219 2537; 2229 2693; 2229 2707; 2280-2729; 2281 2844; 2286-2702; 2290 2475 2306- 2968 2338-2990 2351 -2917 2353-2618 2361- 2690 2366- 3017 2404 2849; 2431 2808; 2432 2808; 2418-2913 2430 2741; 2445-2903; 2445 2702 2452- 3086 2468-2819 2477 -3067 2476-2729 2488- 2859 2516- 2788 2548 3086; 2568 3069; 2589 3185 2575-2632; 2586-3086; 2592-3086; 2591 2997 2591- 2998 2603-2883 2605 -3051 2605-3210 2630- 3086 2653- 2913 2650 2997; 2656 2810; 2664 3238; 2668-3187; 2681-3285; 2670 3250; 2670 2922 2736- 3086 2736-3281 2730 -3187 2736-3338 2750- 3296 2781- 3306 2783 3386; 2790 3360; 2790 3293; 2806-3382; 2810-3367; 2830 3445; 2813 3270 2826- 3187 2852-3348 2858 -3405 2859-3450 2883- 3087 2897- 3422 2933 3194; 2941 3462; 2946 3513 2962-3401; 2995 3471; 2992 3415; 3004 3378 2995- 3583 3125-3588 3125 -3455 3118-3711 3119- 3757 3125- 3584 3125 3494; 3129 3534; 3125 3382; 3125 3737; 3125 3629; 3125-3236; 3125 3607 3126- 3702 3129-3699 3129 -3373 3149-3632 3148- 3740 3150- 3558 3151 3727; 3154 3702; 3171 3712; 3170-3556; 3163 3737; 3163-3615; 3164 3724 3188- 3385 3177-3724 3188 -3739 3193-3583 3192- 3475 3200- 3849 3203 3782; 3207 3838; 3222 3854 3219 3525; 3219 3516; 3226 3807; 3273 3513 3279- 3850 3283-3904 3301 -3848 3314-3518 3348- 3783 3358- 3832 3351 3920; 3358 3820; 3381 3843; 3382-3659; 3412 3934; 3400-3871; 3416 3894 3418- 3663 3418-4180 3419 -3727 3418-3915 3430- 3673 3431- 4002 3431 3723; 3504 3790; 3912 4152; 3933 4184; 3943 4505; 3948 4317; 4003 4646 3984- 4319 3989-4317 3991 -4319 3995-4321 4016- 4275 4034- 4315 4023 4661; 4029 4106; 4094 4322; 4103 4307; 4114 4317; 4123 4319; 4136 4322 4143- 4695 4177-4319 4170 -4380 4176-4423 4291- 4790 4304- 4796 4436 5059; 4436 4946; 4436 4969; 1-211; 22 226; 36-228; 3728 4287; 373 4323 3728- 3992 3728-4058 3735 -4133 3738-4000 3751-4281 3770- 4287 3771 4280; 3779 4389; 3779 4279 3778 4219; 3786-4278; 3800 4105; 3868 4391 3813- 4159 3814-4078 3832 -4359 3838-4280 3827-4125 3848- 4134 3844 3940; 3856 4287; 3863 4076; 3863 4318; 3856 4119; 3873 4319; 3873 4323 3888- 4134 3892-4136 3885 -4178 3947-4480 298/LI:2323 86.31 :2001MAY17 II 24 10-28 26; 2411-26 61; 24 15^27 82; 2 429-2677; 2439-3081; 2451- 2727; 2454 2705 2459-2705; 2459-2700; 2463 -2971 2471- 2745; 2471- 2705; 2475-2610 2476 -2727 ; 2521-3101 2523-2763 ; 2535-2755; 2535-2783; 2535-2754; 2536 2833; 2540-2784; 2540-2753; 2552-2819 ; 2558- 2977; 2574- 2857; 2570-3136 2573 -3136 ; 2582-2807 2585-2826 ; 2590-2850; 2608-2836; 2620-2901; 2631 2903; 2633-3062; 2633-2881; 2634-2898 ; 2644- 2809; 2644- 2875; 2656-3240 2658 -2968 ,- 2656-2847 2659-2881 ; 2668-2902; 2675-3156; 2692-3253; 2705 2994; 2718-2988; 2718-2973; 2721-2927 ; 2732- 2963; 2737- 3320; 2733-3018 2740 -2964 ; 2740-3105 2743-3205 ; 2745-3157; 2747-2971; 2771-3037; 2773 3015; 2775-3204; 2789-3166; 2794-3070 ; 2794- 3064; 2796- 2993; 2801-3066 2853 -3135 ; 2858-3323 2865-3320 ; 2866-3325; 2872-3138; 2873-3103; 2883 3325; 2887-3147; 2887 3153; 2890-3296 ; 2893- 3203; 2896- 3150; 2906-3320 2910 3320 ; 2911-3322 2916-3321 ; 2918-3322; 2923-3326; 2971-3141; 2979 3240; 2983-3454; 2991-3461; 2991-3179 ; 2999- 3454; 2999- 3461; 3008-3320 3009 3229 ; 3014-3295 3022-3205 ; 3031-3312; 3039-3309; 3054-3327; 3068 3453; 3073 -3454; 3101-3276; 3166-3321 ; 3292- 3452; 1359- 1734; 1367-1819 1433 1739 ; 1476-1724 1481-2191 ; 1481-2131; 1491-1977; 1484-1953; 1487 1761; 1477-1787; 1477-1739; 1511-2007 ; 1532- 1833; 1532- 1644; 1542-1829 1532 2119 ; 1532-1755 1550-1679 ; 1566-1970; 1586-1835; 1586-1809; 1588 1901; 1603-2144; 1621 1720; 1631-2246 ; 1697- 1961; 1697- 2188; 1700-2182 1705 2038 ; 1715-2214 1732-2177 ; 1756-2219; 1758-2214; 1771-2214; 1764 2180; 1775-2203; 1781 2214; 1785-2080 ; 1800- 2040; 1801- 2203; 1813-2033 1821 2203 ; 1820-2214 1819-2214 ; 1825-2086; 1825-2203; 1824-2203; 1831 2203; 1841-2082; 1855 2218; 1858-2003 ; 1860- Table 5
2203; 1865 2399; 1871-2106; 1854 2204; 1875-2203; 1878-2203; 1885 -2214
1906-2173; 1930- 2212; 1930-2158; 1939-2203; 1939-2212; 1944-2220; 1951
2202; 1963 2166; 1992-2195; 1998 2326; 1999-2203; 2000-2203; 2002 -2212
2002-2203; 2024- 2214; 2034-2172; 2035-2216; 2081-2203; 2083-2327; 2090
2200; 2110 2375; 2120-2214; 2122 2214; 2124-2203; 2227-2700; 2233 -2469
2257-2719; 2257- 2891; 2258-2479; 2266-2449; 2268-2553; 2269-2476; 2269
2662; 2269 2647; 2269-2632; 2269 2631; 2273-2519; 2273-2479; 2273 -2441
2273-2430; 2273- 2429; 2273-2420; 2278-2896; 2288-2624; 2300-2690; 2302
2596; 2306 2863; 2308-2577; 2309 2594; 2311-2659; 2311-2551; 2324 -2701
2328-2913; 2364- 2644; 2365-2631; 2386-2646; 2268-2596; 2269-2624; 2275
2520; 2306 2541; 2312-2702; 2374 2701; 2989-3322; 3005-3309; 3031 -3309
3076-3321; 2269- 2698; 1-3158; 4- 548; 57-673; 90-638; 179-583; 212 -644; 241
3157; 264- 2214; 300-625; 300-622 ,- 722-772; 830-1366; 850-1284; 85 7-1461;
867-1538; 875-1: 53; 896-1179; 97 1-1184; 1056-1594; 1065-1116; 106 7-1255;
1153-1392; 1227- 1670; 1226-1595; 1303-1624; 1308-1793; 1313-1813; 1331-
1844; 2272 -2588; 2058-2166; 2364 -2608; 1940-2203; 2269-2581; 2298 -2638;
2335-2701; 2269- 2704
299/LI:233 089.2; 2001MAY17 I I 434 9-4 503; 440 9-4609 1-57 77; 42-557; ; 52-633;
158-490; 3 12-91] ; 326-884; 327-911; 615-808 ; 637 1187; 1286-1809; 1287-
1914 1313 -1797; 1315-1603; 1345-18 00 1391-1836 1434 1933 1478- -1936 1549 1955; 1558- 2021; 1565-1790 1580 2079; 1585 1746; 1585 1738; 1631 1925 1642 -2240; 1727-2248; 192 -2498 1960-2498 1958 2550 1961- -2554 1964 2531; 1972- 2615; 1975-2498 20 57-2599; 2057 2604; 2059-2495; 2072 2307 2076 -2498; 2076-2422; 2103-23 08 2110-2741 2112 2596 2112- -2571 2127 2653; 2140- 2497; 2136-2779 21 54-2772; 2161 2439; 2162-2845; 2199 2759 2198 -2656; 2209-2645; 2214-28 39 2216-2757 2254 2757 2276- -2930 2286 2906; 2288- 2771; 2311-2931 2330 2918; 2332 2859; 2344 2757; 2369 2778 2375 -2947; 2376-2758; 2403-2496 2565-3095 2585 3057 2599- -3123 2600 3138; 2602- 3097; 2611-3042 2614 2990; 2671 3054; 2675 3138; 2699 3045 2763 -3131; 2779-3133; 2783-3123 2829-2923 3091 3554 3098- -3433 3101 3579; 3103- 3163; 3156-3410 31 96-3553; 3196 3451; 3196 3303; 3197 3348 3197 -3303; 3611-4101; 362 -38 37 3634-3836 3801 3968 3802- -4244 3802 4250; 3802- 4066; 3811-4064 3835 4062; 3864 4087; 3977-4251; 4095 4349 4269 4528; 4274-4537; 4277-4561 4313-4789 4346 4747 4348- -4403 4364 4724; 4364- 4599; 4402-4866 4402 4656; 4450 5029; 4457-4718; 4485 4838 4632 4910; 4633-5165; 463 -4918 4651-5026 4651 5155 4651- -4898 4679 4980; 4690- 5097; 4718-4921 47 24-4973; 4745 5014; 4780 5013; 4781 5010 4802 5007; 4865-5288; 498 -52 01 4989-5215 5001-5242 5002- -5244 5047 5290; 5068- 5701; 5079-5687 5085 5375; 5086 5350; 5108 5352; 5114 5408 5154 5395; 5184-5635; 522 -5815 5250-5524 5253-5737 5259- -5568 5259 5702; 5268- 5705; 5291-5677 5292 5726; 5302 5684; 5306-5778; 5306 5539 5318 5826; 5320-5539; 533 -5778 5337-5777 5338- 5725 5361- -5777 5365 5778; 5366- 5777; 5379-5651 5387 5777; 5390 5653; 5390 5651; 5395 5853 5395 5863; 5403-5737; 5404-5864 5411-5868 5411-5777 5413- -5777 5417 5777; 5448- 5697; 5450-5694 54 51-5676; 5453 5758; 5473 5777; 5477 5777 5491 5777; 5496-5844; 549 -57 77 5505-5768 5511-5777 5512- -5773
5515-5773; 5520- 5777; 5525-5777 5533 5749; 5543 5776; 5558 5777; 5584
5778 5597 5870; 5603-5777; 5703-5863 5714-5852 5715-5864 5721- -5822
5728-5864 300/LI:240 641.10: 2001MAY17 II i- 565; 1-590 9-484; 9-20 1; 23-588; 45-505; 51-584; 73-291; 72-292; 92 -246; 132-679; 350-961; 394-867; 469-1054; 493- 636; 518-765; 521 1058; 78 5-1258 ; 785-1050 785-1011; 826-1484; 833-1063; 946-1182; 1035-1328; 1062- 1328; 1126-1403; 1126-1402; 1150-1382; 1213-1673; 1228-1673; 1232-1675; 1248 -1710; 1245-1531 1248-1702; 1253-1635; 1256- 1880; 1263-1810; 1276-1422 ; 1348-1581; 1363-1968; 1389-1722; 1388-1595; 1394-1843; 1410-1666; 1438 -1654; 1469-1642 1496-1738; 1511-1776; 1512- 1696; 1532-1795; 1535-1848 ; 1566-1800; 1578-2167; 1578-1823; 1579-1883; 1612-2210; 1612-1893; 1618 -1829; 1646-1768 1657-1829; 1658-1888; 1695- 1944; 1699-1943; 1700-1955 ; 1709-1974; 1716-1815; 1724 2345; 1765-2222; 1789-1996; 1793-2263; 1793 -2282; 1794-2176 1793-2164; 1794-2048; 1861- Table 5
2101; 1871-2159 ; 1869-2102 1929-2399; 1946-2 236; 1948 -2233; 1960- 2183
1961-2253; 1972-2414; 1972 2225; 2068-2590; 2013-2229; 2018-2266; 2030
2297; 2068-2343 ; 2075-2303 2082-2393; 2091-2267; 2119 -2385; 2125- 2398
2139-2750; 2138-2383; 2145 2399; 2162-2431; 2191-2395; 2200-2284; 2221
2723; 2219-2404 ; 2278-2692 2284-2762; 2283-2396; 2285 -2530; 2287- 2369
2292-2527; 2308-2762; 2392 2662; 2418-2664; 2428-2696; 2431-2636; 2458
2730; 2461-2741 ; 2485-2929 2485-2784; 2521-2794; 2523 -2805; 2534- 2782
2572-2663; 2582-2900; 2610 2906; 2615-3133; 2684-3241; 2686-2947; 2712
3002; 2760-3037 ; 2792-3023 2798-3074; 2814-3083; 2814 -3085; 2843- 3091
2884-3176; 2912-3299; 2915 3059; 2922-3205; 2939-3237; 2939-3178; 2985
3430; 3077-3279 ; 3089-3207 3126-3278; 3155-3269; 3182 ■3600; 3321- 3764
3340-3597; 3354-3590; 3363 3520; 3374-3596; 3394-3571; 3487-4023; 3502
4035; 3568-3996 ; 3571-3845 3625-4013; 3877-4023
301/LI :243871.4 :2001MAY17 | I 1591-1964; 1292- 1961; 135 0-1960; 131 2-1939;
1590-1939; 1350-1940; 1662-1944; 1643-1946; 1643-2048; 1641-2048; 1597-
2050; 1581-2042 ; 1591-2037; 1578-2035; 1350-2023; 1350 -2018; 1400-1963;
1287-1924; 1270-1824; 1254-1753; 1065-1694; 596-1181; 637-1168; 581-1066;
568-1066; 586-980; 563-979; 660-956; 622-947; 675-916; 247-877; 1-555
302/LI :245597.7 :2001MAY17 | I 2747-2901; 2754-2867; 275 3-3022; 2774-3300;
2783-3037; 2783-3298; 2787-3260; 2799-3057; 2800-3071; 2809-3058; 2818-
3007; 2834-3079 ; 2942-3009 2942-3097; 2942-3126; 2942 -3138 2942 -3093;
2942-3107; 2942-3147; 2942 3206; 2942-3039; 2949-3296; 2966 3181; 2966-
3367; 2973-3154 ,- 2996-3302 3021-3361; 3018-3408; 3018-3243 3019-3271;
3028-3364; 3044-3223; 3049 3546; 3055-3344; 3073-3315; 3095 3362; 3099-
3298; 3099-3538 ; 3106-3361 3136-3455; 3141-3372; 3180-3733 3178-3435;
3180-3462; 3198-3590; 3201 3397; 3201-3755; 3202-3727; 3212 3795; 3223-
3943; 3237-3676 ; 3239-3751 3239-3472; 3241-3490; 3244-3520 3247-3515;
3251-3528; 3262-3704; 3266 3508; 3266-3514; 3267-3797; 3271 3523; 3274-
3558; 3277-3435 ; 3292-3512 3304-3527; 3307-3526; 3315-3578 3315-3544;
3318-3539; 3324-3578; 3327 3671; 3328-3599; 3345-3909; 3379-3925; 3379-
3773; 3397-3789 ; 3398-3677 3398-3691; 3401-3636; 3401 -3661 3401-3806;
3408-3869; 3415-3764; 3417 3677; 3421-3706; 3432-3902; 3444-3729; 3467-
3750; 3470-3658 ; 3469-3731 3485-3724; 3488-3898; 3494 -3748 3497-3737;
3499-3806; 3499-3782; 3517-3734; 3537-3807; 3543-3998; 3553 4003; 3562-
3807; 3564-3858 ; 3572-3809 3573-3926; 3575-4122; 3615-3895 3623-4071;
3624-4084; 3633-4072; 3659-3832; 3684-3944; 3694-4197; 3696 4004; 3706-
4175; 1158-1343 ; 1194-1404 1209-1498; 1218-1500; 1221-1414 1225-1563;
1328-1898; 1387-1691; 1455 1927; 1515-2005; 1540-1797; 1546 1738; 1614-
1776; 1621-2128 ; 1641-1917 1668-2184; 1668-2211; 1668-2024 1669-1899;
1671-1903; 1674-2231; 1690 2068; 1704-1967; 1722-2043; 1759 2023; 1760-
2445; 1849-2373 ; 1871-2126 1875-2440; 1876-2363; 1892-2117 1982-2526;
1990-2518; 1994-2220; 2005 2126; 2033-2691; 2033-2306; 2041 2368; 2058-
2327; 2103-2487 ; 2114-2334 2135-2380; 2140-2701; 2141-2567 2152-2369;
2152-2605; 2147-2611; 2164-2398; 2188-2273; 2208-2525; 2227-2555; 2228-
2486 2278-2617 ; 2288-2746 2288-2536; 2300-2431; 2307 •2867 2320-2791;
2427-2701; 2471-2578; 2480-2867; 2484-2867; 2488-2772; 2528-2776; 2529-
2962; 2536-2867 ; 2536-2789 2550-2761; 2559-2818; 2585 -2840 2585-2805;
2618-2872; 2617-2867; 2619-2847; 2625-2847; 2630-2867; 2642-2871; 2642-
2867; 2657-2999 ; 2661-3002 2676-2867; 2683-2867; 2688 -3197 2689-2867;
2688-2867; 2711-2867; 2710 2901; 2712-3265; 2747-3040; 1-465 ; 20-465; 105-
465; 263-536; 314-821; 377-963; 430-902; 489-1048; 511 -909; 622-1083; 759-
959; 772-1253; 871-1328; 876-1278; 879-1147; 954-1251; 983-1559; 1022-1577;
1033-1480; 1044-1484; 1104-1251; 1105-1338; 1130-1375; 1140-1438; 1141-
1477; 1142-1366 ; 1142-1212 1144-1418; 1146-1413; 1146 -1518; 1146-1387;
1146-1270; 1146-1402; 1146 1514; 1146-1652; 1152-1355; 1153-1375; 1157
1382; 3675-4066 ; 4080-4242 4083-4198; 4083-4219; 4089 -4242; 4089-4240
4090-4236; 4090-4244; 4090-4189; 4092-4210; 4094-4242; 4132-4240; 4138
4242; 4147-4248 ; 4156-4243 3714-4160; 3717-4084; 3717 -4203; 3726-4081
3751-4204; 3763-4205; 3766-4070; 3777-4204; 3779-4241; 3786-4242; 3789
4240; 3802-4240 ; 3805-4246 3814-4241; 3819-4062; 3818 -4245; 3836-4246 Table 5
3836-4072; 3848-4072; 3851-4072; 3855-4215; 3858-4240; 3864-4072; 3870 4072; 3870-4207; 3870-4152 ; 3870-4204; 3871-4215; 3886-4242; 3886-4084 3888-4241; 3889-4242; 4076-4243; 3889-4072; 3889-4147; 3890-4242; 3890 4153; 3891-4073; 3893-4246 ; 3903-4178; 3906-4168; 3907-4148; 3904-4186 3909-4153; 3934-4242; 3934-4178; 3937-4235; 3953-4242; 3958-4241; 3959 4242; 3961-4250; 3967-4247 ; 3970-4241; 3973-4226; 3977-4247; 3977-4249 3991-4224; 4000-4244; 4000-4237; 4011-4240; 4020-4242; 4024-4217; 4059 4242; 4064-4246; 4071-4201 303/LI:256009.31:2001MAY17 | I 1-260; 1-376; 1- 628; 1-590; 29-118; 29-471; 29-395; 29-182; 29-207; 29 260; 29-325; 29-272 ; 29-464; 29-253; 29-383; 35- 589; 35-462; 137-704; 187- 724; 311-842; 322-824; 349-624; 359-649; 367-555; 499-1117; 516-1088; 546-11 36; 613-1206; 649-1175; 663-1100; 670-1274; 689- 1174; 710-1197; 713-1195; 722-1197; 713-1256; 867-1456; 930-1292; 920-1351; 935-1214; 937-1483; 948-12 24; 963-1164; 997-1412; 1178-1471; 1287-1469; 1289-1474; 1290-1404; 1291 -1470; 1436-1498 304/LI: 262221.1:2001MAY17 I I 29-588; 29-630; 2 9-461; 2 9-551 ; 29-380 ; 33- 293; 519-850; 691-899; 790 -1578; 862-1422; 948 1325; 1055-1635; 144 9-2067; 1461-2067; 1494-2067; 1504 -2067; 1506-2067; 1525-2067; 1581 2082; 1 661- 2196; 1799-2067; 1-593; 29 -395; 28-461; 29-467 ; 29-328 ; 29-308; 29- 478; 29- 476; 29-564; 29-577; 29-58 4; 29-626; 29-572; 29-592; 29-556 ; 502-11 08; 502- 921; 502-1074; 507-836; 53 0-1046; 542-1186; 608-1247; 616-1109; 665 -914; 722-1071; 741-1302; 767-13 12; 785-1351; 808-1488; 820-1228; 837-142 6; 894- 1417; 922-1466; 925-1524; 934-1495; 942-1417; 945-1214 ; 958-1569; 9 79-1381; 982-1573; 988-1414; 1079-1 441; 1107-1568; 1114 1634; 1119-1568; 123 8-1395; 1238-1786; 1285-1829; 1271 -1604; 1271-1995; 1272-1991; 1275 1937; 1 277- 1463; 1273-1821; 1362-2067 1409-1494; 1453-2067; 1462-2067 1456-2 196; 1468-2067; 1473-2067; 1482 1859; 1480-2067; 1502-2067; 1505 2067; 1 503- 2067; 1505-2069; 1533-2195 1518-2067; 1517-2067; 1543-2196 1552-2 067; 1562-2067; 1574-2067; 1602 2182; 1616-2067; 1627-2196; 1650 2067; 1 704- 2196; 1714-2067; 1733-2305 1736-2067; 1918-2023; 1941-2069 305/LI : 332957.8 : 2001 AY17 I I 1-270; 31-292; 35 346; 72-710; 122-552 ; 163- 710; 180-439; 180-534; 201 -448; 226-785; 254-523; 273-639; 320-435; 320- 673; 334-609; 370-874; 401 -689; 469-814; 480-754; 519-1004; 527-964 ; 528- 663; 550-725; 593-1004; 59 6-1004; 602-1003; 607-1003; 655-849; 660-1001; 668-1006; 763-1002; 895-15 36; 945-1003; 955-1340; 955-1536; 975-1165; 1042- 1272; 1106-1694; 1117-1693 1264-1806; 1362-1623; 1415-1998 ; 1431-1967; 1661-2164; 1662-2036; 1661 2102; 1691-2305; 1691-2314; 1826-2328; 1858- 2259; 1933-2540; 2141-2326 2143-2313; 2144-2401; 2154-2671 ; 2161-2698; 2175-2671; 2361-2938; 2622 3285; 2765-3083; 3159-3497; 3422-3934; 3692- 4137; 3700-4264; 3731-4003 3734-3915; 3923-4473 306/LI:335352.13:2001MAY17 I I 207-448; 222-489 227-33 0; 23 1-348; 240- 504; 285-973; 377-538; 381-488; 508-773; 525-927; 537-586; 593-1219; 665-13 39; 688-1394; 787-1011; 793-12 12; 803-1011; 820-10 11 851-1011; 874-1142; 896- 1011; 906-1012; 896-1132; 909-1009; 934-1194; 943-1208 ; 962 -1194; 1044 1400; 1049-1290; 1075-1678 1103-1500; 1121-16 63 1148-1388 ; 1148-1429 1155-1466; 1157-1500; 1170 1774; 1180-1507; 11 87-1462; 1196-1452; 1197 1511; 1197-1476; 1200-1450 1218-1353; 1222-15 00 1242 -1499 ; 1255-1658 1258-1500; 1281-1539; 1283 1535; 1284-1580; 1293 1452; 1309-1535; 1309 1496; 1316-1768; 1327-1503 1329-1558; 1344-1772 1349-1820 ; 1366-1819 1372-1500; 1376-1509; 1387 1621; 1389-1614; 1392 1643; 1402 -1643; 1409 1573; 1415-1661; 1418-1804 1427-1824; 1433-1806 1444-1695 ; 1449-1804 1465-1709; 1464-1740; 1-57 5; 117-840; 157-736; 174-390 ; 177-739; 183-3 98; 188-735; 186-324; 188-643; 186-468; 188-947; 88-1006; 189-785; 188-439; 189-352; 195-591 188-963 191-466 190-440; 91-397; 193-429; 194-447 196-505; 198-615 196-294 195-417 196-468; 96-442; 198-469; 198-449 198-738; 198-455 198-498 198-316 196-337; 98-693; 198-454; 201-446 200-446; 202-474 199-467 199-485 203-478; 05-739; 206-475; 196-445 196-449; 198-431 199-525 201-510 207-500; 473-1816 1507-1662; 152 8-
1778; 1530-1765; 1530-1798 1532-1800; 1547-1815; 1553 2008 ; 1556-1813
1564-1789; 1575-1815; 1579- 1815; 1582-1716; 1611-2000; 1614-1901; 1618 Table 5 1815; 1667-1815; 1680-2008; 1686-1812; 1694-2236; 1710-2012; 1714-1998 1727-2237; 1752-2240; 1780-2024; 1810-2014; 1850-2314; 1857-2121; 1858 2012; 1891-2330; 1903-2012; 1909-2140; 1946-2181; 1969-2159; 1987-2499 2053-2293; 2101-2551; 2101-2221; 2106-2600; 2110-2578; 2110-2303; 2121- 2376; 2147-2597; 2153-2600; 2154-2597; 2155-2599; 2157-2594; 2189-2604 2193-2393; 2207-2600; 2210-2584; 2213-2594; 2215-2594; 2298-2594; 2303- 2600; 2310-2594; 2360-2522; 2370-2638; 2522-2600; 2576-2786; 2576-2989 2576-2916; 2767-3027; 2790-3137; 2805-3272; 2809-3274; 3018-3164; 3089-3289 307/LI:343844.7:2001MAY17 || 1-294; 211-915; 224-813; 224-823; 308-611 347-1052; 350-549; 451-906; 450-535; 450-521; 502-1092; 511-903; 538-789; 563-762; 572-959; 571-1007; 580-834; 587-1060; 588-1120; 609-857; 641-917; 645-904; 695-1047; 753-988; 758-994; 895-1279
308/LI:344528.1:2001 AY17 || 1-399; 11-561; 244-800; 1970-2678; 1971-2549; 2083-2247; 2085-2377; 2127-2227; 2341-3127; 2428-2822; 2469-2830; 2875- 3334; 2875-3420; 2877-3116; 2875-3155; 2885-3286; 2767-3031; 2799-3270; 2798-3118; 2891-3118; 2891-3236; 2901-3365; 2906-3365; 2833-3358; 2958- 3555; 2951-3210; 2822-3043; 2855-3370; 2863-3614; 2871-3504; 2963-3365; 3055-3365; 3070-3855; 3080-3364; 3113-3365; 3112-3172; 3114-3353; 3125- 3325; 3125-3523; 3138-3500; 3177-3444; 3177-3497; 3221-3436; 3255-3604; 3288-3520; 3299-3524; 3303-3610; 3309-3772; 3313-3713; 3319-3610; 3326- 3729; 3340-3761; 3393-3610; 3411-3616; 3413-3610; 3414-3606; 3579-3933; 3580-3825; 3597-4015; 3617-4031; 3641-3713; 3691-3973; 3699-3922; 3699- 4049; 3699-3991; 3774-3964; 3782-3992; 1-481; 2469-3167; 2500-2840; 2511- 2840; 2535-2824; 2524-2983; 2524-2665; 2593-3184; 2657-3290; 2623-3149; 2623-2930; 2641-2958; 2664-3264; 2703-2956; 2744-3323; 2757-3004; 3-4031; 1976-2523; 2423-3117; 2469-2783; 2627-3095; 2706-2967; 3561-3990; 3639- 3892; 3723-4031
309/LI:374578.27:200lMAYl7 || 540-1088; 541-1048; 565-1214; 579-1111; 592- 890; 604-1049; 612-1122; 647-1070; 663-889; 686-1044; 689-980; 744-1127; 776-961; 827-1023; 842-1460; 809-1473; 881-1440; 830-1471; 967-1460; 969- 1459; 1025-1185; 1045-1435; 1012-1440; 1073-1440; 1097-1559; 1108-1578; 1120-1386; 1127-1439; 1152-1465; 1169-1432; 1177-1571; 1245-1440; 1215- 1571; 1214-1571; 1293-1446; 1308-1571; 1312-1571; 1327-1571; 1335-1571; 1334-1685; 1481-1594; 1-565; 26-695; 1-517; 1-701; 1-546; 1-668; 1-555; 1- 545; 1-644; 2-633; 3-194; 4-585; 1-456; 26-561; 26-610; 26-538; 28-271; 51 693; 72-517; 92-524; 102-617; 90-518; 109-354; 120-353; 121-400; 122-461; 124-297; 124-432; 124-456; 124-383; 124-401; 125-358; 142-440; 197-557; 202-552; 207-795; 213-682; 232-585; 239-624; 307-687; 370-987; 399-931; 413-971; 425-917; 425-832; 425-895; 426-956; 425-999; 425-861; 425-944; 425-984; 425-919; 425-883; 425-805; 425-737; 426-1001; 426-966; 431-1040; 435-1006; 437-944; 442-1032; 446-1000; 455-702; 456-1016; 467-1058; 477- 1106; 510-799; 529-1011; 529-1150; 539-1036; 538-1134; 539-694 310/LI:381993.13:2001MAY17 || 6375-6635; 6538-6716; 6569-6874; 6572-6879; 6717-6841; 6007-6181; 6118-6336; 6152-6423; 6172-6472; 6202-6481; 6226- 6494; 6267-6848; 6317-6549; 3402-3523; 3402-3499; 3451-4209; 3457-4207 3479-3571; 3480-3541; 3465-4247; 3480-4048; 3472-4246; 3470-4141; 3476 4115; 3454-4101; 3258-3523; 3386-3523; 3403-3971; 3076-3235; 3134-3523 3164-3527; 3224-3843; 3225-3773; 3224-3842; 1846-2518; 1838-2690; 1856 2342; 1867-2169; 1885-2503; 1893-2462; 2080-2636; 2083-2787; 2083-2520 2095-2784; 2108-2638; 2147-2657; 2181-2886; 2296-2570; 2312-2764; 2715- 3427; 2739-3428; 2740-3427; 2823-3416; 3009-3470; 3035-3278; 3033-3297 3066-3524; 1-795; 571-708; 1077-1812; 1265-1930; 1337-2058; 1458-2045; 1597-1936; 1789-2490; 3479-3575; 3531-4240; 3655-4251; 3686-4617; 3810- 4016; 4294-5092; 5039-5699; 5244-5893; 5322-6057; 5393-6066; 5437-5743 5467-6294; 5522-6150; 5611-6238; 5662-6100; 5715-5954; 5913-6450; 5972 6530; 6339-6793; 5346-6036; 5345-5913; 5322-6048; 5349-6046; 5349-5954 5354-5889; 5376-5857; 5381-5893; 5374-6057; 5373-6127; 5371-5949; 5392 6115; 5403-5893; 5408-5972; 5419-6121; 5410-6068; 5423-6057; 5457-5919 5451-6159; 5443-6294; 5462-6073; 5488-6346; 5490-6101; 5502-6095; 5504 5824; 5557-6050; 5551-6119; 5589-6266; 5602-6297; 5602-6223; 5622-5890 Table 5
5619-6414; 5 621-5901; 5640 -6143; 5670-6104; 5669-6212; 5677-6228; 5695- 5813; 5740-6583; 5783-6343 ; 5894-6407; 5894-6414; 5909-6395; 5919-6179; 19- 789; 97-692; 437-1176; 562 -1104; 852-1760; 883-1650; 905-1497; 908-1505; 995-1562; 1094-1580; 1192- .060; 1200-1873; 1244-1997; 1289-1906; 1286-1866; 1289-2090; 1334-2024; 1335 -1868; 1353-1954; 1365-2034; 1389-1943; 1446- 1857; 1468-1711; 1541-1952 ; 1567-2189; 1579-1716; 1635-1816; 1665-1937; 1749-2323; 1757-2445; 1749 -2267; 1821-2531; 1854-2411; 3700-4258; 3718- 4397; 3724-4245; 3788-4251 ; 3854-4237; 3914-4283; 3905-4357; 3951-4331; 4583-5293; 4926-5616; 4978 -5658; 5036-5783; 5107-5659; 3694-4092; 5107- 5914; 5169-5951; 5155-5728 : 5228-5938; 5305-6062; 5317-5960; 5321-6055; 5322-6033; 3542-4060; 3558 -4260; 3565-4239; 3602-4260; 3652-4209; 3480- 3985; 3661-4148; 3495-4256 : 3501-4134; 3509 4110; 3664-4238; 3529-4033 311/LI:400373.2:2001MAY17 I I 2555-2789; 2563-2696; 2563-3020; 2584-3082; 2587-3099; 2591-3095; 2609 -2784; 2612-2846; 2649-2936; 3253-3647; 2649-
2933 2649-3055; 2675-2897 r 2680-2964; 2699 3297; 2733-3255 2775-3256 2823 3061; 3263-3582; 3272 -3582; 3275-3481; 2830-3346; 3281-3647; 3290- 3395 3294-3582; 2829-3390 : 3300-3582; 3307 3533; 2839- 3140 3313 -3723 3328 3610; 3328-3589; 3330 -3582; 3331-3647; 3337- 3593; 3353 3779; 3366- 3647 3389-3647; 2841-2915 : 3396-3688; 3400 3611; 3400- 3620 3400 -3690 3404 3582; 3409-3647; 3405 -3582; 2862-3108; 3411- 3642; 3413 3647; 3423- 3647 3433-3647; 3436-3582 ; 3438-3650; 3441 3679; 2898- 3134 3445 -3647 2914 3404; 2914-3154; 3456 -3647; 3471-3668; 3472- 3647; 3481 3647; 3485- 3680 2936-3178; 3487-3647 : 3495-3582; 3496 3582; 3496- 3647 3521 -3647 2976 3266; 2980-3506; 3088 -3201; 3137-3267; 3149- 3620; 3149 3426; 3150- 3716 3207-3647; 3221-3647 : 3223-3367; 3229-3428; 3237- 3647 3244 -3647 3244 3460; 1762-2557; 1805 -2585; 1813-2557; 1715- 1972; 1852 2557; 1835 1958 1835-1968; 1863-2557 : 1838-2581; 1914-2144; 1938- 2172 1958 -2186 1966 2563; 1962-2644; 1963 -2642; 1963-2616; 1962-2606; 1962-2557; 1964- 2679 1966-2644; 2074-2309 : 2155-2492; 2155-2374; 2191-2429; 2168-2388
2174-2388; 2174-2423; 2194 -2723; 2194-2455; 2205-2465; 2246-2406; 2246-
2489 2264-2769; 2299-2825 : 2297-2670; 2300 2533; 2313-2877; 2325-2644
2355- -2891; 2355-2614; 2358 -2630; 2367-2716; 2429-2891; 2536- 3138; 2538-
3089 2028-2280; 2174-2583 : 2194-2458; 2277 2721; 2325-2784; 2382-2821
3313- -3647; 3331-3582; 3373 -3748; 3401-3647; 3411-3543; 3436- 3647; 3448-
3647 3482-3647; 3520-3647 ; 3523-3647; 3527 3647; 3530-3647; 3533-3647
3544- -3647; 3549-3647; 3550 -3647; 3551-3806; 3554-3647; 3555- 3647; 3567
3647 3571-3683; 3572-3647 : 3579-3647; 3588- 3647; 3590-3647; 3593-3887
3625- -3675; 3794-3880; 3825 -3878; 1715-1996; 1-388; 4-146; 16-266; 59-310;
258-869; 571-684; 592-818; 797-1320; 816-936 ; 915-1552; 997-1444; 1088-
1726 1092-1379; 1099-1593 : 1170-1587; 1216- 1288; 1217-1726; 1255-1624;
1280- -1684; 1382-1673; 1382 -1641; 1400-1998; 1391-2010; 1505-2048; 1505-
2170 1505-2085; 1569-2033 : 1670-2226; 1715- 1980
312/LI:400963.6:2001MAY17 | 2862-3498; 3110 -3396; 2894-3362; 2754-3294;
2716- -3260; 2671-3193; 2671 -3076; 2222-2721; 2157-2721; 2279-2677; 2596-
2677 2207-2504; 1907-2423 : 1919-2400; 1913- 2380; 1607-2189; 1976-2084;
1596- -2074; 1584-2061; 1583 -2061; 1339-1918; 1593-1896; 1247-1837; 1097-
1815 1055-1699; 585-1208; 658-1208; 609-119 0; 557-1119; 617-1081; 651-977;
467-939; 653-866; 651-860; 300-856; 632-857; 253-708; 1-670; 300-617; 303-
493; 300-473 ; 3488-3955; 3:Ϊ73-3764; 3083-3733; 3328-3617; 3046-3586; 3003-
3586 3441-3503; 3104-3495 : 1732-2298; 2670-2858; 2760-3291; 3090-3729;
3347- -3615
313/LI:40487 4.8:2001MAY17 || 864-1104; 973-1507; 1344-1586; 1995-2507;
2344- -2600; 2593-3159; 2928-3217; 3179-3351; 1-256; 1-485; 29-484; 166-3215;
209-570; 226-550; 365-942; 556-1004; 651-1315; 705-1216; 813-1161; 883-
1194 966-1464; 968-1520; 971-1270; 1021-1620; 1005-1252; 1233-1735; 1342-
1797 1437-1580; 1944-2189; 1944-2410; 1959-2540; 2075-2685; 2075-2304;
2125- -2697; 2128-2431; 2272-2392; 2348-2891; 2533-3018; 2559-2855; 2584-
3034 2685-3204; 2716-3175; 2753-3175; 2797-3175; 2947-3175; 2993-3190;
3053- -3174; 3090-3736; 3207-3557; 3365-3562; 3402-3545 Table5
314/LI:405158.18:2001MAY17 || 5674-6080; 5675-6082; 1- 1033; 664-1267; 785
1024, 946-: 1438; 950-1224; 950-1253; 1138-1890; 1135-1891; 1141-1538; 1207
1715, 1227- -1616, 1231 -1465 1289 -1925 1457 -1792 1534 -1714 1771 -2299;
2602- -3086; 5681- -6081; 5689- -6082; 5681- -5909; 5684- -6079; 5691- -6086; 5686-
6082; 5692- -5967, 5702 -6082, 5723- -6082, 5716 -6077, 5715 -6077, 5717- -6077;
5718- -6089; 5800- -6045; 5800- -6038; 5800- -6116; 5805- -6082; 5813- -6082; 5812-
6038, 5813- -6078, 5817- -6061, 5824- -6067, 5824 -6071, 4565 -4955, 4568 -4761;
4568- -4906; 4567- -4797; 4580- -4835; 4582- -4851; 4598- -4983; 4640- -4895; 4641-
5066, 4654- -4925, 4668 -4838, 4679- -4914, 4690 -5212, 4694 -4930 4703 -4955;
4705- -4947; 4728- -5342; 4732- -5080; 4735- -4973; 4771- -5001; 4768- -5071; 4788-
5074, 4792- -5218; 4804 -5050, 4813- -5229, 4819 -5069, 4822 -5102, 4823- -5142;
4848- -5271; 4848- -5222; 4849- -5071; 4873- -5455; 4878- -5460; 4894- -5132; 4900-
5133, 4913- -5153, 4929 -5586, 4930- -5071, 4942 -5115, 4948 -5275, 4963 -5408;
4963- -5467; 5010- -5500; 5038- -5321; 5069- -5325; 5079- -5326; 5087- -5506; 5097-
5573, 5097- -5362, 5121 -5386, 5125- -5358 5131 -5412, 5134 -5387, 5159 -5573;
5161- -5301; 5191- -5381; 5200- -5276; 5206- -5637; 5224- -5586; 5225- -5474; 5239-
5433, 5272- -5722, 5272 -5536, 5293- -5744 5299 -5515, 5298 -5478, 5316 -5572;
5338- -5594; 5345- -5521; 5358- -5936; 5373- -5625; 5378- -5615; 5388- -5548; 5397-
5589, 5398 -5621, 5397 -5684, 5433- -5871 5436 -5740, 5446 -5696, 5447 -5813;
5448- -5738; 5451- -5706; 5451- -5911; 5458- -5915; 5460- -5709; 5468- -5664; 5471-
5722, 5494 -5862, 5494 -6015, 5495- -5707 5496 -5719, 5500 -5911, 5517 -5912;
5534- -6084; 5539- -6036; 5555- -6078; 5569- -6040; 5574- -6077; 5584- -6040; 5584-
6035, 5584 -6077, 5585 -5835, 5590- -6044 5595 -5874, 5606 -6081, 5613 -5909;
5612- -5911; 5624- -5910; 5625- -6038; 5627- -6083; 5628- -6077; 5632- -6081; 5633-
6077 5634 -6067, 5981 -6082, 5984 -6224 6069 -6476 6096 -6330, 6149 -6469;
6307- -6745; 5907- -6081; 5908- -6077; 5911- -6083; 5912- -6169; 5917- -6206; 5928-
6079, 5929- -6077, 5748 -6084, 5752- -6081, 5753 -6077, 5758- -6077, 5768- -6082;
5785- -6073; 5785- -6085; 5788- -6082; 5789- -6082; 5789- -6073; 5793- -6073; 5795-
6085, 5797- -6075, 5725 -6077, 5727- -5902, 5729 -6077, 5736- -6027, 5877- -6077;
5894- -6040; 5897- -6077; 5896- -6080; 5897- -6083; 5906- -6077; 5904- -6075; 3660-
4031, 3664 -4034, 3669 -3953, 3670- -4033, 3696 -4033, 3696 -4032, 3700- -4031;
3708- -4032; 3710- -4033; 3754- -4021; 3758- -4033; 3766- -4038; 3769- -4031; 3780-
3939, 3794 -4033, 3796 -4027, 3801- -4027, 3800 -4025, 3803 -4036, 3814- -4033;
3826- -3993; 3827- -4025; 3857- -4033; 3859- -4033; 3885- -4155; 3911- -4033; 3914-
4033, 3922 -4188, 3922 -4205, 3945 -4033, 4039 -4269, 4046 -4564, 4061- -4246;
4064- -4337; 4066- -4297; 4090- -4339; 4093- -4300; 4117- -4713; 4117- -4408; 4123-
4382, 4129 -4445, 4152 -4484, 4173 -4552, 4180 -4439, 4183 -4736, 4182- -4690;
4189- -4610; 4192- -4690; 4200- -4440; 4208- -4827; 4216- -4768; 4219- -4651; 4258-
4755, 4274 -4539, 4285 -4526, 4289 -4546, 4299 -4528, 4316 -4944, 4323- -4874;
4350- -4595; 4375- -4624; 4394- -4646; 4411- -4544; 4423- -4640; 4439- -4657; 4454-
4670 4455 -4712, 4455 -4757, 4456 -4661, 4459 -4737, 4466 -4774, 4500- -4788;
4503- -4740; 4502- -4677; 4511- -4777; 4543- -4775; 2823- -3262; 2827- -3203; 2838-
3114 2865 -3126, 2886 -3265, 2921 -3229, 2942 -3309, 2972 -3204, 2972- -3026;
2984- -3476; 3024- -3267; 3045- -3566; 3069- -3677; 3137- -3377; 3164- -3324; 3175-
3430 3205 -3394, 3213 -3550, 3213 -3814, 3219 -3432, 3272 -3535, 3278- -3538;
3299- -3610; 3304- -3576; 3323- -3585; 3323- -3838; 3348- -3581; 3351- -3592; 3352-
3656, 3355 -3712, 3363- -3932, 3364- -3458, 3391- -3861, 3399- -3615, 3402- -3894;
3402- -3912; 3408- -3709; 3413- -3609; 3415- -3692; 3416- -3662; 3434- -3670; 3475-
3791, 3491 -3743, 3491- -3956, 3494- -4038, 3509 -3935, 3509- -3739, 3520- -4024;
3521- -3710; 3532- -3887; 3533- -3738; 3535- -3999; 3535- -3824; 3549- -3784; 3560-
3785, 3562 -4037, 3572- -3996, 3582- -4033, 3583 -4036, 3585- -3994, 3589- -4033;
3592- -3890; 3594- -4036; 3595- -4033; 3596- -3995; 3602- -4034; 3605- -4026; 3611-
3664, 3611 -4033, 3618- -4033, 3623- -4038, 3626- -4033, 3627- -4034, 3632- -4034;
3638- -4033; 3641- -4033; 3654- -4033; 3654- -3830; 3658- -4034; 5719- -6085; 5719-
6079, 5718 -6077, 5719- -6077, 5725- -6082, 5825- -6082, 5826- -6079, 5830- -6064;
5846- -6077; 5851- -6082; 5852- -6022; 5874- -6077; 5876- -6085; 5594- -6035; 5621-
5857, 5630 -6078, 5933- -6187, 5970- -6215; 5972- -6077, 5932- -6031, 5636- -5908;
5638- -6080; 5638- -6083; 5639- -6083; 5639- -5911; 5640- -6040; 5640- -6077; 5642-
5887, 5643 -6075, 5649 -6075, 5648- -5911; 5649- -5873, 5656- -5915, 5656- -5866; Table 5
5662-6077; 56 62-5807; 5666 -6077; 5669-6082; 5671-6077; 5672-5911; 5672- 6083; 5673-5911 315/LI:405889 .22:2001MAY17 || 1428-1664; 1434-1706; 1437-168 1; 1448-1512; 1451-1681; 1460-1675; 1460 -1696; 1460-1685; 1460-1935; 1460- 1673; 1460- 2015; 1460-1584; 1465-1681 1471-1690; 1472-2013; 1477-1675; 1484-1681; 1490-1681; 1510-1664; 1514 -1676; 1528-1681; 1544-1686; 1546- 1664; 1556- 1704; 1569-1681; 1597-1681 1603-1681; 1620-1681; 1621-1681; 1628-1681; 1742-2029; 1752-1996; 1769 -1963; 1774-2124; 1774-1863; 1774- 1850; 1821- 2045; 1847-2117; 940-1165; 944-1487; 955-1238; 995-1507; 995-1225; 1006- 1368; 1007-1371; 1017-1201 1030-1297; 1032-1300; 1043-1280 1066-1531; 1078-1670; 1101-1371; 1106 -1655; 1106-1656; 1130-1531; 1132 1526; 1140- 1246; 1149-1268; 1154-1409 1195-1314; 1210-1443; 1236-1686 1254-1490; 1257-1675; 1257-1489; 1257 -1404; 1306-1675; 1311-1590; 1315 1681; 1325- 1611; 1326-1681; 1333-1616 1350-1690; 1350-1600; 1350-1572 1354-1635; 1357-1681; 1361-1568; 1375 -1681; 1374-1446; 1375-1524; 1376 1681; 1378- 1645; 1385-1612; 1392-1575 1405-1675; 1404-1523; 1404-1526 1404-1527; 1415-1967; 1417-1597; 1421 -1686; 1-579; 33-464; 72-579; 92-447; 92-753; 157-550; 157-379; 194-561; 199-447; 264-483; 265-421; 272-569; 274-533; 316-557; 319- 555; 332-581; 391-464; 401-657; 411-724; 411-723; 412-933; 412-879; 417-542; 432-1157 451-769; 446-682; 452-704; 487-1078; 493-716; 522-1117; 540-797; 562-915 562-805; 592-1281; 599-1292; 600 848; 604-859; 625-899; 644-933; 658-1289 662-930; 661-755; 676-977; 700-947; 704-1022; 704-1006; 704-946; 704-924 713-938; 760-1021; 788-998; 938 1352; 819-1078; 819-1061; 845-1164; 893-1111; 896-1111; 916-1216; 916-1383; 924-1496; 930- 1147; 1141-1675; 1018-1626 316/LI:411151.31:2001MAY17 II i- 529; 1-628; 13-4235; 2 2-581 22-5 62 ; 22 - 558; 22-546; 22-537; 22-47 8; 22-341; 42-460 42-433; 42-482 53-334 ; 82 - 494; 85-197; 93-325; 138-776; 154-379 3503 3587; 3508-3557 3523 -3967 ; 3524-4123; 3590-4199; 3613 -4048; 3656 4093; 3661-4098; 3694-4230; 3727-
3962 3751-4154; 3753-4026 ; 3778-4230 3854 4235; 3853-3949; 3895 -4445 ; 3893 4099; 3906-4311; 3949-4291; 4016 4443; 4042-4270 4334-4444; 3492 - 4121 3455-3945; 3471-3687 ; 357-652; 498-87 5; 720-936 908-1159; 1436 -1999 ;
1544-1974; 1685-2079; 1742-2217; 1749 2035; 1750-2051 1796-2057; 1829-
2407 1866-2464; 1887-2076 ; 1921-2120 1944 2383; 1959-2203; 2025 2534 ;
2027-2607; 2040-2308; 2097-2515; 2133 2341; 2157-2671; 2222-2742; 2227 -
2693 2235-2517; 2239-2417 ; 2266-2785 2308 2791; 2326-2925; 2373 -3019 ;
2384-2683; 2387-2996; 2390-2655; 2431 3007; 2443-2933; 2448-2949; 2449-
2980 2450-3050; 2451-2695 ; 2454-2900 2465 3029; 2469-2750; 2483 -2767 ;
2489-2735; 2490-2888; 2533 -3094; 2544 3082; 2573-3141; 2586-3205; 2598-
3137 2642-3214; 2644-3149 ; 2698-2882 2711 -3222; 2728-3217; 2727 -3214 ; 2727 2981; 2730-3267; 2774-3368; 2781 3032; 2781-3394; 2785-3010; 2785- 3432 2791-2970; 2796-3407 ; 2802-3342 2815 -3155; 2874-3445; 2877 -3508 ;
2891-3460; 2954-3158; 2970-3358; 2996 3169; 2997-3255; 2999-3460; 3000-
3214 3010-3612; 3013-3279 ; 3027-3297 3040 -3572; 3038-3330; 3048 -3530 ;
3048-3529; 3060-3503; 3068-3346; 3079 3738; 3088-3246; 3099-3407; 3143 -
3495 3169-3682; 3177-3418 ; 3210-3760 3266 -3832; 3273 -3558; 3321 -3954 ;
3323-3873; 3351-3980; 3393-3654; 3409 3957; 3436-4032; 3436-4013; 3439-
3894; 3441-4030; 3442-3966 ; 3442-3656 2674 -3146; 5-539; 4334-4430 ; 1107 -
1332; 1870-2322; 2865-3340 ; 42-516; 1831-23 14; 2282-2777; 1404-1904 ; 2056-
2592; 1963-2519; 309-884; 2507-3084; 2019-2 617; 2172-2788; 2096-2719 ; 2815-
3448; 3530-4191
317/LI :411313 .51:2001MAY17 | | 43 -378 ; 43 -274 ; 43 -944 ; 44-630 ; 42-775 ; 48 -
797; 5 1-577; 58-813; 54-328 ; 56-576 ; 65-779 ; 43 -832 ; 43 -703 ; 43 -575 ; 43 -
726; 6 0-648 43-778; 2633- 3113 ; 2521-2776 ; 2567 -2848 ; 2650-3122 ; 2650-2945 ;
2613-2 900; 1843-2073; 1843 -2060 ; 1843 -1956 ; 1844-2060 ; 1852 -2073 ; 1900-
2058; 1900-2054; 1900-2039 1900 -2038 ; 1907 -2039 ; 1928-2060 ; 1942 -2241 ;
2003-2 061; 2003-2060; 2099 2332 ; 2107-2283 ; 2110-2340 ; 2115-2211 ; 2148-
2502; 2148-2348; 1-556; 2789-3211 ; 2799-2997 ; 2807 -3209 ; 2753 -3209 ; 2817 -
3210; 2857-3146; 2866-3207 ; 2871-3207 ; 2761-3065 ; 2916-3209 ; 2786-3209 ;
2966-3 209; 3021-3207; 3027 -3173 ; 3035-3209 ; 3050-3207 ; 3124-3282 ; 2185- Table 5
2290; 2398-2635; 2402-2864 ; 2440 -3013 2500 -2739 2521 -2836; 173-725; 2714- 3177; 2723-3076; 2715-2816 ; 2715 -2997 ■ 2747 -3209 2714 -3181, 39-341; 39- 306; 39-302; 39-298; 39-28 4; 39- 279; 39-270 ; 29-. 560; 26-577, 43-414; 36- 584; 39-584; 43-893; 38-22 4; 39- 601; 39-551 ; 39-464; 2657-2921; 2679-2949; 2679-2872; 2681-3175; 2688 -3169; 2691- -2798; 2691 -3184; 2700- -3176; 2172- 2337; 177-776; 186-868; 19 9-269; 211-( 521; 249-1031; 255-381, 260-( 544; 260- 537; 266-486; 273-604; 275 -553; 284-467; 319-914 331- 570; 3164-3479; 3181- 3342; 3181-3414; 3240-3447 ; 3255 -3458 129- 388; . 136-424; 147-482; 60-296; 60-322; 62-300; 66-278; 72 -250; 72-512; 77- 525; . 111-330; 12_ '-418; 127-831; 129-396; 43-658; 41-3209; 41-2073; 41- -768; 11-302; 41- 277; 41-269 42-318; 43-873; 43-911; 43-870; 34 9-479; 358-593; 370-864; 382 -863; 406-783; 407- 669; 509-733; 567-863; 636 -1183; 839-1122; 346-1441; 863-1618; 969-1197; 1027-1590; 1057-1599; 1057 -1663; 1058- -1169; 1085 -1639; 1081- -1856; 1084- 1254; 1142-1291; 1156-1343 ; 1179 -1399 1198 -1474 1207 -1440, 1212- -1665; 1217-1580; 1222-1712; 1252 -1632; 1333- -1578; 1336- -1436; 1339- -1544; 1349- 1820; 1352-1877; 1354-1875 ; 1358 -1601 1381 -1631 1396 -1537, 1405- -1855; 1405-1681; 1406-1650; 1411 -1969; 1441- -1600; 1443- -1655; 1455- -2081; 1461- 1680; 1488-1995; 1569-1782 ; 1626 -2073 1625 -2029 1632 -2055, 1659- -1855; 1667-1914; 1673-1782; 1675 -1949; 1680- -2025; 1705- -2071; 1705- -1954; 1709- 2073; 1711-2032; 1742-2071 ; 1750 -2073 1749 -1905 1782 -2040, 1794- -2188; 1794-2050; 1825-2070; 1131 -1447; 41-288; 1929-2061; 1833-1944; 46- -605; 1638-1801; 1226-1401; 1136 -1319; 1603- -1807; 507-773; 1317-1689; 2415-2791; 43-426; 1491-1883; 1149-15 69; 666-1128; 263 -802; 1052- 1596; 1255-: 1803; 2352-2903; 938-1498; 482-1 036; 642-1209; 1482-2049; 471-1046; 92-( 569; 43- 660; 1288-1906; 382-999; 3 7-675; 1165- -1843; 802-. 1499; 764-1486; 43-749; 995-1702; 43-757; 158-366 318/LI: 417127.1:2001MAY17 | | 1-540; 1- -556; ' 1-283 376- 632 319/LI: 429817.44 :2001MAY17 II i- 237; 1-485; 117-. 534; 134-386; 138- -396; 225- 789; 256-556; 256-787; 283 -778; 283-742; 291-537 - 293- 741; 293-757; 296- 741; 299-841; 300-644; 323 -771; 328-744; 335-778 349- 746; 350-557; 416- 636; 434-974; 431-1027; 43 7-533; 492-731; 511-730; 522 -729; 540-752; 610- 887; 780-865; 820-1057; 86 5-1108 ; 872- -1045; 976-. 1215; 986-1216; 1089-1362; 1179-1363; 1270-1363; 1279 -1363; 1314- -1539; 1353 -1757; 1-106; 1452-1800; 15-106; 1567-1905; 1584-18 15; 1584-1729; 1589-1840; 1710-1928; 1715-1959; 1722-1962; 1728-1884; 1828 -1937; 1907- -1965; 321-479; 377-720; 459- -771; 563- 779; 943-1131; 1263-1888; 1354-1695; 1638-1878; . 1766-1965 320/LI : 474134.23 : 2001MAY17 II i- 534; 121-907; 161-561; 182-960; 162-968; 183-891; 198-672; 207-752; 212-802; 221-808 ; 221 -600; 227-767; 254-719; 277-691; 319-899; 323-780; 342-892; 342-903 ; 351 -734; 355-808; 356-802; 359-755; 356-741; 365-1158 ; 367- 1291; 374-482; 389-1313; 426-975; 430-910; 430-1154; 443-760; 450-822 ; 469- 1129; 469-1131; < 185-1028; 488-981 1520- 1751; 1551-1805; 1563-1806 ; 1569 -1654 1572 -1805 - 1572 -1804, 1576- -1816; 1576-1798; 1578-1815; 1587 -1804; 1599- -1804; 1602 -1806; 1610- -1806; 1610- 1816; 1610-1804; 1620-2132 ; 1622 -1775 1625 -2417 1628 -1767, 1628- -1806; 1645-1806; 1654-1782; 1658 -1804; 1654- -1774; 1655 -1806; 1655- -1807; 1663- 1907; 1668-1796; 1681-1806 ; 1699 -2171 1699 -1811 1699 -1806, 1699- -2156; 1699-2203; 1699-1804; 1707 -1804; 1711- -1818; 1717- -1785; 1720- -2210; 1719- 1806; 1722-1799; 1725-1804 ; 1740 -1805 1755 -1805 1764 -1886, 1764- -1945; 911-1146; 904-1499; 904-11 39; 925-1031; 915 -1590 915- 1129; 938-1239; 940- 1208; 927-1182; 930-1147; 945-1134; 953-1247; 945-1528 ; 968- -1230; 957-1140; 999-1153; 1009-1218; 1002- 1184; 1018-1147; 1031-. 1147; 1090-1224; 1097-1539; 1111-1344; 1134-1634; 1141 -1967; 1144- -1683; 1149- -1339; 1150- -1518; 1150- 1381; 1152-1381; 1159-1589 ; 1176 -1731 1181 -1390 1186 -1367, 1211- -1429; 1226-1745; 1229-1515; 1235 -1495; 1268- -1815; 1267 -1486; 1277- -1705; 1277- 1528; 1289-1494; 1292-1527 ; 1307 -1591 1308 -1816 1327 -1551, 1330- -1621; 1332-1553; 1343-1764; 1360 -1604; 1385- -1805; 1383 -1635; 1385- -1679; 1388- 1650; 1412-1664; 1470-1816 ; 1476 -1750 1482 -1804 1487 -1765, 1493- -1740; 1507-1654; 1511-1777; 488- 684; 494-684; 487- -1132 509- 1131; 525-1108; 513- 939; 545-1120; 545-885; 54 1-1157 ; 531- -1388; 561-1040; 561-835; 564-683; 565-676; 577-1109; 564-102 3; 564 -1016 566-: 1477; 590-1050; 602-1087; 611- Table 5 711; 605-994; 612-1288; 629-1211; 615-1224; 619-888; 643-1106; 645-1143; 631-1291; 636-1113; 638-1477; 665-1147; 654-917; 673-1107; 673-1148; 685- 902; 685-913; 702-1145; 689-1382; 696-1149; 737-1402; 730-1324; 733-1151; 746-1476; 757-1304; 762-1147; 765-1146; 766-1148; 771-1242; 772-1058; 770- 1146; 781-1147; 780-1147; 807-959; 796-1304 ; 822-1325; 832-956; 843-1099; 835-1372; 849-1066; 857-1103; 851-1481; 853-1147; 910-1228; 910-1117 321/LI:475378.3:2001MAY17 || 1-591; 45-576; 101-807; 101-220; 120-736; 142- 511; 204-426; 283-669; 303-501; 2615-2984; 3458-3725; 3513-3921; 3533-3763; 3561-3700; 3591-3875; 3632-3889; 4080-4331; 4118-4324; 4192-4452; 685-1020; 745-1020; 759-1230; 800-1294; 463-1020; 490 1079; 555-1077; 579-699; 645- 966; 3698-3934; 3727-3988; 3734-4281; 3736-4235; 3741-4342; 3751-3993; 3768-4093; 3788-4240; 3810-4091; 3813-4235; 3816-4329; 3838-4108; 3850- 4181; 3850-4135; 3850-4293; 3849-4331; 3850 4124; 3863-4288; 3870-4093; 3869-4134; 3870-4349; 3880-4338; 3882-4332; 3899-4084; 3919-4333; 3936- 4119; 3955-4331; 3960-4250; 3968-4446; 3980 4407; 3983-4288; 3992-4202; 4009-4333; 4019-4331; 4049-4446; 4054-4510; 4055-4324; 4054-4448; 4061- 4510; 4069-4319; 4081-4335; 4085-4449; 4092 4331; 4098-4331; 4111-4328; 4146-4290; 4169-4323; 4169-4446; 4178-4446; 4204-4444; 4294-4514; 4316- 4446; 4443-4840; 2718-3300; 2747-3331; 2757 3030; 2763-3371; 2764-3321; 2782-3050; 2783-2980; 2863-3426; 2865-3136; 2867-3094; 2884-3280; 2895- 3353; 2894-3383; 2900-3185; 2958-3520; 2974 3041; 2987-3347; 2993-3390; 2995-3369; 2996-3377; 2999-3390; 3011-3378; 3014-3378; 3017-3329; 3027- 3530; 3028-3316; 3029-3384; 3030-3384; 3034 3294; 3034-3238; 3037-3316; 3040-3646; 3047-3647; 3049-3562; 3064-3596; 3060-3352; 3059-3459; 3065- 3309; 3072-3383; 3076-3532; 3076-3339; 3085 3234; 3085-3385; 3089-3709; 3076-3816; 3094-3359; 3104-3618; 3107-3743; 3092-3857; 3109-3380; 3123- 3380; 3136-3697; 3149-3729; 3179-3698; 3185-3458; 3186-3395; 3191-3378; 3208-3380; 3213-3713; 3248-3798; 3281-3800; 3291-3379; 3281-3378; 3304- 3383; 3313-3862; 3337-4087; 3343-4087; 3355-3648; 3359-4087; 3387-3780; 3394-3937; 3404-3691; 3409-3829; 3409-3663; 3411-3633; 3433-3653; 3458- 3909; 3458-3905; 3468-3817; 3474-3564; 3491-3738; 3518-4065; 3535-3812; 3525-3723; 3529-4062; 3532-3739; 3537-4165; 3542-4076; 3551-4031; 3564- 3692; 3567-3812; 3567-3804; 3586-4051; 3599-4126; 3601-4016; 3611-3881; 3623-4101; 3632-4201; 3654-4217; 3690-4063; 3694-4326; 2709-2860; 811-1359; 822-1416; 1024-1490; 1061-1623; 1062-1567; 1190-1393; 1211-1414; 1242-1518; 1289-1725; 1306-1830; 1350-1652; 1366-1650; 1475-1701; 1491-1670; 1535- 1795; 1536-1813; 1536-1924; 1536-1918; 1540-1901; 1554-2100; 1637-1889; 1747-2148; 1830-2340; 1828-2105; 1830-2309; 1830-2249; 1830-2311; 1830- 2319; 1830-2344; 1830-2435; 1830-2308; 1830-2416; 1830-2023; 1830-2389; 1830-2407; 1830-2195; 1830-2191; 1830-2296; 1883-2170; 1900-2189; 1949- 2543; 1986-2520; 1988-2530; 2001-2605; 2032-2313; 2038-2313; 2060-2597; 2061-2605; 2062-2617; 2077-2286; 2084-2605; 2091-2141; 2091-2312; 2150- 2762; 2155-2365; 2169-2348; 2250-2698; 2270-2621; 2280-2899; 2307-2946; 2317-2494; 2320-2836; 2341-2919; 2356-2922; 2370-2977; 2452-3006; 2487- 3022; 2484-3120; 2504-2979; 2510-3127; 2527-2855; 2572-2821; 2609-3167; 2631-3195; 2655-3055; 2664-3158; 2667-3085; 800-1429 322/LI:749588.15:200lMAY17 || 1664-2077; 1851-2131; 2136-2252; 2342-2625; 1-262; 52-636; 176-717; 498-921; 498-1123; 737-1371; 753-1163; 771-1163; 811-1163; 827-1142; 829-1456; 833-1163; 873 -1409; 878-1163; 910-1138; 917- 1507; 917-1520; 917-1515; 917-1503; 928-1525; 968-1163; 979-1163; 1055- 1663; 1055-1163; 1055-1495; 1238-1359; 1346-1690; 1350-1979; 1506-1915; 1516-1770; 1690-1927; 1704-1959; 1775-2295; 1800-2239; 1800-2064; 1918- 2024; 1965-2024; 2051-2367; 2169-2252; 2244-2787; 2244-2791; 2259-2489; 2351-2765; 2358-2771; 2368-2618; 2387-2637; 2400-2600; 2425-2704; 2462- 3034; 2475-3000; 2488-2994; 2513-2992; 2533-3045; 2569-2802; 2571-2825; 2574-3035; 2581-2790; 2624-3032; 2695-2751; 2939-3264; 2939-3127; 2945- 3001; 3022-3132; 3180-3836; 3529-3600 323/LI:757736.17:2001MAYl7 || 6095-6611; 60 98-6618; 6121-6421; 6136-6618; 6136-6565; 6136-6394; 6145-6587; 6154-6396; 6166-6618; 6175-6646; 6197- 6623; 6198-6582; 6207-6418; 6269-6625; 6411-6579; 6529-6633; 3673-4134; Table 5
3676- 3914; 3682 3924; 3684 3938; 3700-4010 ; 3713 -3957 ; 3714-3948; 3724- 3974; 3725-3924 3730-4031 3738 3855 3743- -4204; ; 3745 4204 3780- 4047; 3788-4052; 3785 4118; 3820 4144; 3818 4237; 3831- -4207; 3838 4244; 3838- 4108; 3870-4124 3854-4244 3856-4072 3873- -4031; ; 3884 4244 3887- 4110; 3892-4152; 3892 4244; 3898 4211; 3894 4099; 3905- -4244; 3908-4145; 3935- 4226; 3933-4175 3935-4118 3938-4244 3945- -4201; : 3945 4169 3960-4248; 3972-4235; 3972 4141; 3974 4249; 3981 4473; 3986- -4245; 4002 4222; 4005- 4244; 4024-4247 4025-4245 4048-4323 4063- -4243; : 4069 4243 4075-4220; 4074-4696; 4083 4244; 4109 4246; 4117 4200; 4125- -4345; 4245-4720; 4263- 4698; 4265-4464 4296-4828 4307-4507 4394- -4714; : 4394 4711 4422-4681; 4422-4762; 4428 4801; 4428 4670; 4433 4691; 4673- -4856; 4806 4971; 4815- 5211; 4815-5047 4815-5029 4833-5077 4847- -5105; : 4868 5240 4949-5202; 4949-5595; 4978 5316; 4978 5240; 5019-5275; 5028-5210; 5034 5508; 5078- 5328; 5150-5369 5171-5481 5247 -5605 5272- 5687; 5274 5595 5283-5607; 5315-5642; 5315 5558; 5342 5605; 5379 6031; 5402-5677; 5412 5605; 5434- 6067; 5442-5639 5443 -5605 5444-6032 5498- 6078; 5505 5605 5516-6017; 5516-6008; 5516 6073; 5516 6058; 5516 5634; 5516-5632; 5516 5605; 6022- 6521; 6041-6295 6046-6313 6045-6474 6046- 6428; 6050 6422 6050-6582; 5949-6070; 5949 6066; 5949 6024; 5949 6071; 5949-6067; 5961 6394; 5959- 6203; 5961-6082 5962-6104 5962-6315 5962- 6144; 5969- 6067 5969-6401; 5969-6325; 5969 6388; 6011 6528; 2983 3434; 2992-3604; 2993 3572; 3006- 3604; 3016-3535 3020-3436 3047-3567 3053- 3614 3077- 3375 3078-3329; 3100-3537; 3096 3435; 3101 3373; 3115 3368; 3119-3370; 3124 3390; 3145- 3474; 3188-3388 3187-3449 3195-3369 3205- 3335; 3216- 3436 3217-3453; 3220-3350; 3220 3436; 3232 3512; 3222 3773; 3248-3481; 3255-3785; 3263- 3552; 3278-3500 3285-3833 3298-3562 3320- 3491; 3319 3524 3339-3436; 3333-3640; 3356 3607; 3381 3641; 3394 4033; 3397-3698; 3403-3975; 3409- 3960; 3409-3715 3430-3670 3429-3679 3434- 3887; 3441 3655 3445-3739; 3449-3712; 3449 3941; 3458 3984; 3458-3742; 3465-3841; 3471 4010; 3486- 3734; 3517-4001 3517-3750 3518 -3780 3519-3721; 3530- 4191 3533-3762; 3533-3719; 3533 3813; 3541 4102; 3543 4143; 3563-3725; 3574 4161 3572- 3815; 3581-4160 3581-4148 3582-3756 3585-3969; 3584- 3871 3573-3991; 3604-3834; 3608 3881; 3619 4172; 3632 3889; 3648-3903; 3662-3997; 3686- 4136; 1505-2111 1550-2163 1552-1811 1573-1676; 1586- 1920 1586-1856; 1615-2210; 1629 2196; 1631 2079; 1681 2128; 1687-1933; 1707-1896; 1711- 1959; 1711-1990 1714-1941 1716-1960 1748-1886; 1813- 2548 1820- 2062; 1824-2510; 1830 2085; 1845 2260; 1859 2116; 1877-2109; 1895-2425; 1896- 2286; 1926-2203 1937-2238 1939-2529 1967-2505; 1969- 2249 1971 2486; 1982-2616; 1998 2085; 2015 2569; 2038-2715; 2046-2661; 2047 2678; 2054- 2477; 2070-2564 2080-2682 2129 -2364 2135-2387; 2146-2621 2168-2810; 2186-2708; 2221 2503; 2231 2583; 2231-2689; 2235-2495; 2246 2498; 2251- 2808; 2265-2850 2290-2523 2297 -2564 2297-2559; 2298- 2838 2298 2545; 2303-2893; 2309 2554; 2334 2455; 2345-2798; 2363-2950; 2416 2761; 2418- 2541; 2445-2709 2461-2554 2469 -3102 2495-2736; 2495- 2734 2488 3132; 2511-2671; 2521 2821; 2534 2716; 2542-2997; 2547-2827; 2585 2824; 2592- 3233; 2614-3237 2661-2835 2668 -3171, ; 2676- -3095; 2707-3329 2710-3383; 2733-3104; 2749 3136; 2806 3376; 2809- -3434; 2863- 3413; 2863 3087; 2881- 3373; 2905-3372 2909-3089 2909 -3075; ; 2915- -3523; 2971-3120 1-681 1-707; 50-835; 66-753; 223-758; 2 3-855 ; 336- -956; 448-695; 498-1115; 545-1100; 567-867; 601-86 ; 601-1113 601- 837; 613-847; 613 -880; 638-898; 638-894; 638-881; 683-12 2; 683-123 ; 683 -1197;r 683-1240; 683-1255; 683-1227; 683- 1155; 683-1289; 683-1042; 83-10 92; 683-1015; 683 -1083; 683-818; 683-975; 683-963; 683-73 ; 698-1338 739- 1046; 741-1280; 764-1137; 807-1358 ; 880- 1314; 907-1110; 941-1501; 42-15 01; 962-1223; 966 1-1530; 977-1544; 985-1443; 1026-1646; 1032 1287; 1042 1133; 1075- -1598; 1096- 1588; 1121-1629; 1142- 1410; 1149-1490 1167-1355 1191 -1486; ; 1213- -1472; 1235-1673; 1237-1678; 1250-1649; 1253 1772; 1294 1581; 1306- -1638; 1331- 1857; 1347-1626; 1373- 1620; 1434-1722 1467-1884 1471 -1697; ; 1491- -1812; 1491-1783; 5526-5605; 5528-6063; 5529 6018; 5533 5605; 5538- -5619; 5627- 6073; 5918-6420; 5922- Table 5 6518; 5922-6287; 5922-6138; 5937-6206; 5948-6070; 5949-6204; 5949-6168; 3420-4050; 393-1046
324/LI: 817278.4 :2001MAY17 || 505-944; 485-933; 475-933; 256- 929; 634-928; 431-894; 225-887; 444-763; 444-585; 1-550; 37-546; 1-478; 49-512; 49-509; 1-490; 29-478; 28-461; 30-444; 1-373; 1-311; 1-271; 29-229; 30-169; 1-167 325/LI:027320.5:2001MAY17 || 234-668; 391-775; 391-622; 410-838; 458-821; 458-861; 473-857; 702-838; 858-1288; 1-303; 1-571; 120-503; 183-578; 205- 777; 205-632; 206-758; 246-668; 261-773; 391-839; 391-911; 391-682; 391- 728; 391-838; 392-908; 392-796; 392-834; 404-728; 427-659; 439-838; 458- 838; 458-910; 458-837; 458-911; 458-857; 459-910; 460-838; 473-838; 473- 911; 511-838; 548-968; 571-910; 626-1111; 721-1255; 729-1111 ; 729-838; 833- 1182; 854-1148; 866-1287; 885-1111; 944-1231 326/LI:204635.5:2001MAY17 || 1-673; 124-567; 145-698; 145-37 8; 196-564; 315-749; 355-718; 365-746; 414-749; 415-741; 483-683; 521-615; 664-919 327/LI: 215532.38 :2001MAY17 || 33-578; 33-395 : 33-276; 35-260 ; 39-281; 42- 254; 47-295; 51-202; 63-333; 99-864; 101-298 : 113-775; 112-729; 122-281; 127-288; 133-305; 134-238; 134-563; 136-278; 152-225; 179-411; 190-296; 210-466; 250-864; 321-914; 341-911; 359-921; 509-1153; 522-1207; 586-1165; 612-1215; 626-1289; 657-1293; 693-920; 742-1005; 745-1282 47-1004; 754-
943; 7 69-1049; : 775-1040; 1123-1697; 1134-2028; 1-245; 2-274; 2-284; 5-269;
2-198; 4-253; 5-265; 5-280; 13-255; 13-277; 16-287; 17-410; 17-251; 24-285;
32-232
328/LI :228 319.6 :2001 AY17 1-495; 1-324; 97-647; 187-805; 193-638; 242-
899; 523-1 091
329/LI :236 589.2 4:2001MAY17 I I 3274-3679; 3282-3679; 3385-3529; 3328-3679;
3332-3678; 3336-3514; 3336- 3687; 3343-3679; 3430-3699; 3431-3679; 3520-
3851; 3453 -3782 ; 3497-3835; 3522-3696; 3508-4195; 3564-4024; 3565-4025;
3672-4125; 3672-4121; 3647- 3889; 3725-4148; 3735-4148; 3780-4036; 3788-
4018; 3801-4098 ; 3909-4535; 3921-4407; 3964-4510; 3947-4201; 3958-4251;
3978-4480; 3982-4441; 3988- 4265; 38-138; 1-448; 1-267; 9-441; 25-445; 3-
426; 8 287 ; 26-307; 1-246; 5-215; 10-178; 1131-1363; 2037-2695; 2055-2325;
2089-2556; 2151-2541; 1164- 1630; 1164-1537; 1164-1693; 1164-1651; 1164-
1670; 1164-1771 ; 1164-1737; 1341-1898; 1400-2114; 1434-1721; 1442-2060;
1478-1813; 1496-2077; 1526- 1695; 1551-2146; 1566-2243; 1582-2294; 1589-
2265; 1593-2227 ,- 1603-2346; 1630-2178; 1636-2419; 1649-2145; 1656-2339;
1682-2318; 1688-2282; 1702- 2326; 1704-2079; 1708-2361; 1727-2145; 1727-
2295; 1729-2353 ; 1738-1982; 1751-2300; 1768-2036; 1792-2416; 1794-2441;
1800-2079; 1806-2180; 1813- 2336; 1813-2462; 1824-2416; 1823-2302; 1832-
2365; 1833-2304 ; 1839-2492; 1849-2400; 1849-2045; 1856-2280; 1861-2111;
1861-2121; 1867-2492; 1906- 2439; 1912-2414; 1932-2413; 1948-2112; 1965-
2368; 1973-2506 ,- 1992-2417; 2029-2449; 2158-2745; 2152-2658; 2160-2410;
2161-2421; 2169-2765; 2171- 2478; 2178-2434; 2215-2385; 2211-2368; 2216-
2497; 2233-2768 ; 2235-2825; 2251-2509; 2250-2661; 2250-2755; 2305-2704;
2314-2775; 2316-2863; 2372- 2791; 2383-2803; 2371-2802; 2407-3038; 2473-
2830; 2508-3211 ; 2508-2998; 2526-2908; 2533-3177; 2507-3129; 2509-3217;
2506-3263; 2507-2984; 2506- 3164; 2498-2757; 2499-2738; 2506-2944; 2502-
2851; 2521-2906 ; 2524-3287; 2538-2885; 2544-3082; 2559-2906; 2561-2848;
2569-2968; 2614-3235; 2627- 3175; 2626-2820; 2635-2899; 2648-2751; 2648-
2844; 2648-2895 ; 2663-3235; 2661-2728; 2665-2938; 2667-2929; 2672-2926;
2681-2944; 2701-3203; 2702- 3112; 2702-3285; 2728-3253; 2737-2987; 2742-
3105; 2752-3271 ; 2764-3014; 2769-3112; 2775-3287; 2775-3075; 2746-3161;
2814-3285; 2821-3285; 2818- 3076; 2822-3285; 2823-3046; 2824-3285; 2826-
3287; 2826-3104 ; 2811-3287; 2823-3291; 2850-3285; 2856-3287; 2862-3285;
2869-3335; 2869-3285; 2869- 3195; 2870-3286; 2873-3286; 2872-3285; 2879-
3289; 2882-3285 ; 2885-3285; 2884-3285; 2898-3289; 2858-3473; 2900-3170;
2903-3158; 2907-3285; 2915- 3298; 2932-3292; 2930-3155; 2936-3286; 2936-
3149; 2941-3071 ; 2949-3158; 2950-3286; 2959-3297; 2962-3158; 2980-3285;
2989-3285; 2993 -3285; 2998- 3288; 1-642; 3014-3297; 3015-3238; 3011-3634;
3022-3287; 3024-3285; 3027- 3269; 3029-3291; 3031-3285; 3041-3187; 3064-
3645; 3068-3282 ; 3072-3619; 3089-3249; 3096-3282; 3097-3285; 3105-3293; Table 5 3109-3860; 3157-3288; 3177-3671; 3165-3291; 3165-3389; 3189-3287; 3208- 3684; 3253-3425; 3244-3680; 3301-3545; 14-464; 18-163; 21-457; 40-272; 128- 739; 217-715; 280-3684; 594-1194; 700-1335; 700-950; 824-1058; 898-1533; 1027-1565; 1056-1535; 1076-1345; 1091-1335; 1100-1578; 1109-1572; 1121- 1335; 1-495; 236-2410; 890-1452; 1088-1386
330/LI:247444.3:2001MAYl7 || 157-735; 166-395; 184-614; 215-394; 250-655; 244-722; 252-660; 252-505; 256-493; 277-695; 277-391; 308-653; 310-657; 311-462; 1-600; 50-522; 68-304; 67-499; 84-230; 111-444; 142-395; 143-304; 162-593; 316-566; 328-740; 333-598; 335-998; 334-604; 360-551; 381-653; 392-725; 409-613; 412-657; 428-796; 470-711; 508-992; 519-993; 533-1037; 547-965; 561-818; 571-842; 623-998; 623-751; 652-902; 653-962; 653-991; 656-1001; 656-915; 656-786; 659-1000; 659-804; 660-996; 679-1004; 694-999; 740-1129; 744-1001; 775-966; 803-1052; 857-1001; 857-999; 857-992; 858-960; 905-1455; 924-1105; 941-1374; 1047-1279; 1143-1586; 1284-1651; 1309-1785; 1404-1690; 1442-1728
331/LI:332404.20:2001MAY17 || 1992-2609; 2046-2313; 2059-2504; 2078-2248; 2449-3220; 2508-2693; 2579-2695; 1-294; 10-135; 145-514; 406-512; 469-891; 469-571; 793-1183; 818-1630; 1014-1784; 1020-1525; 1041-1686; 1073-1498; 1081-1622; 1013-1719; 1076-1543; 1076-1670; 1076-1642; 1076-1695; 1076-
1564; 1076-1715; 1078-1650; 1108-1774; 1108-1778 1108-1775; 1108-1541;
1054-1865; 1122-1600; 1134-1245; 1155-1330; 1198-2057; 1217-1822; 1219
1483; 1249-1704; 1255-1687; 1249-2043; 1291-1925; 1295-1822; 1278-2065; 1367-2159; 1386-1580; 1385-2178; 1402-2010; 1430- 1559; 1486-1921; 1482- 1980; 1508-2132; 1516-2065; 1536-2152; 1557-2152; 1553-2118; 1585-2119; 1627-2101; 1643-2197; 1677-2345; 1659-2606; 1706- 2346; 1731-2119; 1723- 2110; 1734-2111; 1762-2243; 1764-2093; 1763-2243; 1781-2399; 1781-2126; 1776-2606; 1808-2243; 1823-2115; 1856-2211; 1887-2480; 1922-2629; 1925- 2448; 1946-2548; 1089-1818 332/LG:1088459.4 :2001JU 22 | | 1-640 333/LG:1501495.1 :2001JUN22 jj 1-263; 135-829; 141-516; 232-827; 342-516; 347-927; 502-864 ; 554-973; 723-902; 823-1318; 823-1454 ; 1079-1186; 1159- 1413; 1265-1673; 1629-2261; 1642-2205; 1719-2205; 1739-2321; 1765-2327; 1881-2196; 1998 2153; 2107-2681; 2196-2638; 2201-2465; 2382-2634; 1632- 1904; 1725-2215; 1724-2320; 2355-2612; 843-1395; 843-1126 334/LG:334284.10 :2001JUN22 || 607-938; 707-931; 422-88 6; 589-877; 454-866; 561-854; 480-854 ; 484-854; 507-854; 553-854; 599-854; 611-854; 788-854; 351-852; 579-814 ; 478-796; 276-772; 478-708; 122-661; 1-622; 181-611; 1- 551; 184-465 335/LG:345279.19 :2001JUN22 II i- 1871; 560-8 28; 60 5-116 1; 64 9-1196 ; 688-853; 834-1348; 860-1380; 860-13 89; 860-1322; 871-1462; 877-1485; 881-1139; 897- 1460; 920-1173; 935-1192; 951-1190; 952-1503; 962-1501 ; 964-1180; 964-1051; 976-1211; 976-1185; 991-1246; 1055-1237; 1067-1611; 1067-1325; 1118-1367; 1186-1726; 1189-1411; 1203-1813; 1241-1785; 1245- 1843; 1250-1870; 1259- 1514; 1290-1875; 1293-1818 1282-1520 ; 1295-1864; 1297-1556 ; 1321-1852; 1319-1763; 1331-1843; 1329 1585; 1329-1531; 1329- 1498; 1329-1480; 1342 1833; 1344-1620; 1345-1858 1356-1874 ; 1339-1594; 1357-1718 ; 1354-1825 1373-1573; 1389 1858; 1379 1838; 1379-1863; 1379- 1690; 1395-1863; 1384 1891; 1385-1636; 1396-1861 1396-1665 ; 1396-1679; 1387-1874 ; 1403-1864 1407-1653; 1409-1864; 1410 1883; 1411-1875; 1401-1882; 1401-1883; 1401 1858; 1415-1690; 1424-1870 1425-1876 ; 1412-1860; 1420-1840 ; 1427-1868 1417-1871; 1430-1720; 1434 1595; 1437-1877; 1429-1873; 1428-1875; 1445 1862; 1454-1703; 1449-1862 ; 1462-1873 ; 1472-1887; 1482-1789 ; 1485-1799 1480-1883; 1483- 1838; 1483-1875; 1497-1870; 1488-1874; 1500-1707; 1489 1880; 1489-1870; 1502-1900 ; 1492 -2017 ; 1492-1992; 1494-1905 ; 1508-1878 1509-1876; 1508-1759; 1508-1690; 1511-1674; 1500-1863; 1514-1875; 1515- 1673; 1504-1935; 1505-1573 ; 1506-1958 ; 1508-1955; 1508-1904 ; 1509-1962 1521-1754; 1510-1967; 1513-1871; 1515-1913; 1515-1950; 1515-1692; 1515 1672; 1542-1750; 1542-1742 ; 1549-1724 ; 1538-1875; 1549-1704 ; 1539-1924 1553-1874; 1549-1871; 1549-1688; 1553-2016; 1565-1862; 1566-1823; 1562 1915; 1566-2027; 1584-1756 ; 1590-1850 ; 1590-1805; 1580-1877 ; 1582-1686 Table 5
1599-2127; 1603-1853; 1618-1981; 1647-1824; 1643-2181; 1676-1946; 1678- 2096; 1678-1915; 1690-2166; 1708-2190; 1726-1947; 1732-1947; 1726-1894; 1748-2229; 1785-2427; 1805-1867; 1797-2151; 1812-2220; 1812-2223; 1833- 2450; 1822-2229; 1837-2080; 1853-2166; 1864-2038; 1977-2151; 2070-2220; 2106-2233; 1735-1834; 1597-1724; 1743-1871; 1687-1880; 1674-1873; 1595- 1834; 1583-1830; 1584-1873; 1588-1880; 1557-1874; 1540-1874; 1540-1871; 1508-1829; 1489-1838; 1498-1842; 1511-1874; 1501-1859; 1485-1839; 1504- 1862; 1513-1864; 1515-1870; 1460-1834; 1444-1839; 1382-1838 336/LG:7689681.1:2001JU 22 || 1-615; 34-620; 87-580; 87-693; 87-694; 87- 601; 87-386; 285-763; 342-763; 420-939; 438-763; 459-718; 513-755; 553-755; 561-763; 561-753
337/LG:7690093.1:2001JU 22 || 1-551; 1-264; 24-717; 346-622; 349-739; 402- 722; 418-949; 425-846; 429-852; 599-868; 786-1061; 962-1136; 1092-1372 338/LG:7690175.3:200lJUN22 || 1-275; 162-795; 183-355; 168-710; 208-706; 278-1001; 274-882; 330-748; 565-738; 750-1298; 750-1312; 1101-1353; 1291- 1743; 1363-1770; 1490-1736; 1529-1640
339/LG:7697128.1:2001JUN22 || 1-252; 213-486; 307-464
340/LG:006394.20:2001JUN22 jj 1-389; 2-274; 280-903; 358-963; 426-680; 471- 684; 472-733; 512-655; 571-1089; 587-1173; 615-1210; 647-1210; 648-1057; 656-1150; 656-903; 677-1210; 717-1224; 720-1214; 720-1223; 726-1224; 731- 924; 732-1204; 737-1195; 733-1195; 742-1206; 760-1224; 745-1192; 749-1206; 773-1214; 773-1178; 771-929; 773-1058; 777-908; 784-1195; 791-1333; 787- 908; 788-1223; 791-1224; 794-908; 802-1224; 801-1195; 803-1224; 820-1224; 824-1203; 825-1195; 828-1459; 829-1313; 832-1195; 828-990; 836-1224; 854- 1339; 839-1206; 875-1696; 862-1224; 864-1224; 895-1350; 881-1215; 884-1224; 894-1224; 905-1224; 905-1188; 914-1224; 916-1224; 924-1185; 924-1156; 926- 1159; 921-1086; 925-1079; 939-1195; 957-1277; 940-1223; 951-1215; 951-1182; 958-1173; 990-1516; 980-1312; 992-1292; 1004-1563; 996-1556; 1010-1610; 1012-1616; 1018-1224; 1020-1206; 1045-1358; 1092-1296; 1092-1191; 1018- 1470; 1029-1224; 1098-1234; 1049-1709; 1034-1223; 1054-1643; 1064-1709; 1049-1223; 1103-1565; 1112-1653; 1123-1640; 1129-1772; 1125-1195; 1163- 1679; 1184-1373; 1220-1385; 1187-1741; 1218-1372; 1171-1689; 1229-1372; 1217-1437; 1232-1724; 1218-1544; 1226-1794; 1228-1742; 1226-1734; 1226- 1676; 1226-1735; 1226-1687; 1226-1396; 1228-1815; 1228-1806; 1226-1707; 1228-1819; 1232-1802; 1231-1815; 1233-1728; 1235-1627; 1251-1518; 1241- 1445; 1256-1481; 1243-1838; 1257-1785; 1257-1372; 1264-1533; 1264-1499; 1188-1469; 1246-1471; 1259-1826; 1260-1887; 1257-1528; 1237-1527; 1239- 1536; 1276-1704; 1276-1586; 1276-1512; 1276-1697; 1276-1676; 1276-1631; 1276-1673; 1276-1539; 1276-1521; 1276-1430; 1276-1707; 1252-1520; 1276- 1537; 1276-1670; 1276-1748; 1276-1607; 1280-1677; 1284-1452; 1290-1509; 1276-1552; 1276-1375; 1299-1855; 1290-1779; 1286-1549; 1310-1608; 1310- 1605; 1313-1553; 1338-1720; 1340-1886; 1341-1627; 1349-1627; 1351-1989; 1382-1857; 1383-1690; 1382-1645; 1364-1608; 1374-1857; 1428-1923; 1356- 1666; 1391-1665; 1379-1615; 1347-1720; 1397-1636; 1387-1756; 1304-1856; 1400-1712; 1311-1429; 1401-1697; 1401-1692; 1419-1700; 1400-1643; 1390- 1477; 1389-1832; 1313-1444; 1418-1823; 1412-1554; 1417-1867; 1415-1821; 1341-1500; 1399-1554; 1421-1821; 1433-1659; 1437-1695; 1440-1737; 1435- 1693; 1437-1767; 1450-1680; 1427-1549; 1452-1978; 1452-1923; 1457-1757; 1469-1758; 1456-2048; 1448-1707; 1484-1732; 1485-1787; 1501-1688; 1491- 1682; 1502-1664; 1502-1755; 1494-1838; 1495-1611; 1517-1811; 1505-1784; 1519-1827; 1500-1943; 1515-1770; 1571-1933; 1516-1727; 1528-1770; 1571- 1959; 1534-1802; 1534-1796; 1535-1738; 1552-1661; 1545-1790; 1544-1962; 1540-1729; 1554-1781; 1555-1775;' 1572-1767; 1578-1737; 1581-1846; 1578- 1857; 1592-1874; 1612-1861; 1622-1767; 1634-2094; 1641-1870; 1688-2163; 1712-2163; 1744-2169; 1752-2163; 1780-1959; 1791-1944; 1770-2154; 1773- 1996; 1790-2163; 1798-2181; 1802-2137; 1824-1942; 1819-2091; 1896-2163; 1926-2393; 1984-2220; 2044-2702; 2083-2297; 2091-2272; 2102-2691; 2111- 2485; 2124-2648; 2146-2698; 2165-2707; 2161-2706; 2178-2531; 2179-2444; 2183-2710; 2185-2442; 2193-2542; 2194-2528; 2196-2600; 2198-2764; 2204- 2571; 2211-2487; 2216-2647; 2226-2742; 2249-2746; 2255-2500; 2260-2743; Table 5 2266-2511; 2268-2659; 2282-2568; 2282-2749; 2294-2749; 2297-2746; 2299- 2707; 2313-2558; 2317-2744; 2325-2457; 2337-2615; 2346-2749; 2362-2746; 2364-2747; 2370-2746; 2374-2748; 2388-2749; 2392-2747; 2394-2459; 2395- 2750; 2398-2750; 2404-2748; 2406-2725; 2406-2643; 2413-2749; 2427-2748; 2430-2749; 2455-2754; 2453-2742; 2455-2709; 2467-2707; 2470-2747; 2472- 2746; 2482-2744; 2494-2752; 2496-2746; 2546-2746; 2550-2752; 2557-2752; 2558-2747; 2575-2746; 2576-2752; 2575-2769; 2621-2746; 2627-2746; 2626-2742 341/LG:1012069.1:2001JUN22 || 1-493; 434-1037; 437-1018; 516-879; 516-990; 516-1133; 812-1420; 983-1340
342/LG: 104533.11 :2001JUN22 || 1-781; 254-877; 290-877; 307-781; 318-760; 558-890; 644-1232; 663-743; 663-849; 771-1287; 778-1149; 844-1310; 1032- 1516; 1255-1546; 1319-1943; 1547-1803; 1550-1983; 1617-1855; 1669-1908; 1855-2095; 1855-2087; 1885-2120; 1907-2188; 1907-2197; 1909-2143; 1922- 2209; 1933-2227; 1935-2062; 1940-2220; 1945-2195; 1983-2239 343/LG:1045853.23:2001JU 22 || 1-228; 1-669; 164-478; 186-477; 252-559; 282-871; 365-830; 438-968; 590-1242; 594-771; 605-1233; 609-1191; 1059- 1167; 1112-1641; 1119-1641; 1146-1430; 1158-1638; 1276-1913; 1346-1641; 1366-1629; 1434-1786; 1434-1803; 1450-2045; 1827-2430; 2046-2526; 2178- 2561; 2228-2757; 2310-2800; 2380-2804; 2392-2961; 2597-3140; 2603-3200; 2626-3261; 2627-3206; 2745-3026; 3040-3710; 3112-3294; 3112-3373; 3285- 3538; 3285-3508; 3342-3621; 3548-4022; 3806-4298; 3809-4083; 4070-4653; 4133-4687
344/LG:1081017.8:2001JUN22 || 1-227; 6-676; 60-362; 74-409; 74-227; 80-338; 84-361; 92-765; 242-528; 246-840; 246-507 345/LG:1090358.6:2001JUN22 || 1-248; 164-792
346/LG:1135312.7:2001JUN22 jj 1-577; 1-192; 304-697; 345-832; 472-1051; 740-1387; 964-1403; 1044-1195; 1129-1634; 1129-1377; 1129-1369; 1472-1653; 1516-1654; 1597-1650
347/LG:1328501.2:2001JUN22 || 1-229; 1-529; 3-256; 65-376; 161-331; 219- 625; 448-614; 489-1047; 497-914
348/LG:133095.1:200lJUN22 || 1-421; 5-443; 9-455; 66-303; 84-363; 128-220; 130-400; 275-505; 372-885; 409-694; 426-751; 611-884; 714-1158; 755-1370; 758-1064; 767-1231; 776-993; 807-1369; 869-1128; 926-1334; 929-1172; 991- 1551; 1044-1364; 1093-1584; 1135-1533; 1138-1623; 1253-1513; 1262-1525; 1351-1814; 1358-1814; 1359-1806; 1361-1813; 1400-1814; 1401-1809; 1433- 1815; 1434-1814; 1435-1809; 1507-1809; 1521-1815; 1550-1816; 1561-1816; 1569-1816; 1623-1779; 1688-1816; 1690-1789; 1703-1797
349/LG:135379.5:200UUN22 || 1-324; 2-210; 56-627; 118-367; 359-635; 359- 912; 759-925; 767-1023; 775-928; 794-1054; 794-1188; 845-1070; 898-1180; 925-1161; 933-1207; 960-1250; 960-1212; 962-1237; 1015-1534; 1060-1309; 1102-1698; 1106-1370; 1116-1335; 1193-1825; 1191-1689; 1207-1848; 1248- 1435; 1266-1826; 1373-1890; 1484-1930; 1491-1930; 1491-1694; 1509-1894; 1513-1930; 1536-1929; 1567-1934; 1583-1835; 1680-1838; 1714-1929; 1717- 1828; 1807-1930; 1811-2050; 1811-2114; 1811-2160; 1823-1932; 1926-2137 350/LG:1365581.3:2001JUN22 || 1-540; 1-487; 10-288; 10-271; 10-252; 10-260; 11-479; 19-255; 29-237; 29-616; 31-548; 31-286; 33-232; 184-288; 228-552; 229-650; 229-381; 331-487; 331-479; 531-1140; 531-686; 700-881; 725-1100; 725-958; 731-1012; 736-959; 740-1078; 757-1014; 766-962; 767-1243; 769- 1316; 770-1336; 773-1330; 773-1198; 773-878; 774-893; 774-1266; 802-1014; 811-1061; 823-1287; 805-1389; 827-1490; 831-958; 844-1287; 844-1090; 882- 1009; 908-1162; 896-1118; 899-1040; 908-1431; 937-1392; 945-1381; 938-1386; 945-1428; 971-1430; 974-1413; 1009-1392; 1018-1432; 1027-1428; 1029-1294; 1034-1197; 1034-1258; 1044-1318; 1060-1408; 1047-1283; 1047-1288; 1082- 1282; 1124-1428; 1145-1430; 1160-1430; 1182-1430; 1182-1418; 1182-1288; 1185-1429; 1187-1444; 1187-1386; 1187-1377; 1203-1430; 1203-1428; 1224- 1399; 1275-1430; 1300-1430
351/LG:1383156.20:2001JUN22 | | 1-408; 1-328; 36-248; 36-275; 53-338; 64- 365; 65-466; 87-242; 177-458; 220-478; 249-500; 266-382; 307-498; 354-557; 429-671; 449-693; 552-697; 568-842; 615-814; 619-698; 631-916; 657-1646; 669-895; 696-1207; 701-887; 701-942; 702-945; 703-1249; 703-932; 705-884; Table 5 705-930; 706-898; 708-1010; 714-1066; 717-958; 720-1179; 724-942; 735-1015; 740-942; 741-942; 743-1044; 743-942; 745-911; 746-929; 750-1018; 754-942; 755-1030; 759-1051; 764-917; 766-942; 773-1040; 773-1052; 774-1019; 775- 1072; 780-1010; 786-1027; 786-1058; 789-1033; 790-1034; 800-1024; 802-1019; 804-1041; 804-1645; 805-1099; 807-942; 807-1058; 807-895; 806-1077; 807- 1041; 807-1014; 807-914; 807-919; 807-934; 807-1048; 808-1050; 808-942; 808-957; 809-1053; 809-935; 809-903; 809-902; 809-942; 809-1041; 809-955; 809-981; 809-1034; 809-1097; 809-1090; 809-1084; 809-1035; 810-942; 810- 1329; 810-1081; 810-1043; 810-1041; 810-1140; 810-945; 810-908; 810-1037; 810-946; 810-944; 810-1031; 810-934; 810-1011; 810-1094; 810-1060; 810- 1423; 810-1049; 810-1279; 811-943; 811-942; 812-893; 810-1052; 811-954; 811-958; 811-1058; 812-942; 811-1034; 812-958; 812-897; 812-921; 812-955; 812-944; 812-892; 813-942; 812-879; 813-1019; 813-1078; 814-1076; 811-1066; 814-942; 815-912; 815-942; 816-1298; 816-1103; 816-1076; 816-958; 816-945; 816-1058; 816-1071; 816-948; 816-944; 816-1102; 817-1058; 818-1339; 821- 1421; 819-955; 820-1153; 821-1056; 821-942; 825-1144; 829-1525; 838-1066; 839-1068; 840-1140; 843-1141; 847-954; 852-1138; 864-942; 893-1122; 955- 1126; 953-1151; 961-1154; 961-1152; 961-1162; 961-1155; 961-1113; 992-1549; 1004-1413; 1002-1287; 1011-1280; 1015-1073; 1023-1249; 1037-1304; 1037- 1342; 1044-1293; 1050-1258; 1050-1309; 1055-1244; 1073-1308; 1088-1433; 1106-1352; 1110-1333; 1111-1350; 1133-1359; 1144-1403; 1145-1424; 1146- 1523; 1154-1635; 1153-1634; 1182-1608; 1196-1577; 1203-1508; 1205-1652; 1214-1405; 1215-1504; 1215-1405; 1217-1652; 1217-1429; 1218-1450; 1218- 1335; 1218-1275; 1219-1513; 1230-1521; 1245-1461; 1245-1653; 1246-1523; 1249-1655; 1253-1330; 1253-1488; 1255-1517; 1255-1582; 1266-1481; 1267- 1493; 1268-1522; 1271-1653; 1272-1480; 1282-1391; 1283-1646; 1282-1553; 1284-1646; 1289-1491; 1289-1555; 1290-1490; 1297-1646; 1313-1514; 1320- 1536; 1322-1609; 1326-1646; 1327-1560; 1349-1554; 1347-1645; 1361-1637; 1361-1552; 1360-1610; 1361-1612; 1373-1585; 1373-1652; 1390-1548; 1395- 1515; 1397-1560; 1407-1642; 1439-1492; 1506-1646; 1510-1653; 1535-1652; 1537-1611; 1582-1646; 816-942; 1591-1652; 1559-1652; 980-1069; 973-1061; 817-904; 809-894; 816-895; 817-925; 837-942; 1538-1642; 841-942; 842-942; 843-942; 817-942; 493-548; 810-930; 822-942; 961-1011; 959-1071; 816-933; 826-942; 815-931; 1104-1242; 820-957; 1387-1523; 1513-1649; 814-940; 810- 938; 1510-1640; 810-951; 810-953; 872-942; 992-1160; 807-957; 85-137; 982- 1159; 1463-1646; 961-1054; 961-1046; 1461-1636; 1263-1451; 830-942; 961- 1156; 818-942; 568-668; 1455-1652; 961-1086; 819-942; 1449-1646; 1023-1228; 1443-1646; 1123-1264; 961-1167; 1055-1260; 961-1171; 1035-1244; 818-911; 834-942; 1408-1627; 1081-1295; 1058-1278; 1436-1652; 961-1179; 828-942; 961-1048; 961-1183; 1118-1264; 1413-1633; 1422-1646; 1400-1624; 976-1200; 820-942; 980-1207; 1086-1264; 1421-1649; 961-1052; 1280-1426; 818-939; 960- 1196; 809-944; 961-1077; 960-1201; 447-547; 991-1234; 961-1062; 823-942; 961-1090; 89-139; 961-1073; 961-1118; 959-1218; 1128-1264; 961-1070; 961- 1074; 961-1081; 964-1234; 1062-1332; 961-1089; 1034-1305; 961-1099; 1360- 1628; 962-1238; 961-1087; 961-1092; 961-1097; 85-163; 961-1103; 961-1104; 961-1114; 961-1106; 961-1095; 961-1105; 85-169; 402-548; 961-1110; 961- 1115; 961-1117; 85-152; 867-942; 962-1121; 961-1121; 85-183; 1332-1646; 85- 206; 578-695; 961-1157; 85-236; 85-247; 85-241; 85-246; 85-244; 961-1217; 1165-1592; 1216-1646; 961-1395
352/LG:1501767.18:2001JUN22 || 1-455; 1-249; 352-571; 402-632; 466-726; 468-760; 564-691; 680-1203; 695-1302; 773-1075; 862-1102; 924-1153; 953- 1407; 991-1297; 1022-1227; 1044-1407; 1048-1103; 1065-1298; 1083-1407; 1108-1463; 1111-1372; 1122-1300; 1141-1407; 1224-1297; 1224-1463; 1238- 1363; 1238-1407; 1238-1349; 1238-1395; 1270-1431; 1293-1484; 1306-1502; 1306-1558; 1360-1603; 1420-1633; 1440-1695; 1474-1923; 1487-1939; 1534- 1760; 1538-1817; 1538-1819; 1559-1923; 1587-2185; 1629-1910; 1652-1925; 1661-1864; 1684-1923; 1746-1895; 1779-1923; 1823-1923; 1841-1923; 1850- 1923; 1853-1923; 1855-1923; 1950-2639; 1995-2179; 1995-2396; 1995-2251; 2023-2381; 2048-2625; 2154-2639; 2165-2381; 2252-2776 Table 5 353/LG:1501890.8:2001JUN22 || 1-657; 24-417; 49-496; 56-330; 56-122; 57- 296; 58-330; 59-194; 62-185; 64-303; 67-297; 68-296; 67-123; 69-296; 94- 352; 109-353; 148-726; 154-254; 153-255; 169-451; 160-764; 186-427; 249- 969; 262-557; 301-573; 323-561; 339-2091; 348-2636; 426-950; 436-686; 463- 1040; 466-731; 472-702; 472-669; 472-820; 543-1067; 582-1102; 645-1211; 701-959; 759-1117; 781-1289; 772-886; 791-991; 832-987; 846-1175; 849-1089; 876-1425; 899-1143; 990-1494; 990-1222; 982-1209; 990-1209; 990-1205; 990- 1198; 990-1196; 990-1168; 1220-1488; 1244-1297; 1283-1666; 1413-1587; 1417- 1724; 1479-1699; 1473-1747; 1473-1743; 1506-2018; 1543-1836; 1558-1777; 1560-2018; 1586-2115; 1612-1900; 1638-2096; 1652-1924; 1652-1914; 1695- 2048; 1871-2056; 1923-2002; 1986-2212; 2123-2336; 2124-2274; 2145-2644; 2175-2639; 2210-2641; 2212-2638; 2213-2636; 2246-2639; 2275-2398; 2298- 2519; 2335-2636; 2340-2542; 2404-2639; 2489-2601; 2496-2639 354/LG:203434.23:2001JUN22 || 1-205; 116-585; 177-685; 353-884; 353-587; 572-772; 581-810; 593-816; 610-801; 612-802; 612-783; 620-812; 742-1305; 1003-1632; 1051-1274; 1054-1436; 1057-1458; 1135-1615; 1166-1434; 1217- 1632; 1271-1590; 1272-1690; 1650-2135; 1656-1894; 1787-1857; 1959-2388; 1959-2235; 2005-2260; 2050-2286; 2073-2177; 2087-2272; 2107-2337; 2135- 2426; 2158-2407; 2176-2396; 2176-2418; 2188-2785; 2244-2487; 2274-2832; 2449-2681; 2453-2586; 2453-2582; 2462-2729; 2462-2936; 2488-2767; 2526- 2866; 2554-3123; 2554-2819; 2661-2866; 2692-2870; 2735-3007; 2790-2870; 2877-3002; 2918-3187; 3049-3297; 3054-3229; 3054-3151; 3054-3488; 3065- 3383; 3070-3141; 3262-3345; 3272-3812; 3279-3356; 3467-3851; 3602-3849; 645-824; 1534-1749; 130-753
355/LG: 204724.5 :2001JUN22 || 3-617; 1-274; 2-458; 2-290; 2-315; 3-274; 3- 302; 4-292; 3-643; 3-679; 5-314; 1-709; 6-288; 6-318; 8-230; 8-203; 17-310; 18-305; 18-106; 18-340; 32-264; 32-154; 77-534; 77-716; 387-951; 652-794; 663-797; 722-963; 879-1169; 893-1187; 949-1325; 949-1310; 952-1153; 958- 1083; 972-1277; 989-1283; 1056-1293; 1090-1336; 1090-1517; 1107-1415; 1128- 1667; 1277-1590; 1360-1605; 1360-2124; 1362-1669; 1370-1627; 1399-1563; 1413-1719; 1534-1849; 1537-1742; 1647-1931; 1677-1919; 1799-1975; 1819- 2224; 1825-2231; 1823-2002; 1853-2240; 1862-2247; 1874-2092; 1909-2018; 1967-2276; 1969-2276; 1969-2237
356/LG:257107.16:2001JUN22 || 1-171; 1-151; 92-535; 92-513; 92-462; 92-151; 92-153; 335-909; 375-749; 435-527; 448-697; 450-1054; 490-1130; 507-844; 524-1131; 612-749; 712-1321; 718-946; 720-1082; 720-965; 720-1321; 726-998; 761-956; 826-925; 845-1308; 851-1093; 892-1236; 904-1081; 960-1572; 964- 1204; 981-1145; 1038-1679; 1063-1148; 1202-1326; 1225-1656; 1230-1767; 1305-1600; 1320-1580; 1462-1707; 1507-1781; 1535-2150; 1542-1807; 1557- 1613; 1628-1893; 1644-1908; 1655-1898; 1655-1894; 1666-2217; 1672-2162; 1672-1927; 1737-1996; 1737-1990; 1741-1958; 1748-1878; 1767-2149; 1766- 2140; 1766-1986; 1777-1908; 1829-2113; 1842-2411; 1843-2115; 1904-2114; 1910-2161; 1914-2140; 1958-2508; 1994-2146; 2027-2672; 2026-2594; 2050- 2660; 2072-2169; 2079-2136; 2135-2704; 2139-2420; 2139-2375; 2155-2342; 2177-2775; 2179-2567; 2185-2394; 2192-2443; 2195-2419; 2200-2386; 2244- 2502; 2275-2803; 2340-2876; 2360-2943; 2384-2657; 2387-2980; 2411-2941; 2419-2603; 2448-2943; 2451-2712; 2456-2902; 2456-2708; 2472-2935; 2489- 2877; 2484-2748; 2493-2591; 2484-2937; 2494-2924; 2488-2758; 2491-2976; 2490-2941; 2493-2947; 2495-2941; 2511-2867; 2511-2742; 2512-2938; 2515- 2980; 2522-2980; 2531-2677; 2532-2981; 2532-2980; 2555-2825; 2561-2941; 2569-2980; 2572-2980; 2577-2980; 2583-2980; 2598-2800; 2604-2982; 2604- 2980; 2604-2817; 2613-2941; 2618-2930; 2617-2830; 2618-2766; 2622-2945; 2622-2883; 2623-2866; 2624-2981; 2626-2980; 2631-2981; 2633-2985; 2648- 2984; 2669-2904; 2679-2910; 2681-2981; 2689-2981; 2695-2983; 2711-2930; 2711-2900; 2711-2981; 2722-2976; 2747-2980; 2779-2964; 2788-2980; 2815- 2984; 2848-2979; 2869-2977; 2879-2980; 2907-2983
357/LG:353530.4:2001JU 22 || 1-700; 84-626; 324-1000; 505-597; 324-838; 506-685; 511-1080; 542-810; 548-904; 548-780; 553-815; 614-980; 668-1235; 668-1231; 745-982; 743-1272; 744-1303; 744-1154; 874-1302; 915-1135; 911- 1534; 989-1234; 1061-1645; 1107-1553; 1297-1838; 1439-1657; 1442-1698; Table 5 1472-1620; 1486-1734; 1507-1790; 1545-1963; 1545-1779; 1545-1766; 1573- 2027; 1596-1848; 1597-1819; 1626-1878; 1635-1811; 1664-1877; 1688-1932; 1725-2109; 1778-2154; 1778-2072; 1779-1999; 1804-1954; 1817-2090; 1837- 2247; 1900-2531; 1953-2203; 1994-2197; 1997-2327; 2020-2327; 2027-2470; 2058-2315; 2064-2559; 2064-2286; 2133-2201; 2135-2364; 2143-2448; 2159- 2694; 2205-2450; 2206-2491; 2206-2303; 2227-2409; 2250-2450; 2255-2484; 2279-2533; 2304-2542; 2310-2505; 2317-2545; 2335-2627; 2355-2736; 2365- 2495; 2372-2852; 2372-2617; 2388-2900; 2391-2878; 2407-2742; 2433-2632; 2478-2724; 2528-2893; 2531-2812; 2558-3132; 2663-2821; 2670-2935; 2676- 2911; 2692-2926; 2695-2919; 2694-3136; 2704-3144; 2704-2948; 2710-3148; 2714-3298; 2714-3284; 2714-2976; 2734-3131; 2734-3111; 2736-3018; 2741- 3256; 2782-3209; 2766-3280; 2772-2958; 2773-3062; 2782-3282; 2792-3139; 2797-3281; 2814-3082; 2820-3031; 2835-3024; 2845-3323; 2852-3322; 2854- 3323; 2866-3321; 2874-3320; 2873-3320; 2877-3320; 2877-3204; 2872-3072; 2898-3320; 2891-3174; 2915-3153; 2920-3320; 2920-3221; 2924-3320; 2924- 3323; 2925-3320; 2926-3324; 2927-3320; 2926-3067; 2928-3320; 2929-3336; 2928-3058; 2931-3320; 2933-3319; 2936-3325; 2937-3320; 2945-3314; 2947- 3184; 2952-3279; 2955-3320; 2958-3321; 2959-3320; 2962-3320; 2973-3170; 2978-3337; 2996-3235; 3013-3320; 3043-3318; 3039-3299; 3053-3319; 3077- 3319; 3073-3259; 3072-3314; 3082-3320; 3090-3321; 3093-3321; 3091-3320; 3092-3313; 3106-3322; 3110-3319; 3144-3320; 3148-3320; 3158-3318; 3204-3320 358/LG:7683573.3:2001JUN22 || 1-222; 24-241; 24-568; 27-269; 27-553; 35- 286; 113-324
359/LG:7684224.1:2001JUN22 || 1-709; 410-958
360/LG:7690365.2:2001JUN22 jj 1-458; 100-458; 176-750; 307-593; 490-750; 583-1185; 586-804; 600-849; 786-1086; 786-1014; 792-1384; 792-1049; 1196- 1788
361/LG:968691.1:2001JU 22 || 1-649; 1-230; 4-713; 3-238; 192-354; 192-248; 192-277; 202-641; 215-354
362/LG:983076.7:200lJU 22 || 1-482; 77-327; 106-726; 106-711; 106-353; 115- 660; 185-533; 222-625; 225-953; 312-548; 484-986; 688-1162; 709-854; 741- 832; 741-1199; 765-1291; 841-1112; 843-1345; 868-1456; 895-1126; 926-1554; 1138-1339; 1170-1422; 1185-1602; 1229-1372; 1231-1486; 1311-1444; 1263- 1642; 1263-1487; 1270-1876; 1345-1631; 1378-1582; 1426-1985; 1426-1880; 1661-1914; 1664-2052; 1668-1788; 1910-2434; 1932-2148; 2036-2543; 2036- 2552; 2036-2339; 2077-2231; 2091-2518; 2099-2313; 2103-2353; 2122-2379; 2124-2610; 2135-2567; 2137-2424; 2143-2447; 2248-2466; 2290-2531; 2291- 2537; 2238-2425; 2318-2885; 2356-2831; 2356-2605; 2371-2644; 2413-2659; 2430-2933; 2481-2644; 2481-2698; 2554-2798; 2567-2689; 2630-2754; 2641- 2890; 2728-2878; 2741-2830
363/LG:986291.1:2001JUN22 || 1-736; 1-164; 1-612; 1-66; 1-269; 1-358; 1- 621; 227-891; 251-925; 253-891; 257-894; 274-889; 523-993
364/LG:990347.41:2001JUN22 || 1-179; 1-315; 4-605; 71-429; 344-1067; 653- 911; 656-1090; 723-1091; 728-1150; 914-1541; 919-1541; 928-1050; 1008-1145; 1115-1623; 1372-1949; 1378-1846; 1378-1661; 1378-1606; 1378-1468; 1397- 1862; 1397-1639; 1426-1792; 1435-1715; 1442-1632; 1546-1698; 1561-1820; 1562-1763; 1711-2248; 1734-2271; 1798-1932; 1836-2105; 1875-2439 365/LG:998305.4:2001JUN22 || 1-569; 48-317; 49-563; 161-655; 163-475; 217- 679; 359-526; 380-679; 410-690; 414-690; 432-679; 593-679; 609-679 366/LG:463420.16:2001JUN22 || 1-572; 11-393; 40-570; 49-371; 51-285; 72- 554; 109-585; 122-573; 122-556; 175-570; 188-554; 189-554; 209-450; 215- 554; 230-554; 277-554; 278-554; 287-554; 294-954; 298-350; 298-554; 298- 383; 305-554; 423-554; 424-554; 439-570; 458-1016; 518-570; 694-983; 835- 928; 851-1100; 851-1379; 854-1437; 860-1222; 860-1221; 860-1115; 860-1012; 860-921; 866-1130; 869-1216; 877-1112; 877-1074; 880-1085; 893-1424; 900- 1126; 918-1018; 924-1438; 928-1377; 938-1202; 949-1192; 954-1489; 955-1451; 1036-1322; 1051-1588; 1063-1480; 1063-1601; 1091-1600; 1091-1586; 1098- 1649; 1106-1654; 1111-1611; 1118-1223; 1130-1511; 1133-1511; 1163-1658; 1174-1698; 1183-1637; 1217-1855; 1237-1828; 1251-1840; 1251-1682; 1269- 1761; 1281-1866; 1293-1539; 1301-1846; 1314-1617; 1322-1714; 1326-1877; Table 5
1352-1720; 1392 -1900; 1408 1698; 1412-1663; 1415 1954; 1428 1717; 1434-
1740 1444-2040 1445- 1675 1452 -2051; 1453-•1940 1500-■2122 1502 -1770; 1505 1920; 1504 -1809; 1507 1829; 1507-1745; 1511 2016; 1511 2111; 1511- 2096 1511-2098 1511- 2078 1511 -2076; 1520- 1780 1530- 1751 1550 -1827; 1539 2058; 1599 -2201; 1550 1833; 1550-1821; 1551 1797; 1552 1792; 1564- 2194 1565-2156 1586- 1748 1596 -1824; 1599- 2216 1606-•1735 1618 -2074;
1628-2015; 1630 -2212; 1628 1865; 1628-1776; 1629 1890; 1630 1872; 1646-
2171 1655-2197 1656- 2202 1655 -1947; 1660- 1808 1663- 1917 1676 -2289; 1670 2223; 1670 -2228; 1677 2056; 1676-1827; 1676 1881; 1677 1888; 1682- 2249 1683-2222 1689- 2230 1693 -2135; 1690- 1959 1693- 2354 1700 -1942; 1707 2265; 1707 -1904; 1698 2230; 1713-1922; 1714 2245; 1724 2239; 1724- 1955 1725-1960 1729- 1935 1738 -2424; 1739- 2315 1665- 1895 1742 -2311;
1744-2289; 1674 -1910; 1754 2352; 1722-1919; 1721 1920; 1760 2316; 1761-
2362 1763-2062 1738- 2015 1725 -1961; 1743- 1878 1769- 2044 1774 -2035;
1774-1980; 1707 -1938; 1769 2264; 1735-2000; 1776 2268; 1753 1991; 1754-
1876 1778-2030 1781- 2052 1786 -2029; 1786- 1969 1786- 1921 1787 -2103; 1789 2033; 1791 -2350; 1801 2051; 1801-2010; 1803 1959; 1806 2305; 1806- 2031 1806-2032 1807- 1929 1813 -2151; 1873- 2157 1807-•2447 1826 -2334;
1837-2461, 1830 -2293; 1830 2097; 1835-2161; 1834 1936; 1842 2289; 1840-
1988 1844-2058 1845- 2077 1846 -2404; 1879- 2498 1873-•2145 1873 -2134; 1873 2085; 1873 -1970; 1883 2135; 1897-2259; 1897 2261; 1898 2146; 1917- 2193 1917-2161 1918- 2171 1918 -2170; 1911- 2163 1898-2105 1937 -2170;
1923-2420; 1931 -2152; 1935 2207; 1929-2418; 1940 2202; 1940 2190; 1950-
2155 1922-2365 1947- 2197 1983 -2587; 1959- 2171 1966-•2247 1969 -2230;
1963-2164, 1965 -2473; 1973-2247; 1977-2287; 1971 2074; 1977 2228; 2000-
2513 2011-2162 2017- 2357 2021 -2319; 2024- 2630 2027- 2320 2047 -2318; 2044 2630; 2046 -2133; 2054 2311; 2062-2317; 2064 2455; 2062 2326; 2061- 2354 2097-2380 2104- 2384 2106 -2350; 2108- 2391 2116- 2388 2120 -2619; 2134 2396; 2135 -2377; 2135 2321; 2137-2592; 2148 2364; 2177 2422; 2177- 2406 2081-2249 2170- 2423 2174 -2544; 2195- 2424 2127- 2553 2168 -2616; 2131 2548; 2175 -2619; 2207 2572; 2153-2419; 2217 2450; 2220 2455; 2200- 2380 2163-2383 2165- 2403 2233 -2476; 2168- 2421 2237- 2528 2244 -2458; 2242 2537; 2243 -2487; 2176 2386; 2259-2512; 2274 2637; 2209 2415; 2231- 2381 2264-2475 2292- 2628 2309 -2630; 2414- 2967 2441- 2630 2414 -2895; 2450 2631; 2427 -2992; 2444 2709; 2456-2728; 2459 3123; 2464 2750; 2469- 2986 2493-3020 2529- 3145 2499 -2749; 2503- 3073 2503- 2758 2505 -3125; 2504 2741; 2518 -3035; 2586 2691; 2578-2795; 2571 3125; 2582 2894; 2572- 3125 2583-2815 2574- 2787 2577 -2800; 2577- 2786 2592- 2722 2609 -3135; 2616 2786; 2614 -3064; 2631 3134; 2632-3134; 2632 2993; 2632 3133; 2642- 3125 2639-3125 2652- 3134 2644 -3134; 2661- 2929 2659- 3134 2664 -3134; 2665 3134; 2667 -3124; 2677 2954; 2685-3134; 2688 3135; 2687 3134; 2690- 3109 2694-3109 2694- 3133 2701 -3109; 2705- 3134 2705- 3116 2712 -3134; 2710 3134; 2716 -3109; 2714 3133; 2720-3135; 2730 3118; 2730 3124; 2735- 3124 2737-3125 2740- 3134 2745 -2857; 2751- 3135 2758- 3135 2763 -3129; 2772 3125; 2769 -3075; 2784 3116; 2794-3134; 2748 3332; 2805 3116; 2753- 3335 2808-3047 : 2818- 3078 2836 -3134; 2839- 3127 2850- 3127 2848 -3127; 2853 3136; 2870 -3134; 2831 3326; 2902-3135; 2911 3134; 2918 3125; 2919- 3125 2932-3125 2934- 3125 2954 -3074; 2958- 3065 2967- 3109 2970 -3133;
3056-3342; 1-23 367/LG:979059 . 3 2001JUN22 I I 1-446 ; 223 980; 494- 954; 506-800; 506-558; 509-938; 509 -93 510-888; 531-801 ; 539 1110 713 949; 824-1200; 824-1047; 848-1407; 848-1 26; 989-1590; 1200 -1832 ; 1217-1862; 1249-1833; 1524-1762; 1528-1742; 1564 1874; 1618-2277; 1 651-2043; 1698 2041; 1699-1954; 1725- 1846; 1737-1919 1722-1989; 1729-1 971; 1729-1961 1730-1920; 1729-2186; 1781-2016; 1788 2330; 1796-2253; 1 821-2049; 1805 1920; 1810-1940; 1842- 2289; 1842-2140 1840-1987; 1851-2 119; 1868-1951 1877-2297; 1902-2146; 1932-2497; 1940 2049; 1957-2616; 1 975-2192; 1980 2217; 1983-2526; 2010- 2533; 2076 2387 2091-2299; 2094-2 577; 2103 2534 2101-2525; 2120-2533, 2131-2351; 2148 2529; 2155-2572; 2 164-2493; 2176 2572; 2187-2452; 2241- 2580; 2240 2572 2251-2575; 2252-2 575; 2253 2575 2257-2502; 2265-2575; Table 5 2285-2550; 2320-2570; 2330-2575; 2332-2556; 2332-2572; 2341-2572; 2372- 2572; 2399-2572; 2410-2509; 2478-2570
368/LG:1045509.22:200UUN22 || 1-317; 2-291; 246-600; 500-1086; 676-926; 847-1162; 875-1298; 877-1157; 885-1169; 898-1156; 1065-1306; 1142-1487; 1194-1674; 1411-2083; 1419-1878; 2015-2161
369/LG:246935.4:2001JUN22 || 1-491; 1-531; 6-273; 21-123; 280-683; 286-516; 319-559; 320-561; 320-548; 320-521; 376-840; 390-665; 421-683; 569-1155; 586-1282; 613-878; 619-968; 621-1007; 624-896; 633-901; 640-916; 681-903; 694-899; 710-920; 715-821; 726-1018; 740-837; 752-1012; 793-1003; 850-1014; 1157-1768; 1196-1767; 1280-1775; 1286-1532; 1366-1614; 1461-2018; 1550- 1822; 1550-2036; 1575-1759; 1621-2199; 1632-1880; 1632-2007; 1634-1866; 1663-1933; 1701-2029; 1762-2312; 1762-2040; 1785-2060; 1796-2012; 1812- 2075; 1853-2124; 1883-2115; 1886-2052; 1898-2100; 1906-2156; 1923-2231; 1954-2182; 1980-2248; 1980-2418; 1980-2234; 1980-2264; 2023-2686; 2056- 2503; 2106-2301; 2158-2212; 2169-2723; 2204-2804; 2204-2465; 2211-2578; 2212-2447; 2270-2530; 2282-2533; 2307-2906; 2339-2878; 2424-2838; 2424- 2629; 2443-2905; 2446-2905; 2449-2905; 2449-2909; 2450-2679; 2453-2908; 2452-2712; 2479-2922; 2481-2754; 2487-2871; 2491-2878; 2494-2916; 2494- 2913; 2494-2732; 2504-2905; 2510-2871; 2511-2909; 2512-2906; 2515-2909; 2522-2916; 2522-2754; 2526-2788; 2573-2760; 2576-2853; 2579-2909; 2579- 2759; 2589-2899; 2587-2908; 2588-2899; 2611-2931; 2627-2905; 2663-2878; 2694-2827; 2687-2916; 2690-2859; 2695-2834
370/LG:321069.2:2001JUN22 || 1-315; 5-451; 6-304; 8-324; 376-941; 631-811; 865-1395; 880-1520; 1185-1449; 1205-1822; 1234-1688; 1237-1517; 1440-2059; 1479-1671; 1514-1759; 1591-2149; 1796-2026; 1807-2080; 1828-2094; 1866- 2196; 1866-2087; 1867-2243; 1966-2244; 2017-2202; 2071-2563; 2071-2334; 2128-2368; 2128-2267; 2133-2388; 2143-2683; 2145-2338; 2195-2431; 2196- 2467; 2205-2443; 2215-2482; 2227-2518; 2227-2413; 2241-2495; 2245-2339; 2263-2463; 2279-2529; 2282-2429; 2409-2731; 2431-2637; 2441-2541; 2489- 2938; 2502-2735; 2505-2745; 2533-2785; 2548-2803; 2573-2746; 2583-2848; 2583-2788; 2597-2893; 2612-2795; 2606-2936; 2612-3196; 2612-2980; 2612- 3021; 2612-2951; 2612-2909; 2629-2927; 2642-2868; 2648-3359; 2671-2941; 2676-2884; 2690-2940; 2691-3113; 2701-2938; 2705-2967; 2728-3023; 2750- 2964; 2790-3187; 2790-3073; 2798-3032; 2798-3078; 2827-3075; 2829-3437, 2829-3066; 2843-3428; 2861-3054; 2865-3439; 2866-3089; 2883-3441; 2952- 3210; 2954-3245; 2968-3357; 2986-3267; 2989-3134; 3003-3465; 3005-3475; 3013-3478; 3013-3472; 3016-3481; 3026-3475; 3030-3472; 3058-3472; 3072- 3475; 3074-3343; 3076-3472; 3077-3472; 3079-3438; 3092-3478; 3099-3479; 3108-3411; 3115-3472; 3124-3478; 3133-3475; 3134-3472; 3136-3478; 3145- 3397; 3154-3619; 3158-3527; 3159-3653; 3180-3643; 3196-3401; 3212-3469; 3220-3467; 3248-3465; 3271-3472; 3271-3480; 3286-3472; 3290-3472; 3312- 3478; 3319-3472; 3324-3624; 3339-3623; 3346-3619; 3349-3475; 3356-3612; 3358-3607; 3368-3485; 3384-3577; 3389-3722; 3389-3714; 3394-3654; 3396- 3577; 3433-3641; 3574-4031; 3778-3834; 3790-4031; 3800-3884
371/LG:346724.14:2001JUN22 || 1-303; 1-2237; 2-1460; 292-843; 402-935; 404- 645; 411-762; 526-1037; 613-899; 641-899; 682-904; 686-1188; 714-929; 701- 1189; 712-1026; 752-1115; 810-1118; 856-1260; 896-1020; 909-1223; 909-1164; 910-1261; 920-1257; 949-1117; 966-1540; 989-1546; 1001-1106; 1019-1460; 1020-1475; 1053-1461; 1074-1385; 1075-1273; 1090-1307; 1095-1458; 1110- 1401; 1144-1458; 1146-1395; 1198-1458; 1201-1546; 1206-1458; 1245-1746; 1460-2082; 1517-1782; 1556-1729; 1635-1875; 1648-1910; 1648-1900; 1653- 1905; 1658-2211; 1659-2287; 1687-2234; 1732-2233; 1732-1992; 1799-2058; 1894-2236; 1905-2191; 1905-2236; 1937-2173; 1942-2166; 2013-2237; 2024- 2237; 2072-2598; 2209-2748; 2235-2547; 2244-2512; 2249-2521; 2337-2915; 2341-2593; 2346-2590; 2347-2804; 2350-2906; 2350-2518; 2350-2481; 2350- 2457; 2350-2593; 2359-2835; 2361-2697; 2361-2639; 2361-2625; 2363-2585; 2366-2619; 2369-2713; 2369-2618; 2369-2577; 2369-2476; 2369-2475; 2369- 2464; 2369-2456; 2369-2599; 2369-2564; 2369-2561; 2369-2553; 2374-2719; 2374-2573; 2374-2534; 2374-2500; 2374-2456; 2374-2791; 2374-2488; 2380- 2647; 2406-2719; 2408-2504; 2410-2847; 2410-2796; 2413-2771; 2423-2571; Table 5 2440-3117; 2448-3087; 2445-2709; 2453-2701; 2456-2738; 2458-2740; 2481- 2727; 2483-2826; 2500-2641; 2503-2764; 2515-2746; 2519-2639; 2541-2806; 2546-3086; 2552-3161; 2578-2794; 2582-3102; 2593-2876; 2602-3196; 2602- 2876; 2622-2878; 2630-3087; 2628-2927; 2628-2850; 2628-3118; 2634-2983, 2669-3213; 2684-2924; 2684-2913; 2695-3127; 2688-2951; 2695-3235; 2696- 2955; 2698-3158; 2709-3122; 2712-3121; 2714-3199; 2714-2964; 2715-3090; 2715-2982; 2718-2959; 2721-2825; 2723-2976; 2728-3122; 2735-3051; 2740- 2990; 2740-2969; 2745-3199; 2746-3204; 2745-3004; 2750-3199; 2752-3202; 2754-3200; 2755-3200; 2762-3205; 2762-3197; 2761-3302; 2764-3233; 2768- 3199; 2779-3206; 2780-3156; 2782-3199; 2787-3205; 2787-3200; 2787-3056; 2787-2901; 2790-3056; 2790-3068; 2793-3199; 2794-3199; 2799-3240; 2807- 3125; 2809-3242; 2810-3200; 2810-3198; 2822-3200; 2814-3202; 2815-3200; 2813-3043; 2813-2976; 2815-3060; 2824-3235; 2830-3067; 2837-3200; 2838- 3198; 2841-3200; 2839-3050; 2844-3199; 2846-3198; 2855-3054; 2855-3084; 2863-3137; 2864-3111; 2870-3200; 2868-3101; 2872-3199; 2872-3057; 2875- 3152; 2884-3114; 2891-3233; 2907-3202; 2896-3197; 2895-3199; 2895-3184; 2900-3130; 2901-3199; 2901-3123; 2902-3199; 2906-3151; 2908-3164; 2910- 3118; 2914-3166; 2916-3159; 2916-3188; 2917-3144; 2918-3157; 2923-3182; 2926-3206; 2924-3170; 2924-3140; 2924-3272; 2927-3181; 2928-3201; 2933- 3146; 2935-3206; 2940-3207; 2952-3101; 2969-3199; 2972-3198; 2975-3199; 2975-3183; 3008-3197; 3013-3199; 3023-3199; 3032-3206; 3040-3199; 3045- 3203; 3046-3199; 3048-3199; 3052-3199; 3053-3199; 3059-3245; 3102-3268; 3110-3199; 3048-3293; 3098-3416; 3048-3411; 2770-3237
372/LG:411043.3:2001JU 22 || 1-544; 6-216; 33-152; 47-600; 51-350; 53-394; 74-364; 67-565; 113-382; 113-356; 121-333; 125-660; 134-628; 137-720; 140- 407; 274-485; 405-617; 410-678; 502-762; 521-1018; 659-895; 666-1290; 667- 933; 689-1016; 925-1334; 926-1128; 926-1360; 941-1229; 967-1205; 969-1557; 1013-1280; 1021-1376; 1092-1362; 1139-1299; 1206-1501; 1355-1709; 1361- 1676; 1362-1692; 1420-1676; 1426-1676; 1430-1678; 1434-1678; 1467-2065; 1620-1698; 1632-2092; 1634-1802; 1654-2039; 1729-1816; 1781-2045; 1849- 2124; 1889-2124; 1921-2124; 1944-2124; 1977-2124; 1984-2139; 2051-2112 373/LG:978620.7:2001JU 22 || 1089-1546; 1095-1546; 1184-1539; 884-1525; 1342-1483; 1023-1465; 594-1122; 952-1053; 381-897; 597-889; 240-661; 250- 661; 1-555; 1-490
374/LG:982784.1:2001JUN22 || 1906-2146; 1615-2147; 1403-2133; 1671-2115; 850-1473; 959-1177; 769-1062; 691-993; 679-987; 693-988; 600-986; 526-986; 677-986; 683-984; 716-981; 497-941; 490-933; 570-927; 750-892; 222-872; 605-871; 282-834; 673-795; 307-695; 383-677; 1-581; 84-574; 137-324; 84-240 375/LG:007574.21:2001JUN22 || 1-588; 30-588; 420-856; 795-1521; 909-1521; 1382-1908; 1556-1767; 1582-2165; 1587-2187; 1756-2163; 1756-2066; 1757- 2073; 1820-2191; 2000-2583; 2031-2452; 2066-2241; 2147-2399; 2177-2698; 2264-2707; 2307-2415; 2322-2860; 2396-2938; 2425-2735; 2455-2941; 2457- 2574; 2467-2669; 2515-2849; 2584-3128; 2615-2814; 2706-2996; 2795-3272; 3220-3815; 3337-3878; 3347-3608; 3653-3878; 3667-4036; 3729-4146; 3753- 3879; 3842-4097; 3842-4205; 3900-4161; 3906-4152; 4032-4211; 4040-4211; 4079-4211; 4085-4225; 4105-4211; 4158-4658; 4296-4465; 4311-4578; 4313- 4514; 4332-4487; 4332-4514; 4332-4481; 4332-4397; 4332-4530; 4332-4550; 4332-4496; 4332-4410; 4333-4575; 4334-4427; 4337-4454; 4377-4631; 4397- 4657; 4479-5004; 4490-5013; 4515-5004; 4539-5049; 4540-5000; 4542-5042; 4552-4971; 4587-5049; 4595-5050; 4597-5050; 4599-5054; 4600-5049; 4602- 5048; 4604-5007; 4605-5049; 4608-5056; 4609-5049; 4621-5054; 4627-4952; 4630-5049; 4632-5037; 4642-5049; 4644-5054; 4645-5050; 4650-5051; 4650- 5049; 4654-5051; 4668-5052; 4669-5209; 4686-5049; 4715-4940; 4721-5049; 4720-5056; 4720-5049; 4722-5050; 4731-5054; 4736-5050; 4738-5051; 4740- 5046; 4746-5049; 4771-5024; 4771-5030; 4802-5054; 4808-4987; 4825-5025; 4828-5051; 4846-5048; 4843-5049; 4949-5054
376/LG:013856.18:200lJUN22 || 1-265; 130-780; 181-548; 440-847; 489-3603; 489-804; 492-765; 543-704; 548-900; 644-1124; 674-946; 680-974; 714-1021; 739-940; 742-913; 760-991; 800-1044; 955-1023; 968-1229; 1015-3596; 1056- 1607; 1059-1317; 1104-1302; 1116-1357; 1118-1404; 1119-1411; 1550-1905; Table 5
1554-1933; 1600 2202; 1643 2231; 1681-2199; 1712- 2323; 1729 2340; 1733
1974 1741 -2201 1747-1975 1751 2229 1789 •1902; 1822- 2358 1827-2370 1834 2089; 1844 2130; 1845 2155; 1862-2347; 1868-2189; 1871 2128; 1876 2137 1880 -2187 1883-2126 1890 •2355 1897 2133; 1905- 2046 1913- 2370 1973 2329; 1958 2328; 1971 2354; 1983 2342; 1985-2311; 1985 2299; 1986 2297 1990 -2231 2007-2358 2018 2516 2018 2332; 2023- 2202 2023-■2277 2030 2247; 2045 2358; 2045-2273; 2053 2358; 2055-2452; 2073 2277; 2084 2358 2084 -2312 2104-2358 2117 •2333 2117- 2348; 2119- 2355 2121-•2243 2128 2423; 2134 2368; 2135-2384; 2148 2674; 2154-2425; 2160 2434; 2160 2358 2161 -2496 2196-2420 2199 •2358 2208 2358; 2211- 2772 2210-•2452 2215 2559; 2223 2710; 2215-2531; 2248 2838; 2255-2515; 2288 2690; 2285 2358 2300 -2560 2290-2577 2296 •2541 2301 2538; 2370- 2639 2398-2678 2399 2931; 2399 2871; 2399 2664; 2407 2876; 2415-2688; 2415 2573; 2417 2709 2423 -2896 2423-2629 2426 2635 2433 2686; 2442- 2700 2444- 2681 2446 2661; 2451 2507; 2463-2687; 2469 2701; 2469-2934; 2469 2717; 2470 2731 2471 -2726 2493-2658 2503 2565 2510 •2897; 2509- 2772 2511-•2767 2513 2789; 2519 2800; 2527 2790; 2529 2763; 2532-2729; 2544 2719; 2557 3099 2555 -3183 2555-3061 2557 2809 2557 ■2814; 2570- 2811 2577-•2820 2581 2821; 2585 2972; 2588 2906; 2593 2804; 2596-2872; 2598 2870; 2606 2847 2605 -2864 2625-3141 2631 3163 2631 2928; 2631- 2829 2642-2918 2650 2889; 2657 2991; 2657-2767; 2663 2971; 2663-2892; 2669 2934; 2679 3203 2683 -3261 2683-2872 2737 2788 2742 2881; 2745- 3002 2750- 2885 2750 2989; 2750 2979; 2752 3035; 2767 3046; 2768-3256; 2770 2931; 2808 3302 2703 -2962 2778-3066 2780 3382 2778 •3063; 2778- 3051 2778- 3032 2778 3020; 2778 3012; 2780 3272; 2785 3321; 2789-3381; 2802 3362; 2802 3162 2801 -3063 2804-3120 2804 •3077 2806 3058; 2806- 3294 2809- 3100 2811 3067; 2814 2964; 2826-3079; 2835 3063; 2837-3089; 2837 3096; 2837 3071 2843 -3054 2844-3434 2851 •3040 2853 3132; 2853- 3105 2863- 3204
2863-3124 2864 3329; 2876-3329; 2879 3306; 2880-3345; 2886 3425; 2885
3147 2886 -3134 2892-3280 2892 •3156 2892 •3143; 2892- 3011 2896- 3128
2899-3184; 2900 3184; 2925 3197; 2939 3125; 2940-3174; 2941 3198; 2940
3212 2941 -3567 2945-3205 2947 •3666 2958 3186; 2963- 3219 2964- 3268 2964 3568; 2974 3185; 2977 3185; 2979 3189; 2979-3170; 2979 3337; 2979 3264 2981 3237 2986-3264 2988 3207 2990 3262; 2993- 3267 3017-•3274 3020 3288; 3026 3262; 3026-3289; 3029 3302; 3027-3565; 3032 3594; 3033 3567 3038 3521 3039-3299 3079 •3249 3044 •3447; 3045- 3559 3050- 3555 3055 3319; 3065 3360; 3074 3479; 3075 3534; 3074-3258; 3075 3551; 3075 3337 3077 3341 3081-3567 3102 •3249 3104 3387; 3115- 3584 3116- 3353 3128 3543; 3128 3555; 3134-3561; 3137-3499; 3143-3372; 3145 3598; 3145 3410 3156 3612 3159-3601 3159 3446 3161 3339; 3163- 3423 3167- 3555 3167 3410; 3167 3605; 3169-3348; 3171-3604; 3175-3607; 3182 3605; 3183 3453 3183 3405 3185-3599 3194 3606 3193 3595; 3194- 3483 3194- 3443
3195-3605; 3197 3605; 3198-3605; 3199 3605; 3200-3604; 3206 3608; 3209
3606 3210 3616 3218-3608 3221 •3609 3223 3605; 3224-3446 3226- 3610 3227 3371; 3232 3601; 3239 3601; 3238-3589; 3238-3595; 3240 3589; 3242 3452 3245 3604 3245-3598 3248 •3573 3250 3605; 3253- 3475 3254- 3500 3272 3587; 3270 3602; 3283 3603; 3283 3599; 3286- 3605; 3286 3598; 3289 3603 3292 -3598 3298-3600 3305 •3598 3307- 3546; 3309- 3602 3309- 3534
3315-3568; 3336 3603; 3356 3607; 3370 3582; 3379-3605; 3381 3584; 3385
3598 3387 -3580 3398-3595 3414 •3548 3414- 3605; 3415- 3605 3418- 3556 3425 3605; 3424 3551; 3434 3605; 3441-3605; 3442-3561; 3449 3605; 3449 3570 3460 -3605 3481-3598 3484 3604 3485- 3605; 3496- 3605 3496- 3602
3503-3601; 3520 3609 377/LG:027 320.7 2001JU 22 I I 1-303; 1-571; 120-503; 234-668 246-668; 261- 773; 427-6 59; 5 9-1006; 886 -1178; 907-1459; 906-1326; 952-1301; 973-1267; 985-1406; 990-1 84; 1063-1350; 1138-1411 378/LG:077 967.9 2001JU 22 I I 1-2592; 9-2594; 59-640; 90-479; 93-226; 148- 2055; 220- 543; 20-483; 369 -604; 659-902; 1054-1292; 1094-1312; 1095-1599; 1219-1470; 1273 1353; 1273- 1714; 1273-1690; 1273-1501; 1324-1588; 1365- 1520; 1375 -1902 1396-1566; 1418-1729; 1418-1691; 1434-1652; 1463 -1711 ; Table 5
1538-1985; 1 538-1782; 1567 1901; 1608-1887; 1610- 1879; 1613 -1886; 1649 1892; 1660-1908; 1670-1940 1659 2220; 1805-2092 1860- 2050 ; 1875- 2032 1931-2222; 1921-2332; 1961 2217; 1961-2399; 1968 2518; 1980-2292; 1988 2447; 1988-2204; 2008-2181 2013-2239; 2026-2256 2032- 2557 ; 2031- 2114 2047-2549; 2046-2284; 2071 2554; 2099-2592; 2102 2534; 2102-2473; 2102 2284; 2107-2615; 2119-2201 2128-2598; 2130-2592 2134- 2598 ; 2134- 2367 2144-2592; 2148-2592; 2157 2445; 2161-2598; 2161 2592; 2167-2642; 2165 2440; 2169-2642; 2169-2592 2170-2637; 2170-2442 2172- 2587 ; 2180- 2654 2181-2284; 2188-2614; 2196 2641; 2193-2642; 2193 2592; 2194-2592; 2195 2651; 2200-2591; 2204-2654 2210 2654; 2217-2642 2222- 2646 ; 2225- 2654 2225-2598; 2243-2654; 2258 2653; 2288-2650; 2301 2654; 2308-2655; 2308- 2592; 2308-2598; 2319-2658 2328-2653; 2336-2588 2337- 2592 ; 2343- 2650 2357-2600; 2374-2650; 2376 2592; 2411-2592; 2421 2659; 2435-2592; 2437- 2509; 2445-2995; 2452-2655 2469-2592; 2482-2592 2481- 2612 ; 2491- 2654 2492-2642; 2513-2633; 2554 2654; 2572-2962; 2671 3108; 2668-3223; 2673- 3271; 2671-2940; 2671-2899 2671-2865; 2727-2934 2727- 3223 ; 2778- 3005 2866-3226; 2895-3223; 2956 3226; 2957-3235; 2980- 3504; 2990-3289; 2994- 3224; 3050-3226; 3063-3226 3167-3226 379/LG:128475.9:2001JUN22 I 1-4 57; 248-873 ; 255- 849; 273-821; 515-676; 564-784; 670-927; 670-1177 985-1336; 1123-1703; 1129-1599; 1213-1345; 1268-1483; 1325-1941; 1412 1680; 1487-1761; 1522- 2011; 1588-1845; 1641- 1872; 1643-1921; 1663-2224 1663-1904; 1730-2263; 1896-2429; 1966-2471; 1980-2207; 2013-2485; 2047 2490; 2077-2490; 2083- 2491; 2131-2347; 2149- 2490; 2151-2407; 2192-2411 2233 -2469; 2278-2509; 2433-2567; 2493-2874; 2529-2711; 2613-3196 380/LG:1398104.15:2001JU 2 2 I 2267-2 385; 2 207-2 339; 1928-2334; 2112-2333; 2187-2333; 2034-2333; 1700 2332; 1900-2332; 2013-2332; 2015-2328; 2223- 2329; 2062-2328; 2073-2328 2094-2328 ; 2207-2328 ; 2214-2328; 2216-2328; 2245-2328; 2268-2328; 2272 2328; 1889-2326; 2071-2326; 2083-2326; 2028- 2317; 2087-2314; 2212-2314 1686-2310 ; 2103-2310 ; 2110-2309; 1865-2308; 2102-2309; 2088-2305; 2210 2290; 2026-2290; 2118-2287; 2062-2285; 2118- 2279; 2087-2276; 1735-2250 1901-2228 ; 1603-2225 ; 1691-2195; 1583-2197; 1501-2117; 1946-2091; 1879 2012; 1417-1983; 1561-1979; 1812-1903; 1320- 1862; 1719-1815; 1370-1743 1129-1565 ; 1259-1492 ; 1147-1436; 928-1401; 848- 1402; 1066-1374; 1160-1320 1113-1294 384-936; 394-832; 376-816; 424-805; 385-738; 423 -738; 384-731; 385-729; 412-641 ; 18-498; 1-440; 2-419; 35-383; 129-383; 83-383; 242-383; 5-339; 25 208; 16-80 381/LG:1454018.10:2001JUN2 I I 1-497; 1-255 ; 16- 360; 22-2969; 91-634; 391- 892; 429-770 ; 431-610; 437 1051; 457-1008 574-1129; 614-1120; 693-924; 740-1062; 743-988; 776-102 ; 779-1027 ; 770-1268; 838-1399; 854-1126; 866- 1146; 866-1098; 870-1112; 97-1040; 898-1085; 909-1079; 954-1540; 999-1355; 998-1606; 998-1426; 1077-1 74; 1122-1659; 1134-1391; 1134-1238; 1148-1386; 1148-1380; 1148-1371; 1153 1868; 1218 1520; 1259-1467; 1282-1425; 1290- 1503; 1294-1866; 1300-1855 1328-1656 1349-1866 ; 1393-1516; 1393-1903; 1461-1799; 1467-1849; 1530 2039; 1536 1727; 1542-1617; 1616-2012; 1674- 2252; 1686-1848; 1900-2419 1905-2336 2022-2574 ; 2069-2203; 2070-2406; 2132-2437; 2150-2270; 2208 2336; 2242-2943; 2267-2609; 2301-2356; 2323- 2585; 2363-2579; 2380-2645 2417-2660 ; 2452-2677 ; 2480-2561; 2506-2944; 2525-2712; 2532-2726; 2626 2968; 2661-2931; 2738-2962; 2756-2968; 2763- 2965; 2768-2968; 2778-2969 2816-2962 ; 2820-3071 ; 2820-2962; 2821-2969; 2823-2968; 2823-2965; 2824 2968; 2825-2968; 2826-2965; 2826-2961; 2826- 2959; 2827-2968; 2829-2968 2838-2968 ; 2839-2962 ; 2842-2959; 2843-2968; 2845-3117; 2848-2959; 2876 2962; 2899-2961; 2907-2961; 2916-3391; 2916- 3213; 2916-3198; 2916-3192 2947-3176 ; 2962-3227 ; 2974-3509; 2999-3141; 3026-3290; 3028-3294; 3097 3383; 3156-3866; 3101-3453; 3065-3654; 3127- 3425; 3164-3435; 3204-3708 3210-3290 ; 3210-3459 ; 3199-3472; 3200-3467; 3249-3821; 3259-3830; 3267 3380; 3272-3860; 3271-3609; 3273-3505; 3281- 3663; 3294-3870; 3295-3885 3304-3560 ; 3307-3600 ; 3305-3572; 3305-3501; 3308-3562; 3326-3619; 3333 3669; 3320-3811; 3371-3714; 3386-3923; 3386- 3795; 3397-3669; 3396-3646 3407-3954 ; 3420-3676 ; 3445-3708; 3451-3707; Table 5
3451-3682 ; 3454- 3807; 3457 -3717; 3496-3741; 3718; 3562 -4001; 3504 3753 ; 3509-3762; 3515- 3771 ; 3519 -3790; 3550- 3621-•4055 ; 3574-3855 3580-3803 ; 3585-3698; 3619-3845; 3608-3832; 3919; 3638 -4020; 3613 4016 ; 3614-4010; 3625- 3999 ; 3631 -3900; 3690- 3632- 4016 ; 3637-3890 3641-3905 ; 3701-3936; 3646-4174; 3646-3883; 4016; 3653 -3703; 3718- 3959 ; 3666-3958; 3667- 3957 ; 3676 -3891; 3747- 3718- 4022 ; 3718-3910 3698-3891 ; 3699-4001; 3718-4150; 3708-3886; 3965; 3735 -3989; 3753 4030 ; 3788-4033; 3744- 3905 ; 3790 -4017; 3841- 3810- 4005 ; 3802-4031 3813 -4042 ; 3817-4028; 3823-4033; 3825-4028; 4041; 3827 -4017; 3874 4035 ; 3837-3972; 3839- 4032 ; 3853 -4029; 3853- 3855- 4050 ; 3884-4029 3891-4411 ; 3901-4149; 3904-4033; 3923-4328; 4153; 3940 -4192; 3942 4042 ; 3944-4166; 3953- 4199 ; 3959 -4357; 4025- 4059- 4367 ; 4060-4373 4060-4199 ; 4065-4413; 4066-4390; 4066-4327; 4266; 4066 -4241; 4066 4193 ; 4066-4184; 4066- 4126 ; 4070 -4417; 4103- 4099- 4405 ; 4133-4371 4117-4208 ; 4116-4383; 4120-4410; 4125-4405; 4404; 4143 -4401; 4168 4480 ; 4177-4522; 4187- 4413 ; 4195 -4411; 4204- 4205- 4411 ; 4223-4411 4225-4405 ; 4228-4371; 4232-4372; 4247-4409; 4405; 4306 -4528; 4307 4405 ; 4336-4411 382 /LG : 221548.14 :2001JUN22 II i- 565; 1-590; 45- 505; 49-281 ; 73-291; 72 -292 ; 92-246; 132-679; 3 50-961 ; 493 -636; 5; 521-105 8; 785 -1258; 785-1050 ; 785-1011; 826-1484; 833-106 3; 946 1035 1328 ; 1062 -1328; 1126-1402 ; 1126-1403; 1150-1382; 1213 1673; 1673; 1232 -1675; 1245-
1531 1248-1710 1248-1702 ; 1253-1635 1256 1263-1810 ; 1275-1710; 1276 1422; 1348-1581; 1363-1968; 1388 -1595; 1666; 1438 -1654; 1469- 1642 1477-1843 1496-1738 ; 1511-1776 1512 1532-1795 ; 1535-1848;
1566-1800 ; 1578 2167; 1578-1823; 1579 1883; 2210; 1612 -1893; 1618-
1829 1646-1768 1657-1829 ; 1658-1888 1695 1699-1943 ; 1700-1955; 1709 1974; 1716 1815; 1724-2345; 1765 2222; 1996; 1793 -2175; 1794- 2048 1861-2101 1871-2159 ; 1869-2102 1929 1946-2236 ; 1948-2233; 1960 2183; 1961-2253; 1972-2225; 1972 2414; 2590; 2013 -2229; 2018- 2266 2030-2297 2068-2343 ; 2082-2393 2091 2119-2385 ; 2125-2398; 2138 2383; 2139-2750; 2145-2399; 2157 2790; 2431; 2191 -2395; 2200- 2284 2207-2676 2221-2723 ; 2219 2404 2278 2283-2396 ; 2284-2762; 2287 2369; 2285 2530; 2292-2527; 2308 2762; 2662; 2418 -2664; 2428- 2696 2431-2636 2458-2730 ; 2461 2741 2485 2485-2929 ; 2521-2794;
2523-2805; 2534 2782; 2572-2663; 2582 2900; 2906; 2615 -3133; 2684-
3241 2686-2947 2712-3002 ; 2760 3037 2792 2798-3074 ; 2814-3083; 2814 3085; 2843 3091; 2884-3176; 2912 3299; 3205; 2925 -3075; 2939- 3178 2939-3237 2985-3430 ; 3077-3279 3089 3123-3597 ; 3126-3278; 3155 3269; 3182 3600; 3321-3764; 3340 3597; 3590; 3363 -3520; 3374- 3596 3394-3571 3487-4115 ; 3487-4023 3502 3568-3996 ; 3571-3845; 3625 4013; 3877 4023; 4003-4428; 4010 4543; 4123; 4010 -4566; 4027- 4780 4080-4411 4139-4343 ; 4213-5767 4226 4240-4481 ; 4240-4482;
4578-4705; 4593 4875; 4620-9061; 4646 -5114; 5288; 4957 -5256; 5144-
5412 5144-5388 5236-5399 ; 5253-5529 5318 5341-5583 ; 5464-5763; 5479 5762; 5541 5767; 5578-5763; 5580 -6291; 5884; 5638 -5823; 5681- 6265 5683-6263 5689-5920 ; 5863-6138 5978 5978-6229 ; 5990-6228; 6041 6258; 6050 6289; 6085-6359; 6114 6561; 6578; 6217 -6395; 6258- 6501 6277-6568 6284-6396 ; 6294-6785 6350 6350-6598 ; 6350-6612, 6410 6872; 6505 7055; 6507-6761; 6560 -6780; 6905; 6582 -6831; 6614- 7118 6686-6940 6686-7051 ; 6686-6914 6694 6695-6954 ; 6731-6985; 6745 7004; 6755 7068; 6796-7101; 6818 7028; 7117; 6898 -7180; 6898- 6977 6923-7453 6933-7394 ; 6943-7192 6948 6967-7493 ; 6968-7207; 6970 7203; 6973 7220; 6993-7183; 7024 -7491; 7540; 7044 -7500; 7044- 7494 7046-7494 7047-7254 ; 7055-7398 7068 7074-7400 ; 7087-7394; 7110 7507; 7165 7491; 7173-7250; 7176 -7377; 7496; 7203 -7494; 7207- 7322 7234-7438 7252-7545 ; 7270-7549 7285 7298-7658 ; 7299-7498; 7324 7788; 7324 7572; 7339-7593; 7347 7487; 7449; 7361 -7496; 7422- 7688 7438-7649 7491-7758 ; 7498-7677 7531 7551-8126 ; 7552-7655;
7581-7884; 7617 7851; 7625-8061; 7634 -7864; 7910; 7644 -7888; 7684- Table 5
8068; 7683-7938; 7684-8196 7685 -8294 7693- 7970; 7707-7968; 7741 -7861; 7761-8142; 7773-8003; 7780 8157; 7780 7939; 7785-8024; 7790-8022; 7790- 8024; 7790-8032; 7801-8015 7809 -7986 7841- 8289; 7856-8100; 7856 -8249; 7882-8156; 7890-8230; 7893 8155; 7912-8090; 7916-8201; 7917-8218; 7945- 8389; 7945-8212; 7963-8210 7971 -8245 7971-8154; 7980-8231; 7985 -8248; 7994-8252; 8008-8239; 8027 8195; 8049 8224; 8049-8255; 8054-8310; 8073- 8277; 8079-8624; 8084-8666 8088-8403 8089-8260; 8095-8383; 8101 -8442; 8112-8258; 8116-8365; 8116 8419; 8133 8455; 8151-8723; 8150-8453; 8244- 8798; 8244-8767; 8252-8647 8262-8456 8262-8460; 8264-8544; 8271 -8515; 8271-8473; 8271-8588; 8271 8743; 8273 8539; 8281-8472; 8320-8544; 8332- 8568; 8339-8616; 8356-8617 8360-8656 8365-8973; 8381-8691; 8383 -8625; 8394-8986; 8395-8705; 8402 8614; 8402 8752; 8414-9013; 8415-8664; 8420- 8601; 8435-9020; 8435-9021 8439-9010 8471-8858; 8471-8742; 8480 -9065; 8487-8980; 8491-8752; 8497 8668; 8515 8784; 8532-8907; 8550-8624; 8554- 8730; 8567-9012; 8576-9061 8580-8820 8585 9053; 8600-9065; 8599 -8850; 8602-9061; 8603-9057; 8604-9064; 8608 9057; 8610- 9061; 8616-9061; 8619- 9057; 8620-9057; 8622-8838 8627-9065 8642 9061; 8647-9061; 8647 -8863; 8650-9061; 8661-9085; 8660-9062; 8661-9061; 8661-8862; 8662 9024; 8666- 9013; 8669-9015; 8671-9024 8673 -9063 8683- 9059; 8683-8948; 8710 -8940; 8718-9060; 8728-8961; 8733 9037; 8735 9057; 8742-9061; 8746-9002; 8747- 9057; 8758-9061; 8779-8986 8779 -8908 8781- 9028; 8805-9061; 8827 -9061; 8827-9033; 8851-9037; 8862-9017; 8870 -9075; 8904- 9061; 8983-9229 383/LG:227500.5:2001JUN22 | I l-i98; 36-297; 82-317; 89-719; 103-6 84; 87- 644; 91-371; 103-511; 106-7 64; 139-661; 239-482 259-802; 272-801 ; 270-802; 297-802; 313-647; 313-454; 313-451; 316-801; 450-817; 450-681; 52 1-871; 615-1142; 620-1217; 635-1217; 692-1234; 757-906; 809-1307; 809-13 35; 809- 1414; 809-1398; 809-1363; 809-1128; 876-1204 ; 911-1508; 924-1255; 924-1194; 924-1035; 944-1262; 991-1464; 989-1199; 1176-1385 ; 1193-1690 ; 132 0-1549; 1323-1943; 1484-2071; 1575-2099; 1635-1806; 1695- 2016; 1698-2222; 1698- 1945; 1726-1852; 1733-1847 1751-2357 ; 1757-2189; 1758-2020; 1775 -2112; 1818-2410; 1828-2000; 1851 2319; 1853-2424; 1855- 2412; 1982-2236; 2177- 2237; 2311-2582; 2332-2588 2335-2588 ; 2340-2665; 2359-2588 2375 -2934; 2375-2551; 2389-2677; 2389 2588; 2407-2588; 2463-2704; 2463-2588; 2490- 2746; 2497-2780; 2516-2760 2623-3125 ; 2623-3073; 2623-3018 2647 -3013; 2648-3056; 2662-3041; 2683 3279; 2733-2819; 2804-3329; 2817-3308; 2877- 3344; 2877-3272; 2877-3087 2887-3344 ; 2890-3504; 2891-3344; 2893 -3344; 2894-3015; 2906-3345; 2916 3344; 2917-3344; 2924-3344; 2945-3344; 2947- 3135; 2951-3344; 2958-3344 2993 -3480 ; 2998-3162; 3008-3231; 3049 -3367; 3069-3351; 3078-3291; 3105-3320; 3106-3344; 3109- 3307; 3110-3725; 3477-3663 384/LG: 228273.22 :2001JUN22 II i-4325; 1433-1687; 1433-1672; 1544- 1991; 1826-2271; 1919-2483; 2010- 2390; 2010-2249; 2023-2088; 2229 2693; 2229- 2707; 2286-2702; 2404-2849 2445-2903 ; 2445-2702; 2488-2859; 2575 -2632; 2603-2883; 2670-2922; 2731 3343; 2883-3638; 2995-3473; 3009-3086; 3127- 3238; 3131-3536; 3131-3375 3141-3351 ; 3147-3394; 3221-3527; 3221 -3518; 3275-3515; 3303-3850; 3316 3520; 3383-3845; 3384-3661; 3420- 3665; 3428- 4003; 3433-4004; 3432-3675 3433 -3725 ; 3526-3791; 3538-3813; 3615 -3869; 3646-4248; 3664-4363; 3675 4242; 3689-4396; 3691-4384; 3700- 4241; 3730- 4141; 3730-4060; 3730-3994 3730-4289 ; 3740-4325; 3740-4002; 3737 -4135; 3758-3950; 3772-4289; 3773-4282; 3788-4280; 3791- 4276; 3814- 4113; 3815- 4161; 3816-4080; 3829-4324 3829-4127 ; 3858-4289; 3858-4121; 3865 -4320; 3865-4078; 3875-4321; 3875-4325; 3879-4258; 3887-4180; 3907-4321; 3914- 4154; 3935-4186; 3945-4507 3950 4319 ; 3986-4321; 3991-4319; 3993 -4321; 3997-4323; 4018-4277; 4036-4317; 4096-4324; 4105-4309; 4116- 4319; 4125- 4321; 4138-4324; 4179-4321 4298 4619 ; 4371-4615; 4371-4619; 4402 -4619; 4517-4619
385/LG:235432.1:2001JUN22 | I 1-199; 1-286; 1-256; 46-608; 52-1913; 54-505; 62-2340; 114-651; 200-440; 312-813; 312-581; 350-665; 363-607; 371-824; 371-641; 451-603; 473-619; 588-826; 589-1135; 673-1300; 702-1246; 703-1246; 707-1064; 721-1135; 738-1268; 774-1329; 775-1064; 840-1353; 897-1310; 897- 1215; 933-1180; 983-1472; 1016-1374; 1016-1282; 1042-1422; 1036-1615; 1072- Table 5
1634; 1088-1318; 1180-1470 1344-1662; 1374-1728; 1449-1844; 1449-1657;
1493-2050; 1469-1700; 1481 -1818; 1498-1743; 1498-1676; 1509-1912; 1531-
1818; 1533-1587; 1545-1815 1684-1818; 1733-1818; 1938-2340; 1954-2340;
2184-2340
386/LG: 236904.20 :2001JU 22 II i- 4680; 1-484; 74-643; 75-631 ; 384- 932; 438-
704; 482-975; 524-1116; 55 -1067 ; 575-925; 575-831; 657-844 ; 672-1263; 751-
1012 797-1046; 799-1047; 44-1097; 889-1167; 891-1114; 903 -1165; 903-1140; 1279 1754; 1331-1754; 1353 1730; 1360-1754; 1387-1754; 1453 -1754; 1467- 1712 1500-2228; 1569-1754 1578-1641 1575-1754 1653-1754 ; 1653-1730; 2057 2244; 2057-2236; 2318 2910; 2369 2859; 2445 2895; 2457-2724; 2603- 2764 2648-2858; 2656-3226 2654-2932 2690-3188 2690-2962 ; 2703-2772; 2707 2946; 2707-2935; 2741 3019; 2748 -3143; 2766-2968; 2767-3015; 2804- 3357 2804-3066; 2804-3046 2816-2995 2839-3460 2852-3018 ; 2881-3059;
2903-3162; 2907-3053; 2915-3163; 2916 -3579; 2928 3171; 2928-3014; 2930-
3182 2932-3214; 2932-3136, 2952-3496 2972-3188 2978-3238 ; 3008-3151;
3045-3322; 3049-3542; 3050- 3292; 3086 3535; 3113 3575; 3168-3536; 3173-
3543 3174-3536; 3203-3436, 3203-3439 3204-3428 3206-3543 ; 3206-3518;
3208-3661; 3217-3465; 3219- 3777; 3237 3536; 3275-3545; 3275-3533; 3298-
3538 3298-3534; 3321-3478, 3342 -3540 3345-3541 3358-3540 ; 3355-3996;
3381-3763; 3381-3602; 3404- 3564; 3399 3647; 3404 3728; 3418-3633; 3462-
3717 3496-3833; 3574-3855, 3595-3815 3628-3877 3685-4159 ; 3712-3964;
3712-3850; 3714-3810; 3719- 3871; 3813 -4137; 3813 4022; 3833-4017; 3853-
4132 3872-4128; 3916-4156 3980-4201 4006-4267 4023-4610 ; 4056-4643;
4076-4550; 4086-4653; 4118- 4636; 4106 4366; 4118-4672; 4132-4500; 4132-
4382 4152-4673; 4183-4680 4188-4268 4189-4636 4189-4450 ; 4190-4458; 4193 4503; 4202-4612; 4205- 4675; 4207 -4673; 4208-4458; 4212-4668; 4215- 4488 4219-4684; 4222-4450 4225-4461 4225-4487 4230-4677 ; 4236-4675; 4243 4679; 4252-4497; 4253 4713; 4270 4675; 4272 4480; 4275-4673; 4279- 4686 '4282-4673; 4284-4680 4285-4673 4285-4678 4287-4683 ; 4292-4686;
4293-4515; 4302-4680; 4307- 4517; 4314 -4676; 4328 4631; 4328-4580; 4330- 4627; 4344-4488; 4345-4633, 4346-4680 4354-4666 4364-4633 ; 4372 -4663; 4384-4648; 4385-4676; 4401- 4676; 4404 -4673; 4413 4638; 4435-4673; 4449- 4712; 4458-4675; 4462-4680; 4468-4675 4478-4614 4566-4677 ; 4590-4676; 4589-4663; 4605-4675; 4609- 4673; 4625 -4687 387 /LG: 253193.21 :2001JUN22 II i-539; 388-512; 388-538; 403- 552; 410-651; 419-552; 423-858; 423-547; 423-564; 4 31-848; 435-547; 435-564; 617-1058; 617-809; 626-1227; 635-851, 660-1101; 660-902; 683-1367; 788-1329; 790- 1271; 884-1050; 1005-1517; 1073-1197; 1073-1315; 1146-1370; 1146-1352; 1213-1518; 1215-1464; 1257- 1348; 1317 -1559; 1350-1454; 1352-1463; 1372- 1911; 1436-1869; 1436-1677; 1483-1677 1586-1806; 1586-2022 ; 1601-1850; 1608-1849; 1611-1893; 1612- 1875; 1634 -2209; 1634-1914; 1636-2323; 1669- 1920; 1686-2119; 1703-2240, 1708-1973 1745-2209; 1746-1998 ; 1764-2095; 1771-2010; 1771-2151; 1779- 1952; 1793 -2336; 1797-2019; 1800-2269; 1815- 2016; 1832-2048; 1836-2414, 1836-2069 1853-2045; 1865-2107 ; 1963-2270; ' 1963-2183; 1970-2150; 1985- 2510; 1985 2489; 1985-2186; 2040-2572; 2101- 2150; 2108-2667; 2113-2597, 2127-2395 2130-2672; 2129-2378 ; 2137-2395; 2144-2237; 2162-2879; 2154- 2274; 2231 2667; 2238-2422; 2239-2499; 2238- 2761; 2244-2632; 2245-2297; 2249 2739 2251-2678; 2253-2721 ; 2256-2730; 2266-2730; 2271-2668; 2272- 2707; 2274 2739; 2276-2665; 2280-2527; 2296- 2740; 2300-2651; 2314-2739, 2309 2658 2328-2446; 2335-2671 ; 2354-2608; 2354-2739; 2354-2636; 2354- 2617; 2362 2686; 2366-2667; 2367-2739; 2368- 2707; 2374-2707; 2391-2577, 2399 2704 2413-2707; 2424-2654 ; 2458-2715; 2455-2619; 2467-2575; 2568- 2659; 2600 -2739; 2648-2714 388/LG : 332161.3: 2001JUN22 I 1-748; 7 2-526; 200-749; 413-80 9; 440-712; 604- 754; 605-731; 604-1255; 601 -847; 694- 893; 793-1332; 842-1305; 852-1305; 1089-1528; 1400-1625; 1447- 1717; 1486 -1587; 1511-1773; 1637-2078; 1688- 2095; 1699-1934; 1700-1935; 1715-1990 ; 1792-2059; 1924-2177 ; 1943-2067; 1974-2364; 2011-2236; 2011- 2212; 2033 -2270; 2103-2173; 2106-2449; 2145- 2371; 2187-2588; 2208-2528; 2300-2588 ; 2325-2635; 2349-2586 ; 2358-2592; 2365-2686; 2400-2848; 2400- 2607; 2402 -2654; 2439-2600; 2439-2556; 2439- Table 5 2488; 2441-2701; 2441-2652; 2444-2928; 2451-2998; 2464-2744; 2503-2959; 2503-2798; 2503-2751; 2507-2769; 2545-2607; 2577-2846; 2589-3135; 2590- 2652; 2589-2830; 2602-3072; 2666-2984; 2671-3272; 2664-3160; 2664-3184; 2672-2897; 2672-3042; 2698-3202; 2704-2922; 2715-3231; 2725-2992; 2756- 3022; 2756-3020; 2769-3017; 2784-2923; 2786-3077; 2815-3317; 2829-3270; 2824-2916; 2829-3005; 2829-3059; 2845-3301; 2845-3238; 2845-3082; 2849- 3329; 2857-3360; 2863-3145; 2864-3105; 2899-3175; 2898-3366; 2905-3360; 2908-3360; 2909-3362; 2914-3357; 2929-3360; 2972-3098; 2981-3253; 2982- 3107; 2991-3268; 3010-3357; 3014-3360; 3034-3359; 3040-3360; 3050-3360; 3078-3320; 3078-3241; 3079-3353; 3085-3360; 3091-3360; 3119-3357; 3124- 3319; 3138-3309; 3197-3357; 3244-3357; 3247-3353; 3251-3330
389/LG:332923.5:2001JUN22 || 1-578; 15-594; 15-566; 24-597; 25-124; 46-730; 58-463; 60-498; 73-786; 73-654; 87-720; 87-589; 211-783; 571-6124; 685- 1288; 686-1350; 686-1212; 700-1362; 860-1258; 1152-1465; 1184-1736; 1198- 1704; 1198-1419; 1249-1736; 1253-1412; 1257-1770; 1257-1892; 1374-2087; 1427-1692; 1484-1742; 1516-1915; 1516-1782; 1871-2488; 1985-2471; 1985- 2213; 2011-2253; 2019-2437; 2092-2432; 2091-2382; 2092-2434; 2092-2281; 2112-2473; 2646-2892; 3259-3699; 3436-4048; 3445-3978; 3554-4174; 3607- 4147; 3766-4315; 3771-3870; 3970-4247; 4038-4454; 4080-4597; 4079-4321; 4225-4490; 4290-4555; 4438-4859; 4443-4682; 4508-4662; 4525-4662; 4708- 4921; 4709-4853; 4719-5263; 4719-4985; 4738-5309; 4739-5087; 4756-5347; 4775-5227; 4780-5015; 4790-4976; 4894-5251; 4936-5247; 4941-5189; 4973- 5361; 5012-5479; 4996-5522; 4996-5272; 4996-5255; 5048-5336; 5073-5316; 5105-5331; 5207-5788; 5219-5524; 5224-5774; 5250-5505; 5268-5666; 5302- 5552; 5311-5575; 5327-5558; 5478-5819; 5501-5994; 5501-5779; 5506-5555; 5552-5810; 5572-6083; 5591-6096; 5612-5846; 5656-5899; 5658-5851; 5767- 6122; 5768-6021; 5862-6001; 5860-6120
390/LG:343500.27:2001JUN22 || 1-523; 1-576; 5-231; 11-218; 12-249; 14-274; 14-278; 16-300; 20-260; 262-717; 264-724; 347-590; 354-735; 354-772; 405- 964; 441-666
391/LG:369703.9:2001JUN22 || 1-678; 5-719; 426-975; 469-753; 690-802; 690- 867; 705-947; 705-1054; 710-1310; 715-1324; 717-966; 719-1178; 719-920; 738-950; 749-1434; 796-1351; 796-1274; 796-1064; 796-1350; 807-1065; 810- 1430; 830-1220; 833-1494; 958-1111; 962-1434; 978-1489; 978-1510; 978-1550; 1017-1522; 1009-1273; 1015-1291; 1087-1302; 1111-1619; 1130-1374; 1133- . 1286; 1253-1847; 1355-1927; 1357-1947; 1407-1616; 1415-1874; 1522-1956; 1650-1856; 1662-1957; 1675-2340; 1738-1960; 1795-1957; 1813-1955; 1897- 1947; 2187-2512; 2202-2512; 2287-2512; 2287-2498; 2287-2492; 2287-2479; 2287-2466; 2287-2437; 2287-2410; 2287-2398; 2287-2387; 2287-2385; 2287- 2346; 2295-2512; 2408-2909; 2411-2690; 2720-3016; 2762-3159; 2783-3036; 2783-3310; 2812-3165; 2814-3045; 2923-3429; 2947-3429; 2984-3450; 3078- 3293; 3185-3439; 3185-3420; 3185-3450; 3200-3471; 3277-3471; 3320-3453; 3335-3457
392/LG:415378.3:2001JUN22 || 1-440; 1-191; 9-586; 17-405; 32-298; 41-478; 38-363; 49-467; 66-266; 156-714; 234-379; 314-872; 315-898; 555-791; 560- 1031; 564-900; 564-819; 583-4582; 626-1122; 678-900; 700-1272; 704-1172; 736-1015; 757-948; 837-1098; 884-1116; 962-1238; 1163-1357; 1197-3998; 1244-1501; 1243-1501; 1293-1455; 1302-1944; 1311-1544; 1341-1625; 1387- 1654; 1404-1929; 1459-1608; 1538-1721; 1587-2142; 1606-1913; 1639-2217; 1670-1947; 1672-2273; 1700-2283; 1720-2253; 1759-2315; 1759-2418; 1762- 1973; 1830-2315; 1846-2240; 1873-2393; 1873-2053; 1884-2453; 1894-2475; 1931-2420; 1945-2467; 1977-2275; 1977-2247; 2010-2598; 2049-2307; 2043- 2573; 2066-2408; 2086-2646; 2088-2461; 2118-2614; 2117-2384; 2154-2561; 2165-2536; 2170-2440; 2186-2424; 2192-2401; 2218-2791; 2235-2509; 2321- 2939; 2326-2590; 2338-2773; 2348-2529; 2349-2595; 2350-2945; 2355-2949; 2356-2860; 2356-2829; 2380-2619; 2416-2775; 2426-2638; 2473-2815; 2480- 2807; 2510-2754; 2512-2895; 2554-2776; 2585-3058; 2604-3072; 2596-2779; 2606-2954; 2645-3089; 2645-2877; 2676-3089; 2681-3089; 2686-3089; 2691- 2967; 2719-3063; 2742-3162; 2763-3089; 2796-3123; 2799-3087; 2801-2959; 2811-3092; 2823-3089; 2831-3406; 2833-3089; 2853-3332; 2856-3089; 2848- Table 5
3089; 2837 3219; 2856-3355; 2857 -3091; 2871- 3089; 2861- 3064 2883- 3089; 2887-3089; 2888-3292; 2901-3379; 2925-3199; 2947-3089; 2949 3123; 2956- 3484; 2956 3461; 2956-3197; 3023 -3268; 3092- 3401; 3112- 3483 3097- 3624; 3119-3509; 3112-3336; 3112-3313; 3112-3279; 3125-3337; 3127 3473; 3141- 3382; 3142 3287; 3142-3378; 3164 -3534; 3179-■3442; 3179- 3376 3181- 3400; 3200-3444; 3255-3870; 3255-3529; 3261-3836; 3261-3496; 3263 3507; 3286- 3439; 3331 3849; 3343-3611; 3320 -3943; 3363- 3938; 3363- 3616 3371- 3657; 3371-3648; 3421-3716; 3425-4036; 3428-3598; 3437-3648; 3448 4028; 3449- 3870; 3466 3716; 3469-4186; 3471 -4063; 3476- 3871; 3475- 3733 3476- 3724; 3477-3760; 3483-3812; 3489-3671; 3506-3683; 3509-3680; 3509 3767; 3509- 3624; 3511 3684; 3520-3948; 3525 -3674; 3543- 3831; 3545- 3866 3552- 3778; 3559-3984; 3561-3837; 3566-3998; 3565-3693; 3573-4034; 3571 3836; 3587- 3998; 3590-3877; 3591-3998; 3592 -3774; 3604- 3857; 3604- 3892 3627- 4252; 3640-3998; 3670-3915; 3660-3881; 3696-3996; 3695-4132; 3696 3896; 3699- 4053; 3700-3905; 3708-4130; 3711 -3917; 3719- 4225; 3719- 3797 3722- 3877; 3756-4032; 3786-4173; 3800-4110; 3806-4080; 3806-4009; 3806 3994; 3819- 4065; 3819 4166; 3821-4070; 3830 -4091; 3834- 3883; 3836- 4079 3845- 3998; 3845-3983; 3845-3955; 3847-3974; 3851-4118; 3851-4031; 3861 4103; 3861- 4314; 3875 4144; 3876-4080; 3876 -4129; 3877-•4160; 3865- 4001 3875- 4350; 3928-4133; 3929-4278; 3921-4227; 3925-4197; 3928-4579; 3964 4575; 3968- 4261; 3970-4250; 3967-4543; 3966 -4211; 3996- 4544; 3993- 4257 4010- 4574; 4013-4468; 4005-4505; 4005-4277; 4009-4618; 4031-4194; 4033 4535; 4031- 4513; 4038 4236; 4039-4575; 4051 -4264; 4072- 4517; 4075- 4479 4080- 4210; 4083-4368; 4071-4264; 4077-4564; 4078-4538; 4108-4575; 4104 4575; 4122- 4572; 4125 4584; 4112-4575 4130 -4584; 4132- 4581; 4123- 4582 4124- 4536; 4130-4575; 4132-4576; 4133-4580; 4135-4574; 4151-4416; 4140 4574; 4154- 4408; 4141 4537; 4144-4256; 4158 -4575; 4161- 4575; 4154- 4580 4167- 4575; 4156-4572; 4173-4575; 4164-4582; 4181-4582; 4182-4435; 4187 4463; 4187- 4573; 4180 4575; 4195-4310; 4199 -4576; 4199- 4582; 4188- 4575 4201- 4572; 4202-4576; 4190-4574; 4191-4649; 4191-4395; 4206-4519; 4209 4583; 4199- 4660; 4199-4575; 4201-4660; 4200 -4574; 4214- 4672; 4202- 4580 4203- 4568; 4219-4382; 4207-4581; 4222-4432; 4209-4567; 4209-4579; 4222 4381; 4223- 4518; 4223 4501; 4211-4532 4225--4505; 4227- 4647; 4230- 4575 4229- 4653; 4230-4675; 4243-4514; 4245-4575; 4248-4360; 4238-4645; 4255 4572; 4268- 4582; 4273 4575; 4275-4582; 4276 -4545; 4277- 4525; 4284- 4582 4284- 4580; 4284-4575; 4284-4569; 4284-4488; 4291-4648; 4293-4582; 4281 4576; 4284- 4655; 4284 4649; 4283-4460; 4298 -4481; 4291- 4779; 4293- 4555 4307- 4478; 4317-4587; 4321-4576; 4340-4582; 4330-4870; 4345-4576; 4356 4644; 4342- 4832; 4364 4539; 4379-4583; 4380 -4556; 4372- 4652; 4384- 4587 4373- 4653; 4384-4490; 4384-4478; 4384-4649; 4385-4653; 4382-4563; 4414 4576; 4415- 4873; 4420 4874; 4424-4870; 4436--4538; 4437- 4870; 4447- 4708 4465- 4575; 4461-4864; 4471-4582; 4462-4653; 4465-4878; 4466-4871; 4466 4870; 4484- 4575; 4487 4871; 4493-4878; 4522--4902; 4524- 4861; 4536- 4694 4554- 4878; 4559-4865; 4571-4871; 4571-4863; 4590-4871; 4605-4871; 4626 4878; 4628- 4871; 4628 4834; 4630-4871; 4637 -4878; 4672- 4875; '4687- 4871 4765- 4871; 4852-5311; 5156-5557; 5186-5409; 5201-5380; 5201-5367; 5270 5326; 5270- 5399; 5274-5399; 5476-5557 393/LG:458583.1: 2001JUN22 | 1-303; 125-335; 125-680; 383-715; 627-972 394/LG:7690373.1 :2001JUN22 I 1-252; 28-191; 28-112; 33-561; 197-659; 345- 497; 354-48 395/LG:8983 24.13:2001JUN22 || 403-830; 405-830; 415-828; 596-828; 467-827; 316-797; 258-678; 364-665; 284-611; 1-626; 62-376 396/LG:9791 67.5:2001JUN22 || 1-505; 165-239; 237-908; 311-878; 369-952; 687-1191; 725-941; 895-1386; 911-1175; 918-1516; 929-1570; 934-1384; 991- 1214; 1012-1230; 1022-1286; 1067-1690; 1073-1441; 1073-1318; 1097-1416; 1097-1323; 1179-1649; 1313-1538; 1356-1788; 1345-1546; 1361-1914; 1394- 1578; 1394-1681; 1427-2144; 1427-2128; 1482-1874; 1488-1597; 1491-1864; 1492-1754; 1491-1897; 1491-1639; 1502-1765; 1524-1697; 1524-1753; 1526- 1597; 1531-2110; 1560-1795; 1560-2092; 1580-2126; 1619-1961; 1588-1698; 1593-1657; 1628-1789; 1596-1666; 1610-2008; 1648-1863; 1648-1908; 1684- Table 5 2086; 1688-1980; 1690-2083; 1705-1960; 1735-2084; 1762-2034; 1762-1996; 1762-2250; 1788-2089; 1798-2080; 1791-2512; 1792-2047; 1831-2212; 1855- 2069; 1839-2074; 1903-2211; 1925-2213; 1925-2134; 1951-2082; 1957-2139; 1993-2194; 2010-2259; 2059-2208; 2069-2212; 2083-2411; 2148-2204; 2409- 2461; 2409-2910; 2426-2515; 2425-2478; 2425-2489; 2756-2995; 2771-3004; 2771-2972; 2771-3286; 2771-3259; 2775-3193; 2782-3260; 2796-3183; 2795- 3040; 2812-2967; 2814-3156; 2816-2991; 2816-2940; 2816-2974; 2817-2965; 2817-3051; 2873-3091; 2894-3129; 2899-3482; 2902-3413; 2902-3076; 2910- 3481; 2927-3201; 2940-3188; 2943-3457; 2965-3426; 2970-3427; 2992-3547; 2995-3172; 2995-3444; 2995-3173; 3025-3630; 3069-3512; 3094-3541; 3101- 3549; 3109-3356; 3109-3570; 3112-3587; 3115-3591; 3119-3553; 3120-3589; 3121-3587; 3127-3586; 3148-3590; 3145-3582; 3151-3590; 3157-3586; 3161- 3574; 3162-3582; 3173-3587; 3195-3448; 3205-3586; 3216-3586; 3223-3374; 3237-3541; 3240-3586; 3245-3589; 3252-3547; 3268-3582; 3271-3586; 3299- 3593; 3364-3588; 3373-3535; 3391-3581; 3410-3556; 3419-3582; 3430-3574; 3447-3589; 3480-3574; 3480-3586; 3483-3543; 3499-3586
TABLE 6
SEQ ID NO: Template ID Tissue Distribution
1 LG:036272.1 :2001 MAR30 Germ Cells - 20%, Urinary Tract - 17%
2 LG:093337.3:2001 MAR30 Cardiovascular System - 47%, Endocrine System - 27%, Hemic and Immune System - 20%
3 LG: 1049927.6:2001 AR30 Female Genitalia - 30%, Connective Tissue - 30%, Respiratory System - 22%
4 LG: 1051891.34:2001 MAR30 Nervous System - 35%, Endocrine System - 24%, Digestive System - 12%, Male Genitalia - 12%, Female Genitalia - 12%
5 LG:1089626.1 :2001 MAR30 Skin - 14%, Male Genitalia - 13%, Respiratory System - 12%
6 LG: 1 101416.6:2001 MAR30 Skin - 1 1 %
7 LG: 1295974.1 :2001 MAR30 Pancreas - 62%, Digestive System - 14%, Female Genitalia - 12%
8 LG: 1400572.2:2001 MAR30 Female Genitalia - 100%
9 LG:1446621.1 :2001 AR30 Endocrine System - 65%, Urinary Tract - 15%, Female Genitalia - 10%, Nervous System - 10%
10 LG:1499752.1 :2001 AR30 Liver - 33%, Cardiovascular System - 26%, Digestive System - 15%, Male Genitalia - 15%
1 1 LG: 1503044.7:2001 MAR30 Nervous System - 43%, Male Genitalia - 29%, Digestive System - 29%
12 LG:1503588.1 :2001 MAR30 Endocrine System - 100%
13 LG: 1503589.2:2001 MAR30 Exocrine Glands - 42%, Nervous System - 21%, Hemic and Immune System - 16%
14 LG: 1506339.4:2001 MAR30 Connective Tissue - 54%, Hemic and Immune System - 46%
15 LG:220648.6:2001 MAR30 Nervous System - 33%, Exocrine Glands - 27%, Cardiovascular System - 27%
16 LG:236654.1 :2001 MAR30 Unclassified/Mixed - 33%, Respiratory System - 17%, Digestive System - 10%
17 LG:237699.26:2001 MAR30 Connective Tissue - 21%, Female Genitalia - 13%, Cardiovascular System - 13%
18 LG:31 1541.16:2001 MAR30 Germ Cells - 30%, Urinary Tract - 17%, Liver - 12%
19 LG:335923J:2001 MAR30 Germ Cells - 71%, Unclassified/Mixed - 25%
20 LG:350342.14:2001 MAR30 Sense Organs - 37%, Nervous System - 14%,
Stomatognathic System - 13%
21 LG:369301.32:2001 MAR30 Connective Tissue - 16%, Unclassified/Mixed -
13%
22 LG:452089.1 :2001 MAR30 Nervous System - 100%
23 LG:454087.3:2001 MAR30 Hemic and Immune System - 24%, Connective
Tissue - 24%, Cardiovascular System - 14%,
Endocrine System - 14%
24 LG:466302.1 :2001 MAR30 Liver - 75%, Respiratory System - 17%
25 LG:474267.1 :2001 MAR30 Endocrine System - 15%, Urinary Tract - 14%,
Germ Cells - 13%
26 LG:995613.10:2001 MAR30 Liver - 26%, Urinary Tract - 20%, Respiratory
System - 14%
27 LG:01 1843.5:2001 MAR30 Embryonic Structures - 32%, Endocrine System -
32%, Nervous System - 14%
28 LG:075904.32:2001 MAR30 Urinary Tract - 29%, Respiratory System - 14%,
Nervous System - 13% TABLE 6
SEQ ID NO: Template ID Tissue Distribution
29 LG: 1004781.3:2001 MAR30 Urinary Tract - 38%, Nervous System - 38%, Respiratory System - 25%
30 LG: 1041807.8:2001 MAR30 Nervous System - 18%, Liver - 17%, Sense Organs - 14%
31 LG: 1044448.2:2001 MAR30 Unclassified/Mixed - 17%, Urinary Tract - 1 1%, Germ Cells - 10%
32 LG: 1080598.9 2001 MAR30 Embryonic Structures - 22%, Liver - 1 1% 33 LG: 1081017.1 2001 MAR30 Respiratory System - 15%, Pancreas - 13% 34 LG: 1083120.2: 2001 MAR30 Endocrine System - 67%, Female Genitalia - 33% 35 LG: 1097492.12:2001 MAR30 Liver - 12% 36 LG: 1 18834.9:2001 MAR30 Embryonic Structures - 26%, Germ Cells - 21%, Endocrine System - 12%, Unclassified/Mixed - 12%
37 LG: 1227408.25:2001 MAR30 Nervous System - 41 %, Pancreas - 15%, Respiratory System - 1 1%, Connective Tissue - 1 1%, Male Genitalia - 1 1%
38 LG: 1326953.1 :2001 MAR30 Male Genitalia - 47%, Exocrine Glands - 27%, Urinary Tract - 20%
39 LG: 1397821.17:2001 MAR30 Female Genitalia - 1 1% 40 LG: 1512507.1 :2001 MAR30 Liver - 100% 41 LG: 196583.5:2001 MAR30 Connective Tissue - 46%, Cardiovascular System - 12%
42 LG:198669.1 :2001 MAR30 Sense Organs - 12%, Nervous System - 1 1%, Pancreas - 1 1%
43 LG:202943.1 :2001 MAR30 Embryonic Structures - 57%, Musculoskeletal System - 1 1%
44 LG:204724.3:2001 MAR30 Urinary Tract - 100% 45 LG:206425.10:2001 MAR30 Sense Organs - 30%, Pancreas - 14%, Skin - 1 1%
46 LG:208190.2:2001 MAR30 Germ Cells - 31%, Exocrine Glands - 17%, Urinary
Tract - 14%
47 LG:222927.2:2001 MAR30 Uver - 14%, Musculoskeletal System - 1 1%
48 LG:228046.5:2001 MAR30 Stomatognathic System - 21%
49 LG:230980.1 :2001 MAR30 Liver - 38%, Digestive System - 33%,
Unclassified/Mixed - 15%
50 LG:236976.2:2001 MAR30 Germ Cells - 77%, Unclassified/Mixed - 13%
51 LG:238322.6:2001 MAR30 Musculoskeletal System - 25%, Sense Organs -
14%
52 LG:341461.1 :2001 MAR30 Germ Cells - 39%, Male Genitalia - 26%,
Exocrine Glands - 14%
53 LG:354088.1 :2001 MAR30 Respiratory System - 23%, Liver - 21%, Digestive
System - 19%
54 LG:376275.1 :2001 MAR30 Exocrine Glands - 67%, Hemic and Immune
System - 17%, Nervous System - 17%
55 LG:399281.3:2001 MAR30 Endocrine System - 27%, Female Genitalia -
19%, Hemic and Immune System - 13%,
Digestive System - 13%
56 LG:404921.10:2001 MAR30 Endocrine System - 1 1 %
57 LG:444677.34:2001 MAR30 Nervous System - 35%, Male Genitalia - 28%,
Cardiovascular System - 18%
58 LG:968691.1 :2001 MAR30 Hemic and Immune System - 100% TABLE 6
SEQ ID NO: Template ID Tissue Distribution
59 LG:983862.1 :2001 MAR30 Unclassified/Mixed - 15%, Liver - 15%, Nervous System - 12%
60 LG:984130.1 :2001 MAR30 Embryonic Structures - 30%, Unclassified/Mixed - 10%, Male Genitalia - 10%
61 LG:986291.1 :2001 MAR30 Hemic and Immune System - 100%
62 LGO45210.8:2001 MAR30 Germ Cells - 41%, Skin - 31%, Unclassified/Mixed 10%
63 LG:229284.39:2001 MAR30 Embryonic Structures - 1 1%, Connective Tissue - 10%, Nervous System - 10%
64 LG:337810.20:2001 MAR30 Skin - 38%, Germ Cells - 18%
65 LG:463420.1 :2001 MAR30 Nervous System - 19%, Skin - 1 1%
66 LG: 1080918.1 :2001 MAR30 Connective Tissue - 38%, Respiratory System - 14%, Exocrine Glands - 1 1%, Endocrine System - 1 1%
67 LG: 1093747.15:2001 MAR30 Germ Cells - 22%, Embryonic Structures - 14%, Urinary Tract - 1 1%
68 LG: 1096896.47:2001 MAR30 Embryonic Structures - 40%, Urinary Tract - 15%, Unclassified/Mixed - 15%
69 LG: 1098931.39:2001 MAR30 Exocrine Glands - 14%, Germ Cells - 14%, Cardiovascular System - 1 1 %
70 LG: 1 100823.1 :2001 MAR30 Liver - 53%, Female Genitalia - 41%
71 LG: 1 166387.1 :2001 MAR30 Connective Tissue - 1 1%, Unclassified/Mixed - 1 1%
72 LG 1383036.49:2001 MAR30 widely distributed
73 LG 1452353.14:2001 MAR30 Sense Organs - 25%, Unclassified/Mixed - 1 1%
74 LG 1452435.15:2001 MAR30 Liver - 43%, Musculoskeletal System - 13%
75 LG 1498774.1 :2001 MAR30 Musculoskeletal System - 75%, Nervous System - 25%
76 LG: 197180.1 :2001 MAR30 Pancreas - 1 1%, Female Genitalia - 10%
77 LG: 199489.1 :2001 MAR30 Musculoskeletal System - 26%, Unclassified/Mixed - 17%, Germ Cells - 1 1%
78 LG:201908.3:2001 MAR30 Germ Cells - 41%, Unclassified/Mixed - 18%
79 LG:247245.26:2001 MAR30 Germ Cells - 28%, Exocrine Glands - 22%
80 LG:256365.2:2001 MAR30 Male Genitalia - 31%, Urinary Tract - 12%, Cardiovascular System - 12%, Respiratory System - 12%
81 LG:332923.4:2001 MAR30 Nervous System - 23%, Sense Organs - 22%, Germ Cells - 12%
82 LG:335276.1 :2001 MAR30 Nervous System - 30%, Exocrine Glands - 16%, Urinary Tract - 14%, Connective Tissue - 14%
83 LG:350272.2:2001 MAR30 Musculoskeletal System - 18%
84 LG:350921.2:2001 MAR30 Liver - 18%, Embryonic Structures - 18%, Digestive System - 16%
85 LG:406568.1 :2001 MAR30 Stomatognathic System - 49%, Musculoskeletal System - 23%, Cardiovascular System - 21 %
86 LG:41 1043.3:2001 MAR30 Pancreas - 18%, Urinary Tract - 14%, Nervous System - 1 1%, Cardiovascular System - 1 1%
87 LG:414376.20:2001 MAR30 Nervous System - 42%, Pancreas - 15%, Exocrine Glands - 13%
88 LG:457695.1 :2001 MAR30 Nervous System - 100%
89 LG:902390.2:2001 MAR30 Nervous System - 100% TABLE 6
SEQ ID NO: Template ID Tissue Distribution
90 LG:903565.20:2001 MAR30 Urinary Tract - 18%, Hemic and Immune System - 15%, Liver - 12%, Nervous System - 12%
91 LG:978182.4:2001 MAR30 Unclassified/Mixed - 17%, Germ Cells - 12%, Skin 12%
92 LG:986827.1 :2001 MAR30 Male Genitalia - 87%, Digestive System - 13%
93 LG:013792.1 :2001 MAR30 Germ Cells - 86%
94 LG:018258.1 :2001 MAR30 Digestive System - 33%, Endocrine System - 33%, Urinary Tract - 25%
95 LG:023126.3:2001 MAR30 Hemic and Immune System - 92%
96 LG:023618.1 :2001 MAR30 Nervous System - 41%, Connective Tissue - 10%
97 LG:030999.1 :2001 MAR30 Sense Organs - 36%, Embryonic Structures - 18%
98 LG: 103508.1 :2001 MAR30 Embryonic Structures - 46%, Unclassified/Mixed -
21%
99 LG: 107976.15:2001 MAR30 Nervous System - 13%, Sense Organs - 12%
100 LG:1080096.1 :2001 MAR30 Sense Organs - 29%, Stomatognathic System -
26%
101 LG: 1080275.1 :2001 MAR30 Musculoskeletal System - 32%, Cardiovascular
System - 29%, Endocrine System - 1 1%
102 LG: 1090358.10:2001 MAR30 Liver - 13%, Embryonic Structures - 13%,
Pancreas - 13%, Male Genitalia - 13%
103 LG: 1095833.9:2001 MAR30 Unclassified/Mixed - 19%, Embryonic Structures -
15%, Skin - 13%
104 LG 1383121.25:2001 MAR30 Nervous System - 15%, Liver - 13%
105 LG 1386609.2:2001 MAR30 Liver - 1 1%, Skin - 10%
106 LG 1398465.1 :2001 MAR30 Sense Organs - 19%, Embryonic Structures - 10%,
Cardiovascular System - 10%
107 LG 1453417.10:2001 MAR30 Nervous System - 26%, Skin - 18%
108 LG 147869.3:2001 MAR30 Endocrine System - 69%, Nervous System - 31%
109 LG 148485.5:2001 MAR30 Exocrine Glands - 48%, Urinary Tract - 28%,
Female Genitalia - 16%
110 LG 1501818.12:2001 MAR30 Sense Organs - 15%
111 LG 1508275.1 :2001 MAR30 Liver - 100%
112 LG 1509771.1 :2001 MAR30 Respiratory System - 100%
113 LG 1512998.13:2001 MAR30 Sense Organs - 20%
114 LG 198251.7:2001 MAR30 Nervous System - 13%, Embryonic Structures -
1 1%, Sense Organs - 10%
1 15 LG:198296.1 :2001 MAR30 Unclassified/Mixed - 1 1%, Cardiovascular
System - 1 1%
1 16 LG: 198876.13:2001 MAR30 Sense Organs - 1 1 %
1 17 LG:200704.1 :2001 MAR30 Liver - 36%, Female Genitalia - 28%, Endocrine
System - 16%, Nervous System - 16%
1 18 LG:206593.3:2001 MAR30 Exocrine Glands - 28%, Unclassified/Mixed -
24%, Endocrine System - 14%, Nervous System -
14%
1 19 LG:223970.1 1 :2001 MAR30 Skin - 1 1%
120 LG:227500.5:2001 MAR30 Connective Tissue - 17%, Embryonic Structures -
17%, Cardiovascular System - 1 1 %
121 LG:227722.7:2001 MAR30 Pancreas - 39%, Urinary Tract - 30%, Male
Genitalia - 17%
122 LG:229105.1 :2001 MAR30 Nervous System - 36%, Digestive System - 23% TABLE 6
SEQ ID NO: Template ID Tissue Distribution
123 LG:233761.4:2001 MAR30 widely distributed
124 LG:234326.67:2001 MAR30 Nervous System - 12%, Sense Organs - 10%
125 LG:236056.27:2001 MAR30 Skin - 23%
126 LG:253889.31 :2001 MAR30 Germ Cells - 12%, Female Genitalia - 10%
127 LG:270833.135:2001 MAR30 Skin - 22%, Sense Organs - 16%, Pancreas - 1 1 %
128 LG.-292613.7:2001 MAR30 Unclassified/Mixed - 19% 129 LG:331546.2:2001 MAR30 Stomatognathic System - 1 1 % 130 LG:332027.6:2001 MAR30 Digestive System - 13%, Nervous System - 12%,
Male Genitalia - 10%
131 LG:336998.1 :2001 MAR30 Hemic and Immune System - 12%,
Unclassified/Mixed - 1 1 %
132 LG:338010.8:2001 MAR30 Exocrine Glands - 33%, Cardiovascular System -
14%, Connective Tissue - 14%
133 LG:344597.1 :2001 MAR30 Nervous System - 35%, Germ Cells - 33%,
Respiratory System - 1 1%
134 LG:347361.2:2001 MAR30 Germ Cells - 10% 135 LG:349293.17:2001 MAR30 Germ Cells - 14%, Hemic and Immune System -
13%, Unclassified/Mixed - 13%
136 LG:410595.19:2001 MAR30 Sense Organs - 23%, Germ Cells - 12% 137 LG:41 1 151.35:2001 MAR30 Musculoskeletal System - 32%, Cardiovascular
System - 29%, Stomatognathic System - 1 1%
138 LG:41 1334.8:2001 MAR30 Unclassified/Mixed - 15%, Connective Tissue -
14%, Male Genitalia - 12%
139 LG:458583.1 :2001 MAR30 Nervous System - 100% 140 LG:475378.1 :2001 MAR30 Respiratory System - 13% 141 LG:481572.1 :2001 MAR30 Skin - 14% 142 LG:481704.1 :2001 MAR30 Pancreas - 26%, Hemic and Immune System -
21%, Cardiovascular System - 21%
143 LG:898195.4 2001 MAR30 Embryonic Structures - 15% 144 LG:903785.1 2001 MAR30 Germ Cells - 24%, Unclassified/Mixed - 15% 145 LG:977454.3: 2001 MAR30 Embryonic Structures - 17%, Cardiovascular
System - 13%
146 LG:977724.12:2001 MAR30 Connective Tissue - 15% 147 LG:978215.19:2001 MAR30 Sense Organs - 25%, Nervous System - 14%,
Unclassified/Mixed - 13%
148 LG:981795.1 :2001 MAR30 Female Genitalia - 38%, Urinary Tract - 32%,
Unclassified/Mixed - 20%
149 LG:982784.1 :2001 MAR30 Germ Cells - 53%
150 LG:987322.4:2001 MAR30 Unclassified/Mixed - 1 1%, Embryonic Structures -
1 1%
151 LG:006242J:2001 MAR30 widely distributed
152 LG:027320J:2001 MAR30 Unclassified/Mixed - 35%, Embryonic Structures -
24%, Cardiovascular System - 1 1%, Exocrine
Glands - 1 1%
153 LG: 147541.44:2001 MAR30 widely distributed
154 LG:228319.2:2001 MAR30 Musculoskeletal System - 43%, Hemic and
Immune System - 29%, Respiratory System - 14%,
Digestive System - 14%
155 LG:238754.19:2001 MAR30 widely distributed
156 LG:405751.12:2001 MAR30 Exocrine Glands - 13% TABLE 6
SEQ ID NO: Template ID Tissue Distribution
157 U:01 1822.6:2001 MAYl 7 Nervous System - 38%, Cardiovascular System - 25%, Female Genitalia - 16%
159 U: l 169981.13:2001 MAY17 Hemic and Immune System - 20%, Embryonic Structures - 18%, Pancreas - 18%
160 U:1 171553.1 :2001 MAY17 Sense Organs - 19%
161 LI: 1 183156.3:2001 MAYl 7 Musculoskeletal System - 26%, Respiratory System - 1 %, Hemic and Immune System - 19%
162 LI: 1 188500.6:2001 MAYl 7 Liver - 61%, Unclassified/Mixed - 16%, Female
Genitalia - 16%
163 LI: 147333.12:2001 MAY17 Connective Tissue - 39%, Liver - 25%, Exocrine
Glands - 14%
164 U:147523J:2001 MAY17 Connective Tissue - 58%, Cardiovascular System
- 33%
165 LI: 197388.10:2001 MAYl 7 Endocrine System - 17%, Skin - 14%, Connective
Tissue - 13%
166 U:2049216.1 :2001 MAY17 Connective Tissue - 64%, Hemic and Immune
System - 27%
167 Ll:2051624.2:2001 MAYl 7 Liver - 35%, Endocrine System - 35%,
Unclassified/Mixed - 19%
168 LI:2121838.1 :2001 MAY17 Germ Cells - 56%, Musculoskeletal System - 18%,
Exocrine Glands - 13%
169 U:2122954.8:2001 MAYl 7 Nervous System - 100%
170 Ll:2198064.2:2001 MAYl 7 Female Genitalia - 50%, Hemic and Immune
System - 50%
171 U:2206583.1 :2001 MAY17 Nervous System - 100%
172 U:235663.6:2001 MAY17 Digestive System - 62%, Respiratory System -
23%, Female Genitalia - 15%
173 LI:236386J:2001 MAY17 Stomatognathic System - 23%, Skin - 13%
174 LI:236654.3:2001 MAY17 Respiratory System - 23%, Exocrine Glands - 1 1%,
Unclassified/Mixed - 1 1%, Male Genitalia - 1 1%
175 LI:256059.46:2001 MAY17 Stomatognathic System - 19%
176 U:279978.22:2001 AY17 Liver - 48%, Urinary Tract - 44%
177 U:31 1541.6:2001 MAYl 7 Germ Cells - 35%, Urinary Tract - 31%
178 Ll:346123.1 :2001 MAYl 7 Exocrine Glands - 71%, Nervous System - 29%
179 Ll:38121 1.5:2001 MAYl 7 Skin - 17%, Sense Organs - 1 1%
180 U:412197.82:2001 MAY17 Exocrine Glands - 14%
181 Ll:412936.49:2001 MAYl 7 Sense Organs - 16%, Germ Cells - 1 1%, Pancreas
- 1 1%
182 Ll:427792.139:2001 MAYl 7 Sense Organs - 13%
183 U:450229.1 :2001 MAY17 Nervous System - 100%
185 LIJ64701.8:2001 MAYl 7 Hemic and Immune System - 25%, Male
Genitalia - 25%, Digestive System - 13%
186 Ll:024124.2:2001 MAYl 7 Germ Cells - 62%, Nervous System - 18%, Urinary
Tract - 14%
187 U:038252.3:2001 MAY17 Embryonic Structures - 13%, Germ Cells - 12%
188 LI:056882.1 :2001 AY17 Exocrine Glands - 63%, Female Genitalia - 25%,
Nervous System - 13%
189 Ll:059530.1 :2001 MAYl 7 Stomatognathic System - 65%, Urinary Tract -
1 1% TABLE 6
SEQ ID NO: Template ID Tissue Distribution
190 U:089950.30:2001 MAY17 Skin - 31%, Male Genitalia - 15%, Pancreas - 10%
191 LI: 1072906.38:2001 MAYl 7 Embryonic Structures - 18%
192 LI: 1 158936.4:2001 MAYl 7 Musculoskeletal System - 39%, Endocrine System
- 28%, Exocrine Glands - 28%
193 LI: 1 173412.15:2001 MAYl 7 Germ Cells - 31%, Pancreas - 13%
194 LI: 1 174279.14: 2001 MAY 17 Embryonic Structures - 22%, Liver - 20%, Male
Genitalia - 1 1%
195 LI: 1 174809.1 :2001 MAYl 7 Hemic and Immune System - 86%, Nervous
System - 14%
196 LI: 1 175131.1 :2001 MAYl 7 Germ Cells - 23%, Urinary Tract - 21%, Female
Genitalia - 12%, Male Genitalia - 12%
197 LI: 1 188801.10:2001 MAYl 7 Digestive System - 53%, Urinary Tract - 21%,
Connective Tissue - 13%
198 LI: 1 189176.27:2001 MAYl 7 Skin - 59%, Cardiovascular System - 15%
199 U:197739.4:2001 MAY17 Cardiovascular System - 25%, Hemic and
Immune System - 17%, Endocrine System - 17%
200 LI:2049016.1 :2001 MAY17 Unclassified/Mixed - 42%, Embryonic Structures -
42%
201 Ll:2049137.1 :2001 MAYl 7 Germ Cells - 67%, Unclassified/Mixed - 10%
202 Ll:2051907.1 :2001 MAYl 7 Digestive System - 38%, Unclassified/Mixed -
31%, Nervous System - 1 %
203 Ll:21 17996.13:2001 MAYl 7 Digestive System - 100%
204 LI :21 18683.15:2001 MAY 17 Unclassified/Mixed - 45%, Germ Cells - 22%,
Digestive System - 1 1 %
205 Ll:2120312.1 :2001 MAYl 7 Embryonic Structures - 43%, Hemic and Immune
System - 22%, Respiratory System - 13%
207 Ll:2121802.5:2001 MAYl 7 Digestive System - 100%
209 U:216129.45:2001 MAYl 7 Endocrine System - 14%, Skin - 12%
210 U:2186630.1 :2001 MAYl 7 Endocrine System - 100%
21 1 LI:2188206.2:2001 MAY17 Unclassified/Mixed - 26%, Connective Tissue -
18%, Male Genitalia - 18%
212 LI:2199710.9:2001 MAY17 Sense Organs - 78%
213 U:2209335.2:2001 MAY17 Nervous System - 86%, Male Genitalia - 14%
214 Ll:230980.13:2001 MAYl 7 Digestive System - 68%, Unclassified/Mixed - 23%
215 Ll:244421.37:2001 MAYl 7 Nervous System - 15%, Musculoskeletal System -
13%, Female Genitalia - 13%, Male Genitalia -
13%
216 Ll:341998.1 :2001 MAYl 7 Unclassified/Mixed - 33%, Hemic and Immune
System - 33%, Female Genitalia - 13%, Male
Genitalia - 13%
217 Ll:347931.10:2001 MAYl 7 Endocrine System - 14%, Digestive System - 1 1%,
Respiratory System - 10%
218 Ll:350771.42:2001 MAYl 7 Pancreas - 22%, Male Genitalia - 16%, Digestive
System - 1 1%, Embryonic Structures - 1 1%
219 U:354423.6:2001 MAY17 Stomatognathic System - 40%, Exocrine Glands -
15%
220 LI:399333.8:2001 MAY17 Pancreas - 16%, Germ Cells - 1 1 %
221 LI:445084.36:2001 MAY17 Germ Cells - 29%, Cardiovascular System - 23%, u'ver - 12% TABLE 6
SEQ ID NO: Template ID Tissue Distribution
222 U:454087.3:2001 MAY17 Hemic and Immune System - 41%, Connective Tissue - 32%
223 Ll:474887.1 :2001 MAYl 7 Unclassified/Mixed - 20%, Sense Organs - 20%, Endocrine System - 12%
224 UJ45251.1 :2001 MAYl 7 Hemic and Immune System - 62%, Unclassified/Mixed - 38%
225 LIJ47717.9:2001 MAYl 7 Respiratory System - 60%, Digestive System - 40%
226 U:80621 1.3:2001 MAYl 7 Nervous System - 44%, Respiratory System - 33%,
Male Genitalia - 22%
227 Ll:815072.1 :2001 MAYl 7 Male Genitalia - 41%, Exocrine Glands - 29%,
Urinary Tract - 24%
228 U:817052.8:2001 MAYl 7 Liver - 14%, Skin - 12%, Sense Organs - 1 1%,
Nervous System - 1 1 %
229 U:903392.45:2001 MAY17 Germ Cells - 33%, Nervous System - 10%
230 U:013724.1 :2001 MAYl 7 Embryonic Structures - 42%, Sense Organs - 26%,
Skin - 14%
231 LI: 191726.16:2001 MAYl 7 Urinary Tract - 19%, Skin - 19%, Musculoskeletal
System - 16%
232 U:202270.2:2001 MAY17 Liver - 42%, Nervous System - 16%,
Unclassified/Mixed - 12%
233 U:21 19352.6:2001 MAYl 7 Unclassified/Mixed - 17%, Female Genitalia -
15%, Embryonic Structures - 1 1%
234 U:2207776.1 1 :2001 MAYl 7 Digestive System - 20%, Connective Tissue - 14%,
Male Genitalia - 12%
235 Ll:256442.1 :2001 MAYl 7 Respiratory System - 32%, Female Genitalia -
20%, Digestive System - 16%, Cardiovascular
System - 16%
237 U:018494.1 :2001 MAYl 7 Urinary Tract - 34%, Endocrine System - 33%,
Respiratory System - 19%
238 Ll:023518.2:2001 MAYl 7 Urinary Tract - 55%, Musculoskeletal System -
32%, Respiratory System - 14%
239 U:053488.46:2001 MAY17 Urinary Tract - 17%, Musculoskeletal System -
1 1 %, Cardiovascular System - 10%
240 LI:058298.27:2001 MAY17 Exocrine Glands - 100%
241 U:l 110046.1:2001 MAYl7 Liver - 26%, Digestive System - 23%,
Unclassified/Mixed - 19%
242 LI:1166752.11:2001 MAYl 7 Embryonic Structures - 20%, Urinary Tract - 12%
243 LI:1173766.1:2001 MAYl7 Stomatognathic System - 24%, Sense Organs -
21%
244 LI:1177952.4:2001 MAYl7 Germ Cells - 15%, Skin - 1 1%, Female Genitalia -
10%
245 LI:1178064.3:2001 MAYl 7 Germ Cells - 40%, Unclassified/Mixed - 16%,
Urinary Tract - 1 1%
246 LI:1183121.1:2001 MAYl7 Sense Organs - 33%, Pancreas - 23%
247 LI:1190431.13:2001 MAYl 7 Hemic and Immune System - 40%, Pancreas -
12%, Liver - 1 1%
248 LI:199121.14:2001MAYl7 Connective Tissue - 14%, Cardiovascular System
- 1 1%
249 U:202630.5:2001 MAY17 Liver - 36%, Pancreas - 19% TABLE 6
SEQ ID NO: Template ID Tissue Distribution
250 U:2034488.1 :2001 MAYl 7 Digestive System - 29%, Female Genitalia - 25%, Connective Tissue - 25%
251 LI:2051434.8:2001 MAY17 Connective Tissue - 63%, Unclassified/Mixed - 14%
252 Ll:21 18475.9:2001 MAYl 7 Unclassified/Mixed - 28%, Hemic and Immune System - 21%, Connective Tissue - 19%
253 Ll:218849.24:2001 MAYl 7 Respiratory System - 1 1%, Musculoskeletal System - 1 1%
254 LI:2199824.5:2001 MAY17 Male Genitalia - 24%, Cardiovascular System - 19%, Urinary Tract - 19%
255 Ll:233018.32:2001 MAYl 7 Embryonic Structures - 16%
256 LI:236295.8:2001 MAY17 Urinary Tract - 53%, Unclassified/Mixed - 33%, Hemic and Immune System - 13%
257 U:286989.14:2001 MAY17 Embryonic Structures - 14%, Sense Organs - 10%
258 LI:345320.4:2001 MAY17 Hemic and Immune System - 30%, Liver - 18%,
Germ Cells - 12%
259 Ll:355693.18:2001 MAYl 7 Nervous System - 15%, Respiratory System - 1 1%
260 Ll:359876.1 :2001 MAYl 7 Exocrine Glands - 100%
261 LI:406664.32:2001 MAY17 Cardiovascular System - 28%, Embryonic
Structures - 1 1%, Liver - 1 1%
262 Ll:410324.1 :2001 MAYl 7 Sense Organs - 41%, Endocrine System - 12%
263 LI:414376.12:2001 MAY17 Nervous System - 38%, Pancreas - 14%, Exocrine
Glands - 12%
264 Ll:452089.1 :2001 MAYl 7 Nervous System - 100%
265 LI:481614.43:2001 MAY17 Nervous System - 12%
266 U:809605.2:2001 MAY17 Sense Organs - 37%, Pancreas - 12%
267 Ll:816437.25:2001 MAYl 7 Nervous System - 96%
268 Ll:817827.5:2001 MAYl 7 Musculoskeletal System - 78%, Nervous System -
22%
269 Ll:002345.15:2001 MAYl 7 Stomatognathic System - 14%
270 LI:022629.5:2001 MAY17 Germ Cells - 50%, Unclassified/Mixed - 24%
271 LI:061031.4:2001 MAY17 Connective Tissue - 30%, Pancreas - 22%,
Nervous System - 22%
272 LI: 108232.2:2001 MAYl 7 Liver - 50%, Hemic and Immune System - 16%,
Endocrine System - 13%
273 LI:1085493.16:2001 MAY17 Skin - 18%, Pancreas - 12%, Embryonic Structures
- 1 1%
274 LI: 1085513.2:2001 MAY17 Musculoskeletal System - 17%,
Unclassified/Mixed - 15%, Nervous System - 12%,
Cardiovascular System - 12%
275 LI: 1086797.9:2001 MAYl 7 Embryonic Structures - 20%, Stomatognathic
System - 13%, Liver - 12%
276 LI: 1088446.1 :2001 MAYl 7 Embryonic Structures - 25%, Endocrine System -
23%, Nervous System - 13%
277 LI: 1 133764.3:2001 MAYl 7 Germ Cells - 23%, Unclassified/Mixed - 16%,
Urinary Tract - 13%
278 LI:1 147614.5:2001 MAY17 Musculoskeletal System - 14%, Sense Organs -
13%, Connective Tissue - 13% TABLE 6
SEQ ID NO: Template ID Tissue Distribution
279 LI: 1 181710.1 :2001 MAYl 7 Hemic and Immune System - 33%, Male Genitalia - 33%, Nervous System - 33%
280 U: 1 183192.1 :2001 MAY17 Cardiovascular System - 28%, Musculoskeletal System - 23%, Urinary Tract - 20%
281 LI: 1 188786.15: 2001 MAYl 7 Embryonic Structures - 17%, Urinary Tract - 13%
282 LI: 145626.1 :2001 MAYl 7 Sense Organs - 44%, Respiratory System - 16%, Male Genitalia - 14%
283 LI: 147869.3:2001 MAYl 7 Endocrine System - 69%, Nervous System - 31%
284 LI: 151747.4:2001 MAYl 7 Male Genitalia - 10%
285 LI: 198296.1 :2001 MAYl 7 Cardiovascular System - 1 1%
286 Ll:2001 17.4:2001 MAYl 7 Embryonic Structures - 13%, Unclassified/Mixed - 12%
287 LI: 200704.1 :2001 MAYl 7 Female Genitalia - 37%, Endocrine System - 26%, Nervous System - 21%
288 LI:2049995.3:2001 MAY17 Germ Cells - 29%
289 U:2052097.2:2001 MAY17 Liver - 23%, Skin - 20%, Pancreas - 12%
290 U:209351.22:2001 MAYl 7 Exocrine Glands - 12%, Connective Tissue - 1 1%, Pancreas - 1 1%
291 U:2120481.1 :2001 MAYl 7 Female Genitalia - 21 %, Musculoskeletal System - 21%, Connective Tissue - 21 %
293 Ll:2191585.1 :2001 MAYl 7 Liver - 100%
294 U:2198562.3:2001 MAYl 7 Pancreas - 20%, Hemic and Immune System - 1 1%
295 LI:2209684.5:2001 MAY17 Hemic and Immune System - 27%, Female Genitalia - 23%, Exocrine Glands - 23%
296 U:222795.28:2001 MAY17 widely distributed
297 U:228273.25:2001 MAY17 Nervous System - 16%, Embryonic Structures - 14%, Male Genitalia - 10%
298 LI:232386.31 :2001 MAY17 Unclassified/Mixed - 14%
299 U:233089.2:2001 MAY17 Female Genitalia - 10%, Liver - 10%
300 Ll:240641.10:2001 MAYl 7 Sense Organs - 18%, Germ Cells - 12%
301 Ll:243871.4:2001 MAYl 7 Hemic and Immune System - 20%, Nervous System - 20%, Embryonic Structures - 19%
302 U:245597J:2001 MAY17 Skin - 18%, Hemic and Immune System - 12%
303 LI:256009.31 :2001 MAY17 Urinary Tract - 24%, Hemic and Immune System - 18%, Endocrine System - 15%, Male Genitalia - 15%, Exocrine Glands - 15%
304 U:262221.1 :2001 MAYl 7 Nervous System - 48%, Endocrine System - 15%
305 LI:332957.8:2001 MAY17 Stomatognathic System - 29%, Germ Cells - 18%
306 U:335352.13:2001 MAYl 7 widely distributed
307 LI:343844J:2001 MAY17 Germ Cells - 69%, Connective Tissue - 22%
308 Ll:344528.1 :2001 MAYl 7 Pancreas - 22%, Hemic and Immune System - 17%, Unclassified/Mixed - 16%
309 U:374578.27:2001 MAY17 Embryonic Structures - 20%, Sense Organs - 16%, Connective Tissue - 1 1%
310 Ll:381993.13:2001 MAYl 7 Germ Cells - 16%, Cardiovascular System - 15%, Unclassified/Mixed - 15%
31 1 LI:400373.2:2001 MAY17 Exocrine Glands - 12%, Sense Organs - 12%
312 U:400963.6:2001 MAY17 Embryonic Structures - 32%, Endocrine System - 15%, Female Genitalia - 1 1 %, Digestive System - 1 1% TABLE 6
SEQ ID NO: Template ID Tissue Distribution
313 LI:404874.8:2001 MAY17 Germ Cells - 37%
314 Ll:405158.18:2001 MAYl 7 Germ Cells - 13%, Skin - 10%
315 U:405889.22:2001 AY17 Pancreas - 15%, Skin - 1 1%
316 Ll:41 1 151 .31 :2001 MAYl 7 Cardiovascular System - 41%, Musculoskeletal System - 32%
317 LI:41 1313.51 :2001 MAY17 Nervous System - 16%, Skin - 14%
318 LI:417127.1 :2001 MAY17 Connective Tissue - 88%, Nervous System - 13%
319 Ll:429817.44:2001 MAYl 7 Germ Cells - 23%, Female Genitalia - 16%, Pancreas - 1 1 %
320 LI:474134.23:2001 MAY17 Stomatognathic System - 16%, Liver - 14%
321 LI:475378.3:2001 MAY17 Respiratory System - 1 1%
322 UJ49588.15:2001 MAYl 7 Skin - 18%, Unclassified/Mixed - 15%, Female Genitalia - 13%
323 UJ57736.17:2001 MAYl 7 Stomatognathic System - 1 1%, Musculoskeletal System - 10%
324 Ll:817278.4:2001 MAYl 7 Unclassified/Mixed - 90%
325 LI:027320.5:2001 MAY17 Embryonic Structures - 32%, Unclassified/Mixed - 16%, Exocrine Glands - 16%
326 U:204635.5:2001 MAY17 Respiratory System - 37%, Embryonic Structures - 29%, Male Genitalia - 20%
327 U:215532.38:2001 MAY17 Sense Organs - 20%, Pancreas - 14%
328 LI: 228319.6: 2001 MAY 17 Musculoskeletal System - 54%, Digestive System - 15%, Hemic and Immune System - 15%, Nervous System - 15%
329 LI:236589.24:2001 MAY17 Embryonic Structures - 10%
330 LI:247444.3:2001 MAY17 Unclassified/Mixed - 20%, Female Genitalia - 15%, Liver - 12%, Male Genitalia - 12%
331 LI:332404.20:2001 MAY17 Endocrine System - 36%, Nervous System - 21%, Digestive System - 14%, Hemic and Immune System - 14%, Female Genitalia - 14%
332 LG:1088459.4:200UUN22 Female Genitalia - 100%
333 LG: 1501495.1 :200UUN22 Unclassified/Mixed - 28%, Nervous System - 23%, Digestive System - 13%
334 LG:334284.10:200UUN22 Unclassified/Mixed - 60%
335 LG:345279.19:200UUN22 Sense Organs - 22%, Germ Cells - 21%
336 LG:7689681.1 :200UUN22 Unclassified/Mixed - 35%, Digestive System - 24%, Nervous System - 18%
337 LG:7690093.1 :200UUN22 Stomatognathic System - 80%
338 LG:7690175.3:200UUN22 Cardiovascular System - 23%, Unclassified/Mixed - 20%, Respiratory System -
339 LG:7697128.1 :200UUN22 Exocrine Glands - 67%, Respiratory System - 33%
340 LG:006394.20:200UUN22 Sense Organs - 15%, Digestive System - 14%,
Germ Cells - 10%
341 LG:1012069.1 :200UUN22 Liver - 85%, Male Genitalia - 10%
342 LG: 104533.1 1 :200 UUN22 Pancreas - 35%, Liver - 34%, Digestive System -
13%
343 LG:1045853.23:200UUN22 Endocrine System - 22%, Digestive System - 14%,
Pancreas - 1 1%, Male Genitalia - 1 1% TABLE 6
SEQ ID NO: Template ID Tissue Distribution
344 LLGG: 1081017.8:2001JUN22 Male Genitalia - 38%, Nervous System - 25%, Hemic and Immune System - 19%, Urinary Tract - 19%
345 L LGG: 1090358.6:2001 JUN22 Unclassified/Mixed - 86%, Nervous System - 14%
346 LLGG:1 135312.7:2001JUN22 Unclassified/Mixed - 33%, Male Genitalia - 28%, Pancreas - 23%
347 LG 1328501.2:2001 JUN22 Endocrine System - 62%, Exocrine Glands - 19%
348 LG 133095.1 :2001JUN22 Unclassified/Mixed - 20%
349 LG 135379.5:2001 JUN22 Sense Organs - 56%
350 LG 1365581.3:2001 JUN22 Embryonic Structures - 21%, Nervous System - 16%, Male Genitalia - 1 1%
351 LG 1383156.20:2001JUN22 Respiratory System - 90%
352 LG 1501767.18:2001JUN22 Germ Cells - 24%
353 LG 1501890.8:2001JUN22 Hemic and Immune System - 17%, Urinary Tract - 1 1%, Cardiovascular System - 1 1%
354 LG:203434.23:2001JUN22 Exocrine Glands - 20%, Urinary Tract - 17%, Embryonic Structures - 17%
355 LG:204724.5:2001JUN22 Urinary Tract - 99%
356 LG:257107.16:2001JUN22 Skin - 12%
357 LG:353530.4:2001JUN22 Embryonic Structures - 15%, Skin - 14%
358 LG:7683573.3:2001JUN22 Endocrine System - 33%, Male Genitalia - 33%, Respiratory System - 17%, Nervous System - 17%
359 LG:7684224.1 :2001JUN22 Liver - 100%
360 LG:7690365.2:2001JUN22 Liver - 28%, Embryonic Structures - 28%,
Cardiovascular System - 13%, Exocrine Glands -
13%
361 LG:968691.1 :2001JUN22 Hemic and Immune System - 100%
362 LG:983076.7:2001JUN22 Pancreas - 19%, Germ Cells - 1 1%
363 LG:986291.1 :2001JUN22 Hemic and Immune System - 100%
364 LG:990347.41 :2001JUN22 Sense Organs - 31%, Embryonic Structures - 14%,
Skin - 1 1%
365 LG:998305.4:2001JUN22 Liver - 30%, Pancreas - 30%, Nervous System -
20%
366 LG:463420.16:2001 JUN22 Skin - 16%, Nervous System - 15%, Exocrine
Glands - 1 1%
367 LG:979059.3:2001JUN22 Skin - 25%, Unclassified/Mixed - 20%, Exocrine
Glands - 1 1%
368 LG: 1045509.22:2001JUN2. Connective Tissue - 28%, Urinary Tract - 15%,
Musculoskeletal System - 13%
369 LG:246935.4:2001JUN22 Germ Cells - 30%
370 LG:321069.2:2001JUN22 Unclassified/Mixed - 13%, Stomatognathic
System - 13%, Urinary Tract - 12%
371 LG:346724.14:2001JUN22 Unclassified/Mixed - 17%, Sense Organs - 13%,
Embryonic Structures - 10%
372 LG:41 1043.3:2001JUN22 Pancreas - 15%, Exocrine Glands - 13%, Nervous
System - 12%, Urinary Tract - 12%
373 LG:978620.7:2001JUN22 Embryonic Structures - 30%, Unclassified/Mixed -
20%, Digestive System - 13%, Male Genitalia -
13%, Exocrine Glands - 13%
374 LG:982784.1 :2001JUN22 Germ Cells - 52% TABLE 6
SEQ ID NO: Template ID Tissue Distribution
375 LG:007574.21 :2001JUN22 Unclassified/Mixed - 22%, Pancreas - 1 1%, Digestive System - 10%
376 LG:013856.18:2001 JUN22 Skin - 14%, Female Genitalia - 10%
377 LG:027320.7:2001JUN22 Unclassified/Mixed - 27%, Liver - 19%, Embryonic Structures - 19%
378 LG:077967.9:2001JUN22 Germ Cells - 33%, Hemic and Immune System - 10%
379 LG:128475.9:2001JUN22 Unclassified/Mixed - 15%, Musculoskeletal System - 15%, Embryonic Structures - 15%
380 LG: 1398104.15:2001JUN22 Germ Cells - 31%, Unclassified/Mixed - 19%
381 LG: 1454018.10:2001JUN22 Germ Cells - 15%
382 LG:221548.14:2001JUN22 Germ Cells - 12%, Sense Organs - 12%
383 LG:227500.5:2001JUN22 Connective Tissue - 26%, Embryonic Structures - 15%
384 LG:228273.22:2001JUN22 Unclassified/Mixed - 15%, Nervous System - 15%, Embryonic Structures - 13%
385 LG:235432.1 :2001JUN22 Embryonic Structures - 20%, Germ Cells - 15%, Hemic and Immune System - 14%
386 LG:236904.20:2001JUN22 Cardiovascular System - 14%, Skin - 1 1%
387 LG:253193.21 :2001JUN22 Liver - 22%, Embryonic Structures - 12%
388 LG:332161.3:2001JUN22 Nervous System - 32%
389 LG:332923.5:2001JUN22 Sense Organs - 42%, Nervous System - 35%, Embryonic Structures - 15%
390 LG:343500.27:2001JUN22 Unclassified/Mixed - 30%, Embryonic Structures - 21%, Male Genitalia - 14%
391 LG:369703.9:2001JUN22 Urinary Tract - 13%, Nervous System - 12%, Respiratory System - 10%
392 LG:415378.3:2001 JUN22 Germ Cells - 18%, Embryonic Structures - 14%, Female Genitalia - 10%
393 LG:458583.1 :2001 JUN22 Male Genitalia - 50%, Nervous System - 50%
394 LGJ690373.1 :2001JUN22 Male Genitalia - 40%, Nervous System - 40%, Hemic and Immune System - 20%
395 LG:898324.13:200UUN22 Skin - 30%, Unclassified/Mixed - 28%, Connective Tissue - 15%
396 LG:979167.5:2001 JUN22 Sense Organs - 17%
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Sc Annotation
397 2 273 1385 2203 g12846107 l.OOE-113 data source:SPTR, source key:Q9RYW0, evidence:ISS~putative~related to ACYL-COA DEHYDROGENASE, PUTATIVE
397 2 273 1385 2203 g13277578 l.OOE-102 Unknown (protein for MGC:5601)
397 2 273 1385 2203 g9948609 4.00E-80 probable acyl-CoA dehydrogenase
398 2 321 53 1015 g12652727 1.00E-31 Unknown (protein for I MAGE: 3352566)
398 2 321 53 1015 g1049301 5.00E-26 KRAB zinc finger protein; Method: conceptual translation supplied by
398 2 321 53 1015 g15080547 2.00E-25 Unknown (protein for MGC21259)
399 3 250 3 752 g16551755 4.00E-49 unnamed protein product
399 3 250 3 752 g12053235 9.00E-46 hypothetical protein
399 3 250 3 752 g7981299 3.00E-45 dJ31316.6 (zinc finger protein 165)
400 1 459 1 1377 g186774 0 zinc finger protein
400 1 459 1 1377 g16306806 0 zinc finger protein 43 (HTF6)
400 1 459 1 1377 g38032 0 ZNF43
401 3 480 3 1442 g16549180 0 unnamed protein product
401 3 480 3 1442 g488555 l.OOE-138 zinc finger protein ZNF135
401 3 480 3 1442 g5441615 l.OOE-138 zinc finger protein
403 2 227 2 682 g50952 l.OOE-104 ferritin heavy subunit (AA 1 - 182)
403 2 227 2 682 g485373 l.OOE-104 ferritin heavy chain
403 2 227 2 682 g309232 l.OOE-104 ferritin heavy chain
404 1 in 1 333 g14042850 2.00E-21 unnamed protein product
404 1 111 1 333 g12851033 3.00E-11 data source:SPTR, source key:Q9JIB8, evidence:ISS~putative~similar to KRAB ZINC FINGER PROTEIN
404 1 111 1 333 g12805201 4.00E-11 Similar to zinc finger protein 97
405 3 202 24 629 g7959207 2.00E-38 KIAA 1473 protein
405 3 202 24 629 g3342002 6.00E-36 hematopoietic cell derived zinc finger protein
405 3 202 24 629 g16553225 9.00E-35 unnamed protein product
407 197 253 843 g2558516 8.00E-95 Rab5 GDP/GTP exchange factor, Rabex5
407 197 253 843 g15929821 2.00E-94 putative Rab5 GDP/GTP exchange factor homologue
407 197 253 843 g6013006 2.00E-94 Rab5 GDP/GTP exchange factor homologue
408 117 1 351 g7959207 1.00E-38 KIAA 1473 protein
408 117 1 351 g3342002 3.00E-36 hematopoietic cell derived zinc finger protein
408 117 1 351 g16553225 4.00E-35 unnamed protein product
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability So Annotation
409 3 254 327 1088 g16552245 l.OOE-l48 unnamed protein product
409 3 254 327 1088 gl6552172 1.00E-115 unnamed protein product
409 3 254 327 1088 g7239109 l.OOE-108 HSPC059
410 2 224 2 673 g34392 l.OOE-124 put. LLRep3 protein (AA 1-221)
410 2 224 2 673 g2920833 l.OOE-124 ribosomal protein S2
410 2 224 2 673 g18203799 l.OOE-124 Unknown (protein for MGC: 15956)
411 3 189 210 776 gl 2310941 1.00E-60 unnamed protein product
411 3 189 210 776 g5059156 2.00E-52 Ly-6/neurotoxin homolog
411 3 189 210 776 g12851336 2.00E-52 Lyό/neurotoxin l ~data source:MGD, source key:MGI: 1345180, evidence:ISS~putative
412 1 363 1 1089 g17939572 0 Similar to zinc finger protein 296
412 1 363 1 1089 g12843135 l.OOE-135 data source:MGD, source key:MGI: 1926956, evidence:ISS~putative~zinc finger protein 296
412 1 363 1 1089 gl 1602755 l.OOE-134 zinc finger protein κ> 413 3 231 3 695 g388168 l.OOE-128 Bax beta w 413 3 231 3 695 g15559636 2.00E-88 Unknown (protein for MGC:20956)
413 3 231 3 695 g12309964 2.00E-88 Human Bax
414 2 370 155 1264 g15209690 0 unnamed protein product
414 2 370 155 1264 g13676427 1.00E-77 hypothetical protein
414 2 370 155 1264 g14250369 2.00E-39 Unknown (protein for IMAGE:4178394)
415 2 136 2 409 g15717944 3.00E-62 bA14C22.1 (novel protein similar to lysozyme)
415 2 136 2 409 gl 1990770 2.00E-60 bA534G20.1.1 (novel protein similar to Lysozyme C-l (1,4-beta-N- acylmuramidase C, EC 3.2.1.17) (isoform 1 ))
415 2 136 2 409 g18204355 8.00E-60 similar to lysozyme C-l (1 ,4-beta-N-acylmuramidase C, EC 3.2.1.17)
416 3 265 198 992 g15079361 6.00E-95 Similar to PCTAIRE-motif protein kinase 3
416 3 265 198 992 g12653035 6.00E-95 Unknown (protein for I MAGE: 3357514)
416 3 265 198 992 g297102 2.00E-92 serine/threonine protein kinase
417 1 239 469 1185 g14149068 l.OOE-129 hypothetical protein
417 1 239 469 1185 g13929449 l.OOE-129 dJ337018.4 (novel protein)
417 1 239 469 1185 g14719307 l.OOE-129 SNX21
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Score Annotation
418 2 207 14 634 g7340874 3.00E-88 ESTs D15590(C0900),D48950(S15542),D22684(C0900) correspond to a region of the predicted gene. -Similar to Arabidopsis thaliana 60S ribosomal protein LI 1 A (L16A). (P42795)
418 2 207 14 634 g10799832 6.00E-87 ribosomal protein LI 1-like
418 2 207 14 634 g9758681 8.00E-87 ribosomal protein LI 1-like
419 437 106 1416 g2689446 0 R27945J
419 437 106 1416 g16549907 l.OOE-l46 unnamed protein product
419 437 106 1416 g3289985 1.00E-141 KIAA0412
420 172 25 540 g57111 4.00E-97 ribosomal protein L22
420 172 25 540 g13278090 4.00E-97 ribosomal protein LI 7
420 172 25 540 g12847063 4.00E-97 data source:MGD, source key:MGI:96103, evidence: ISS-hexokinase 1 -putative
421 3 191 147 719 g15487218 3.00E-17 MORN-domain protein
421 3 191 147 719 g12323331 7.00E-13 putative phosphatidylinositol-4-phosphate 5-kinase; 1 1335-7537 421 3 191 147 719 g18491177 7.00E-13 putative phosphatidylinositol-4-phosphate 5-kinase 422 1 281 1027 1869 g6807718 l.OOE-l 29 hypothetical protein
422 1 281 1027 1869 g3641527 l.OOE-121 low-density lipoprotein receptor-related protein 5
422 1 281 1027 1869 g3582145 l.OOE-121 Upoprotein Receptor Related Protein 5
423 3 697 3 2093 g10998440 0 EGF-related protein SCUBE1
423 3 697 3 2093 g8052237 0 CEGP1 protein
423 3 697 3 2093 g8052320 0 Cegpl protein
425 474 1 1422 g14794726 0 CUB and sushi multiple domains 1 protein
425 474 1 1422 g14787176 0 CSMD1
425 474 1 1422 g15620827 l.OOE-175 KIAA1884 protein
426 714 247 2388 g6808293 0 hypothetical protein
426 714 247 2388 g2477513 0 F25965_3
426 714 247 2388 g15559435 3.00E-89 Unknown (protein for IMAGE:4300179)
427 3 556 969 2636 g14043803 0 Unknown (protein for MGC: 14333)
427 3 556 969 2636 g18654480 0 Unknown (protein for MGC: 17396)
427 3 556 969 2636 g14307 16 0 myosin phosphatase targeting subunit 3 MYPT3
428 3 524 84 1655 g7019945 l.OOE-180 unnamed protein product
428 3 524 84 1655 g12804721 l.OOE-l40 Unknown (protein for MGC:2663)
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability So Annotation
428 3 524 84 1655 g16552245 l.OOE-109 unnamed protein product
429 2 182 245 790 g7768736 4.00E-17 putative gene, ankirin like, possible dual specifity Ser/Thr/Tyr kinase domain
429 2 182 245 790 g6808021 6.00E-17 hypothetical protein
429 2 182 245 790 g14245729 6.00E-17 probable dual-specificity Ser/Thr/Tyr kinase
430 2 270 23 832 g14348588 4.00E-69 KRAB zinc finger protein
430 2 270 23 832 g13752754 1.00E-67 zinc finger 1 1 1 1
430 2 270 23 832 g10047297 6.00E-67 KIAA161 1 protein
431 2 1195 2 3586 g10047329 0 KIAA1626 protein
431 2 1195 2 3586 g18256873 0 Unknown (protein for IMAGE:4016433)
431 2 1195 2 3586 g7022610 0 unnamed protein product
432 1 368 1 1104 g7301264 5.00E-90 CG9996 gene product
432 1 368 1 1104 g15990444 8.00E-78 Unknown (protein for IMAGE:4649498)
432 1 368 1 1104 g3878455 2.00E-11 contains similarity to Pfam domain: PF01501 (Glycosyl transferase family 8), Score=-25.1, E-value=7.4e-05, N=l
434 1 123 115 483 g407466 3.00E-34 QM protein
434 1 123 115 483 g402827 3.00E-34 QM
434 1 123 115 483 gl90814 3.00E-34 Wilm's tumor-related protein
435 3 316 96 1043 g12060855 l.OOE-173 serologically defined breast cancer antigen NY-BR-96
435 3 316 96 1043 g12847582 l.OOE-161 data source:SPTR, source key:Q9H272, evidence:ISS~homolog to SEROLOGICALLY DEFINED BREAST CANCER ANTIGEN NY-BR-96~putative
435 3 316 96 1043 g14249854 7.00E-73 amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 2
436 2 169 2 508 g7259240 2.00E-79 unnamed protein product
436 2 169 2 508 g12834293 2.00E-79 data source:MGD, source key:MGI:1891227, evidence:ISS~endothelial differentiation-related factor 1 -putative
436 2 169 2 508 g12832255 2.00E-79 data source:MGD, source key:MGI: 1891227, evidence:ISS~endothelial differentiation-related factor 1 -putative
437 2 454 2 1363 g17483854 0 a disintegrin-like and metalloprotease with thrombospondin type 1 motif 14 precursor
437 2 454 2 1363 g15523694 0 unnamed protein product
437 2 454 2 1363 gl865716 2.00E-56 procollagen I N-proteinase
439 1 882 1 2646 gl 1177164 0 polydom protein
439 1 882 1 2646 g12060830 l.OOE-l 70 serologically defined breast cancer antigen NY-BR-38
TABLE 7
I ID NO: Frame Length Start Stop Gl Number Probability So Annotation
439 1 882 1 2646 g14787176 l.OOE-117 CSMD1
440 2 496 305 1792 g58491 0 El b 55k protein (transformation)
440 2 496 305 1792 g209820 0 transformation-associated protein
440 2 496 305 1792 g17105043 l.OOE-169 54.7 kDa
441 1 415 367 1611 g15558943 0 guanylate binding protein 4
441 1 415 367 1611 g17512480 l.OOE-169 Similar to guanylate nucleotide binding protein 3
441 1 415 367 1611 gl 174187 l.OOE-168 purine nucleotide binding protein
442 1 473 58 1476 g15559603 0 Unknown (protein for MGC:20847)
442 1 473 58 1476 g4559318 l.OOE-128 BC273239J
442 1 473 58 1476 g15929737 l.OOE-128 Similar to zinc finger protein 347
443 1 353 1 1059 g12836052 0 data source:SPTR, source key:Q9H334, evidence:ISS~homolog to FORKHEAD BOX PROTEIN PI -putative
443 1 353 1 1059 g16877224 l.OOE-172 Unknown (protein for IMAGE:3885983)
443 1 353 1 1059 g15919272 l.OOE-114 putative forkhead/winged-helix transcription factor
444 3 431 615 1907 g3413918 0 KIAA0478 protein
444 3 431 615 1907 g220637 7.00E-53 zinc finger protein
444 3 431 615 1907 g53133 3.00E-52 mkr3
445 1 420 16 1275 g12842288 0 Ank repeat containing protein-data source:Pfam, source key:PF00023, evidence:ISS~putative
445 1 420 16 1275 g7303380 4.00E-38 CGI 3320 gene product
445 1 420 16 1275 g7293339 l.OOE-14 f gene product
446 3 172 66 581 g3900848 8.00E-77 match to EST AA361 1 17 (NID:g2013436)
446 3 172 66 581 g5441412 1.OOE-20 dJ513M9.1 (novel Homeobox domain protein)
446 3 172 66 581 g13620482 8.00E-15 hypothetical protein
447 1 718 1150 3303 g18462030 0 semaphorin Y short isoform 1
447 1 718 1150 3303 g12081909 0 semaphorin Y
447 1 718 1150 3303 g14017955 0 KIAA1869 protein
448 3 200 243 842 g14334177 l.OOE-l20 beta cysteine string protein
448 3 200 243 842 g16876924 l.OOE-120 Unknown (protein for MGC:26226)
448 3 200 243 842 g12838488 l.OOE-110 data source:SPTR, source key:P54101 , evidence:ISS~putative~similar to CYSTEINE STRING PROTEIN (CSP)
451 349 3 1049 g6453538 5.00E-86 hypothetical protein
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Sc Annotation
451 3 349 3 1049 g6634025 3.00E-28 KIAA0379 protein
451 3 349 3 1049 g7385113 5.00E-28 ankyrin 1
452 2 1060 107 3286 gl6549119 0 FLJ00040 protein
452 2 1060 107 3286 g12053081 0 hypothetical protein
452 2 1060 107 3286 g16741323 0 Similar to hypothetical protein DKFZp434L0718
454 216 1 648 gl7105197 l.OOE-108 kelch-like protein KLHL6
454 216 1 648 g10439155 6.00E-33 unnamed protein product
454 216 1 648 g6329805 2.00E-26 KIAA1 129 protein
455 701 139 2241 g14274810 0 unnamed protein product
455 701 139 2241 gl 1691855 0 pakδ protein
455 701 139 2241 g9082306 0 p21 -activated protein kinase 6
456 2 415 182 1426 g10434090 0 unnamed protein product
456 2 415 182 1426 g12836022 3.00E-59 data source:SPTR, source key:Q9P2N7, evidence: ISS-homolog to HYPOTHETICAL PROTEIN KIAA1309 (FRAGMENT)~putative
456 2 415 182 1426 g7243089 1.00E-58 KIAA 1354 protein
457 1 298 1 894 g206734 l.OOE-165 ribosomal protein L5
457 1 298 1 894 g57125 l.OOE-163 ribosomal protein L5 (AA 1-297)
457 1 298 1 894 g12850263 l.OOE-162 data source:MGD, source key: MGI: 102854, evidence:ISS~putative~ribosomal protein L5
458 1 159 1 477 g2827474 1.00E-87 predicted protein dJ257A7.2
458 1 159 1 477 g10241527 2.00E-51 dJ899C14.1 (novel protein similar to KIAA0680)
458 1 159 1 477 g15485622 2.00E-51 Q9H4T4 like
459 3 399 1845 3041 g5419859 0 hypothetical protein
459 3 399 1845 3041 g10436084 0 unnamed protein product
459 3 399 1845 3041 g6683745 l.OOE-176 HOTTL protein
460 2 220 2 661 g14603176 l.OOE-120 Similar to RIKEN cDNA 2410153K17 gene
460 2 220 2 661 g4106984 l.OOE-120 R30923
460 2 220 2 661 g13277582 l.OOE-104 Unknown (protein for IMAGE:3461982)
461 2 594 1535 3316 g7959265 0 KIAA 1502 protein
461 2 594 1535 3316 g5764665 0 cerebral cell adhesion molecule
461 2 594 1535 3316 g14035822 0 unnamed protein product
462 1 500 1 1500 g16549907 0 unnamed protein product
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Score Annotation
462 1 500 1 1500 g2887445 l.OOE-160 KIAA0412
462 1 500 1 1500 g3289985 l.OOE-160 KIAA0412
463 3 490 492 1961 g13436440 0 Unknown (protein for MGC4400)
463 3 490 492 1961 g10435411 l.OOE-l25 unnamed protein product
463 3 490 492 1961 g10442700 l.OOE-125 zinc-finger protein ZBRK1
464 2 236 2 709 g12655061 2.00E-90 succinate dehydrogenase complex, subunit A, flavoprotein (Fp)
464 2 236 2 709 g506338 2.00E-90 flavoprotein subunit of complex II
464 2 236 2 709 g347134 6.00E-90 succinate dehydrogenase flavoprotein subunit
465 2 953 4337 7195 g452316 0 acetyl-CoA carboxylase
465 2 953 4337 7195 g2138330 0 acetyl-CoA carboxylase
465 2 953 4337 7195 g3080546 0 acetyl-CoA carboxylase
466 1 128 10 393 g55602 1.OOE-37 ad 1 -antigen
466 1 128 10 393 g5410605 1.OOE-37 tetraspanin membrane protein CD63
466 1 128 10 393 g15126559 1.OOE-37 Similar to Cd63 antigen
467 2 391 371 1543 g7159799 0 dJ351 K20.1.1 (novel C3HC4 type Zinc finger (RING finger) protein (isoform
467 2 391 371 1543 g14042318 0 unnamed protein product
467 2 391 371 1543 g7159800 0 dJ351 K20.1.2 (novel C3HC4 type Zinc finger (RING finger) protein (isoform
468 3 324 3 974 g296650 l.OOE-158 hnmp al protein
468 3 324 3 974 g193324 l.OOE-158 RNA binding protein
468 3 324 3 974 gl711242 l.OOE-158 TIS
469 2 1653 56 5014 g189165 0 GAP-related protein
469 2 1653 56 5014 g292354 0 neurofibromin
469 2 1653 56 5014 gl841314 0 neurofibromin
470 3 1536 906 5513 g178646 0 ankyrin
470 3 1536 906 5513 g28702 0 ankyrin (variant 2.1)
470 3 1536 906 5513 g1845265 0 ankyrin
471 2 184 2 553 g2668738 2.00E-89 translation initiation factor 5A
471 2 184 2 553 gl546919 2.00E-89 translation initiation factor 5A
471 2 184 2 553 g3789948 2.00E-83 translation initiation factor 5A
472 3 184 192 743 g50797 1.00E-58 Elongation factor 1 -alpha (AA 1 - 461)
472 3 184 192 743 g927065 2.00E-57 eukaryotic translation elongation factor 1 alpha 1-like 14
472 3 184 192 743 g7649316 2.00E-57 elongation factor 1 alpha
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Sc Annotation
473 2 714 2 2143 g849051 0 cationic amino acid transporter 2
473 2 714 2 2143 g2252786 0 hCAT-2A
473 2 714 2 2143 g476725 0 T-cell early activation protein
474 1 947 34 2874 g6329952 0 KIAA1 141 protein
474 1 947 34 2874 g17391340 0 Unknown (protein for MGC:20009)
474 1 947 34 2874 g17981470 0 zinc finger protein ZFP100
475 2 426 353 1630 gl 6551429 l.OOE-161 unnamed protein product
475 2 426 353 1630 g1613848 l.OOE-150 zinc finger protein zfpό
475 2 426 353 1630 g14042415 l.OOE-132 unnamed protein product
476 3 93 909 1187 g54912 2.00E-43 tropomyosin 5
476 3 93 909 1187 g438878 2.00E-43 tropomyosin
476 3 93 909 1187 g312928 2.00E-43 tropomyosin isoform 6
477 3 1067 15 3215 g14388339 0 hypothetical protein
477 3 1067 15 3215 g9845485 0 protocadherin-9
477 3 1067 15 3215 g13874450 0 hypothetical protein
478 3 345 264 1298 g1477586 l.OOE-107 DLX-1
478 3 345 264 1298 g1477588 l.OOE-107 DLX-1
478 3 345 264 1298 g1620514 2.00E-91 Dlxl
479 1 211 322 954 g12845866 5.00E-73 Zinc finger, C3HC4 type (RING finger) containing protein-data source:Pfam, source key:PF00097, evidence: ISS-putative
479 1 21 1 322 954 g!2833017 3.00E-22 Zinc finger, C3HC4 type (RING finger) containing protein-data source:Pfam, source key:PF00097, evidence:ISS~putative
479 1 211 322 954 g458726 l.OOE-17 estrogen responsive finger protein (efp)
480 2 465 278 1672 g16508652 0 unnamed protein product
480 2 465 278 1672 g16508650 0 unnamed protein product
480 2 465 278 1672 g7717310 2.00E-63 human ubiquitin processing protease, EC 3.1.2.15
481 1 536 19 1626 g12656196 l.OOE-122 cardiac leiomodin
481 1 536 19 1626 g17389801 1.00E-73 Unknown (protein for IMAGE:4291 177)
481 1 536 19 1626 g28969 2.00E-72 64 Kd autoantigen
482 3 358 150 1223 g18204012 0 Similar to RIKEN cDNA B830026H24 gene
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Score Annotation 482 3 358 150 1223 gl 2861800 0 data source:SPTR, source key:P97584, evidence: ISS-homolog to NADP- DEPENDENT LEUKOTRIENE B4 12-HYDROXYDEHYDROGENASE (EC 1.1.1.-) (DITHIOLETHIONE-INDUCIBLE GENE-l)-putative
482 358 150 1223 g3878713 5.00E-84 weak similarity with quinone oxidoreductase, contains similarity to Pfam domain: PF00107 (Zinc-binding dehydrogenases), Score=-80.6, E-value=6.2e- 06, N=l -cDNA EST ykl64b4.5 comes from this gene-cDNA EST ykl64b4.3 comes from this gene-cDNA EST yk264f3.5 comes from this gene
483 2 449 1112 2458 g32033 0 put. HBK2 protein (AA 1-529)
483 2 449 1112 2458 g57667 0 put. RCK2 protein (AA 1-530)
483 2 449 1112 2458 g199893 0 murine potassium channel protein
484 2 253 2 760 g18655395 1.OOE-111 AT3gl3580/K20M4_2
484 2 253 2 760 g14532552 l.OOE-111 AT3gl 3580/K20M4_2
484 2 253 2 760 gl 1994560 1.OOE-111 60S ribosomal protein L7
485 2 100 2 301 g12860912 1.00E-36 data source:SPTR, source key:P07108, evidence: ISS-homolog to ACYL-COA BINDING PROTEIN (ACBP) (DIAZEPAM BINDING INHIBITOR) (DBI)
©
© (ENDOZEPINE) (EP)~putative
485 2 100 2 301 g514280 1.00E-35 diazepam-binding inhibitor
485 2 100 2 301 g765223 3.00E-35 ACBP/DBI
486 1 556 1033 2700 g2330553 0 PACE4A-II
486 1 556 1033 2700 g2281776 0 PACE4A-II
486 1 556 1033 2700 g189532 0 subtilisin-like protease
487 2 695 176 2260 g2827086 0 DNA recombination and repair protein
487 2 695 176 2260 g13324574 0 meiotic recombination 1 1
487 2 695 176 2260 g3328152 0 endo/exonuclease Mrel 1
488 2 220 98 757 g12855841 6.00E-76 ADP-ribosylation factor family containing protein-data source: Pfam, source key:PF00025, evidence:ISS~putative
488 2 220 98 757 g17736646 4.00E-41 dJ341 D10.2 (similar to ADP ribosylation factor 3)
488 2 220 98 757 g12855722 6.00E-39 ADP-ribosylation factor family containing protein-data source:Pfam, source key:PF00025, evidence: ISS-putative
489 2 63 602 790 gl5021881 2.00E-10 hypothetical protein
489 2 63 602 790 g7239109 3.00E-10 HSPC059
489 2 63 602 790 g8575775 4.00E-10 KRAB zinc finger protein
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Score Annotation 490 2 241 2 724 g 12832288 l .OOE-1 1 1 data source:SPTR, source key:075989, evidence: ISS-homolog to DJ422F24.1 (PUTATIVE NOVEL PROTEIN SIMILAR TO C. ELEGANS C02C2.5) (FRAGMENT)~putative
490 2 241 2 724 g3757719 1.00E-88 dJ422F24.1 (PUTATIVE novel protein similar to C. elegans C02C2.5)
490 2 241 2 724 g7294769 3.00E-44 CG6279 gene product
491 3 214 3 644 g2276313 6.00E-20 match: multiple proteins; match: Q08151 P28185 Q01 1 1 1 Q43554; match: Q08150 Q40195 P20340 Q39222; match: Q40368 P36412 P40393 Q40723; match: CE01798 Q38923 Q40191 Q41022; match: Q39433 Q40177 Q40218 Q08146; match: PI 0949 1 1023 Q 16948 Q20337; match: Q25389 P25228 P20336 P05713; match: P35276 Q08147 P17609 P22128; match: Q15771 P36410 P35291; GTP-binding
491 3 214 3 644 g17939907 2.00E-06 UL36 protein
491 3 214 3 644 g310200 9.00E-06 proline-rich proteoglycan
492 3 196 3 590 g6651438 7.00E-24 putative N-acetγltransferase Camello 2
492 3 196 3 590 g18043508 3.00E-22 camello-like 4
©
1—' 492 3 196 3 590 g12833022 3.00E-22 camello-like 4~data source:MGD, source key:MGI: 1915646, evidence:ISS~putative
493 1 273 25 843 g7271471 l.OOE-159 Rab-related GTP-binding protein RabJ
493 1 273 25 843 g14486426 l.OOE-149 Rab-related GTP-binding protein
493 1 273 25 843 g806722 1.00E-24 YptC4
494 3 293 483 1361 g14039836 l.OOE-171 beta 1,3 N-acetyglucosaminyltransferase Lc3 synthase
494 3 293 483 1361 g13568434 l.OOE-171 beta 1 ,3-N-acetylglucosaminyltransferase 5
494 3 293 483 1361 g14597533 l.OOE-171 unnamed protein product
495 2 922 692 3457 g4151328 0 high-risk human papilloma viruses E6 oncoproteins targeted protein E6TP1 alpha; putative GAP protein alpha
495 2 922 692 3457 gl7128219 0 unnamed protein product
495 2 922 692 3457 gl7128217 0 unnamed protein product
496 651 1953 g5080758 0 BC331 191J
496 651 1953 gl5021881 l.OOE-177 hypothetical protein
496 651 1953 g3540177 l.OOE-176 F23269_2
497 242 726 g13938261 8.00E-89 Unknown (protein for MGC: 15514)
497 242 726 g5262557 8.00E-89 hypothetical protein
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Score Annotation
497 1 242 1 726 g16552172 3.00E-86 unnamed protein product
498 1 309 685 1611 g3540177 l.OOE-109 F23269.2
498 1 309 685 1611 g5080758 l.OOE-109 BC331 191J
498 1 309 685 1611 g12855931 4.00E-63 data source:SPTR, source key:P16374, evidence:ISS~putative~similar to ZINC FINGER PROTEIN 60 (ZFP-60) (ZINC FINGER PROTEIN MFG-3)
499 2 1212 518 4153 g5726476 0 transcription factor NFAT5 isoform b
499 2 1212 518 4153 g4240143 0 KIAA0827 protein
499 2 1212 518 4153 gl4571715 0 tonicity-responsive enhancer binding protein
500 1 130 121 510 g7582292 3.00E-61 BM-010
500 1 130 121 510 g673433 1.00E-49 protein synthesis initiation factor 4A
500 1 130 121 510 g16198386 1.00E-49 Unknown (protein for MGC27241)
501 2 665 2 1996 g6330433 0 KIAA 1203 protein
501 2 665 2 1996 g18204471 l.OOE-106 Unknown (protein for MGC38313)
501 2 665 2 1996 g7291841 3.00E-52 CG3872 gene product
Ul 502 1 221 2410 3072 g5410334 l.OOE-129 WSB-1 isoform
©
502 1 221 2410 3072 g7145106 l.OOE-109 WSB1 protein
502 1 221 2410 3072 g6563198 l.OOE-l09 WSB-1 protein
503 2 2894 2 8683 g9828190 0 FLAMINGO 1
503 2 2894 2 8683 g5832711 0 Flamingo 1
503 2 2894 2 8683 g1665821 0 Similar to D. melanogaster cadherin-related tumor suppressor
504 1 493 1 1479 g16549477 0 unnamed protein product
504 1 493 1 1479 g12214288 6.00E-87 dJ402H5.2 (novel protein similar to worm and fly proteins)
504 1 493 1 1479 g7302178 3.00E-48 CGI 1212 gene product
505 3 299 3 899 g16768654 4.00E-45 HL01494p
505 3 299 3 899 g7292299 2.00E-42 CGI 271 gene product
505 3 299 3 899 gl5141022 1.00E-39 probable glycerol kinase, similar to sugar kinases protein
506 3 397 90 1280 g13177623 0 dopamine-responsive protein
506 3 397 90 1280 g13543692 0 COBW-like protein
506 3 397 90 1280 g15488579 0 COBW-like protein
507 2 97 26 316 g57175 4.00E-48 S- 100 protein
507 2 97 26 316 g206825 4.00E-48 SI 00 protein
507 2 97 26 316 g404769 1.00E-47 SI 00 beta protein
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Sc Annotation
508 130 1 390 g12804565 3.00E-41 Unknown (protein for IMAGE:2989556)
508 130 1 390 g12847848 6.00E-16 data source:SPTR, source key:P22978, evidence:ISS~putative~related to HEAT SHOCK PROTEIN 67B2
508 130 1 390 g8063 l.OOE-l4 heat shock protein
509 224 439 1110 g18266358 l.OOE-116 RUFY2
509 224 439 1110 g15625568 l.OOE-116 Run- and FYVE-domain containing protein Rabip4R
509 224 439 1110 g7959341 l.OOE-116 KIAA1537 protein
511 420 1 1260 g12853497 0 BTB/POZ domain containing protein-data source:Pfam, source key:PF00651, evidence: ISS-putative
511 420 1 1260 g18204103 0 RIKEN cDNA 4930429H24 gene
511 420 1 1260 g7019911 0 unnamed protein product
512 347 352 1392 g13359199 0 KIAA 1663 protein
512 347 352 1392 g6469034 0 Tob2
512 347 352 1392 g6572197 0 bK223H9.1 (TOB4 (BTGl family protein))
Uι 513 2 303 2 910 g13444976 l.OOE-146 unnamed protein product
© u 513 2 303 2 910 g12309630 l.OOE-146 bA438B23.1 (neuronal leucine-rich repeat protein)
513 2 303 2 910 g16551759 l.OOE-146 unnamed protein product
514 2 153 692 1150 g15928468 2.00E-51 Unknown (protein for MGC:25259)
514 2 153 692 1150 g3953593 2.00E-51 Zinc finger protein si 1-6
514 2 153 692 1150 g8050899 7.00E-51 ZNF180
515 3 466 207 1604 g4514554 0 Rodl
515 3 466 207 1604 g13879326 0 Similar to regulator of differentiation (in S. pombe) 1
515 3 466 207 1604 g4514552 0 Rodl
516 2 839 284 2800 g16551917 0 unnamed protein product
516 2 839 284 2800 g16356673 0 LIM protein prickle b
516 2 839 284 2800 g14595658 0 LIM protein prickle
517 2 214 2 643 g18461184 2.00E-60 putative katanin
517 2 214 2 643 g3128218 3.00E-53 putative katanin
517 2 214 2 643 gll071813 9.00E-48 probable katanin-like protein
518 3 390 3 1172 g16554016 0 unnamed protein product
518 3 390 3 1172 g13279059 l.OOE-173 fatty acid hydroxylase
518 3 390 3 1172 g12803687 l.OOE-173 Unknown (protein for MGQ4282)
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability So Annotation
519 3 490 105 1574 g12407377 0 tripartite motif protein TRIM4 isoform alpha
519 3 490 105 1574 g12407379 0 tripartite motif protein TRIM4 isoform beta
519 3 490 105 1574 g15079952 l.OOE-116 Similar to tripartite motif protein 4
520 2 983 773 3721 g4240261 0 KIAA0886 protein
520 2 983 773 3721 gl 1610575 0 RTN-xL
520 2 983 773 3721 g10039551 0 reticulon 4a
521 1 349 673 1719 gl3543110 0 Similar to SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 2
521 1 349 673 1719 g2723484 0 BAFόOb
521 1 349 673 1719 g2723486 0 BAF60b
522 2 309 98 1024 gl89310 l.OOE-164 nucleolysin TIAR
522 2 309 98 1024 g14714709 l.OOE-163 TIA1 cytotoxic granule-associated RNA-binding protein-like 1
522 2 309 98 1024 g1592563 l.OOE-160 RNA binding protein TIAR
523 1 361 124 1206 g12844788 3.00E-67 evidence:NAS~hypothetical protein-putative w 523 1 361 124 1206 g12578471 2.00E-31 unnamed protein product
® 523 1 361 124 1206 g12405785 4.00E-30 unnamed protein product
524 3 478 810 2243 g10241461 l.OOE-108 dJ1 121G12.1 ,2 (A novel protein containing a putative PHD finger domain, isoform 2)
524 3 478 810 2243 gl3195151 l.OOE-108 transcription factor TZP
524 3 478 810 2243 gl5030164 2.00E-96 Unknown (protein for I MAGE: 3709746)
525 1 516 1 1548 gl401126 0 TAK1 binding protein
525 1 516 1 1548 g5834565 0 dJ407F17.1 (TAB1 (TAK1 binding protein 1))
525 1 516 1 1548 g3057038 0 TAB1
526 3 431 393 1685 g12832845 l.OOE-161 Domain of unknown function DUF36 containing protein-data source:Pfam, source key:PF01795, evidence:ISS~putative
526 3 431 393 1685 g10726441 6.00E-65 CGI 4683 gene product
526 3 431 393 1685 gl5291185 6.00E-65 GH10770p
527 3 3478 3 10436 g1490271 0 ALL-1 protein
527 3 3478 3 10436 g184394 0 HRX
527 3 3478 3 10436 gό88443 0 All-l protein
528 2 268 284 1087 g12860837 l.OOE-163 DHHC zinc finger domain containing protein-data source: Pfam, source key : PF01529, evidence : ISS-putative
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Score Annotation
528 2 268 284 1087 g 16769014 4.00E-28 LD14687p
528 2 268 284 1087 g7297775 4.00E-28 Dnzl gene product
529 777 1 2331 g 13603398 0 SEZ6L
529 777 1 2331 g4886439 0 hypothetical protein
529 777 1 2331 g6941613 0 dJ268D13.1.2 (seizure related gene 6 (mouse)-like (KIAA0927) (isoform 2))
530 635 1624 3528 g6330900 0 KIAA1255 protein
530 635 1624 3528 g2914017 0 Ankhzn
530 635 1624 3528 g6759376 0 ANKHZN
531 3 788 39 2402 g6330948 0 KIAA1261 protein
531 3 788 39 2402 g7239366 0 groucho-related protein 4
531 3 788 39 2402 g4033595 0 groucho protein
532 1 316 163 1 1 10 g 13960126 l .OOE-l 25 Similar to leucine-rich neuronal protein
532 1 316 163 1 1 10 g 14714829 l .OOE-1 14 Unknown (protein for IMAGE:4152627)
532 1 316 163 1 1 10 g6808196 2.00E-64 hypothetical protein u 533 3 633 3 1901 g5441369 0 ZASP protein
©
Ul 533 3 633 3 1901 g3327040 0 KIAA0613 protein
533 3 633 3 1901 g6969631 0 oracle 2 protein
534 3 537 675 2285 g2851884 0 unnamed protein product
534 3 537 675 2285 g 16073993 0 unnamed protein product
534 3 537 675 2285 g 1537030 0 LPP
535 1 13 21 1 549 g6714707 1.00E-52 hypothetical protein
535 1 13 21 1 549 g 16589079 1.00E-52 WD repeat protein BIG-3
535 1 13 21 1 549 g 16359284 1.00E-52 Similar to hypothetical protein
536 873 1 2619 g7243105 l .OOE-l 18 KIAA 1362 protein
536 873 1 2619 g7023688 l .OOE-109 unnamed protein product
536 873 1 2619 g 12855942 l .OOE-108 data source:MGD, source key:MGI: 1261419, evidence:ISS~ethanol decreased 4~putative
537 689 1 2067 g6331213 0 KIAA1268 protein
537 689 1 2067 g7023247 l .OOE-172 unnamed protein product
537 689 1 2067 gl 2751 141 6.00E-58 B aggressive lymphoma short isoform
538 3 1 14 279 620 g 16553621 3.00E-31 unnamed protein product
538 3 1 14 279 620 g7959193 7.00E-31 KIAA 1466 protein
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Sc Annotation
538 3 114 279 620 g18076262 9.00E-29 Pol protein
539 2 650 74 2023 g4650844 0 Kelch motif containing protein
539 2 650 74 2023 g12314036 0 dJ383J4.1 (A Kelch motif-containing protein)
539 2 650 74 2023 g18044145 0 Unknown (protein for MGC:28950)
540 3 738 246 2459 g7242951 0 KIAA 1298 protein
540 3 738 246 2459 g18376659 0 hSSH-l L
540 3 738 246 2459 g18376661 l.OOE-179 hSSH-lS
541 1 163 1 489 g12844142 2.00E-69 data source:SPTR, source key:Q00277, evidence:ISS~putative~related to GLUTATHIONE PEROXIDASE (EC 1.1 1.1 .9) (GPX)
541 163 1 489 g18044310 3.00E-69 RIKEN cDNA 2310016C16 gene
541 163 1 489 g14042546 1.00E-45 unnamed protein product
542 890 265 2934 g3002588 0 Plenty of SH3s; POSH
542 890 265 2934 g10432612 0 unnamed protein product
542 890 265 2934 g7959249 0 KIAA1494 protein u 543 3 567 498 2198 g9309467 l.OOE-136 leucine-rich glioma-inactivated 1 protein precursor
©
543 3 567 498 2198 g18490910 l.OOE-136 leucine-rich, glioma inactivated 1
543 3 567 498 2198 g4091819 l.OOE-136 leucine-rich glioma-inactivated protein precursor
544 1 258 205 978 g5410527 l.OOE-150 paracellin-1
544 1 258 205 978 g5545337 l.OOE-131 claudin-16
544 1 258 205 978 g13926043 l.OOE-130 paracellin-1
545 3 221 3 665 g16553391 l.OOE-137 unnamed protein product
545 3 221 3 665 g12483900 4.00E-67 zinc finger protein HIT-4
545 3 221 3 665 g14456631 3.00E-44 dJ54B20.4 (novel KRAB box containing C2H2 type zinc finger protein)
546 2 774 2 2323 g7555471 0 sirtuin type 1
546 2 774 2 2323 gl 1596121 0 SIR2alpha protein
546 2 774 2 2323 g6693711 0 Sir2alpha protein
547 3 526 3 1580 g3970833 0 RPB5 meidating protein
547 3 526 3 1580 g17382188 0 unnamed protein product
547 3 526 3 1580 g9997097 0 unnamed protein product
548 2 276 2 829 g16553765 l.OOE-l 27 unnamed protein product
548 2 276 2 829 g12839186 l.OOE-121 data source:SPTR, source key:Q9VS60, evidence: ISS-putative-related to CG8576 PROTEIN
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Sc Annotation
548 2 276 2 829 g1072250 5.00E-28 F53B1 .2 gene product
549 2 198 164 757 g7023491 6.00E-85 unnamed protein product
549 2 198 164 757 g6899846 6.00E-85 cisplatin resistance-associated overexpressed protein
549 2 198 164 757 g14318590 5.00E-79 Unknown (protein for MGCJ100)
550 246 646 1383 gl6041142 l.OOE-l 33 hypothetical protein
550 246 646 1383 gl4017813 1.00E-88 KIAA1798 protein
550 246 646 1383 g3811111 2.00E-84 l(3)mbt protein homolog
551 182 1 546 g14318767 2.00E-68 hypothetical protein MGC 10500
551 182 1 546 g13477109 2.00E-68 RIKEN cDNA 0610043B10 gene
551 182 1 546 g12833998 2.00E-68 data source:SPTR, source key:Q9ESC7, evidence:ISS~putative~similar to MDGL-1
552 2 471 269 1681 g2343085 0 nuclear antigen H731-like protein
552 2 471 269 1681 g1384078 0 apoptosis-inducible
552 2 471 269 1681 g3426155 0 TIS u 553 3 603 108 1916 g16359265 4.00E-87 Similar to hypothetical protein DKFZp434G2226
©
~4 553 3 603 108 1916 g2239242 1.00E-86 kinesin-like protein
553 3 603 108 1916 gl6151809 1.00E-86 kinesin-like protein Klp5
554 3 306 3 920 g18033747 l.OOE-170 myosin IIIB
554 3 306 3 920 g16550592 l.OOE-169 unnamed protein product
554 3 306 3 920 g10440888 l.OOE-122 myosin heavy chain FM3A
555 2 409 101 1327 g4235144 l.OOE-158 BC39498J
555 2 409 101 1327 g7959207 l.OOE-157 KIAA1473 protein
555 2 409 101 1327 g16041769 l.OOE-151 Unknown (protein for MGC:23189)
556 3 527 399 1979 g16549180 0 unnamed protein product
556 3 527 399 1979 g488555 l.OOE-138 zinc finger protein ZNF135
556 3 527 399 1979 g5441615 l.OOE-138 zinc finger protein
557 2 628 209 2092 g16553661 0 unnamed protein product
557 2 628 209 2092 g4164083 0 zinc finger protein EZNF
557 2 628 209 2092 g2970038 0 HKL1
558 3 433 198 1496 g14042513 0 unnamed protein product
558 3 433 198 1496 g12836332 0 data source:SPTR, source key:P93647, evidence: ISS~putative~related to MITOCHONDRIAL LON PROTEASE HOMOLOG 1 PRECURSOR (EC 3.4.21.-)
TABLE 7
_ ID NO: Frame Length Start Stop Gl Number Probability So Annotation
558 3 433 198 1496 g16508614 0 unnamed protein product
559 2 201 1100 1702 g12654987 4.00E-61 Unknown (protein for MGC:5621)
559 2 201 1100 1702 g10435998 3.00E-60 unnamed protein product
559 2 201 1100 1702 g18314540 3.00E-56 Similar to DKFZP586B 1621 protein
560 3 153 99 557 g6018682 1.00E-85 superoxide dismutase-4AP
560 3 153 99 557 g1885354 2.00E-83 superoxide dismutase 4A
560 3 153 99 557 g6018746 2.00E-83 superoxide dismutase-4A
561 2 321 191 1153 g13279311 l.OOE-165 Similar to RIKEN cDNA 1500017E 18 gene
561 2 321 191 1153 g12837716 l.OOE-133 data source:SPTR, source key:Q16775, evidence:ISS~homolog to HYDROXYACYLGLUTATHIONE HYDROLASE (EC 3.1.2.6) (GLYOXALASE II) (GLX 11) -putative
561 2 321 191 1153 g14336718 l.OOE-124 similar to HAGH
562 2 260 2 781 g15866260 l.OOE-148 MRIP2
562 2 260 2 781 g5689535 l.OOE-136 KIAA 1099 protein u 562 2 260 2 781 g15625584 l.OOE-136 centaurin gamma2
©
563 3 340 45 1064 g14602654 0 Unknown (protein for MGC: 15400)
563 3 340 45 1064 gl 8128747 0 unnamed protein product
563 3 340 45 1064 gl8128749 0 unnamed protein product
564 3 187 3 563 g16552172 l.OOE-114 unnamed protein product
564 3 187 3 563 g16552245 2.00E-81 unnamed protein product
564 3 187 3 563 g498721 2.00E-79 zinc finger protein
565 1 185 541 1095 g16550881 3.00E-91 unnamed protein product
565 1 185 541 1095 g10435738 2.00E-84 unnamed protein product
565 1 185 541 1095 g6088100 3.00E-77 zinc finger protein (ZFD25)
566 3 88 3 266 g12652727 1.00E-29 Unknown (protein for IMAGE:3352566)
566 3 88 3 266 g7020166 2.00E-29 unnamed protein product
566 3 88 3 266 g5679450 2.00E-29 dJ153G14.3 (novel C2H2 type Zinc Finger protein)
567 3 209 3 629 g16553223 7.00E-55 unnamed protein product
567 3 209 3 629 g15488954 1.00E-35 Unknown (protein for MGC8872)
567 3 209 3 629 g15080235 1.00E-35 Similar to zinc finger protein 1 13
568 3 298 12 905 g16973457 3.00E-56 beta-3-galactosyltransferase
568 3 298 12 905 g14290592 2.00E-54 beta-1 ,3-N-acetylglucosaminyltransferase 1
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Sc Annotation
568 3 298 12 905 gl5421160 2.00E-54 beta-l,3-N-acetylglucosaminyltransferase
569 2 413 1025 2263 g17511850 l.OOE-170 Unknown (protein for MGC:32065)
569 2 413 1025 2263 g15042691 2.00E-88 sorting nexin 18
569 2 413 1025 2263 g15559064 2.00E-74 SNAG1
570 3 361 3 1085 g17939572 0 Similar to zinc finger protein 296
570 3 361 3 1085 gl 1602755 l.OOE-134 zinc finger protein
570 3 361 3 1085 g12843135 l.OOE-134 data source:MGD, source key:MGI: 1926956, evidence: ISS-putative-zinc finger protein 296
571 1 295 22 906 g306852 l.OOE-116 HLA-E class I protein precursor
571 1 295 22 906 g15277235 l.OOE-116 Class lb gene, CD94/NKG2 ligand
571 1 295 22 906 g13279158 l.OOE-116 Unknown (protein for IMAGE:3622619)
572 2 541 2 1624 g3127193 0 kidney-specific protein
572 2 541 2 1624 g16553412 0 unnamed protein product
572 2 541 2 1624 g5070357 0 xenobiotic/medium-chain fatty acid:CoA ligase form XL-Ill u 573 3 371 141 1253 g15209690 0 unnamed protein product
® 573 3 371 141 1253 g13676427 l.OOE-126 hypothetical protein
573 3 371 141 1253 g9558479 8.00E-21 cysteine-rich protease inhibitor
574 2 282 2 847 g217974 l.OOE-143 triosephosphate isomerase
574 2 282 2 847 g168647 l.OOE-143 triosephosphate isomerase 1
574 2 282 2 847 g169821 l.OOE-128 triosephosphate isomerase
575 3 330 1296 2285 g14042682 4.00E-19 unnamed protein product
575 3 330 1296 2285 g15080180 9.00E-16 Unknown (protein for MGC:20504)
575 3 330 1296 2285 gl 3160045 9.00E-16 dJ734P14.5 (novel C2H2 type zinc finger protein)
576 2 139 1250 1666 g553841 4.00E-49 ribosomal protein S2
576 2 139 1250 1666 g34392 4.00E-49 put. LLRep3 protein (AA 1 -221)
576 2 139 1250 1666 g2920833 4.00E-49 ribosomal protein S2
577 1 213 64 702 g4995305 3.00E-88 PQBP-1 protein
577 1 213 64 702 g4586431 3.00E-88 nuclear protein containing a WW domain (Npw38)
577 1 213 64 702 g3114820 3.00E-88 JM26
578 3 145 27 461 g291888 3.00E-58 cathepsin B
578 3 145 27 461 gl81178 3.00E-58 lysosomal proteinase cathepsin B
578 3 145 27 461 g16307393 3.00E-58 cathepsin B
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Sc Annotation
579 1 217 1 651 g4588906 7.00E-97 ribosomal protein S7
579 1 217 1 651 g14787424 5.00E-94 Ribosomal protein S7
579 1 217 1 651 g4128206 1.00E-82 40S ribosome protein S7
580 3 212 3 638 g16553223 2.00E-77 unnamed protein product
580 3 212 3 638 g16550444 2.00E-49 unnamed protein product
580 3 212 3 638 g16551429 3.00E-27 unnamed protein product
581 2 190 833 1402 gl2841311 2.00E-90 data source:SPTR, source key:Q9WTR7, evidence: ISS-homolog to SIGNAL PEPTIDASE 21 KDA SUBUNIT-putative
581 2 190 833 1402 g16307229 3.00E-90 Unknown (protein for MGC:9299)
581 2 190 833 1402 g13182747 3.00E-90 microsomal signal peptidase subunit
582 3 343 387 1415 gl 1094293 0 brain link protein-1
582 3 343 387 1415 gl 1094311 0 brain link protein-1
582 3 343 387 1415 gl 1094297 0 brain link protein-1
583 501 247 1749 g10434596 0 unnamed protein product 583 501 247 1749 g15929209 0 hypothetical protein FU 12707 583 501 247 1749 g10434367 0 unnamed protein product
584 119 217 573 g6249687 1.00E-59 R31 155J
584 119 217 573 g7243243 1.00E-21 KIAA1431 protein
584 119 217 573 g16550359 4.00E-21 unnamed protein product
586 3 461 63 1445 g14585869 0 hypothetical protein SB146
586 3 461 63 1445 g14042915 0 unnamed protein product
586 3 461 63 1445 g14328009 l.OOE-172 Unknown (protein for IMAGE:39421 1 1)
587 2 572 419 2134 g14915787 0 WAC
587 2 572 419 2134 g16550684 0 unnamed protein product
587 2 572 419 2134 g13279044 0 hypothetical protein PR01741
588 1 287 1 861 g13274611 l.OOE-169 glutamate rich WD repeat protein
588 1 287 1 861 g12803253 l.OOE-169 Similar to CGI 2792 gene product
588 1 287 1 861 gl4198122 l.OOE-159 Similar to glutamate rich WD repeat protein GRWD
589 2 485 248 1702 g9187612 0 hypothetical protein, similar to (AF091072.1) predicted protein
589 2 485 248 1702 g10436076 0 unnamed protein product
589 2 485 248 1702 g14602971 0 Unknown (protein for MGC: 14981)
590 3 405 54 1268 g3540177 0 F23269 2
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Score Annotation
590 3 405 54 1268 g5080758 l.OOE-174 BC331 191J
590 3 405 54 1268 g12855931 l.OOE-111 data source:SPTR, source key:P16374, evidence:ISS~putative~similar to ZINC FINGER PROTEIN 60 (ZFP-60) (ZINC FINGER PROTEIN MFG-3)
591 2 172 2 517 g7959207 7.00E-50 KIAA 1473 protein
591 2 172 2 517 g16041769 2.00E-48 Unknown (protein for MGC:23189)
591 2 172 2 517 g4235144 5.00E-47 BC39498J
592 2 728 2 2185 g12052983 0 hypothetical protein
592 2 728 2 2185 g4519270 0 Kruppel-type zinc finger protein
592 2 728 2 2185 g6467206 0 gonadotropin inducible transcription repressor-4
593 1 583 1 1749 g5231271 0 autoimmune enteropathy-related antigen AIE-75
593 1 583 1 1749 g3170200 0 antigen NY-CO-38
593 1 583 1 1749 g16359185 0 Similar to PDZ-73 protein
594 2 375 2 1126 g15823640 4.00E-79 Als2
594 2 375 2 1126 g15823636 8.00E-79 long form
594 2 375 2 1126 gl0047191 8.00E-79 KIAA1563 protein
595 3 349 18 1064 g3417297 0 Unknown gene product
595 3 349 18 1064 g16552168 0 unnamed protein product
595 3 349 18 1064 g15559282 5.00E-98 Unknown (protein for MGC20208)
596 2 94 143 424 g16550359 7.00E-40 unnamed protein product
596 2 94 143 424 g7243243 1.00E-31 KIAA 1431 protein
596 2 94 143 424 g4567178 2.00E-29 R31665_2
597 2 390 80 1249 g14042550 l.OOE-108 unnamed protein product
597 2 390 80 1249 g13937909 l.OOE-108 Similar to KIAA0961 protein
597 2 390 80 1249 g16552245 3.00E-95 unnamed protein product
598 3 467 42 1442 g12804493 0 Unknown (protein for MGC:2615)
598 3 467 42 1442 gl8128717 0 unnamed protein product
598 3 467 42 1442 g16549529 0 unnamed protein product
599 3 351 3 1055 g18652252 l.OOE-167 target of myb 1-like protein 2
599 3 351 3 1055 g3256185 l.OOE-121 dJ510Hlό. l (target of mybl (chicken) homolog)
599 3 351 3 1055 g3319953 l.OOE-121 TO 1
600 1 535 1 1605 g13676443 l.OOE-117 hypothetical protein
600 1 535 1 1605 g6808105 5.00E-91 hypothetical protein
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Score Annotation
600 1 535 1 1605 gl8146831 4.00E-86 RGL1
602 3 184 234 785 gl2314195 4.00E-74 bA255Al 1.3 (novel protein similar to KIAA1074)
602 3 184 234 785 gl2314164 1.00E-73 bA526D8.2 (novel protein similar to KIAA1074)
602 3 184 234 785 g12053099 3.00E-56 hypothetical protein
603 2 387 131 1291 g16550359 0 unnamed protein product
603 2 387 131 1291 g16550064 l.OOE-l42 unnamed protein product
603 2 387 131 1291 g13560888 l.OOE-l20 EZFIT-related protein 1
604 1 195 31 615 g14794726 9.00E-95 CUB and sushi multiple domains 1 protein
604 1 195 31 615 gl4787181 9.00E-95 CUB and sushi multiple domains protein 1 short form
604 1 195 31 615 g15620839 9.00E-95 KIAA1890 protein
605 3 484 3 1454 g13160492 0 UBX domain-containing protein 1
605 3 484 3 1454 gl 3160494 0 UBX domain-containing protein 1
605 3 484 3 1454 g14249831 0 UBX domain-containing 2
606 3 118 3 356 g16549907 2.00E-41 unnamed protein product w 606 3 118 3 356 g2887445 2.00E-24 KIAA0412
K 606 3 118 3 356 g3289985 2.00E-24 KIAA0412
607 3 158 453 926 g4185943 5.00E-73 pol protein
607 3 158 453 926 g5802821 7.00E-72 Gag-Pro-Pol protein
607 3 158 453 926 g4456990 7.00E-72 polymerase
608 3 630 3 1892 g499204 1.00E-75 D-E-A-D box protein
608 3 630 3 1892 g4972732 1.00E-75 unknown
608 3 630 3 1892 g7294064 1.00E-75 Dbp73D gene product
609 3 268 756 1559 gl2314164 l.OOE-l 51 bA526D8.2 (novel protein similar to KIAA1074)
609 3 268 756 1559 gl2314195 l.OOE-134 bA255Al 1.3 (novel protein similar to KIAA1074)
609 3 268 756 1559 g12053099 3.00E-96 hypothetical protein
610 1 372 13 1128 g12842288 l.OOE-l66 Ank repeat containing protein-data source:Pfam, source key:PF00023, evidence: ISS-putative
610 1 372 13 1128 g7303380 3.00E-21 CGI 3320 gene product
610 1 372 13 1128 g7293339 6.00E-10 f gene product
612 2 132 203 598 g17016967 2.00E-67 NUANCE
612 2 132 203 598 g17016965 2.00E-67 NUANCE-N-33
612 2 132 203 598 g17016969 2.00E-59 NUANCE
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Sc Annotation
613 2 617 608 2458 g6634023 0 KIAA0356 protein
613 2 617 608 2458 g7899288 0 unnamed protein product
613 2 617 608 2458 g9367856 l.OOE-172 hypothetical protein KIAA0356
614 3 211 93 725 g4314340 l.OOE-103 Human alpha-adaptin A homolog
614 3 211 93 725 g15963476 l.OOE-103 alpha-adaptin A related protein
614 3 211 93 725 g49878 4.00E-95 alpha-adaptin (A) (AA 1-977)
615 3 487 762 2222 g14042035 0 unnamed protein product
615 3 487 762 2222 g6063139 6.00E-41 BTB/POZ domain zinc finger factor HOF-L
615 3 487 762 2222 g4886505 6.00E-41 hypothetical protein
616 2 972 2 2917 gl8314381 0 Similar to mitotic control protein dis3 homolog
616 2 972 2 2917 g15559519 0 Unknown (protein for IMAGE:4561365)
616 2 972 2 2917 g17225572 l.OOE-154 KIAA1008 protein
617 3 100 183 482 g18650590 3.00E-34 archease
617 3 100 183 482 g12841926 3.00E-34 data source:SPTR, source key:Q9VD92, evidence:ISS~putative~related to u CG6353 PROTEIN w 617 3 100 183 482 g12840887 3.00E-34 data source:SPTR, source key:Q9VD92, evidence:ISS~putative~related to CG6353 PROTEIN
618 1 438 106 1419 g2689446 0 R27945J
618 1 438 106 1419 g16549907 l.OOE-144 unnamed protein product
618 1 438 106 1419 g3289985 l.OOE-138 KIAA0412
619 2 138 2870 3283 g5262325 1.00E-43 C358B7.1 (ubiquitin-conjugating enzyme E2I (homologous to yeast UBC9))
619 2 138 2870 3283 g4079643 1.00E-43 ubiquitin-conjugating enzyme UbcE2A
619 2 138 2870 3283 g2597931 1.00E-43 ubiquitin-conjugating enzyme, UBC9
620 329 1 987 gl7105197 l.OOE-173 kelch-like protein KLHLό
620 329 1 987 g18044145 7.00E-50 Unknown (protein for MGQ28950)
620 329 1 987 g12314036 7.00E-50 dJ383J4.1 (A Kelch motif-containing protein)
621 380 73 1212 g14575679 0 hemicentin
621 380 73 1212 gl6551710 0 unnamed protein product
621 380 73 1212 gl 1544425 l.OOE-170 bG15303.1 (similar to C. elegans hemicentin precursor)
622 3 232 366 1061 g7019945 l.OOE-117 unnamed protein product
622 3 232 366 1061 g12804721 2.00E-50 Unknown (protein for MGC:2663)
622 3 232 366 1061 g7959207 2.00E-46 KIAA1473 protein
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Score Annotation
623 136 115 522 g407466 4.00E-34 QM protein
623 136 115 522 g402827 4.00E-34 QM
623 136 115 522 gl90814 4.00E-34 Wilm's tumor-related protein
624 838 37 2550 g6331377 0 KIAA1285 protein
624 838 37 2550 g18614026 l.OOE-108 zinc finger DNA binding protein p71
624 838 37 2550 g5630080 l.OOE-106 similar to HUB1; similar to BAA24380 (PID:g2789430)
625 3 255 3 767 g18027350 l.OOE-l48 unknown
625 3 255 3 767 g15072406 l.OOE-147 TNFAIP1 -like protein
625 3 255 3 767 g16152040 l.OOE-145 polymerase delta-interacting protein 1
626 2 327 2 982 g13277864 l.OOE-161 Similar to ATPase, H+ transporting, lysosomal (vacuolar proton pump) 42kD
626 2 327 2 982 g15082451 l.OOE-153 Unknown (protein for MGC:20253)
626 2 327 2 982 g37643 4.00E-93 vacuolar proton-ATPase
627 2 264 11 802 g1208742 l.OOE-137 protein B
627 2 264 11 802 g1200503 l.OOE-137 B
627 2 264 11 802 g16878002 l.OOE-137 Unknown (protein for MGC: 12569)
628 3 163 1377 1865 g16549383 6.00E-75 unnamed protein product
628 3 163 1377 1865 g15824463 2.00E-57 DiGeorge syndrome-related protein FKSG4
628 3 163 1377 1865 g3094014 2.00E-56 unknown
629 1 262 1 786 g14043223 2.00E-95 Unknown (protein for MGC: 15677)
629 1 262 1 786 g16076870 2.00E-52 LD37206p
629 1 262 1 786 g7297712 3.00E-49 CG6144 gene product
630 3 323 879 1847 g7294748 7.00E-48 CG7616 gene product
630 3 323 879 1847 g12847351 2.00E-30 data source:SPTR, source key:Q9UIE6, evidence:ISS~homolog to HYPOTHETICAL 52.0 KDA PROTEIN -putative
630 3 323 879 1847 gl4714781 2.00E-30 RIKEN cDNA 2610005A10 gene
632 175 61 585 g17064172 1.00E-80 NALP4
632 175 61 585 g16552162 1.00E-28 unnamed protein product
632 175 61 585 g17901636 6.00E-20 unnamed protein product
633 561 1 1683 g17389275 0 Unknown (protein for MGC: 19357)
633 561 1 1683 g15209718 l.OOE-173 unnamed protein product
633 561 1 1683 g3702269 l.OOE-151 sodium iodide symporter
634 3 276 30 857 g3955100 2.00E-75 vacuolar adenosine triphosphatase subunit D
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Score Annotation
634 3 276 30 857 g15029719 2.00E-75 Unknown (protein for MGC: 18332)
634 3 276 30 857 g14250784 2.00E-75 Unknown (protein for MGC: 15351)
635 1 398 490 1683 g3712671 l.OOE-l 37 vascular endothelial growth factor
635 1 398 490 1683 g340301 l.OOE-133 vascular permeability factor precursor
635 1 398 490 1683 g340215 l.OOE-133 vascular endothelial growth factor
636 2 197 689 1279 g17045994 l.OOE-101 unnamed protein product
636 2 197 689 1279 g36615 1.00E-82 serine/threonine protein kinase
636 2 197 689 1279 g7297009 8.00E-72 CG7236 gene product
637 3 307 3 923 g15488871 l.OOE-172 aquaporin 3
637 3 307 3 923 g1854374 l.OOE-172 aquaporin 3
637 3 307 3 923 g4416299 l.OOE-164 aquaporin-3; AQP3
638 3 263 708 1496 g16549180 l.OOE-102 unnamed protein product
638 3 263 708 1496 g5441615 l.OOE-101 zinc finger protein
638 3 263 708 1496 g488555 1.00E-99 zinc finger protein ZNF135 w 639 1 673 241 2259 g5080758 0 BC331 191J uι 639 1 673 241 2259 g1769491 0 kruppel-related zinc finger protein
639 1 673 241 2259 g3135968 0 D34I8.1 (zinc finger protein 184 (Kruppel-like))
640 3 198 66 659 g12805201 3.00E-17 Similar to zinc finger protein 97
640 3 198 66 659 g14042682 3.00E-15 unnamed protein product
640 3 198 66 659 g5453423 3.00E-13 epstein-barr virus-induced zinc finger protein
641 1 947 34 2874 g6329952 0 KIAA1 141 protein
641 1 947 34 2874 gl 7391340 0 Unknown (protein for MGC20009)
641 1 947 34 2874 g17981470 0 zinc finger protein ZFP100
642 3 285 318 1172 g15489325 l.OOE-163 Similar to hypothetical protein MGC 10520
642 3 285 318 1172 g16549189 l.OOE-110 unnamed protein product
642 3 285 318 1172 g488555 l.OOE-107 zinc finger protein ZNF135
643 1 2044 16 6147 g30186 0 CR1 precursor protein
643 1 2044 16 6147 g306680 0 complement receptor 1
643 1 2044 16 6147 g557725 0 complement receptor 1
644 3 827 60 2540 g1235672 0 metalloprotease/disintegrin/cysteine-rich protein precursor
644 3 827 60 2540 g6630618 0 KIAA0021 protein
644 3 827 60 2540 g1235676 0 metalloprotease/disintegrin/cysteine rich protein precursor
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Sc Annotation
645 2 378 821 1954 g14134965 0 unnamed protein product
645 2 378 821 1954 g219867 6.00E-57 HM74
645 2 378 821 1954 gl 1558406 8.00E-57 putative seven transmembrane spanning receptor
646 2 263 2 790 g15277259 l.OOE-157 zinc finger protein homologous to mouse Zfp91
646 2 263 2 790 g15865601 l.OOE-157 FKSG1 1
646 2 263 2 790 g453376 l.OOE-154 zinc finger protein PZF
647 256 856 1623 g13436164 l.OOE-152 carbonic anhydrase III, muscle specific
647 256 856 1623 g179789 l.OOE-152 carbonic anhydrase III
647 256 856 1623 gl 5029812 l.OOE-140 carbonic anhydrase 3
648 359 1 1077 g512464 0 u-PA receptor
648 359 1 1077 g4335703 0 UPARJHUMAN; GPI-ANCHORED FORM PRECURSOR; U-PAR; MONOCYTE ACTIVATION ANTIGEN M03; CD87 ANTIGEN
648 1 359 1 1077 g37605 0 urokinase plasminogen activator receptor
649 2 727 233 2413 g5006263 0 organic anion transporter OATP-B w 649 2 727 233 2413 g4240249 0 KIAA0880 protein
£ 649 2 727 233 2413 gl 1990589 0 organic anion transporter polypeptide-related protein 2
650 3 93 909 1187 g54912 2.00E-43 tropomyosin 5
650 3 93 909 1187 g438878 2.00E-43 tropomyosin
650 3 93 909 1187 g312928 2.00E-43 tropomyosin isoform 6
651 2 374 185 1306 g13365855 0 hypothetical protein
651 2 374 185 1306 g2072425 1.00E-70 non-lens beta gamma-crystallin like protein
651 2 374 185 1306 g15207879 1.00E-65 hypothetical protein
652 233 592 1290 g33967 l.OOE-124 interferon regulatory factor-2 (AA 1 -349)
652 233 592 1290 g16041826 l.OOE-124 interferon regulatory factor 2
652 233 592 1290 g6090306 l.OOE-116 unnamed protein product
653 564 1 1692 g6733355 0 unnamed protein product
653 564 1 1692 g2967646 0 Smad2
653 564 1 1692 g2695663 0 MAD-related protein Smad2
654 2 499 299 1795 g1289371 0 Ikaros/LyF-l homolog
654 2 499 299 1795 gl911483 0 hlkl
654 2 499 299 1795 g2330595 0 Ikaros transcription factor
655 1 1968 481 6384 g3413888 0 KIAA0463 protein
TABLE 7 o -o -
SEQ ID oNO: Frame Length Start Stop Gl Number Probability So Annotation
655 1 1968 481 6384 g1655432 0 plexin 2
655 1 1968 481 6384 g6010215 0 OCT/plexin-A2 protein
656 2 321 458 1420 g18480242 l.OOE-152 olfactory receptor MORI 38-2
656 2 321 458 1420 g15293713 l.OOE-123 olfactory receptor
656 2 321 458 1420 g18480166 l.OOE-106 olfactory receptor MORI 38-1
657 1 415 493 1737 g1197538 0 myocyte-specific enhancer factor 2A, C4 form
657 1 415 493 1737 g34536 0 myocyte-specific enhancer factor 2 (MEF2)
657 1 415 493 1737 g432656 0 serum response factor-related protein
658 2 578 905 2638 g14009457 0 protocadherin-beta 12
658 2 578 905 2638 g5457031 0 protocadherin beta 12
658 2 578 905 2638 g5457029 0 protocadherin beta 11
659 2 449 1112 2458 g32033 0 put. HBK2 protein (AA 1-529)
659 2 449 1112 2458 g57667 0 put. RCK2 protein (AA 1-530)
659 2 449 1112 2458 g199893 0 murine potassium channel protein
2 206 14 631 g7340874 2.00E-96 ESTs D15590(C0900),D48950(S15542),D22684(C0900) correspond to a region of the predicted gene. -Similar to Arabidopsis thaliana 60S ribosomal protein LI 1A (L16A). (P42795)
660 2 206 14 631 g7630065 1.00E-94 ribosomal protein LI 1-like
660 2 206 14 631 g14517470 1.00E-94 AT4gl8730/F28A21_140
661 3 423 36 1304 g17225038 l.OOE-173 CaMKK beta 1 isoform
661 3 423 36 1304 g17225036 l.OOE-173 CaMKK beta 1 isoform
661 3 423 36 1304 g14522878 l.OOE-173 calcium/calmodulin-dependent protein kinase kinase b2
662 3 446 693 2030 g4096339 0 zinc finger protein
662 3 446 693 2030 g6691968 l.OOE-168 dJ148M19.1 (zinc finger protein)
662 3 446 693 2030 g5457352 2.00E-78 AP-2rep protein
663 3 842 3 2528 g2343289 0 NMDAR1 subunit isoform 4b
663 3 842 3 2528 g2343287 0 NMDAR1 subunit isoform 3b
663 3 842 3 2528 g56765 0 NMDA receptor subunit, type NMDAR1-LL
664 2 184 2 553 g2668738 2.00E-89 translation initiation factor 5A
664 2 184 2 553 gl546919 2.00E-89 translation initiation factor 5A
664 2 184 2 553 g3789948 2.00E-83 translation initiation factor 5A
665 3 267 903 1703 g14139788 l.OOE-154 unnamed protein product
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability So Annotation
665 3 267 903 1703 g12405805 l.OOE-154 unnamed protein product
665 3 267 903 1703 g6453491 l.OOE-154 hypothetical protein
666 2 298 5 898 g13879442 l.OOE-119 Similar to RIKEN cDNA 2310035M22 gene
666 2 298 5 898 g12855490 l.OOE-114 data source:SPTR, source key:P24390, evidence:ISS~homolog to ER LUMEN PROTEIN RETAINING RECEPTOR 1 (KDEL RECEPTOR l)~putative
666 2 298 5 898 g12848905 l.OOE-111 data source:SPTR, source key:O60858, evidence: ISS-homolog to LEUKEMIA ASSOCIATED PROTEIN 5 (B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA TUMOR SUPPRESSOR LEU5)~putative
667 2 232 128 823 g1763638 l.OOE-111 alpha 1 A-voltage-dependent calcium channel
667 2 232 128 823 g1763636 l.OOE-111 alpha! A-voltage-dependent calcium channel
667 2 232 128 823 g1763632 l.OOE-111 alpha 1 A-voltage-sensitive calcium channel
668 2 154 206 667 g12837586 1.00E-64 data source:SPTR, source key:P37545, evidence:ISS~putative~related to HYPOTHETICAL 29.2 KDA PROTEIN IN METS-KSGA INTERGENIC REGION
668 2 154 206 667 g2632306 5.00E-13 similar to hypothetical proteins w 668 2 154 206 667 g467428 5.00E-13 unknown
∞ 669 1 287 1 861 g14042544 l.OOE-158 unnamed protein product
669 1 287 1 861 g7650202 l.OOE-151 CECR1 protein
669 1 287 1 861 g17646182 l.OOE-116 CECR1
670 3 538 1 5 1808 g16307285 0 Unknown (protein for IMAGE:3877337)
670 3 538 195 1808 g15208051 l.OOE-157 hypothetical protein
670 3 538 195 1808 g12855904 8.00E-96 evidence:NAS~hypothetical protein-putative
671 1 474 2767 4188 g10434329 0 unnamed protein product
671 1 474 2767 4188 gl4133251 0 KIAA 1479 protein
671 1 474 2767 4188 g10434456 0 unnamed protein product
672 3 424 501 1772 g4589566 0 KIAA0961 protein
672 3 424 501 1772 g13676461 0 hypothetical protein
672 3 424 501 1772 g456269 0 zinc finger protein 30
673 2 425 155 1429 g5262574 0 hypothetical protein
673 2 425 155 1429 g17861380 0 nesprin-2 beta
673 2 425 155 1429 g17016967 0 NUANCE
674 3 514 3 1544 g17049366 0 unnamed protein product
674 3 514 3 1544 g13447749 0 fibroblast growth factor receptor 5
TABLE 7
SEQ ID NO Frame Length Start Stop Gl Number Probability Sc Annotation
674 3 514 3 1544 g10944887 0 FGFR-like protein
675 1 149 145 591 g7959207 200E-26 KIAA 1473 protein
675 1 149 145 591 g498736 400E-26 zinc finger protein
675 1 149 145 591 g16551398 600E-26 unnamed protein product
676 2 347 134 1174 g13938261 400E-91 Unknown (protein for MGC 15514)
676 2 347 134 1174 g5262557 400E-91 hypothetical protein
676 2 347 134 1174 g15488954 100E-89 Unknown (protein for MGC 8872)
677 3 552 3 1658 g12803309 0 hypothetical protein FU20481
677 3 552 3 1658 g7020611 0 unnamed protein product
677 3 552 3 1658 g12853070 0 EF hand containing protein-data source Pfam, source key PF00036, evidence ISS~putatιve
678 488 1 1464 g14794726 0 CUB and sushi multiple domains 1 protein
678 488 1 1464 g14787176 0 CSMD1
678 488 1 1464 g15620827 100E-172 KIAA 1884 protein w 679 398 4 1197 g16549477 0 unnamed protein product
S 679 398 4 1197 g12214288 5 OOE-87 dJ402H5 2 (novel protein similar to worm and fly proteins)
679 398 4 1197 g7302178 500E-27 CG 1 1212 gene product
680 613 103 1941 g3643115 0 protein inhibitor of activated STAT protein PIASx-beta
680 613 103 1941 g13542785 0 Unknown (protein for MGC 1 1445)
680 613 103 1941 g3643113 0 protein inhibitor of activated STAT protein PIASx-alpha
681 420 1 1260 g12853497 0 BTB/POZ domain containing protein-data source Pfam, source key PF00651, evidence ISS~putatιve
681 420 1260 g18204103 0 RIKEN cDNA 4930429H24 gene
681 420 1260 g7019911 0 unnamed protein product
682 287 861 g18027414 1 OOE-111 unknown
682 287 861 g13358646 100E-96 hypothetical protein
682 287 861 g12843142 300E-91 TPR Domain containing protein-data source Pfam, source key PF00515, evidence ISS~putatιve
683 3 428 621 1904 g12309630 0 bA438B23 1 (neuronal leucine-rich repeat protein)
683 3 428 621 1904 g16551759 0 unnamed protein product
683 3 428 621 1904 g15029689 1 OOE-122 Unknown (protein for MGC 17422)
684 1 809 25 2451 g6633952 0 KIAA0137 protein
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Score Annotation
684 1 809 25 2451 g2217933 0 PKU-beta
684 1 809 25 2451 g6063017 0 tousled-like kinase 1
685 3 543 234 1862 g12836718 0 data source:SPTR, source key:Q9l8M2, evidence:ISS~putative~related to PUTATIVE N-TERMINAL ACETYLTRANSFERASE
685 3 543 234 1862 g13195460 0 putative acetyltransferase
685 3 543 234 1862 g14589342 0 putative N-acetyltransferase
686 3 442 3 1328 g12856025 0 WD domain, G-beta repeat containing protein-data source:Pfam, source key:PF00400, evidence:ISS~putative
686 3 442 3 1328 g12846941 l.OOE-107 WD domain, G-beta repeat containing protein-data source:Pfam, source key:PF00400, evidence:ISS~putative
686 3 442 3 1328 g17488592 l.OOE-107 unknown protein
687 3 502 126 1631 g10800564 0 bA338Ll 1 .1 (novel CUB domain protein similar to attractin)
687 3 502 126 1631 g8118082 l.OOE-137 membrane attractin precursor
687 3 502 126 1631 g8118083 l.OOE-137 secreted attractin precursor u 688 3 316 3 950 g18480302 1.OOE-111 olfactory receptor MOR262-10
© 688 3 316 3 950 g5869927 l.OOE-104 olfactory receptor
688 3 316 3 950 g8919698 l.OOE-104 olfactory receptor
689 1 265 1 795 g12846015 l.OOE-153 data source:SPTR, source key:Q9NZ01 , evidence:ISS~homolog to SYNAPTIC GLYCOPROTEIN SC2 (UNKNOWN) (PROTEIN FOR MGC: 14589) (SIMILAR TO CGI 0849 GENE PRODUCT)~putative
689 1 265 1 795 g256994 l.OOE-150 SC2
689 1 265 1 795 g18044806 l.OOE-l50 RIKEN cDNA A230102P12 gene
690 2 182 905 1450 g6015476 4.00E-60 C-terminal binding protein 2
690 2 182 905 1450 g15426462 4.00E-60 Unknown (protein for MGC: 13751)
690 2 182 905 1450 g12034656 4.00E-60 ribeye
691 2 613 119 1957 g15020827 0 dJ29Kl .2 (KIAA0426 (C2H2 type zinc finger protein))
691 2 613 119 1957 g2887427 0 KIAA0426
691 2 613 119 1957 g4097501 0 zinc finger protein 96
692 1 978 337 3270 g14602998 0 Unknown (protein for IMAGE:4121355)
692 1 978 337 3270 g1657837 0 pl lόRip
692 1 978 337 3270 g10803059 0 P1 16RIP
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Score Annotation
693 2 538 2 1615 gl 1323324 0 dJ138B7.3.2 (lethal (3) malignant brain tumor (l(3)mbt) protein (Drosophila) homolog (isoform 2) (KIAA0681))
693 2 538 2 1615 g3327176 0 KIAA0681 protein
693 2 538 2 1615 g11323323 0 dJ138B7.3.1 (continued from dJ862K6.1 in Em:AL031681)
694 3 414 669 1910 g7960216 0 RACK-like protein PRKCBP1
694 3 414 669 1910 gl 1385648 0 CTCL tumor antigen sel4-3
694 3 414 669 1910 g17980969 0 sel4-3r protein
695 2 503 1157 2665 g7242977 0 KIAA131 1 protein
695 2 503 1157 2665 g14042145 l.OOE-113 unnamed protein product
695 2 503 1157 2665 g14041949 l.OOE-112 unnamed protein product
696 2 1270 224 4033 gl 1596412 0 GAC-1
696 2 1270 224 4033 g10437204 0 unnamed protein product
696 2 1270 224 4033 g7019901 0 unnamed protein product
697 2 349 2 1048 g6599275 l.OOE-111 hypothetical protein w 697 2 349 2 1048 g5805208 l.OOE-111 fas-associated factor 1
^ 697 2 349 2 1048 g4680647 l.OOE-111 CGI-03 protein
699 1 150 982 1431 g16603814 2.00E-75 small GTP-binding protein
699 1 150 982 1431 gl3177778 2.00E-75 SARI protein
699 1 150 982 1431 g12052967 2.00E-75 hypothetical protein
700 3 664 204 2195 g7959343 l.OOE-161 KIAA1538 protein
700 3 664 204 2195 g12844361 1.00E-87 BTB/POZ domain containing protein-data source:Pfam, source key:PF00651 , evidence:ISS~putative
700 3 664 204 2195 g2085786 4.00E-32 similar to zinc finger 5 protein from Gallus gallus, U51640 (PID:g 1399185)
701 3 274 3 824 g10434090 l.OOE-142 unnamed protein product
701 3 274 3 824 g12836022 2.00E-53 data source:SPTR, source key:Q9P2N7, evidence:ISS~homolog to HYPOTHETICAL PROTEIN KIAA1309 (FRAGMENT)~putative
701 3 274 3 824 g7243089 7.00E-53 KIAA 1354 protein
702 2 281 2 844 g306487 l.OOE-l30 cap-binding protein
702 2 281 2 844 g15214959 l.OOE-129 Similar to eukaryotic translation initiation factor 4E
702 2 281 2 844 g7673694 l.OOE-128 translation initiation factor elF-4E
703 3 210 3 632 g13544026 4.00E-98 putative zinc finger protein from EUROIMAGE 566589
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Score Annotation
703 3 210 3 632 g5102580 4.00E-98 hypothetical protein, similar to (AF134804) putative zinc finger transcription factor OVOl
703 3 210 3 632 g10433647 2.00E-97 unnamed protein product
704 625 40 1914 g3256264 0 MTG8-related protein MTGlόa
704 625 40 1914 g3256266 0 MTG8-related protein MTGlόb
704 625 40 1914 g2723941 0 ETO/MTG8-related protein ETO-2
705 424 76 1347 g2664429 0 hypothetical protein
705 424 76 1347 g16549891 0 unnamed protein product
705 424 76 1347 g18461369 l.OOE-l 79 hexaribonucleotide binding protein 2
706 3 592 2766 4541 g17223624 0 ATP-binding cassette A9
706 3 592 2766 4541 g4240130 0 KIAA0822 protein
706 3 592 2766 4541 g17223626 0 ATP-binding cassette A10
707 1 661 274 2256 g17017251 0 MEGF12
707 1 661 274 2256 g17386053 0 Jedi protein
707 1 661 274 2256 g18252658 l.OOE-116 Jedi-736 protein
708 3 608 252 2075 g6634025 l.OOE-172 KIAA0379 protein
708 3 608 252 2075 g6453538 l.OOE-160 hypothetical protein
708 3 608 252 2075 g4803678 5.00E-48 ankyrin (brank-2)
709 2 860 266 2845 g10434450 0 unnamed protein product
709 2 860 266 2845 g6002623 0 putative RNA-binding protein Q99
709 2 860 266 2845 g10047199 0 KIAA 1567 protein
710 2 1215 2 3646 g7243153 0 KIAA1386 protein
710 2 1215 2 3646 g6807862 0 hypothetical protein
710 2 1215 2 3646 g7022270 0 unnamed protein product
711 2 468 2 1405 g13097657 0 Unknown (protein for IMAGE:361 1719)
711 2 468 2 1405 g8885518 0 hypothetical protein
711 2 468 2 1405 g12854661 l.OOE-164 Ank repeat containing protein-data source:Pfam, source key:PF00023, evidence: ISS-putative
712 1 738 1 2214 g3327040 0 KIAA0613 protein
712 1 738 1 2214 gl 1612596 0 cypher 1
712 1 738 1 2214 g6969629 0 oracle 1 protein
713 2 565 2 1696 g4126475 0 BAP2-alpha protein
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability So Annotation
713 2 565 2 1696 g4239984 0 insulin receptor substrate protein of 53 kDa (a shorter form)
713 2 565 2 1696 g15559320 0 Similar to BAH -associated protein 2
714 1 86 370 627 g12652727 5.00E-44 Unknown (protein for IMAGE:3352566)
714 1 86 370 627 g16552245 5.00E-13 unnamed protein product
714 1 86 370 627 g4567180 l.OOE-12 BC37295_2 (partial)
715 3 221 3 665 g12655189 l.OOE-117 testin
715 3 221 3 665 g10443903 l.OOE-117 TESTIN 3
715 3 221 3 665 g10443902 l.OOE-117 TESTIN 2
716 3 330 3 992 g13516831 0 MAIL
716 3 330 3 992 g13442951 l.OOE-l 78 MAIL
716 3 330 3 992 g13702146 l.OOE-173 IL-1 inducible nuclear ankyrin-repeat protein
717 2 1036 2 3109 g7243105 l.OOE-118 KIAA 1362 protein
717 2 1036 2 3109 g7023688 l.OOE-109 unnamed protein product
717 2 1036 2 3109 g12855942 l.OOE-108 data source:MGD, source key:MGI:1261419, evidence: ISS-ethanol u decreased 4~putative w 718 3 532 1404 2999 g7020464 l.OOE-l59 unnamed protein product
718 3 532 1404 2999 g757872 l.OOE-150 env
718 3 532 1404 2999 g5802822 l.OOE-150 envelope protein
719 1 1373 1 4119 g12240161 0 uveal autoantigen
719 1 1373 1 4119 g12240158 0 uveal autoantigen
719 1 1373 1 4119 gl0944718 0 C3VS protein
720 2 280 2 841 g18034491 l.OOE-152 SRrp35
720 2 280 2 841 g18203864 l.OOE-151 Similar to FUS interacting protein (serine-arginine rich) 2
720 2 280 2 841 g3327976 1.00E-63 TLS-associated protein TASR-2 .
721 2 288 2 865 g16553765 l.OOE-l34 unnamed protein product
721 2 288 2 865 gl 2839186 l.OOE-128 data source:SPTR, source key:Q9VS60, evidence: ISS-putative-related to CG8576 PROTEIN
721 2 288 2 865 g1072250 1.00E-31 F53B1.2 gene product
722 2 175 200 724 g18645200 9.00E-93 hypothetical gene supported by XM_059671
723 2 385 92 1246 g12803351 l.OOE-136 Unknown (protein for IMAGE:3050476)
723 2 385 92 1246 g18204315 l.OOE-136 Unknown (protein for MGC31975)
723 2 385 92 1246 g2352822 2.00E-42 glucose-6-phosphatase
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Sc Annotation
724 2 269 284 1090 g16041142 l.OOE-133 hypothetical protein
724 2 269 284 1090 gl4017813 4.00E-88 KIAA1798 protein
724 2 269 284 1090 g11323323 5.00E-84 dJ138B7.3.1 (continued from dJ862K6.1 in Em:AL031681)
725 2 552 299 1954 g17064170 0 HSV-I stimulating-related protein
725 2 552 299 1954 g4240233 0 KIAA0872 protein
725 2 552 299 1954 g14495695 l.OOE-114 Unknown (protein for MGC: 15935)
726 2 296 8 895 g13435476 l.OOE-133 Unknown (protein for MGC6708)
726 2 296 8 895 g12849125 l.OOE-129 DNA segment, Chr 10, University of California at Los Angeles 1 -data source:MGD, source key:MGI:88930, evidence:ISS~putative
726 2 296 8 895 g12842006 6.00E-97 DNA segment, Chr 10, University of California at Los Angeles 1 -data source:MGD, source key:MGI:88930, evidence:ISS~putative
727 3 462 645 2030 g10047211 0 KIAA1573 protein
727 3 462 645 2030 g14388334 2.00E-85 hypothetical protein
727 3 462 645 2030 g7298275 4.00E-13 BG:DS07473.1 gene product
728 2 126 209 586 g2306773 2.00E-20 zinc finger protein 728 2 126 209 586 gl 1137801 2.00E-20 dJ265C24.2 (zinc finger protein 192 (LD5-1))
728 2 126 209 586 g1373394 2.00E-20 zinc finger protein
729 474 1 1422 g7959207 0 KIAA1473 protein
729 474 1 1422 g1017722 0 repressor transcriptional factor
729 474 1 1422 g16041769 0 Unknown (protein for MGC:23189)
730 241 1 723 g12855389 1.00E-41 data source:SPTR, source key:Q9N5L6, evidence:ISS~putative~related to H23L24.3 PROTEIN
730 241 1 723 g15718609 1.00E-40 Hypothetical protein H23L24.3
730 241 1 723 g7301565 1.00E-33 CG5987 gene product
731 258 70 843 gl 199602 1.00E-116 cyclophilin-like protein
731 258 70 843 g1199598 l.OOE-116 cyclophilin-like protein CyP-60
731 258 70 843 gl 199600 l.OOE-116 cyclophilin-like protein
732 161 46 528 gl7511871 6.00E-94 Unknown (protein for MGC32104)
732 161 46 528 g14042715 2.00E-68 unnamed protein product
732 161 46 528 g7023417 2.00E-68 unnamed protein product
733 3 456 3 1370 g16306806 0 zinc finger protein 43 (HTF6)
733 3 456 3 1370 g38032 0 ZNF43
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number f Drobabilitγ Score Annotation
733 3 456 3 1370 g186774 0 zinc finger protein
734 2 454 2 1363 g14042850 l.OOE-117 unnamed protein product
734 2 454 2 1363 g12052983 6.00E-85 hypothetical protein
734 2 454 2 1363 g487785 6.00E-76 zinc finger protein ZNF136
735 2 153 2 460 g37910 1.00E-59 precursor
735 2 153 2 460 g17511825 5.00E-59 Similar to immunoglobulin kappa constant
735 2 153 2 460 g560842 1.00E-58 anti-Sm antibody VL chain (V kappa 4/J kappa 3)
736 319 235 1191 g6808105 9.00E-80 hypothetical protein
736 319 235 1191 g13676443 3.00E-79 hypothetical protein
736 319 235 1191 gl8146831 9.00E-63 RGL1
737 245 433 1167 g18034086 l.OOE-133 ankyrin repeat domain-containing SOCS box protein Asb-15
737 245 433 1167 g18034106 l.OOE-125 ankyrin repeat domain-containing SOCS box protein Asb-15
737 245 433 1167 g15451412 l.OOE-105 hypothetical protein
738 2 432 2 1297 g5050962 4.00E-19 dJ34B21.5 (PUTATIVE novel protein with ZU5 domain similar to part of Tight Junction Protein ZOl (TJP1) and UNC5 Homologs) 738 2 432 2 1297 g2088527 7.00E-17 rostral cerebellar malformation protein
738 2 432 2 1297 g2055394 5.00E-15 transmembrane receptor UNC5H2
739 1 1206 40 3657 g7297900 l.OOE-l32 CG6734 gene product
739 1 1206 40 3657 g3880102 6.00E-25 contains similarity to Pfam domain: PF00400 (WD domain, G-beta repeat), Score=38.1, E-value=6.5e-08, N=3; PF01363 (FYVE zinc finger), Score=l 15.4, E- value=1.3e-31, N=l; PF02138 (Beige/BEACH domain), Score=773.7, E- value=2.4e-229, N=l -cDNA EST ykl36hl2.5 comes from this gene-cDNA EST yk265b4.5 comes from this gene-cDNA EST yk319c2.5 comes from this gene-cDNA EST yk359g9.5 comes from this gene-cDNA EST yk635c4.5 comes from this gene-cDNA EST ykl93g4.5 comes from this gene-cDNA EST yk342c8.5 comes from this gene-cDNA EST yk356bl .5 comes from this gene-cDNA EST yk399d2.5 comes from this gene
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Score Annotation 739 1 1206 40 3657 g3880448 6.00E-25 contains similarity to Pfam domain: PF00400 (WD domain, G-beta repeat), Score=38.1, E-value=6.5e-08, N=3; PF01363 (FYVE zinc finger), Score=l 15.4, E- value=1.3e-31, N=l; PF02138 (Beige/BEACH domain), Score=773.7, E- value=2.4e-229, N=l -cDNA EST ykl36hl2.5 comes from this gene-cDNA EST yk265b4.5 comes from this gene-cDNA EST yk319c2.5 comes from this gene-cDNA EST yk359g9.5 comes from this gene-cDNA EST yk635c4.5 comes from this gene-cDNA EST ykl93g4.5 comes from this gene-cDNA EST yk342c8.5 comes from this gene-cDNA EST yk356bl .5 comes from this gene-cDNA EST yk399d2.5 comes from this gene
741 3 115 447 791 g5080758 8.00E-17 BC331 191J
741 3 115 447 791 g10047183 2.00E-13 KIAA 1559 protein
741 3 115 447 791 gl5021881 3.00E-13 hypothetical protein
742 2 215 2 646 g14279194 l.OOE-l09 aldo-keto reductase loopADR
742 2 215 2 646 g12804019 l.OOE-109 Similar to aldo-keto reductase
742 2 215 2 646 g15215178 1.00E-68 RIKEN cDNA 1810061110 gene
743 1 290 166 1035 g16551783 l.OOE-115 unnamed protein product
743 1 290 166 1035 g881564 8.00E-46 ZNF157
743 1 290 166 1035 g14456632 1.00E-62 dJ54B20.6 (zinc finger protein 81 (HFZ20))
744 3 519 3 1559 g15559662 0 Unknown (protein for MGC20975)
744 3 519 3 1559 g16877077 0 Unknown (protein for MGC24494)
744 3 519 3 1559 g9886891 4.00E-45 zinc finger protein 276 C2H2 type
745 1 514 1 1542 g16552010 0 unnamed protein product
745 1 514 1 1542 g12836633 l.OOE-120 data source:Pfam, source key:PF00093, evidence:ISS~putative~von Willebrand factor type C domain containing protein
745 1 514 1 1542 g7768636 1.00E-54 Kielin
746 1 63 157 345 g347906 4.00E-18 zinc finger protein
746 1 63 157 345 g13435780 3.00E-16 Similar to Kruppel associated box (KRAB) zinc finger 1
746 1 63 157 345 g5823276 5.00E-16 kruppel-like protein
748 3 168 399 902 gl 1611571 2.00E-54 hypothetical protein
748 3 168 399 902 g9886891 2.00E-52 zinc finger protein 276 C2H2 type
748 3 168 399 902 g16877077 9.00E-19 Unknown (protein for MGC:24494)
749 1 694 1 2082 g13936547 0 formin-binding protein 17
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Sc Annotation
749 1 694 1 2082 g3043632 0 KIAA0554 protein
749 1 694 1 2082 g10435680 0 unnamed protein product
751 3 448 453 1796 g58491 0 El b 55k protein (transformation)
751 3 448 453 1796 g209820 0 transformation-associated protein
751 3 448 453 1796 gl 7105043 l.OOE-163 54.7 kDa
752 3 800 387 2786 g9992893 0 phosphoinositol 3-phosphate binding protein-1
752 3 800 387 2786 g18204000 0 Similar to pleckstrin homology domain-containing, family A (phosphoinositide binding specific) member 4
752 3 800 387 2786 g10045840 1.00E-33 TPC2
753 846 1 2538 g6329945 0 KIAA1 140 protein
753 846 1 2538 g4972746 l.OOE-146 unknown
753 846 1 2538 g7302173 l.OOE-146 BcDNA:LD21719 gene product
754 117 217 567 g16550444 4.00E-28 unnamed protein product
754 117 217 567 g12652759 7.00E-27 hypothetical protein FU20557 u 754 117 217 567 g7020745 7.00E-27 unnamed protein product
KJ ~4 755 211 1 633 g487284 l.OOE-131 CRP2 (cysteine-rich protein 2)
755 211 1 633 g12805265 l.OOE-130 cysteine-rich protein 2
755 211 1 633 g12805261 l.OOE-130 cysteine-rich protein 2
756 3 386 630 1787 g12052983 l.OOE-176 hypothetical protein
756 3 386 630 1787 g5262560 l.OOE-124 hypothetical protein
756 3 386 630 1787 g10434856 l.OOE-118 unnamed protein product
757 1 237 1 711 gl7105197 l.OOE-120 kelch-like protein KLHL6
757 1 237 1 711 g10439155 3.00E-36 unnamed protein product
757 1 237 1 711 g6329805 6.00E-31 KIAA1 129 protein
758 2 972 2 2917 gl8314381 0 Similar to mitotic control protein dis3 homolog
758 2 972 2 2917 g15559519 0 Unknown (protein for I MAGE: 4561365)
758 2 972 2 2917 g17225572 l.OOE-154 KIAA1008 protein
759 1 313 1 939 g206734 l.OOE-173 ribosomal protein L5
759 1 313 1 939 g57125 l.OOE-171 ribosomal protein L5 (AA 1 -297)
759 1 313 1 939 g12850263 l.OOE-171 data source:MGD, source key:MGI: 102854, evidence: ISS~putative~ribosomal protein L5
760 3 217 1614 2264 g3327090 l.OOE-118 KIAA0638 protein
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Score Annotation
760 3 217 1614 2264 g14042238 l.OOE-109 unnamed protein product
760 3 217 1614 2264 g15991879 l.OOE-109 Unknown (protein for MGC4704)
761 3 229 3 689 gl2314195 l.OOE-121 bA255Al 1.3 (novel protein similar to KIAA1074)
761 3 229 3 689 gl2314164 3.00E-97 bA526D8.2 (novel protein similar to KIAA1074)
761 3 229 3 689 g12053099 2.00E-71 hypothetical protein
762 594 958 2739 g7959265 0 KIAA 1502 protein
762 594 958 2739 g14035822 0 unnamed protein product
762 594 958 2739 g5764665 0 cerebral cell adhesion molecule
763 689 364 2430 g13623407 0 Similar to RIKEN cDNA 2810468K17 gene
763 689 364 2430 g14495695 0 Unknown (protein for MGC: 15935)
763 689 364 2430 g13874543 0 hypothetical protein
764 2 248 743 1486 g2997747 4.00E-29 tetraspan TM4SF; Tspan-4
764 2 248 743 1486 g17939510 4.00E-29 transmembrane 4 superfamily member 7
764 2 248 743 1486 g12653241 4.00E-29 transmembrane 4 superfamily member 7
765 1 304 91 1002 g12232324 l.OOE-161 hUPF3B
765 1 304 91 1002 g12620408 l.OOE-158 UPF3X
765 1 304 91 1002 g12860428 6.00E-76 data source:SPTR, source key:Q9HU0, evidence:ISS~homolog to HUPF3B~putative
766 1 128 439 822 g12856090 7.00E-62 data source:SPTR, source key:Q9Z2B2, evidence:ISS~putative-similar to BRAIN MITOCHONDRIAL CARRIER PROTEIN-1 (BMCP-1)
766 1 128 439 822 g12854104 7.00E-62 data source:SPTR, source key:Q9Z2B2, evidence:ISS~putative~similar to BRAIN MITOCHONDRIAL CARRIER PROTEIN-1 (BMCP-1)
766 1 128 439 822 g4678718 5.00E-51 dJ20l3.1 (brain mitochondrial carrier protein-1 (BMCP1))
767 1 378 139 1272 g508729 0 thymopoietin gamma
767 1 378 139 1272 g3283900 0 thymopoietin gamma
767 1 378 139 1272 g1335847 l.OOE-177 thymopoietin gamma
768 2 358 218 1291 g18204012 0 Similar to RIKEN cDNA B830026H24 gene
768 2 358 218 1291 g12861800 0 data source:SPTR, source key:P97584, evidence: ISS-homolog to NADP- DEPENDENT LEUKOTRIENE B4 12-HYDROXYDEHYDROGENASE (EC 1.1.1.-) (DITHIOLETHIONE-INDUCIBLE GENE-l)-putative
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Score Annotation 768 2 358 218 1291 g3878713 5.00E-84 weak similarity with quinone oxidoreductase, contains similarity to Pfam domain: PF00107 (Zinc-binding dehydrogenases), Score=-80.6, E-value=6.2e- 06, N=l -cDNA EST ykl64b4.5 comes from this gene-cDNA EST ykl64b4.3 comes from this gene-cDNA EST yk264f3.5 comes from this gene
769 3 420 42 1301 g438007 1.00E-22 alpha-2-macroglobulin receptor
769 3 420 42 1301 g8926243 3.00E-20 low density lipoprotein receptor related protein LRP1 B/LRP-DIT
769 3 420 42 1301 g7291057 3.00E-20 CGI 2139 gene product
770 3 221 3 665 g16553391 l.OOE-137 unnamed protein product
770 3 221 3 665 g12483900 4.00E-67 zinc finger protein HIT-4
770 3 221 3 665 g14456631 3.00E-44 dJ54B20.4 (novel KRAB box containing C2H2 type zinc finger protein)
771 1 664 1477 3468 g4589670 0 KIAA1010 protein
771 1 664 1477 3468 g15207833 1.00E-75 hypothetical protein
771 1 664 1477 3468 g12845768 9.00E-63 data source:SPTR, source key:Q9Y2L3, evidence.lSS-homolog to KIAAIOIO PROTEIN (FRAGMENT)~putative
772 2 418 1433 2686 g4589678 0 KIAA1014 protein
772 2 418 1433 2686 g10434696 0 unnamed protein product
772 2 418 1433 2686 g6808095 0 hypothetical protein
773 2 276 2 829 g16553765 l.OOE-127 unnamed protein product
773 2 276 2 829 g12839186 l.OOE-121 data source:SPTR, source key:Q9VS60, evidence:ISS~putative~related to CG8576 PROTEIN
773 2 276 2 829 g1072250 5.00E-28 F53B1.2 gene product
774 1 636 145 2052 g12804475 0 Similar to spleen tyrosine kinase
774 1 636 145 2052 g12804209 0 Similar to spleen tyrosine kinase
774 1 636 145 2052 g479013 0 protein tyrosine kinase
776 3 225 48 722 g18027350 l.OOE-l02 unknown
776 3 225 48 722 g15072406 l.OOE-l02 TNFAIP1 -like protein
776 3 225 48 722 g16152040 2.00E-99 polymerase delta-interacting protein 1
777 3 796 276 2663 g1749794 0 serine/threonine protein kinase
777 3 796 276 2663 g14250622 0 Similar to ELKL motif kinase
777 3 796 276 2663 g57920 0 serine/threonine protein kinase
778 2 2067 224 6424 gl 1596412 0 GAC-1
778 2 2067 224 6424 g4240237 0 KIAA0874 protein
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Score Annotation
778 2 2067 224 6424 g10437204 0 unnamed protein product
779 2 839 284 2800 g16551917 0 unnamed protein product
779 2 839 284 2800 g16356673 0 LIM protein prickle b
779 2 839 284 2800 g14595658 0 LIM protein prickle
780 2 538 2 1615 g11323324 0 dJ138B7.3.2 (lethal (3) malignant brain tumor (l(3)mbt) protein (Drosophila) homolog (isoform 2) (KIAA0681))
780 2 538 2 1615 g3327176 0 KIAA0681 protein
780 2 538 2 1615 gl 1323323 0 dJ138B7.3.1 (continued from dJ862K6.1 in Em:AL031681)
781 1 564 118 1809 g5764636 0 DNA binding protein p96PIF
781 1 564 118 1809 g12655229 0 glucocorticoid modulatory element binding protein 1
781 1 564 118 1809 g9863866 0 glucocorticoid modulatory element binding protein 1
782 3 428 18 1301 g3327094 l.OOE-179 KIAA0640 protein
782 3 428 18 1301 g7381109 l.OOE-167 SWAP-70 homolog
782 3 428 18 1301 g12653667 l.OOE-167 SWAP-70 protein u 783 2 157 2291 2761 g7688677 4.00E-45 mitochondrial solute carrier u
© 783 2 157 2291 2761 g7578783 4.00E-45 HT015 protein
783 2 157 2291 2761 g16506178 2.00E-42 mitochondrial solute carrier-like protein
784 2 238 2 715 g16555334 l.OOE-110 Rig protein
784 2 238 2 715 g16508176 l.OOE-110 small GTP-binding tumor suppressor 1
784 2 238 2 715 g4235148 l.OOE-110 BC41 195J
785 2 1213 656 4294 g9845485 0 protocadherin-9
785 2 1213 656 4294 g14388339 0 hypothetical protein
785 2 1213 656 4294 g13874450 0 hypothetical protein
786 3 212 72 707 g18615326 l.OOE-104 unnamed protein product
786 3 212 72 707 g12854500 2.00E-88 Mitochondrial carrier proteins containing protein-data source: Pfam, source key:PF00153, evidence:ISS~putative
786 3 212 72 707 g15277499 2.00E-87 Similar to RIKEN cDNA 4930433D19 gene
787 1 521 241 1803 g16741627 0 Similar to RIKEN cDNA 3830421 M04 gene
787 1 521 241 1803 g12859683 0 data source:SPTR, source key:Q63615, evidence:ISS~homolog to VACUOLAR PROTEIN SORTING HOMOLOG R-VPS33A-putative
787 1 521 241 1803 g1477468 0 vacuolar protein sorting homolog r-vps33a
788 1 818 1 2454 gl 1320820 0 VSGP/F-spondin
TABLE 7
SEQ ID NO: Frame Length Start Stop Gl Number Probability Score Annotation
788 1 818 1 2454 gl l 320818 0 VSGP/F-spondin
788 818 1 2454 g204177 0 f-spondin
789 1 13 21 1 549 g6714707 1.00E-52 hypothetical protein
789 1 13 21 1 549 g 16589079 1.00E-52 WD repeat protein BIG-3
789 1 13 21 1 549 g 16359284 1.00E-52 Similar to hypothetical protein
790 149 145 591 g7959207 2.00E-26 KIAA1473 protein
790 149 145 591 g498736 4.00E-26 zinc finger protein
790 1 149 145 591 g 16551398 6.00E-26 unnamed protein product
791 1 178 1 534 g 16551459 l .OOE-100 unnamed protein product
791 1 178 1 534 g7303923 3.00E-25 CG8027 gene product
791 1 178 1 534 g 12057020 2.00E-08 putative notch receptor protein
792 3 373 171 1289 g 12856757 l .OOE-132 data source:SPTR, source key:Q9VKF0, evidence: ISS-putative-related to CGI 4939 PROTEIN
792 3 373 171 1289 g 15788437 l .OOE-132 cyclin-box carrying protein u 792 3 373 171 1289 g 15451434 l .OOE-124 hypothetical protein u
TABLE 8
Program Description Reference Parameter Threshold ABI FACTURA A program that removes vector sequences and masks Applied Biosystems, Foster City, CA. ambiguous bases in nucleic acid sequences.
ABI/PARACEL FDF A Fast Data Finder useful in comparing and annotating Applied Biosystems, Foster City, CA; Paracel Mismatch <50% amino acid or nucleic acid sequences. Inc., Pasadena, CA.
ABI AutoAssembler A program that assembles nucleic acid sequences. Applied Biosystems, Foster City, CA. BLAST A Basic Local Alignment Search Tool useful in sequence Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403- ESTs: Probability value= l.OE-8 or less; similarity search for amino acid and nucleic acid 410; Altschul, S.F. et al. (1997) Nucleic Acids Full Length sequences: Probability valu sequences. BLAST includes five functions: blastp, Res. 25:3389-3402. l.OE-lO or less blastn, blastx, tblastn, and tblastx.
FASTA A Pearson and Lipman algorithm that searches for Pearson, W.R. and DJ. Lipman (1988) Proc. ESTs: fasta E value=1.06E-6; Assemble similarity between a query sequence and a group of Natl. Acad Sci. USA 85:2444-2448; Pearson, ESTs: fasta Identity= 95% or greater an u sequences of the same type. FASTA comprises as least W.R. (1990) Methods Enzymol. 183:63-98; and Match length=200 bases or greater; fast u five functions: fasta, tfasta, fastx, tfastx, and ssearch. Smith, T.F. and M.S. Waterman (1981) Adv. value=1.0E-8 or less; Full Length Appl. Math. 2:482-489. sequences: fastx score=100 or greater
BLIMPS A BLocks IMProved Searcher that matches a sequence Henikoff, S. and J.G. Henikoff (1991) Nucleic Probability value= 1.0E-3 or less against those in BLOCKS, PRINTS, DOMO, PRODOM, Acids Res. 19:6565-6572; Henikoff, J.G. and S. and PFAM databases to search for gene families, Henikoff (1996) Methods Enzymol. 266:88-105; sequence homology, and structural fingerprint regions. and Attwood, T.K. et al. (1997) J. Chem. Inf.
Comput. Sci. 37:417-424.
HMMER An algorithm for searching a query sequence against Krogh, A. et al. (1994) J. Mol. Biol. 235:1501- PFAM hits: Probability value= 1.0E-3 o hidden Markov model (HMM)-based databases of 1531; Sonnhammer, E.L.L. et al. (1988) Nucleic less; protein family consensus sequences, such as PFAM. Acids Res. 26:320-322; Durbin, R. et al. (1998) Signal peptide hits: Score= 0 or greater
Our World View, in a Nutshell, Cambridge
Univ. Press, pp. 1-350.
ProfϊleScan An algorithm that searches for structural and sequence Gribskov, M. et al. (1988) CABIOS 4:61-66; Normalized quality score≥GCG-specifie motifs in protein sequences that match sequence patterns Gribskov, M. et al. (1989) Methods Enzymol. "HIGH" value for that particular Prosite defined in Prosite. 183:146-159; Bairoch, A. et al. (1997) Nucleic motif. Generally, score= 1.4-2.1.
Acids Res. 25:217-221.
TABLE 8
Program Description Reference Parameter Threshold Phred A base-calling algorithm that examines automated Ewing, B. et al. (1998) Genome Res. 8:175-185; sequencer traces with high sensitivity and probability. Ewing, B. and P. Green (1998) Genome Res. 8:186-194.
Phrap A Phils Revised Assembly Program including SWAT Smith, T.F. and M.S. Waterman (1981) Adv. Score= 120 or greater; and CrossMatch, programs based on efficient Appl. Math. 2:482-489; Smith, T.F. and M.S. Match length= 56 or greater implementation of the Smith-Waterman algorithm, Waterman (1981) J. Mol. Biol. 147: 195-197; useful in searching sequence homology and assembling and Green, P., University of Washington, DNA sequences. Seattle, WA.
Consed A graphical tool for viewing and editing Phrap Gordon, D. et al. (1998) Genome Res. 8:195- assemblies. 202. SPScan A weight matrix analysis program that scans protein Nielson, H. et al. (1997) Protein Engineering Score=3.5 or greater sequences for the presence of secretory signal peptides. 10:1-6; Claverie, J.M. and S. Audic (1997) u u CABIOS 12:431-439. u
TMAP A program that uses weight matrices to delineate Persson, B. and P. Argos (1994) J. Mol. Biol. transmembrane segments on protein sequences and 237: 182-192; Persson, B. and P. Argos (1996) determine orientation. Protein Sci. 5:363-371.
TMHMMER A program that uses a hidden Markov model (HMM) to Sonnhammer, E.L. et al. (1998) Proc. Sixth Intl. delineate transmembrane segments on protein sequences Conf. On Intelligent Systems for Mol. Biol., and determine orientation. Glasgow et al., eds., The Am. Assoc. for Artificial Intelligence (AAAI) Press, Menlo Park, CA, and MIT Press, Cambridge, MA, pp. 175-182.
Motifs A program that searches amino acid sequences for Bairoch, A. et al. (1997) Nucleic Acids Res. patterns that matched those defined in Prosite. 25:217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.

Claims

CLAIMS What is claimed is:
1. An isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of: a) a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396, b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a) through d).
2. An isolated polynucleotide of claim 1, comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-396.
3. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 1.
4. A composition for the detection of expression of disease detection and treatment molecule polynucleotides comprising at least one of the polynucleotides of claim 1 and a detectable label.
5. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 1, the method comprising: a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.
6. A method for detecting a target polynucleotide in a sample, said target polynucleotide comprising a sequence of a polynucleotide of claim 1 , the method comprising: a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.
7. A method of claim 5, wherein the probe comprises at least 30 contiguous nucleotides.
8. A method of claim 5, wherein the probe comprises at least 60 contiguous nucleotides.
9. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 1.
10. A cell transformed with a recombinant polynucleotide of claim 9.
11. A transgenic organism comprising a recombinant polynucleotide of claim 9.
12. A method for producing a disease detection and treatment molecule polypeptide, the method comprising: a) culturing a cell under conditions suitable for expression of the disease detection and treatment molecule polypeptide, wherein said cell is transformed with a recombinant polynucleotide of claim 9, and b) recovering the disease detection and treatment molecule polypeptide so expressed.
13. A purified disease detection and treatment molecule polypeptide (MDDT) encoded by at least one of the polynucleotides of claim 2.
14. An isolated antibody which specifically binds to a disease detection and treatment molecule polypeptide of claim 13.
15. A method of identifying a test compound which specifically binds to the disease detection and treatment molecule polypeptide of claim 13, the method comprising the steps of: a) providing a test compound; b) combining the disease detection and treatment molecule polypeptide with the test compound for a sufficient time and under suitable conditions for binding; and c) detecting binding of the disease detection and treatment molecule polypeptide to the test compound, thereby identifying the test compound which specifically binds the disease detection and treatment molecule polypeptide.
16. A microarray wherein at least one element of the microarray is a polynucleotide of claim
3.
17. A method for generating a transcript image of a sample which contains polynucleotides, the method comprising the steps of: a) labeling the polynucleotides of the sample, b) contacting the elements of the microarray of claim 16 with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and c) quantifying the expression of the polynucleotides in the sample.
18. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide sequence of claim 1, the method comprising: a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide, b) detecting altered expression of the target polynucleotide, and c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.
19. A method for assessing toxicity of a test compound, said method comprising: a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 1 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 1 or fragment thereof; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.
20. An array comprising different nucleotide molecules affixed in distinct physical locations on a solid substrate, wherein at least one of said nucleotide molecules comprises a first oligonucleotide or polynucleotide sequence specifically hybridizable with at least 30 contiguous nucleotides of a target polynucleotide, said target polynucleotide having a sequence of claim 1.
21. An array of claim 20, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 30 contiguous nucleotides of said target polynucleotide.
22. An array of claim 20, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 60 contiguous nucleotides of said target polynucleotide
23. An array of claim 20, which is a microarray.
24. An array of claim 20, further comprising said target polynucleotide hybridized to said first oligonucleotide or polynucleotide.
25. An array of claim 20, wherein a linker joins at least one of said nucleotide molecules to said solid substrate.
26. An array of claim 20, wherein each distinct physical location on the substrate contains multiple nucleotide molecules having the same sequence, and each distinct physical location on the substrate contains nucleotide molecules having a sequence which differs from the sequence of nucleotide molecules at another physical location on the substrate.
27. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of: a) an amino acid sequence selected from the group consisting of SEQ ID NO: 397-792, b) a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:397-792, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:397-792, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:397-792.
28. An isolated polypeptide of claim 27, comprising a polypeptide sequence selected from the group consisting of SEQ ID NO:397-792.
EP02744104A 2001-03-28 2002-03-27 Molecules for disease detection and treatment Ceased EP1383894A2 (en)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US27961901P 2001-03-28 2001-03-28
US279619P 2001-03-28
US28006701P 2001-03-29 2001-03-29
US28006801P 2001-03-29 2001-03-29
US280068P 2001-03-29
US280067P 2001-03-29
US29128001P 2001-05-16 2001-05-16
US291280P 2001-05-16
US29184901P 2001-05-17 2001-05-17
US29182901P 2001-05-17 2001-05-17
US291829P 2001-05-17
US291849P 2001-05-17
US29942801P 2001-06-19 2001-06-19
US299428P 2001-06-19
US30000101P 2001-06-20 2001-06-20
US29977601P 2001-06-20 2001-06-20
US300001P 2001-06-20
US299776P 2001-06-20
PCT/US2002/009944 WO2002079449A2 (en) 2001-03-28 2002-03-27 Molecules for disease detection and treatment

Publications (1)

Publication Number Publication Date
EP1383894A2 true EP1383894A2 (en) 2004-01-28

Family

ID=27578771

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02744104A Ceased EP1383894A2 (en) 2001-03-28 2002-03-27 Molecules for disease detection and treatment

Country Status (4)

Country Link
EP (1) EP1383894A2 (en)
AU (2) AU2002338265A1 (en)
CA (2) CA2442705A1 (en)
WO (2) WO2002079449A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244827B2 (en) 2000-04-12 2007-07-17 Agensys, Inc. Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
WO2002074906A2 (en) * 2001-03-16 2002-09-26 Eli Lilly And Company Lp mammalian proteins; related reagents
ATE364690T1 (en) * 2001-11-09 2007-07-15 Proteologics Inc POSH NUCLEIC ACID, POLYPEPTIDES AND RELATED METHODS
US8753822B2 (en) * 2001-12-04 2014-06-17 Wayne State University Neoepitope detection of disease using protein arrays
AU2003228084A1 (en) * 2002-05-28 2003-12-12 Omrix Biopharmaceuticals Inc. Method for obtaining anti-idiotype antibodies
CA2488382A1 (en) 2002-06-05 2003-12-18 Case Western Reserve University Methods and compositions for detecting cancers
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
TW200418988A (en) * 2002-09-30 2004-10-01 Oncotherapy Science Inc Method for diagnosing prostate cancer
AU2003271149A1 (en) * 2002-10-11 2004-05-04 Yamanouchi Pharmaceutical Co., Ltd. Method of screening remedy for renal failure
EP2314676A1 (en) * 2002-11-26 2011-04-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1589110A4 (en) * 2002-12-27 2006-06-07 Nat Inst Of Advanced Ind Scien Glycosyltransferase, nucleic acid encoding the glycosyltransferase and method of testing canceration using the nucleic acid
GB0315827D0 (en) * 2003-07-05 2003-08-13 Imp College Innovations Ltd Methods
US20080274975A1 (en) * 2004-04-12 2008-11-06 The Trustees Of Columbia University In The City Of New Yourk Methods and Compositions for Inhibiting Abad/Abeta Protein Interaction
EP1627922A1 (en) * 2004-08-18 2006-02-22 Sanofi-Aventis Deutschland GmbH Method of screening for a carnitine transporter agonist or antagonist and its uses
GB0423126D0 (en) * 2004-10-18 2004-11-17 Ares Trading Sa Protein
US7727725B2 (en) 2006-04-27 2010-06-01 Celera Corporation Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
US8652472B2 (en) 2006-12-05 2014-02-18 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US20110250218A1 (en) * 2008-10-29 2011-10-13 Fong Lawrence H Disease-Associated Antigens and Methods of Use Thereof
US9175353B2 (en) 2008-11-14 2015-11-03 Gen-Probe Incorporated Compositions, kits and methods for detection of campylobacter nucleic acid
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
EP2552947A4 (en) 2010-03-26 2013-11-13 Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
CA2810928A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
CN104321333A (en) 2012-03-21 2015-01-28 沃泰克斯药物股份有限公司 Solid forms of a thiophosphoramidate nucleotide prodrug
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
AU2013312211B2 (en) 2012-09-07 2018-03-29 King's College London VISTA modulators for diagnosis and treatment of cancer
WO2015097536A2 (en) 2013-12-24 2015-07-02 Janssen Pharmaceutical Nv Anti-vista antibodies and fragments
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
AU2015274504B2 (en) 2014-06-11 2021-02-04 Kathy A. Green Use of VISTA agonists and antagonists to suppress or enhance humoral immunity
AU2015357463B2 (en) 2014-12-05 2021-10-07 Immunext, Inc. Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
BR112017027870A2 (en) 2015-06-24 2018-08-28 Janssen Pharmaceutica Nv antibodies and anti-sight fragments
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
CA3020848A1 (en) 2016-04-15 2017-10-19 Janssen Pharmaceuticals, Inc. Anti-human vista antibodies and use thereof
US20210223232A1 (en) * 2018-06-26 2021-07-22 Duke University Synthetic odorant receptors
CN110714017B (en) * 2019-11-06 2023-09-01 河南师范大学 Koi ptps gene, coded protein and application
CN111621525B (en) * 2020-06-18 2021-04-23 中赛干细胞基因工程有限公司 Application of STX1B gene in promoting growth and differentiation of human adipose-derived mesenchymal stem cells
CN114317732B (en) * 2021-04-08 2023-08-18 博尔诚(北京)科技有限公司 Composition for lung cancer screening and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO02079449A3 *

Also Published As

Publication number Publication date
WO2002079449A3 (en) 2003-03-20
AU2002344208A8 (en) 2005-11-17
WO2002097031A2 (en) 2002-12-05
AU2002344208A1 (en) 2002-12-09
WO2002097031A3 (en) 2005-05-12
CA2447183A1 (en) 2002-10-10
WO2002079449A2 (en) 2002-10-10
CA2442705A1 (en) 2002-12-05
AU2002338265A1 (en) 2002-10-15

Similar Documents

Publication Publication Date Title
EP1383894A2 (en) Molecules for disease detection and treatment
EP1409504A2 (en) Secretory molecules
US20060216706A1 (en) Proteins associated with cell growth, differentiation, and death
WO2002040715A2 (en) Molecules for disease detection and treatment
CA2449440A1 (en) Structural and cytoskeleton-associated proteins
US20040253598A1 (en) Vesicle-associated proteins
US20030198975A1 (en) Proteins associated with cell growth, differentiation, and death
EP1358326A2 (en) Proteins associated with cell growth, differentiation, and death
WO2003062385A2 (en) Secretory molecules
US20050069878A1 (en) Proteins associated with cell growth, differentiation, and death
EP1320598A2 (en) Polypeptides and corresponding molecules for disease detection and treatment
US20040171012A1 (en) Nucleic acid-associated proteins
WO2003010329A2 (en) Nucleic acid-associated proteins
CA2410679A1 (en) Secretion and trafficking molecules
WO2004031364A2 (en) Proteins associated with cell growth, differentiation, and death
JP2005511028A (en) Disease detection and therapeutic molecules
US20050118582A1 (en) Nucleic acid-associated proteins
JP2004519217A (en) Microtubule-associated proteins and tubulin
WO2000075298A2 (en) Molecules for disease detection and treatment
US20040033942A1 (en) Transriotion factors
WO2003095622A2 (en) Proteins associated with cell growth, differentiation, and death
US20050186569A1 (en) Nucleic acid-associated proteins
US20040096828A1 (en) Cytoskeleton-associated proteins
US20030186379A1 (en) Secretion and trafficking molecules
CA2430906A1 (en) Proteins associated with cell growth, differentiation, and death

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031024

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: URASHKA, MICHAEL E.

Inventor name: LAN, RUTH Y.

Inventor name: LO, AUDREY

Inventor name: MARWAHA, RAKESH

Inventor name: MULLAHY-FLORES, VINCENT

Inventor name: HARRIS, BERNARD

Inventor name: PANZER, SCOTT R.

Inventor name: CHEN, ALICE J.

Inventor name: LEWIS, SAMANTHA A.

Inventor name: DAVID, MARIE H.

Inventor name: PERALTA, CAREYNA, H.

Inventor name: GERSTIN, EDWARD, H., JR.

Inventor name: KLEEFELD, YAEL

Inventor name: NGUYEN, DUY-VIET, AN

Inventor name: LIU, TOMMY, F.

Inventor name: DAM, TAM, C.

Inventor name: DAUGHERTY, SEAN, C.

Inventor name: AMSHEY, STEFAN, R.

Inventor name: YAP, PIERRE, E.

Inventor name: TUASON, OLIVIA

Inventor name: YU, JIMMY, Y.

Inventor name: JACKSON, JENNIFER, L.

Inventor name: DUFOUR, GERARD, E.

Inventor name: CHINN, JOYCE

Inventor name: GIETZEN, DARRYL

Inventor name: DAHL, CHRISTOPHER, R.

Inventor name: TRAN, ALANNA-PHUNG, B.

Inventor name: JONES, ANISSA, L.

Inventor name: DAFFO, ABEL

RIN1 Information on inventor provided before grant (corrected)

Inventor name: URASHKA, MICHAEL E.

Inventor name: LAN, RUTH Y.

Inventor name: LO, AUDREY

Inventor name: MARWAHA, RAKESH

Inventor name: MULLAHY-FLORES, VINCENT, Z.

Inventor name: HARRIS, BERNARD

Inventor name: PANZER, SCOTT R.

Inventor name: CHEN, ALICE J.

Inventor name: LEWIS, SAMANTHA A.

Inventor name: DAVID, MARIE H.

Inventor name: PERALTA, CAREYNA, H.

Inventor name: GERSTIN, EDWARD, H., JR.

Inventor name: KLEEFELD, YAEL

Inventor name: NGUYEN, DUY-VIET, AN

Inventor name: LIU, TOMMY, F.

Inventor name: DAM, TAM, C.

Inventor name: DAUGHERTY, SEAN, C.

Inventor name: AMSHEY, STEFAN, R.

Inventor name: YAP, PIERRE, E.

Inventor name: TUASON, OLIVIA

Inventor name: YU, JIMMY, Y.

Inventor name: JACKSON, JENNIFER, L.

Inventor name: DUFOUR, GERARD, E.

Inventor name: CHINN, JOYCE

Inventor name: GIETZEN, DARRYL

Inventor name: DAHL, CHRISTOPHER, R.

Inventor name: TRAN, ALANNA-PHUNG, B.

Inventor name: JONES, ANISSA, L.

Inventor name: DAFFO, ABEL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20040613